01140000000000445000450099100020000070000020000270600020000470100020000609100090
00081300038000174210024000551510026000792300038001050350010001434800038001530300
02400191031000300215032000200218036000700220930000500227042000200232117000600234
08500030024020000020024306500090024512200030025404800140025704900250027104900280
02960490035003240490022003590480014003810480024003950490024004190490030004430490
02300473043006500496043006500561043006800626#1#0#i#1#20080211#Revista Panamerica
na de Salud Pública#Rev Panam Salud Publica#Rev. panam. salud pública#Pan Americ
an Journal of Public Health#1020-4989#Organización Panamericana de la Salud#Rev 
Panam Salud Publica#22#6#200711#RPSP#1#other#nd#0#20071200#13#^les^hSumario#^les
^cRPSP020^tArtículos#^les^cRPSP030^tInstantáneas#^les^cRPSP050^tTemas de Actuali
dad#^les^cRPSP100^tCartas#^lpt^hSumário#^len^hTable of Contents#^len^cRPSP020^tA
rticles#^len^cRPSP050^tCurrent Topics#^len^cRPSP100^tLetters#^les^tRev Panam Sal
ud Publica^vv.22^nn.6^cWashington^mdic.^a2007#^lpt^tRev Panam Salud Publica^vv.2
2^nn.6^cWashington^mdez.^a2007#^len^tRev Panam Salud Publica^vvol.22^nno.6^cWash
ington^mDec.^a2007##
00275000000000169000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700910009000720920007000810020013000887030
00400101#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a01v22n6.htm#S#o#1#1#article#1
#20080215#102614#a01v22n6.htm#187##
06258000000000625000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000400090121000300094049000800097158000300105030002400108
03100030013203200020013506500090013701400110014603500100015701201680016701201510
03350100033004860100037005190100033005560100042005890700121006310832299007520850
00803051085002503059085002503084085003103109085002003140085001903160083226403179
08500080544308500300545108500250548108500250550608500190553111700060555007200030
5556112000905559111002205568114000905590113002005599002001305619#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a01v22n6.htm#S#h#2#1#article#1#oa#es#br1.1#1#3.1#TAB#0
1#RPSP020#nd#Rev Panam Salud Publica#22#6#20071200#^f369^l375#1020-4989#Determin
antes del riesgo de desnutrición en los adultos mayores de la comunidad: análisi
s secundario del estudio Salud, Bienestar y Envejecimiento (SABE) en México^les#
Determinants of malnutrition risk among the older adult community: a secondary a
nalysis of the Health, Wellbeing, and Aging Study (SABE) in Mexico^len#^rND^1A01
^nNubia^sFranco-Álvarez#^rND^1A01^nJosé Alberto^sÁvila-Funes#^rND^1A01^nLiliana^
sRuiz-Arreguí#^rND^1A01^nLuis Miguel^sGutiérrez-Robledo#Instituto Nacional de Ci
encias Médicas y Nutrición Salvador Zubirán^iA01^1Clínica de Geriatría^cCiudad d
e México^pMéxico#^les^aOBJETIVO: Determinar los factores psicosociales y de salu
d asociados con el riesgo de desnutrición (RD) en los adultos mayores que viven 
en la comunidad en la Ciudad de México, México. MÉTODOS: Estudio transversal. An
álisis secundario de los datos de las personas de 60 años o más de la zona metro
politana de la Ciudad de México participantes en el estudio multicéntrico Salud,
 Bienestar y Envejecimiento (SABE) realizado entre 1999 y 2000. Se utilizó la in
formación de 820 participantes (edad media 69,7 &plusmn; 7,6 años; 62,9% mujeres
). Además del RD (variable dependiente), establecido mediante la evaluación míni
ma del estado nutricional, se analizaron otras variables (sociodemográficas, índ
ice de masa corporal, comorbilidad, síntomas depresivos, salud bucal, función me
ntal, capacidad funcional, entre otras). Se analizaron las asociaciones independ
ientes entre las variables y el RD mediante análisis de regresión simple y multi
factorial. Se calcularon la razón de posibilidades (odds ratio, OR) y los interv
alos de confianza de 95% (IC95%). RESULTADOS: El RD estuvo presente en 261 (31,8
%) participantes. El análisis de regresión logística multifactorial ajustado por
 posibles variables confusoras mostró que el no recibir una jubilación (OR ajust
ada = 1,45; IC95%: 1,01 a 2,38), la percepción de no tener el suficiente dinero 
para vivir (OR ajustada = 2,52; IC95%: 1,69 a 3,74), tener artrosis (OR ajustada
 = 2,34; IC95%: 1,42 a 3,85), tener menor índice de masa corporal (OR ajustada =
 0,89; IC95%: 0,85 a 0,93 ), la presencia de síntomas depresivos (OR ajustada = 
5,41; IC95%: 1,90 a 15,34), el hacer sólo una (OR ajustada = 12,95; IC95%: 5,19 
a 32,28) o dos comidas al día (OR ajustada = 3,27; IC95%: 2,18 a 4,9) y el tener
 dificultades para acostarse solo (OR ajustada = 3,25; IC95%: 1,58 a 6,68), sali
r solo (OR ajustada = 2,70; IC95%: 1,54 a 4,73) y utilizar el teléfono (OR ajust
ada = 1,95; IC95%: 1,10 a 3,43) mostraron asociación significativa e independien
te con el RD en la muestra de adultos mayores estudiada. CONCLUSIONES: Los deter
minantes del riesgo de desnutrición son múltiples y diversos. Para establecer el
 RD se debe evaluar de forma intencionada la situación económica y social del ad
ulto mayor, además de la información de salud y antropométrica tradicional.#^dnd
^i1#^tm^les^kDesnutrición^i1#^tm^les^kalimentación^i1#^tm^les^kfactores de riesg
o^i1#^tm^les^kanciano^i1#^tm^les^kMéxico^i1#^len^aOBJECTIVE: To determine the ps
ychosocial and health determinants associated with malnutrition risk (MR) among 
older adults living in the community of Mexico City, Mexico. METHODS: This was a
 cross-sectional study. Secondary analysis was performed on the data of adults w
ho were 60 or more years of age, living in the metropolitan area of Mexico city,
 and had participated in the multi-city study on Health, Wellbeing, and Aging in
 1999 and 2000. Information on 820 participants was analyzed (mean age 69.7 &plu
smn; 7.6 years; 62.9% female). In addition to the MR (dependent variable) that w
as established through a basic nutrition evaluation, the following variables wer
e analyzed: sociodemographics, body mass index, comorbidity, symptoms of depress
ion, oral health, mental function, functional capability, among others. Independ
ent associations from among the variables and the MR were calculated by univaria
te and multivariate logistic regression analysis. Odds ratios (OR) and 95% confi
dence intervals (95%CI) were determined. RESULTS: MR was present in 261 (31.8%) 
participants. The univariate logistic regression analysis adjusted for possible 
confounding variables showed that the following variables demonstrated significa
nt and independent associations with MR among the study sample population: not h
aving a pension (adjusted OR = 1.45; 95%CI: 1.01 - 2.38); feeling that one did n
ot have enough money to live on (adjusted OR = 2.52; 95%CI: 1.69 - 3.74); having
 osteoarthritis (adjusted OR = 2.34; 95%CI: 1.42 - 3.85); having a low body mass
 index (adjusted OR = 0.89; 95%CI: 0.85 - 0.93); having symptoms of depression (
adjusted OR = 5.41; 95%CI: 1.90 - 15.34); eating only once daily (adjusted OR = 
12.95; 95%CI: 5.19 - 32.28) or twice daily (adjusted OR = 3.27; 95%CI: 2.18 - 4.
9); and having physical difficulty with getting to bed (adjusted OR = 3.25; CI 9
5%: 1.58 - 6.68), going out alone (adjusted OR = 2.70; CI 95%: 1.54 - 4.73), and
 using the telephone (adjusted OR = 1.95; CI 95%: 1.10 - 3.43). CONCLUSIONS: The
re are multiple and various determinants of malnutrition risk. To determine MR, 
the older adult's financial and social situation must be carefully evaluated alo
ng with the more traditional health and anthropometric information.#^dnd^i2#^tm^
len^kElderly nutrition^i2#^tm^len^kmalnutrition^i2#^tm^len^krisk factors^i2#^tm^
len^kMexico^i2#other#48#20061017#17 de octubre de 2006#20070801#1 de agosto de 2
007#a01v22n6.htm##
06406000000000625000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000400090121000300094049000800097158000300105030002400108
03100030013203200020013506500090013701400110014603500100015701201820016701201650
03490100033005140100037005470100033005840100042006170700121006590832371007800850
00803151085002503159085002503184085003103209085002003240085001903260083231203279
08500080559108500300559908500250562908500250565408500190567911700060569807200030
5704112000905707111002205716114000905738113002005747002001305767#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a01v22n6.htm#S#f#3#1#article#1#oa#es#br1.1#1#3.1#TAB#0
1#RPSP020#nd#Rev Panam Salud Publica#22#6#20071200#^f369^l375#1020-4989#<B>Deter
minantes del riesgo de desnutrición en los adultos mayores de la comunidad</B>: 
<B>análisis secundario del estudio Salud, Bienestar y Envejecimiento (SABE) en M
éxico</B>^les#<B>Determinants of malnutrition risk among the older adult communi
ty</B>: <B>a secondary analysis of the Health, Wellbeing, and Aging Study (SABE)
 in Mexico</B>^len#^rND^1A01^nNubia^sFranco-Álvarez#^rND^1A01^nJosé Alberto^sÁvi
la-Funes#^rND^1A01^nLiliana^sRuiz-Arreguí#^rND^1A01^nLuis Miguel^sGutiérrez-Robl
edo#Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán^iA01^1Cl
ínica de Geriatría^cCiudad de México^pMéxico#^les^a<B>OBJETIVO:</B>&nbsp;&nbsp;D
eterminar los factores psicosociales y de salud asociados con el riesgo de desnu
trición (RD) en los adultos mayores que viven en la comunidad en la Ciudad de Mé
xico, México. <B>MÉTODOS:</B>&nbsp;&nbsp;Estudio transversal. Análisis secundari
o de los datos de las personas de 60 años o más de la zona metropolitana de la C
iudad de México participantes en el estudio multicéntrico Salud, Bienestar y Env
ejecimiento (SABE) realizado entre 1999 y 2000. Se utilizó la información de 820
 participantes (edad media 69,7 &plusmn; 7,6 años; 62,9% mujeres). Además del RD
 (variable dependiente), establecido mediante la evaluación mínima del estado nu
tricional, se analizaron otras variables (sociodemográficas, índice de masa corp
oral, comorbilidad, síntomas depresivos, salud bucal, función mental, capacidad 
funcional, entre otras). Se analizaron las asociaciones independientes entre las
 variables y el RD mediante análisis de regresión simple y multifactorial. Se ca
lcularon la razón de posibilidades (odds ratio, OR) y los intervalos de confianz
a de 95% (IC95%). <B>RESULTADOS:</B>&nbsp;&nbsp;El RD estuvo presente en 261 (31
,8%) participantes. El análisis de regresión logística multifactorial ajustado p
or posibles variables confusoras mostró que el no recibir una jubilación (OR aju
stada = 1,45; IC95%: 1,01 a 2,38), la percepción de no tener el suficiente diner
o para vivir (OR ajustada = 2,52; IC95%: 1,69 a 3,74), tener artrosis (OR ajusta
da = 2,34; IC95%: 1,42 a 3,85), tener menor índice de masa corporal (OR ajustada
 = 0,89; IC95%: 0,85 a 0,93 ), la presencia de síntomas depresivos (OR ajustada 
= 5,41; IC95%: 1,90 a 15,34), el hacer sólo una (OR ajustada = 12,95; IC95%: 5,1
9 a 32,28) o dos comidas al día (OR ajustada = 3,27; IC95%: 2,18 a 4,9) y el ten
er dificultades para acostarse solo (OR ajustada = 3,25; IC95%: 1,58 a 6,68), sa
lir solo (OR ajustada = 2,70; IC95%: 1,54 a 4,73) y utilizar el teléfono (OR aju
stada = 1,95; IC95%: 1,10 a 3,43) mostraron asociación significativa e independi
ente con el RD en la muestra de adultos mayores estudiada. <B>CONCLUSIONES:</B>&
nbsp;&nbsp;Los determinantes del riesgo de desnutrición son múltiples y diversos
. Para establecer el RD se debe evaluar de forma intencionada la situación econó
mica y social del adulto mayor, además de la información de salud y antropométri
ca tradicional.#^dnd^i1#^tm^les^kDesnutrición^i1#^tm^les^kalimentación^i1#^tm^le
s^kfactores de riesgo^i1#^tm^les^kanciano^i1#^tm^les^kMéxico^i1#^len^a<B>OBJECTI
VE:</B>&nbsp;To determine the psychosocial and health determinants associated wi
th malnutrition risk (MR) among older adults living in the community of Mexico C
ity, Mexico. <B>METHODS:</B>&nbsp;This was a cross-sectional study. Secondary an
alysis was performed on the data of adults who were 60 or more years of age, liv
ing in the metropolitan area of Mexico city, and had participated in the multi-c
ity study on Health, Wellbeing, and Aging in 1999 and 2000. Information on 820 p
articipants was analyzed (mean age 69.7 &plusmn; 7.6 years; 62.9% female). In ad
dition to the MR (dependent variable) that was established through a basic nutri
tion evaluation, the following variables were analyzed: sociodemographics, body 
mass index, comorbidity, symptoms of depression, oral health, mental function, f
unctional capability, among others. Independent associations from among the vari
ables and the MR were calculated by univariate and multivariate logistic regress
ion analysis. Odds ratios (OR) and 95% confidence intervals (95%CI) were determi
ned. <B>RESULTS:</B>&nbsp;MR was present in 261 (31.8%) participants. The univar
iate logistic regression analysis adjusted for possible confounding variables sh
owed that the following variables demonstrated significant and independent assoc
iations with MR among the study sample population: not having a pension (adjuste
d OR = 1.45; 95%CI: 1.01 - 2.38); feeling that one did not have enough money to 
live on (adjusted OR = 2.52; 95%CI: 1.69 - 3.74); having osteoarthritis (adjuste
d OR = 2.34; 95%CI: 1.42 - 3.85); having a low body mass index (adjusted OR = 0.
89; 95%CI: 0.85 - 0.93); having symptoms of depression (adjusted OR = 5.41; 95%C
I: 1.90 - 15.34); eating only once daily (adjusted OR = 12.95; 95%CI: 5.19 - 32.
28) or twice daily (adjusted OR = 3.27; 95%CI: 2.18 - 4.9); and having physical 
difficulty with getting to bed (adjusted OR = 3.25; CI 95%: 1.58 - 6.68), going 
out alone (adjusted OR = 2.70; CI 95%: 1.54 - 4.73), and using the telephone (ad
justed OR = 1.95; CI 95%: 1.10 - 3.43). <B>CONCLUSIONS:</B>&nbsp;There are multi
ple and various determinants of malnutrition risk. To determine MR, the older ad
ult's financial and social situation must be carefully evaluated along with the 
more traditional health and anthropometric information.#^dnd^i2#^tm^len^kElderly
 nutrition^i2#^tm^len^kmalnutrition^i2#^tm^len^krisk factors^i2#^tm^len^kMexico^
i2#other#48#20061017#17 de octubre de 2006#20070801#1 de agosto de 2007#a01v22n6
.htm##
06629000000000649000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700640013000720710003000850400003000880010
00600091042000200097120000400099038000400103121000300107049000800110158000300118
03000260012103100030014703200020015006500090015201400110016103500100017201201680
01820120151003500100033005010100037005340100033005710100042006040700123006460832
43900769085000803208085002503216085002503241085003103266085002003297085001903317
08323620333608500080569808500300570608500250573608500250576108500190578611700060
58050720003058111120009058141110022058231140009058451130020058540020013058740080
09205887#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a01v22n6.htm#S#l#4#1#article#1
#^mdic.^a2007#oa#es#br1.1#1#3.1#tab#01#RPSP020#nd#Rev. panam. salud pública#22#6
#20071200#^f369^l375#1020-4989#Determinantes del riesgo de desnutrición en los a
dultos mayores de la comunidad: análisis secundario del estudio Salud, Bienestar
 y Envejecimiento (SABE) en México^les#Determinants of malnutrition risk among t
he older adult community: a secondary analysis of the Health, Wellbeing, and Agi
ng Study (SABE) in Mexico^len#^rND^1A01^nNubia^sFranco-Álvarez#^rND^1A01^nJosé A
lberto^sÁvila-Funes#^rND^1A01^nLiliana^sRuiz-Arreguí#^rND^1A01^nLuis Miguel^sGut
iérrez-Robledo#^iA01^1Instituto Nacional de Ciencias Médicas y Nutrición Salvado
r Zubirán^2Clínica de Geriatría^cCiudad de México^pMéxico#^les^aOBJETIVO: Determ
inar los factores psicosociales y de salud asociados con el riesgo de desnutrici
ón (RD) en los adultos mayores que viven en la comunidad en la Ciudad de México,
 México. MÉTODOS: Estudio transversal. Análisis secundario de los datos de las p
ersonas de 60 años o más de la zona metropolitana de la Ciudad de México partici
pantes en el estudio multicéntrico Salud, Bienestar y Envejecimiento (SABE) real
izado entre 1999 y 2000. Se utilizó la información de 820 participantes (edad me
dia 69,7 &plusmn; 7,6 años; 62,9 por ciento mujeres). Además del RD (variable de
pendiente), establecido mediante la evaluación mínima del estado nutricional, se
 analizaron otras variables (sociodemográficas, índice de masa corporal, comorbi
lidad, síntomas depresivos, salud bucal, función mental, capacidad funcional, en
tre otras). Se analizaron las asociaciones independientes entre las variables y 
el RD mediante análisis de regresión simple y multifactorial. Se calcularon la r
azón de posibilidades (odds ratio, OR) y los intervalos de confianza de 95 por c
iento (IC95 por ciento). RESULTADOS: El RD estuvo presente en 261 (31,8 por cien
to) participantes. El análisis de regresión logística multifactorial ajustado po
r posibles variables confusoras mostró que el no recibir una jubilación (OR ajus
tada = 1,45; IC95 por ciento: 1,01 a 2,38), la percepción de no tener el suficie
nte dinero para vivir (OR ajustada = 2,52; IC95 por ciento: 1,69 a 3,74), tener 
artrosis (OR ajustada = 2,34; IC95 por ciento: 1,42 a 3,85), tener menor índice 
de masa corporal (OR ajustada = 0,89; IC95 por ciento: 0,85 a 0,93 ), la presenc
ia de síntomas depresivos (OR ajustada = 5,41; IC95 por ciento: 1,90 a 15,34), e
l hacer sólo una (OR ajustada = 12,95; IC95 por ciento: 5,19 a 32,28) o dos comi
das al día (OR ajustada = 3,27; IC95 por ciento: 2,18 a 4,9) y el tener dificult
ades para acostarse solo (OR ajustada = 3,25; IC95 por ciento: 1,58 a 6,68), sal
ir solo (OR ajustada = 2,70; IC95 por ciento: 1,54 a 4,73) y utilizar el teléfon
o (OR ajustada = 1,95; IC95 por ciento: 1,10 a 3,43) mostraron asociación signif
icativa e independiente con el RD en la muestra de adultos mayores estudiada. CO
NCLUSIONES: Los determinantes del riesgo de desnutrición son múltiples y diverso
s. Para establecer el RD se debe evaluar de forma intencionada la situación econ
ómica y social del adulto mayor, además de la información de salud y antropométr
ica tradicional.#^dnd^i1#^tm^les^kDesnutrición^i1#^tm^les^kalimentación^i1#^tm^l
es^kfactores de riesgo^i1#^tm^les^kanciano^i1#^tm^les^kMéxico^i1#^len^aOBJECTIVE
: To determine the psychosocial and health determinants associated with malnutri
tion risk (MR) among older adults living in the community of Mexico City, Mexico
. METHODS: This was a cross-sectional study. Secondary analysis was performed on
 the data of adults who were 60 or more years of age, living in the metropolitan
 area of Mexico city, and had participated in the multi-city study on Health, We
llbeing, and Aging in 1999 and 2000. Information on 820 participants was analyze
d (mean age 69.7 &plusmn; 7.6 years; 62.9 percent female). In addition to the MR
 (dependent variable) that was established through a basic nutrition evaluation,
 the following variables were analyzed: sociodemographics, body mass index, como
rbidity, symptoms of depression, oral health, mental function, functional capabi
lity, among others. Independent associations from among the variables and the MR
 were calculated by univariate and multivariate logistic regression analysis. Od
ds ratios (OR) and 95 percent confidence intervals (95 percentCI) were determine
d. RESULTS: MR was present in 261 (31.8 percent) participants. The univariate lo
gistic regression analysis adjusted for possible confounding variables showed th
at the following variables demonstrated significant and independent associations
 with MR among the study sample population: not having a pension (adjusted OR = 
1.45; 95 percentCI: 1.01 - 2.38); feeling that one did not have enough money to 
live on (adjusted OR = 2.52; 95 percentCI: 1.69 - 3.74); having osteoarthritis (
adjusted OR = 2.34; 95 percentCI: 1.42 - 3.85); having a low body mass index (ad
justed OR = 0.89; 95 percentCI: 0.85 - 0.93); having symptoms of depression (adj
usted OR = 5.41; 95 percentCI: 1.90 - 15.34); eating only once daily (adjusted O
R = 12.95; 95 percentCI: 5.19 - 32.28) or twice daily (adjusted OR = 3.27; 95 pe
rcentCI: 2.18 - 4.9); and having physical difficulty with getting to bed (adjust
ed OR = 3.25; CI 95 percent: 1.58 - 6.68), going out alone (adjusted OR = 2.70; 
CI 95 percent: 1.54 - 4.73), and using the telephone (adjusted OR = 1.95; CI 95 
percent: 1.10 - 3.43). CONCLUSIONS: There are multiple and various determinants 
of malnutrition risk. To determine MR, the older adult's financial and social si
tuation must be carefully evaluated along with the more traditional health and a
nthropometric information.#^dnd^i2#^tm^len^kElderly nutrition^i2#^tm^len^kmalnut
rition^i2#^tm^len^krisk factors^i2#^tm^len^kMexico^i2#other#48#20061017#17 de oc
tubre de 2006#20070801#1 de agosto de 2007#a01v22n6.htm#Internet^ihttp://www.sci
elosp.org/scielo.php?script=sci_arttext&pid=S1020-49892007001100001##
00354000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704012100074002001300195#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a01v22n6.htm#S#p#5#1#article#135#<p align="right"><fon
t size="2" face="Verdana"><b>INVESTIGACI&Oacute;N ORIGINAL</b> ORIGINAL RESEARCH
</font></p>     ^cY#a01v22n6.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a01v22n6.htm#S#p#6#2#article#135#<p>&nbsp;</p>     ^cY
#a01v22n6.htm##
00483000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704025000074002001300324#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a01v22n6.htm#S#p#7#3#article#135#<p><font size="4" fac
e="verdana"><b>Determinantes del riesgo de desnutrici&oacute;n    en los adultos
 mayores de la comunidad: an&aacute;lisis secundario del estudio    Salud, Biene
star y Envejecimiento (SABE) en M&eacute;xico</b></font></p>     ^cY#a01v22n6.ht
m##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a01v22n6.htm#S#p#8#4#article#135#<p>&nbsp;</p>     ^cY
#a01v22n6.htm##
00445000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704021200074002001300286#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a01v22n6.htm#S#p#9#5#article#135#<p><font size="3" fac
e="verdana"><b>Determinants of malnutrition risk among the    older adult commun
ity: a secondary analysis of the Health, Wellbeing, and Aging    Study (SABE) in
 Mexico</b></font></p>     ^cY#a01v22n6.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704002200075002001300097#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a01v22n6.htm#S#p#10#6#article#135#<p>&nbsp;</p>     ^c
Y#a01v22n6.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704002200075002001300097#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a01v22n6.htm#S#p#11#7#article#135#<p>&nbsp;</p>     ^c
Y#a01v22n6.htm##
00431000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704019700075002001300272#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a01v22n6.htm#S#p#12#8#article#135#<p><font size="2" fa
ce="Verdana"><b>Nubia Franco-&Aacute;lvarez; Jos&eacute; Alberto    &Aacute;vila
-Funes; Liliana Ruiz-Arregu&iacute;; Luis Miguel Guti&eacute;rrez-Robledo</b></f
ont></p>     ^cY#a01v22n6.htm##
00904000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704067000075002001300745#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a01v22n6.htm#S#p#13#9#article#135#<p><font size="2" fa
ce="Verdana">Cl&iacute;nica de Geriatr&iacute;a, Instituto    Nacional de Cienci
as M&eacute;dicas y Nutrici&oacute;n Salvador Zubir&aacute;n,    Ciudad de M&eac
ute;xico, M&eacute;xico. La correspondencia se debe dirigir a    Nubia Franco-&A
acute;lvarez, Cl&iacute;nica de Geriatr&iacute;a, Instituto Nacional    de Cienc
ias M&eacute;dicas y Nutrici&oacute;n Salvador Zubir&aacute;n, Vasco    de Quiro
ga No. 15, Tlalpan CP 14000, M&eacute;xico, D.F., M&eacute;xico. Tel&eacute;fono
:    52 (55) 54 87 09 00 ext. 2258. Correo electr&oacute;nico:<a href="mailto:nu
bia_franco_alvarez@yahoo.com.mx">nubia_franco_alvarez@yahoo.com.mx</a></font></p
>     ^cY#a01v22n6.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a01v22n6.htm#S#p#14#10#article#135#<p>&nbsp;</p>     ^
cY#a01v22n6.htm##
00279000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704004400076002001300120#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a01v22n6.htm#S#p#15#11#article#135#<p>&nbsp;</p> <hr s
ize="1" noshade>     ^cY#a01v22n6.htm##
00302000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704006700076002001300143#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a01v22n6.htm#S#p#16#12#article#135#<p><font size="2" f
ace="Verdana"><b>RESUMEN</b></font></p>     ^cY#a01v22n6.htm##
00508000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704027300076002001300349#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a01v22n6.htm#S#p#17#13#article#135#<p><font size="2" f
ace="Verdana"><B>OBJETIVO:</b>&nbsp;&nbsp;Determinar los factores    psicosocial
es y de salud asociados con el riesgo de desnutrici&oacute;n (RD)    en los adul
tos mayores que viven en la comunidad en la Ciudad de M&eacute;xico,    M&eacute
;xico.    ^cY#a01v22n6.htm##
01302000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704106700076002001301143#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a01v22n6.htm#S#p#18#14#article#135#<br>   <B>M&Eacute;
TODOS:</b>&nbsp;&nbsp;Estudio transversal. An&aacute;lisis secundario    de los 
datos de las personas de 60 a&ntilde;os o m&aacute;s de la zona metropolitana   
 de la Ciudad de M&eacute;xico participantes en el estudio multic&eacute;ntrico 
   Salud, Bienestar y Envejecimiento (SABE) realizado entre 1999 y 2000. Se util
iz&oacute;    la informaci&oacute;n de 820 participantes (edad media 69,7 &plusm
n; 7,6 a&ntilde;os;    62,9% mujeres). Adem&aacute;s del RD (variable dependient
e), establecido mediante    la evaluaci&oacute;n m&iacute;nima del estado nutric
ional, se analizaron otras    variables (sociodemogr&aacute;ficas, &iacute;ndice
 de masa corporal, comorbilidad,    s&iacute;ntomas depresivos, salud bucal, fun
ci&oacute;n mental, capacidad funcional,    entre otras). Se analizaron las asoc
iaciones independientes entre las variables    y el RD mediante an&aacute;lisis 
de regresi&oacute;n simple y multifactorial.    Se calcularon la raz&oacute;n de
 posibilidades (odds ratio, OR) y los intervalos    de confianza de 95% (IC95%).
    ^cY#a01v22n6.htm##
01373000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704113800076002001301214#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a01v22n6.htm#S#p#19#15#article#135#<br>   <B>RESULTADO
S:</b>&nbsp;&nbsp;El RD estuvo presente en 261 (31,8%) participantes.    El an&a
acute;lisis de regresi&oacute;n log&iacute;stica multifactorial ajustado    por 
posibles variables confusoras mostr&oacute; que el no recibir una jubilaci&oacut
e;n    (OR ajustada = 1,45; IC95%: 1,01 a 2,38), la percepci&oacute;n de no tene
r el    suficiente dinero para vivir (OR ajustada = 2,52; IC95%: 1,69 a 3,74), t
ener    artrosis (OR ajustada = 2,34; IC95%: 1,42 a 3,85), tener menor &iacute;n
dice    de masa corporal (OR ajustada = 0,89; IC95%: 0,85 a 0,93 ), la presencia
 de    s&iacute;ntomas depresivos (OR ajustada = 5,41; IC95%: 1,90 a 15,34), el 
hacer    s&oacute;lo una (OR ajustada = 12,95; IC95%: 5,19 a 32,28) o dos comida
s al    d&iacute;a (OR ajustada = 3,27; IC95%: 2,18 a 4,9) y el tener dificultad
es para    acostarse solo (OR ajustada = 3,25; IC95%: 1,58 a 6,68), salir solo (
OR ajustada    = 2,70; IC95%: 1,54 a 4,73) y utilizar el tel&eacute;fono (OR aju
stada = 1,95;    IC95%: 1,10 a 3,43) mostraron asociaci&oacute;n significativa e
 independiente    con el RD en la muestra de adultos mayores estudiada.    ^cY#a
01v22n6.htm##
00596000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704036100076002001300437#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a01v22n6.htm#S#p#20#16#article#135#<br>   <B>CONCLUSIO
NES:</b>&nbsp;&nbsp;Los determinantes del riesgo de desnutrici&oacute;n    son m
&uacute;ltiples y diversos. Para establecer el RD se debe evaluar de forma    in
tencionada la situaci&oacute;n econ&oacute;mica y social del adulto mayor,    ad
em&aacute;s de la informaci&oacute;n de salud y antropom&eacute;trica tradiciona
l.</font></p>     ^cY#a01v22n6.htm##
00421000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704018600076002001300262#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a01v22n6.htm#S#p#21#17#article#135#<p><font size="2" f
ace="Verdana"><b>Palabras clave: </b>Desnutrici&oacute;n, alimentaci&oacute;n,  
  factores de riesgo, anciano, M&eacute;xico.</font></p> <hr size="1" noshade>  
   ^cY#a01v22n6.htm##
00303000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704006800076002001300144#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a01v22n6.htm#S#p#22#18#article#135#<p><font size="2" f
ace="Verdana"><b>ABSTRACT</b></font></p>     ^cY#a01v22n6.htm##
00464000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704022900076002001300305#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a01v22n6.htm#S#p#23#19#article#135#<p><font size="2" f
ace="Verdana"><B>OBJECTIVE:</b>&nbsp;To determine the psychosocial    and health
 determinants associated with malnutrition risk (MR) among older adults    livin
g in the community of Mexico City, Mexico.    ^cY#a01v22n6.htm##
01151000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704091600076002001300992#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a01v22n6.htm#S#p#24#20#article#135#<br>   <B>METHODS:<
/b>&nbsp;This was a cross-sectional study. Secondary analysis was    performed o
n the data of adults who were 60 or more years of age, living in    the metropol
itan area of Mexico city, and had participated in the multi-city    study on Hea
lth, Wellbeing, and Aging in 1999 and 2000. Information on 820 participants    w
as analyzed (mean age 69.7 &plusmn; 7.6 years; 62.9% female). In addition to the
 MR    (dependent variable) that was established through a basic nutrition evalu
ation,    the following variables were analyzed: sociodemographics, body mass in
dex, comorbidity,    symptoms of depression, oral health, mental function, funct
ional capability,    among others. Independent associations from among the varia
bles and the MR were    calculated by univariate and multivariate logistic regre
ssion analysis. Odds    ratios (OR) and 95% confidence intervals (95%CI) were de
termined.    ^cY#a01v22n6.htm##
01280000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704104500076002001301121#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a01v22n6.htm#S#p#25#21#article#135#<br>   <B>RESULTS:<
/b>&nbsp;MR was present in 261 (31.8%) participants. The univariate    logistic 
regression analysis adjusted for possible confounding variables showed    that t
he following variables demonstrated significant and independent associations    
with MR among the study sample population: not having a pension (adjusted OR    
= 1.45; 95%CI: 1.01 – 2.38); feeling that one did not have enough money to live 
   on (adjusted OR = 2.52; 95%CI: 1.69 – 3.74); having osteoarthritis (adjusted 
   OR = 2.34; 95%CI: 1.42 – 3.85); having a low body mass index (adjusted OR =  
  0.89; 95%CI: 0.85 – 0.93); having symptoms of depression (adjusted OR = 5.41; 
   95%CI: 1.90 – 15.34); eating only once daily (adjusted OR = 12.95; 95%CI: 5.1
9    – 32.28) or twice daily (adjusted OR = 3.27; 95%CI: 2.18 – 4.9); and having
    physical difficulty with getting to bed (adjusted OR = 3.25; CI 95%: 1.58 – 
   6.68), going out alone (adjusted OR = 2.70; CI 95%: 1.54 – 4.73), and using  
  the telephone (adjusted OR = 1.95; CI 95%: 1.10 – 3.43).    ^cY#a01v22n6.htm##
00526000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704029100076002001300367#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a01v22n6.htm#S#p#26#22#article#135#<br>   <B>CONCLUSIO
NS:</b>&nbsp;There are multiple and various determinants of malnutrition    risk
. To determine MR, the older adult's financial and social situation must    be c
arefully evaluated along with the more traditional health and anthropometric    
information.</font></p>     ^cY#a01v22n6.htm##
00386000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704015100076002001300227#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a01v22n6.htm#S#p#27#23#article#135#<p><font size="2" f
ace="Verdana"><b>Key words: </b>Elderly nutrition, malnutrition,    risk factors
, Mexico. </font></p> <hr size="1" noshade>     ^cY#a01v22n6.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a01v22n6.htm#S#p#28#24#article#135#<p>&nbsp;</p>     ^
cY#a01v22n6.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a01v22n6.htm#S#p#29#25#article#135#<p>&nbsp;</p>     ^
cY#a01v22n6.htm##
01409000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704117400076002001301250#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a01v22n6.htm#S#p#30#26#article#135#<p><font size="2" f
ace="Verdana">En los &uacute;ltimos a&ntilde;os, la estructura    de la poblaci&
oacute;n de M&eacute;xico y el mundo se ha transformado aceleradamente.    El au
mento de la poblaci&oacute;n de adultos mayores ha provocado el inter&eacute;s  
  de los investigadores en identificar los factores que pueden condicionar un   
 envejecimiento saludable y con buena cali-dad de vida (1–4). El estado nutricio
nal    adecuado, entre otros factores, es un componente fundamental para la cons
ervaci&oacute;n    de la autonom&iacute;a funcional de los adultos mayores. La d
esnutrici&oacute;n    —como estado patol&oacute;gico caracterizado por la falta 
de aportes adecuados    de energ&iacute;a y nutrientes acordes con las necesidad
es biol&oacute;gicas—    afecta a la salud en general de las personas, especialm
ente de los adultos mayores    por su mayor vulnerabilidad (3). Es as&iacute; qu
e la evaluaci&oacute;n del    riesgo de desnutrici&oacute;n (RD) puede contribui
r a predecir de forma independiente    la p&eacute;rdida funcional, los estados 
depresivos y la mala calidad de vida    de este importante sector de la poblaci&
oacute;n (5–8).</font></p>     ^cY#a01v22n6.htm##
00633000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704039800076002001300474#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a01v22n6.htm#S#p#31#27#article#135#<p><font size="2" f
ace="Verdana">Por diferentes causas, los adultos mayores son    un grupo demogr&
aacute;fico con alto riesgo de desnutrici&oacute;n (9). En Am&eacute;rica    Lat
ina, la prevalencia de desnutrici&oacute;n en adultos mayores que viven en    la
 comunidad var&iacute;a entre 4,6% y 18,0%, mientras que en los hospitalizados  
  asciende a m&aacute;s de 50% (10–14).</font></p>     ^cY#a01v22n6.htm##
01590000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704135500076002001301431#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a01v22n6.htm#S#p#32#28#article#135#<p><font size="2" f
ace="Verdana">No obstante, es dif&iacute;cil establecer con    precisi&oacute;n 
y oportunamente el riesgo de desnutrici&oacute;n de los adultos    mayores, por 
lo que se han utilizado diversos m&eacute;todos para su diagn&oacute;stico    y 
para estimar sus factores de riesgo, como el c&aacute;lculo del &iacute;ndice   
 de masa corporal (IMC), algunas mediciones antropom&eacute;tricas (per&iacute;m
etros,    circunferencias, etc.) y varios par&aacute;metros bioqu&iacute;micos (
nivel    s&eacute;rico de alb&uacute;mina, etc.) (15). Sin embargo, la interpret
aci&oacute;n    de los indicadores resultantes no es sencilla. En el IMC influye
n, por ejemplo,    los cambios que ocurren en la composici&oacute;n corporal del
 anciano, los que    muchas veces hacen que el IMC sea poco representativo del e
stado nutricional    real (16–19). Uno de los instrumentos m&aacute;s confiables
 para estimar de    manera r&aacute;pida el estado nutricional de los adultos ma
yores es la evaluaci&oacute;n    m&iacute;nima del estado nutricional (EMEN). Es
ta evaluaci&oacute;n consta de    cuatro apartados que abordan los datos antropo
m&eacute;tricos de la persona,    la evaluaci&oacute;n general de su salud, los 
par&aacute;metros diet&eacute;ticos    y la valoraci&oacute;n subjetiva del esta
do de salud y nutrici&oacute;n (20).</font></p>     ^cY#a01v22n6.htm##
01826000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704159100076002001301667#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a01v22n6.htm#S#p#33#29#article#135#<p><font size="2" f
ace="Verdana">Los adultos mayores constituyen un sector muy    heterog&eacute;ne
o de la poblaci&oacute;n y son m&uacute;ltiples los factores    f&iacute;sicos, 
materiales, psicol&oacute;gicos y sociales que pueden influir    en su aporte nu
tricional. Esos factores interact&uacute;an con otros elementos    que determina
n la compra, la preparaci&oacute;n y el consumo de las comidas    y el desequili
brio en alguno de esos factores y elementos puede llevar al adulto    mayor a la
 desnutrici&oacute;n (21). Ese desequilibrio puede deberse a cambios    en los s
istemas del organismo y las funciones fisiol&oacute;gicas asociados    con el en
vejecimiento (como la disminuci&oacute;n en la producci&oacute;n de    saliva, l
os cambios en la percepci&oacute;n de los sabores y en el vaciamiento    g&aacut
e;strico, entre otros), el consumo de medicamentos y las enfermedades    cr&oacu
te;nicas (diabetes, artrosis, etc.) (22–26). Algunos factores psicosociales,    
como vivir solo, contar con una red de apoyo social deficiente y tener dificulta
des    econ&oacute;micas para obtener los alimentos, tambi&eacute;n est&aacute;n
 asociados    con el RD (27–29). Durante la evaluaci&oacute;n cl&iacute;nica de 
los adultos    mayores, muchas veces se minimiza la importancia de estos factore
s psicosociales,    lo que impide tener una visi&oacute;n m&aacute;s amplia de l
os elementos que    determinan el estado nutricional de estos pacientes y establ
ecer las medidas    preventivas necesarias para evitar las enfermedades relacion
adas con la desnutrici&oacute;n.</font></p>     ^cY#a01v22n6.htm##
00494000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704025900076002001300335#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a01v22n6.htm#S#p#34#30#article#135#<p><font size="2" f
ace="Verdana">El objetivo del presente trabajo fue determinar    los factores ps
icosociales y de salud asociados con el RD en los adultos mayores    que viven e
n la comunidad en la Ciudad de M&eacute;xico, M&eacute;xico.</font></p>     ^cY#
a01v22n6.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a01v22n6.htm#S#p#35#31#article#135#<p>&nbsp;</p>     ^
cY#a01v22n6.htm##
00322000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704008700076002001300163#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a01v22n6.htm#S#p#36#32#article#135#<p><font size="3" f
ace="Verdana"><b>MATERIALES Y M&Eacute;TODOS</b></font></p>     ^cY#a01v22n6.htm
##
01893000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704165800076002001301734#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a01v22n6.htm#S#p#37#33#article#135#<p><font size="2" f
ace="Verdana">Este trabajo es un an&aacute;lisis secundario    de los datos de l
as personas de 60 a&ntilde;os o m&aacute;s de la zona metropolitana    de la de 
Ciudad de M&eacute;xico participantes en el estudio multic&eacute;ntrico    Salu
d, Bienestar y Envejecimiento (SABE). En ese estudio transversal multinacional  
  realizado entre 1999 y 2000 se investigaron las condiciones de salud de los   
 adultos mayores en siete ciudades de Am&eacute;rica Latina y el Caribe: Bridget
own,    Barbados; Buenos Aires, Argentina; Ciudad de La Habana, Cuba; Ciudad de 
M&eacute;xico,    M&eacute;xico; Montevideo, Uruguay; Santiago, Chile; y S&atild
e;o Paulo, Brasil.    Los detalles del estudio se publicaron con anterioridad y 
est&aacute;n disponibles    en Internet (30). El objetivo principal del proyecto
 SABE fue describir las    condiciones de salud de los adultos mayores y su rela
ci&oacute;n con las enfermedades    agudas y cr&oacute;nicas, la discapacidad y 
el deterioro f&iacute;sico y mental.    En esa investigaci&oacute;n tambi&eacute
;n se evalu&oacute; el grado de acceso    y uso de los servicios de salud y se c
ompararon el apoyo familiar, la asistencia    p&uacute;blica, el acceso a los se
rvicios y los comportamientos saludables en    las ciudades estudiadas. Adem&aac
ute;s de las variables sociodemogr&aacute;ficas    habituales, la encuesta recab
&oacute; informaci&oacute;n sobre el estado cognoscitivo,    la situaci&oacute;n
 de salud, el estado funcional, los h&aacute;bitos alimentarios    y el uso de y
 el acceso a los servicios de salud por parte de los adultos mayores    de las c
iudades estudiadas.</font></p>     ^cY#a01v22n6.htm##
01447000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704121200076002001301288#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a01v22n6.htm#S#p#38#34#article#135#<p><font size="2" f
ace="Verdana">En el caso espec&iacute;fico de M&eacute;xico,    se seleccionaron
 aleatoriamente personas mayores de 60 a&ntilde;os y una muestra    adicional de
 mujeres mayores de 50 a&ntilde;os que viv&iacute;an en la zona    metropolitana
 de M&eacute;xico, D.F. (pero que no formaron parte de la muestra    empleada en
 el presente an&aacute;lisis). Para ello se sigui&oacute; un muestreo    en tres
 etapas por conglomerados, con estratificaci&oacute;n de los niveles    m&aacute
;s altos de agregaci&oacute;n. Los participantes se identificaron a    partir de
 la Encuesta de Hogares, del Instituto Nacional de Estad&iacute;stica,    Geogra
f&iacute;a e Inform&aacute;tica. La tasa de respuesta en M&eacute;xico,    D.F.,
 fue de 83,7%. En 5,9% de las 1 876 entrevistas logradas, las respuestas    las 
dieron informantes sustitutos de la persona seleccionada (c&oacute;nyuge    o pa
riente que viv&iacute;a con ella). Toda la informaci&oacute;n recolectada,    ex
cepto las medidas antropom&eacute;tricas (peso, talla y circunferencia de    la 
cintura y la cadera), se obtuvieron a partir del autoinforme de los encuestados 
   o de las respuestas de los informantes sustitutos.</font></p>     ^cY#a01v22n
6.htm##
00338000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010300076002001300179#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a01v22n6.htm#S#p#39#35#article#135#<p><font size="2" f
ace="Verdana"><b>Variables e instrumentos de medici&oacute;n</b></font></p>     
^cY#a01v22n6.htm##
00465000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704023000076002001300306#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a01v22n6.htm#S#p#40#36#article#135#<p><font size="2" f
ace="Verdana">Adem&aacute;s de la informaci&oacute;n sociodemogr&aacute;fica    
necesaria para describir la muestra (edad, sexo, escolaridad, etc.), se estudiar
on    las siguientes variables:</font></p>     ^cY#a01v22n6.htm##
00610000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704037500076002001300451#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a01v22n6.htm#S#p#41#37#article#135#<p><font size="2" f
ace="Verdana"><B>Riesgo de desnutrici&oacute;n (RD). </b>Se    consider&oacute; 
que hab&iacute;a RD cuando el resultado de la EMEN fue menor    de 23,5 (de los 
30 puntos posibles). Con este punto de corte se puede lograr    una sensibilidad
 de 96% y una especificidad de 98% en la detecci&oacute;n del    RD de los adult
os mayores (20).</font></p>     ^cY#a01v22n6.htm##
00485000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704025000076002001300326#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a01v22n6.htm#S#p#42#38#article#135#<p><font size="2" f
ace="Verdana"><B>&Iacute;ndice de masa corporal (IMC). </b>Se    calcul&oacute; 
a partir del peso en kilogramos dividido entre la talla expresada    en metros c
uadrados. Se utiliz&oacute; como variable continua.</font></p>     ^cY#a01v22n6.
htm##
00779000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704054400076002001300620#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a01v22n6.htm#S#p#43#39#article#135#<p><font size="2" f
ace="Verdana"><B>Comorbilidad. </b>Se consider&oacute; la suma    de siete enfer
medades cr&oacute;nicas (diabetes mellitus, hipertensi&oacute;n    arterial, enf
ermedad pulmonar obstructiva cr&oacute;nica, artrosis, cardiopat&iacute;a    isq
u&eacute;mica, enfermedad cerebrovascular y osteoporosis) como variable continua
.    La declaraci&oacute;n de glaucoma, cataratas, ca&iacute;das y fracturas de 
cadera    o de mu&ntilde;eca se consideraron como variables dicot&oacute;micas (
presencia    o ausencia).</font></p>     ^cY#a01v22n6.htm##
00816000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704058100076002001300657#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a01v22n6.htm#S#p#44#40#article#135#<p><font size="2" f
ace="Verdana"><B>S&iacute;ntomas depresivos.</b> Los s&iacute;ntomas    depresiv
os se evaluaron mediante la escala de depresi&oacute;n geri&aacute;trica    de Y
esavage en su versi&oacute;n de 15 enunciados (31). En esta escala, los    parti
cipantes deb&iacute;an responder "s&iacute;" o "no"    a las preguntas sobre su 
estado de &aacute;nimo en las &uacute;ltimas dos semanas.    El punto de corte p
ara considerar que hab&iacute;a s&iacute;ntomas depresivos    fue la respuesta a
firmativa en al menos 6 de las 15 preguntas (? 6 puntos) (32).</font></p>     ^c
Y#a01v22n6.htm##
00819000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704058400076002001300660#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a01v22n6.htm#S#p#45#41#article#135#<p><font size="2" f
ace="Verdana"><B>Salud bucal.</b> El &iacute;ndice de valoraci&oacute;n    de la
 salud bucal geri&aacute;trica (<I>Geriatric Oral Health Assessment Index</I>)  
  se utiliz&oacute; para cuantificar la necesidad de atenci&oacute;n odontol&oac
ute;gica    del adulto mayor a partir del autoinforme de su estado de salud buca
l en los    &uacute;ltimos 12 meses. La puntuaci&oacute;n m&aacute;xima era de 6
0 y una    respuesta negativa en 3 de los 12 enunciados de la encuesta (&lt; 45 
puntos)    indicaba que la salud bucal no era satisfactoria (33).</font></p>    
 ^cY#a01v22n6.htm##
00797000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704056200076002001300638#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a01v22n6.htm#S#p#46#42#article#135#<p><font size="2" f
ace="Verdana"><B>Funci&oacute;n mental.</b> Se evalu&oacute;    mediante una ver
si&oacute;n abreviada del examen m&iacute;nimo del estado mental    (<I>Mini Men
tal State Examination,</I> EMEM) de Folstein y colaboradores (34,    35). La pun
tuaci&oacute;n m&aacute;xima posible era de 19 y un total por debajo    de 13 in
dicaba que la persona presentaba deterioro cognoscitivo. La sensibilidad    del 
EMEM en la detecci&oacute;n del deterioro cognoscitivo var&iacute;a entre    82%
 y 94% y su especificidad, entre 94% y 99%.</font></p>     ^cY#a01v22n6.htm##
01077000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704084200076002001300918#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a01v22n6.htm#S#p#47#43#article#135#<p><font size="2" f
ace="Verdana"><B>Capacidad funcional.</b> Se utiliz&oacute;    el &iacute;ndice 
de Katz o de actividades b&aacute;sicas de la vida diaria (36)    para evaluar l
a capacidad de realizar sin ayuda seis funciones b&aacute;sicas:    ba&ntilde;ar
se, vestirse, usar el sanitario, trasladarse dentro del hogar, controlar    los 
esf&iacute;nteres y alimentarse. Este &iacute;ndice es un m&eacute;todo    objet
ivo para clasificar a grupos heterog&eacute;neos de personas con enfermedades   
 cr&oacute;nicas y discapacidades, as&iacute; como para describir sus necesidade
s    de salud y su evoluci&oacute;n. Con un puntaje m&aacute;ximo posible de 6 p
untos    (respuesta positiva a las 6 preguntas), se consider&oacute; que la p&ea
cute;rdida    de al menos una funci&oacute;n reflejaba cierto grado de dependenc
ia.</font></p>     ^cY#a01v22n6.htm##
00638000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704040300076002001300479#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a01v22n6.htm#S#p#48#44#article#135#<p><font size="2" f
ace="Verdana"><B>Otras actividades.</b> Se explor&oacute; como    variable dicot
&oacute;mica la dificultad para correr o caminar una o varias    calles, subir u
no o varios pisos por las escaleras, estar sentado m&aacute;s    de 2 horas, aga
charse, halar o empujar un objeto, utilizar el tel&eacute;fono,    levantar los 
brazos y las piernas, y levantar una moneda.</font></p>     ^cY#a01v22n6.htm##
00535000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704030000076002001300376#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a01v22n6.htm#S#p#49#45#article#135#<p><font size="2" f
ace="Verdana"><B>Situaci&oacute;n econ&oacute;mica y social.    </b>Se analiz&oa
cute; si el participante recib&iacute;a o no una pensi&oacute;n,    si viv&iacut
e;a solo, si ten&iacute;a vivienda y si consideraba que ten&iacute;a    dinero s
uficiente para vivir.</font></p>     ^cY#a01v22n6.htm##
00463000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704022800076002001300304#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a01v22n6.htm#S#p#50#46#article#135#<p><font size="2" f
ace="Verdana"><B>Otras variables.</b> Se pregunt&oacute; el    n&uacute;mero de 
comidas hechas al d&iacute;a, como variable categ&oacute;rica    (menos de una, 
de dos a tres, o m&aacute;s).</font></p>     ^cY#a01v22n6.htm##
00329000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009400076002001300170#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a01v22n6.htm#S#p#51#47#article#135#<p><font size="2" f
ace="Verdana"><b>An&aacute;lisis estad&iacute;stico</b></font></p>     ^cY#a01v2
2n6.htm##
02141000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704190600076002001301982#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a01v22n6.htm#S#p#52#48#article#135#<p><font size="2" f
ace="Verdana">Para describir la muestra se calcularon la media    y la desviaci&
oacute;n est&aacute;ndar de las variables continuas y la frecuencia    y el porc
entaje de las variables categ&oacute;ricas. Inicialmente se emplearon    las pru
ebas de la t de Student y de la ji al cuadrado, seg&uacute;n el tipo    de varia
ble, para comparar los grupos con RD y sin RD (variable dependiente)    en un an
&aacute;lisis simple. Las variables que mostraron una asociaci&oacute;n    signi
ficativa con el RD se probaron de manera individual en modelos de regresi&oacute
;n    log&iacute;stica bifactoriales para demostrar si esa asociaci&oacute;n era
 independiente.    Posteriormente, se elaboraron diversos modelos de regresi&oac
ute;n por grupos    de variables —por ejemplo, sociodemogr&aacute;ficas o de act
ividades de la vida    diaria—, y las que resultaron significativas se utilizaro
n en un an&aacute;lisis    de regresi&oacute;n log&iacute;stica multifactorial p
ara identificar las variables    asociadas de forma independiente con el RD. Est
e &uacute;ltimo modelo se ajust&oacute;    por posibles variables de confusi&oac
ute;n. Mediante el an&aacute;lisis residual    y la prueba de Hosmer-Lemeshow (3
7, 38) se verific&oacute; el respeto de los    postulados de base asumidos en la
 validez de la regresi&oacute;n log&iacute;stica,    as&iacute; como el buen aju
ste del modelo. Se calcularon la raz&oacute;n de    posibilidades (odds ratio, O
R) y los intervalos de confianza de 95% (IC95%).    Se utiliz&oacute; el nivel d
e significaci&oacute;n estad&iacute;stica P &lt;    0,05, excepto en la construc
ci&oacute;n del modelo final, donde se emple&oacute;    un criterio m&aacute;s r
iguroso (P &lt; 0,01). Para todos los an&aacute;lisis    se utiliz&oacute; el pa
quete estad&iacute;stico SPSS versi&oacute;n 13.0 para    Windows<SUP>&reg;</SUP
> (SPSS Inc., Chicago, IL).</font></p>     ^cY#a01v22n6.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a01v22n6.htm#S#p#53#49#article#135#<p>&nbsp;</p>     ^
cY#a01v22n6.htm##
00305000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704007000076002001300146#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a01v22n6.htm#S#p#54#50#article#135#<p><font size="3" f
ace="Verdana"><b>RESULTADOS</b></font></p>     ^cY#a01v22n6.htm##
00962000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704072700076002001300803#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a01v22n6.htm#S#p#55#51#article#135#<p><font size="2" f
ace="Verdana">De 1 876 entrevistas realizadas en el estudio    SABE correspondie
nte a M&eacute;xico, D.F., 820 (43,7%) contaban con la informaci&oacute;n    com
pleta del EMEN y constituyeron la muestra de estudio. El promedio de edad    fue
 de 69,7 &plusmn; 7,6 a&ntilde;os (m&iacute;nima: 60 a&ntilde;os; m&aacute;xima:
    97 a&ntilde;os); 516 (62,9%) eran mujeres y 304 (37,1%) eran hombres. Las en
fermedades    cr&oacute;nicas m&aacute;s frecuentes fueron la hipertensi&oacute;
n arterial    (48,5%), la artrosis (36,3%) y la diabetes mellitus (27,0%). Las c
aracter&iacute;sticas    generales de la muestra se presentan en los <a href="#q
dr01">cuadros 1</a> y    <a href="#qdr02">2</a>.</font></p>     ^cY#a01v22n6.htm
##
00271000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704003600076002001300112#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a01v22n6.htm#S#p#56#52#article#135#<p><a name="qdr01">
</a></p>     ^cY#a01v22n6.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a01v22n6.htm#S#p#57#53#article#135#<p>&nbsp;</p>     ^
cY#a01v22n6.htm##
00315000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704008000076002001300156#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a01v22n6.htm#S#p#58#54#article#135#<p align="center"><
img src="/img/revistas/rpsp/v22n6/a01cdr01.gif"></p>     ^cY#a01v22n6.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a01v22n6.htm#S#p#59#55#article#135#<p>&nbsp;</p>     ^
cY#a01v22n6.htm##
00271000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704003600076002001300112#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a01v22n6.htm#S#p#60#56#article#135#<p><a name="qdr02">
</a></p>     ^cY#a01v22n6.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a01v22n6.htm#S#p#61#57#article#135#<p>&nbsp;</p>     ^
cY#a01v22n6.htm##
00315000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704008000076002001300156#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a01v22n6.htm#S#p#62#58#article#135#<p align="center"><
img src="/img/revistas/rpsp/v22n6/a01cdr02.gif"></p>     ^cY#a01v22n6.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a01v22n6.htm#S#p#63#59#article#135#<p>&nbsp;</p>     ^
cY#a01v22n6.htm##
01385000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704115000076002001301226#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a01v22n6.htm#S#p#64#60#article#135#<p><font size="2" f
ace="Verdana">En general, 261 participantes (31,8%) presentaban    RD. En compar
aci&oacute;n con el grupo sin RD, en el grupo con riesgo hubo un    n&uacute;mer
o significativamente mayor de participantes que no asistieron a    la escuela (<
I>P</I> &lt; 0,01), que no recib&iacute;an una pensi&oacute;n (<I>P</I>    &lt; 
0,01) y que informaron no tener suficiente dinero para vivir (<I>P</I>    &lt; 0
,01) (<a href="#qdr03">cuadro 3</a>). Tambi&eacute;n informaron un mayor    n&ua
cute;mero de enfermedades cr&oacute;nicas con respecto al grupo de participantes
    sin RD, aunque la diferencia no fue significativa (<I>P</I> = 0,10). En el g
rupo    con RD hubo m&aacute;s personas con mala salud bucal (<I>P</I> &lt; 0,01
), deterioro    cognoscitivo (<I>P</I> &lt; 0,01) y s&iacute;ntomas depresivos (
<I>P</I> &lt;    0,01) que en el grupo sin RD. En contraste, en el grupo sin RD 
hab&iacute;a    significativamente menos personas que sufrieron ca&iacute;das (<
I>P</I> &lt;    0,01) y que informaron tener dificultad para la realizaci&oacute
;n de las actividades    f&iacute;sicas evaluadas (<I>P</I> &lt; 0,01).</font></
p>     ^cY#a01v22n6.htm##
00271000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704003600076002001300112#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a01v22n6.htm#S#p#65#61#article#135#<p><a name="qdr03">
</a></p>     ^cY#a01v22n6.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a01v22n6.htm#S#p#66#62#article#135#<p>&nbsp;</p>     ^
cY#a01v22n6.htm##
00315000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704008000076002001300156#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a01v22n6.htm#S#p#67#63#article#135#<p align="center"><
img src="/img/revistas/rpsp/v22n6/a01cdr03.gif"></p>     ^cY#a01v22n6.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a01v22n6.htm#S#p#68#64#article#135#<p>&nbsp;</p>     ^
cY#a01v22n6.htm##
01484000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704124900076002001301325#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a01v22n6.htm#S#p#69#65#article#135#<p><font size="2" f
ace="Verdana">Mediante el an&aacute;lisis multifactorial se    comprob&oacute; q
ue, aun despu&eacute;s de ajustar por posibles variables confusoras    (la edad,
 el sexo, la presencia de deterioro cognoscitivo y el n&uacute;mero    de enferm
edades cr&oacute;nicas), el no recibir una jubilaci&oacute;n (OR ajustada    = 1
,45; IC95%: 1,01 a 2,38), la percepci&oacute;n de no tener el suficiente    dine
ro para vivir (OR ajustada = 2,52; IC95%: 1,69 a 3,74), tener artrosis (OR    aj
ustada = 2,34; IC95%: 1,42 a 3,85), tener menor &iacute;ndice de masa corporal  
  (OR ajustada = 0,89; IC95%: 0,85 a 0,93 ), la presencia de s&iacute;ntomas dep
resivos    (OR ajustada = 5,41; IC95%: 1,90 a 15,34), el hacer s&oacute;lo una (
OR ajustada    = 12,95; IC95%: 5,19 a 32,28) o dos comidas al d&iacute;a (OR aju
stada = 3,27;    IC95%: 2,18 a 4,9) y el tener dificultades para acostarse solo 
(OR ajustada    = 3,25; IC95%: 1,58 a 6,68), para salir solo (OR ajustada = 2,70
; IC95%: 1,54    a 4,73) y para utilizar el tel&eacute;fono (OR ajustada = 1,95;
 IC95%: 1,10    a 3,43) mostraron asociaci&oacute;n significativa e independient
e con el RD    en la muestra de adultos mayores estudiada (<a href="#qdr04">cuad
ro 4</a>).</font></p>     ^cY#a01v22n6.htm##
00271000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704003600076002001300112#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a01v22n6.htm#S#p#70#66#article#135#<p><a name="qdr04">
</a></p>     ^cY#a01v22n6.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a01v22n6.htm#S#p#71#67#article#135#<p>&nbsp;</p>     ^
cY#a01v22n6.htm##
00315000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704008000076002001300156#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a01v22n6.htm#S#p#72#68#article#135#<p align="center"><
img src="/img/revistas/rpsp/v22n6/a01cdr04.gif"></p>     ^cY#a01v22n6.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a01v22n6.htm#S#p#73#69#article#135#<p>&nbsp;</p>     ^
cY#a01v22n6.htm##
00446000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704021100076002001300287#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a01v22n6.htm#S#p#74#70#article#135#<p><font size="2" f
ace="Verdana">Finalmente, los resultados del an&aacute;lisis    de residuos y de
 la prueba de Hosmer-Lemeshow demostraron el buen ajuste del    modelo (<I>P</I>
 &gt; 0,05).</font></p>     ^cY#a01v22n6.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a01v22n6.htm#S#p#75#71#article#135#<p>&nbsp;</p>     ^
cY#a01v22n6.htm##
00311000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704007600076002001300152#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a01v22n6.htm#S#p#76#72#article#135#<p><font size="3" f
ace="Verdana"><b>DISCUSI&Oacute;N</b></font></p>     ^cY#a01v22n6.htm##
00972000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704073700076002001300813#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a01v22n6.htm#S#p#77#73#article#135#<p><font size="2" f
ace="Verdana">El estado nutricional de los adultos mayores    es particularmente
 importante debido a su influencia en la capacidad funcional    (39). La desnutr
ici&oacute;n tiene una grave repercusi&oacute;n sobre la salud    de estas perso
nas y puede llevarlas a la p&eacute;rdida de su capacidad funcional,    a la dep
resi&oacute;n y a una mala calidad de vida. Este estudio confirm&oacute;    la g
ran diversidad de los factores asociados con el RD en los adultos mayores    y p
uso de manifiesto lo dif&iacute;cil que puede resultar que intervenciones    ais
ladas prevengan o corrijan esta situaci&oacute;n de riesgo en la que vive    una
 gran parte de este sensible grupo de la poblaci&oacute;n.</font></p>     ^cY#a0
1v22n6.htm##
01267000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704103200076002001301108#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a01v22n6.htm#S#p#78#74#article#135#<p><font size="2" f
ace="Verdana">En un estudio realizado con 145 canadienses de    60 a 94 a&ntilde
;os de edad que recib&iacute;an cuidados a domicilio, Payette    y colaboradores
 encontraron que las personas que presentaban dependencia para    realizar las a
ctividades de la vida diaria y las que hab&iacute;an sufrido recientemente    ev
entos estresantes ten&iacute;an una baja ingesta de calor&iacute;as, poco    ape
tito, disminuci&oacute;n de la agudeza visual o padec&iacute;an enfermedades    
cr&oacute;nicas como artrosis, diabetes e hipertensi&oacute;n arterial (21).    
A pesar de las diferencias culturales y socioecon&oacute;micas existentes entre 
   los participantes en ese estudio y los de la presente investigaci&oacute;n,  
  en ambos casos se comprob&oacute; la asociaci&oacute;n significativa entre las
    dificultades para realizar las actividades de la vida diaria, las enfermedad
es    cr&oacute;nicas (como la artrosis) y la baja ingesta de alimentos, por una
 parte,    con el RD por la otra.</font></p>     ^cY#a01v22n6.htm##
01098000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704086300076002001300939#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a01v22n6.htm#S#p#79#75#article#135#<p><font size="2" f
ace="Verdana">La artrosis result&oacute; un determinante independiente    del RD
. Esta enfermedad reum&aacute;tica —la m&aacute;s frecuente en los adultos    ma
yores— provoca dolor y deformaciones articulares que generan dificultades    par
a la obtenci&oacute;n, preparaci&oacute;n e ingesti&oacute;n de los alimentos   
 (21, 40). Tanto la artrosis como otras enfermedades cr&oacute;nico-degenerativa
s,    como la hipertensi&oacute;n arterial y la diabetes, afectan a la capacidad
 funcional    de los adultos mayores y los pueden llevar a la discapacidad parci
al o total.    La discapacidad, por su parte, influye negativamente en el desemp
e&ntilde;o    de las actividades de la vida diaria, la estabilidad econ&oacute;m
ica y el estado    emocional (5, 8), lo que aumenta aun m&aacute;s el RD de los 
adultos mayores    (21).</font></p>     ^cY#a01v22n6.htm##
01144000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704090900076002001300985#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a01v22n6.htm#S#p#80#76#article#135#<p><font size="2" f
ace="Verdana">Los s&iacute;ntomas depresivos tambi&eacute;n    favorecen el RD p
or su asociaci&oacute;n con la p&eacute;rdida del apetito y    de peso. Adem&aac
ute;s, diversos estudios han demostrado la asociaci&oacute;n    que existe entre
 algunos factores psicosociales y el estado nutricional (41,    42). Si bien la 
EMEM analiza la presencia de "problemas psiqui&aacute;tricos"    o "estr&eacute;
s psicol&oacute;gico" —lo que pudo haber influido en    la variable "presencia d
e s&iacute;ntomas depresivos" en el modelo    final—, en la encuesta SABE esta v
ariable se midi&oacute; mediante la escala    de depresi&oacute;n geri&aacute;tr
ica, cuya validez y confiabilidad ha sido    demostrada (43). Tanto el an&aacute
;lisis simple inicial como el multifactorial    demostraron que los s&iacute;nto
mas depresivos est&aacute;s asociados significativamente    con el RD.</font></p
>     ^cY#a01v22n6.htm##
01435000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704120000076002001301276#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a01v22n6.htm#S#p#81#77#article#135#<p><font size="2" f
ace="Verdana">La interrelaci&oacute;n entre los factores sociales,    los psicol
&oacute;gicos y los nutricionales no se ha estudiado suficientemente.    En un e
studio transversal que evalu&oacute; la asociaci&oacute;n entre algunos    facto
res psicosociales, nutricionales y funcionales con la discapacidad en 54    adul
tos mayores canadienses de 65 a 98 a&ntilde;os de edad, Johnson y colaboradores 
   encontraron que, seg&uacute;n la EMEN, 17% de las personas estudiadas present
aban    RD (44). Tambi&eacute;n encontraron una asociaci&oacute;n significativa 
entre    el tener discapacidad por una parte y el RD, la depresi&oacute;n, el ma
l apoyo    social y la insatisfacci&oacute;n personal, por la otra. Sin embargo,
 la asociaci&oacute;n    independiente entre el RD y la depresi&oacute;n se perd
i&oacute; cuando se tomaron    en cuenta los aspectos funcionales de las persona
s estudiadas. Posiblemente,    el RD y la depresi&oacute;n influyen en la aparic
i&oacute;n de un mal desempe&ntilde;o    f&iacute;sico (por anhedonia o por la d
isminuci&oacute;n de la masa muscular    y la fuerza, entre otros factores), lo 
que finalmente conduce a la discapacidad.</font></p>     ^cY#a01v22n6.htm##
00973000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704073800076002001300814#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a01v22n6.htm#S#p#82#78#article#135#<p><font size="2" f
ace="Verdana">Aunque las caracter&iacute;sticas sociales y    la suficiencia eco
n&oacute;mica no est&aacute;n contempladas en la EMEN, en    el presente estudio
 resultaron factores determinantes del RD. Por ello, en lo    adelante estas car
acter&iacute;sticas se deben tomar en cuenta tambi&eacute;n    al hacer la evalu
aci&oacute;n integral de salud de los adultos mayores y se    les debe dar la mi
sma importancia que a la depresi&oacute;n. No es sorprendente    que algunas var
iables, como el n&uacute;mero de comidas o el &iacute;ndice de    masa corporal,
 estuvieran asociadas significativamente con el RD en el modelo    final, ya que
 ambas tambi&eacute;n est&aacute;n contempladas en la EMEN.</font></p>     ^cY#a
01v22n6.htm##
01531000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704129600076002001301372#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a01v22n6.htm#S#p#83#79#article#135#<p><font size="2" f
ace="Verdana">Llama la atenci&oacute;n la asociaci&oacute;n    significativa e i
ndependiente encontrada en el presente estudio entre el RD    y la dificultad pa
ra utilizar el tel&eacute;fono y salir solo, variables representativas    de las
 funciones ejecutivas. Este hallazgo podr&iacute;a estar relacionado con    la e
levada prevalencia encontrada de diabetes e hipertensi&oacute;n, enfermedades   
 cr&oacute;nico-degenerativas asociadas con lesiones vasculares "estrat&eacute;g
icas"    en determinados circuitos cerebrales (45) que pudieran manifestarse en 
problemas    en la realizaci&oacute;n de funciones ejecutivas. Se ha descrito qu
e el deterioro    cognoscitivo con cambios en el control de las funciones ejecut
ivas es suficiente    para explicar el deterioro funcional general, y que las pe
rsonas con deterioro    cognoscitivo amn&eacute;sico tienen menor riesgo de lleg
ar a la demencia que    las que presentan problemas en el control de funciones e
jecutivas (46, 47).    En un estudio realizado por Royall y colaboradores se des
cribe que los cambios    en el control de las funciones ejecutivas est&aacute;n 
relacionadas con las    actividades instrumentales de la vida diaria y, por lo t
anto, con el deterioro    de la capacidad funcional (48).</font></p>     ^cY#a01
v22n6.htm##
01442000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704120700076002001301283#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a01v22n6.htm#S#p#84#80#article#135#<p><font size="2" f
ace="Verdana">La principal limitaci&oacute;n de este estudio    es que sus resul
tados se derivan de un dise&ntilde;o transversal, lo que no    permite conocer l
a direcci&oacute;n de las asociaciones encontradas. As&iacute;,    por ejemplo, 
no es posible afirmar que la presencia de s&iacute;ntomas depresivos    conduce 
al RD o que un mal estado nutricional favorece la aparici&oacute;n de    s&iacut
e;ntomas depresivos. Adem&aacute;s, el estudio SABE no se dise&ntilde;&oacute;  
  espec&iacute;ficamente para dar respuesta al objetivo de este trabajo. Es nece
sario    dise&ntilde;ar investigaciones longitudinales en las que, adem&aacute;s
 de evaluar    las funciones relacionadas con el adecuado desempe&ntilde;o de la
s actividades    de la vida diaria, se analicen otros factores determinantes men
os estudiados    que puedan estar asociados con el RD —como la situaci&oacute;n 
econ&oacute;mica,    el nivel de satisfacci&oacute;n personal, el apoyo social, 
las situaciones de    estr&eacute;s y los s&iacute;ntomas depresivos— para conoc
er la direcci&oacute;n    de las asociaciones existentes entre estos factores y 
el estado nutricional    de los adultos mayores.</font></p>     ^cY#a01v22n6.htm
##
00917000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704068200076002001300758#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a01v22n6.htm#S#p#85#81#article#135#<p><font size="2" f
ace="Verdana">Como conclusi&oacute;n, se puede afirmar que    los determinantes 
del RD son m&uacute;ltiples y diversos, por tanto, para establecer    si un adul
to mayor presenta RD se debe evaluar de forma intencionada la situaci&oacute;n  
  econ&oacute;mica y social, adem&aacute;s de la informaci&oacute;n general de  
  salud y las medidas antropom&eacute;tricas tradicionales. La informaci&oacute;
n    acerca de los factores asociados con el RD permitir&aacute; dise&ntilde;ar 
programas    m&aacute;s integrales dirigidos a prevenir y tratar el RD, y con el
lo mejorar    las condiciones de salud y la calidad de vida de los adultos mayor
es.</font></p>     ^cY#a01v22n6.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a01v22n6.htm#S#p#86#82#article#135#<p>&nbsp;</p>     ^
cY#a01v22n6.htm##
00306000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704007100076002001300147#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a01v22n6.htm#S#p#87#83#article#135#<p><font size="3" f
ace="Verdana"><b>REFERENCIAS</b></font></p>     ^cY#a01v22n6.htm##
00388000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704013900078002001300217#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a01v22n6.htm#S#p#88#84#article#135#1#<p><f
ont size="2" face="Verdana">1. Novelo H. Aspectos demogr&aacute;ficos    del adu
lto mayor. Nutr Clin. 2003;6:63–9.</font></p>     ^cY#a01v22n6.htm##
00479000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704023000078002001300308#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a01v22n6.htm#S#p#89#85#article#135#2#<p><f
ont size="2" face="Verdana">2. Tapia J, Ram&iacute;rez V. Par&aacute;metros    o
bjetivos regionales de evaluaci&oacute;n nutricional en una poblaci&oacute;n    
de adultos mayores. Nutr Clin. 2003;6: 27–35.</font></p>     ^cY#a01v22n6.htm##
00512000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704026300078002001300341#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a01v22n6.htm#S#p#90#86#article#135#3#<p><f
ont size="2" face="Verdana">3. Cervantes L, Montoya M, N&uacute;&ntilde;ez    L,
 Borges A, Guti&eacute;rrez-Robledo LM. Aporte diet&eacute;tico de energ&iacute;
a    y nutrimentos en adultos mayores de M&eacute;xico. Nutr Clin. 2003;6:2–8.</
font></p>     ^cY#a01v22n6.htm##
00906000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704065700078002001300735#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a01v22n6.htm#S#p#91#87#article#135#4#<p><f
ont size="2" face="Verdana">4. Instituto Nacional de Estad&iacute;stica,    Geog
raf&iacute;a e Inform&aacute;tica (INEGI). Los adulto mayores en M&eacute;xico. 
   Perfil sociodemogr&aacute;fico al inicio del siglo XXI &#91;sitio en Internet
&#93;.    M&eacute;xico, D.F.: Instituto Nacional de Estad&iacute;sticas, Geogra
f&iacute;a    e Inform&aacute;tica; 2005. Hallado en: <a href="http://www.inegi.
gob.mx/prod_serv/contenidos/espanol/biblioteca/abrepdf.asp?upc=702825001083" tar
get="_blank">http://www.    inegi.gob.mx/prod_serv/contenidos/ espanol/bibliotec
a/abrepdf.asp?upc=702825001083</a>.    Acceso el 8 de noviembre de 2006.</font><
/p>     ^cY#a01v22n6.htm##
00465000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704021600078002001300294#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a01v22n6.htm#S#p#92#88#article#135#5#<p><f
ont size="2" face="Verdana">5. Keller HH, Ostbye T, Goy R. Nutritional    risk p
redicts quality of life in elderly community-living Canadians. J Gerontol    A B
iol Sci Med Sci. 2004;59:68–74.</font></p>     ^cY#a01v22n6.htm##
00448000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704019900078002001300277#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a01v22n6.htm#S#p#93#89#article#135#6#<p><f
ont size="2" face="Verdana">6. Casimiro C, Garc&iacute;a de Lorenzo A,    Usan L
. Evaluation of nutritional risk in ambulatory elderly patients. Nutr    Hosp. 2
001;16:97–103.</font></p>     ^cY#a01v22n6.htm##
00564000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704031500078002001300393#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a01v22n6.htm#S#p#94#90#article#135#7#<p><f
ont size="2" face="Verdana">7. Mart&iacute;nez Olmos MA, Mart&iacute;nez    V&aa
cute;zquez MJ, L&oacute;pez Sierra A, Morales Gorria MJ, Cal Bouz&oacute;n    S,
 Castro N&uacute;&ntilde;ez I, et al. Detection of malnutrition risk in hospital
ized    elderly patients. Nutr Hosp. 2002;17:22–7.</font></p>     ^cY#a01v22n6.h
tm##
00415000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704016600078002001300244#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a01v22n6.htm#S#p#95#91#article#135#8#<p><f
ont size="2" face="Verdana">8. Flanagan JC. Measurement of quality of    life: c
urrent state of the art. Arch Phys Med Rehabil. 1982;63:56–9.</font></p>     ^cY
#a01v22n6.htm##
00414000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704016500078002001300243#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a01v22n6.htm#S#p#96#92#article#135#9#<p><f
ont size="2" face="Verdana">9. Brownie S. Why are elderly individuals    at risk
 of nutritional deficiency? Int J Nurs Pract. 2006;12:110–8.</font></p>     ^cY#
a01v22n6.htm##
00410000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704016000079002001300239#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a01v22n6.htm#S#p#97#93#article#135#10#<p><
font size="2" face="Verdana">10. Morley JE. Anorexia and weight loss in    older
 persons. J Gerontol A Biol Sci Med Sci. 2003; 58:131–7.</font></p>     ^cY#a01v
22n6.htm##
00454000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704020400079002001300283#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a01v22n6.htm#S#p#98#94#article#135#11#<p><
font size="2" face="Verdana">11. Poulsen I, Rahm Hallberg I, Schroll M.    Nutri
tional status and associated factors on geriatric admission. J Nutr Health    Ag
ing. 2006;10: 84–90.</font></p>     ^cY#a01v22n6.htm##
00405000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704015500079002001300234#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a01v22n6.htm#S#p#99#95#article#135#12#<p><
font size="2" face="Verdana">12. Edington J. Problems of nutritional assessment 
   in the community. Proc Nutr Soc. 1999; 58:47–51.</font></p>     ^cY#a01v22n6.
htm##
00480000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073888000300077704022900080002001300309#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a01v22n6.htm#S#p#100#96#article#135#13#<p>
<font size="2" face="Verdana">13. G&oacute;mez Ramos MJ, Gonz&aacute;lez    Valv
erde FM, S&aacute;nchez &Aacute;lvarez C. Nutritional status of an hospitalised 
   aged population. Nutr Hosp. 2005;20:286–92.</font></p>     ^cY#a01v22n6.htm##
00490000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073888000300077704023900080002001300319#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a01v22n6.htm#S#p#101#97#article#135#14#<p>
<font size="2" face="Verdana">14. Morillas J, Garc&iacute;a-Talavera N,    Mart&
iacute;n-Pozuelo G, Reina AB, Zafrilla P. Detection of hyponutrition risk    in 
non-institutionalised elderly. Nutr Hosp. 2006;21:650–6.</font></p>     ^cY#a01v
22n6.htm##
00496000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073888000300077704024500080002001300325#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a01v22n6.htm#S#p#102#98#article#135#15#<p>
<font size="2" face="Verdana">15. Payette H, Guigoz Y, Vellas B. Study design   
 for nutritional assessment in the elderly. En: Yu BP, ed. Methods in aging rese
arch.    Boca Raton, Florida: CRC Press LLC; 1999. Pp. 301–20.</font></p>     ^c
Y#a01v22n6.htm##
00400000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073888000300077704014900080002001300229#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a01v22n6.htm#S#p#103#99#article#135#16#<p>
<font size="2" face="Verdana">16. Morley JE. Anorexia of aging: physiologic    a
nd pathologic. Am J Clin Nutr. 1997;66:760–73.</font></p>     ^cY#a01v22n6.htm##
00456000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704020400081002001300285#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a01v22n6.htm#S#p#104#100#article#135#17#<p
><font size="2" face="Verdana">17. Alem&aacute;n-Mateo H, P&eacute;rez F.    Los
 indicadores del estado de nutrici&oacute;n y el proceso de envejecimiento.    N
utr Clin. 20036:46–51.</font></p>     ^cY#a01v22n6.htm##
00550000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704029800081002001300379#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a01v22n6.htm#S#p#105#101#article#135#18#<p
><font size="2" face="Verdana">18. Covinsky KE, Martin GE, Beyth RJ, Justice    
AC, Sehgal AR, Landefeld CS. The relationship between clinical assessments of   
 nutritional status and adverse outcomes in older hospitalized medical patients.
    J Am Geriatr Soc. 1999;47:532–8.</font></p>     ^cY#a01v22n6.htm##
00514000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704026200081002001300343#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a01v22n6.htm#S#p#106#102#article#135#19#<p
><font size="2" face="Verdana">19. Sharkey JR. Risk and presence of food    insu
fficiency are associated with low nutrient intakes and multimorbidity among    h
omebound older women who receive home-delivered meals. J Nutr. 2003;133:3485–91.
</font></p>     ^cY#a01v22n6.htm##
00519000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704026700081002001300348#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a01v22n6.htm#S#p#107#103#article#135#20#<p
><font size="2" face="Verdana">20. Vellas B, Guigoz Y, Garry PJ, Nourhashemi    
F, Bennahum D, Lauque S, et al. The Mini Nutritional Assessment (MNA) and its   
 use in grading the nutritional state of elderly patients. Nutrition. 1999;15:11
6–22.</font></p>     ^cY#a01v22n6.htm##
00488000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704023600081002001300317#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a01v22n6.htm#S#p#108#104#article#135#21#<p
><font size="2" face="Verdana">21. Payette H, Gray-Donald K, Cyr R, Boutier    V
. Predictors of dietary intake in a functionally dependent elderly population   
 in the community. Am J Public Health. 1995;85:677–83.</font></p>     ^cY#a01v22
n6.htm##
00454000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704020200081002001300283#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a01v22n6.htm#S#p#109#105#article#135#22#<p
><font size="2" face="Verdana">22. Vel&aacute;zquez C, Rodr&iacute;guez S,    He
rn&aacute;ndez ML. Desnutrici&oacute;n en las personas de edad avanzadas.    Nut
r Clin. 2003;6:70–9.</font></p>     ^cY#a01v22n6.htm##
00465000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704021300081002001300294#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a01v22n6.htm#S#p#110#106#article#135#23#<p
><font size="2" face="Verdana">23. Vel&aacute;zquez C, Rodr&iacute;guez S,    He
rn&aacute;ndez ML. La importancia de la educaci&oacute;n nutricional en los    a
ncianos. Nutr Clin. 20036:84–8.</font></p>     ^cY#a01v22n6.htm##
00412000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704016000081002001300241#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a01v22n6.htm#S#p#111#107#article#135#24#<p
><font size="2" face="Verdana">24. Schiffman SS. Taste and smell losses in    no
rmal aging and disease. J Am Med Assoc. 1997; 278:1357–62.</font></p>     ^cY#a0
1v22n6.htm##
00376000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704012400081002001300205#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a01v22n6.htm#S#p#112#108#article#135#25#<p
><font size="2" face="Verdana">25. Noel M, Reddy M. Nutrition and aging.    Prim
 Care. 2005;32:659–69.</font></p>     ^cY#a01v22n6.htm##
00490000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704023800081002001300319#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a01v22n6.htm#S#p#113#109#article#135#26#<p
><font size="2" face="Verdana">26. Rivera JA, Sep&uacute;lveda Amor J. Conclusio
ns    from the Mexican National Nutrition Survey 1999: translating results into 
nutrition    policy. Salud Publica Mex. 2003;45:S565–75.</font></p>     ^cY#a01v
22n6.htm##
00503000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704025100081002001300332#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a01v22n6.htm#S#p#114#110#article#135#27#<p
><font size="2" face="Verdana">27. Clark F, Azen SP, Zemke R, Jackson J,    Carl
son M, Mandel D, et al. Occupational therapy for independent-living older    adu
lts. A randomized controlled trial. J Am Med Assoc. 1997; 278:1321–6.</font></p>
     ^cY#a01v22n6.htm##
00471000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704021900081002001300300#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a01v22n6.htm#S#p#115#111#article#135#28#<p
><font size="2" face="Verdana">28. Ho SC, Woo J, Lau J, Chan SG, Yuen YK,    Cha
n YK, et al. Life satisfaction and associated factors in older Hong Kong    Chin
ese. J Am Geriatr Soc. 1995;43:252–5.</font></p>     ^cY#a01v22n6.htm##
00506000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704025400081002001300335#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a01v22n6.htm#S#p#116#112#article#135#29#<p
><font size="2" face="Verdana">29. Bianchetti A, Rozzini R, Carabellese C,    Za
netti O, Trabucchi M. Nutritional intake, socioeconomic conditions, and health  
  status in a large elderly population. J Am Geriatr Soc. 1990;38:521–6.</font><
/p>     ^cY#a01v22n6.htm##
00622000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704037000081002001300451#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a01v22n6.htm#S#p#117#113#article#135#30#<p
><font size="2" face="Verdana">30. Organizaci&oacute;n Panamericana de la    Sal
ud. Manual del usuario de la base de datos SABE. Washington, D.C.: OPS; 2004.   
 . Hallado en: <a href="http://www.ssc.wisc.edu/sabe/codebookSABEspanish.pdf" ta
rget="_blank">http://www.ssc.wisc.edu/sabe/codebookSABEspanish.pdf</a>.    Acces
o el 8 de noviembre de 2007.</font></p>     ^cY#a01v22n6.htm##
00445000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704019300081002001300274#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a01v22n6.htm#S#p#118#114#article#135#31#<p
><font size="2" face="Verdana">31. Brink TL, Yesavage JA, Lum O, Heersema    PH,
 Adey M, Rose TL. Screening tests for geriatric depression. Clin Gerontol.    19
82;1:37–43.</font></p>     ^cY#a01v22n6.htm##
00501000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704024900081002001300330#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a01v22n6.htm#S#p#119#115#article#135#32#<p
><font size="2" face="Verdana">32. Yesavage JA, Brink TL, Rose TL, Lum O,    Hua
ng V, Adey M, et al. Development and validation of a geriatric depression    scr
eening scale: a preliminary report. J Psychiatr Res. 1983;17:37–49.</font></p>  
   ^cY#a01v22n6.htm##
00421000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704016900081002001300250#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a01v22n6.htm#S#p#120#116#article#135#33#<p
><font size="2" face="Verdana">33. Atchison KA, Dolan TA. Development of    the 
Geriatric Oral Health Assessment Index. J Dent Educ. 1990;54:680–7.</font></p>  
   ^cY#a01v22n6.htm##
00485000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704023300081002001300314#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a01v22n6.htm#S#p#121#117#article#135#34#<p
><font size="2" face="Verdana">34. Folstein MF, Folstein SE, McHugh PR. Mini-men
tal    state. A practical method for grading the cognitive state of patients for
 the    clinician. J Psychiatr Res. 1975;12:189–98.</font></p>     ^cY#a01v22n6.
htm##
00710000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704045800081002001300539#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a01v22n6.htm#S#p#122#118#article#135#35#<p
><font size="2" face="Verdana">35. Icaza MG, Albala C. Mini-Mental State    Exam
ination (MMSE) del estudio de la demencia en Chile: an&aacute;lisis estad&iacute
;stico.    Washington, D.C.: Organizaci&oacute;n Panamericana de la Salud; 1999.
 Hallado    en: <a href="http://www.paho.org/spanish/hdp/hdr/serie07composite.pd
f" target="_blank">http://www.paho.org/spanish/hdp/hdr/serie07composite.pdf</a>.
    Acceso el 21 de octubre de 2007.</font></p>     ^cY#a01v22n6.htm##
00367000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704011500081002001300196#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a01v22n6.htm#S#p#123#119#article#135#36#<p
><font size="2" face="Verdana">36. Katz S, Akpom CA. Index of ADL. Med Care.    
1976;4:116–8.</font></p>     ^cY#a01v22n6.htm##
00470000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704021800081002001300299#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a01v22n6.htm#S#p#124#120#article#135#37#<p
><font size="2" face="Verdana">37. Lemeshow S, Hosmer DW Jr. A review of    good
ness of fit statistics for use in the development of logistic regression    mode
ls. Am J Epidemiol. 1982;115:92–106.</font></p>     ^cY#a01v22n6.htm##
00463000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704021100081002001300292#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a01v22n6.htm#S#p#125#121#article#135#38#<p
><font size="2" face="Verdana">38. Hosmer DW, Taber S, Lemeshow S. The importanc
e    of assessing the fit of logistic regression models: a case study. Am J Publ
ic    Health. 1991;81:1630–5.</font></p>     ^cY#a01v22n6.htm##
00550000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704029800081002001300379#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a01v22n6.htm#S#p#126#122#article#135#39#<p
><font size="2" face="Verdana">39. Beck AM, Ovesen L, Osler M. The Mini Nutritio
nal    Assessment (MNA) and the Determine Your Nutritional Health Checklist (NSI
 Checklist)    as predictors of morbidity and mortality in an elderly Danish pop
ulation. Br    J Nutr. 1999;81:31–6.</font></p>     ^cY#a01v22n6.htm##
00608000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704035600081002001300437#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a01v22n6.htm#S#p#127#123#article#135#40#<p
><font size="2" face="Verdana">40. Men&eacute;ndez J, Guevara A, Arcia N,    Le&
oacute;n D&iacute;az EM, Mar&iacute;n C, Alfonso JC. Enfermedades cr&oacute;nica
s    y limitaci&oacute;n funcional en adultos mayores: estudio comparativo en si
ete    ciudades de Am&eacute;rica Latina y el Caribe. Rev Panam Salud Publica. 2
005;17:353–61.</font></p>     ^cY#a01v22n6.htm##
00560000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704030800081002001300389#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a01v22n6.htm#S#p#128#124#article#135#41#<p
><font size="2" face="Verdana">41. Nakanishi N, Tatara K, Nishina M, Nakajima   
 K, Naramura H, Yoneda H. Relationships of disability, health management and    
psychosocial conditions to cause-specific mortality among a community-residing  
  elderly people. J Epidemiol. 1998;8:195–202.</font></p>     ^cY#a01v22n6.htm##
00563000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704031100081002001300392#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a01v22n6.htm#S#p#129#125#article#135#42#<p
><font size="2" face="Verdana">42. &Aacute;vila-Funes JA, Garant MP, Aguilar-Nav
arro    S. Relaci&oacute;n entre los factores que determinan los s&iacute;ntomas
 depresivos    y los h&aacute;bitos alimentarios en adultos mayores de M&eacute;
xico. Rev Panam    Salud Publica. 2006;19:321–30.</font></p>     ^cY#a01v22n6.ht
m##
00390000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704013800081002001300219#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a01v22n6.htm#S#p#130#126#article#135#43#<p
><font size="2" face="Verdana">43. Yesavage JA. Geriatric Depression Scale.    P
sychopharmacol Bull. 1988;24:709–11.</font></p>     ^cY#a01v22n6.htm##
00419000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704016700081002001300248#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a01v22n6.htm#S#p#131#127#article#135#44#<p
><font size="2" face="Verdana">44. Johnson CS. Psychosocial correlates of    nut
ritional risk in older adults. Can J Diet Prac Res. 2005;66:95–7.</font></p>    
 ^cY#a01v22n6.htm##
00494000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704024200081002001300323#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a01v22n6.htm#S#p#132#128#article#135#45#<p
><font size="2" face="Verdana">45. Husain MM, McDonald WM, Doraiswamy PM,    Fig
iel GS, Na C, Escalona PR, et al. A magnetic resonance imaging study of putamen 
   nuclei in major depression. Psychiatry Res. 1991;40:95–9.</font></p>     ^cY#
a01v22n6.htm##
00476000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704022400081002001300305#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a01v22n6.htm#S#p#133#129#article#135#46#<p
><font size="2" face="Verdana">46. Royall DR, Palmer R, Chiodo LK, Polk MJ.    D
ecline in learning ability best predicts future dementia type: the Freedom    Ho
use Study. Exp Aging Res. 2003;29:385–406.</font></p>     ^cY#a01v22n6.htm##
00457000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704020500081002001300286#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a01v22n6.htm#S#p#134#130#article#135#47#<p
><font size="2" face="Verdana">47. Royall DR, Chiodo LK, Polk MJ. Misclassificat
ion    is likely in the assessment of mild cognitive impairment. Neuroepidemiolo
gy.    2004; 23:185–91.</font></p>     ^cY#a01v22n6.htm##
00516000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704026400081002001300345#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a01v22n6.htm#S#p#135#131#article#135#48#<p
><font size="2" face="Verdana">48. Royall DR, Palmer R, Chiodo LK, Polk MJ.    E
xecutive control mediates memory's association with change in instrumental    ac
tivities of daily living: the Freedom House Study. J Am Geriatr Soc. 2005;53:11–
7.</font></p>     ^cY#a01v22n6.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a01v22n6.htm#S#p#136#132#article#135#<p>&nbsp;</p>    
 ^cY#a01v22n6.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a01v22n6.htm#S#p#137#133#article#135#<p>&nbsp;</p>    
 ^cY#a01v22n6.htm##
00323000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704008600078002001300164#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a01v22n6.htm#S#p#138#134#article#135#<p><font size="2"
 face="Verdana">Manuscrito recibido el 17 de octubre de 2006.    ^cY#a01v22n6.ht
m##
00343000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704010600078002001300184#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a01v22n6.htm#S#p#139#135#article#135#<br>   Aceptado p
ara publicaci&oacute;n, tras revisi&oacute;n, el 1 de agosto de 2007.</font></p>
     ^cY#a01v22n6.htm##
00447000000000253000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100017000770120043000940300
01100137710000200148065000900150064000500159031000200164014000500166865000900171
002001300180#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a01v22n6.htm#S#c#140#1#art
icle#48#1#^rND^sNovelo^nH.#Aspectos demográficos del adulto mayor^les#Nutr Clin.
#2#20030000#2003#6#63-9#20071200#a01v22n6.htm##
00559000000000277000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100015000770100017000920120
09800109030001000207065000900217064000500226031000200231014000600233865000900239
002001300248035001000261801001000271#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a0
1v22n6.htm#S#c#141#2#article#48#2#^rND^sTapia^nJ#^rND^sRamírez^nV#Parámetros obj
etivos regionales de evaluación nutricional en una población de adultos mayores^
les#Nutr Clin#20030000#2003#6#27-35#20071200#a01v22n6.htm#0211-6057#Nutr Clin##
00633000000000313000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100019000770100017000960100
01500113010001600128010002800144012007500172030001000247065000900257064000500266
031000200271014000400273865000900277002001300286035001000299801001000309#v22n6#v
:\scielo\serial\rpsp\v22n6\markup\a01v22n6.htm#S#c#142#3#article#48#3#^rND^sCerv
antes^nL#^rND^sMontoya^nM#^rND^sNúñez^nL#^rND^sBorges^nA#^rND^sGutiérrez-Robledo
^nLM#Aporte dietético de energía y nutrimentos en adultos mayores de México^les#
Nutr Clin#20030000#2003#6#2-8#20071200#a01v22n6.htm#0211-6057#Nutr Clin##
00734000000000265000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750170059000770180102001360660
00700238062006000245065000900305064000500314037009500319110000900414109002300423
865000900446002001300455#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a01v22n6.htm#S
#c#143#4#article#48#4#Instituto Nacional de Estadística, Geografía e Informática
#Los adulto mayores en México: Perfil sociodemográfico al inicio del siglo XXI [
sitio en Internet]^les#México#Instituto Nacional de Estadísticas, Geografía e In
formática#20050000#2005#http://www. inegi.gob.mx/prod_serv/contenidos/ espanol/b
iblioteca/abrepdf.asp?upc=702825001083#20061108#8 de noviembre de 2006#20071200#
a01v22n6.htm##
00548000000000265000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100017000770100016000940100
01300110012008400123033003000207065000900237064000500246031000300251014000600254
865000900260002001300269#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a01v22n6.htm#S
#c#144#5#article#48#5#^rND^sKeller^nHH#^rND^sOstbye^nT#^rND^sGoy^nR#Nutritional 
risk predicts quality of life in elderly community-living Canadians^len#J Geront
ol A Biol Sci Med Sci#20040000#2004#59#68-74#20071200#a01v22n6.htm##
00568000000000289000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100018000770100027000950100
01400122012006600136030001000202065000900212064000500221031000300226014000700229
865000900236002001300245035001000258801001000268#v22n6#v:\scielo\serial\rpsp\v22
n6\markup\a01v22n6.htm#S#c#145#6#article#48#6#^rND^sCasimiro^nC#^rND^sGarcía de 
Lorenzo^nA#^rND^sUsan^nL#Evaluation of nutritional risk in ambulatory elderly pa
tients^len#Nutr Hosp#20010000#2001#16#97-103#20071200#a01v22n6.htm#0212-1611#Nut
r Hosp##
00704000000000337000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100025000770100027001020100
02200129010002500151010002000176010002200196810000600218012006800224030001000292
06500090030206400050031103100030031601400050031986500090032400200130033303500100
0346801001000356#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a01v22n6.htm#S#c#146#7
#article#48#7#^rND^sMartínez Olmos^nMA#^rND^sMartínez Vázquez^nMJ#^rND^sLópez Si
erra^nA#^rND^sMorales Gorria^nMJ#^rND^sCal Bouzón^nS#^rND^sCastro Núñez^nI#et al
#Detection of malnutrition risk in hospitalized elderly patients^len#Nutr Hosp#2
0020000#2002#17#22-7#20071200#a01v22n6.htm#0212-1611#Nutr Hosp##
00521000000000265000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100019000770120061000960300
02200157065000900179064000500188031000300193014000500196865000900201002001300210
035001000223801002200233#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a01v22n6.htm#S
#c#147#8#article#48#8#^rND^sFlanagan^nJC#Measurement of quality of life: current
 state of the art^len#Arch Phys Med Rehabil#19820000#1982#63#56-9#20071200#a01v2
2n6.htm#0003-9993#Arch Phys Med Rehabil##
00516000000000265000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100017000770120067000940300
01700161065000900178064000500187031000300192014000600195865000900201002001300210
035001000223801001700233#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a01v22n6.htm#S
#c#148#9#article#48#9#^rND^sBrownie^nS#Why are elderly individuals at risk of nu
tritional deficiency?^len#Int J Nurs Pract#20060000#2006#12#110-8#20071200#a01v2
2n6.htm#1322-7114#Int J Nurs Pract##
00523000000000265000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790120046000960300
03000142065000900172064000500181031000300186014000600189865000900195002001300204
035001000217801003000227#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a01v22n6.htm#S
#c#149#10#article#48#10#^rND^sMorley^nJE#Anorexia and weight loss in older perso
ns^len#J Gerontol A Biol Sci Med Sci#20030000#2003#58#131-7#20071200#a01v22n6.ht
m#1079-5006#J Gerontol A Biol Sci Med Sci##
00550000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100023000960100
01700119012006900136030002000205710000200225065000900227064000500236031000300241
014000600244865000900250002001300259#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a0
1v22n6.htm#S#c#150#11#article#48#11#^rND^sPoulsen^nI#^rND^sRahm Hallberg^nI#^rND
^sSchroll^nM#Nutritional status and associated factors on geriatric admission^le
n#J Nutr Health Aging#2#20060000#2006#10#84-90#20071200#a01v22n6.htm##
00502000000000265000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790120056000970300
01400153065000900167064000500176031000300181014000600184865000900190002001300199
035001000212801001400222#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a01v22n6.htm#S
#c#151#12#article#48#12#^rND^sEdington^nJ#Problems of nutritional assessment in 
the community^len#Proc Nutr Soc#19990000#1999#58#47-51#20071200#a01v22n6.htm#002
9-6651#Proc Nutr Soc##
00578000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100022000790100028001010100
02500129012005800154030001000212065000900222064000500231031000300236014000700239
865000900246002001300255035001000268801001000278#v22n6#v:\scielo\serial\rpsp\v22
n6\markup\a01v22n6.htm#S#c#152#13#article#48#13#^rND^sGómez Ramos^nMJ#^rND^sGonz
ález Valverde^nFM#^rND^sSánchez Álvarez^nC#Nutritional status of an hospitalised
 aged population^len#Nutr Hosp#20050000#2005#20#286-92#20071200#a01v22n6.htm#021
2-1611#Nutr Hosp##
00638000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100025000970100
02400122010001600146010001800162012006900180030001000249065000900259064000500268
031000300273014000600276865000900282002001300291035001000304801001000314#v22n6#v
:\scielo\serial\rpsp\v22n6\markup\a01v22n6.htm#S#c#153#14#article#48#14#^rND^sMo
rillas^nJ#^rND^sGarcía-Talavera^nN#^rND^sMartín-Pozuelo^nG#^rND^sReina^nAB#^rND^
sZafrilla^nP#Detection of hyponutrition risk in non-institutionalised elderly^le
n#Nutr Hosp#20060000#2006#21#650-6#20071200#a01v22n6.htm#0212-1611#Nutr Hosp##
00597000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100016000960100
01600112012005900128016001300187018003000200066002000230062001400250065000900264
064000500273014000700278865000900285002001300294#v22n6#v:\scielo\serial\rpsp\v22
n6\markup\a01v22n6.htm#S#c#154#15#article#48#15#^rND^sPayette^nH#^rND^sGuigoz^nY
#^rND^sVellas^nB#Study design for nutritional assessment in the elderly^len#^rED
^sYu^nBP#Methods in aging research^len#Boca Raton^eFlorida#CRC Press LLC#1999000
0#1999#301-20#20071200#a01v22n6.htm##
00498000000000265000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790120050000960300
01500146065000900161064000500170031000300175014000700178865000900185002001300194
035001000207801001500217#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a01v22n6.htm#S
#c#155#16#article#48#16#^rND^sMorley^nJE#Anorexia of aging: physiologic and path
ologic^len#Am J Clin Nutr#19970000#1997#66#760-73#20071200#a01v22n6.htm#0002-916
5#Am J Clin Nutr##
00543000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100022000790100015001010120
07500116030001000191065000900201064000500210031000200215014000600217865000900223
002001300232035001000245801001000255#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a0
1v22n6.htm#S#c#156#17#article#48#17#^rND^sAlemán-Mateo^nH#^rND^sPérez^nF#Los ind
icadores del estado de nutrición y el proceso de envejecimiento^les#Nutr Clin#20
030000#2003#6#46-51#20071200#a01v22n6.htm#0211-6057#Nutr Clin##
00733000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100019000790100017000980100
01600115010001800131010001700149010002000166012013200186030001700318065000900335
06400050034403100030034901400060035286500090035800200130036703500100038080100170
0390#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a01v22n6.htm#S#c#157#18#article#48
#18#^rND^sCovinsky^nKE#^rND^sMartin^nGE#^rND^sBeyth^nRJ#^rND^sJustice^nAC#^rND^s
Sehgal^nAR#^rND^sLandefeld^nCS#The relationship between clinical assessments of 
nutritional status and adverse outcomes in older hospitalized medical patients^l
en#J Am Geriatr Soc#19990000#1999#47#532-8#20071200#a01v22n6.htm#0002-8614#J Am 
Geriatr Soc##
00600000000000265000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790120165000970300
00700262065000900269064000500278031000400283014000800287865000900295002001300304
035001000317801000700327#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a01v22n6.htm#S
#c#158#19#article#48#19#^rND^sSharkey^nJR#Risk and presence of food insufficienc
y are associated with low nutrient intakes and multimorbidity among homebound ol
der women who receive home-delivered meals^len#J Nutr#20030000#2003#133#3485-91#
20071200#a01v22n6.htm#0022-3166#J Nutr##
00709000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100016000950100
01600111010002100127010001800148010001600166810000600182012010700188030001000295
06500090030506400050031403100030031901400070032286500090032900200130033803500100
0351801001000361#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a01v22n6.htm#S#c#159#2
0#article#48#20#^rND^sVellas^nB#^rND^sGuigoz^nY#^rND^sGarry^nPJ#^rND^sNourhashem
i^nF#^rND^sBennahum^nD#^rND^sLauque^nS#et al#The Mini Nutritional Assessment (MN
A) and its use in grading the nutritional state of elderly patients^len#Nutritio
n#19990000#1999#15#116-22#20071200#a01v22n6.htm#0029-6600#Nutrition##
00640000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100021000960100
01300117010001700130012009700147030001900244065000900263064000500272031000300277
014000700280865000900287002001300296035001000309801001900319#v22n6#v:\scielo\ser
ial\rpsp\v22n6\markup\a01v22n6.htm#S#c#160#21#article#48#21#^rND^sPayette^nH#^rN
D^sGray-Donald^nK#^rND^sCyr^nR#^rND^sBoutier^nV#Predictors of dietary intake in 
a functionally dependent elderly population in the community^len#Am J Public Hea
lth#19950000#1995#85#677-83#20071200#a01v22n6.htm#0090-0036#Am J Public Health##
00551000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100019000790100019000980100
02000117012005100137030001000188065000900198064000500207031000200212014000500214
865000900219002001300228035001000241801001000251#v22n6#v:\scielo\serial\rpsp\v22
n6\markup\a01v22n6.htm#S#c#161#22#article#48#22#^rND^sVelázquez^nC#^rND^sRodrígu
ez^nS#^rND^sHernández^nML#Desnutrición en las personas de edad avanzadas^les#Nut
r Clin#20030000#2003#6#70-9#20071200#a01v22n6.htm#0211-6057#Nutr Clin##
00563000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100019000790100019000980100
02000117012006300137030001000200065000900210064000500219031000200224014000500226
865000900231002001300240035001000253801001000263#v22n6#v:\scielo\serial\rpsp\v22
n6\markup\a01v22n6.htm#S#c#162#23#article#48#23#^rND^sVelázquez^nC#^rND^sRodrígu
ez^nS#^rND^sHernández^nML#La importancia de la educación nutricional en los anci
anos^les#Nutr Clin#20030000#2003#6#84-8#20071200#a01v22n6.htm#0211-6057#Nutr Cli
n##
00473000000000253000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100020000790120055000990300
01500154710000200169065000900171064000500180031000400185014000800189865000900197
002001300206#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a01v22n6.htm#S#c#163#24#ar
ticle#48#24#^rND^sSchiffman^nSS#Taste and smell losses in normal aging and disea
se^len#J Am Med Assoc#2#19970000#1997#278#1357-62#20071200#a01v22n6.htm##
00486000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100014000790100015000930120
02400108030001000132065000900142064000500151031000300156014000700159865000900166
002001300175035001000188801001000198#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a0
1v22n6.htm#S#c#164#25#article#48#25#^rND^sNoel^nM#^rND^sReddy^nM#Nutrition and a
ging^len#Prim Care#20050000#2005#32#659-69#20071200#a01v22n6.htm#0095-4543#Prim 
Care##
00598000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100024000960120
10700120030001800227065000900245064000500254031000300259014000800262865000900270
002001300279035001000292801001800302#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a0
1v22n6.htm#S#c#165#26#article#48#26#^rND^sRivera^nJA#^rND^sSepúlveda Amor^nJ#Con
clusions from the Mexican National Nutrition Survey 1999: translating results in
to nutrition policy^len#Salud Publica Mex#20030000#2003#45#S565-75#20071200#a01v
22n6.htm#0036-3634#Salud Publica Mex##
00662000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100015000790100015000940100
01500109010001700124010001700141010001600158810000600174012009200180030001500272
71000020028706500090028906400050029803100040030301400070030786500090031400200130
0323#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a01v22n6.htm#S#c#166#27#article#48
#27#^rND^sClark^nF#^rND^sAzen^nSP#^rND^sZemke^nR#^rND^sJackson^nJ#^rND^sCarlson^
nM#^rND^sMandel^nD#et al#Occupational therapy for independent-living older adult
s: A randomized controlled trial^len#J Am Med Assoc#2#19970000#1997#278#1321-6#2
0071200#a01v22n6.htm##
00668000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100013000790100013000920100
01300105010001500118010001500133010001500148810000600163012007200169030001700241
06500090025806400050026703100030027201400060027586500090028100200130029003500100
0303801001700313#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a01v22n6.htm#S#c#167#2
8#article#48#28#^rND^sHo^nSC#^rND^sWoo^nJ#^rND^sLau^nJ#^rND^sChan^nSG#^rND^sYuen
^nYK#^rND^sChan^nYK#et al#Life satisfaction and associated factors in older Hong
 Kong Chinese^len#J Am Geriatr Soc#19950000#1995#43#252-5#20071200#a01v22n6.htm#
0002-8614#J Am Geriatr Soc##
00674000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100020000790100017000990100
02100116010001700137010001900154012009800173030001700271065000900288064000500297
031000300302014000600305865000900311002001300320035001000333801001700343#v22n6#v
:\scielo\serial\rpsp\v22n6\markup\a01v22n6.htm#S#c#168#29#article#48#29#^rND^sBi
anchetti^nA#^rND^sRozzini^nR#^rND^sCarabellese^nC#^rND^sZanetti^nO#^rND^sTrabucc
hi^nM#Nutritional intake, socioeconomic conditions, and health status in a large
 elderly population^len#J Am Geriatr Soc#19900000#1990#38#521-6#20071200#a01v22n
6.htm#0002-8614#J Am Geriatr Soc##
00573000000000265000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760170038000790180048001170660
01700165062000400182065000900186064000500195037005300200110000900253109002300262
865000900285002001300294#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a01v22n6.htm#S
#c#169#30#article#48#30#Organización Panamericana de la Salud#Manual del usuario
 de la base de datos SABE^les#Washington^eD.C.#OPS#20040000#2004#http://www.ssc.
wisc.edu/sabe/codebookSABEspanish.pdf#20071108#8 de noviembre de 2007#20071200#a
01v22n6.htm##
00628000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100019000950100
01300114010001900127010001400146010001500160012004500175030001400220065000900234
06400050024303100020024801400060025086500090025600200130026503500100027880100140
0288#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a01v22n6.htm#S#c#170#31#article#48
#31#^rND^sBrink^nTL#^rND^sYesavage^nJA#^rND^sLum^nO#^rND^sHeersema^nPH#^rND^sAde
y^nM#^rND^sRose^nTL#Screening tests for geriatric depression^len#Clin Gerontol#1
9820000#1982#1#37-43#20071200#a01v22n6.htm#0731-7115#Clin Gerontol##
00697000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100019000790100016000980100
01500114010001300129010001500142010001400157810000600171012009500177030001600272
06500090028806400050029703100030030201400060030586500090031100200130032003500100
0333801001600343#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a01v22n6.htm#S#c#171#3
2#article#48#32#^rND^sYesavage^nJA#^rND^sBrink^nTL#^rND^sRose^nTL#^rND^sLum^nO#^
rND^sHuang^nV#^rND^sAdey^nM#et al#Development and validation of a geriatric depr
ession screening scale: a preliminary report^len#J Psychiatr Res#19830000#1983#1
7#37-49#20071200#a01v22n6.htm#0022-3956#J Psychiatr Res##
00533000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100019000790100016000980120
06200114030001200176065000900188064000500197031000300202014000600205865000900211
002001300220035001000233801001200243#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a0
1v22n6.htm#S#c#172#33#article#48#33#^rND^sAtchison^nKA#^rND^sDolan^nTA#Developme
nt of the Geriatric Oral Health Assessment Index^len#J Dent Educ#19900000#1990#5
4#680-7#20071200#a01v22n6.htm#0022-0337#J Dent Educ##
00616000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100019000790100019000980100
01700117012010400134030001600238065000900254064000500263031000300268014000700271
865000900278002001300287035001000300801001600310#v22n6#v:\scielo\serial\rpsp\v22
n6\markup\a01v22n6.htm#S#c#173#34#article#48#34#^rND^sFolstein^nMF#^rND^sFolstei
n^nSE#^rND^sMcHugh^nPR#Mini-mental state: A practical method for grading the cog
nitive state of patients for the clinician^len#J Psychiatr Res#19750000#1975#12#
189-98#20071200#a01v22n6.htm#0022-3956#J Psychiatr Res##
00667000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760160016000790160016000950180
09900111066001700210062003800227065000900265064000500274037005700279110000900336
109002200345865000900367002001300376#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a0
1v22n6.htm#S#c#174#35#article#48#35#^rND^sIcaza^nMG#^rND^sAlbala^nC#Mini-Mental 
State Examination (MMSE) del estudio de la demencia en Chile: análisis estadísti
co^les#Washington^eD.C.#Organización Panamericana de la Salud#19990000#1999#http
://www.paho.org/spanish/hdp/hdr/serie07composite.pdf#20071021#21 de octubre de 2
007#20071200#a01v22n6.htm##
00476000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100014000790100016000930120
01700109030000900126065000900135064000500144031000200149014000600151865000900157
002001300166035001000179801000900189#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a0
1v22n6.htm#S#c#175#36#article#48#36#^rND^sKatz^nS#^rND^sAkpom^nCA#Index of ADL^l
en#Med Care#19760000#1976#4#116-8#20071200#a01v22n6.htm#0025-7079#Med Care##
00582000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100020000970120
10000117030001500217065000900232064000500241031000400246014000700250865000900257
002001300266035001000279801001500289#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a0
1v22n6.htm#S#c#176#37#article#48#37#^rND^sLemeshow^nS#^rND^sHosmer^nDW Jr#A revi
ew of goodness of fit statistics for use in the development of logistic regressi
on models^len#Am J Epidemiol#19820000#1982#115#92-106#20071200#a01v22n6.htm#0002
-9262#Am J Epidemiol##
00597000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100015000960100
01800111012008400129030001900213065000900232064000500241031000300246014000700249
865000900256002001300265035001000278801001900288#v22n6#v:\scielo\serial\rpsp\v22
n6\markup\a01v22n6.htm#S#c#177#38#article#48#38#^rND^sHosmer^nDW#^rND^sTaber^nS#
^rND^sLemeshow^nS#The importance of assessing the fit of logistic regression mod
els: a case study^len#Am J Public Health#19910000#1991#81#1630-5#20071200#a01v22
n6.htm#0090-0036#Am J Public Health##
00672000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100015000790100016000940100
01500110012018300125030001000308065000900318064000500327031000300332014000500335
865000900340002001300349035001000362801001000372#v22n6#v:\scielo\serial\rpsp\v22
n6\markup\a01v22n6.htm#S#c#178#39#article#48#39#^rND^sBeck^nAM#^rND^sOvesen^nL#^
rND^sOsler^nM#The Mini Nutritional Assessment (MNA) and the Determine Your Nutri
tional Health Checklist (NSI Checklist) as predictors of morbidity and mortality
 in an elderly Danish population^len#Br J Nutr#19990000#1999#81#31-6#20071200#a0
1v22n6.htm#0007-1145#Br J Nutr##
00749000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100017000970100
01500114010002000129010001500149010001800164012013700182030002400319065000900343
06400050035203100030035701400070036086500090036700200130037603500100038980100240
0399#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a01v22n6.htm#S#c#179#40#article#48
#40#^rND^sMenéndez^nJ#^rND^sGuevara^nA#^rND^sArcia^nN#^rND^sLeón Díaz^nEM#^rND^s
Marín^nC#^rND^sAlfonso^nJC#Enfermedades crónicas y limitación funcional en adult
os mayores: estudio comparativo en siete ciudades de América Latina y el Caribe^
les#Rev Panam Salud Publica#20050000#2005#17#353-61#20071200#a01v22n6.htm#1020-4
989#Rev Panam Salud Publica##
00738000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100019000790100016000980100
01700114010001800131010001800149010001600167012014900183030001200332065000900344
06400050035303100020035801400080036086500090036800200130037703500100039080100120
0400#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a01v22n6.htm#S#c#180#41#article#48
#41#^rND^sNakanishi^nN#^rND^sTatara^nK#^rND^sNishina^nM#^rND^sNakajima^nK#^rND^s
Naramura^nH#^rND^sYoneda^nH#Relationships of disability, health management and p
sychosocial conditions to cause-specific mortality among a community-residing el
derly people^len#J Epidemiol#19980000#1998#8#195-202#20071200#a01v22n6.htm#0917-
5040#J Epidemiol##
00664000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100022000790100017001010100
02500118012012700143030002400270065000900294064000500303031000300308014000700311
865000900318002001300327035001000340801002400350#v22n6#v:\scielo\serial\rpsp\v22
n6\markup\a01v22n6.htm#S#c#181#42#article#48#42#^rND^sÁvila-Funes^nJA#^rND^sGara
nt^nMP#^rND^sAguilar-Navarro^nS#Relación entre los factores que determinan los s
íntomas depresivos y los hábitos alimentarios en adultos mayores de México^les#R
ev Panam Salud Publica#20060000#2006#19#321-30#20071200#a01v22n6.htm#1020-4989#R
ev Panam Salud Publica##
00493000000000265000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100019000790120031000980300
02100129065000900150064000500159031000300164014000700167865000900174002001300183
035001000196801002100206#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a01v22n6.htm#S
#c#182#43#article#48#43#^rND^sYesavage^nJA#Geriatric Depression Scale^len#Psycho
pharmacol Bull#19880000#1988#24#709-11#20071200#a01v22n6.htm#0048-5764#Psychopha
rmacol Bull##
00481000000000253000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790120064000970300
02000161710000200181065000900183064000500192031000300197014000500200865000900205
002001300214#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a01v22n6.htm#S#c#183#44#ar
ticle#48#44#^rND^sJohnson^nCS#Psychosocial correlates of nutritional risk in old
er adults^len#Can J Diet Prac Res#2#20050000#2005#66#95-7#20071200#a01v22n6.htm#
#
00689000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100019000960100
02100115010001700136010001200153010001900165810000600184012007700190030001500267
06500090028206400050029103100030029601400050029986500090030400200130031303500100
0326801001500336#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a01v22n6.htm#S#c#184#4
5#article#48#45#^rND^sHusain^nMM#^rND^sMcDonald^nWM#^rND^sDoraiswamy^nPM#^rND^sF
igiel^nGS#^rND^sNa^nC#^rND^sEscalona^nPR#et al#A magnetic resonance imaging stud
y of putamen nuclei in major depression^len#Psychiatry Res#19910000#1991#40#95-9
#20071200#a01v22n6.htm#0165-1781#Psychiatry res##
00623000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100016000960100
01700112010001500129012009200144030001400236065000900250064000500259031000300264
014000800267865000900275002001300284035001000297801001400307#v22n6#v:\scielo\ser
ial\rpsp\v22n6\markup\a01v22n6.htm#S#c#185#46#article#48#46#^rND^sRoyall^nDR#^rN
D^sPalmer^nR#^rND^sChiodo^nLK#^rND^sPolk^nMJ#Decline in learning ability best pr
edicts future dementia type: the Freedom House Study^len#Exp Aging Res#20030000#
2003#29#385-406#20071200#a01v22n6.htm#0361-073X#Exp Aging Res##
00589000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100017000960100
01500113012007900128030001800207065000900225064000500234031000300239014000700242
865000900249002001300258035001000271801001800281#v22n6#v:\scielo\serial\rpsp\v22
n6\markup\a01v22n6.htm#S#c#186#47#article#48#47#^rND^sRoyall^nDR#^rND^sChiodo^nL
K#^rND^sPolk^nMJ#Misclassification is likely in the assessment of mild cognitive
 impairment^len#Neuroepidemiology#20040000#2004#23#185-91#20071200#a01v22n6.htm#
0251-5350#Neuroepidemiology##
00666000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100016000960100
01700112010001500129012013200144030001700276065000900293064000500302031000300307
014000500310865000900315002001300324035001000337801001700347#v22n6#v:\scielo\ser
ial\rpsp\v22n6\markup\a01v22n6.htm#S#c#187#48#article#48#48#^rND^sRoyall^nDR#^rN
D^sPalmer^nR#^rND^sChiodo^nLK#^rND^sPolk^nMJ#Executive control mediates memory's
 association with change in instrumental activities of daily living: the Freedom
 House Study^len#J Am Geriatr Soc#20050000#2005#53#11-7#20071200#a01v22n6.htm#00
02-8614#J Am Geriatr Soc##
00275000000000169000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700910009000720920007000810020013000887030
00400101#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a02v22n6.htm#S#o#1#1#article#1
#20080215#102617#a02v22n6.htm#139##
05151000000000661000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000500090038000400095121000300099049000800102158000300110
03000240011303100030013703200020014006500090014201400110015103500100016201201400
01720120189003120100027005010100030005280100025005580100025005830700081006080700
07800689070008100767083152900848085000802377085002702385085002702412085002602439
08500210246508317790248608500080426508500320427308500320430508500280433708500210
43650580034043861170006044200720003044261120009044291110013044381140009044511130
01604460002001304476#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a02v22n6.htm#S#h#2
#1#article#1#oa#en#br1.1#1#3.1#ILUS#TAB#02#RPSP020#nd#Rev Panam Salud Publica#22
#6#20071200#^f376^l382#1020-4989#Uptake of health care services and health statu
s of HIV-infected women diagnosed through antenatal HIV screening in Barbados, 1
996-2004^len#Utilización de los servicios de atención sanitaria y estado de salu
d de las mujeres seropositivas al VIH diagnosticadas mediante el tamizaje prenat
al para el VIH en Barbados, 1996-2004^les#^rND^1A01 A02^nAlok^sKumar#^rND^1A03^n
Krishna R.^sKilaru#^rND^1A03^nSheila^sForde#^rND^1A03^nIra^sWaterman#The Univers
ity of the West Indies^iA01^1School of Clinical Medicine and Research#The Queen 
Elizabeth Hospital^iA02^1Associate Consultant^cBridgetown^pBarbados#Ministry of 
Health^iA03^1Ladymeade HIV/AIDS Reference Unit^cBridgetown^pBarbados#^len^aOBJEC
TIVES: To study utilization of HIV-related health care services and to describe 
the health status of HIV-infected women diagnosed through antenatal voluntary co
unseling and testing (VCT) for HIV infection in Barbados. METHODS: This is a des
criptive study. The study population includes all HIV-infected women in Barbados
 diagnosed as HIV-infected through VCT for HIV infection during 1996-2004. RESUL
TS: The median duration of HIV infection from time of diagnosis to the time of t
his report for the 163 women diagnosed during the study period was 72 months (lo
w range, 9 months; high range, 117 months). Of the 163 women, 102 (62.6%) had at
tended the centralized HIV/AIDS clinic for follow-up (care, treatment, and monit
oring), whereas 61 (37.4%) had never attended the clinic. The median time lag be
tween diagnosis of HIV infection and first presentation to the HIV/AIDS clinic w
as 36 months (low range, 1 month; high range, 114 months). Of the HIV-infected w
omen who attended the HIV/AIDS clinic, more than one-fourth had severe immunodef
iciency at the time of their first follow-up visit. Of the 53 women undergoing h
ighly active anti-retroviral therapy (HAART) at the time of the study, 23 (43.4%
) began the therapy within three months of their first follow-up visit. CONCLUSI
ONS: Early HIV diagnosis through antenatal VCT is not enough to ensure that wome
n with HIV will get adequate and timely HIV-related health care. These women suf
fer significant premature mortality, largely related to inadequate follow-up.#^d
nd^i1#^tm^len^kHIV infections^i1#^tm^len^kpregnant women^i1#^tm^len^khealth stat
us^i1#^tm^len^kBarbados^i1#^les^aOBJETIVOS: Estudiar la utilización de los servi
cios de atención sanitaria relacionados con el VIH y describir el estado de salu
d de las mujeres infectadas con este virus, diagnosticadas mediante el asesorami
ento y la prueba de detección del VIH de carácter voluntario (APDV) durante el p
eríodo prenatal en Barbados. MÉTODOS: Este es un estudio descriptivo. La poblaci
ón de estudio abarcó a todas las mujeres infectadas por el VIH, diagnosticadas e
n Barbados mediante el APDV en 1996-2004. RESULTADOS: La mediana de la duración 
de la infección por el VIH -desde el diagnóstico hasta el momento de este inform
e- en las 163 mujeres diagnosticadas durante el período de estudio fue de 72 mes
es (nivel bajo: 9 meses; nivel alto: 117 meses). De las 163 mujeres, 102 (62,6%)
 asistieron a la clínica centralizada para el VIH/sida para su seguimiento (aten
ción, tratamiento y monitoreo), mientras que 61 (37,4%) nunca asistieron a la cl
ínica. La mediana del lapso entre el diagnóstico de la infección por el VIH y la
 primera presentación a la clínica para el VIH/sida fue de 36 meses (nivel bajo:
 1 mes; nivel alto: 114 meses). Más de la cuarta parte de las mujeres infectadas
 que acudieron a la clínica presentaban inmunodeficiencia grave en el momento de
 su primera consulta de seguimiento. De las 53 mujeres que se sometieron al trat
amiento antirretroviral de gran actividad (HAART) durante el estudio, 23 (43,4%)
 comenzaron el tratamiento en los tres meses siguientes a su primera visita de s
eguimiento. CONCLUSIONES: El diagnóstico temprano mediante el APDV no garantiza 
que las mujeres con VIH reciban una atención adecuada y oportuna para tratar esa
 infección. Estas mujeres sufren una mortalidad significativamente prematura, en
 gran parte debido al inadecuado seguimiento.#^dnd^i2#^tm^les^kInfecciones por V
IH^i2#^tm^les^kmujeres embarazadas^i2#^tm^les^kestado de salud^i2#^tm^les^kBarba
dos^i2#Caribbean Health Research Council#other#21#20060717#17 July 2006#20071029
#29 October 2007#a02v22n6.htm##
05251000000000661000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000500090038000400095121000300099049000800102158000300110
03000240011303100030013703200020014006500090014201400110015103500100016201201470
01720120196003190100027005150100030005420100025005720100025005970700081006220700
07800703070008100781083157200862085000802434085002702442085002702469085002602496
08500210252208318220254308500080436508500320437308500320440508500280443708500210
44650580034044861170006045200720003045261120009045291110013045381140009045511130
01604560002001304576#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a02v22n6.htm#S#f#3
#1#article#1#oa#en#br1.1#1#3.1#ILUS#TAB#02#RPSP020#nd#Rev Panam Salud Publica#22
#6#20071200#^f376^l382#1020-4989#<B>Uptake of health care services and health st
atus of HIV-infected women diagnosed through antenatal HIV screening in Barbados
, 1996-2004</B>^len#<B>Utilización de los servicios de atención sanitaria y esta
do de salud de las mujeres seropositivas al VIH diagnosticadas mediante el tamiz
aje prenatal para el VIH en Barbados, 1996-2004</B>^les#^rND^1A01 A02^nAlok^sKum
ar#^rND^1A03^nKrishna R.^sKilaru#^rND^1A03^nSheila^sForde#^rND^1A03^nIra^sWaterm
an#The University of the West Indies^iA01^1School of Clinical Medicine and Resea
rch#The Queen Elizabeth Hospital^iA02^1Associate Consultant^cBridgetown^pBarbado
s#Ministry of Health^iA03^1Ladymeade HIV/AIDS Reference Unit^cBridgetown^pBarbad
os#^len^a<B>OBJECTIVES:</B>&nbsp;To study utilization of HIV-related health care
 services and to describe the health status of HIV-infected women diagnosed thro
ugh antenatal voluntary counseling and testing (VCT) for HIV infection in Barbad
os. <B>METHODS:&nbsp;</B>This is a descriptive study. The study population inclu
des all HIV-infected women in Barbados diagnosed as HIV-infected through VCT for
 HIV infection during 1996-2004. <B>RESULTS:&nbsp;</B>The median duration of HIV
 infection from time of diagnosis to the time of this report for the 163 women d
iagnosed during the study period was 72 months (low range, 9 months; high range,
 117 months). Of the 163 women, 102 (62.6%) had attended the centralized HIV/AID
S clinic for follow-up (care, treatment, and monitoring), whereas 61 (37.4%) had
 never attended the clinic. The median time lag between diagnosis of HIV infecti
on and first presentation to the HIV/AIDS clinic was 36 months (low range, 1 mon
th; high range, 114 months). Of the HIV-infected women who attended the HIV/AIDS
 clinic, more than one-fourth had severe immunodeficiency at the time of their f
irst follow-up visit. Of the 53 women undergoing highly active anti-retroviral t
herapy (HAART) at the time of the study, 23 (43.4%) began the therapy within thr
ee months of their first follow-up visit. <B>CONCLUSIONS: </B>Early HIV diagnosi
s through antenatal VCT is not enough to ensure that women with HIV will get ade
quate and timely HIV-related health care. These women suffer significant prematu
re mortality, largely related to inadequate follow-up.#^dnd^i1#^tm^len^kHIV infe
ctions^i1#^tm^len^kpregnant women^i1#^tm^len^khealth status^i1#^tm^len^kBarbados
^i1#^les^a<B>OBJETIVOS:</B>&nbsp;Estudiar la utilización de los servicios de ate
nción sanitaria relacionados con el VIH y describir el estado de salud de las mu
jeres infectadas con este virus, diagnosticadas mediante el asesoramiento y la p
rueba de detección del VIH de carácter voluntario (APDV) durante el período pren
atal en Barbados. <B>MÉTODOS:&nbsp;</B>Este es un estudio descriptivo. La poblac
ión de estudio abarcó a todas las mujeres infectadas por el VIH, diagnosticadas 
en Barbados mediante el APDV en 1996-2004. <B>RESULTADOS: </B>La mediana de la d
uración de la infección por el VIH -desde el diagnóstico hasta el momento de est
e informe- en las 163 mujeres diagnosticadas durante el período de estudio fue d
e 72 meses (nivel bajo: 9 meses; nivel alto: 117 meses). De las 163 mujeres, 102
 (62,6%) asistieron a la clínica centralizada para el VIH/sida para su seguimien
to (atención, tratamiento y monitoreo), mientras que 61 (37,4%) nunca asistieron
 a la clínica. La mediana del lapso entre el diagnóstico de la infección por el 
VIH y la primera presentación a la clínica para el VIH/sida fue de 36 meses (niv
el bajo: 1 mes; nivel alto: 114 meses). Más de la cuarta parte de las mujeres in
fectadas que acudieron a la clínica presentaban inmunodeficiencia grave en el mo
mento de su primera consulta de seguimiento. De las 53 mujeres que se sometieron
 al tratamiento antirretroviral de gran actividad (HAART) durante el estudio, 23
 (43,4%) comenzaron el tratamiento en los tres meses siguientes a su primera vis
ita de seguimiento. <B>CONCLUSIONES:&nbsp;</B>El diagnóstico temprano mediante e
l APDV no garantiza que las mujeres con VIH reciban una atención adecuada y opor
tuna para tratar esa infección. Estas mujeres sufren una mortalidad significativ
amente prematura, en gran parte debido al inadecuado seguimiento.#^dnd^i2#^tm^le
s^kInfecciones por VIH^i2#^tm^les^kmujeres embarazadas^i2#^tm^les^kestado de sal
ud^i2#^tm^les^kBarbados^i2#Caribbean Health Research Council#other#21#20060717#1
7 July 2006#20071029#29 October 2007#a02v22n6.htm##
05338000000000685000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700640013000720710003000850400003000880010
00600091042000200097120000400099038000500103038000400108121000300112049000800115
15800030012303000260012603100030015203200020015506500090015701400110016603500100
01770120140001870120189003270100027005160100029005430100025005720100025005970700
08300622070008000705070008300785083155000868085000802418085002702426085002702453
08500260248008500210250608318090252708500080433608500320434408500320437608500280
44080850021044360580034044571170006044910720003044971120009045001110013045091140
00904522113001604531002001304547008009204560#v22n6#v:\scielo\serial\rpsp\v22n6\m
arkup\a02v22n6.htm#S#l#4#1#article#1#^mDec.^a2007#oa#en#br1.1#1#3.1#ilus#tab#02#
RPSP020#nd#Rev. panam. salud pública#22#6#20071200#^f376^l382#1020-4989#Uptake o
f health care services and health status of HIV-infected women diagnosed through
 antenatal HIV screening in Barbados, 1996-2004^len#Utilización de los servicios
 de atención sanitaria y estado de salud de las mujeres seropositivas al VIH dia
gnosticadas mediante el tamizaje prenatal para el VIH en Barbados, 1996-2004^les
#^rND^1A01 A02^nAlok^sKumar#^rND^1A03^nKrishna R^sKilaru#^rND^1A03^nSheila^sFord
e#^rND^1A03^nIra^sWaterman#^iA01^1The University of the West Indies^2School of C
linical Medicine and Research#^iA02^1The Queen Elizabeth Hospital^2Associate Con
sultant^cBridgetown^pBarbados#^iA03^1Ministry of Health^2Ladymeade HIV/AIDS Refe
rence Unit^cBridgetown^pBarbados#^len^aOBJECTIVES: To study utilization of HIV-r
elated health care services and to describe the health status of HIV-infected wo
men diagnosed through antenatal voluntary counseling and testing (VCT) for HIV i
nfection in Barbados. METHODS: This is a descriptive study. The study population
 includes all HIV-infected women in Barbados diagnosed as HIV-infected through V
CT for HIV infection during 1996-2004. RESULTS: The median duration of HIV infec
tion from time of diagnosis to the time of this report for the 163 women diagnos
ed during the study period was 72 months (low range, 9 months; high range, 117 m
onths). Of the 163 women, 102 (62.6 percent) had attended the centralized HIV/AI
DS clinic for follow-up (care, treatment, and monitoring), whereas 61 (37.4 perc
ent) had never attended the clinic. The median time lag between diagnosis of HIV
 infection and first presentation to the HIV/AIDS clinic was 36 months (low rang
e, 1 month; high range, 114 months). Of the HIV-infected women who attended the 
HIV/AIDS clinic, more than one-fourth had severe immunodeficiency at the time of
 their first follow-up visit. Of the 53 women undergoing highly active anti-retr
oviral therapy (HAART) at the time of the study, 23 (43.4 percent) began the the
rapy within three months of their first follow-up visit. CONCLUSIONS: Early HIV 
diagnosis through antenatal VCT is not enough to ensure that women with HIV will
 get adequate and timely HIV-related health care. These women suffer significant
 premature mortality, largely related to inadequate follow-up.#^dnd^i1#^tm^len^k
HIV infections^i1#^tm^len^kpregnant women^i1#^tm^len^khealth status^i1#^tm^len^k
Barbados^i1#^les^aOBJETIVOS: Estudiar la utilización de los servicios de atenció
n sanitaria relacionados con el VIH y describir el estado de salud de las mujere
s infectadas con este virus, diagnosticadas mediante el asesoramiento y la prueb
a de detección del VIH de carácter voluntario (APDV) durante el período prenatal
 en Barbados. MÉTODOS: Este es un estudio descriptivo. La población de estudio a
barcó a todas las mujeres infectadas por el VIH, diagnosticadas en Barbados medi
ante el APDV en 1996-2004. RESULTADOS: La mediana de la duración de la infección
 por el VIH -desde el diagnóstico hasta el momento de este informe- en las 163 m
ujeres diagnosticadas durante el período de estudio fue de 72 meses (nivel bajo:
 9 meses; nivel alto: 117 meses). De las 163 mujeres, 102 (62,6 por ciento) asis
tieron a la clínica centralizada para el VIH/sida para su seguimiento (atención,
 tratamiento y monitoreo), mientras que 61 (37,4 por ciento) nunca asistieron a 
la clínica. La mediana del lapso entre el diagnóstico de la infección por el VIH
 y la primera presentación a la clínica para el VIH/sida fue de 36 meses (nivel 
bajo: 1 mes; nivel alto: 114 meses). Más de la cuarta parte de las mujeres infec
tadas que acudieron a la clínica presentaban inmunodeficiencia grave en el momen
to de su primera consulta de seguimiento. De las 53 mujeres que se sometieron al
 tratamiento antirretroviral de gran actividad (HAART) durante el estudio, 23 (4
3,4 por ciento) comenzaron el tratamiento en los tres meses siguientes a su prim
era visita de seguimiento. CONCLUSIONES: El diagnóstico temprano mediante el APD
V no garantiza que las mujeres con VIH reciban una atención adecuada y oportuna 
para tratar esa infección. Estas mujeres sufren una mortalidad significativament
e prematura, en gran parte debido al inadecuado seguimiento.#^dnd^i2#^tm^les^kIn
fecciones por VIH^i2#^tm^les^kmujeres embarazadas^i2#^tm^les^kestado de salud^i2
#^tm^les^kBarbados^i2#Caribbean Health Research Council#other#21#20060717#17 Jul
y 2006#20071029#29 October 2007#a02v22n6.htm#Internet^ihttp://www.scielosp.org/s
cielo.php?script=sci_arttext&pid=S1020-49892007001100002##
00357000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704012400074002001300198#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a02v22n6.htm#S#p#5#1#article#114#<p align="right"><fon
t size="2" face="Verdana"><b>INVESTIGACI&Oacute;N ORIGINAL</b>    ORIGINAL RESEA
RCH</font></p>     ^cY#a02v22n6.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a02v22n6.htm#S#p#6#2#article#114#<p>&nbsp;</p>     ^cY
#a02v22n6.htm##
00434000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704020100074002001300275#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a02v22n6.htm#S#p#7#3#article#114#<p><font size="4" fac
e="verdana"><b>Uptake of health care services and health    status of HIV-infect
ed women diagnosed through antenatal HIV screening in Barbados,    1996–2004</b>
</font></p>     ^cY#a02v22n6.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a02v22n6.htm#S#p#8#4#article#114#<p>&nbsp;</p>     ^cY
#a02v22n6.htm##
00497000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704026400074002001300338#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a02v22n6.htm#S#p#9#5#article#114#<p><font size="3" fac
e="verdana"><b>Utilizaci&oacute;n de los servicios de atenci&oacute;n    sanitar
ia y estado de salud de las mujeres seropositivas al VIH diagnosticadas    media
nte el tamizaje prenatal para el VIH en Barbados, 1996–2004</b></font></p>     ^
cY#a02v22n6.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704002200075002001300097#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a02v22n6.htm#S#p#10#6#article#114#<p>&nbsp;</p>     ^c
Y#a02v22n6.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704002200075002001300097#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a02v22n6.htm#S#p#11#7#article#114#<p>&nbsp;</p>     ^c
Y#a02v22n6.htm##
00405000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704017100075002001300246#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a02v22n6.htm#S#p#12#8#article#114#<p><font size="2" fa
ce="Verdana"><b>Alok Kumar<sup>I</sup>; Krishna R. Kilaru<sup>II</sup>;    Sheil
a Forde<sup>II</sup>; Ira Waterman<SUP>II</SUP></b></font></p>     ^cY#a02v22n6.
htm##
00854000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704062000075002001300695#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a02v22n6.htm#S#p#13#9#article#114#<p><font size="2" fa
ce="Verdana"><SUP>I</sup>Lecturer, School of Clinical Medicine    and Research, 
The University of the West Indies (Cave Hill), and Associate Consultant,    The 
Queen Elizabeth Hospital, Bridgetown, Barbados. Send correspondence and    reque
sts for reprints to: Alok Kumar, School of Clinical Medicine and Research,    Th
e University of the West Indies, Cave Hill Campus University Drive, Cave Hill,  
  St. Michael, Bridgetown, Barbados, West Indies; telephone: (246) 436-6450; fax
:    (246) 429 5374; e-mail: <a href="mailto:alokkumar.uwichill@gmail. com">alok
kumar.uwichill@gmail.    com</a>    ^cY#a02v22n6.htm##
00353000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704011800076002001300194#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a02v22n6.htm#S#p#14#10#article#114#<br>   <SUP>II</sup
>Ladymeade HIV/AIDS Reference    Unit, Ministry of Health, Bridgetown, Barbados<
/font></p>     ^cY#a02v22n6.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a02v22n6.htm#S#p#15#11#article#114#<p>&nbsp;</p>     ^
cY#a02v22n6.htm##
00279000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704004400076002001300120#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a02v22n6.htm#S#p#16#12#article#114#<p>&nbsp;</p> <hr s
ize="1" noshade>     ^cY#a02v22n6.htm##
00303000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704006800076002001300144#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a02v22n6.htm#S#p#17#13#article#114#<p><font size="2" f
ace="Verdana"><b>ABSTRACT</b></font></p>     ^cY#a02v22n6.htm##
00519000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704028400076002001300360#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a02v22n6.htm#S#p#18#14#article#114#<p><font size="2" f
ace="Verdana"><B>OBJECTIVES:</b>&nbsp;To study utilization    of HIV-related hea
lth care services and to describe the health status of HIV-infected    women dia
gnosed through antenatal voluntary counseling and testing (VCT) for    HIV infec
tion in Barbados.    ^cY#a02v22n6.htm##
00444000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704020900076002001300285#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a02v22n6.htm#S#p#19#15#article#114#<br>   <B>METHODS:&
nbsp;</b>This is a descriptive study. The study population includes    all HIV-i
nfected women in Barbados diagnosed as HIV-infected through VCT for    HIV infec
tion during 1996–2004.    ^cY#a02v22n6.htm##
01171000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704093600076002001301012#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a02v22n6.htm#S#p#20#16#article#114#<br>   <B>RESULTS:&
nbsp;</b>The median duration of HIV infection from time of diagnosis    to the t
ime of this report for the 163 women diagnosed during the study period    was 72
 months (low range, 9 months; high range, 117 months). Of the 163 women,    102 
(62.6%) had attended the centralized HIV/AIDS clinic for follow-up (care,    tre
atment, and monitoring), whereas 61 (37.4%) had never attended the clinic.    Th
e median time lag between diagnosis of HIV infection and first presentation    t
o the HIV/AIDS clinic was 36 months (low range, 1 month; high range, 114 months)
.    Of the HIV-infected women who attended the HIV/AIDS clinic, more than one-f
ourth    had severe immunodeficiency at the time of their first follow-up visit.
 Of the    53 women undergoing highly active anti-retroviral therapy (HAART) at 
the time    of the study, 23 (43.4%) began the therapy within three months of th
eir first    follow-up visit.    ^cY#a02v22n6.htm##
00523000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704028800076002001300364#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a02v22n6.htm#S#p#21#17#article#114#<br>   <B>CONCLUSIO
NS: </b>Early HIV diagnosis through antenatal VCT is not    enough to ensure tha
t women with HIV will get adequate and timely HIV-related    health care. These 
women suffer significant premature mortality, largely related    to inadequate f
ollow-up.</font></p>     ^cY#a02v22n6.htm##
00387000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704015200076002001300228#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a02v22n6.htm#S#p#22#18#article#114#<p><font size="2" f
ace="Verdana"><b>Key words: </b>HIV infections, pregnant women,    health status
, Barbados.</font></p> <hr size="1" noshade>     ^cY#a02v22n6.htm##
00302000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704006700076002001300143#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a02v22n6.htm#S#p#23#19#article#114#<p><font size="2" f
ace="Verdana"><b>RESUMEN</b></font></p>     ^cY#a02v22n6.htm##
00650000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704041500076002001300491#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a02v22n6.htm#S#p#24#20#article#114#<p><font size="2" f
ace="Verdana"><B>OBJETIVOS:</b>&nbsp;Estudiar la utilizaci&oacute;n    de los se
rvicios de atenci&oacute;n sanitaria relacionados con el VIH y describir    el e
stado de salud de las mujeres infectadas con este virus, diagnosticadas    media
nte el asesoramiento y la prueba de detecci&oacute;n del VIH de car&aacute;cter 
   voluntario (APDV) durante el per&iacute;odo prenatal en Barbados.    ^cY#a02v
22n6.htm##
00461000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704022600076002001300302#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a02v22n6.htm#S#p#25#21#article#114#<br>   <B>M&Eacute;
TODOS:&nbsp;</b>Este es un estudio descriptivo. La poblaci&oacute;n    de estudi
o abarc&oacute; a todas las mujeres infectadas por el VIH, diagnosticadas    en 
Barbados mediante el APDV en 1996–2004.    ^cY#a02v22n6.htm##
01396000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704116100076002001301237#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a02v22n6.htm#S#p#26#22#article#114#<br>   <B>RESULTADO
S: </b>La mediana de la duraci&oacute;n de la infecci&oacute;n por    el VIH —de
sde el diagn&oacute;stico hasta el momento de este informe— en las    163 mujere
s diagnosticadas durante el per&iacute;odo de estudio fue de 72 meses    (nivel 
bajo: 9 meses; nivel alto: 117 meses). De las 163 mujeres, 102 (62,6%)    asisti
eron a la cl&iacute;nica centralizada para el VIH/sida para su seguimiento    (a
tenci&oacute;n, tratamiento y monitoreo), mientras que 61 (37,4%) nunca asistier
on    a la cl&iacute;nica. La mediana del lapso entre el diagn&oacute;stico de l
a    infecci&oacute;n por el VIH y la primera presentaci&oacute;n a la cl&iacute
;nica    para el VIH/sida fue de 36 meses (nivel bajo: 1 mes; nivel alto: 114 me
ses).    M&aacute;s de la cuarta parte de las mujeres infectadas que acudieron a
 la cl&iacute;nica    presentaban inmunodeficiencia grave en el momento de su pr
imera consulta de    seguimiento. De las 53 mujeres que se sometieron al tratami
ento antirretroviral    de gran actividad (HAART) durante el estudio, 23 (43,4%)
 comenzaron el tratamiento    en los tres meses siguientes a su primera visita d
e seguimiento.    ^cY#a02v22n6.htm##
00577000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704034200076002001300418#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a02v22n6.htm#S#p#27#23#article#114#<br>   <B>CONCLUSIO
NES:&nbsp;</b>El diagn&oacute;stico temprano mediante el APDV no    garantiza qu
e las mujeres con VIH reciban una atenci&oacute;n adecuada y oportuna    para tr
atar esa infecci&oacute;n. Estas mujeres sufren una mortalidad significativament
e    prematura, en gran parte debido al inadecuado seguimiento.</font></p>     ^
cY#a02v22n6.htm##
00404000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704016900076002001300245#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a02v22n6.htm#S#p#28#24#article#114#<p><font size="2" f
ace="Verdana"><b>Palabras clave: </b>Infecciones por VIH, mujeres    embarazadas
, estado de salud, Barbados.</font></p> <hr size="1" noshade>     ^cY#a02v22n6.h
tm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a02v22n6.htm#S#p#29#25#article#114#<p>&nbsp;</p>     ^
cY#a02v22n6.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a02v22n6.htm#S#p#30#26#article#114#<p>&nbsp;</p>     ^
cY#a02v22n6.htm##
01756000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704152100076002001301597#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a02v22n6.htm#S#p#31#27#article#114#<p><font size="2" f
ace="Verdana">Realizing the full potential benefits of antenatal    voluntary co
unseling and testing (VCT) for HIV infection is both an economic    compulsion a
nd a necessary public health objective for any successful and viable    HIV/AIDS
 prevention program (1–4). Antenatal testing is undertaken primarily    to offer
 interventions for prevention of mother-to-child transmission (PMTCT)    of HIV.
 However, the HIV diagnosis has implications for the mother herself,    which is
 often forgotten. Many, including the mothers themselves, wonder about    the si
gnificance of the letter "M" in "PMTCT" programs,    given the way such programs
 are implemented in developing countries. This is    particularly disturbing in 
the era of highly active anti-retroviral therapy    (HAART), given that model-ba
sed estimates indicate identifying patients early    through antenatal screening
, rather than through case finding, and beginning    therapy when the CD4 count<
a name="tx01"></a><a href="#nt01"><SUP>1</SUP></a>    is 350 cells/&#181;L, rath
er than waiting until values    drop to less than 200 cells/&#181;L, resulted in
 a survival    advantage (5, 6). Equally troublesome is developing countries' te
ndency to advocate    support for home care, community programs, and government 
services as effective    responses to the global orphan tragedy (7) without addr
essing the cause, that    is, preventing the creation of orphans by developing s
trategies to save the    lives of parents.</font></p>     ^cY#a02v22n6.htm##
01325000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704109000076002001301166#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a02v22n6.htm#S#p#32#28#article#114#<p><font size="2" f
ace="Verdana">Since 1996, more than four-fifths of pregnant    women in Barbados
 have received VCT for HIV infection during antenatal care    (8). In 2002, the 
national Mother-to-Child Transmission Plus (MTCT-Plus) initiative    was establi
shed to meet the needs of every family member infected or affected    by HIV/AID
S. Before that time, programs to prevent mother-to-child transmission    of HIV 
did not provide care and treatment to HIV-infected pregnant women and    mothers
. To fill this gap, the MTCT-Plus initiative expanded PMTCT programs    to inclu
de comprehensive treatment services for pregnant and postpartum women.    Nevert
heless, the question remains whether the full benefits of VCT are being    reali
zed in terms of making a difference in the health of HIV-infected women.    To a
nswer this question, this study analyzed the use of HIV-related follow-up    hea
lth services (care, treatment, and monitoring) by postpartum HIV-infected    wom
en, and their health status at first follow-up visit after the delivery of    th
eir babies.</font></p>     ^cY#a02v22n6.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a02v22n6.htm#S#p#33#29#article#114#<p>&nbsp;</p>     ^
cY#a02v22n6.htm##
00316000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704008100076002001300157#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a02v22n6.htm#S#p#34#30#article#114#<p><font size="3" f
ace="Verdana"><b>MATERIALS AND METHODS</b></font></p>     ^cY#a02v22n6.htm##
00311000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704007600076002001300152#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a02v22n6.htm#S#p#35#31#article#114#<p><font size="2" f
ace="Verdana"><b>Study population</b></font></p>     ^cY#a02v22n6.htm##
00694000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704045900076002001300535#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a02v22n6.htm#S#p#36#32#article#114#<p><font size="2" f
ace="Verdana">This is a descriptive study. The study population    includes all 
HIV-infected women in Barbados diagnosed through antenatal VCT    for HIV infect
ion from January 1996 through December 2004. The study participants,    like all
 new mothers in Barbados diagnosed with HIV, and their newborns, are    enrolled
 in the Pediatric HIV Surveillance Program provided through national    public h
ealth care services.</font></p>     ^cY#a02v22n6.htm##
01552000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704131700076002001301393#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a02v22n6.htm#S#p#37#33#article#114#<p><font size="2" f
ace="Verdana">Barbados has a well-organized antenatal care    delivery system de
livered through three main types of health care facilities:    state-run polycli
nics—national primary care facilities where most pregnant women    receive their
 antenatal care; private offices of obstetricians and general practitioners;    
and The Queen Elizabeth Hospital (QEH) in Bridgetown, Barbados' tertiary care   
 referral hospital. Both the polyclinics and private doctors' offices liaise    
closely with QEH, where most deliveries are carried out. Following delivery,    
most women return to their respective polyclinics for postnatal follow-up, while
    others receive follow-up at the private obstetrician or general practitioner
's    office where they received antenatal care. HIV-exposed newborns are follow
ed    up at the QEH Pediatric Clinic, whereas HIV-infected mothers are referred 
to    the centralized HIV/ AIDS clinic run by the Ministry of Health (MOH). Esta
blished    in the early 1990s for the sole purpose of providing continuous follo
w-up to    all HIV-infected persons in the country, the clinic was located at th
e QEH Respiratory    Unit (RU) until 2002, when it was moved to its current loca
tion at the Ladymeade    Reference Unit (LRU) at MOH facilities in Bridgetown.</
font></p>     ^cY#a02v22n6.htm##
01012000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704077700076002001300853#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a02v22n6.htm#S#p#38#34#article#114#<p><font size="2" f
ace="Verdana">Follow-up of HIV-infected women involves monitoring    their gener
al health; conducting CD4 cell counts; and providing prophylaxis,    as well as 
treatment of opportunistic infections. Since 2001, HAART (highly    active anti-
retroviral therapy) has been provided for all HIV-infected persons    in Barbado
s; the therapy is provided free of cost at the point of delivery,    based on U.
S. Department of Health and Human Services (DHHS) guidelines modified    for the
 Caribbean. A CD4 cell count of less than 200 cells/&#181;L    is an absolute in
dication for commencing HAART. Some persons with a CD4 cell    count between 200
 and 350 cells/&#181;L are also treated,    based on their clinical stage and/or
 viral load level.</font></p>     ^cY#a02v22n6.htm##
00307000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704007200076002001300148#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a02v22n6.htm#S#p#39#35#article#114#<p><font size="2" f
ace="Verdana"><b>Study ethics</b></font></p>     ^cY#a02v22n6.htm##
00960000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704072500076002001300801#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a02v22n6.htm#S#p#40#36#article#114#<p><font size="2" f
ace="Verdana">All HIV-infected women who delivered from 1996    through 2004 wer
e identified from the Pediatric HIV Surveillance Program database.    The women 
were contacted, and informed consent for the study was obtained. Study    partic
ipants were assured of the complete confidentiality of all information    provid
ed for the purpose of the study. They were also assured that their information  
  would in no way influence their ongoing HIV/AIDS care or future medical care. 
   The study method was approved by the Institutional Review Board for ethical  
  issues in research at The University of the West Indies (Cave Hill) School of 
   Clinical Medicine and Research in Barbados.</font></p>     ^cY#a02v22n6.htm##
00322000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704008700076002001300163#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a02v22n6.htm#S#p#41#37#article#114#<p><font size="2" f
ace="Verdana"><b>Data collection methodology</b></font></p>     ^cY#a02v22n6.htm
##
01153000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704091800076002001300994#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a02v22n6.htm#S#p#42#38#article#114#<p><font size="2" f
ace="Verdana">Information on study participants' demographic    data, including 
age, employment status, living arrangements, and marital status,    was collecte
d from records of their antenatal care maintained at the QEH. Information    on 
their use of HIV-related health services and the status of their health with    
respect to HIV/AIDS–related illness, including time and year of diagnosis and   
 admission, and outcome, at the QEH; follow-up at the HIV/AIDS clinic at the    
QEH RU (before 2002) or the LRU (after 2002); treatment, and adherence to treatm
ent    (if any); and deaths (if any) was collected from LRU and QEH medical reco
rds.    For women who received follow-up at the HIV/AIDS clinic at RU/LRU, infor
mation    on their first presentation at the clinic, their health status at the 
time,    and their CD4 counts was collected from records maintained at the LRU.<
/font></p>     ^cY#a02v22n6.htm##
00335000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010000076002001300176#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a02v22n6.htm#S#p#43#39#article#114#<p><font size="2" f
ace="Verdana"><b>Outcome measures and statistical methods</b></font></p>     ^cY
#a02v22n6.htm##
00690000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704045500076002001300531#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a02v22n6.htm#S#p#44#40#article#114#<p><font size="2" f
ace="Verdana">Outcome measures included proportion of study    participants atte
nding the RU/LRU for HIV/AIDS–related illness, time interval    between HIV diag
nosis and first visit to the RU/LRU, CD4 cell counts at first    visit to the RU
/LRU, proportion of study participants on HAART, time interval    between first 
presentation to the RU/LRU and initiation of HAART, compliance    with follow-up
, and mortality.</font></p>     ^cY#a02v22n6.htm##
01290000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704105500076002001301131#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a02v22n6.htm#S#p#45#41#article#114#<p><font size="2" f
ace="Verdana">All data collected for the study were stored    in a pre-designed 
Microsoft Access database and analyzed using SPSS statistical    software packag
e, version 11. The 9-year study period was further divided, based    on the avai
lability of HAART, into three 3-year sub-periods: 1996–1998, 1999–2001,    and 2
002–2004. For the purpose of comparison, the 1996–1998 period, when no    antivi
ral therapy was available for treatment of HIV-infected persons in the    countr
y, was selected as a baseline and compared with the 2002–2004 period,    when HA
ART was available for treatment. Antiretroviral therapy (mostly dual    therapy)
 was also available during the 1999–2001 period, but only for a few    HIV-infec
ted individuals. The 95% confidence interval (CI) was corrected for    continuit
y. Chi-square tests were used to analyze proportional data, and a <I>p    </I>va
lue <U>&lt;</U> 0.05 was considered statistically significant. Graphs    were pr
epared with Microsoft Excel for Windows XP, version 7.0.</font></p>     ^cY#a02v
22n6.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a02v22n6.htm#S#p#46#42#article#114#<p>&nbsp;</p>     ^
cY#a02v22n6.htm##
00302000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704006700076002001300143#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a02v22n6.htm#S#p#47#43#article#114#<p><font size="3" f
ace="Verdana"><b>RESULTS</b></font></p>     ^cY#a02v22n6.htm##
00340000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010500076002001300181#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a02v22n6.htm#S#p#48#44#article#114#<p><font size="2" f
ace="Verdana"><b>Socio-demographic profile of study population</b></font></p>   
  ^cY#a02v22n6.htm##
01379000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704114400076002001301220#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a02v22n6.htm#S#p#49#45#article#114#<p><font size="2" f
ace="Verdana">During the study period, 163 HIV-infected women    were diagnosed 
for the first time through antenatal screening. <a href="#tab01">Table    1</a> 
shows the relevant socio-demographic profile of these women. Most of them    wer
e in the 21–30 age group (56.4%), single (80.4%), and unemployed (42.3%);    151
 (92.6%, 95% CI = 87.2%, 95.9%) were asymptomatic at the time of their diagnosis
.    Twenty-four (14.7%, 95% CI = 9.8%, 21.3%) women were deceased, and the wher
eabouts    and status of 5 (3.1%, 95% CI = 1.3%, 6.9%) were unknown. The remaini
ng 134    (82.2%, 95% CI = 75.6%, 87.3%) were alive at the time of the study (<a
 href="#tab02">Table    2</a>). The median duration of HIV infection from the ti
me of diagnosis up to    the time of this study was 72 months (low range, 9 mont
hs; high range, 117 months).    Sixty-eight (41.7%, 95% CI = 34.4%, 49.4%) women
 were diagnosed during the period    1996– 1998, 58 (35.6%, 95% CI = 28.6%, 43.2
%) were diagnosed during 1999– 2001,    and 37 (22.7%, 95% CI = 16.9%, 29.7%) we
re diagnosed during 2002– 2004 (<a href="#tab03">Table    3</a>).</font></p>    
 ^cY#a02v22n6.htm##
00271000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704003600076002001300112#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a02v22n6.htm#S#p#50#46#article#114#<p><a name="tab01">
</a></p>     ^cY#a02v22n6.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a02v22n6.htm#S#p#51#47#article#114#<p>&nbsp;</p>     ^
cY#a02v22n6.htm##
00315000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704008000076002001300156#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a02v22n6.htm#S#p#52#48#article#114#<p align="center"><
img src="/img/revistas/rpsp/v22n6/a02tab01.gif"></p>     ^cY#a02v22n6.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a02v22n6.htm#S#p#53#49#article#114#<p>&nbsp;</p>     ^
cY#a02v22n6.htm##
00271000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704003600076002001300112#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a02v22n6.htm#S#p#54#50#article#114#<p><a name="tab02">
</a></p>     ^cY#a02v22n6.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a02v22n6.htm#S#p#55#51#article#114#<p>&nbsp;</p>     ^
cY#a02v22n6.htm##
00315000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704008000076002001300156#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a02v22n6.htm#S#p#56#52#article#114#<p align="center"><
img src="/img/revistas/rpsp/v22n6/a02tab02.gif"></p>     ^cY#a02v22n6.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a02v22n6.htm#S#p#57#53#article#114#<p>&nbsp;</p>     ^
cY#a02v22n6.htm##
00271000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704003600076002001300112#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a02v22n6.htm#S#p#58#54#article#114#<p><a name="tab03">
</a></p>     ^cY#a02v22n6.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a02v22n6.htm#S#p#59#55#article#114#<p>&nbsp;</p>     ^
cY#a02v22n6.htm##
00315000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704008000076002001300156#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a02v22n6.htm#S#p#60#56#article#114#<p align="center"><
img src="/img/revistas/rpsp/v22n6/a02tab03.gif"></p>     ^cY#a02v22n6.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a02v22n6.htm#S#p#61#57#article#114#<p>&nbsp;</p>     ^
cY#a02v22n6.htm##
00364000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704012900076002001300205#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a02v22n6.htm#S#p#62#58#article#114#<p><font size="2" f
ace="Verdana"><b>Follow-up of women diagnosed through antenatal    VCT as HIV-in
fected</b></font></p>     ^cY#a02v22n6.htm##
00977000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704074200076002001300818#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a02v22n6.htm#S#p#63#59#article#114#<p><font size="2" f
ace="Verdana">As shown in <a href="#tab02">Table 2</a>, of    the 163 women diag
nosed as HIV-infected through antenatal screening, 102 (62.6%,    95% CI = 54.9%
, 69.6%) had attended the centralized HIV/AIDS clinic (RU/LRU)—the    only clini
c for complete and comprehensive follow-up (care, treatment, and monitoring)    
of HIV-infected persons in Barbados—and 61 (37.4%, 95% CI = 30.0%, 45.3%) had   
 never attended the clinic for follow-up. For the 102 HIV-infected women who    
had attended the centralized HIV/ AIDS clinic, the median time interval between 
   diagnosis of HIV infection and first presentation to the clinic for follow-up
    was 36 months (low range, 1 month; high range, 114 months).</font></p>     ^
cY#a02v22n6.htm##
00358000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704012300076002001300199#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a02v22n6.htm#S#p#64#60#article#114#<p><font size="2" f
ace="Verdana"><b>Health status of HIV-infected women at first    follow-up visit
</b></font></p>     ^cY#a02v22n6.htm##
01427000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704119200076002001301268#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a02v22n6.htm#S#p#65#61#article#114#<p><font size="2" f
ace="Verdana">More than one-fourth (28.4%, 95% CI = 20.1%,    38.4%) of those wh
o presented for follow-up and had a CD4 cell count done at    the time of their 
first presentation to the RU/LRU had severe immunodeficiency    (CD4 cell counts
 &lt;200/&#181;L) (<a href="#tab02">Table    2</a>). Of the 102 women who attend
ed the follow-up clinic, 53 (52.0%, 95% CI    = 41.9%, 61.9%) were undergoing HA
ART up to the time of this study. Of those    who received HAART, 23 (43.4%, 95%
 CI = 30.1%, 57.6%) had begun the therapy    within three months of their first 
follow-up visit. Adherence to HAART was reported    as good (taking more than or
 equal to 96% of their prescribed medicine) in over    four-fifths (43, or 81.1%
) of those receiving the therapy. Among the 102 study    participants attending 
the follow-up clinic, adherence to follow-up schedules    was considered good (a
ttended the clinic at least once every three months after    their initial visit
) for 63 (61.8%) women and poor (lost to follow-up or presented    for follow-up
 less frequently than once every three months) in the case of 39    (38.2%) wome
n (<a href="#tab03">Table 3</a>).</font></p>     ^cY#a02v22n6.htm##
00378000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704014300076002001300219#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a02v22n6.htm#S#p#66#62#article#114#<p><font size="2" f
ace="Verdana"><b>Trends in uptake of health care services and    health status o
f HIV-infected women</b></font></p>     ^cY#a02v22n6.htm##
01077000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704084200076002001300918#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a02v22n6.htm#S#p#67#63#article#114#<p><font size="2" f
ace="Verdana">Trends in accessing HIV-related (follow-up) health    services by 
the 163 HIV-infected women diagnosed through antenatal screening,    and their h
ealth status, are shown in <a href="#tab03">Table 3</a>. Of those    diagnosed a
s HIV-infected during the 1996–1998 period, 55.9% had attended the    centralize
d HIV/AIDS clinic (RU/LRU) at some point; the corresponding figure    for 2002–2
004 increased to 78.4% (chi-square tests for trend; <i>p</i> = 0.049).    Only 5
0% of HIV- infected women diagnosed during 1996–1998 who attended the    central
ized HIV/AIDS clinic for follow-up services had good adherence to follow-up    s
chedules (at least once every three months), while the corresponding figure    f
or 2002–2004 increased to 72.4% (chi-square tests for trend; <i>p</i> = 0.034). 
   </font></p>     ^cY#a02v22n6.htm##
01054000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704081900076002001300895#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a02v22n6.htm#S#p#68#64#article#114#<p> <font size="2" 
face="Verdana">For HIV-infected women who presented for follow-up    at the cent
ralized HIV/AIDS care clinic, the median time interval between diagnosis    of H
IV infection and first presentation to the follow-up clinic dropped from    53 m
onths during 1996–1998 to 4 months during 2002–2004 (<a href="#fig01">Figure    
1</a>). The proportion of all HIV-infected women attending the RU/LRU who presen
ted    for follow-up within six months of their diagnosis of HIV infection incre
ased    from 21% during 1996–1998 to 67% during 2002–2004 (<I>p</I> &lt; 0.0001)
. During    1996–1998, 32% of all HIV-infected women who presented for follow-up
 and underwent    a CD4 cell count had values of less than 200/&#181;L;    this 
figure decreased to 14% during 2002–2004 (<I>p</I> = 0.048).</font></p>     ^cY#
a02v22n6.htm##
00271000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704003600076002001300112#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a02v22n6.htm#S#p#69#65#article#114#<p><a name="fig01">
</a></p>     ^cY#a02v22n6.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a02v22n6.htm#S#p#70#66#article#114#<p>&nbsp;</p>     ^
cY#a02v22n6.htm##
00315000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704008000076002001300156#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a02v22n6.htm#S#p#71#67#article#114#<p align="center"><
img src="/img/revistas/rpsp/v22n6/a02fig01.gif"></p>     ^cY#a02v22n6.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a02v22n6.htm#S#p#72#68#article#114#<p>&nbsp;</p>     ^
cY#a02v22n6.htm##
00305000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704007000076002001300146#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a02v22n6.htm#S#p#73#69#article#114#<p><font size="3" f
ace="Verdana"><b>DISCUSSION</b></font></p>     ^cY#a02v22n6.htm##
02175000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704194000076002001302016#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a02v22n6.htm#S#p#74#70#article#114#<p><font size="2" f
ace="Verdana">Barbados is one of the smaller countries in the    English-speakin
g Caribbean, with an estimated 2001 population of 266,800 and    a per capita gr
oss national product of US$ 18 200 (2006). The estimated (crude)    mortality ra
te for Barbados for 2001 was 8.3 per 1000 population (9), and the    adult preva
lence rate of HIV in the country is estimated at 1.75%, with a male-to-female   
 ratio of 2:1 (10). The Government of Barbados views health care as a fundamenta
l    right of all Barbadians and aims to provide comprehensive health care to al
l    its citizens through its elaborate government-controlled health care system
,    free of cost at the point of delivery. Since the early 1990s, a number of i
nterventions    were targeted to reduce mother-to-child transmission of HIV in t
he country.    These included the provision of free antenatal VCT (voluntary cou
nseling and    testing) for HIV infection since 1991 and free antiretroviral dru
gs for perinatal    prophylaxis since 1996, resulting in a dramatic decline in t
he rate of perinatal    transmission of HIV in the country (11). These measures 
were followed up by    the provision of free antiretroviral treatment for all el
igible HIV-infected    individuals in the country since 2002, coupled with HIV/A
IDS education interventions    targeting the general public. All potential benef
its of VCT must be realized    in order for it to be a cost-effective and powerf
ul tool in the fight against    the spread of HIV/AIDS. Early detection of HIV i
nfection in childbearing women    through antenatal screening following VCT is a
n important tool with huge potential    benefits, especially when coupled with t
he provision of HAART (6, 7). The findings    of this study are therefore releva
nt, and important, particularly in view of    the lack of any other published re
ports on these types of studies from the Caribbean    region.</font></p>     ^cY
#a02v22n6.htm##
00334000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009900076002001300175#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a02v22n6.htm#S#p#75#71#article#114#<p><font size="2" f
ace="Verdana"><b>Delayed follow-up of HIV-infected women</b></font></p>     ^cY#
a02v22n6.htm##
01928000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704169300076002001301769#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a02v22n6.htm#S#p#76#72#article#114#<p><font size="2" f
ace="Verdana">The socio-demographic profile of the HIV-infected    women in this
 study was consistent with those of the authors' earlier report,    which descri
bed the socio-demographic profile of HIV-infected postpartum women    in Barbado
s (12). It should be noted that more than 40 percent of the women    under study
 had been diagnosed with HIV for 6 to 9 years, while the HIV status    of more t
han four-fifths had been known for more than 3 years. Keeping these    figures i
n mind, it is a cause of great concern that more than one-third of    the 163 wo
men diagnosed through antenatal screening as HIV-infected after VCT    had never
 attended the centralized HIV/AIDS clinic at the RU/LRU, which was    designed t
o serve as a "one-stop shopping center" for persons affected    by HIV/AIDS. Equ
ally worrisome was the fact that entry into the follow-up system    for those wh
o did seek HIV-related care and treatment was significantly delayed    (with a m
edian time lag of 16 months between diagnosis of HIV infection and    first pres
entation to follow-up clinic). This suggests the loss of much of the    potentia
l advantage gained through early diagnosis during the antenatal period    follow
ing VCT. More than one-third of those who sought follow-up had poor adherence   
 to it or were lost to the follow-up system altogether. Loss to follow-up, signi
ficantly    long delays in seeking follow-up (following HIV diagnosis), and fail
ure to comply    with follow-up schedules are serious challenges to Barbados' MT
CT-Plus initiative.    The findings from this study reinforce observations made 
in other studies from    developing countries (13–15).</font></p>     ^cY#a02v22
n6.htm##
00311000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704007600076002001300152#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a02v22n6.htm#S#p#77#73#article#114#<p><font size="2" f
ace="Verdana"><b>The HAART factor</b></font></p>     ^cY#a02v22n6.htm##
02217000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704198200076002001302058#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a02v22n6.htm#S#p#78#74#article#114#<p><font size="2" f
ace="Verdana">There are two interesting findings in regard    to HAART and HIV-i
nfected women diagnosed through antenatal screening. First,    the unavailabilit
y of HAART during the initial (1996–2001) part of the study    period could have
 been partly responsible for the reluctance on the part of    these women to acc
ess health care services. It should be noted, however, that    most of these wom
en were asymptomatic at the time of their diagnosis and therefore    would not h
ave needed HAART until much later in the course of the disease. A    second and 
somewhat troublesome finding is that even during the sub-periods    when HAART w
as available, late presentation at advanced stage of the disease    was reflecte
d in a high percentage of women, most of whom were young (nearly    three-fourth
s under 30) and asymptomatic (more than 90%) at the time of diagnosis.    By the
 time most of these women made their first visit to the centralized HIV/AIDS    
clinic (RU/LRU), they had CD4 cell counts of less than 200/&#181;L;    therefore
, most were started on HAART within three months of their first presentation.   
 Given the evidence for poor outcome for HAART when initiated in patients with  
  CD4 cell counts of less than 200/&#181;L (16–19), these    numbers indicate a 
failure to capitalize on early diagnosis of HIV infection    in women who have w
illingly undergone HIV screening during antenatal VCT. They    also imply the fa
ilure to prevent the orphaning of many of the infants born    to these women, am
ong whom HIV infection has been avoided through the use of    perinatal ZDV/NVP<
a name="tx02"></a><a href="#nt02"><SUP>2</SUP></a> prophylaxis    (11). This sug
gests that the unavailability of HAART for the major part of the    study period
 (1996–2001) may have been a major limitation of the MTCT-Plus initiative    as 
well as a reason for delayed access of services for HIV follow-up by HIV-infecte
d    women in Barbados.</font></p>     ^cY#a02v22n6.htm##
00328000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009300076002001300169#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a02v22n6.htm#S#p#79#75#article#114#<p><font size="2" f
ace="Verdana"><b>Role of stigma and discrimination</b></font></p>     ^cY#a02v22
n6.htm##
01098000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704086300076002001300939#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a02v22n6.htm#S#p#80#76#article#114#<p><font size="2" f
ace="Verdana">Despite the provision of HAART free of cost,    there has been a p
oor return on follow-up of HIV-infected women diagnosed through    antenatal VCT
. This could be an indicator of the high degree of HIV/AIDS–associated    stigma
 and discrimination prevalent among this population; whether real, or    perceiv
ed, or both, stigma and discrimination may be the biggest hurdle to the    uptak
e of care and treatment services by HIV-infected women. A high prevalence    of 
HIV/AIDS–associated stigma and discrimination associated with a low rate    of s
elf disclosure of HIV serostatus has been reported in previous studies of    thi
s population (20, 21). Until very recently, as in other parts of the developing 
   world, HIV/AIDS–associated stigma and discrimination did not receive enough  
  attention in Barbados.</font></p>     ^cY#a02v22n6.htm##
00344000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010900076002001300185#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a02v22n6.htm#S#p#81#77#article#114#<p><font size="2" f
ace="Verdana"><b>Trends and future outlook for the VCT program    </b></font></p
>     ^cY#a02v22n6.htm##
01103000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704086800076002001300944#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a02v22n6.htm#S#p#82#78#article#114#<p><font size="2" f
ace="Verdana">In analyzing trends in HIV-related follow-up    services and their
 uptake by women in the study, it is heartening to note that    both the median 
time interval between diagnosis and first follow-up visit and    the proportion 
of women with a CD4 cell count less than 200/&#181;L    declined significantly d
uring 2002–2004 compared to 1996–1998. These results    should be viewed with ca
ution, however, for even during 2002–2004 (when HAART    was available free of c
ost for all HIV-infected persons in the country), more    than one-fifth (21.6%)
 of HIV-infected women diagnosed through antenatal screening    during this peri
od never attended the centralized HIV/AIDS clinic for follow-up,    and more tha
n one-seventh (14%) of those who did eventually seek follow-up had    a CD4 cell
 count less than 200/&#181;L.</font></p>     ^cY#a02v22n6.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a02v22n6.htm#S#p#83#79#article#114#<p>&nbsp;</p>     ^
cY#a02v22n6.htm##
00326000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009100076002001300167#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a02v22n6.htm#S#p#84#80#article#114#<p><font size="3" f
ace="Verdana"><b>CONCLUSIONS AND RECOMMENDATIONS</b></font></p>     ^cY#a02v22n6
.htm##
01426000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704119100076002001301267#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a02v22n6.htm#S#p#85#81#article#114#<p><font size="2" f
ace="Verdana">During the follow-up period, which ranged from    one to nine year
s, there was a significant level of mortality among the HIV-infected    women di
agnosed through antenatal VCT. This was associated with inadequate adherence    
to follow-up, or delayed seeking of follow-up (until relatively advanced stages 
   of the disease), in many cases compounded by the unavailability of HAART duri
ng    most of the study period. This indicates that HIV diagnosis alone is not e
nough    to ensure that all women with HIV will receive adequate and timely heal
th care.    One constraint may be the fragmented structure of the present system
 for postnatal    follow-up of HIV-infected women and their exposed newborns. In
 this system,    the mother receives her postnatal follow-up at the clinic where
 she received    antenatal care, but is referred to the centralized HIV/AIDS cli
nic for her HIV    follow-up, while her baby receives follow-up at the QEH. This
 system of fragmented    health care delivery, which requires visits to differen
t health clinics located    in different parts of the island, could have hampere
d study participants' follow-up.</font></p>     ^cY#a02v22n6.htm##
01204000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704096900076002001301045#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a02v22n6.htm#S#p#86#82#article#114#<p><font size="2" f
ace="Verdana">Counseling and testing recommendations should    highlight the int
rinsic value of early diagnosis. Ongoing counseling from different    members of
 the health care team involved in the care and treatment of these    women, with
 frequent reinforcement and without stigmatization or discrimination,    may inc
rease the uptake of HIV-specific health care services by this population.    Int
egrating antenatal and HIV/AIDS care for these women and their HIV-exposed    in
fants in one clinic would add continuity and could thus strengthen the rapport  
  between the HIV-infected women and their care provider. It may also improve   
 adherence to and the quality of their follow-up. Conducting focus group discuss
ions    with these women to gain further insight into barriers to follow-up as p
erceived    by these women may be useful in identifying system constraints as we
ll as more    appropriate and effective solutions.</font></p>     ^cY#a02v22n6.h
tm##
00467000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704023200076002001300308#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a02v22n6.htm#S#p#87#83#article#114#<p><font size="2" f
ace="Verdana"><B>Acknowledgement. </b>This study was supported    by a research 
grant for 2005 from the Caribbean Health Research Council, Port    of Spain, The
 Republic of Trinidad and Tobago.</font></p>     ^cY#a02v22n6.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a02v22n6.htm#S#p#88#84#article#114#<p>&nbsp;</p>     ^
cY#a02v22n6.htm##
00305000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704007000076002001300146#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a02v22n6.htm#S#p#89#85#article#114#<p><font size="3" f
ace="Verdana"><B>REFERENCES</b></font></p>     ^cY#a02v22n6.htm##
00492000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704024300078002001300321#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a02v22n6.htm#S#p#90#86#article#114#1#<p><f
ont size="2" face="Verdana">1. Newell ML, Dabis F, Tolley K, Whynes    D. Cost-e
ffectiveness and cost-benefit in the prevention of mother-to-child    transmissi
on of HIV in developing countries. AIDS. 1998; 12:1571–80.</font></p>     ^cY#a0
2v22n6.htm##
00473000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704022400078002001300302#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a02v22n6.htm#S#p#91#87#article#114#2#<p><f
ont size="2" face="Verdana">2. Marseille E, Kahn JG, Saba J. Cost-effectiveness 
   of antiviral drug therapy to reduce mother-to-child HIV transmission in sub-S
aharan    Africa. AIDS. 1998;12:939–48.</font></p>     ^cY#a02v22n6.htm##
00518000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704026900078002001300347#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a02v22n6.htm#S#p#92#88#article#114#3#<p><f
ont size="2" face="Verdana">3. Wilkinson D, Floyd K, Gilks CF. Antiretroviral   
 drugs as a public health intervention for pregnant HIV-infected women in rural 
   South Africa: an issue of cost-effectiveness and capacity. AIDS. 1998;12:1675
–82.</font></p>     ^cY#a02v22n6.htm##
00532000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704028300078002001300361#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a02v22n6.htm#S#p#93#89#article#114#4#<p><f
ont size="2" face="Verdana">4. Michael S, Steven G, Gloria S, Colin    F, Donald
 B, Claudes K, et al. Cost-effectiveness of voluntary HIV-1 counselling    and t
esting in reducing sexual transmission of HIV-1 in Kenya and Tanzania.    Lancet
. 2000;356:113–21.</font></p>     ^cY#a02v22n6.htm##
00669000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704042000078002001300498#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a02v22n6.htm#S#p#94#90#article#114#5#<p><f
ont size="2" face="Verdana">5. Hunter S, Williamson J. Children on the    brink 
2000: updated estimates and recommendations for intervention. &#91;Executive    
Summary&#93;. Washington: USAID; 2000. Available from: <a href="http://www.usaid
.gov/press/releases/2000/childrenreport.pdf" target="_blank">http://www.usaid.go
v/press/releases/2000/childrenreport.pdf</a>.    Accessed 28 February 2005.</fon
t></p>     ^cY#a02v22n6.htm##
00523000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704027400078002001300352#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a02v22n6.htm#S#p#95#91#article#114#6#<p><f
ont size="2" face="Verdana">6. Sanders GD, Bayoumi AM, Sundaram V, Bilir    SP, 
Neukermans CP, Rydzak CE, et al. Cost-effectiveness of screening for HIV    in t
he era of highly active antiretroviral therapy. N Engl J Med. 2005 Feb 10;352(6)
:570–85. </font></p>     ^cY#a02v22n6.htm##
00469000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704022000078002001300298#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a02v22n6.htm#S#p#96#92#article#114#7#<p><f
ont size="2" face="Verdana">7. Gibb DM, Ades AE, Gupta R, Sculpher MJ.    Costs 
and benefits to the mother of antenatal HIV testing: estimates from simulation  
  modelling. AIDS. 1999;13:1569–76.</font></p>     ^cY#a02v22n6.htm##
00595000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704034600078002001300424#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a02v22n6.htm#S#p#97#93#article#114#8#<p><f
ont size="2" face="Verdana">8. Kumar A, St. White H, Carter AO. Trends    in the
 uptake of antenatal voluntary counseling and testing for HIV and the    HIV pre
valence among childbearing women in Barbados, 1993–2004: evidence to    gauge th
e effectiveness of HIV prevention measures. West Indian Med J. 2007;56(1):167–70
.</font></p>     ^cY#a02v22n6.htm##
00541000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704029200078002001300370#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a02v22n6.htm#S#p#98#94#article#114#9#<p><f
ont size="2" face="Verdana">9. Pan American Health Organization. Country    prof
ile–Barbados. PAHO. Available from: <a href="http://www.paho.org/English/DD/AIS/
cp_052.htm" target="_blank">http://www.paho.org/English/DD/AIS/cp_052.htm</a>.  
  Accessed 17 January 2006.</font></p>     ^cY#a02v22n6.htm##
00505000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704025500079002001300334#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a02v22n6.htm#S#p#99#95#article#114#10#<p><
font size="2" face="Verdana">10. Caribbean Epidemiology Centre; Pan American    
Health Organization/World Health Organization. Status and trends: analysis of   
 the Caribbean HIV/AIDS epidemic 1982–2002. Port of Spain: CAREC; 2004.</font></
p>     ^cY#a02v22n6.htm##
00503000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073888000300077704025200080002001300332#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a02v22n6.htm#S#p#100#96#article#114#11#<p>
<font size="2" face="Verdana">11. St. John MA, Kumar A, Cave C. Reduction    in 
perinatal transmission and mortality from human immunodeficiency virus after    
intervention with zidovudine. Pediatr Infect Dis J. 2003;22(5):422–6.</font></p>
     ^cY#a02v22n6.htm##
00435000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073888000300077704018400080002001300264#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a02v22n6.htm#S#p#101#97#article#114#12#<p>
<font size="2" face="Verdana">12. Kumar A, Vent B. Characteristics of    HIV inf
ected childbearing women in Barbados. Pan Am J Public Health. 2003 Jan;13(1):1–9
.</font></p>     ^cY#a02v22n6.htm##
00653000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073888000300077704040200080002001300482#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a02v22n6.htm#S#p#102#98#article#114#13#<p>
<font size="2" face="Verdana">13. Manzi M, Zachariah R, Teck R, Buhendwa    L, K
azima J, Bakali E, et al. High acceptability of voluntary counselling and    HIV
-testing but unacceptable loss to follow up in a prevention of mother-to-child  
  HIV transmission program in rural Malawi: scaling-up requires a different way 
   of acting. Trop Med Int Health. 2005 Dec;10(12):1242–50.</font></p>     ^cY#a
02v22n6.htm##
00467000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073888000300077704021600080002001300296#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a02v22n6.htm#S#p#103#99#article#114#14#<p>
<font size="2" face="Verdana">14. Ickovics JR, Forsyth B, Ethier KA, Harris    P
, Rodin J. Delayed entry into health care for women with HIV disease. AIDS    Pa
tient Care STDS. 1996;10(1):21–4.</font></p>     ^cY#a02v22n6.htm##
00514000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704026200081002001300343#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a02v22n6.htm#S#p#104#100#article#114#15#<p
><font size="2" face="Verdana">15. Segurado AC, Miranda SD, Latorre MD;    Brazi
lian Enhancing Care Initiative Team. Evaluation of the care of women living    w
ith HIV/AIDS in Sao Paulo, Brazil. AIDS Patient Care STDS. 2003;17(2):85–93.    
</font></p>     ^cY#a02v22n6.htm##
00600000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704034800081002001300429#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a02v22n6.htm#S#p#105#101#article#114#16#<p
><font size="2" face="Verdana">16. Paredes R, Mocroft A, Kirk O, Lazzarin    A, 
Barton SE, van Lunzen J, et al. Predictors of virological success and ensuing   
 failure in HIV-positive patients starting highly active antiretroviral therapy 
   in Europe: results from the EuroSIDA study. Arch Intern Med. 2000; 160(8): 11
23–32.</font></p>     ^cY#a02v22n6.htm##
00590000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704033800081002001300419#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a02v22n6.htm#S#p#106#102#article#114#17#<p
><font size="2" face="Verdana">17. Palella FJ Jr, Deloria-Knoll M, Chmiel    JS,
 Moorman AC, Wood KC, Greenberg AE, et al. HIV Outpatient Study Investigators.  
  Survival benefit of initiating antiretroviral therapy in HIV-infected persons 
   in different CD4+ cell strata. Ann Intern Med. 2003 Apr 15;138(8): 620–6.</fo
nt></p>     ^cY#a02v22n6.htm##
00594000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704034200081002001300423#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a02v22n6.htm#S#p#107#103#article#114#18#<p
><font size="2" face="Verdana">18. Ormaasen V, Bruun JN, Sandvik L, Holberg-Pete
rsen    M, Gaarder PI. Prognostic value of changes in CD4 count and HIV RNA duri
ng the    first six months on highly active antiretroviral therapy in chronic hu
man immunodeficiency    virus infection. Scand J Infect Dis. 2003;35(6-7):383–8.
</font></p>     ^cY#a02v22n6.htm##
00526000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704027400081002001300355#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a02v22n6.htm#S#p#108#104#article#114#19#<p
><font size="2" face="Verdana">19. Hogg RS, Yip B, Chan KJ, Wood E, Craib    KJ,
 O'Shaughnessy MV, et al. Rates of disease progression by baseline CD4 cell    c
ount and viral load after initiating triple-drug therapy. JAMA. 2001 Nov 28;286(
20):2568–77.</font></p>     ^cY#a02v22n6.htm##
00519000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704026700081002001300348#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a02v22n6.htm#S#p#109#105#article#114#20#<p
><font size="2" face="Verdana">20. Kumar A, Kilaru KR, Forde S, Kumari    G. Pre
valence and correlates of serostatus disclosure in HIV-infected adults    attend
ing the follow up and treatment clinic in Barbados. Social Medicine. 2007;2(2):8
9–97.</font></p>     ^cY#a02v22n6.htm##
00518000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704026600081002001300347#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a02v22n6.htm#S#p#110#106#article#114#21#<p
><font size="2" face="Verdana">21. Kumar A, Waterman I, Kumari G. Prevalence    
and correlates of HIV serostatus disclosure: a prospective study among HIV-infec
ted    postparturient women in Barbados. AIDS Patient Care STDS. 2006;20(10):724
–30.</font></p>     ^cY#a02v22n6.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a02v22n6.htm#S#p#111#107#article#114#<p>&nbsp;</p>    
 ^cY#a02v22n6.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a02v22n6.htm#S#p#112#108#article#114#<p>&nbsp;</p>    
 ^cY#a02v22n6.htm##
00314000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704007700078002001300155#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a02v22n6.htm#S#p#113#109#article#114#<p><font size="2"
 face="Verdana">Manuscript received on 17 July 2006.    ^cY#a02v22n6.htm##
00324000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704008700078002001300165#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a02v22n6.htm#S#p#114#110#article#114#<br>   Revised ve
rsion accepted for publication on 29 October 2007.</font></p>     ^cY#a02v22n6.h
tm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a02v22n6.htm#S#p#115#111#article#114#<p>&nbsp;</p>    
 ^cY#a02v22n6.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a02v22n6.htm#S#p#116#112#article#114#<p>&nbsp;</p>    
 ^cY#a02v22n6.htm##
00574000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704033700078002001300415#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a02v22n6.htm#S#p#117#113#article#114#<p><font size="2"
 face="Verdana"><a name="nt01"></a><a href="#tx01">1</a> CD4    cell count is a 
marker of the degree of immunodeficiency in persons infected    with HIV. Normal
 CD4 cell count is usually greater than 750 cells/&#181;L.    Values less than 2
00 cells/&#181;L are considered to represent    severe immunodeficiency.    ^cY#
a02v22n6.htm##
00614000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704037700078002001300455#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a02v22n6.htm#S#p#118#114#article#114#<br>   <a name="n
t02"></a><a href="#tx02">2</a> St. John MA, Kumar A, Cave C, Carmichael    K. Ef
ficacy of nevirapine administration on the mother to child transmission    of HI
V using a modified HIVNET 012 regimen. &#91;Conference presentation&#93;. At: Ca
ribbean    Health Research Council 48th Annual Scientific Meeting, Nassau, Baham
as, 1–3    May 2003.</font></p>     ^cY#a02v22n6.htm##
00631000000000301000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100017000770100015000940100
01600109010001600125012012100141030000500262065000900267064000500276031000300281
014000800284865000900292002001300301035001000314801000500324#v22n6#v:\scielo\ser
ial\rpsp\v22n6\markup\a02v22n6.htm#S#c#119#1#article#21#1#^rND^sNewell^nML#^rND^
sDabis^nF#^rND^sTolley^nK#^rND^sWhynes^nD#Cost-effectiveness and cost-benefit in
 the prevention of mother-to-child transmission of HIV in developing countries^l
en#AIDS#19980000#1998#12#1571-80#20071200#a02v22n6.htm#0269-9370#AIDS##
00595000000000289000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100019000770100015000960100
01400111012011400125030000500239065000900244064000500253031000300258014000700261
865000900268002001300277035001000290801000500300#v22n6#v:\scielo\serial\rpsp\v22
n6\markup\a02v22n6.htm#S#c#120#2#article#21#2#^rND^sMarseille^nE#^rND^sKahn^nJG#
^rND^sSaba^nJ#Cost-effectiveness of antiviral drug therapy to reduce mother-to-c
hild HIV transmission in sub-Saharan Africa^len#AIDS#19980000#1998#12#939-48#200
71200#a02v22n6.htm#0269-9370#AIDS##
00640000000000289000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100019000770100015000960100
01600111012015600127030000500283065000900288064000500297031000300302014000800305
865000900313002001300322035001000335801000500345#v22n6#v:\scielo\serial\rpsp\v22
n6\markup\a02v22n6.htm#S#c#121#3#article#21#3#^rND^sWilkinson^nD#^rND^sFloyd^nK#
^rND^sGilks^nCF#Antiretroviral drugs as a public health intervention for pregnan
t HIV-infected women in rural South Africa: an issue of cost-effectiveness and c
apacity^len#AIDS#19980000#1998#12#1675-82#20071200#a02v22n6.htm#0269-9370#AIDS##
00718000000000337000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100017000770100016000940100
01600110010001500126010001600141010001700157810000600174012012900180030000700309
06500090031606400050032503100040033001400070033486500090034100200130035003500100
0363801000700373#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a02v22n6.htm#S#c#122#4
#article#21#4#^rND^sMichael^nS#^rND^sSteven^nG#^rND^sGloria^nS#^rND^sColin^nF#^r
ND^sDonald^nB#^rND^sClaudes^nK#et al#Cost-effectiveness of voluntary HIV-1 couns
elling and testing in reducing sexual transmission of HIV-1 in Kenya and Tanzani
a^len#Lancet#20000000#2000#356#113-21#20071200#a02v22n6.htm#0099-5355#Lancet##
00647000000000277000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750160016000770160020000930180
10800113066001100221062000600232065000900238064000500247037006000252110000900312
109002600321865000900347002001300356#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a0
2v22n6.htm#S#c#123#5#article#21#5#^rND^sHunter^nS#^rND^sWilliamson^nJ#Children o
n the brink 2000: updated estimates and recommendations for intervention. [Execu
tive Summary]^len#Washington#USAID#20000000#2000#http://www.usaid.gov/press/rele
ases/2000/childrenreport.pdf#20050228#Accessed 28 February 2005#20071200#a02v22n
6.htm##
00728000000000349000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100018000770100018000950100
01800113010001600131010002100147010001700168810000600185012009500191030001300286
06500090029906400120030803100040032003200020032401400070032686500090033300200130
0342035001000355801001300365#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a02v22n6.h
tm#S#c#124#6#article#21#6#^rND^sSanders^nGD#^rND^sBayoumi^nAM#^rND^sSundaram^nV#
^rND^sBilir^nSP#^rND^sNeukermans^nCP#^rND^sRydzak^nCE#et al#Cost-effectiveness o
f screening for HIV in the era of highly active antiretroviral therapy^len#N Eng
l J Med#20050210#2005 Feb 10#352#6#570-85#20071200#a02v22n6.htm#0028-4793#N Engl
 J Med##
00609000000000301000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100015000770100015000920100
01500107010001900122012009900141030000500240065000900245064000500254031000300259
014000800262865000900270002001300279035001000292801000500302#v22n6#v:\scielo\ser
ial\rpsp\v22n6\markup\a02v22n6.htm#S#c#125#7#article#21#7#^rND^sGibb^nDM#^rND^sA
des^nAE#^rND^sGupta^nR#^rND^sSculpher^nMJ#Costs and benefits to the mother of an
tenatal HIV testing: estimates from simulation modelling^len#AIDS#19990000#1999#
13#1569-76#20071200#a02v22n6.htm#0269-9370#AIDS##
00738000000000301000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100015000770100019000920100
01700111012021400128030001800342065000900360064000500369031000300374032000200377
014000700379865000900386002001300395035001000408801001800418#v22n6#v:\scielo\ser
ial\rpsp\v22n6\markup\a02v22n6.htm#S#c#126#8#article#21#8#^rND^sKumar^nA#^rND^sS
t. White^nH#^rND^sCarter^nAO#Trends in the uptake of antenatal voluntary counsel
ing and testing for HIV and the HIV prevalence among childbearing women in Barba
dos, 1993-2004: evidence to gauge the effectiveness of HIV prevention measures^l
en#West Indian Med J#20070000#2007#56#1#167-70#20071200#a02v22n6.htm#0043-3144#W
est Indian Med J##
00450000000000217000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750170033000770180029001100370
04600139110000900185109001600194865000900210002001300219#v22n6#v:\scielo\serial\
rpsp\v22n6\markup\a02v22n6.htm#S#c#127#9#article#21#9#Pan American Health Organi
zation#Country profile-Barbados^len#http://www.paho.org/English/DD/AIS/cp_052.ht
m#20060117#17 January 2006#20071200#a02v22n6.htm##
00532000000000229000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760170090000790180077001690660
01400246062000600260065000900266064000500275865000900280002001300289#v22n6#v:\sc
ielo\serial\rpsp\v22n6\markup\a02v22n6.htm#S#c#128#10#article#21#10#Pan American
 Health Organization/World Health Organization^dCaribbean Epidemiology Centre#St
atus and trends: analysis of the Caribbean HIV/AIDS epidemic 1982-2002^len#Port 
of Spain#CAREC#20040000#2004#20071200#a02v22n6.htm##
00611000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100019000790100015000980100
01400113012012300127030002200250710000200272065000900274064000500283031000300288
032000200291014000600293865000900299002001300308#v22n6#v:\scielo\serial\rpsp\v22
n6\markup\a02v22n6.htm#S#c#129#11#article#21#11#^rND^sSt. John^nMA#^rND^sKumar^n
A#^rND^sCave^nC#Reduction in perinatal transmission and mortality from human imm
unodeficiency virus after intervention with zidovudine^len#Pediatr Infect Dis J.
#2#20030000#2003#22#5#422-6#20071200#a02v22n6.htm##
00527000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100015000790100014000940120
06700108030002300175710000200198065000900200064000900209031000300218032000200221
014000400223865000900227002001300236#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a0
2v22n6.htm#S#c#130#12#article#21#12#^rND^sKumar^nA#^rND^sVent^nB#Characteristics
 of HIV infected childbearing women in Barbados^len#Pan Am J Public Health#2#200
30100#2003 Jan#13#1#1-9#20071200#a02v22n6.htm##
00859000000000349000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100015000790100019000940100
01400113010001800127010001600145010001600161810000600177012022200183030002000405
06500090042506400090043403100030044303200030044601400080044986500090045700200130
0466035001000479801002000489#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a02v22n6.h
tm#S#c#131#13#article#21#13#^rND^sManzi^nM#^rND^sZachariah^nR#^rND^sTeck^nR#^rND
^sBuhendwa^nL#^rND^sKazima^nJ#^rND^sBakali^nE#et al#High acceptability of volunt
ary counselling and HIV-testing but unacceptable loss to follow up in a preventi
on of mother-to-child HIV transmission program in rural Malawi: scaling-up requi
res a different way of acting^len#Trop Med Int Health#20051200#2005 Dec#10#12#12
42-50#20071200#a02v22n6.htm#1360-2276#Trop Med Int Health##
00653000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100019000790100017000980100
01700115010001600132010001500148012006200163030002300225065000900248064000500257
03100030026203200020026501400050026786500090027200200130028103500100029480100230
0304#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a02v22n6.htm#S#c#132#14#article#21
#14#^rND^sIckovics^nJR#^rND^sForsyth^nB#^rND^sEthier^nKA#^rND^sHarris^nP#^rND^sR
odin^nJ#Delayed entry into health care for women with HIV disease^len#AIDS Patie
nt Care STDS#19960000#1996#10#1#21-4#20071200#a02v22n6.htm#1087-2914#Aids Patien
t Care STDS##
00659000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100019000790100018000980100
01800116012012000134030002300254065000900277064000500286031000300291032000200294
014000600296865000900302002001300311035001000324801002300334#v22n6#v:\scielo\ser
ial\rpsp\v22n6\markup\a02v22n6.htm#S#c#133#15#article#21#15#^rND^sSegurado^nAC#^
rND^sMiranda^nSD#^rND^sLatorre^nMD#Brazilian Enhancing Care Initiative Team: Eva
luation of the care of women living with HIV/AIDS in Sao Paulo, Brazil^len#AIDS 
Patient Care STDS#20030000#2003#17#2#85-93#20071200#a02v22n6.htm#1087-2914#Aids 
Patient Care STDS##
00802000000000349000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100017000960100
01400113010001800127010001700145010002000162810000600182012017200188030001600360
06500090037606400050038503100040039003200020039401400080039686500090040400200130
0413035001000426801001600436#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a02v22n6.h
tm#S#c#134#16#article#21#16#^rND^sParedes^nR#^rND^sMocroft^nA#^rND^sKirk^nO#^rND
^sLazzarin^nA#^rND^sBarton^nSE#^rND^svan Lunzen^nJ#et al#Predictors of virologic
al success and ensuing failure in HIV-positive patients starting highly active a
ntiretroviral therapy in Europe: results from the EuroSIDA study^len#Arch Intern
 Med#20000000#2000#160#8#1123-32#20071200#a02v22n6.htm#0003-9926#Arch Intern Med
##
00792000000000349000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100021000790100023001000100
01700123010001800140010001500158010002000173810000600193012014800199030001500347
06500090036206400120037103100040038303200020038701400060038986500090039500200130
0404035001000417801001500427#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a02v22n6.h
tm#S#c#135#17#article#21#17#^rND^sPalella^nFJ Jr#^rND^sDeloria-Knoll^nM#^rND^sCh
miel^nJS#^rND^sMoorman^nAC#^rND^sWood^nKC#^rND^sGreenberg^nAE#et al#HIV Outpatie
nt Study Investigators: Survival benefit of initiating antiretroviral therapy in
 HIV-infected persons in different CD4+ cell strata^len#Ann Intern Med#20030415#
2003 Apr 15#138#8#620-6#20071200#a02v22n6.htm#0003-4819#Ann Intern Med##
00772000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100016000970100
01700113010002600130010001800156012017500174030001900349065000900368064000500377
03100030038203200040038501400060038986500090039500200130040403500100041780100190
0427#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a02v22n6.htm#S#c#136#18#article#21
#18#^rND^sOrmaasen^nV#^rND^sBruun^nJN#^rND^sSandvik^nL#^rND^sHolberg-Petersen^nM
#^rND^sGaarder^nPI#Prognostic value of changes in CD4 count and HIV RNA during t
he first six months on highly active antiretroviral therapy in chronic human imm
unodeficiency virus infection^len#Scand J Infect Dis#20030000#2003#35#6-7#383-8#
20071200#a02v22n6.htm#0036-5548#Scand J Infect Dis##
00722000000000349000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100015000790100013000940100
01500107010001400122010001600136010002400152810000600176012011200182030000500294
06500090029906400120030803100040032003200030032401400080032786500090033500200130
0344035001000357801000500367#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a02v22n6.h
tm#S#c#137#19#article#21#19#^rND^sHogg^nRS#^rND^sYip^nB#^rND^sChan^nKJ#^rND^sWoo
d^nE#^rND^sCraib^nKJ#^rND^sO'Shaughnessy^nMV#et al#Rates of disease progression 
by baseline CD4 cell count and viral load after initiating triple-drug therapy^l
en#JAMA#20011128#2001 Nov 28#286#20#2568-77#20071200#a02v22n6.htm#0098-7484#JAMA
##
00643000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100015000790100017000940100
01500111010001600126012013500142030001600277710000200293065000900295064000500304
031000200309032000200311014000600313865000900319002001300328#v22n6#v:\scielo\ser
ial\rpsp\v22n6\markup\a02v22n6.htm#S#c#138#20#article#21#20#^rND^sKumar^nA#^rND^
sKilaru^nKR#^rND^sForde^nS#^rND^sKumari^nG#Prevalence and correlates of serostat
us disclosure in HIV-infected adults attending the follow up and treatment clini
c in Barbados^len#Social Medicine#2#20070000#2007#2#2#89-97#20071200#a02v22n6.ht
m##
00667000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100015000790100018000940100
01600112012013200128030002300260065000900283064000500292031000300297032000300300
014000700303865000900310002001300319035001000332801002300342#v22n6#v:\scielo\ser
ial\rpsp\v22n6\markup\a02v22n6.htm#S#c#139#21#article#21#21#^rND^sKumar^nA#^rND^
sWaterman^nI#^rND^sKumari^nG#Prevalence and correlates of HIV serostatus disclos
ure: a prospective study among HIV-infected postparturient women in Barbados^len
#AIDS Patient Care STDS#20060000#2006#20#10#724-30#20071200#a02v22n6.htm#1087-29
14#Aids Patient Care STDS##
00275000000000169000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700910009000720920007000810020013000887030
00400101#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a03v22n6.htm#S#o#1#1#article#1
#20080215#102620#a03v22n6.htm#143##
05808000000000637000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000400090121000300094049000800097158000300105030002400108
03100030013203200020013506500090013701400110014603500100015701201450016701201420
03120100032004540100030004860100043005160700053005590700049006120832121006610850
00802782085002002790085002002810085002702830085004302857085002202900083202502922
08500080494708500220495508500190497708500270499608500360502308500220505911700060
5081072000305087112000905090111002405099114000905123113002505132002001305157#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a03v22n6.htm#S#h#2#1#article#1#oa#es#br1.1
#1#3.1#TAB#03#RPSP020#nd#Rev Panam Salud Publica#22#6#20071200#^f383^l388#1020-4
989#Frecuencia relativa de carcinoma escamoso y adenocarcinoma esofágicos en una
 serie de biopsias endoscópicas realizadas en Rosario, Argentina^les#Relative fr
equency of esophageal squamous carcinoma and adenocarcinoma in a series of endos
copic biopsies performed in Rosario, Argentina^len#^rND^1A01^nAriel Enrique^sNav
es#^rND^1A02^nFlorencia^sLapalma#^rND^1A02^nJosé Ignacio^sRodríguez Ciancio#Inst
ituto de Histopatología^iA01^cRosario^pArgentina#Instituto Universitario Italian
o de Rosario^iA02#^les^aOBJETIVOS: Determinar en una serie de biopsias endoscópi
cas esofágicas consecutivas registradas en un laboratorio de anatomía patológica
 de la ciudad de Rosario, Argentina, la frecuencia relativa de adenocarcinoma y 
carcinoma escamoso, comparando los períodos 1992-1999 y 2000-2006. Verificar si 
se observa un aumento en la frecuencia relativa de adenocarcinoma esofágico con 
respecto al carcinoma escamoso, similar al notificado en otros países occidental
es. MÉTODOS: Se estudiaron las biopsias endoscópicas esofágicas con diagnóstico 
de adenocarcinoma y carcinoma escamoso infiltrantes, y de esófago de Barrett (EB
) realizadas entre 1992 y 2006. Se compararon las frecuencias relativas de estos
 cánceres en los períodos 1992-1999 y 2000-2006 por la prueba de la Z y se anali
zó la distribución por edad y sexo mediante la prueba de la ji2, con un nivel de
 significación (alfa) de 0,05. RESULTADOS: Se detectaron, en total, 125 carcinom
as escamosos y adenocarcinomas infiltrantes. La frecuencia relativa adenocarcino
ma/carcinoma escamoso fue 0,33/0,67 en toda la serie, 0,28/0,72 en el período 19
92-1999 y 0,38/0,62 en el período 2000-2006. Las diferencias no fueron estadísti
camente significativas. Los hombres representaron 75,6% de los casos de adenocar
cinoma y 57,1% de los de carcinoma escamoso; esta diferencia resultó significati
va (P<0,05). La edad media de los pacientes en el momento del diagnóstico era de
 66,0años en el caso del adenocarcinoma y 67,9años en el del carcinoma escamoso.
 La frecuencia de carcinomas infiltrantes fue mayor entre los hombres menores de
 65años que entre las mujeres del mismo grupo etario (P<0,025). El EB se diagnos
ticó en una proporción de 6 a 1 con respecto al adenocarcinoma. CONCLUSIONES: El
 adenocarcinoma y el carcinoma escamoso predominaron en hombres, pero el adenoca
rcinoma en mayor proporción. La frecuencia relativa del adenocarcinoma aumentó e
n 10% en los últimos siete años de la serie con respecto a los primeros siete añ
os. Esta diferencia no resultó significativa, pero puede representar una tendenc
ia en nuestro medio similar a la descrita en otros países.#^dnd^i1#^tm^les^kEsóf
ago^i1#^tm^les^kbiopsia^i1#^tm^les^kadenocarcinoma^i1#^tm^les^kcarcinoma de célu
las escamosas^i1#^tm^les^kArgentina^i1#^len^aOBJECTIVES: To determine the relati
ve frequency of adenocarcinoma and squamous carcinoma in a series of endoscopic 
biopsies of the esophagus registered in consecutive order in a pathology laborat
ory in the city of Rosario, Argentina, during two time periods: 1992-1999 and 20
00-2006. To determine if the relative frequency of esophageal adenocarcinoma has
 increased over that of squamous carcinoma, in keeping with the trends noted in 
other Western countries. METHODS: We studied the endoscopic esophageal biopsies 
diagnosed with infiltrating adenocarcinoma and squamous carcinoma and Barrett's 
esophagus (BE) between 1992 and 2006. The relative frequency of these cancers we
re compared for the periods 1992-1999 and 2000-2006 using the z-test. A distribu
tion analysis for age and sex was performed by the chi-square test using a confi
dence level (alpha) of 0.05. RESULTS: In all, 125 infiltrating squamous carcinom
as and adenocarcinomas were found. The relative frequency of adenocarcinoma/squa
mous carcinoma for the entire series was 0.33/0.67; for the period from 1992-199
0, 0.28/0.72; and from 2000-2006, 0.38/0.62. The differences were not statistica
lly significant. Males constituted 75.6% of the cases of adenocarcinoma and 57.1
% of the cases of squamous carcinomas; this difference was statistically signifi
cant (P<0.05). The mean age of the patients at the time of diagnosis was 66.0 ye
ars of age for adenocarcinoma and 67.9years for squamous carcinoma. The frequenc
y of infiltrating carcinoma was greater among the men than among the women of th
e age group under 65 years (P<0.025). BE was diagnosed at a rate of 6:1 relative
 to adenocarcinoma. CONCLUSIONS: Adenocarcinoma and squamous carcinoma were pred
ominant among men, though adenocarcinoma was the major part of these. The relati
ve frequency of adenocarcinoma rose 10% in the last 7 years of the series compar
ed with the first 7 years. This difference was not significant, but it may signa
l a general trend similar to that described in other countries.#^dnd^i2#^tm^len^
kEsophagus^i2#^tm^len^kbiopsy^i2#^tm^len^kadenocarcinoma^i2#^tm^len^ksquamous ce
ll carcinoma^i2#^tm^len^kArgentina^i2#other#22#20061214#14 de diciembre de 2006#
20070912#12 de septiembre de 2007#a03v22n6.htm##
05974000000000637000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000400090121000300094049000800097158000300105030002400108
03100030013203200020013506500090013701400110014603500100015701201520016701201490
03190100032004680100030005000100043005300700053005730700049006260832216006750850
00802891085002002899085002002919085002702939085004302966085002203009083208203031
08500080511308500220512108500190514308500270516208500360518908500220522511700060
5247072000305253112000905256111002405265114000905289113002505298002001305323#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a03v22n6.htm#S#f#3#1#article#1#oa#es#br1.1
#1#3.1#TAB#03#RPSP020#nd#Rev Panam Salud Publica#22#6#20071200#^f383^l388#1020-4
989#<B>Frecuencia relativa de carcinoma escamoso y adenocarcinoma esofágicos en 
una serie de biopsias endoscópicas realizadas en Rosario, Argentina</B>^les#<B>R
elative frequency of esophageal squamous carcinoma and adenocarcinoma in a serie
s of endoscopic biopsies performed in Rosario, Argentina</B>^len#^rND^1A01^nArie
l Enrique^sNaves#^rND^1A02^nFlorencia^sLapalma#^rND^1A02^nJosé Ignacio^sRodrígue
z Ciancio#Instituto de Histopatología^iA01^cRosario^pArgentina#Instituto Univers
itario Italiano de Rosario^iA02#^les^a<B>OBJETIVOS:</B> Determinar en una serie 
de biopsias endoscópicas esofágicas consecutivas registradas en un laboratorio d
e anatomía patológica de la ciudad de Rosario, Argentina, la frecuencia relativa
 de adenocarcinoma y carcinoma escamoso, comparando los períodos 1992-1999 y 200
0-2006. Verificar si se observa un aumento en la frecuencia relativa de adenocar
cinoma esofágico con respecto al carcinoma escamoso, similar al notificado en ot
ros países occidentales. <B>MÉTODOS: </B>Se estudiaron las biopsias endoscópicas
 esofágicas con diagnóstico de adenocarcinoma y carcinoma escamoso infiltrantes,
 y de esófago de Barrett (EB) realizadas entre 1992 y 2006. Se compararon las fr
ecuencias relativas de estos cánceres en los períodos 1992-1999 y 2000-2006 por 
la prueba de la Z y se analizó la distribución por edad y sexo mediante la prueb
a de la <FONT FACE="Symbol">c</FONT><SUP>2</SUP>, con un nivel de significación 
(<FONT FACE="Symbol">a</FONT>) de 0,05. <B>RESULTADOS:</B> Se detectaron, en tot
al, 125 carcinomas escamosos y adenocarcinomas infiltrantes. La frecuencia relat
iva adenocarcinoma/carcinoma escamoso fue 0,33/0,67 en toda la serie, 0,28/0,72 
en el período 1992-1999 y 0,38/0,62 en el período 2000-2006. Las diferencias no 
fueron estadísticamente significativas. Los hombres representaron 75,6% de los c
asos de adenocarcinoma y 57,1% de los de carcinoma escamoso; esta diferencia res
ultó significativa (P&lt;0,05). La edad media de los pacientes en el momento del
 diagnóstico era de 66,0años en el caso del adenocarcinoma y 67,9años en el del 
carcinoma escamoso. La frecuencia de carcinomas infiltrantes fue mayor entre los
 hombres menores de 65años que entre las mujeres del mismo grupo etario (P&lt;0,
025). El EB se diagnosticó en una proporción de 6 a 1 con respecto al adenocarci
noma. <B>CONCLUSIONES:</B> El adenocarcinoma y el carcinoma escamoso predominaro
n en hombres, pero el adenocarcinoma en mayor proporción. La frecuencia relativa
 del adenocarcinoma aumentó en 10% en los últimos siete años de la serie con res
pecto a los primeros siete años. Esta diferencia no resultó significativa, pero 
puede representar una tendencia en nuestro medio similar a la descrita en otros 
países.#^dnd^i1#^tm^les^kEsófago^i1#^tm^les^kbiopsia^i1#^tm^les^kadenocarcinoma^
i1#^tm^les^kcarcinoma de células escamosas^i1#^tm^les^kArgentina^i1#^len^a<B>OBJ
ECTIVES: </B>To determine the relative frequency of adenocarcinoma and squamous 
carcinoma in a series of endoscopic biopsies of the esophagus registered in cons
ecutive order in a pathology laboratory in the city of Rosario, Argentina, durin
g two time periods: 1992-1999 and 2000-2006. To determine if the relative freque
ncy of esophageal adenocarcinoma has increased over that of squamous carcinoma, 
in keeping with the trends noted in other Western countries. <B>METHODS: </B>We 
studied the endoscopic esophageal biopsies diagnosed with infiltrating adenocarc
inoma and squamous carcinoma and Barrett's esophagus (BE) between 1992 and 2006.
 The relative frequency of these cancers were compared for the periods 1992-1999
 and 2000-2006 using the z-test. A distribution analysis for age and sex was per
formed by the chi-square test using a confidence level (<FONT FACE="Symbol">a</F
ONT>) of 0.05. <B>RESULTS: </B>In all, 125 infiltrating squamous carcinomas and 
adenocarcinomas were found. The relative frequency of adenocarcinoma/squamous ca
rcinoma for the entire series was 0.33/0.67; for the period from 1992-1990, 0.28
/0.72; and from 2000-2006, 0.38/0.62. The differences were not statistically sig
nificant. Males constituted 75.6% of the cases of adenocarcinoma and 57.1% of th
e cases of squamous carcinomas; this difference was statistically significant (P
&lt;0.05). The mean age of the patients at the time of diagnosis was 66.0 years 
of age for adenocarcinoma and 67.9years for squamous carcinoma. The frequency of
 infiltrating carcinoma was greater among the men than among the women of the ag
e group under 65 years (P&lt;0.025). BE was diagnosed at a rate of 6:1 relative 
to adenocarcinoma. <B>CONCLUSIONS: </B>Adenocarcinoma and squamous carcinoma wer
e predominant among men, though adenocarcinoma was the major part of these. The 
relative frequency of adenocarcinoma rose 10% in the last 7 years of the series 
compared with the first 7 years. This difference was not significant, but it may
 signal a general trend similar to that described in other countries.#^dnd^i2#^t
m^len^kEsophagus^i2#^tm^len^kbiopsy^i2#^tm^len^kadenocarcinoma^i2#^tm^len^ksquam
ous cell carcinoma^i2#^tm^len^kArgentina^i2#other#22#20061214#14 de diciembre de
 2006#20070912#12 de septiembre de 2007#a03v22n6.htm##
05994000000000661000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700640013000720710003000850400003000880010
00600091042000200097120000400099038000400103121000300107049000800110158000300118
03000260012103100030014703200020015006500090015201400110016103500100017201201450
01820120142003270100032004690100030005010100043005310700055005740700051006290832
15100680085000802831085002002839085002002859085002702879085004302906085002202949
08320460297108500080501708500220502508500190504708500270506608500360509308500220
51291170006051510720003051571120009051601110024051691140009051931130025052020020
01305227008009205240#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a03v22n6.htm#S#l#4
#1#article#1#^mdic.^a2007#oa#es#br1.1#1#3.1#tab#03#RPSP020#nd#Rev. panam. salud 
pública#22#6#20071200#^f383^l388#1020-4989#Frecuencia relativa de carcinoma esca
moso y adenocarcinoma esofágicos en una serie de biopsias endoscópicas realizada
s en Rosario, Argentina^les#Relative frequency of esophageal squamous carcinoma 
and adenocarcinoma in a series of endoscopic biopsies performed in Rosario, Arge
ntina^len#^rND^1A01^nAriel Enrique^sNaves#^rND^1A02^nFlorencia^sLapalma#^rND^1A0
2^nJosé Ignacio^sRodríguez Ciancio#^iA01^1Instituto de Histopatología^cRosario^p
Argentina#^iA02^1Instituto Universitario Italiano de Rosario#^les^aOBJETIVOS: De
terminar en una serie de biopsias endoscópicas esofágicas consecutivas registrad
as en un laboratorio de anatomía patológica de la ciudad de Rosario, Argentina, 
la frecuencia relativa de adenocarcinoma y carcinoma escamoso, comparando los pe
ríodos 1992-1999 y 2000-2006. Verificar si se observa un aumento en la frecuenci
a relativa de adenocarcinoma esofágico con respecto al carcinoma escamoso, simil
ar al notificado en otros países occidentales. MÉTODOS: Se estudiaron las biopsi
as endoscópicas esofágicas con diagnóstico de adenocarcinoma y carcinoma escamos
o infiltrantes, y de esófago de Barrett (EB) realizadas entre 1992 y 2006. Se co
mpararon las frecuencias relativas de estos cánceres en los períodos 1992-1999 y
 2000-2006 por la prueba de la Z y se analizó la distribución por edad y sexo me
diante la prueba de la ji2, con un nivel de significación (alfa) de 0,05. RESULT
ADOS: Se detectaron, en total, 125 carcinomas escamosos y adenocarcinomas infilt
rantes. La frecuencia relativa adenocarcinoma/carcinoma escamoso fue 0,33/0,67 e
n toda la serie, 0,28/0,72 en el período 1992-1999 y 0,38/0,62 en el período 200
0-2006. Las diferencias no fueron estadísticamente significativas. Los hombres r
epresentaron 75,6 por ciento de los casos de adenocarcinoma y 57,1 por ciento de
 los de carcinoma escamoso; esta diferencia resultó significativa (P<0,05). La e
dad media de los pacientes en el momento del diagnóstico era de 66,0años en el c
aso del adenocarcinoma y 67,9años en el del carcinoma escamoso. La frecuencia de
 carcinomas infiltrantes fue mayor entre los hombres menores de 65años que entre
 las mujeres del mismo grupo etario (P<0,025). El EB se diagnosticó en una propo
rción de 6 a 1 con respecto al adenocarcinoma. CONCLUSIONES: El adenocarcinoma y
 el carcinoma escamoso predominaron en hombres, pero el adenocarcinoma en mayor 
proporción. La frecuencia relativa del adenocarcinoma aumentó en 10 por ciento e
n los últimos siete años de la serie con respecto a los primeros siete años. Est
a diferencia no resultó significativa, pero puede representar una tendencia en n
uestro medio similar a la descrita en otros países.#^dnd^i1#^tm^les^kEsófago^i1#
^tm^les^kbiopsia^i1#^tm^les^kadenocarcinoma^i1#^tm^les^kcarcinoma de células esc
amosas^i1#^tm^les^kArgentina^i1#^len^aOBJECTIVES: To determine the relative freq
uency of adenocarcinoma and squamous carcinoma in a series of endoscopic biopsie
s of the esophagus registered in consecutive order in a pathology laboratory in 
the city of Rosario, Argentina, during two time periods: 1992-1999 and 2000-2006
. To determine if the relative frequency of esophageal adenocarcinoma has increa
sed over that of squamous carcinoma, in keeping with the trends noted in other W
estern countries. METHODS: We studied the endoscopic esophageal biopsies diagnos
ed with infiltrating adenocarcinoma and squamous carcinoma and Barrett's esophag
us (BE) between 1992 and 2006. The relative frequency of these cancers were comp
ared for the periods 1992-1999 and 2000-2006 using the z-test. A distribution an
alysis for age and sex was performed by the chi-square test using a confidence l
evel (alpha) of 0.05. RESULTS: In all, 125 infiltrating squamous carcinomas and 
adenocarcinomas were found. The relative frequency of adenocarcinoma/squamous ca
rcinoma for the entire series was 0.33/0.67; for the period from 1992-1990, 0.28
/0.72; and from 2000-2006, 0.38/0.62. The differences were not statistically sig
nificant. Males constituted 75.6 percent of the cases of adenocarcinoma and 57.1
 percent of the cases of squamous carcinomas; this difference was statistically 
significant (P<0.05). The mean age of the patients at the time of diagnosis was 
66.0 years of age for adenocarcinoma and 67.9years for squamous carcinoma. The f
requency of infiltrating carcinoma was greater among the men than among the wome
n of the age group under 65 years (P<0.025). BE was diagnosed at a rate of 6:1 r
elative to adenocarcinoma. CONCLUSIONS: Adenocarcinoma and squamous carcinoma we
re predominant among men, though adenocarcinoma was the major part of these. The
 relative frequency of adenocarcinoma rose 10 percent in the last 7 years of the
 series compared with the first 7 years. This difference was not significant, bu
t it may signal a general trend similar to that described in other countries.#^d
nd^i2#^tm^len^kEsophagus^i2#^tm^len^kbiopsy^i2#^tm^len^kadenocarcinoma^i2#^tm^le
n^ksquamous cell carcinoma^i2#^tm^len^kArgentina^i2#other#22#20061214#14 de dici
embre de 2006#20070912#12 de septiembre de 2007#a03v22n6.htm#Internet^ihttp://ww
w.scielosp.org/scielo.php?script=sci_arttext&pid=S1020-49892007001100003##
00357000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704012400074002001300198#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a03v22n6.htm#S#p#5#1#article#117#<p align="right"><fon
t size="2" face="Verdana"><b>INVESTIGACI&Oacute;N ORIGINAL</b>    ORIGINAL RESEA
RCH</font></p>     ^cY#a03v22n6.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a03v22n6.htm#S#p#6#2#article#117#<p>&nbsp;</p>     ^cY
#a03v22n6.htm##
00453000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704022000074002001300294#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a03v22n6.htm#S#p#7#3#article#117#<p><font size="4" fac
e="verdana"><b>Frecuencia relativa de carcinoma escamoso    y adenocarcinoma eso
f&aacute;gicos en una serie de biopsias endosc&oacute;picas    realizadas en Ros
ario, Argentina</b></font></p>     ^cY#a03v22n6.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a03v22n6.htm#S#p#8#4#article#117#<p>&nbsp;</p>     ^cY
#a03v22n6.htm##
00437000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704020400074002001300278#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a03v22n6.htm#S#p#9#5#article#117#<p><font size="3" fac
e="verdana"><b>Relative frequency of esophageal squamous    carcinoma and adenoc
arcinoma in a series of endoscopic biopsies performed in    Rosario, Argentina <
/b></font></p>     ^cY#a03v22n6.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704002200075002001300097#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a03v22n6.htm#S#p#10#6#article#117#<p>&nbsp;</p>     ^c
Y#a03v22n6.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704002200075002001300097#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a03v22n6.htm#S#p#11#7#article#117#<p>&nbsp;</p>     ^c
Y#a03v22n6.htm##
00419000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704018500075002001300260#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a03v22n6.htm#S#p#12#8#article#117#<p><font size="2" fa
ce="Verdana"><b>Ariel Enrique Naves<sup>I</sup>; Florencia    Lapalma<SUP>II</SU
P>; Jos&eacute; Ignacio Rodr&iacute;guez Ciancio<SUP>II</sup></b></font></p>    
 ^cY#a03v22n6.htm##
00663000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704042900075002001300504#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a03v22n6.htm#S#p#13#9#article#117#<p><font size="2" fa
ce="Verdana"><SUP>I</sup>Instituto de Histopatolog&iacute;a,    Rosario, Argenti
na. La correspondencia debe dirigirse a Ariel Enrique Naves,    Instituto de His
topatolog&iacute;a, Montevideo 1788, (2000) Rosario, Provincia    de Santa Fe, A
rgentina; tel.: +54 (341) 421-0606, fax: +54 (341) 440-2281, correo    electr&oa
cute;nico: <a href="mailto:arielenaves@yahoo.com.ar">arielenaves@yahoo.com.ar</a
>    ^cY#a03v22n6.htm##
00321000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704008600076002001300162#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a03v22n6.htm#S#p#14#10#article#117#<br>   <SUP>II</sup
>Instituto Universitario Italiano    de Rosario</font></p>     ^cY#a03v22n6.htm#
#
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a03v22n6.htm#S#p#15#11#article#117#<p>&nbsp;</p>     ^
cY#a03v22n6.htm##
00279000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704004400076002001300120#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a03v22n6.htm#S#p#16#12#article#117#<p>&nbsp;</p> <hr s
ize="1" noshade>     ^cY#a03v22n6.htm##
00302000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704006700076002001300143#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a03v22n6.htm#S#p#17#13#article#117#<p><font size="2" f
ace="Verdana"><b>RESUMEN</b></font></p>     ^cY#a03v22n6.htm##
00809000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704057400076002001300650#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a03v22n6.htm#S#p#18#14#article#117#<p><font size="2" f
ace="Verdana"><B>OBJETIVOS:</b> Determinar en una serie de    biopsias endosc&oa
cute;picas esof&aacute;gicas consecutivas registradas en un    laboratorio de an
atom&iacute;a patol&oacute;gica de la ciudad de Rosario, Argentina,    la frecue
ncia relativa de adenocarcinoma y carcinoma escamoso, comparando los    per&iacu
te;odos 1992–1999 y 2000–2006. Verificar si se observa un aumento en    la frecu
encia relativa de adenocarcinoma esof&aacute;gico con respecto al carcinoma    e
scamoso, similar al notificado en otros pa&iacute;ses occidentales.    ^cY#a03v2
2n6.htm##
00832000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704059700076002001300673#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a03v22n6.htm#S#p#19#15#article#117#<br>   <B>M&Eacute;
TODOS: </b>Se estudiaron las biopsias endosc&oacute;picas esof&aacute;gicas    c
on diagn&oacute;stico de adenocarcinoma y carcinoma escamoso infiltrantes,    y 
de es&oacute;fago de Barrett (EB) realizadas entre 1992 y 2006. Se compararon   
 las frecuencias relativas de estos c&aacute;nceres en los per&iacute;odos 1992–
1999    y 2000–2006 por la prueba de la Z y se analiz&oacute; la distribuci&oacu
te;n    por edad y sexo mediante la prueba de la <font face="Symbol">c</font><SU
P>2</SUP>,    con un nivel de significaci&oacute;n (<font face="Symbol">a</font>
) de 0,05.    ^cY#a03v22n6.htm##
00602000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704036700076002001300443#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a03v22n6.htm#S#p#20#16#article#117#<br>   <B>RESULTADO
S:</b> Se detectaron, en total, 125 carcinomas escamosos y adenocarcinomas    in
filtrantes. La frecuencia relativa adenocarcinoma/carcinoma escamoso fue 0,33/0,
67    en toda la serie, 0,28/0,72 en el per&iacute;odo 1992–1999 y 0,38/0,62 en 
el    per&iacute;odo 2000–2006. Las diferencias no fueron estad&iacute;sticament
e    significativas.    ^cY#a03v22n6.htm##
00845000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704061000076002001300686#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a03v22n6.htm#S#p#21#17#article#117#<br>   Los hombres 
representaron 75,6% de los casos de    adenocarcinoma y 57,1% de los de carcinom
a escamoso; esta diferencia result&oacute;    significativa (P&lt;0,05). La edad
 media de los pacientes en el momento del    diagn&oacute;stico era de 66,0a&nti
lde;os en el caso del adenocarcinoma y 67,9a&ntilde;os    en el del carcinoma es
camoso. La frecuencia de carcinomas infiltrantes fue mayor    entre los hombres 
menores de 65a&ntilde;os que entre las mujeres del mismo grupo    etario (P&lt;0
,025). El EB se diagnostic&oacute; en una proporci&oacute;n de    6 a 1 con resp
ecto al adenocarcinoma.    ^cY#a03v22n6.htm##
00727000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704049200076002001300568#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a03v22n6.htm#S#p#22#18#article#117#<br>   <B>CONCLUSIO
NES:</b> El adenocarcinoma y el carcinoma escamoso predominaron    en hombres, p
ero el adenocarcinoma en mayor proporci&oacute;n. La frecuencia    relativa del 
adenocarcinoma aument&oacute; en 10% en los &uacute;ltimos siete    a&ntilde;os 
de la serie con respecto a los primeros siete a&ntilde;os. Esta    diferencia no
 result&oacute; significativa, pero puede representar una tendencia    en nuestr
o medio similar a la descrita en otros pa&iacute;ses.</font></p>     ^cY#a03v22n
6.htm##
00426000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704019100076002001300267#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a03v22n6.htm#S#p#23#19#article#117#<p><font size="2" f
ace="Verdana"><b>Palabras clave: </b>Es&oacute;fago, biopsia,    adenocarcinoma,
 carcinoma de c&eacute;lulas escamosas, Argentina.</font></p> <hr size="1" nosha
de>     ^cY#a03v22n6.htm##
00303000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704006800076002001300144#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a03v22n6.htm#S#p#24#20#article#117#<p><font size="2" f
ace="Verdana"><b>ABSTRACT</b></font></p>     ^cY#a03v22n6.htm##
00760000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704052500076002001300601#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a03v22n6.htm#S#p#25#21#article#117#<p><font size="2" f
ace="Verdana"><B>OBJECTIVES: </b>To determine the relative    frequency of adeno
carcinoma and squamous carcinoma in a series of endoscopic    biopsies of the es
ophagus registered in consecutive order in a pathology laboratory    in the city
 of Rosario, Argentina, during two time periods: 1992–1999 and 2000–2006.    To 
determine if the relative frequency of esophageal adenocarcinoma has increased  
  over that of squamous carcinoma, in keeping with the trends noted in other Wes
tern    countries.    ^cY#a03v22n6.htm##
00698000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704046300076002001300539#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a03v22n6.htm#S#p#26#22#article#117#<br>   <B>METHODS: 
</b>We studied the endoscopic esophageal biopsies diagnosed with    infiltrating
 adenocarcinoma and squamous carcinoma and Barrett's esophagus (BE)    between 1
992 and 2006. The relative frequency of these cancers were compared    for the p
eriods 1992–1999 and 2000–2006 using the z-test. A distribution analysis    for 
age and sex was performed by the chi-square test using a confidence level    (<f
ont face="Symbol">a</font>) of 0.05.    ^cY#a03v22n6.htm##
01080000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704084500076002001300921#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a03v22n6.htm#S#p#27#23#article#117#<br>   <B>RESULTS: 
</b>In all, 125 infiltrating squamous carcinomas and adenocarcinomas    were fou
nd. The relative frequency of adenocarcinoma/squamous carcinoma for    the entir
e series was 0.33/0.67; for the period from 1992–1990, 0.28/0.72; and    from 20
00–2006, 0.38/0.62. The differences were not statistically significant.    Males
 constituted 75.6% of the cases of adenocarcinoma and 57.1% of the cases    of s
quamous carcinomas; this difference was statistically significant (P&lt;0.05).  
  The mean age of the patients at the time of diagnosis was 66.0 years of age   
 for adenocarcinoma and 67.9years for squamous carcinoma. The frequency of infil
trating    carcinoma was greater among the men than among the women of the age g
roup under    65 years (P&lt;0.025). BE was diagnosed at a rate of 6:1 relative 
to adenocarcinoma.    ^cY#a03v22n6.htm##
00644000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704040900076002001300485#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a03v22n6.htm#S#p#28#24#article#117#<br>   <B>CONCLUSIO
NS: </b>Adenocarcinoma and squamous carcinoma were predominant among    men, tho
ugh adenocarcinoma was the major part of these. The relative frequency    of ade
nocarcinoma rose 10% in the last 7 years of the series compared with the    firs
t 7 years. This difference was not significant, but it may signal a general    t
rend similar to that described in other countries.</font></p>     ^cY#a03v22n6.h
tm##
00401000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704016600076002001300242#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a03v22n6.htm#S#p#29#25#article#117#<p><font size="2" f
ace="Verdana"><b>Key words: </b>Esophagus, biopsy, adenocarcinoma,    squamous c
ell carcinoma, Argentina.</font></p> <hr size="1" noshade>     ^cY#a03v22n6.htm#
#
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a03v22n6.htm#S#p#30#26#article#117#<p>&nbsp;</p>     ^
cY#a03v22n6.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a03v22n6.htm#S#p#31#27#article#117#<p>&nbsp;</p>     ^
cY#a03v22n6.htm##
00967000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704073200076002001300808#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a03v22n6.htm#S#p#32#28#article#117#<p><font size="2" f
ace="Verdana">En los &uacute;ltimos a&ntilde;os se ha registrado    un aumento e
n la incidencia del adenocarcinoma esof&aacute;gico con respecto    al carcinoma
 escamoso —en cifras absolutas y en frecuencia relativa— en varios    pa&iacute;
ses occidentales. En los Estados Unidos se ha llegado a considerar    que se ha 
producido un aumento "epid&eacute;mico" del n&uacute;mero    de casos de adenoca
rcinoma esof&aacute;gico (1) —con incrementos anuales comprendidos    entre el 4
% y el 10% en los hombres durante el per&iacute;odo 1976–1987—. En    algunas se
ries, la frecuencia del adenocarcinoma esof&aacute;gico incluso super&oacute;   
 a la del carcinoma escamoso esof&aacute;gico (2, 3).</font></p>     ^cY#a03v22n
6.htm##
00491000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704025600076002001300332#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a03v22n6.htm#S#p#33#29#article#117#<p><font size="2" f
ace="Verdana">Durante el mismo per&iacute;odo, la incidencia    del carcinoma es
camoso esof&aacute;gico permaneci&oacute; estable o incluso    disminuy&oacute; 
en relaci&oacute;n con las d&eacute;cadas anteriores (4).</font></p>     ^cY#a03
v22n6.htm##
00629000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704039400076002001300470#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a03v22n6.htm#S#p#34#30#article#117#<p><font size="2" f
ace="Verdana">En Canad&aacute;, se observ&oacute; un aumento    de la incidencia
 anual del adenocarcinoma de es&oacute;fago distal entre 1964    y 2002, tanto e
n hombres (incremento anual medio del 9,5%) como en mujeres (incremento    anual
 medio del 4,3%). La incidencia del carcinoma escamoso en el mismo per&iacute;od
o    permaneci&oacute; estable (5).</font></p>     ^cY#a03v22n6.htm##
00534000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704029900076002001300375#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a03v22n6.htm#S#p#35#31#article#117#<p><font size="2" f
ace="Verdana">Como reflejo de estos cambios, la frecuencia    relativa del carci
noma escamoso con respecto al adenocarcinoma fue decreciendo.    As&iacute;, en 
una serie estadounidense, dicha frecuencia disminuy&oacute; de    2:1 a 1,2:1 en
tre 1988 y 1994 (6).</font></p>     ^cY#a03v22n6.htm##
00405000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704017000076002001300246#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a03v22n6.htm#S#p#36#32#article#117#<p><font size="2" f
ace="Verdana">Estos adenocarcinomas emergen-tes tienen alta    prevalencia en ho
mbres, pero son relativamente raros en mujeres (7).</font></p>     ^cY#a03v22n6.
htm##
00683000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704044800076002001300524#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a03v22n6.htm#S#p#37#33#article#117#<p><font size="2" f
ace="Verdana">La explicaci&oacute;n m&aacute;s probable del    aumento de la inc
idencia del adenocarcinoma y la base fenot&iacute;pica para    su desarrollo es 
su relaci&oacute;n con el es&oacute;fago de Barrett (EB) como    lesi&oacute;n p
recursora o asociada. Se ha afirmado que la prevalencia de este    "carcinoma de
 Barrett" se ha incrementado r&aacute;pidamente en los    &uacute;ltimos a&ntild
e;os (8).</font></p>     ^cY#a03v22n6.htm##
00819000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704058400076002001300660#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a03v22n6.htm#S#p#38#34#article#117#<p><font size="2" f
ace="Verdana">No se dispone de datos derivados de series amplias    de la ciudad
 argentina de Rosario (Provincia de Santa Fe, Argentina) sobre las    frecuencia
s relativas del carcinoma escamoso y el adenocarcinoma esof&aacute;gico,    ni s
obre la distribuci&oacute;n de los pacientes por sexo y edad en el momento    de
l diagn&oacute;stico. Tampoco se ha determinado si en dicha ciudad se ha produci
do    una variaci&oacute;n en la frecuencia relativa de estos c&aacute;nceres si
milar    a la hallada en diversos pa&iacute;ses occidentales (9).</font></p>    
 ^cY#a03v22n6.htm##
00980000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704074500076002001300821#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a03v22n6.htm#S#p#39#35#article#117#<p><font size="2" f
ace="Verdana">Los objetivos de este trabajo fueron: a) determinar,    en una ser
ie de biopsias endosc&oacute;picas esof&aacute;gicas consecutivas    registradas
 en un laboratorio de anatom&iacute;a patol&oacute;gica de la ciudad    de Rosar
io, las frecuencias relativas de carcinoma escamoso y de adenocarcinoma    de es
&oacute;fago, relacionando los datos con la edad y el sexo de los pacientes,    
b) investigar si existi&oacute; una variaci&oacute;n en la frecuencia relativa  
  de ambos tipos de carcinoma entre los primeros y los &uacute;ltimos a&ntilde;o
s    de la serie, y c) cuantificar en la misma poblaci&oacute;n los casos de EB 
con    o sin displasia diagnosticados histopatol&oacute;gicamente.</font></p>   
  ^cY#a03v22n6.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a03v22n6.htm#S#p#40#36#article#117#<p>&nbsp;</p>     ^
cY#a03v22n6.htm##
00322000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704008700076002001300163#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a03v22n6.htm#S#p#41#37#article#117#<p><font size="3" f
ace="Verdana"><b>MATERIALES Y M&Eacute;TODOS</b></font></p>     ^cY#a03v22n6.htm
##
01154000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704091900076002001300995#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a03v22n6.htm#S#p#42#38#article#117#<p><font size="2" f
ace="Verdana">Se revisaron los registros de archivo de todas    las biopsias end
osc&oacute;picas de es&oacute;fago estudiadas en el Instituto    de Histopatolog
&iacute;a de Rosario entre 1992 y 2006, y se consignaron los    casos de adenoca
rcinoma esof&aacute;gico, carcinoma escamoso esof&aacute;gico,    EB sin displas
ia y con displasia, lesi&oacute;n escamosa intraepitelial y otros    tumores eso
f&aacute;gicos. En cada caso, se registr&oacute; el sexo y la edad    del pacien
te. Los pacientes estudiados eran ambulatorios, estaban afiliados    a organismo
s de medicina prepaga o a obras sociales, y pertenec&iacute;an en    su mayor pa
rte a la clase media baja o la clase media t&iacute;pica (10). Se    reevaluaron
 los diagn&oacute;sticos dudosos o incompletos, consultando los protocolos    co
mpletos originales o reexaminando los preparados histol&oacute;gicos archivados.
</font></p>     ^cY#a03v22n6.htm##
00619000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704038400076002001300460#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a03v22n6.htm#S#p#43#39#article#117#<p><font size="2" f
ace="Verdana">Se excluyeron los pacientes menores de 18 a&ntilde;os,    los regi
strados en el archivo con diagn&oacute;sticos que no encuadraban en    las categ
or&iacute;as previamente enumeradas y aquellos con diagn&oacute;stico    dudoso 
para los que no se cont&oacute; con protocolos completos o material histol&oacut
e;gico    para reevaluar.</font></p>     ^cY#a03v22n6.htm##
00567000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704033200076002001300408#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a03v22n6.htm#S#p#44#40#article#117#<p><font size="2" f
ace="Verdana">Cuando para un mismo paciente se hab&iacute;a    registrado en el 
archivo m&aacute;s de un estudio bi&oacute;psico, la clasificaci&oacute;n    par
a la evaluaci&oacute;n final se bas&oacute; en la lesi&oacute;n m&aacute;s    av
anzada presentada en el curso de la evoluci&oacute;n.</font></p>     ^cY#a03v22n
6.htm##
00429000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704019400076002001300270#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a03v22n6.htm#S#p#45#41#article#117#<p><font size="2" f
ace="Verdana">Los diagn&oacute;sticos de adenocarcinoma y carcinoma    escamoso 
se consideraron como tales solamente en los casos de neoplasia infiltrante.</fon
t></p>     ^cY#a03v22n6.htm##
00537000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704030200076002001300378#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a03v22n6.htm#S#p#46#42#article#117#<p><font size="2" f
ace="Verdana">Los carcinomas infiltrantes poco diferenciados    o indiferenciado
s, que no pudieron clasificarse claramente como adenocarcinoma    o carcinoma es
camoso, se agruparon dentro de la categor&iacute;a "otros    tumores", como carc
inomas indiferenciados.</font></p>     ^cY#a03v22n6.htm##
00800000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704056500076002001300641#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a03v22n6.htm#S#p#47#43#article#117#<p><font size="2" f
ace="Verdana">Para el diagn&oacute;stico de EB se fij&oacute;    como requisito 
el criterio de existencia de metaplasia intestinal del es&oacute;fago    documen
tada histol&oacute;gicamente (11), consider&aacute;ndola presente cuando    se h
allaron claramente c&eacute;lulas caliciformes, confirmadas por tinci&oacute;n  
  con azul alciano a pH 2,5 en casos paucicelulares. El diagn&oacute;stico y la 
   graduaci&oacute;n de la displasia se realizaron seg&uacute;n los criterios re
visados    por un consenso internacional (12).</font></p>     ^cY#a03v22n6.htm##
00740000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704050500076002001300581#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a03v22n6.htm#S#p#48#44#article#117#<p><font size="2" f
ace="Verdana">Se describieron las frecuencias relativas de    adenocarcinoma y c
arcinoma escamoso infiltrantes en toda la serie y en los per&iacute;odos    1992
–1996 y 2002– 2006, y se realiz&oacute; una comparaci&oacute;n por medio    de l
a prueba <I>z</I> y se analiz&oacute; la distribuci&oacute;n por edad y    sexo 
mediante la prueba de la <font face="Symbol">c</font><SUP>2</SUP>, con    un niv
el de significaci&oacute;n (<font face="Symbol">a</font>) de 0,05.</font></p>   
  ^cY#a03v22n6.htm##
00647000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704041200076002001300488#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a03v22n6.htm#S#p#49#45#article#117#<p><font size="2" f
ace="Verdana">En doce casos de adenocarcinoma, 25 casos de    carcinoma escamoso
 y 54 casos de EB sin displasia faltaron da-tos sobre la edad    del paciente. L
os resultados relativos a la edad se obtuvieron tomando en cuenta    solamente l
os casos con edad conocida. Las comparaciones se realizaron por medio    de la p
rueba de la <font face="Symbol">c</font><SUP>2</SUP>.</font></p>     ^cY#a03v22n
6.htm##
00646000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704041100076002001300487#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a03v22n6.htm#S#p#50#46#article#117#<p><font size="2" f
ace="Verdana">Los pacientes con EB con o sin displasia sometidos    a m&aacute;s
 de un estudio bi&oacute;psico se incluyeron en la serie general    con el diagn
&oacute;stico m&aacute;s avanzado que presentaron en el curso de    la evoluci&o
acute;n, pero se analizaron adem&aacute;s por separado, para determinar    el co
mportamiento de las lesiones durante el seguimiento.</font></p>     ^cY#a03v22n6
.htm##
00441000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704020600076002001300282#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a03v22n6.htm#S#p#51#47#article#117#<p><font size="2" f
ace="Verdana">Los an&aacute;lisis estad&iacute;sticos se realizaron    con el pr
ograma SPSS <I>(Statistical Product and Service Solutions)</I>, versi&oacute;n  
  15.5.</font></p>     ^cY#a03v22n6.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a03v22n6.htm#S#p#52#48#article#117#<p>&nbsp;</p>     ^
cY#a03v22n6.htm##
00305000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704007000076002001300146#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a03v22n6.htm#S#p#53#49#article#117#<p><font size="3" f
ace="Verdana"><b>RESULTADOS</b></font></p>     ^cY#a03v22n6.htm##
00942000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704070700076002001300783#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a03v22n6.htm#S#p#54#50#article#117#<p><font size="2" f
ace="Verdana">En el per&iacute;odo 1992–2006 se realizaron    en el Instituto de
 Histopato-log&iacute;a de la ciudad de Rosario 3 655 biopsias    endosc&oacute;
picas esof&aacute;gicas. A partir de estas biopsias, se diagnosticaron    41 ade
nocarcinomas infiltrantes y 84 carcinomas escamosos infiltrantes. Cuando    se a
nalizaron por separado los datos relativos a los per&iacute;odos 1992– 1999    y
 2000–2006, se encontraron los resultados presentados en el <a href="#qdr01">cua
dro    1</a>. Las diferencias entre las frecuencias relativas de adenocarcinoma 
y de    carcinoma escamoso entre estos dos per&iacute;odos no resultaron signifi
cativas    (prueba de la Z).</font></p>     ^cY#a03v22n6.htm##
00271000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704003600076002001300112#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a03v22n6.htm#S#p#55#51#article#117#<p><a name="qdr01">
</a></p>     ^cY#a03v22n6.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a03v22n6.htm#S#p#56#52#article#117#<p>&nbsp;</p>     ^
cY#a03v22n6.htm##
00315000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704008000076002001300156#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a03v22n6.htm#S#p#57#53#article#117#<p align="center"><
img src="/img/revistas/rpsp/v22n6/a03cdr01.gif"></p>     ^cY#a03v22n6.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a03v22n6.htm#S#p#58#54#article#117#<p>&nbsp;</p>     ^
cY#a03v22n6.htm##
00478000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704024300076002001300319#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a03v22n6.htm#S#p#59#55#article#117#<p><font size="2" f
ace="Verdana">Al analizar la distribuci&oacute;n por sexo de    los casos de ade
nocarcinoma y carcinoma escamoso infiltrantes se hallaron los    resultados pres
entados en el <a href="#qdr02">cuadro 2</a>.</font></p>     ^cY#a03v22n6.htm##
00271000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704003600076002001300112#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a03v22n6.htm#S#p#60#56#article#117#<p><a name="qdr02">
</a></p>     ^cY#a03v22n6.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a03v22n6.htm#S#p#61#57#article#117#<p>&nbsp;</p>     ^
cY#a03v22n6.htm##
00315000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704008000076002001300156#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a03v22n6.htm#S#p#62#58#article#117#<p align="center"><
img src="/img/revistas/rpsp/v22n6/a03cdr02.gif"></p>     ^cY#a03v22n6.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a03v22n6.htm#S#p#63#59#article#117#<p>&nbsp;</p>     ^
cY#a03v22n6.htm##
00883000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704064800076002001300724#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a03v22n6.htm#S#p#64#60#article#117#<p><font size="2" f
ace="Verdana">La variable "edad" se analiz&oacute;    mediante la prueba de norm
alidad de Kolmogorov-Smirnov, en la que se obtuvo    un valor <I>P</I> de 0,001 
(distribuci&oacute;n normal). La edad media de los    pacientes en el momento de
l diagn&oacute;stico fue de 66,0a&ntilde;os en el    caso del adenocarcinoma (de
sviaci&oacute;n est&aacute;ndar &#91;DE&#93;: 14,6a&ntilde;os,    edad m&iacute;
nima: 42a&ntilde;os, edad m&aacute;xima: 91a&ntilde;os) y de 67,9a&ntilde;os    
en el caso del carcinoma escamoso (DE: 12,6a&ntilde;os, edad m&iacute;nima:    4
2a&ntilde;os, edad m&aacute;xima: 91a&ntilde;os).</font></p>     ^cY#a03v22n6.ht
m##
00540000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704030500076002001300381#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a03v22n6.htm#S#p#65#61#article#117#<p><font size="2" f
ace="Verdana">Al clasificar los casos de carcinoma infiltrante    (adenocarcinom
a o carcinoma escamoso) por sexo y grupo etario (menos de 65a&ntilde;os    y 65a
&ntilde;os o m&aacute;s), se obtuvieron los resultados presentados en el    <a h
ref="#qdr03">cuadro 3</a>.</font></p>     ^cY#a03v22n6.htm##
00271000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704003600076002001300112#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a03v22n6.htm#S#p#66#62#article#117#<p><a name="qdr03">
</a></p>     ^cY#a03v22n6.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a03v22n6.htm#S#p#67#63#article#117#<p>&nbsp;</p>     ^
cY#a03v22n6.htm##
00315000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704008000076002001300156#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a03v22n6.htm#S#p#68#64#article#117#<p align="center"><
img src="/img/revistas/rpsp/v22n6/a03cdr03.gif"></p>     ^cY#a03v22n6.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a03v22n6.htm#S#p#69#65#article#117#<p>&nbsp;</p>     ^
cY#a03v22n6.htm##
00720000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704048500076002001300561#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a03v22n6.htm#S#p#70#66#article#117#<p><font size="2" f
ace="Verdana">En el mismo per&iacute;odo, se identificaron    244 pacientes con 
diagn&oacute;stico de EB (6,7% de las biopsias): 231 sin displasia    (119 hombr
es y 112 mujeres) y 13 con displasia (todos hombres). En todos los    casos de E
B con displasia se hab&iacute;a registrado la edad del paciente. El    EB se hal
l&oacute; en una proporci&oacute;n de 6 a 1 con respecto a los adenocarcinomas  
  registrados durante el mismo per&iacute;odo.</font></p>     ^cY#a03v22n6.htm##
00695000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704046000076002001300536#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a03v22n6.htm#S#p#71#67#article#117#<p><font size="2" f
ace="Verdana">En 47 (18,6%) de los 231 casos de diagn&oacute;stico    inicial de
 EB sin displasia, se hab&iacute;a realizado por lo menos una biopsia    de segu
imiento; en uno de ellos, la lesi&oacute;n hab&iacute;a desaparecido    durante 
el seguimiento, en tres, hab&iacute;a progresado a displasia (a los    45, 32 y 
9 meses de seguimiento, respectivamente) y en los restantes, hab&iacute;a    per
manecido sin cambios.</font></p>     ^cY#a03v22n6.htm##
00594000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704035900076002001300435#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a03v22n6.htm#S#p#72#68#article#117#<p><font size="2" f
ace="Verdana">En cuatro de los trece casos de EB con displasia,    se hab&iacute
;a realizado por lo menos una biopsia de seguimiento; en uno de    ellos, la les
i&oacute;n hab&iacute;a progresado a adenocarcinoma a los siete    meses de segu
imiento, y en tres, el cuadro no hab&iacute;a variado durante el    seguimiento.
</font></p>     ^cY#a03v22n6.htm##
00422000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704018700076002001300263#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a03v22n6.htm#S#p#73#69#article#117#<p><font size="2" f
ace="Verdana">Se contabilizaron, adem&aacute;s, ocho casos    de lesi&oacute;n e
scamosa intraepitelial, tres de bajo grado y cinco de alto    grado.</font></p> 
    ^cY#a03v22n6.htm##
00717000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704048200076002001300558#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a03v22n6.htm#S#p#74#70#article#117#<p><font size="2" f
ace="Verdana">Por &uacute;ltimo, en la categor&iacute;a "otros    tumores", se c
lasificaron siete carcinomas infiltrantes que no pudieron    identificarse con s
eguridad como adenocarcinoma o carcinoma escamoso (tres de    ellos con caracter
&iacute;sticas de carcinoma de c&eacute;lulas peque&ntilde;as),    y se agruparo
n como "carcinomas indiferenciados", dos papilomas, dos    melanomas, dos leiomi
omas, dos linfomas y un hemangioma capilar.</font></p>     ^cY#a03v22n6.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a03v22n6.htm#S#p#75#71#article#117#<p>&nbsp;</p>     ^
cY#a03v22n6.htm##
00311000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704007600076002001300152#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a03v22n6.htm#S#p#76#72#article#117#<p><font size="3" f
ace="Verdana"><b>DISCUSI&Oacute;N</b></font></p>     ^cY#a03v22n6.htm##
00703000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704046800076002001300544#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a03v22n6.htm#S#p#77#73#article#117#<p><font size="2" f
ace="Verdana">La incidencia del adenocarcinoma de es&oacute;fago    se ha increm
entado r&aacute;pidamente en las &uacute;ltimas tres d&eacute;cadas.    As&iacut
e;, entre los hombres estadounidenses blancos, se produjo un aumento    del 350%
 entre mediados de la d&eacute;cada del setenta y 1994. En el mismo    per&iacut
e;odo, la incidencia anual de carcinoma escamoso por 100000 habitantes    descen
di&oacute; de 3,4 a 2,2 (13).</font></p>     ^cY#a03v22n6.htm##
00495000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704026000076002001300336#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a03v22n6.htm#S#p#78#74#article#117#<p><font size="2" f
ace="Verdana">En un estudio del <I>American College of Surgeons</I>    se hall&o
acute; que la incidencia relativa del carcinoma escamoso respecto del    adenoca
rcinoma decreci&oacute; de 2:1 a 1,2:1 entre 1988 y 1994 (6).</font></p>     ^cY
#a03v22n6.htm##
00525000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704029000076002001300366#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a03v22n6.htm#S#p#79#75#article#117#<p><font size="2" f
ace="Verdana">Es probable que en la actualidad, entre los nuevos    casos de car
cinoma esof&aacute;gico diagnosticados en los EstadosUnidos y en    otros pa&iac
ute;ses se encuentren m&aacute;s casos de adenocarcinoma que de    carcinoma esc
amoso (14).</font></p>     ^cY#a03v22n6.htm##
00587000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704035200076002001300428#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a03v22n6.htm#S#p#80#76#article#117#<p><font size="2" f
ace="Verdana">La incidencia del adenocarcinoma de es&oacute;fago    tambi&eacute
;n ha aumentado r&aacute;pidamente en Europa occidental a partir    de la d&eacu
te;cada del setenta; en contraste, la incidencia del carcinoma escamoso    de es
&oacute;fago ha permanecido relativamente constante o ha disminuido (15).</font>
</p>     ^cY#a03v22n6.htm##
01032000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704079700076002001300873#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a03v22n6.htm#S#p#81#77#article#117#<p><font size="2" f
ace="Verdana">El significativo aumento de la incidencia del    adenocarcinoma de
 es&oacute;fago en los pa&iacute;ses de estilo de vida occidental    se ha atrib
uido, al menos en parte, a un aumento del sobrepeso y la obesidad    en las pobl
aciones (4–6). En Irlanda, la incidencia de este adenocarcinoma se    increment&
oacute; en un 38% entre 1995 y 2004, lo cual se asoci&oacute; con    un aumento 
del 67% de la prevalencia de obesidad en el mismo per&iacute;odo    (16). En un 
estudio de casos y controles realizado en dicho pa&iacute;s, el    82% de los pa
cientes con adenocarcinoma de es&oacute;fago eran obesos o presentaban    sobrep
eso, mientras que en la poblaci&oacute;n de referencia esta proporci&oacute;n   
 era del 59% (<I>P</I>&lt;0,001) (16).</font></p>     ^cY#a03v22n6.htm##
00605000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704037000076002001300446#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a03v22n6.htm#S#p#82#78#article#117#<p><font size="2" f
ace="Verdana">Adem&aacute;s de la obesidad, otros factores    pueden explicar lo
s cambios en la frecuencia relativa del adenocarcinoma esof&aacute;gico    respe
cto del carcinoma escamoso, como la disminuci&oacute;n del h&aacute;bito    de f
umar y algunos cambios en los patrones de nutrici&oacute;n y de uso de medicacio
nes    (4).</font></p>     ^cY#a03v22n6.htm##
01138000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704090300076002001300979#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a03v22n6.htm#S#p#83#79#article#117#<p><font size="2" f
ace="Verdana">En Argentina no hay datos sobre la frecuencia    relativa de adeno
carcinoma y carcinoma escamoso esof&aacute;gicos. Seg&uacute;n    el Atlas de mo
rtalidad por c&aacute;ncer en la Rep&uacute;blica Argentina 1997–    2001 (9), d
el total de 144274 casos de c&aacute;ncer en hombres, 6760 (4,7%)    correspondi
eron a c&aacute;ncer de es&oacute;fago (no se discrimina entre adenocarcinomas  
  y carcinomas escamosos); mientras que del total de 119 704 casos en mujeres,  
  2 783 (2,3%) correspondieron a c&aacute;ncer de es&oacute;fago. En la provinci
a    de Santa Fe, donde se halla la ciudad de Rosario —que concentra la mayor po
blaci&oacute;n    urbana de la provincia—, este c&aacute;ncer represent&oacute; 
la sexta causa    de mortalidad por c&aacute;ncer en hombres, mientras que entre
 las mujeres no    figur&oacute; entre las primeras diez causas.</font></p>     
^cY#a03v22n6.htm##
00738000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704050300076002001300579#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a03v22n6.htm#S#p#84#80#article#117#<p><font size="2" f
ace="Verdana">En esta serie de biopsias endosc&oacute;picas    esof&aacute;gicas
 realizadas consecutivamente en un laboratorio de histopatolog&iacute;a    de Ro
sario, la frecuencia relativa de adenocarcinoma y carcinoma escamoso de    es&oa
cute;fago (0,33/0,67) es similar a la observada en series de otros pa&iacute;ses
    (17). En una serie estadounidense de 1986 el adenocarcinoma represent&oacute
;    el 34% de todos los c&aacute;nceres esof&aacute;gicos (18).</font></p>     
^cY#a03v22n6.htm##
00766000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704053100076002001300607#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a03v22n6.htm#S#p#85#81#article#117#<p><font size="2" f
ace="Verdana">Al separar los casos m&aacute;s antiguos (1992–1999)    de los m&a
acute;s recientes (2000– 2006), se observ&oacute; una variaci&oacute;n    de la 
frecuencia relativa, que pas&oacute; de 0,28/ 0,72 a 0,38/0,62 (<a href="#qdr01"
>cuadro    1</a>). Esta diferencia, aunque no resulta estad&iacute;sticamente si
gnificativa,    puede indicar una tendencia en nuestro medio similar, aunque men
os acentuada,    a la descrita en los EstadosUnidos y en pa&iacute;ses de Europa
 occidental.</font></p>     ^cY#a03v22n6.htm##
01246000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704101100076002001301087#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a03v22n6.htm#S#p#86#82#article#117#<p><font size="2" f
ace="Verdana">Si bien la frecuencia relativa en biopsias endosc&oacute;picas    
no es una medida directa de la incidencia ni de la prevalencia del adenocarcinom
a    y del carcinoma escamoso esof&aacute;gico en la poblaci&oacute;n general, e
stos    datos permiten evaluar de manera indirecta el estado actual y la probabl
e evoluci&oacute;n    de la frecuencia del adenocarcinoma esof&aacute;gico entre
 personas de clase    media baja y clase media t&iacute;pica de la ciudad de Ros
ario, teniendo en    cuenta que derivan de estudios endosc&oacute;picos realizad
os en la misma poblaci&oacute;n    y por el mismo grupo de endoscopistas, y cons
iderando que el diagn&oacute;stico    inicial de adenocarcinoma y carcinoma esca
moso esof&aacute;gicos se realiza    casi siempre por biopsia endosc&oacute;pica
. La similitud en el n&uacute;mero    total de carcinomas en los per&iacute;odos
 1992–1999 y 2000–2006 permite asimismo    una comparaci&oacute;n adecuada entre
 los grupos.</font></p>     ^cY#a03v22n6.htm##
00765000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704053000076002001300606#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a03v22n6.htm#S#p#87#83#article#117#<p><font size="2" f
ace="Verdana">Algunos autores separan en sus series los casos    de adenocarcino
ma asociado a EB de los de adenocarcinoma cardial. En esta serie    —que s&oacut
e;lo incluye casos remitidos como biopsias esof&aacute;gicas por    endoscopista
s— no realizamos esa diferencia, incluso si algunos de los casos    pod&iacute;a
n considerarse como adenocarcinoma cardial, teniendo en cuenta que    muchos aut
ores atribuyen una patogenia similar a ambas lesiones y las consideran    en con
junto (19).</font></p>     ^cY#a03v22n6.htm##
00872000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704063700076002001300713#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a03v22n6.htm#S#p#88#84#article#117#<p><font size="2" f
ace="Verdana">En relaci&oacute;n con el sexo, hallamos que    en los hombres, el
 adenocarcinoma representa el 75,6% de los casos y el carcinoma    escamoso, el 
57,1%. La diferencia en la frecuencia de predominio masculino del    adenocarcin
oma respecto del carcinoma escamoso result&oacute; estad&iacute;sticamente    si
gnificativa (<I>P</I>&lt;0,05). Esto es similar a lo descrito en series de    Es
tados Unidos (7) e indica que aunque ambos tipos de carcinoma, de diferente    e
tiopatogenia, son m&aacute;s frecuentes en el sexo masculino, la diferencia    e
s mayor en el caso del adenocarcinoma.</font></p>     ^cY#a03v22n6.htm##
01058000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704082300076002001300899#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a03v22n6.htm#S#p#89#85#article#117#<p><font size="2" f
ace="Verdana">En cuanto a la distribuci&oacute;n por edad,    encontramos que en
 las mujeres, la mayor&iacute;a de los c&aacute;nceres (71,8%)    se diagnostica
ron a partir de los 65 a&ntilde;os, mientras que en los hombres,    algo m&aacut
e;s de la mitad de los diagn&oacute;sticos (54,2%) se realizaron    antes de los
 65 a&ntilde;os (<I>P</I>&lt;0,025) (<a href="#qdr03">cuadro 3</a>).    Estos re
sultados coinciden con la distribuci&oacute;n de la mortalidad por c&aacute;ncer
    de es&oacute;fago seg&uacute;n grupos etarios notificada en la Provincia de 
   Santa Fe: el 57,7% entre los varones mayores de 65a&ntilde;os y el 42,3% entr
e    los menores de 65a&ntilde;os, y el 83,3% entre las mujeres mayores de 65 a&
ntilde;os    y el 16,7% entre las menores de 65 a&ntilde;os (9).</font></p>     
^cY#a03v22n6.htm##
00804000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704056900076002001300645#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a03v22n6.htm#S#p#90#86#article#117#<p><font size="2" f
ace="Verdana">El porcentaje de casos de EB diagnosticados en    las biopsias end
osc&oacute;picas esof&aacute;gicas realizadas (6,67%) es menor    que el observa
do en pacientes asintom&aacute;ticos de otras series (20). No    obstante, cabe 
destacar que en esta serie se incluyeron numerosos casos en los    cuales las bi
opsias se realizaron como parte de procedimientos de endoscopia    digestiva alt
a por indicaciones ajenas a afecci&oacute;n esof&aacute;gica, sin    estudio sis
tem&aacute;tico de la uni&oacute;n escamocolumnar.</font></p>     ^cY#a03v22n6.h
tm##
00978000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704074300076002001300819#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a03v22n6.htm#S#p#91#87#article#117#<p><font size="2" f
ace="Verdana">El EB se diagnostic&oacute; en una proporci&oacute;n    de 6 a 1 c
on respecto al adenocarcinoma. En la gran mayor&iacute;a de los casos    (94,7%)
, no se observ&oacute; displasia asociada en el momento del diagn&oacute;stico  
  inicial. El n&uacute;mero de casos de EB sin displasia fue similar en ambos   
 sexos (119 hombres y 112 mujeres), lo que corresponde a una relaci&oacute;n    
hombres:mujeres menor que la notificada, de 3:1 (21). En cambio, todos los casos
    de EB con displasia de esta serie se diagnosticaron en hombres. Ya se notifi
c&oacute;    anteriormente la alta predominancia masculina del EB, con mayor cap
acidad de    progresi&oacute;n a displasia y c&aacute;ncer (22).</font></p>     
^cY#a03v22n6.htm##
00561000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704032600076002001300402#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a03v22n6.htm#S#p#92#88#article#117#<p><font size="2" f
ace="Verdana">Por &uacute;ltimo, s&oacute;lo se realizaron    biopsias de seguim
iento en el 18,6% de los casos de EB sin displasia, lo que    sugiere que la pro
porci&oacute;n de casos que se controlan luego del diagn&oacute;stico    de mane
ra sistem&aacute;tica en nuestro medio es baja.</font></p>     ^cY#a03v22n6.htm#
#
01168000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704093300076002001301009#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a03v22n6.htm#S#p#93#89#article#117#<p><font size="2" f
ace="Verdana">En resumen, en esta serie se registr&oacute;    un aumento del 10%
 en la frecuencia relativa del adenocarcinoma esof&aacute;gico    respecto del n
&uacute;mero total de casos de carcinoma escamoso y adenocarcinoma    esof&aacut
e;gicos en los &uacute;ltimos siete a&ntilde;os, en comparaci&oacute;n    con lo
s primeros siete a&ntilde;os de la serie. Este aumento no result&oacute;    sign
ificativo, pero puede indicar una tendencia similar en nuestro medio a la    des
crita en otros pa&iacute;ses. Si bien tanto el adenocarcinoma como el carcinoma 
   escamoso predominaron en hombres, el predominio masculino del adenocarcinoma 
   fue mayor. En las mujeres, la mayor&iacute;a de los c&aacute;nceres se diagno
sticaron    despu&eacute;s de los 65 a&ntilde;os, mientras que en los hombres, m
&aacute;s    de la mitad de los diagn&oacute;sticos se realizaron antes de los 6
5 a&ntilde;os.</font></p>     ^cY#a03v22n6.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a03v22n6.htm#S#p#94#90#article#117#<p>&nbsp;</p>     ^
cY#a03v22n6.htm##
00306000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704007100076002001300147#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a03v22n6.htm#S#p#95#91#article#117#<p><font size="3" f
ace="Verdana"><b>REFERENCIAS</b></font></p>     ^cY#a03v22n6.htm##
00403000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704015400078002001300232#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a03v22n6.htm#S#p#96#92#article#117#1#<p><f
ont size="2" face="Verdana">1. Haggitt RC. Adenocarcinoma in Barrett's esophagus
:    a new epidemic? Human Pathol. 1992;23:475–6.</font></p>     ^cY#a03v22n6.ht
m##
00405000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704015600078002001300234#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a03v22n6.htm#S#p#97#93#article#117#2#<p><f
ont size="2" face="Verdana">2. DeVault KR. Epidemiology and significance    of B
arrett's esophagus. Dig Dis. 2000–2001; 18:195–202.</font></p>     ^cY#a03v22n6.
htm##
00388000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704013900078002001300217#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a03v22n6.htm#S#p#98#94#article#117#3#<p><f
ont size="2" face="Verdana">3. Lambert R, Hainaut P. Esophageal cancer. World   
 Gastroenterol News. 2006;11:37–9.</font></p>     ^cY#a03v22n6.htm##
00385000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704013600078002001300214#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a03v22n6.htm#S#p#99#95#article#117#4#<p><f
ont size="2" face="Verdana">4. Enzinger PC, Mayer RJ. Esophageal cancer.    N En
gl J Med. 2003;349(23):2241–52.</font></p>     ^cY#a03v22n6.htm##
00534000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073888000200077704028400079002001300363#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a03v22n6.htm#S#p#100#96#article#117#5#<p><
font size="2" face="Verdana">5. Parfitt JR, Miladinovic Z, Driman DK. Increasing
    incidence of adenocarcinoma of the gastroesophageal junction and distal stom
ach    in Canada—an epidemiological study from 1964– 2002. Can J Gastroenterol.2
006;20(4):    271–6.</font></p>     ^cY#a03v22n6.htm##
00509000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073888000200077704025900079002001300338#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a03v22n6.htm#S#p#101#97#article#117#6#<p><
font size="2" face="Verdana">6. Daly JM, Fry WA, Little AG, Winchester DP,    Mc
Kee RF, Stewart AK, et al. Esophageal cancer: results of an American College    
of Surgeons patient care evaluation study. J Am Coll Surg. 2000;190:562–72.</fon
t></p>     ^cY#a03v22n6.htm##
00460000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073888000200077704021000079002001300289#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a03v22n6.htm#S#p#102#98#article#117#7#<p><
font size="2" face="Verdana">7. Blot JW, Devesa SS, Kneller, RW, Fraumeni    JF 
Jr. Rising incidence of adenocarcinoma of the esophagus and gastric cardia.    J
AMA. 1991; 265(10):1287–9.</font></p>     ^cY#a03v22n6.htm##
00405000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073888000200077704015500079002001300234#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a03v22n6.htm#S#p#103#99#article#117#8#<p><
font size="2" face="Verdana">8. Faller G, Stolte M. Barrett's oesophagus:    tim
e for consensus. Virchows Arch. 2003;443(5): 595–6.</font></p>     ^cY#a03v22n6.
htm##
00600000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000200078704034900080002001300429#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a03v22n6.htm#S#p#104#100#article#117#9#<p>
<font size="2" face="Verdana">9. Matos EL, Loria DI, Zengarini N, Fern&aacute;nd
ez    MM, Guevel CG, Marconi E, et al. Atlas de mortalidad por c&aacute;ncer en 
Argentina,    1997– 2001. Buenos Aires: Ministerio de Salud, Instituto de Oncolo
g&iacute;a    &Aacute;ngel Roffo, Fundaci&oacute;n Bunge y Born, y CPO—Piemonti;
 2003.</font></p>     ^cY#a03v22n6.htm##
00487000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704023500081002001300316#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a03v22n6.htm#S#p#105#101#article#117#10#<p
><font size="2" face="Verdana">10. Salvia A, Tami F (coordinadores). Bar&oacute;
metro    de la deuda social argentina. N.°1: Las grandes desigualdades. Buenos A
ires:    Universidad Cat&oacute;lica Argentina; 2005.</font></p>     ^cY#a03v22n
6.htm##
00523000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704027100081002001300352#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a03v22n6.htm#S#p#106#102#article#117#11#<p
><font size="2" face="Verdana">11. Sharma P, McQuaid K, Dent J, Fennerty MB,    
Sampliner R, Spechler S, et al. A critical review of the diagnosis and managemen
t    of Barrett's Esophagus: The AGA Chicago Workshop. Gastroenterology. 2004;12
7:310–30.</font></p>     ^cY#a03v22n6.htm##
00505000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704025300081002001300334#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a03v22n6.htm#S#p#107#103#article#117#12#<p
><font size="2" face="Verdana">12. Montogomery E, Bronner MP, Goldblum JR, Green
son    JK, Haber MM, Hart J, et al. Reproducibility of the diagnosis of dysplasi
a in    Barrett esophagus: a reaffirmation. Hum Pathol. 2001;32:368–78.</font></
p>     ^cY#a03v22n6.htm##
00468000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704021600081002001300297#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a03v22n6.htm#S#p#108#104#article#117#13#<p
><font size="2" face="Verdana">13. Devesa SS, Blot WJ, Fraumeni JF Jr. Changing 
   patterns in the incidence of esophageal and gastric carcinoma in the United  
  States. Cancer. 1998;83:2049–53.</font></p>     ^cY#a03v22n6.htm##
00514000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704026200081002001300343#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a03v22n6.htm#S#p#109#105#article#117#14#<p
><font size="2" face="Verdana">14. Medical Research Council Oesophageal Cancer  
  Working Group. Surgical resection with or without preoperative chemotherapy   
 in oesophageal cancer: a randomised controlled trial. Lancet. 2002;359:1727–33.
</font></p>     ^cY#a03v22n6.htm##
00553000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704030100081002001300382#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a03v22n6.htm#S#p#110#106#article#117#15#<p
><font size="2" face="Verdana">15. Vaughan TL, Davis S, Kristal A, Thomas DB.   
 Obesity, alcohol, and tobacco as risk factors for cancers of the esophagus and 
   gastric cardia: adenocarcinoma versus squamous cell carcinoma. Cancer Epidemi
ol    Biomarkers Prev. 1995;4(2):85–92.</font></p>     ^cY#a03v22n6.htm##
00505000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704025300081002001300334#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a03v22n6.htm#S#p#111#107#article#117#16#<p
><font size="2" face="Verdana">16. Ryan AM, Rowley SP, Fitzgerald AP, Ravi N,   
 Reynolds JV. Adenocarcinoma of the oesophagus and gastric cardia: male preponde
rance    in association with obesity. Eur J Cancer. 2006; 42(8):1151–8.</font></
p>     ^cY#a03v22n6.htm##
00521000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704026900081002001300350#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a03v22n6.htm#S#p#112#108#article#117#17#<p
><font size="2" face="Verdana">17. Botterweck AA, Schouten LJ, Volovics A, Doran
t    E, van Den Brandt PA. Trends in the incidence of adenocarcinoma of the esop
hagus    and gastric cardia in ten European countries. Int J Epidemiol. 2000;29:
645–54.</font></p>     ^cY#a03v22n6.htm##
00482000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704023000081002001300311#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a03v22n6.htm#S#p#113#109#article#117#18#<p
><font size="2" face="Verdana">18. Wang HH, Antonioli, DA, Goldman, H. Comparati
ve    features of esophageal and gastric adenocarcinomas: recent changes in type
 and    frequency. Hum Pathol. 1986;17(5):482–7.</font></p>     ^cY#a03v22n6.htm
##
00490000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704023800081002001300319#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a03v22n6.htm#S#p#114#110#article#117#19#<p
><font size="2" face="Verdana">19. Chandrasoma P, Makarewicz K, Wickramasinghe  
  K, Demeester T. A proposal for a new validated histological definition of the 
   gastroesophageal junction. Hum Pathol. 2006;37: 40–7.</font></p>     ^cY#a03v
22n6.htm##
00544000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704029200081002001300373#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a03v22n6.htm#S#p#115#111#article#117#20#<p
><font size="2" face="Verdana">20. Ward EM, Wolfsen HC, Achem SR, Loeb DS, Krish
na    M, Hemminger LL, et al. Barrett's esophagus is common in older men and wom
en    undergoing screening colonoscopy regardless of reflux symptoms. Am J Gastr
oenterol.    2006;101(1):12–7.</font></p>     ^cY#a03v22n6.htm##
00521000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704026900081002001300350#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a03v22n6.htm#S#p#116#112#article#117#21#<p
><font size="2" face="Verdana">21. Falk GW, Thota PN, Richter JE, Connor JT,    
Wachserberger DM. Barrett's esophagus in women: demographic features and progres
sion    to high-grade dysplasia and cancer. Clin Gastroenterol Hepatol. 2005;3:1
089–94.</font></p>     ^cY#a03v22n6.htm##
00528000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704027600081002001300357#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a03v22n6.htm#S#p#117#113#article#117#22#<p
><font size="2" face="Verdana">22. Bani-Hani KE, Bani-Hani BK, Martin IG. Charac
teristics    of patients with columnar-lined Barrett's esophagus and risk factor
s for progression    to esophageal adenocarcinoma. World J Gastroenterol. 2005;1
1(43):6807–14.</font></p>     ^cY#a03v22n6.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a03v22n6.htm#S#p#118#114#article#117#<p>&nbsp;</p>    
 ^cY#a03v22n6.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a03v22n6.htm#S#p#119#115#article#117#<p>&nbsp;</p>    
 ^cY#a03v22n6.htm##
00325000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704008800078002001300166#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a03v22n6.htm#S#p#120#116#article#117#<p><font size="2"
 face="Verdana">Manuscrito recibido el 14 de diciembre de 2006.    ^cY#a03v22n6.
htm##
00351000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704011400078002001300192#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a03v22n6.htm#S#p#121#117#article#117#<br>   Aceptado p
ara publicaci&oacute;n, tras revisi&oacute;n, el 12 de septiembre    de 2007.</f
ont></p>     ^cY#a03v22n6.htm##
00468000000000253000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100018000770120059000950300
01300154710000200167065000900169064000500178031000300183014000600186865000900192
002001300201#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a03v22n6.htm#S#c#122#1#art
icle#22#1#^rND^sHaggitt^nRC#Adenocarcinoma in Barrett's esophagus: a new epidemi
c?^len#Human Pathol#2#19920000#1992#23#475-6#20071200#a03v22n6.htm##
00496000000000265000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100018000770120057000950300
00800152065000900160064001000169031000300179014000800182865000900190002001300199
035001000212801000800222#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a03v22n6.htm#S
#c#123#2#article#22#2#^rND^sDeVault^nKR#Epidemiology and significance of Barrett
's esophagus^len#Dig Dis#20010000#2000-2001#18#195-202#20071200#a03v22n6.htm#025
7-2753#Dig Dis##
00470000000000265000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100017000770100017000940120
02200111030002500133710000200158065000900160064000500169031000300174014000500177
865000900182002001300191#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a03v22n6.htm#S
#c#124#3#article#22#3#^rND^sLambert^nR#^rND^sHainaut^nP#Esophageal cancer^len#Wo
rld Gastroenterol News#2#20060000#2006#11#37-9#20071200#a03v22n6.htm##
00511000000000289000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100019000770100016000960120
02200112030001300134065000900147064000500156031000400161032000300165014000800168
865000900176002001300185035001000198801001300208#v22n6#v:\scielo\serial\rpsp\v22
n6\markup\a03v22n6.htm#S#c#125#4#article#22#4#^rND^sEnzinger^nPC#^rND^sMayer^nRJ
#Esophageal cancer^len#N Engl J Med#20030000#2003#349#23#2241-52#20071200#a03v22
n6.htm#0028-4793#N Engl J Med##
00678000000000301000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100018000770100021000950100
01700116012014600133030002000279065000900299064000500308031000300313032000200316
014000600318865000900324002001300333035001000346801002000356#v22n6#v:\scielo\ser
ial\rpsp\v22n6\markup\a03v22n6.htm#S#c#126#5#article#22#5#^rND^sParfitt^nJR#^rND
^sMiladinovic^nZ#^rND^sDriman^nDK#Increasing incidence of adenocarcinoma of the 
gastroesophageal junction and distal stomach in Canada-an epidemiological study 
from 1964- 2002^len#Can J Gastroenterol#20060000#2006#20#4#271-6#20071200#a03v22
n6.htm#0835-7900#Can J Gastroenterol##
00705000000000337000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100015000770100014000920100
01700106010002100123010001600144010001800160810000600178012009600184030001500280
06500090029506400050030403100040030901400070031386500090032000200130032903500100
0342801001500352#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a03v22n6.htm#S#c#127#6
#article#22#6#^rND^sDaly^nJM#^rND^sFry^nWA#^rND^sLittle^nAG#^rND^sWinchester^nDP
#^rND^sMcKee^nRF#^rND^sStewart^nAK#et al#Esophageal cancer: results of an Americ
an College of Surgeons patient care evaluation study^len#J Am Coll Surg#20000000
#2000#190#562-72#20071200#a03v22n6.htm#1072-7515#J Am Coll Surg##
00608000000000313000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100015000770100017000920100
01800109010002200127012007500149030000500224065000900229064000500238031000400243
032000300247014000700250865000900257002001300266035001000279801000500289#v22n6#v
:\scielo\serial\rpsp\v22n6\markup\a03v22n6.htm#S#c#128#7#article#22#7#^rND^sBlot
^nJW#^rND^sDevesa^nSS#^rND^sKneller^nRW#^rND^sFraumeni^nJF Jr#Rising incidence o
f adenocarcinoma of the esophagus and gastric cardia^len#JAMA#19910000#1991#265#
10#1287-9#20071200#a03v22n6.htm#0098-7484#JAMA##
00512000000000277000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100016000770120055000930300
01400148065000900162064000500171031000400176032000200180014000600182865000900188
002001300197035001000210801001400220#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a0
3v22n6.htm#S#c#129#8#article#22#8#^rND^sFaller^nG#Stolte M. Barrett's oesophagus
: time for consensus^len#Virchows Arch#20030000#2003#443#5#595-6#20071200#a03v22
n6.htm#0945-6317#Virchows arch##
00718000000000325000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750160016000770160016000930160
01900109016002000128016001700148016001700165810000600182018006100188066001300249
06200200026206200350028206200390031706500090035606400050036586500090037000200130
0379#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a03v22n6.htm#S#c#130#9#article#22#
9#^rND^sMatos^nEL#^rND^sLoria^nDI#^rND^sZengarini^nN#^rND^sFernández^nMM#^rND^sG
uevel^nCG#^rND^sMarconi^nE#et al#Atlas de mortalidad por cáncer en Argentina, 19
97- 2001.^len#Buenos Aires#Ministerio de Salud#Instituto de Oncología Ángel Roff
o#Fundación Bunge y Born, y CPO-Piemonti#20030000#2003#20071200#a03v22n6.htm##
00513000000000241000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760160019000790160017000980180
07600115066001300191062003100204065000900235064000500244865000900249002001300258
#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a03v22n6.htm#S#c#131#10#article#22#10#
^rCOORD^sSalvia^nA#^rCOORD^sTami^nF#Barómetro de la deuda social argentina: N.°1
: Las grandes desigualdades^les#Buenos Aires#Universidad Católica Argentina#2005
0000#2005#20071200#a03v22n6.htm##
00720000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100017000950100
01400112010001900126010001900145010001800164810000600182012010300188030001700291
06500090030806400050031703100040032201400070032686500090033300200130034203500100
0355801001700365#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a03v22n6.htm#S#c#132#1
1#article#22#11#^rND^sSharma^nP#^rND^sMcQuaid^nK#^rND^sDent^nJ#^rND^sFennerty^nM
B#^rND^sSampliner^nR#^rND^sSpechler^nS#et al#A critical review of the diagnosis 
and management of Barrett's Esophagus: The AGA Chicago Workshop^len#Gastroentero
logy#20040000#2004#127#310-30#20071200#a03v22n6.htm#0016-5085#Gastroenterology##
00696000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100021000790100018001000100
01900118010001900137010001600156010001400172810000600186012008800192030001100280
06500090029106400050030003100030030501400070030886500090031500200130032403500100
0337801001100347#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a03v22n6.htm#S#c#133#1
2#article#22#12#^rND^sMontogomery^nE#^rND^sBronner^nMP#^rND^sGoldblum^nJR#^rND^s
Greenson^nJK#^rND^sHaber^nMM#^rND^sHart^nJ#et al#Reproducibility of the diagnosi
s of dysplasia in Barrett esophagus: a reaffirmation^len#Hum Pathol#20010000#200
1#32#368-78#20071200#a03v22n6.htm#0046-8177#Hum Pathol##
00590000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100015000960100
02200111012009600133030000700229065000900236064000500245031000300250014000800253
865000900261002001300270035001000283801000700293#v22n6#v:\scielo\serial\rpsp\v22
n6\markup\a03v22n6.htm#S#c#134#13#article#22#13#^rND^sDevesa^nSS#^rND^sBlot^nWJ#
^rND^sFraumeni^nJF Jr#Changing patterns in the incidence of esophageal and gastr
ic carcinoma in the United States^len#Cancer#19980000#1998#83#2049-53#20071200#a
03v22n6.htm#0008-543X#Cancer##
00593000000000265000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760110058000790120118001370300
00700255065000900262064000500271031000400276014000800280865000900288002001300297
035001000310801000700320#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a03v22n6.htm#S
#c#135#14#article#22#14#Medical Research Council Oesophageal Cancer Working Grou
p#Surgical resection with or without preoperative chemotherapy in oesophageal ca
ncer: a randomised controlled trial^len#Lancet#20020000#2002#359#1727-33#2007120
0#a03v22n6.htm#0099-5355#Lancet##
00727000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100015000970100
01700112010001700129012014500146030003300291065000900324064000500333031000200338
032000200340014000600342865000900348002001300357035001000370801003300380#v22n6#v
:\scielo\serial\rpsp\v22n6\markup\a03v22n6.htm#S#c#136#15#article#22#15#^rND^sVa
ughan^nTL#^rND^sDavis^nS#^rND^sKristal^nA#^rND^sThomas^nDB#Obesity, alcohol, and
 tobacco as risk factors for cancers of the esophagus and gastric cardia: adenoc
arcinoma versus squamous cell carcinoma^len#Cancer Epidemiol Biomarkers Prev#199
50000#1995#4#2#85-92#20071200#a03v22n6.htm#1055-9965#Cancer Epidemiol Biomarkers
 Prev##
00679000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100015000790100017000940100
02100111010001400132010001900146012010400165030001300269065000900282064000500291
03100030029603200020029901400070030186500090030800200130031703500100033080100130
0340#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a03v22n6.htm#S#c#137#16#article#22
#16#^rND^sRyan^nAM#^rND^sRowley^nSP#^rND^sFitzgerald^nAP#^rND^sRavi^nN#^rND^sRey
nolds^nJV#Adenocarcinoma of the oesophagus and gastric cardia: male preponderanc
e in association with obesity^len#Eur J Cancer#20060000#2006#42#8#1151-8#2007120
0#a03v22n6.htm#0014-2964#Eur J Cancer##
00688000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100021000790100019001000100
01800119010001600137010002500153012010800178030001600286065000900302064000500311
031000300316014000700319865000900326002001300335035001000348801001600358#v22n6#v
:\scielo\serial\rpsp\v22n6\markup\a03v22n6.htm#S#c#138#17#article#22#17#^rND^sBo
tterweck^nAA#^rND^sSchouten^nLJ#^rND^sVolovics^nA#^rND^sDorant^nE#^rND^svan Den 
Brandt^nPA#Trends in the incidence of adenocarcinoma of the esophagus and gastri
c cardia in ten European countries^len#Int J Epidemiol#20000000#2000#29#645-54#2
0071200#a03v22n6.htm#0300-5771#Int J Epidemiol##
00617000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100015000790100020000940100
01700114012010500131030001100236065000900247064000500256031000300261032000200264
014000600266865000900272002001300281035001000294801001100304#v22n6#v:\scielo\ser
ial\rpsp\v22n6\markup\a03v22n6.htm#S#c#139#18#article#22#18#^rND^sWang^nHH#^rND^
sAntonioli^nDA#^rND^sGoldman^nH#Comparative features of esophageal and gastric a
denocarcinomas: recent changes in type and frequency^len#Hum Pathol#19860000#198
6#17#5#482-7#20071200#a03v22n6.htm#0046-8177#Hum Pathol##
00633000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100021000790100020001000100
02400120010001900144012009200163030001100255065000900266064000500275031000300280
014000500283865000900288002001300297035001000310801001100320#v22n6#v:\scielo\ser
ial\rpsp\v22n6\markup\a03v22n6.htm#S#c#140#19#article#22#19#^rND^sChandrasoma^nP
#^rND^sMakarewicz^nK#^rND^sWickramasinghe^nK#^rND^sDemeester^nT#A proposal for a
 new validated histological definition of the gastroesophageal junction^len#Hum 
Pathol#20060000#2006#37#40-7#20071200#a03v22n6.htm#0046-8177#Hum Pathol##
00751000000000349000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100015000790100018000940100
01600112010001500128010001700143010002000160810000600180012012000186030001900306
06500090032506400050033403100040033903200020034301400050034586500090035000200130
0359035001000372801001900382#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a03v22n6.h
tm#S#c#141#20#article#22#20#^rND^sWard^nEM#^rND^sWolfsen^nHC#^rND^sAchem^nSR#^rN
D^sLoeb^nDS#^rND^sKrishna^nM#^rND^sHemminger^nLL#et al#Barrett's esophagus is co
mmon in older men and women undergoing screening colonoscopy regardless of reflu
x symptoms^len#Am J Gastroenterol#20060000#2006#101#1#12-7#20071200#a03v22n6.htm
#0002-9270#Am J Gastroenterol##
00652000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100015000790100016000940100
01800110010001700128010002400145012010600169030002700275710000200302065000900304
064000500313031000200318014000800320865000900328002001300337#v22n6#v:\scielo\ser
ial\rpsp\v22n6\markup\a03v22n6.htm#S#c#142#21#article#22#21#^rND^sFalk^nGW#^rND^
sThota^nPN#^rND^sRichter^nJE#^rND^sConnor^nJT#^rND^sWachserberger^nDM#Barrett's 
esophagus in women: demographic features and progression to high-grade dysplasia
 and cancer^len#Clin Gastroenterol Hepatol#2#20050000#2005#3#1089-94#20071200#a0
3v22n6.htm##
00634000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100020000790100020000990100
01700119012013400136030002200270710000200292065000900294064000500303031000300308
032000300311014000800314865000900322002001300331#v22n6#v:\scielo\serial\rpsp\v22
n6\markup\a03v22n6.htm#S#c#143#22#article#22#22#^rND^sBani-Hani^nKE#^rND^sBani-H
ani^nBK#^rND^sMartin^nIG#Characteristics of patients with columnar-lined Barrett
's esophagus and risk factors for progression to esophageal adenocarcinoma^len#W
orld J Gastroenterol#2#20050000#2005#11#43#6807-14#20071200#a03v22n6.htm##
00275000000000169000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700910009000720920007000810020013000887030
00400101#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a04v22n6.htm#S#o#1#1#article#1
#20080215#102624#a04v22n6.htm#159##
05314000000000661000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000400090121000300094049000800097158000300105030002400108
03100030013203200020013506500090013701400110014603500100015701200940016701200950
02610100035003560100027003910100038004180700146004560831834006020850008024360850
02202444085003802466085002602504085002802530085001902558083167202577085000804249
08500230425708500400428008500310432008500270435108500190437805800600439705800530
44570580062045101170006045720720003045781120009045811110020045901140009046101130
02004619002001304639#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a04v22n6.htm#S#h#2
#1#article#1#oa#pt#br1.1#1#3.1#TAB#04#RPSP020#nd#Rev Panam Salud Publica#22#6#20
071200#^f389^l395#1020-4989#Análise de comentários espontâneos elaborados por us
uários de ecstasy em pesquisa on-line^lpt#Analysis of spontaneous comments poste
d by ecstasy users participating in an online survey^len#^rND^1A01^nStella Perei
ra^sAlmeida#^rND^1A01^nJuliana^sBizeto#^rND^1A01^nMaria Teresa Araujo^sSilva#Uni
versidade de São Paulo^iA01^1Instituto de Psicologia^2Departamento de Psicologia
 Experimental^z05508-900^cSão Paulo^sSP^pBrasil^estella@usp.br#^lpt^aOBJETIVO: A
nalisar o conteúdo dos comentários enviados espontaneamente por usuários de ecst
asy que responderam a um questionário on-line correspondente à primeira etapa de
 um projeto de redução de danos (projeto Baladaboa) para usuários dessa droga. M
ÉTODO: Dos 1 140 indivíduos que responderam o questionário, 412 enviaram comentá
rios. Os comentários foram segmentados em cinco categorias (irrelevante, drogas,
 depoimentos, questionário e projeto) e submetidos à análise de conteúdo. A cate
goria "irrelevante" incluiu saudações, comentários irreverentes e manifestações 
ideológicas. A categoria "drogas" incluiu considerações sobre as causas, os efei
tos e as conseqüências do uso de ecstasy ou de outras drogas, solicitações de es
clarecimentos sobre a droga ou comentários que apontavam a informação como uma q
uestão fundamental relacionada a seu uso. A categoria "depoimentos" incluiu come
ntários acerca de vivências pessoais. A categoria "questionário" incluiu comentá
rios sobre o questionário propriamente dito, a formulação das questões, o uso de
 certos critérios e a solicitação de acesso aos resultados da pesquisa. A catego
ria "projeto" incluiu comentários relativos ao projeto Baladaboa. RESULTADOS: Id
entificaram-se 915 segmentos nos 412 comentários. A porcentagem de segmentos cla
ssificados em cada categoria foi: irrelevante, 9,8%; drogas, 16,4%; depoimentos,
 18,1%; questionário, 25,1%; e projeto, 30,6%. A maior parte dos comentários foi
 positiva em relação ao questionário e ao projeto. CONCLUSÕES: A quantidade e o 
teor dos comentários espontaneamente enviados indicaram expressiva receptividade
 ao projeto e aprovação da estratégia de redução de danos pelo público- alvo. O 
envolvimento dos participantes pôde ser observado em todos os comentários, suger
indo que a continuidade do projeto é urgente e oportuna.#^dnd^i1#^tm^lpt^kN-meti
l-3^i1#^tm^lpt^k4-metilenodioxianfetamina^i1#^tm^lpt^kpsicotrópicos^i1#^tm^lpt^k
redução do dano^i1#^tm^lpt^kBrasil^i1#^len^aOBJECTIVE: To analyze the contents o
f spontaneous comments posted by ecstasy users participating in an online survey
 that constitutes phase one of a harm reduction project (projeto Baladaboa) aime
d at users of this drug. METHOD: Of the 1 140 individual respondents, 412 posted
 unprompted comments. These comments were grouped into five categories (irreleva
nt, drugs, testimonies, survey, and project) and submitted to content analysis. 
Salutations, irreverent comments, and ideological remarks were considered "Irrel
evant." Comments on the causes, effects, and consequences of using ecstasy or ot
her drugs; requests for information on the drug; or comments indicating that inf
ormation is a crucial issue associated with the use of ecstasy were labeled "Dru
gs." Personal stories made up the group called "Testimonies." Any comments conce
rning the questionnaire itself, the formulation of questions, the use of certain
 criteria, and requests to see survey results were designated "Survey." Comments
 specifically about the Baladaboa project were categorized as "Project." RESULTS
: Content analysis revealed 915 segments among the 412 comments. The percent dis
tribution of segments among the groups were: irrelevant, 9.8%; drugs, 16.4%; tes
timonies, 18.1%; survey, 25.1%; and project, 30.6%. Most of the comments concern
ing the survey and the project were positive. CONCLUSIONS: The number and conten
t of the spontaneous comments indicate that the project, as well as the harm red
uction strategy, were being well received by the target audience. The participan
ts expressed their engagement with the project and suggested that its continuati
on is both timely and urgent.#^dnd^i2#^tm^len^kN-methyl-3^i2#^tm^len^k4-methylen
edioxyamphetamine^i2#^tm^len^kpsychotropic drugs^i2#^tm^len^kharm reduction^i2#^
tm^len^kBrazil^i2#Coordenação de Aperfeiçoamento de Pessoal de Nível Superior#Fu
ndação de Amparo à Pesquisa do Estado de São Paulo#Conselho Nacional de Desenvol
vimento Científico e Tecnológico#other#40#20060619#19 de junho de 2006#20070730#
30 de julho de 2007#a04v22n6.htm##
05468000000000661000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000400090121000300094049000800097158000300105030002400108
03100030013203200020013506500090013701400110014603500100015701201150016701201020
02820100035003840100027004190100038004460700181004840831877006650850008025420850
02202550085003802572085002602610085002802636085001902664083172002683085000804403
08500230441108500400443408500310447408500270450508500190453205800600455105800530
46110580062046641170006047260720003047321120009047351110020047441140009047641130
02004773002001304793#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a04v22n6.htm#S#f#3
#1#article#1#oa#pt#br1.1#1#3.1#TAB#04#RPSP020#nd#Rev Panam Salud Publica#22#6#20
071200#^f389^l395#1020-4989#<B>Análise de comentários espontâneos elaborados por
 usuários de <I>ecstasy</I> em pesquisa <I>on-line</B></I>^lpt#<B>Analysis of sp
ontaneous comments posted by ecstasy users participating in an online survey</B>
^len#^rND^1A01^nStella Pereira^sAlmeida#^rND^1A01^nJuliana^sBizeto#^rND^1A01^nMa
ria Teresa Araujo^sSilva#Universidade de São Paulo^iA01^1Instituto de Psicologia
^2Departamento de Psicologia Experimental^z05508-900^cSão Paulo^sSP^pBrasil^e<A 
HREF="mailto:stella@usp.br">stella@usp.br</A>#^lpt^a<B>OBJETIVO:&nbsp;</B>Analis
ar o conteúdo dos comentários enviados espontaneamente por usuários de ecstasy q
ue responderam a um questionário on-line correspondente à primeira etapa de um p
rojeto de redução de danos (projeto Baladaboa) para usuários dessa droga. <B>MÉT
ODO:&nbsp;</B>Dos 1 140 indivíduos que responderam o questionário, 412 enviaram 
comentários. Os comentários foram segmentados em cinco categorias (irrelevante, 
drogas, depoimentos, questionário e projeto) e submetidos à análise de conteúdo.
 A categoria "irrelevante" incluiu saudações, comentários irreverentes e manifes
tações ideológicas. A categoria "drogas" incluiu considerações sobre as causas, 
os efeitos e as conseqüências do uso de ecstasy ou de outras drogas, solicitaçõe
s de esclarecimentos sobre a droga ou comentários que apontavam a informação com
o uma questão fundamental relacionada a seu uso. A categoria "depoimentos" inclu
iu comentários acerca de vivências pessoais. A categoria "questionário" incluiu 
comentários sobre o questionário propriamente dito, a formulação das questões, o
 uso de certos critérios e a solicitação de acesso aos resultados da pesquisa. A
 categoria "projeto" incluiu comentários relativos ao projeto Baladaboa. <B>RESU
LTADOS: </B>Identificaram-se 915 segmentos nos 412 comentários. A porcentagem de
 segmentos classificados em cada categoria foi: irrelevante, 9,8%; drogas, 16,4%
; depoimentos, 18,1%; questionário, 25,1%; e projeto, 30,6%. A maior parte dos c
omentários foi positiva em relação ao questionário e ao projeto. <B>CONCLUSÕES:&
nbsp;</B>A quantidade e o teor dos comentários espontaneamente enviados indicara
m expressiva receptividade ao projeto e aprovação da estratégia de redução de da
nos pelo público- alvo. O envolvimento dos participantes pôde ser observado em t
odos os comentários, sugerindo que a continuidade do projeto é urgente e oportun
a.#^dnd^i1#^tm^lpt^kN-metil-3^i1#^tm^lpt^k4-metilenodioxianfetamina^i1#^tm^lpt^k
psicotrópicos^i1#^tm^lpt^kredução do dano^i1#^tm^lpt^kBrasil^i1#^len^a<B>OBJECTI
VE:&nbsp;</B>To analyze the contents of spontaneous comments posted by ecstasy u
sers participating in an online survey that constitutes phase one of a harm redu
ction project (projeto Baladaboa) aimed at users of this drug. <B>METHOD:&nbsp;<
/B>Of the 1 140 individual respondents, 412 posted unprompted comments. These co
mments were grouped into five categories (irrelevant, drugs, testimonies, survey
, and project) and submitted to content analysis. Salutations, irreverent commen
ts, and ideological remarks were considered "Irrelevant." Comments on the causes
, effects, and consequences of using ecstasy or other drugs; requests for inform
ation on the drug; or comments indicating that information is a crucial issue as
sociated with the use of ecstasy were labeled "Drugs." Personal stories made up 
the group called "Testimonies." Any comments concerning the questionnaire itself
, the formulation of questions, the use of certain criteria, and requests to see
 survey results were designated "Survey." Comments specifically about the Balada
boa project were categorized as "Project." <B>RESULTS:&nbsp;</B>Content analysis
 revealed 915 segments among the 412 comments. The percent distribution of segme
nts among the groups were: irrelevant, 9.8%; drugs, 16.4%; testimonies, 18.1%; s
urvey, 25.1%; and project, 30.6%. Most of the comments concerning the survey and
 the project were positive. <B>CONCLUSIONS:&nbsp;</B>The number and content of t
he spontaneous comments indicate that the project, as well as the harm reduction
 strategy, were being well received by the target audience. The participants exp
ressed their engagement with the project and suggested that its continuation is 
both timely and urgent.#^dnd^i2#^tm^len^kN-methyl-3^i2#^tm^len^k4-methylenedioxy
amphetamine^i2#^tm^len^kpsychotropic drugs^i2#^tm^len^kharm reduction^i2#^tm^len
^kBrazil^i2#Coordenação de Aperfeiçoamento de Pessoal de Nível Superior#Fundação
 de Amparo à Pesquisa do Estado de São Paulo#Conselho Nacional de Desenvolviment
o Científico e Tecnológico#other#40#20060619#19 de junho de 2006#20070730#30 de 
julho de 2007#a04v22n6.htm##
05527000000000685000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700640013000720710003000850400003000880010
00600091042000200097120000400099038000400103121000300107049000800110158000300118
03000260012103100030014703200020015006500090015201400110016103500100017201200940
01820120095002760100035003710100027004060100038004330700148004710831879006190850
00802498085002202506085003802528085002602566085002802592085001902620083170702639
08500080434608500230435408500400437708500310441708500270444808500190447505800600
44940580053045540580062046071170006046690720003046751120009046781110020046871140
00904707113002004716002001304736008009204749#v22n6#v:\scielo\serial\rpsp\v22n6\m
arkup\a04v22n6.htm#S#l#4#1#article#1#^mdez.^a2007#oa#pt#br1.1#1#3.1#tab#04#RPSP0
20#nd#Rev. panam. salud pública#22#6#20071200#^f389^l395#1020-4989#Análise de co
mentários espontâneos elaborados por usuários de ecstasy em pesquisa on-line^lpt
#Analysis of spontaneous comments posted by ecstasy users participating in an on
line survey^len#^rND^1A01^nStella Pereira^sAlmeida#^rND^1A01^nJuliana^sBizeto#^r
ND^1A01^nMaria Teresa Araujo^sSilva#^iA01^1Universidade de São Paulo^2Instituto 
de Psicologia^3Departamento de Psicologia Experimental^z05508-900^cSão Paulo^sSP
^pBrasil^estella@usp.br#^lpt^aOBJETIVO: Analisar o conteúdo dos comentários envi
ados espontaneamente por usuários de ecstasy que responderam a um questionário o
n-line correspondente à primeira etapa de um projeto de redução de danos (projet
o Baladaboa) para usuários dessa droga. MÉTODO: Dos 1 140 indivíduos que respond
eram o questionário, 412 enviaram comentários. Os comentários foram segmentados 
em cinco categorias (irrelevante, drogas, depoimentos, questionário e projeto) e
 submetidos à análise de conteúdo. A categoria "irrelevante" incluiu saudações, 
comentários irreverentes e manifestações ideológicas. A categoria "drogas" inclu
iu considerações sobre as causas, os efeitos e as conseqüências do uso de ecstas
y ou de outras drogas, solicitações de esclarecimentos sobre a droga ou comentár
ios que apontavam a informação como uma questão fundamental relacionada a seu us
o. A categoria "depoimentos" incluiu comentários acerca de vivências pessoais. A
 categoria "questionário" incluiu comentários sobre o questionário propriamente 
dito, a formulação das questões, o uso de certos critérios e a solicitação de ac
esso aos resultados da pesquisa. A categoria "projeto" incluiu comentários relat
ivos ao projeto Baladaboa. RESULTADOS: Identificaram-se 915 segmentos nos 412 co
mentários. A porcentagem de segmentos classificados em cada categoria foi: irrel
evante, 9,8 por cento; drogas, 16,4 por cento; depoimentos, 18,1 por cento; ques
tionário, 25,1 por cento; e projeto, 30,6 por cento. A maior parte dos comentári
os foi positiva em relação ao questionário e ao projeto. CONCLUSÕES: A quantidad
e e o teor dos comentários espontaneamente enviados indicaram expressiva recepti
vidade ao projeto e aprovação da estratégia de redução de danos pelo público- al
vo. O envolvimento dos participantes pôde ser observado em todos os comentários,
 sugerindo que a continuidade do projeto é urgente e oportuna.#^dnd^i1#^tm^lpt^k
N-metil-3^i1#^tm^lpt^k4-metilenodioxianfetamina^i1#^tm^lpt^kpsicotrópicos^i1#^tm
^lpt^kredução do dano^i1#^tm^lpt^kBrasil^i1#^len^aOBJECTIVE: To analyze the cont
ents of spontaneous comments posted by ecstasy users participating in an online 
survey that constitutes phase one of a harm reduction project (projeto Baladaboa
) aimed at users of this drug. METHOD: Of the 1 140 individual respondents, 412 
posted unprompted comments. These comments were grouped into five categories (ir
relevant, drugs, testimonies, survey, and project) and submitted to content anal
ysis. Salutations, irreverent comments, and ideological remarks were considered 
"Irrelevant." Comments on the causes, effects, and consequences of using ecstasy
 or other drugs; requests for information on the drug; or comments indicating th
at information is a crucial issue associated with the use of ecstasy were labele
d "Drugs." Personal stories made up the group called "Testimonies." Any comments
 concerning the questionnaire itself, the formulation of questions, the use of c
ertain criteria, and requests to see survey results were designated "Survey." Co
mments specifically about the Baladaboa project were categorized as "Project." R
ESULTS: Content analysis revealed 915 segments among the 412 comments. The perce
nt distribution of segments among the groups were: irrelevant, 9.8 percent; drug
s, 16.4 percent; testimonies, 18.1 percent; survey, 25.1 percent; and project, 3
0.6 percent. Most of the comments concerning the survey and the project were pos
itive. CONCLUSIONS: The number and content of the spontaneous comments indicate 
that the project, as well as the harm reduction strategy, were being well receiv
ed by the target audience. The participants expressed their engagement with the 
project and suggested that its continuation is both timely and urgent.#^dnd^i2#^
tm^len^kN-methyl-3^i2#^tm^len^k4-methylenedioxyamphetamine^i2#^tm^len^kpsychotro
pic drugs^i2#^tm^len^kharm reduction^i2#^tm^len^kBrazil^i2#Coordenação de Aperfe
içoamento de Pessoal de Nível Superior#Fundação de Amparo à Pesquisa do Estado d
e São Paulo#Conselho Nacional de Desenvolvimento Científico e Tecnológico#other#
40#20060619#19 de junho de 2006#20070730#30 de julho de 2007#a04v22n6.htm#Intern
et^ihttp://www.scielosp.org/scielo.php?script=sci_arttext&pid=S1020-498920070011
00004##
00357000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704012400074002001300198#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a04v22n6.htm#S#p#5#1#article#115#<p align="right"><fon
t size="2" face="Verdana"><b>INVESTIGACI&Oacute;N ORIGINAL</b>    ORIGINAL RESEA
RCH</font></p>     ^cY#a04v22n6.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a04v22n6.htm#S#p#6#2#article#115#<p>&nbsp;</p>     ^cY
#a04v22n6.htm##
00426000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704019300074002001300267#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a04v22n6.htm#S#p#7#3#article#115#<p><font size="4" fac
e="verdana"><b>An&aacute;lise de coment&aacute;rios espont&acirc;neos    elabora
dos por usu&aacute;rios de <I>ecstasy</I> em pesquisa <I>on-line</i></b></font><
/p>     ^cY#a04v22n6.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a04v22n6.htm#S#p#8#4#article#115#<p>&nbsp;</p>     ^cY
#a04v22n6.htm##
00387000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704015400074002001300228#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a04v22n6.htm#S#p#9#5#article#115#<p><font size="3" fac
e="verdana"><b>Analysis of spontaneous comments posted by    ecstasy users parti
cipating in an online survey </b></font></p>     ^cY#a04v22n6.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704002200075002001300097#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a04v22n6.htm#S#p#10#6#article#115#<p>&nbsp;</p>     ^c
Y#a04v22n6.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704002200075002001300097#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a04v22n6.htm#S#p#11#7#article#115#<p>&nbsp;</p>     ^c
Y#a04v22n6.htm##
00362000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704012800075002001300203#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a04v22n6.htm#S#p#12#8#article#115#<p><font size="2" fa
ce="Verdana"><b>Stella Pereira Almeida; Juliana Bizeto; Maria    Teresa Araujo S
ilva</b></font></p>     ^cY#a04v22n6.htm##
00739000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704050500075002001300580#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a04v22n6.htm#S#p#13#9#article#115#<p><font size="2" fa
ce="Verdana">Universidade de S&atilde;o Paulo (USP), Instituto    de Psicologia,
 Departamento de Psicologia Experimental. Enviar correspond&ecirc;ncia    para S
tella Pereira Almeida no seguinte endere&ccedil;o: Universidade de S&atilde;o   
 Paulo, Instituto de Psicologia, PSE, Avenida Prof. Mello Moraes 1721, CEP 05508
-900,    S&atilde;o Paulo, SP, Brasil. Fone: +55-11-3091.4176; fax: +55-11-3091.
4357;    e-mail: <a href="mailto:stella@usp.br">stella@usp.br</a></font></p>    
 ^cY#a04v22n6.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a04v22n6.htm#S#p#14#10#article#115#<p>&nbsp;</p>     ^
cY#a04v22n6.htm##
00279000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704004400076002001300120#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a04v22n6.htm#S#p#15#11#article#115#<p>&nbsp;</p> <hr s
ize="1" noshade>     ^cY#a04v22n6.htm##
00301000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704006600076002001300142#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a04v22n6.htm#S#p#16#12#article#115#<p><font size="2" f
ace="Verdana"><b>RESUMO</b></font></p>     ^cY#a04v22n6.htm##
00605000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704037000076002001300446#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a04v22n6.htm#S#p#17#13#article#115#<p><font size="2" f
ace="Verdana"><B>OBJETIVO:&nbsp;</b>Analisar o conte&uacute;do    dos coment&aac
ute;rios enviados espontaneamente por usu&aacute;rios de ecstasy    que responde
ram a um question&aacute;rio on-line correspondente &agrave; primeira    etapa d
e um projeto de redu&ccedil;&atilde;o de danos (projeto Baladaboa) para    usu&a
acute;rios dessa droga.    ^cY#a04v22n6.htm##
01505000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704127000076002001301346#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a04v22n6.htm#S#p#18#14#article#115#<br>   <B>M&Eacute;
TODO:&nbsp;</b>Dos 1 140 indiv&iacute;duos que responderam o question&aacute;rio
,    412 enviaram coment&aacute;rios. Os coment&aacute;rios foram segmentados em
    cinco categorias (irrelevante, drogas, depoimentos, question&aacute;rio e pr
ojeto)    e submetidos &agrave; an&aacute;lise de conte&uacute;do. A categoria "
irrelevante"    incluiu sauda&ccedil;&otilde;es, coment&aacute;rios irreverentes
 e manifesta&ccedil;&otilde;es    ideol&oacute;gicas. A categoria "drogas" inclu
iu considera&ccedil;&otilde;es    sobre as causas, os efeitos e as conseq&uuml;&
ecirc;ncias do uso de ecstasy    ou de outras drogas, solicita&ccedil;&otilde;es
 de esclarecimentos sobre a droga    ou coment&aacute;rios que apontavam a infor
ma&ccedil;&atilde;o como uma quest&atilde;o    fundamental relacionada a seu uso
. A categoria "depoimentos" incluiu    coment&aacute;rios acerca de viv&ecirc;nc
ias pessoais. A categoria "question&aacute;rio"    incluiu coment&aacute;rios so
bre o question&aacute;rio propriamente dito, a    formula&ccedil;&atilde;o das q
uest&otilde;es, o uso de certos crit&eacute;rios    e a solicita&ccedil;&atilde;
o de acesso aos resultados da pesquisa. A categoria    "projeto" incluiu coment&
aacute;rios relativos ao projeto Baladaboa.    ^cY#a04v22n6.htm##
00615000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704038000076002001300456#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a04v22n6.htm#S#p#19#15#article#115#<br>   <B>RESULTADO
S: </b>Identificaram-se 915 segmentos nos 412 coment&aacute;rios.    A porcentag
em de segmentos classificados em cada categoria foi: irrelevante,    9,8%; droga
s, 16,4%; depoimentos, 18,1%; question&aacute;rio, 25,1%; e projeto,    30,6%. A
 maior parte dos coment&aacute;rios foi positiva em rela&ccedil;&atilde;o    ao 
question&aacute;rio e ao projeto.    ^cY#a04v22n6.htm##
00691000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704045600076002001300532#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a04v22n6.htm#S#p#20#16#article#115#<br>   <B>CONCLUS&O
tilde;ES:&nbsp;</b>A quantidade e o teor dos coment&aacute;rios    espontaneamen
te enviados indicaram expressiva receptividade ao projeto e aprova&ccedil;&atild
e;o    da estrat&eacute;gia de redu&ccedil;&atilde;o de danos pelo p&uacute;blic
o-    alvo. O envolvimento dos participantes p&ocirc;de ser observado em todos o
s    coment&aacute;rios, sugerindo que a continuidade do projeto &eacute; urgent
e    e oportuna. </font></p>     ^cY#a04v22n6.htm##
00433000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704019800076002001300274#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a04v22n6.htm#S#p#21#17#article#115#<p><font size="2" f
ace="Verdana"><b>Palavras-chave: </b>N-metil-3,4-metilenodioxianfetamina,    psi
cotr&oacute;picos, redu&ccedil;&atilde;o do dano, Brasil.</font></p> <hr size="1
" noshade>     ^cY#a04v22n6.htm##
00303000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704006800076002001300144#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a04v22n6.htm#S#p#22#18#article#115#<p><font size="2" f
ace="Verdana"><b>ABSTRACT</b></font></p>     ^cY#a04v22n6.htm##
00517000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704028200076002001300358#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a04v22n6.htm#S#p#23#19#article#115#<p><font size="2" f
ace="Verdana"><B>OBJECTIVE:&nbsp;</b>To analyze the contents    of spontaneous c
omments posted by ecstasy users participating in an online survey    that consti
tutes phase one of a harm reduction project (projeto Baladaboa) aimed    at user
s of this drug.    ^cY#a04v22n6.htm##
01139000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704090400076002001300980#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a04v22n6.htm#S#p#24#20#article#115#<br>   <B>METHOD:&n
bsp;</b>Of the 1 140 individual respondents, 412 posted unprompted    comments. 
These comments were grouped into five categories (irrelevant, drugs,    testimon
ies, survey, and project) and submitted to content analysis. Salutations,    irr
everent comments, and ideological remarks were considered "Irrelevant."    Comme
nts on the causes, effects, and consequences of using ecstasy or other    drugs;
 requests for information on the drug; or comments indicating that information  
  is a crucial issue associated with the use of ecstasy were labeled "Drugs."   
 Personal stories made up the group called "Testimonies." Any comments    concer
ning the questionnaire itself, the formulation of questions, the use of    certa
in criteria, and requests to see survey results were designated "Survey."    Com
ments specifically about the Baladaboa project were categorized as "Project."   
 ^cY#a04v22n6.htm##
00563000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704032800076002001300404#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a04v22n6.htm#S#p#25#21#article#115#<br>   <B>RESULTS:&
nbsp;</b>Content analysis revealed 915 segments among the 412 comments.    The p
ercent distribution of segments among the groups were: irrelevant, 9.8%;    drug
s, 16.4%; testimonies, 18.1%; survey, 25.1%; and project, 30.6%. Most of    the 
comments concerning the survey and the project were positive.    ^cY#a04v22n6.ht
m##
00586000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704035100076002001300427#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a04v22n6.htm#S#p#26#22#article#115#<br>   <B>CONCLUSIO
NS:&nbsp;</b>The number and content of the spontaneous comments    indicate that
 the project, as well as the harm reduction strategy, were being    well receive
d by the target audience. The participants expressed their engagement    with th
e project and suggested that its continuation is both timely and urgent.</font><
/p>     ^cY#a04v22n6.htm##
00414000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704017900076002001300255#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a04v22n6.htm#S#p#27#23#article#115#<p><font size="2" f
ace="Verdana"><b>Key words: </b>N-methyl-3,4-methylenedioxyamphetamine,    psych
otropic drugs, harm reduction, Brazil.</font></p> <hr size="1" noshade>     ^cY#
a04v22n6.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a04v22n6.htm#S#p#28#24#article#115#<p>&nbsp;</p>     ^
cY#a04v22n6.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a04v22n6.htm#S#p#29#25#article#115#<p>&nbsp;</p>     ^
cY#a04v22n6.htm##
01039000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704080400076002001300880#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a04v22n6.htm#S#p#30#26#article#115#<p><font size="2" f
ace="Verdana">Ainda que n&atilde;o tenham sido realizadas pesquisas    epidemiol
&oacute;gicas longitudinais relativas ao <i>ecstasy</i> no Brasil,    o seu cons
umo parece seguir a tend&ecirc;ncia de crescimento alarmante constatada    em di
versos pa&iacute;ses (1–5). S&atilde;o indica&ccedil;&otilde;es objetivas    de 
que o consumo de <i>ecstasy</i> est&aacute; em expans&atilde;o no Brasil    o au
mento no volume de apreens&otilde;es e a maior visibilidade na m&iacute;dia,    
as declara&ccedil;&otilde;es de freq&uuml;entadores de casas noturnas sobre    a
 facilidade de obten&ccedil;&atilde;o de comprimidos e os relatos de profissiona
is    de sa&uacute;de que atuam na &aacute;rea do uso de drogas sobre o crescent
e    n&uacute;mero de casos atendidos (6, 7).</font></p>     ^cY#a04v22n6.htm##
01650000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704141500076002001301491#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a04v22n6.htm#S#p#31#27#article#115#<p><font size="2" f
ace="Verdana">Embora haja ind&iacute;cios de que o uso de <I>ecstasy</I>    tenh
a conseq&uuml;&ecirc;ncias adversas e possa ser neurot&oacute;xico em seres    h
umanos, persistem as controv&eacute;rsias (8–10). No entanto, sabe-se que existe
    uma rela&ccedil;&atilde;o entre o uso de <I>ecstasy</I> e problemas de mem&o
acute;ria,    quadros psicopatol&oacute;gicos agudos e casos espor&aacute;dicos 
de intoxica&ccedil;&atilde;o    levando a coma ou morte (11–18). Al&eacute;m dis
so, indiv&iacute;duos sob o    efeito do <I>ecstasy</I> apresentam um aumento na
 freq&uuml;&ecirc;ncia de comportamentos    de risco tais como dirigir sob o efe
ito de drogas, usar concomitantemente diferentes    psicoativos, fazer exerc&iac
ute;cios f&iacute;sicos em ambientes muito quentes,    alimentar-se e dormir pou
co e expor-se mais freq&uuml;entemente a pr&aacute;ticas    sexuais de risco (19
–22). Portanto, o uso de <I>ecstasy</I> pode efetivamente    comportar risco, n&
atilde;o s&oacute; para a sa&uacute;de de seus consumidores,    mas tamb&eacute;
m para aqueles que s&atilde;o expostos ao comportamento dos    indiv&iacute;duos
 sob o efeito da droga. Dessa forma, justifica-se a realiza&ccedil;&atilde;o    
de interven&ccedil;&otilde;es preventivas para minimizar os danos do uso dessa  
  droga, iniciativa da qual n&atilde;o se tem not&iacute;cia at&eacute; o moment
o    no Brasil. </font></p>     ^cY#a04v22n6.htm##
01146000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704091100076002001300987#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a04v22n6.htm#S#p#32#28#article#115#<p><font size="2" f
ace="Verdana">As campanhas preventivas baseadas no amedrontamento,    ou seja, q
ue divulgam informa&ccedil;&otilde;es exacerbando os malef&iacute;cios    das dr
ogas, e cujo objetivo &eacute; a erradica&ccedil;&atilde;o de seu consumo,    ne
m sempre s&atilde;o eficazes (23, 24). Assim, outras estrat&eacute;gias t&ecirc;
m    sido propostas. Uma abordagem alternativa &eacute; a redu&ccedil;&atilde;o 
de    danos (RD) (25), que considera ut&oacute;pica a erradica&ccedil;&atilde;o 
do    consumo de drogas e parte do pressuposto de que existem indiv&iacute;duos 
que    escolhem us&aacute;-las, mas considera poss&iacute;vel reduzir os riscos 
do    uso. Tal estrat&eacute;gia ainda suscita pol&ecirc;mica, particularmente p
elo    temor de que possa estimular o consumo, e tamb&eacute;m pela suspeita de 
que    apenas reduzir ou minimizar os riscos n&atilde;o seja suficiente.</font><
/p>     ^cY#a04v22n6.htm##
00846000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704061100076002001300687#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a04v22n6.htm#S#p#33#29#article#115#<p><font size="2" f
ace="Verdana">Em rela&ccedil;&atilde;o ao <I>ecstasy</I>, diversos    pesquisado
res verificaram que os usu&aacute;rios t&ecirc;m conhecimento de estar    corren
do riscos quando usam a droga, mas nem por isso desejam interromper o    consumo
 (26–29). Uma pesquisa diagn&oacute;stica realizada com usu&aacute;rios    brasi
leiros verificou que a "preocupa&ccedil;&atilde;o com a sa&uacute;de    f&iacute
;sica" &eacute; o fator que mais interfere na freq&uuml;&ecirc;ncia    de uso da
 droga, mas que uma minoria de usu&aacute;rios deseja diminuir ou interromper   
 o uso (26).</font></p>     ^cY#a04v22n6.htm##
00984000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704074900076002001300825#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a04v22n6.htm#S#p#34#30#article#115#<p><font size="2" f
ace="Verdana">Levando em considera&ccedil;&atilde;o esses aspectos,    o projeto
 Baladaboa elegeu a RD como estrat&eacute;gia de interven&ccedil;&atilde;o    pr
eventiva particularmente adequada para usu&aacute;rios de <I>ecstasy</I>.    Val
e observar que, no Brasil, a Pol&iacute;tica Nacional Antidrogas, elaborada    p
ela Secretaria Nacional Antidrogas (SENAD), aprova a RD explicitamente em uma   
 de suas diretrizes, a saber, "apoiar e divulgar as pesquisas cient&iacute;ficas
    submetidas e aprovadas por comit&ecirc; de &eacute;tica, realizadas na &aacu
te;rea    de redu&ccedil;&atilde;o de danos para o aprimoramento e a adequa&cced
il;&atilde;o    da pol&iacute;tica e de suas estrat&eacute;gias" (30).</font></p
>     ^cY#a04v22n6.htm##
01379000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704114400076002001301220#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a04v22n6.htm#S#p#35#31#article#115#<p><font size="2" f
ace="Verdana">O projeto Baladaboa, desenvolvido no Laborat&oacute;rio    de Psic
ofarmacologia do Instituto de Psicologia da Universidade de S&atilde;o    Paulo 
(USP), prev&ecirc; tr&ecirc;s etapas: 1) pesquisa diagn&oacute;stica <I>on-line<
/I>,    2) interven&ccedil;&atilde;o e 3) avalia&ccedil;&atilde;o. A primeira et
apa,    j&aacute; realizada, &eacute; fundamental, dado que qualquer interven&cc
edil;&atilde;o    preventiva &eacute; tanto mais efetiva quanto mais adequada fo
r a seu p&uacute;blico-alvo.    O diagn&oacute;stico foi feito atrav&eacute;s de
 um question&aacute;rio <I>on-line</I>    an&ocirc;nimo dirigido a usu&aacute;ri
os dessa droga (26). No site em que se    encontrava o question&aacute;rio a ser
 respondido, <a href="http://www.psicofarmacousp.psc.br/" target="_blank">http:/
/www.psicofarma    cousp.psc.br/</a>, tamb&eacute;m eram disponibilizadas inform
a&ccedil;&otilde;es    sobre o projeto e sobre a RD. Ao final do question&aacute
;rio <I>on-line</I>,    foi oferecido e utilizado, por centenas de participantes
, um espa&ccedil;o para    coment&aacute;rios espont&acirc;neos. </font></p>    
 ^cY#a04v22n6.htm##
00773000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704053800076002001300614#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a04v22n6.htm#S#p#36#32#article#115#<p><font size="2" f
ace="Verdana">O objetivo do presente trabalho foi analisar    o conte&uacute;do 
dos coment&aacute;rios espont&acirc;neos feitos pelos participantes    na primei
ra etapa do projeto Baladaboa, ou seja, na pesquisa diagn&oacute;stica    <I>on-
line</I>. Pretende-se assim ampliar o conhecimento sobre o universo dos    usu&a
acute;rios de <I>ecstasy </I>no Brasil, fornecendo um importante subs&iacute;dio
    para a efetiva&ccedil;&atilde;o de programas de preven&ccedil;&atilde;o ao u
so    dessa droga. </font></p>     ^cY#a04v22n6.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a04v22n6.htm#S#p#37#33#article#115#<p>&nbsp;</p>     ^
cY#a04v22n6.htm##
00321000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704008600076002001300162#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a04v22n6.htm#S#p#38#34#article#115#<p><font size="3" f
ace="Verdana"><b>MATERIAIS E M&Eacute;TODOS</b></font></p>     ^cY#a04v22n6.htm#
#
01477000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704124200076002001301318#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a04v22n6.htm#S#p#39#35#article#115#<p><font size="2" f
ace="Verdana">O projeto foi aprovado pela Comiss&atilde;o de    &Eacute;tica em 
Pesquisa Humana do Instituto de Psicologia da USP. A an&aacute;lise    de conte&
uacute;do se baseou no material escrito por participantes no &uacute;ltimo    ca
mpo do question&aacute;rio on-line dispon&iacute;vel no site do projeto Baladabo
a.    O campo trazia a seguinte instru&ccedil;&atilde;o: "Se quiser fazer sugest
&otilde;es,    cr&iacute;ticas ou dar opini&otilde;es utilize este espa&ccedil;o
". O question&aacute;rio    diagn&oacute;stico on-line foi desenvolvido especifi
camente para o estudo realizado    e ser&aacute; objeto de outro artigo. Em resu
mo, era direcionado aos usu&aacute;rios    de ecstasy, exigia em torno de 20 min
utos para ser respondido e era composto    por 39 quest&otilde;es sobre padr&oti
lde;es de uso de ecstasy e outras drogas,    dados sociodemogr&aacute;ficos e in
forma&ccedil;&otilde;es b&aacute;sicas sobre    a droga, como efeitos e conseq&u
uml;&ecirc;ncias do uso. O recrutamento dos    participantes foi realizado atrav
&eacute;s de e-mail, banners e artigos em sites,    jornais e revistas. O questi
on&aacute;rio esteve dispon&iacute;vel entre agosto    de 2004 e fevereiro de 20
05.</font></p>     ^cY#a04v22n6.htm##
00342000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010700076002001300183#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a04v22n6.htm#S#p#40#36#article#115#<p><font size="2" f
ace="Verdana"><b>Participantes e procedimentos de an&aacute;lise</b></font></p> 
    ^cY#a04v22n6.htm##
00599000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704036400076002001300440#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a04v22n6.htm#S#p#41#37#article#115#<p><font size="2" f
ace="Verdana">Dentre os 1 140 indiv&iacute;duos que responderam    ao question&a
acute;rio diagn&oacute;stico on-line, 412 utilizaram o campo ao    final do ques
tion&aacute;rio para emitir algum coment&aacute;rio. Estes comp&otilde;em    a a
mostra n&atilde;o-probabil&iacute;stica por conveni&ecirc;ncia do presente    es
tudo.</font></p>     ^cY#a04v22n6.htm##
01059000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704082400076002001300900#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a04v22n6.htm#S#p#42#38#article#115#<p><font size="2" f
ace="Verdana">Em primeiro lugar, foi realizada uma compara&ccedil;&atilde;o    e
ntre os participantes que fizeram coment&aacute;rios e os que n&atilde;o os    f
izeram quanto a dados sociodemogr&aacute;ficos e dados relativos ao uso de    <I
>ecstasy</I>, atrav&eacute;s dos testes <I>t</I> e qui-quadrado (<font face="Sym
bol">c</font><SUP>2</SUP>).    Em seguida, os coment&aacute;rios foram submetido
s &agrave; an&aacute;lise de    conte&uacute;do, uma t&eacute;cnica utilizada pa
ra estudar unidades de comunica&ccedil;&atilde;o.    A t&eacute;cnica consiste n
a cria&ccedil;&atilde;o de categorias para classificar    essas unidades, que po
dem ser palavras, temas ou t&oacute;picos. A comunica&ccedil;&atilde;o    &eacut
e; fracionada de acordo com regras previamente estipuladas (31). </font></p>    
 ^cY#a04v22n6.htm##
01493000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704125800076002001301334#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a04v22n6.htm#S#p#43#39#article#115#<p><font size="2" f
ace="Verdana">Com base nessa t&eacute;cnica, e seguindo um    procedimento anter
iormente utilizado pelas autoras (32), foi feita uma an&aacute;lise    do conte&
uacute;do dos discursos presentes nos 412 coment&aacute;rios digitados    pelos 
participantes, de acordo com as seguintes regras: 1) foi identificada    a id&ea
cute;ia central do coment&aacute;rio, caracterizada como o conte&uacute;do    es
sencial do discurso apreendido (33); 2) os coment&aacute;rios que expressavam   
 mais de uma id&eacute;ia foram fracionados em segmentos; 3) o t&oacute;pico    
principal de cada segmento foi explicitado em uma express&atilde;o<I>-</I>chave,
    correspondente &agrave; transcri&ccedil;&atilde;o literal de parte do discur
so    "que permite o resgate do essencial do conte&uacute;do discursivo dos segm
entos    em que se divide o depoimento" (33, p. 18); 4) tendo por base a sua equ
ival&ecirc;ncia,    as express&otilde;es-chave registradas foram agrupadas em ci
nco categorias de    discurso: irrelevante, drogas, depoimentos, question&aacute
;rio e projeto; 5)    cada segmento foi ent&atilde;o classificado em uma dessas 
cinco categorias;    6) quando pertinente, os segmentos foram ainda classificado
s em subcategorias.</font></p>     ^cY#a04v22n6.htm##
00952000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704071700076002001300793#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a04v22n6.htm#S#p#44#40#article#115#<p><font size="2" f
ace="Verdana">A categoria denominada "irrelevante"    n&atilde;o foi subdividida
 e incluiu sauda&ccedil;&otilde;es, al&eacute;m de    coment&aacute;rios irrever
entes e manifesta&ccedil;&otilde;es ideol&oacute;gicas.    A categoria "drogas" 
foi subdividida nas subcategorias "sobre    o <I>esctasy</I>", "sobre outras dro
gas" (considera&ccedil;&otilde;es    sobre causas, efeitos e conseq&uuml;&ecirc;
ncias do uso de <I>ecstasy</I> ou    de outras drogas) e "informa&ccedil;&otilde
;es sobre o <I>ecstasy</I>"    (segmentos que solicitavam esclarecimentos sobre 
a droga ou que apontavam a    informa&ccedil;&atilde;o como uma quest&atilde;o f
undamental relacionada a seu    uso). </font></p>     ^cY#a04v22n6.htm##
01054000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704081900076002001300895#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a04v22n6.htm#S#p#45#41#article#115#<p><font size="2" f
ace="Verdana">A categoria "depoimentos" foi subdividida    nas subcategorias "se
xualidade", "vida pessoal", "drogas"    e "<I>ecstasy</I>", que inclu&iacute;ram
 coment&aacute;rios acerca    de viv&ecirc;ncias pessoais. A categoria "question
&aacute;rio"    foi subdividida nas subcategorias "question&aacute;rio negativo"
,    "question&aacute;rio positivo", "question&aacute;rio neutro"    e "resultad
os", que inclu&iacute;ram coment&aacute;rios sobre o question&aacute;rio    prop
riamente dito, a formula&ccedil;&atilde;o das quest&otilde;es, o uso de    certo
s crit&eacute;rios e a solicita&ccedil;&atilde;o de acesso aos resultados    da 
pesquisa. A categoria "projeto" tamb&eacute;m n&atilde;o foi subdividida    e in
cluiu os coment&aacute;rios relativos ao projeto Baladaboa. </font></p>     ^cY#
a04v22n6.htm##
00823000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704058800076002001300664#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a04v22n6.htm#S#p#46#42#article#115#<p><font size="2" f
ace="Verdana">Tr&ecirc;s ju&iacute;zes avaliaram independentemente    a segmenta
&ccedil;&atilde;o dos coment&aacute;rios, a atribui&ccedil;&atilde;o    de expre
ss&otilde;es-chave aos segmentos e a sua classifica&ccedil;&atilde;o    em categ
orias e subcategorias. Em caso de diverg&ecirc;ncia, considerou-se v&aacute;lida
    a classifica&ccedil;&atilde;o apontada por dois dos tr&ecirc;s ju&iacute;zes
.    Os tr&ecirc;s ju&iacute;zes, p&oacute;s-graduados em psicologia, tinham exp
eri&ecirc;ncia    pr&eacute;via em an&aacute;lise de conte&uacute;do.</font></p>
     ^cY#a04v22n6.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a04v22n6.htm#S#p#47#43#article#115#<p>&nbsp;</p>     ^
cY#a04v22n6.htm##
00305000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704007000076002001300146#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a04v22n6.htm#S#p#48#44#article#115#<p><font size="3" f
ace="Verdana"><b>RESULTADOS</b></font></p>     ^cY#a04v22n6.htm##
00841000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704060600076002001300682#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a04v22n6.htm#S#p#49#45#article#115#<p><font size="2" f
ace="Verdana">Os 412 participantes que fizeram coment&aacute;rios    corresponde
m a 36,1% da amostra de respondentes do question&aacute;rio diagn&oacute;stico  
  on-line (n = 1 140). N&atilde;o houve diferen&ccedil;as entre o grupo de parti
cipantes    que fez coment&aacute;rios e o grupo que n&atilde;o os fez. A <a hre
f="#tab01">tabela    1</a> mostra as caracter&iacute;sticas sociodemogr&aacute;f
icas e as caracter&iacute;sticas    relativas ao uso de ecstasy (inclusive quant
o &agrave; depend&ecirc;ncia) (34)    dos participantes que fizeram coment&aacut
e;rios.</font></p>     ^cY#a04v22n6.htm##
00271000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704003600076002001300112#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a04v22n6.htm#S#p#50#46#article#115#<p><a name="tab01">
</a></p>     ^cY#a04v22n6.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a04v22n6.htm#S#p#51#47#article#115#<p>&nbsp;</p>     ^
cY#a04v22n6.htm##
00315000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704008000076002001300156#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a04v22n6.htm#S#p#52#48#article#115#<p align="center"><
img src="/img/revistas/rpsp/v22n6/a04tab01.gif"></p>     ^cY#a04v22n6.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a04v22n6.htm#S#p#53#49#article#115#<p>&nbsp;</p>     ^
cY#a04v22n6.htm##
00332000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009700076002001300173#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a04v22n6.htm#S#p#54#50#article#115#<p><font size="2" f
ace="Verdana"><b>An&aacute;lise dos coment&aacute;rios</b></font></p>     ^cY#a0
4v22n6.htm##
00866000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704063100076002001300707#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a04v22n6.htm#S#p#55#51#article#115#<p><font size="2" f
ace="Verdana">Dentre os 412 coment&aacute;rios recebidos, 38    indiv&iacute;duo
s enviaram endere&ccedil;os de e-mail e dois enviaram telefone    de contato, so
licitando resultados e colocando-se &agrave; disposi&ccedil;&atilde;o    para fo
rnecer maiores informa&ccedil;&otilde;es ou para participar de outras    pesquis
as. A todos os participantes que enviaram os seus endere&ccedil;os eletr&ocirc;n
icos    foi remetido um e-mail agradecendo a participa&ccedil;&atilde;o e inform
ando    que o trabalho resultante da pesquisa diagn&oacute;stica realizada seria
 disponibilizado    na Internet.</font></p>     ^cY#a04v22n6.htm##
00820000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704058500076002001300661#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a04v22n6.htm#S#p#56#52#article#115#<p><font size="2" f
ace="Verdana">Foram identificados 915 segmentos nos 412 coment&aacute;rios.    O
 n&uacute;mero m&aacute;ximo de segmentos por coment&aacute;rio foi 9, e a    m&
eacute;dia foi de 2,25 segmentos por coment&aacute;rio. Do conjunto desses    91
5 segmentos, 9,8% foram classificados na categoria "irrelevante",    16,4% na ca
tegoria "drogas", 18,1% na catego-ria "depoimentos",    25,1% na categoria "ques
tion&aacute;rio" e 30,6% na categoria "projeto".    A <a href="#tab02">tabela 2<
/a> mostra exemplos de coment&aacute;rios para cada    categoria. </font></p>   
  ^cY#a04v22n6.htm##
00271000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704003600076002001300112#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a04v22n6.htm#S#p#57#53#article#115#<p><a name="tab02">
</a></p>     ^cY#a04v22n6.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a04v22n6.htm#S#p#58#54#article#115#<p>&nbsp;</p>     ^
cY#a04v22n6.htm##
00315000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704008000076002001300156#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a04v22n6.htm#S#p#59#55#article#115#<p align="center"><
img src="/img/revistas/rpsp/v22n6/a04tab02.gif"></p>     ^cY#a04v22n6.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a04v22n6.htm#S#p#60#56#article#115#<p>&nbsp;</p>     ^
cY#a04v22n6.htm##
01817000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704158200076002001301658#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a04v22n6.htm#S#p#61#57#article#115#<p><font size="2" f
ace="Verdana">Os relatos de experi&ecirc;ncias com o uso de    ecstasy foram os 
mais freq&uuml;entes dentre os depoimentos, correspondendo    a mais de metade d
eles, sendo tamb&eacute;m relatadas experi&ecirc;ncias com    outras drogas. Nas
 subcategorias "sexualidade" e "vida pessoal"    os participantes mostraram-se p
rincipalmente interessados em esclarecer as respostas    para evitar interpreta&
ccedil;&otilde;es err&ocirc;neas. Na categoria "question&aacute;rio",    a subca
tegoria com mais segmentos foi "question&aacute;rio negativo",    sendo a falta 
de op&ccedil;&otilde;es em algumas perguntas a cr&iacute;tica    mais freq&uuml;
ente. Tamb&eacute;m foram feitas cr&iacute;ticas em rela&ccedil;&atilde;o    &ag
rave; classifica&ccedil;&atilde;o socioecon&ocirc;mica utilizada (crit&eacute;ri
o    ABA/ABIPEME de 1982) (35), &agrave; pergunta sobre sexo seguro e &agrave; i
nclus&atilde;o    de ayahuasca na lista de drogas. Muitas vezes, as cr&iacute;ti
cas foram seguidas    de esclarecimentos em rela&ccedil;&atilde;o &agrave;s resp
ostas dadas. Ainda    em rela&ccedil;&atilde;o a essa subcategoria, houve tanto 
reclama&ccedil;&otilde;es    quanto &agrave; extens&atilde;o do question&aacute;
rio como &agrave; falta de    perguntas julgadas importantes pelos participantes
. Em "question&aacute;rio    neutro", os segmentos, na maior parte das vezes, so
licitavam informa&ccedil;&otilde;es    relacionadas &agrave;s perguntas, particu
larmente esclarecimentos relativos    a uma droga fict&iacute;cia que constava d
o question&aacute;rio. </font></p>     ^cY#a04v22n6.htm##
00725000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704049000076002001300566#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a04v22n6.htm#S#p#62#58#article#115#<p><font size="2" f
ace="Verdana">A categoria projeto foi a que conteve mais segmentos.    Tipicamen
te, os segmentos dessa categoria foram elogios &agrave; iniciativa,    est&iacut
e;mulos &agrave; execu&ccedil;&atilde;o do projeto, discursos sobre    a import&
acirc;ncia do projeto ou sobre a RD para o uso de <I>ecstasy</I> e    coment&aac
ute;rios nos quais os participantes se ofereciam para dar maiores    esclarecime
ntos ou participar de outras pesquisas semelhantes.</font></p>     ^cY#a04v22n6.
htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a04v22n6.htm#S#p#63#59#article#115#<p>&nbsp;</p>     ^
cY#a04v22n6.htm##
00311000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704007600076002001300152#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a04v22n6.htm#S#p#64#60#article#115#<p><font size="3" f
ace="Verdana"><b>DISCUSS&Atilde;O</b></font></p>     ^cY#a04v22n6.htm##
01434000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704119900076002001301275#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a04v22n6.htm#S#p#65#61#article#115#<p><font size="2" f
ace="Verdana">Em primeiro lugar, vale dizer que a quantidade    de coment&aacute
;rios espontaneamente enviados foi expressiva, particularmente    tendo em vista
 que o question&aacute;rio on-line demandava em torno de 20 minutos    para ser 
respondido. Em se tratando do uso de uma droga ilegal, surpreende que    quase 1
0% dos participantes que fizeram coment&aacute;rios tenham enviado contatos    e
letr&ocirc;nicos ou telef&ocirc;nicos, demonstrando o interesse em participar   
 mais ativamente do projeto e a confian&ccedil;a quanto &agrave; seriedade da   
 proposta. &Eacute; importante observar que a participa&ccedil;&atilde;o dos    
usu&aacute;rios de drogas nos programas de preven&ccedil;&atilde;o a eles direci
onados    &eacute; absolutamente condizente com a abordagem de RD, que prev&ecir
c; que    os usu&aacute;rios sejam, sempre que poss&iacute;vel, agentes multipli
cadores    (36–38). Portanto, o envio de tais contatos &eacute; um excelente pro
gn&oacute;stico    da participa&ccedil;&atilde;o volunt&aacute;ria de usu&aacute
;rios de ecstasy    nas etapas de interven&ccedil;&atilde;o e avalia&ccedil;&ati
lde;o previstas    no projeto Baladaboa.</font></p>     ^cY#a04v22n6.htm##
01303000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704106800076002001301144#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a04v22n6.htm#S#p#66#62#article#115#<p><font size="2" f
ace="Verdana">O car&aacute;ter espont&acirc;neo dos coment&aacute;rios    &eacut
e; algo que os valoriza sobremaneira. &Eacute; de se supor que tais coment&aacut
e;rios    expressem quest&otilde;es centrais para pessoas especialmente envolvid
as com    o tema, sendo uma fonte de informa&ccedil;&atilde;o valiosa, diversifi
cada e    obtida com um m&iacute;nimo de estimula&ccedil;&atilde;o. Vale ressalt
ar que    a metodologia qualitativa, como pode ser classificada a an&aacute;lise
 de discurso    utilizada neste estudo, auxilia no trabalho de constru&ccedil;&a
tilde;o do objeto    estudado, facilitando a descoberta de dimens&otilde;es aind
a n&atilde;o conhecidas.    &Eacute; uma abordagem particularmente adequada a &a
acute;reas para as quais    n&atilde;o h&aacute; um conhecimento te&oacute;rico 
e conceitual plenamente    desenvolvido, sendo ideal para o estudo de popula&cce
dil;&otilde;es de dif&iacute;cil    acesso e de epidemiologia n&atilde;o demarca
da, como os usu&aacute;rios de <I>ecstasy</I>    no Brasil (39, 40). </font></p>
     ^cY#a04v22n6.htm##
00732000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704049700076002001300573#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a04v22n6.htm#S#p#67#63#article#115#<p><font size="2" f
ace="Verdana">De forma geral, o envolvimento dos participantes    com o projeto 
e com a pesquisa p&ocirc;de ser observado em todos os coment&aacute;rios.    Mes
mo os segmentos da categoria "irrelevante" mostraram, freq&uuml;entemente,    um
a disposi&ccedil;&atilde;o af&aacute;vel para com os pesquisadores. At&eacute;  
  quando continham irrever&ecirc;ncias, essas observa&ccedil;&otilde;es indicava
m    empatia ou humor, sem tra&ccedil;os de agressividade.</font></p>     ^cY#a0
4v22n6.htm##
00780000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704054500076002001300621#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a04v22n6.htm#S#p#68#64#article#115#<p><font size="2" f
ace="Verdana">Na categoria "depoimentos", ob-servou-se    freq&uuml;entemente o 
desejo de colaborar com os pesquisadores, na tentativa    de evitar interpreta&c
cedil;&otilde;es err&ocirc;neas. Nessa categoria tamb&eacute;m    foram relatada
s com freq&uuml;&ecirc;ncia experi&ecirc;ncias pessoais com drogas,    sugerindo
 que um espa&ccedil;o destinado ao compartilhamento de tais experi&ecirc;ncias, 
   com a media&ccedil;&atilde;o de um especialista na &aacute;rea, seria aprecia
do    por usu&aacute;rios.</font></p>     ^cY#a04v22n6.htm##
02047000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704181200076002001301888#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a04v22n6.htm#S#p#69#65#article#115#<p><font size="2" f
ace="Verdana">Na categoria "drogas", ficou evidente,    principalmente, a inten&
ccedil;&atilde;o de aprofundar quest&otilde;es ligadas    ao assunto, fossem ou 
n&atilde;o espec&iacute;ficas do <I>ecstasy</I>. Nessa    categoria observaram-s
e opini&otilde;es de cunho ideol&oacute;gico, an&aacute;lises    sobre poss&iacu
te;veis causas e solu&ccedil;&otilde;es para a quest&atilde;o    das drogas, rev
elando indiv&iacute;duos que ponderam a situa&ccedil;&atilde;o    do usu&aacute;
rio e da pol&iacute;tica relativa &agrave;s drogas. Em alguns    coment&aacute;r
ios dessa categoria, foi abordado exclusivamente o tema prazer,    como naqueles
 que faziam a apologia do uso de drogas e exaltavam os seus efeitos.    Por&eacu
te;m, a grande maioria dos coment&aacute;rios era abrangente e fazia    an&aacut
e;lises elaboradas, o que sugere que esses coment&aacute;rios tenham    sido fei
tos por pessoas para as quais o uso de subst&acirc;ncias ocupa um espa&ccedil;o 
   mais amplo do que o desfrute fugaz de um efeito prazeroso. Em rela&ccedil;&at
ilde;o    aos coment&aacute;rios sobre o "question&aacute;rio", tamb&eacute;m   
 p&ocirc;de ser observado que, de forma geral, houve inten&ccedil;&atilde;o de  
  colaborar, mesmo entre aqueles que criticaram o formato ou o conte&uacute;do  
  das quest&otilde;es. A solicita&ccedil;&atilde;o dos resultados da pesquisa,  
  subcategoria presente em quase um quinto dos coment&aacute;rios, mostrou o int
eresse    dos usu&aacute;rios em conhecer o seu pr&oacute;prio universo. Em aten
&ccedil;&atilde;o    a essa demanda, em dezembro de 2005 a tese advinda de tal p
esquisa foi disponibilizada    na &iacute;ntegra no <I>site</I> <a href="http://
www.teses.usp.br" target="_blank">www.teses.usp.br</a>    e tamb&eacute;m no sit
e do projeto.</font></p>     ^cY#a04v22n6.htm##
00895000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704066000076002001300736#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a04v22n6.htm#S#p#70#66#article#115#<p><font size="2" f
ace="Verdana">Em rela&ccedil;&atilde;o &agrave; categoria "projeto",    a que ma
is coment&aacute;rios suscitou, &eacute; importante notar que foram    enviadas 
observa&ccedil;&otilde;es extremamente favor&aacute;veis &agrave; proposta    do
 projeto Baladaboa. O fato de metade dos coment&aacute;rios tecer elogios    &ag
rave; iniciativa, incentivar os pesquisadores a executar as a&ccedil;&otilde;es 
   propostas, ou oferecer ajuda no que fosse necess&aacute;rio &eacute; ind&iacu
te;cio    de que um projeto de RD, caso implantado, ter&aacute; grande aceita&cc
edil;&atilde;o    entre os usu&aacute;rios de <I>ecstasy</I>.</font></p>     ^cY
#a04v22n6.htm##
00992000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704075700076002001300833#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a04v22n6.htm#S#p#71#67#article#115#<p><font size="2" f
ace="Verdana">Somada &agrave; ascens&atilde;o do consumo da    droga, ao seu com
provado potencial t&oacute;xico e &agrave; inexist&ecirc;ncia    de programas pr
eventivos direcionados a usu&aacute;rios brasileiros at&eacute;    o momento, a 
receptividade do p&uacute;blico-alvo ao projeto Baladaboa, constatada    na pres
ente an&aacute;lise, indica que sua efetiva implanta&ccedil;&atilde;o    n&atild
e;o &eacute; apenas necess&aacute;ria, mas urgente e apropriada ao momento.    Q
uanto antes for implantado o primeiro programa preventivo para o uso de <I>ecsta
sy</I>,    maior ser&aacute; o n&uacute;mero de usu&aacute;rios experimentais e 
recentes    atingidos, aumentando as chances de que incorporem atitudes de RD.</
font></p>     ^cY#a04v22n6.htm##
00649000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704041400076002001300490#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a04v22n6.htm#S#p#72#68#article#115#<p><font size="2" f
ace="Verdana">Em suma, esperamos que o presente trabalho contribua    para sensi
bilizar as autoridades respons&aacute;veis pela pol&iacute;tica p&uacute;blica  
  brasileira em rela&ccedil;&atilde;o a drogas para a import&acirc;ncia da reali
za&ccedil;&atilde;o    de interven&ccedil;&otilde;es que atendam &agrave; demand
a espontaneamente manifestada    pelos usu&aacute;rios.</font></p>     ^cY#a04v2
2n6.htm##
00743000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704050800076002001300584#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a04v22n6.htm#S#p#73#69#article#115#<p><font size="2" f
ace="Verdana"><B>Agradecimentos. </b>Stella Pereira Almeida    recebeu bolsa de 
doutorado da Coordena&ccedil;&atilde;o de Aperfei&ccedil;oamento    de Pessoal d
e N&iacute;vel Superior (CAPES) e bolsa de p&oacute;s-doutorado    da Funda&cced
il;&atilde;o de Amparo &agrave; Pesquisa do Estado de S&atilde;o    Paulo (FAPES
P). Maria Teresa Ara&uacute;jo Silva recebeu aux&iacute;lio do Conselho    Nacio
nal de Desenvolvimento Cient&iacute;fico e Tecnol&oacute;gico (CNPq).</font></p>
     ^cY#a04v22n6.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a04v22n6.htm#S#p#74#70#article#115#<p>&nbsp;</p>     ^
cY#a04v22n6.htm##
00312000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704007700076002001300153#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a04v22n6.htm#S#p#75#71#article#115#<p><font size="3" f
ace="Verdana"><b>REFER&Ecirc;NCIAS</b></font></p>     ^cY#a04v22n6.htm##
00452000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704020300078002001300281#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a04v22n6.htm#S#p#76#72#article#115#1#<p><f
ont size="2" face="Verdana">1. Degenhardt L, Copeland J, Dillon P. Recent    tre
nds in the use of "club drugs": an Australian review. Subst Use    Misuse. 2005;
40 (9–10):1241–56.</font></p>     ^cY#a04v22n6.htm##
00503000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704025400078002001300332#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a04v22n6.htm#S#p#77#73#article#115#2#<p><f
ont size="2" face="Verdana">2. McCambridge J, Mitcheson L, Winstock A, Hunt    N
. Five-year trends in patterns of drug use among people who use stimulants    in
 dance contexts in the United Kingdom. Addiction. 2005;100(8):1140–9.</font></p>
     ^cY#a04v22n6.htm##
00451000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704020200078002001300280#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a04v22n6.htm#S#p#78#74#article#115#3#<p><f
ont size="2" face="Verdana">3. Strote J, Lee JE, Wechsler H. Increasing MDMA    
use among college students: results of a national survey. J Adolesc Health.    2
002;30 (1):64–72.</font></p>     ^cY#a04v22n6.htm##
00469000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704022000078002001300298#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a04v22n6.htm#S#p#79#75#article#115#4#<p><f
ont size="2" face="Verdana">4. Wilkins C, Bhatta K, Pledger M, Casswell S.    Ec
stasy use in New Zealand: findings from the 1998 and 2001 National Drug Surveys.
    N Z Med J. 2003;116(1171):U383.</font></p>     ^cY#a04v22n6.htm##
00422000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704017300078002001300251#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a04v22n6.htm#S#p#80#76#article#115#5#<p><f
ont size="2" face="Verdana">5. Ahmad K. Increased use of amphetamine-type    sti
mulants threatens east Asian countries. Lancet. 2002;359(9321):1927.</font></p> 
    ^cY#a04v22n6.htm##
00519000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704027000078002001300348#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a04v22n6.htm#S#p#81#77#article#115#6#<p><f
ont size="2" face="Verdana">6. de Almeida SP, Silva MT. Hist&oacute;rico,    efe
itos e mecanismo de a&ccedil;&atilde;o do &ecirc;xtase (3-4 metilenodioximetanfe
tamina):    revis&atilde;o da literatura. Rev Panam Salud Publica. 2000;8(6):393
–402.</font></p>     ^cY#a04v22n6.htm##
00585000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704033600078002001300414#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a04v22n6.htm#S#p#82#78#article#115#7#<p><f
ont size="2" face="Verdana">7. United Nations Office on Drugs and Crime (UNODC).
    World Drug Report. New York: UNODC; 2006. Dispon&iacute;vel em: <a href="htt
p://www.unodc.org/unodc/world_drug_report.html" target="_blank">http://www.unodc
.org/unodc/world_drug_report.html</a>.    Acessado em novembro de 2007.</font></
p>     ^cY#a04v22n6.htm##
00456000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704020700078002001300285#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a04v22n6.htm#S#p#83#79#article#115#8#<p><f
ont size="2" face="Verdana">8. Dumont GJ, Verkes RJ. A review of acute effects  
  of 3,4-methylenedioxymethamphetamine in healthy volunteers. J Psychopharmacol.
    2006;20(2):176–87.</font></p>     ^cY#a04v22n6.htm##
00540000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704029100078002001300369#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a04v22n6.htm#S#p#84#80#article#115#9#<p><f
ont size="2" face="Verdana">9. de Win MM, Reneman L, Jager G, Vlieger EJ,    Ola
barriaga SD, Lavini C, et al. A prospective cohort study on sustained effects   
 of low-dose ecstasy use on the brain in new ecstasy users. Neuropsychopharmacol
ogy.    2007;32(2):458–70.</font></p>     ^cY#a04v22n6.htm##
00554000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704030400079002001300383#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a04v22n6.htm#S#p#85#81#article#115#10#<p><
font size="2" face="Verdana">10. Jager G, de Win MM, Vervaeke HK, Schilt T,    K
ahn RS, van den Brink W, et al. Incidental use of ecstasy: no evidence for    ha
rmful effects on cognitive brain function in a prospective fMRI study. Psychopha
rmacology    (Berl). 2007;193(3):403–14.</font></p>     ^cY#a04v22n6.htm##
00454000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704020400079002001300283#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a04v22n6.htm#S#p#86#82#article#115#11#<p><
font size="2" face="Verdana">11. Wareing M, Fisk JE, Murphy PN. Working memory  
  deficits in current and previous users of MDMA (‘ecstasy'). Br J Psychol. 2000
;91    (Pt 2):181–8.</font></p>     ^cY#a04v22n6.htm##
00482000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704023200079002001300311#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a04v22n6.htm#S#p#87#83#article#115#12#<p><
font size="2" face="Verdana">12. Parrott AC. Human research on MDMA (3,4-methyle
ne-dioxymethamphetamine)    neurotoxicity: cognitive and behavioural indices of 
change. Neuropsychobiology.    2000;42(1):17–24.</font></p>     ^cY#a04v22n6.htm
##
00511000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704026100079002001300340#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a04v22n6.htm#S#p#88#84#article#115#13#<p><
font size="2" face="Verdana">13. Morgan MJ, McFie L, Fleetwood H, Robinson    JA
. Ecstasy (MDMA): are the psychological problems associated with its use reverse
d    by prolonged abstinence? Psychopharmacology (Berl). 2002;159(3):294–303.</f
ont></p>     ^cY#a04v22n6.htm##
00476000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704022600079002001300305#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a04v22n6.htm#S#p#89#85#article#115#14#<p><
font size="2" face="Verdana">14. McGuire PK, Cope H, Fahy TA. Diversity of    ps
ychopathology associated with use of 3,4-methylenedioxymethamphetamine (‘Ecstasy
').    Br J Psychiatry. 1994;165(3):391–5.</font></p>     ^cY#a04v22n6.htm##
00487000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704023700079002001300316#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a04v22n6.htm#S#p#90#86#article#115#15#<p><
font size="2" face="Verdana">15. MacInnes N, Handley SL, Harding GF. Former    c
hronic methylenedioxymethamphetamine (MDMA or ecstasy) users report mild depress
ive    symptoms. J Psychopharmacol. 2001;15(3):181–6.</font></p>     ^cY#a04v22n
6.htm##
00473000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704022300079002001300302#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a04v22n6.htm#S#p#91#87#article#115#16#<p><
font size="2" face="Verdana">16. Gamma A, Frei E, Lehmann D, Pascual-Marqui    R
D, Hell D, Vollenweider FX. Mood state and brain electric activity in ecstasy   
 users. Neuroreport. 2000;11(1):157–62.</font></p>     ^cY#a04v22n6.htm##
00542000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704029200079002001300371#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a04v22n6.htm#S#p#92#88#article#115#17#<p><
font size="2" face="Verdana">17. Thomasius R, Petersen K, Buchert R, Andresen   
 B, Zapletalova P, Wartberg L, et al. Mood, cognition and serotonin transporter 
   availability in current and former ecstasy (MDMA) users. Psychopharmacology  
  (Berl). 2003;167(1):85–96.</font></p>     ^cY#a04v22n6.htm##
00465000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704021500079002001300294#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a04v22n6.htm#S#p#93#89#article#115#18#<p><
font size="2" face="Verdana">18. Cohen RS. Subjective reports on the effects    
of the MDMA (‘ecstasy') experience in humans. Prog Neuropsychopharmacol Biol    
Psychiatry. 1995;19(7):1137–45.</font></p>     ^cY#a04v22n6.htm##
00457000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704020700079002001300286#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a04v22n6.htm#S#p#94#90#article#115#19#<p><
font size="2" face="Verdana">19. Almeida SP, Silva MTA. Ecstasy (MDMA): Effects 
   and patterns of use reported by users in S&atilde;o Paulo. Rev Bras Psiquiatr
.    2003;25(1): 11–17.</font></p>     ^cY#a04v22n6.htm##
00454000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704020400079002001300283#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a04v22n6.htm#S#p#95#91#article#115#20#<p><
font size="2" face="Verdana">20. Lee SJ, Galanter M, Dermatis H, McDowell    D. 
Circuit parties and patterns of drug use in a subset of gay men. J Addict    Dis
. 2003;22(4): 47–60.</font></p>     ^cY#a04v22n6.htm##
00441000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704019100079002001300270#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a04v22n6.htm#S#p#96#92#article#115#21#<p><
font size="2" face="Verdana">21. Logan BK, Couper FJ. 3,4-Methylenedioxymethamph
etamine    (MDMA, ecstasy) and driving impairment. J Forensic Sci. 2001; 46(6):1
426–33.</font></p>     ^cY#a04v22n6.htm##
00633000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704038300079002001300462#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a04v22n6.htm#S#p#97#93#article#115#22#<p><
font size="2" face="Verdana">22. Green AR, Sanchez V, O'Shea E, Saadat KS,    El
liott JM, Colado MI. Effect of ambient temperature and a prior neurotoxic    dos
e of 3,4-methylenedioxymethamphetamine (MDMA) on the hyperthermic response    of
 rats to a single or repeated (‘binge' ingestion) low dose of MDMA. Psychopharma
cology    (Berl). 2004; 173(3–4):264–9.</font></p>     ^cY#a04v22n6.htm##
00534000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704028400079002001300363#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a04v22n6.htm#S#p#98#94#article#115#23#<p><
font size="2" face="Verdana">23. Carlini-Cotrim B. Drogas na escola: preven&cced
il;&atilde;o,    toler&acirc;ncia e pluralidade. Em: Aquino JGO, ed. Drogas na e
scola: alternativas    te&oacute;ricas e pr&aacute;ticas. S&atilde;o Paulo: Summ
us; 1998. Pp. 19–30.</font></p>     ^cY#a04v22n6.htm##
00440000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704019000079002001300269#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a04v22n6.htm#S#p#99#95#article#115#24#<p><
font size="2" face="Verdana">24. Cuijpers P. Effective ingredients of school-bas
ed    drug prevention programs. A systematic review. Addict Behav. 2002;27(6):10
09–23.</font></p>     ^cY#a04v22n6.htm##
00510000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073888000300077704025900080002001300339#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a04v22n6.htm#S#p#100#96#article#115#25#<p>
<font size="2" face="Verdana">25. Moreira FG, Silveira DX, Andreoli SB. Situa&cc
edil;&otilde;es    relacionadas ao uso indevido de drogas nas escolas p&uacute;b
licas da cidade    de S&atilde;o Paulo. Rev Saude Publica. 2006;40(5):810–7.</fo
nt></p>     ^cY#a04v22n6.htm##
00722000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073888000300077704047100080002001300551#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a04v22n6.htm#S#p#101#97#article#115#26#<p>
<font size="2" face="Verdana">26. Almeida SP. Sobre o uso de ecstasy: uma pesqui
sa    com vistas &agrave; formula&ccedil;&atilde;o de interven&ccedil;&atilde;o 
preventiva    &#91;tese&#93;. S&atilde;o Paulo: USP; 2005. Dispon&iacute;vel em:
 <a href="http://www.teses.usp.br/teses/disponiveis/47/47135/tde-08022006-110827
/" target="_blank">http://www.teses.usp.br/teses/disponiveis/47/47135/tde-080220
06-110827/</a>.    Acessado em novembro de 2007.</font></p>     ^cY#a04v22n6.htm
##
00450000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073888000300077704019900080002001300279#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a04v22n6.htm#S#p#102#98#article#115#27#<p>
<font size="2" face="Verdana">27. Allott K, Redman J. Patterns of use and harm  
  reduction practices of ecstasy users in Australia. Drug Alcohol Depend. 2006;8
2(2):    168–76.</font></p>     ^cY#a04v22n6.htm##
00474000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073888000300077704022300080002001300303#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a04v22n6.htm#S#p#103#99#article#115#28#<p>
<font size="2" face="Verdana">28. Murphy PN, Wareing M, Fisk J. Users' perceptio
ns    of the risks and effects of taking ecstasy (MDMA): a questionnaire study. 
J    Psychopharmacol. 2006;20(3):447–55.</font></p>     ^cY#a04v22n6.htm##
00520000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704026800081002001300349#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a04v22n6.htm#S#p#104#100#article#115#29#<p
><font size="2" face="Verdana">29. Levy KB, O'Grady KE, Wish ED, Arria AM. An   
 in-depth qualitative examination of the ecstasy experience: results of a focus 
   group with ecstasy-using college students. Subst Use Misuse. 2005;40(9–10):14
27–41.</font></p>     ^cY#a04v22n6.htm##
00571000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704031900081002001300400#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a04v22n6.htm#S#p#105#101#article#115#30#<p
><font size="2" face="Verdana">30. Brasil, Secretaria Nacional Antidrogas (SENAD
).    Pol&iacute;tica Nacional sobre drogas. In: Bras&iacute;lia; SENAD; 2005. D
ispon&iacute;vel    em: <a href="http://www.senad.gov.br/" target="_blank">http:
//www.senad.gov.br/</a>.    Acessado em novembro de 2007.</font></p>     ^cY#a04
v22n6.htm##
00400000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704014800081002001300229#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a04v22n6.htm#S#p#106#102#article#115#31#<p
><font size="2" face="Verdana">31. Aaker DA, Kumar V, Day GS. Marketing research
.    Nova Iorque: John Wiley &amp; Sons; 1988.</font></p>     ^cY#a04v22n6.htm##
00549000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704029700081002001300378#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a04v22n6.htm#S#p#107#103#article#115#32#<p
><font size="2" face="Verdana">32. Barros RS, Almeida SP, Magalh&atilde;es MP,  
  Silva MTA. Id&eacute;ias e imagens suscitadas em universit&aacute;rios numa   
 pesquisa sobre drogas: uma contribui&ccedil;&atilde;o ao trabalho preventivo.  
  Bol Psicol. 1992;42(96/97):15–26.</font></p>     ^cY#a04v22n6.htm##
00490000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704023800081002001300319#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a04v22n6.htm#S#p#108#104#article#115#33#<p
><font size="2" face="Verdana">33. Lef&egrave;vre F, Lef&egrave;vre AMC, Teixeir
a    JJV. O discurso do sujeito coletivo: uma nova abordagem metodol&oacute;gica
    em pesquisa qualitativa. Caxias do Sul: EDUCS; 2000.</font></p>     ^cY#a04v
22n6.htm##
00741000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704048900081002001300570#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a04v22n6.htm#S#p#109#105#article#115#34#<p
><font size="2" face="Verdana">34. Carlini EA, Galdur&oacute;z JCF, Noto AR,    
Nappo SA. Primeiro levantamento domiciliar sobre o uso de drogas psicotr&oacute;
picas    no Brasil. S&atilde;o Paulo: Secretaria Nacional Antidrogas; 2002. Disp
on&iacute;vel    em: <a href="http://www.unifesp.br/dpsicobio/cebrid/levantament
o_brasil/parte_2.pdf" target="_blank">http://www.unifesp.br/dpsicobio/cebrid/lev
antamento_brasil/parte_2.pdf</a>    . Acessado em novembro de 2007.</font></p>  
   ^cY#a04v22n6.htm##
00580000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704032800081002001300409#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a04v22n6.htm#S#p#110#106#article#115#35#<p
><font size="2" face="Verdana">35. Almeida PM, Wickerhauser H. O Crit&eacute;rio
    ABA/ABIPEME—em busca de uma atualiza&ccedil;&atilde;o. Um estudo e uma propo
sta    submetidos &agrave; ABA e &agrave; ABIPEME. S&atilde;o Paulo: Documento d
e circula&ccedil;&atilde;o    restrita da ABA e da ABIPEME; 1991. </font></p>   
  ^cY#a04v22n6.htm##
00492000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704024000081002001300321#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a04v22n6.htm#S#p#111#107#article#115#36#<p
><font size="2" face="Verdana">36. Carlson RG, Falck RS, McCaughan JA, Siegal   
 HA. MDMA/Ecstasy use among young people in Ohio: perceived risk and barriers   
 to intervention. J Psychoactive Drugs. 2004;36(2): 181–9.</font></p>     ^cY#a0
4v22n6.htm##
00550000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704029800081002001300379#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a04v22n6.htm#S#p#112#108#article#115#37#<p
><font size="2" face="Verdana">37. Harm Reduction Coalition. Promoting the healt
h    and dignity of those impacted by drug use. Dispon&iacute;vel em: <a href="h
ttp://www.harmreduction.org/" target="_blank">http://www.harm    reduction.org/<
/a>. Acessado em 30 de maio de 2006.</font></p>     ^cY#a04v22n6.htm##
00466000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704021400081002001300295#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a04v22n6.htm#S#p#113#109#article#115#38#<p
><font size="2" face="Verdana">38. Marlatt GA. Redu&ccedil;&atilde;o de danos:  
  estrat&eacute;gias pr&aacute;ticas para lidar com comportamentos de alto risco
.    Porto Alegre: Artmed; 1999.</font></p>     ^cY#a04v22n6.htm##
00508000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704025600081002001300337#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a04v22n6.htm#S#p#114#110#article#115#39#<p
><font size="2" face="Verdana">39. Serapione M. M&eacute;todos qualitativos    e
 quantitativos na pesquisa social em sa&uacute;de: algumas estrat&eacute;gias   
 para a integra&ccedil;&atilde;o. Cienc Saude Coletiva. 2000;5(1):187–192.</font
></p>     ^cY#a04v22n6.htm##
00417000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704016500081002001300246#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a04v22n6.htm#S#p#115#111#article#115#40#<p
><font size="2" face="Verdana">40. Beck J, Rosenbaum M. Pursuit of Ecstasy.    T
he MDMA experience. Albany: State University of New York; 1994.</font></p>     ^
cY#a04v22n6.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a04v22n6.htm#S#p#116#112#article#115#<p>&nbsp;</p>    
 ^cY#a04v22n6.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a04v22n6.htm#S#p#117#113#article#115#<p>&nbsp;</p>    
 ^cY#a04v22n6.htm##
00321000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704008400078002001300162#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a04v22n6.htm#S#p#118#114#article#115#<p><font size="2"
 face="Verdana">Manuscrito recebido em 19 de junho de 2006.    ^cY#a04v22n6.htm#
#
00320000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704008300078002001300161#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a04v22n6.htm#S#p#119#115#article#115#<br>   Aceito em 
vers&atilde;o revisada el 30 de julho de 2007.</font></p>     ^cY#a04v22n6.htm##
00596000000000301000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100020000770100018000970100
01600115012006700131030001700198065000900215064000500224031000300229032000500232
014000800237865000900245002001300254035001000267801001700277#v22n6#v:\scielo\ser
ial\rpsp\v22n6\markup\a04v22n6.htm#S#c#120#1#article#40#1#^rND^sDegenhardt^nL#^r
ND^sCopeland^nJ#^rND^sDillon^nP#Recent trends in the use of "club drugs": an Aus
tralian review^len#Subst Use Misuse#20050000#2005#40#9-10#1241-56#20071200#a04v2
2n6.htm#1082-6084#Subst Use Misuse##
00659000000000313000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100021000770100019000980100
01800117010001400135012011700149030001000266065000900276064000500285031000400290
032000200294014000700296865000900303002001300312035001000325801001000335#v22n6#v
:\scielo\serial\rpsp\v22n6\markup\a04v22n6.htm#S#c#121#2#article#40#2#^rND^sMcCa
mbridge^nJ#^rND^sMitcheson^nL#^rND^sWinstock^nA#^rND^sHunt^nN#Five-year trends i
n patterns of drug use among people who use stimulants in dance contexts in the 
United Kingdom^len#Addiction#20050000#2005#100#8#1140-9#20071200#a04v22n6.htm#09
65-2140#Addiction##
00595000000000301000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100016000770100014000930100
01800107012007700125030001700202065000900219064000500228031000300233032000200236
014000600238865000900244002001300253035001000266801001700276#v22n6#v:\scielo\ser
ial\rpsp\v22n6\markup\a04v22n6.htm#S#c#122#3#article#40#3#^rND^sStrote^nJ#^rND^s
Lee^nJE#^rND^sWechsler^nH#Increasing MDMA use among college students: results of
 a national survey^len#J Adolesc Health#20020000#2002#30#1#64-72#20071200#a04v22
n6.htm#1054-139X#J Adolesc Health##
00625000000000313000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100017000770100016000940100
01700110010001800127012008600145030001000231065000900241064000500250031000400255
032000500259014000500264865000900269002001300278035001000291801001000301#v22n6#v
:\scielo\serial\rpsp\v22n6\markup\a04v22n6.htm#S#c#123#4#article#40#4#^rND^sWilk
ins^nC#^rND^sBhatta^nK#^rND^sPledger^nM#^rND^sCasswell^nS#Ecstasy use in New Zea
land: findings from the 1998 and 2001 National Drug Surveys^len#N Z Med J#200300
00#2003#116#1171#U383#20071200#a04v22n6.htm#0028-8446#N Z Med J##
00524000000000277000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100015000770120080000920300
00700172065000900179064000500188031000400193032000500197014000500202865000900207
002001300216035001000229801000700239#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a0
4v22n6.htm#S#c#124#5#article#40#5#^rND^sAhmad^nK#Increased use of amphetamine-ty
pe stimulants threatens east Asian countries^len#Lancet#20020000#2002#359#9321#1
927#20071200#a04v22n6.htm#0099-5355#Lancet##
00619000000000289000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100021000770100016000980120
10900114030002400223065000900247064000500256031000200261032000200263014000800265
865000900273002001300282035001000295801002400305#v22n6#v:\scielo\serial\rpsp\v22
n6\markup\a04v22n6.htm#S#c#125#6#article#40#6#^rND^sde Almeida^nSP#^rND^sSilva^n
MT#Histórico, efeitos e mecanismo de ação do êxtase (3-4 metilenodioximetanfetam
ina): revisão da literatura^lpt#Rev Panam Salud Publica#20000000#2000#8#6#393-40
2#20071200#a04v22n6.htm#1020-4989#Rev Panam Salud Publica##
00511000000000241000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750170041000770180039001180650
00900157064000500166037005000171110000900221109001700230865000900247002001300256
#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a04v22n6.htm#S#c#126#7#article#40#7#Un
ited Nations Office on Drugs and Crime#World Drug Report. New York: UNODC^len#20
060000#2006#http://www.unodc.org/unodc/world_drug_report.html#20071100#novembro 
de 2007#20071200#a04v22n6.htm##
00584000000000289000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100017000770100017000940120
08900111030001800200065000900218064000500227031000300232032000200235014000700237
865000900244002001300253035001000266801001800276#v22n6#v:\scielo\serial\rpsp\v22
n6\markup\a04v22n6.htm#S#c#127#8#article#40#8#^rND^sDumont^nGJ#^rND^sVerkes^nRJ#
A review of acute effects of 3,4-methylenedioxymethamphetamine in healthy volunt
eers^len#J Psychopharmacol#20060000#2006#20#2#176-87#20071200#a04v22n6.htm#0269-
8811#J Psychopharmacol##
00754000000000349000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100017000770100017000940100
01500111010001800126010002200144010001600166810000600182012011000188030002400298
06500090032206400050033103100030033603200020033901400070034186500090034800200130
0357035001000370801002400380#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a04v22n6.h
tm#S#c#128#9#article#40#9#^rND^sde Win^nMM#^rND^sReneman^nL#^rND^sJager^nG#^rND^
sVlieger^nEJ#^rND^sOlabarriaga^nSD#^rND^sLavini^nC#et al#A prospective cohort st
udy on sustained effects of low-dose ecstasy use on the brain in new ecstasy use
rs^len#Neuropsychopharmacology#20070000#2007#32#2#458-70#20071200#a04v22n6.htm#0
893-133X#Neuropsychopharmacology##
00770000000000349000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100015000790100017000940100
01900111010001600130010001500146010002300161810000600184012011900190030002600309
06500090033506400050034403100040034903200020035301400070035586500090036200200130
0371035001000384801002600394#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a04v22n6.h
tm#S#c#129#10#article#40#10#^rND^sJager^nG#^rND^sde Win^nMM#^rND^sVervaeke^nHK#^
rND^sSchilt^nT#^rND^sKahn^nRS#^rND^svan den Brink^nW#et al#Incidental use of ecs
tasy: no evidence for harmful effects on cognitive brain function in a prospecti
ve fMRI study^len#Psychopharmacology (Berl)#20070000#2007#193#3#403-14#20071200#
a04v22n6.htm#0033-3158#Psychopharmacology (Berl)##
00594000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100015000960100
01700111012007800128030001300206065000900219064000500228031000300233061000500236
014000600241865000900247002001300256035001000269801001300279#v22n6#v:\scielo\ser
ial\rpsp\v22n6\markup\a04v22n6.htm#S#c#130#11#article#40#11#^rND^sWareing^nM#^rN
D^sFisk^nJE#^rND^sMurphy^nPN#Working memory deficits in current and previous use
rs of MDMA (‘ecstasy')^len#Br J Psychol#20000000#2000#91#Pt 2#181-8#20071200#a04
v22n6.htm#0007-1269#Br J Psychol##
00593000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790120123000970300
01900220065000900239064000500248031000300253032000200256014000600258865000900264
002001300273035001000286801001900296#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a0
4v22n6.htm#S#c#131#12#article#40#12#^rND^sParrott^nAC#Human research on MDMA (3,
4-methylene-dioxymethamphetamine) neurotoxicity: cognitive and behavioural indic
es of change^len#Neuropsychobiology#20000000#2000#42#1#17-24#20071200#a04v22n6.h
tm#0302-282X#Neuropsychobiology##
00684000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100015000960100
01900111010001900130012010900149030002600258065000900284064000500293031000400298
032000200302014000800304865000900312002001300321035001000334801002600344#v22n6#v
:\scielo\serial\rpsp\v22n6\markup\a04v22n6.htm#S#c#132#13#article#40#13#^rND^sMo
rgan^nMJ#^rND^sMcFie^nL#^rND^sFleetwood^nH#^rND^sRobinson^nJA#Ecstasy (MDMA): ar
e the psychological problems associated with its use reversed by prolonged absti
nence?^len#Psychopharmacology (Berl)#20020000#2002#159#3#294-303#20071200#a04v22
n6.htm#0033-3158#Psychopharmacology (Berl)##
00620000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100014000970100
01500111012010200126030001600228065000900244064000500253031000400258032000200262
014000600264865000900270002001300279035001000292801001600302#v22n6#v:\scielo\ser
ial\rpsp\v22n6\markup\a04v22n6.htm#S#c#133#14#article#40#14#^rND^sMcGuire^nPK#^r
ND^sCope^nH#^rND^sFahy^nTA#Diversity of psychopathology associated with use of 3
,4-methylenedioxymethamphetamine (‘Ecstasy')^len#Br J Psychiatry#19940000#1994#1
65#3#391-5#20071200#a04v22n6.htm#0007-1250#Br J Psychiatry##
00633000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100018000970100
01800115012010500133030001800238065000900256064000500265031000300270032000200273
014000600275865000900281002001300290035001000303801001800313#v22n6#v:\scielo\ser
ial\rpsp\v22n6\markup\a04v22n6.htm#S#c#134#15#article#40#15#^rND^sMacInnes^nN#^r
ND^sHandley^nSL#^rND^sHarding^nGF#Former chronic methylenedioxymethamphetamine (
MDMA or ecstasy) users report mild depressive symptoms^len#J Psychopharmacol#200
10000#2001#15#3#181-6#20071200#a04v22n6.htm#0269-8811#J Psychopharmacol##
00667000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100015000790100014000940100
01700108010002500125010001400150010002300164012006000187030001200247065000900259
06400050026803100030027303200020027601400070027886500090028500200130029403500100
0307801001200317#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a04v22n6.htm#S#c#135#1
6#article#40#16#^rND^sGamma^nA#^rND^sFrei^nE#^rND^sLehmann^nD#^rND^sPascual-Marq
ui^nRD#^rND^sHell^nD#^rND^sVollenweider^nFX#Mood state and brain electric activi
ty in ecstasy users^len#Neuroreport#20000000#2000#11#1#157-62#20071200#a04v22n6.
htm#0959-4965#NeuroReport##
00758000000000349000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100019000790100018000980100
01700116010001800133010002100151010001800172810000600190012010200196030002600298
06500090032406400050033303100040033803200020034201400060034486500090035000200130
0359035001000372801002600382#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a04v22n6.h
tm#S#c#136#17#article#40#17#^rND^sThomasius^nR#^rND^sPetersen^nK#^rND^sBuchert^n
R#^rND^sAndresen^nB#^rND^sZapletalova^nP#^rND^sWartberg^nL#et al#Mood, cognition
 and serotonin transporter availability in current and former ecstasy (MDMA) use
rs^len#Psychopharmacology (Berl)#20030000#2003#167#1#85-96#20071200#a04v22n6.htm
#0033-3158#Psychopharmacology (Berl)##
00599000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790120083000950300
04200178065000900220064000500229031000300234032000200237014000800239865000900247
002001300256035001000269801004200279#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a0
4v22n6.htm#S#c#137#18#article#40#18#^rND^sCohen^nRS#Subjective reports on the ef
fects of the MDMA (‘ecstasy') experience in humans^len#Prog Neuropsychopharmacol
 Biol Psychiatry#19950000#1995#19#7#1137-45#20071200#a04v22n6.htm#0278-5846#Prog
 Neuropsychopharmacol Biol Psychiatry##
00539000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100017000970120
07900114030001900193710000200212065000900214064000500223031000300228032000200231
014000600233865000900239002001300248#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a0
4v22n6.htm#S#c#138#19#article#40#19#^rND^sAlmeida^nSP#^rND^sSilva^nMTA#Ecstasy (
MDMA): Effects and patterns of use reported by users in São Paulo^len#Rev Bras P
siquiatr#2#20030000#2003#25#1#11-17#20071200#a04v22n6.htm##
00612000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100014000790100018000930100
01800111010001800129012006800147030001300215065000900228064000500237031000300242
032000200245014000600247865000900253002001300262035001000275801001300285#v22n6#v
:\scielo\serial\rpsp\v22n6\markup\a04v22n6.htm#S#c#139#20#article#40#20#^rND^sLe
e^nSJ#^rND^sGalanter^nM#^rND^sDermatis^nH#^rND^sMcDowell^nD#Circuit parties and 
patterns of drug use in a subset of gay men^len#J Addict Dis#20030000#2003#22#4#
47-60#20071200#a04v22n6.htm#1055-0887#J Addict Dis##
00568000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100017000950120
07700112030001500189065000900204064000500213031000300218032000200221014000800223
865000900231002001300240035001000253801001500263#v22n6#v:\scielo\serial\rpsp\v22
n6\markup\a04v22n6.htm#S#c#140#21#article#40#21#^rND^sLogan^nBK#^rND^sCouper^nFJ
#3,4-Methylenedioxymethamphetamine (MDMA, ecstasy) and driving impairment^len#J 
Forensic Sci#20010000#2001#46#6#1426-33#20071200#a04v22n6.htm#0022-1198#J Forens
ic Sci##
00834000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100017000950100
01600112010001700128010001800145010001700163012020400180030002600384065000900410
06400050041903100040042403200040042801400060043286500090043800200130044703500100
0460801002600470#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a04v22n6.htm#S#c#141#2
2#article#40#22#^rND^sGreen^nAR#^rND^sSanchez^nV#^rND^sO'Shea^nE#^rND^sSaadat^nK
S#^rND^sElliott^nJM#^rND^sColado^nMI#Effect of ambient temperature and a prior n
eurotoxic dose of 3,4-methylenedioxymethamphetamine (MDMA) on the hyperthermic r
esponse of rats to a single or repeated (‘binge' ingestion) low dose of MDMA^len
#Psychopharmacology (Berl)#20040000#2004#173#3-4#264-9#20071200#a04v22n6.htm#003
3-3158#Psychopharmacology (Berl)##
00559000000000265000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100024000790120058001030160
01800161018005500179066001000234062000700244065000900251064000500260014000600265
865000900271002001300280#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a04v22n6.htm#S
#c#142#23#article#40#23#^rND^sCarlini-Cotrim^nB#Drogas na escola: prevenção, tol
erância e pluralidade^lpt#^rED^sAquino^nJGO#Drogas na escola: alternativas teóri
cas e práticas^lpt#São Paulo#Summus#19980000#1998#19-30#20071200#a04v22n6.htm##
00548000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790120088000970300
01300185065000900198064000500207031000300212032000200215014000800217865000900225
002001300234035001000247801001300257#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a0
4v22n6.htm#S#c#143#24#article#40#24#^rND^sCuijpers^nP#Effective ingredients of s
chool-based drug prevention programs: A systematic review^len#Addict Behav#20020
000#2002#27#6#1009-23#20071200#a04v22n6.htm#0306-4603#Addict Behav##
00627000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100019000970100
01900116012009700135030001800232065000900250064000500259031000300264032000200267
014000600269865000900275002001300284035001000297801001800307#v22n6#v:\scielo\ser
ial\rpsp\v22n6\markup\a04v22n6.htm#S#c#144#25#article#40#25#^rND^sMoreira^nFG#^r
ND^sSilveira^nDX#^rND^sAndreoli^nSB#Situações relacionadas ao uso indevido de dr
ogas nas escolas públicas da cidade de São Paulo^lpt#Rev Saude Publica#20060000#
2006#40#5#810-7#20071200#a04v22n6.htm#0034-8910#Rev Saude Publica##
00619000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760160018000790180091000970510
00500188046001000193050000400203045000900207044000500216037007200221065000900293
064001700302865000900319002001300328#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a0
4v22n6.htm#S#c#145#26#article#40#26#^rND^sAlmeida^nSP#Sobre o uso de ecstasy: um
a pesquisa com vistas à formulação de intervenção preventiva^lpt#tese#São Paulo#
USP#20050000#2005#http://www.teses.usp.br/teses/disponiveis/47/47135/tde-0802200
6-110827/#20071100#novembro de 2007#20071200#a04v22n6.htm##
00578000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100016000950120
07900111030002000190065000900210064000500219031000300224032000200227014000700229
865000900236002001300245035001000258801002000268#v22n6#v:\scielo\serial\rpsp\v22
n6\markup\a04v22n6.htm#S#c#146#27#article#40#27#^rND^sAllott^nK#^rND^sRedman^nJ#
Patterns of use and harm reduction practices of ecstasy users in Australia^len#D
rug Alcohol Depend#20060000#2006#82#2#168-76#20071200#a04v22n6.htm#0376-8716#Dru
g Alcohol Depend##
00619000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100017000960100
01400113012009600127030001800223065000900241064000500250031000300255032000200258
014000700260865000900267002001300276035001000289801001800299#v22n6#v:\scielo\ser
ial\rpsp\v22n6\markup\a04v22n6.htm#S#c#147#28#article#40#28#^rND^sMurphy^nPN#^rN
D^sWareing^nM#^rND^sFisk^nJ#Users' perceptions of the risks and effects of takin
g ecstasy (MDMA): a questionnaire study^len#J Psychopharmacol#20060000#2006#20#3
#447-55#20071200#a04v22n6.htm#0269-8811#J Psychopharmacol##
00681000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100015000790100018000940100
01500112010001600127012012800143030001700271065000900288064000500297031000300302
032000500305014000800310865000900318002001300327035001000340801001700350#v22n6#v
:\scielo\serial\rpsp\v22n6\markup\a04v22n6.htm#S#c#148#29#article#40#29#^rND^sLe
vy^nKB#^rND^sO'Grady^nKE#^rND^sWish^nED#^rND^sArria^nAM#An in-depth qualitative 
examination of the ecstasy experience: results of a focus group with ecstasy-usi
ng college students^len#Subst Use Misuse#20050000#2005#40#9-10#1427-41#20071200#
a04v22n6.htm#1082-6084#Subst Use Misuse##
00483000000000241000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760110039000790120035001180660
00900153062000600162037002500168065000900193064001700202865000900219002001300228
#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a04v22n6.htm#S#c#149#30#article#40#30#
Brasil^dSecretaria Nacional Antidrogas#Política Nacional sobre drogas^lpt#Brasíl
ia#SENAD#http://www.senad.gov.br/#20071100#novembro de 2007#20071200#a04v22n6.ht
m##
00467000000000253000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760160016000790160015000950160
01400110018002300124066001200147062001800159065000900177064000500186865000900191
002001300200#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a04v22n6.htm#S#c#150#31#ar
ticle#40#31#^rND^sAaker^nDA#^rND^sKumar^nV#^rND^sDay^nGS#Marketing research^len#
Nova Iorque#John Wiley & Sons#19880000#1988#20071200#a04v22n6.htm##
00666000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100018000960100
02000114010001700134012011800151030001100269065000900280064000500289031000300294
032000600297014000600303865000900309002001300318035001000331801001100341#v22n6#v
:\scielo\serial\rpsp\v22n6\markup\a04v22n6.htm#S#c#151#32#article#40#32#^rND^sBa
rros^nRS#^rND^sAlmeida^nSP#^rND^sMagalhães^nMP#^rND^sSilva^nMTA#Idéias e imagens
 suscitadas em universitários numa pesquisa sobre drogas: uma contribuição ao tr
abalho preventivo^lpt#Bol Psicol#19920000#1992#42#96/97#15-26#20071200#a04v22n6.
htm#0253-5742#Bol Psicol##
00537000000000253000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760160017000790160019000960160
02000115018009200135066001400227062000600241065000900247064000500256865000900261
002001300270#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a04v22n6.htm#S#c#152#33#ar
ticle#40#33#^rND^sLefèvre^nF#^rND^sLefèvre^nAMC#^rND^sTeixeira^nJJV#O discurso d
o sujeito coletivo: uma nova abordagem metodológica em pesquisa qualitativa^lpt#
Caxias do Sul#EDUCS#20000000#2000#20071200#a04v22n6.htm##
00707000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760160018000790160020000970160
01500117016001600132018008300148066001000231062003100241065000900272064000500281
037007100286110000900357109001700366865000900383002001300392#v22n6#v:\scielo\ser
ial\rpsp\v22n6\markup\a04v22n6.htm#S#c#153#34#article#40#34#^rND^sCarlini^nEA#^r
ND^sGalduróz^nJCF#^rND^sNoto^nAR#^rND^sNappo^nSA#Primeiro levantamento domicilia
r sobre o uso de drogas psicotrópicas no Brasil^lpt#São Paulo#Secretaria Naciona
l Antidrogas#20020000#2002#http://www.unifesp.br/dpsicobio/cebrid/levantamento_b
rasil/parte_2.pdf#20071100#novembro de 2007#20071200#a04v22n6.htm##
00570000000000241000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760160018000790160022000970180
11000119066001000229061005300239065000900292064000500301865000900306002001300315
#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a04v22n6.htm#S#c#154#35#article#40#35#
^rND^sAlmeida^nPM#^rND^sWickerhauser^nH#O Critério ABA/ABIPEME-em busca de uma a
tualização: Um estudo e uma proposta submetidos à ABA e à ABIPEME^lpt#São Paulo#
Documento de circulação restrita da ABA e da ABIPEME#19910000#1991#20071200#a04v
22n6.htm##
00656000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100016000970100
02000113010001700133012009300150030002100243065000900264064000500273031000300278
032000200281014000600283865000900289002001300298035001000311801002100321#v22n6#v
:\scielo\serial\rpsp\v22n6\markup\a04v22n6.htm#S#c#155#36#article#40#36#^rND^sCa
rlson^nRG#^rND^sFalck^nRS#^rND^sMcCaughan^nJA#^rND^sSiegal^nHA#MDMA/Ecstasy use 
among young people in Ohio: perceived risk and barriers to intervention^len#J Ps
ychoactive Drugs#20040000#2004#36#2#181-9#20071200#a04v22n6.htm#0279-1072#J Psyc
hoactive Drugs##
00470000000000217000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760170025000790180067001040370
03100171110000900202109001900211865000900230002001300239#v22n6#v:\scielo\serial\
rpsp\v22n6\markup\a04v22n6.htm#S#c#156#37#article#40#37#Harm Reduction Coalition
#Promoting the health and dignity of those impacted by drug use^len#http://www.h
arm reduction.org/#20060530#30 de maio de 2006#20071200#a04v22n6.htm##
00470000000000229000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760160018000790180087000970660
01300184062000700197065000900204064000500213865000900218002001300227#v22n6#v:\sc
ielo\serial\rpsp\v22n6\markup\a04v22n6.htm#S#c#157#38#article#40#38#^rND^sMarlat
t^nGA#Redução de danos: estratégias práticas para lidar com comportamentos de al
to risco^lpt#Porto Alegre#Artmed#19990000#1999#20071200#a04v22n6.htm##
00543000000000265000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100019000790120108000980300
02100206710000200227065000900229064000500238031000200243032000200245014000800247
865000900255002001300264#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a04v22n6.htm#S
#c#158#39#article#40#39#^rND^sSerapione^nM#Métodos qualitativos e quantitativos 
na pesquisa social em saúde: algumas estratégias para a integração^len#Cienc Sau
de Coletiva#2#20000000#2000#5#1#187-192#20071200#a04v22n6.htm##
00470000000000241000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760160014000790160019000930180
04400112066000700156062002900163065000900192064000500201865000900206002001300215
#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a04v22n6.htm#S#c#159#40#article#40#40#
^rND^sBeck^nJ#^rND^sRosenbaum^nM#Pursuit of Ecstasy: The MDMA experience^len#Alb
any#State University of New York#19940000#1994#20071200#a04v22n6.htm##
00275000000000169000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700910009000720920007000810020013000887030
00400101#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a05v22n6.htm#S#o#1#1#article#1
#20080215#102628#a05v22n6.htm#152##
05279000000000649000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000400090121000300094049000800097158000300105030002400108
03100030013203200020013506500090013701400110014603500100015701200960016701201260
02630100036003890100031004250100039004560700159004950700099006540700067007530831
55100820085000802371085003602379085003202415085002302447083180502470085000804275
08500400428308500320432308500230435505801000437806000110447805800640448906000040
45531170006045570720003045631120009045661110016045751140009045911130016046000020
01304616#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a05v22n6.htm#S#h#2#1#article#1
#oa#en#br1.1#1#3.1#TAB#05#RPSP020#nd#Rev Panam Salud Publica#22#6#20071200#^f396
^l401#1020-4989#Prevalence of mild serum vitamin B12 deficiency in rural and urb
an Costa Rican young adults^len#Prevalencia de la deficiencia moderada de vitami
na B12 sérica en jóvenes adultos de zonas rurales y urbanas de Costa Rica^les#^r
ND^1A01^nIleana^sHolst-Schumacher#^rND^1A02^nRafael^sMonge-Rojas#^rND^1A03^nMaur
o^sBarrantes-Santamaría#University of Costa Rica^iA01^1Investigation Center for 
Abnormal Hemoglobins and Related Sicknesses^cSan José^pCosta Rica^z2410-2050^eih
olst@cariari.ucr.ac.cr#Costa Rican Institute for Research and Education on Nutri
tion and Health^iA02^cCartago^pCosta Rica#University of Costa Rica^iA03^1Health 
Office^cSan José^pCosta Rica#^len^aOBJECTIVE: Recent studies have shown an incre
ase of mild serum cobalamin (vitamin B12) deficiency in some Latin American coun
tries; however, no data are available from Costa Rica. The purpose of this work 
was to establish the prevalence of serum vitamin B12 deficiency among Costa Rica
n young adults and to study some factors that may help explain the serum cobalam
in concentrations. METHODS: A cross-sectional survey was conducted among 400 adu
lts aged 20 to 40 years old from urban and rural areas of the central valley of 
Costa Rica to determine serum vitamin B12 levels. Additionally, cobalamin dietar
y intake and the detection of Helicobacter pylori IgG antibodies were studied as
 possible determinants of the serum vitamin B12 concentrations. RESULTS: The mea
n serum concentration of vitamin B12 was 268 &plusmn; 125 pmol/L, and no signifi
cant differences were found by gender or area. Study data indicate an overall pr
evalence of inadequate serum cobalamin levels of 42.4% (11.2% deficient and 31.2
% marginal); more than 50% but less than 75% of individuals had an intake of vit
amin B12 below the U.S. Estimated Average Requirement (EAR) and 61.2% had IgG an
tibodies to H. pylori. CONCLUSIONS: The prevalence of mild serum vitamin B12 def
iciency in young Costa Rican subjects is as high as in other Latin American coun
tries. More investigation should be done to elucidate the etiological factors th
at are generating deficient and marginal serum cobalamin levels in Costa Rican a
dults in order to define appropriate public health actions.#^dnd^i1#^tm^len^kVit
amin B 12 deficiency^i1#^tm^len^kHelicobacter pylori^i1#^tm^len^kCosta Rica^i1#^
les^aOBJETIVO: Aunque estudios recientes han demostrado un incremento en el défi
cit moderado de cobalamina (vitamina B12) sérica en algunos países de América La
tina, no hay datos de Costa Rica. El propósito de este trabajo fue determinar la
 prevalencia de la deficiencia de vitamina B12 sérica en jóvenes adultos de Cost
a Rica y estudiar algunos factores que pueden ayudar a explicar las concentracio
nes séricas de cobalamina. MÉTODOS: Se realizó un estudio transversal para deter
minar los niveles de vitamina B12 en el suero de 400 adultos de 20 a 40 años de 
edad de zonas urbanas y rurales del valle central de Costa Rica. Adicionalmente,
 se estudió la ingesta de cobalamina en la dieta y la presencia de anticuerpos I
gG contra Helicobacter pylori, como posibles factores determinantes de las conce
ntraciones séricas de vitamina B12. RESULTADOS: La concentración media de vitami
na B12 en el suero fue de 268 &plusmn; 125 pmol/L; no se encontraron diferencias
 significativas entre los sexos ni entre las áreas de residencia. Estos datos de
mostraron una prevalencia general de niveles insuficientes de cobalamina sérica 
de 42,4% (11,2% con déficit y 31,2% con concentraciones marginales); de las pers
onas estudiadas más de 50% -aunque menos de 75%- tenían una ingesta de vitamina 
B12 por debajo del valor de las necesidades promedio estimadas para los Estados 
Unidos de América y 61,2% tenía anticuerpos contra H. pylori. CONCLUSIONES: La p
revalencia de deficiencia moderada de vitamina B12 sérica en jóvenes costarricen
ses es tan elevada como en otros países latinoamericanos. Se necesitan más inves
tigaciones para aclarar los factores etiológicos que producen niveles insuficien
tes y marginales de cobalamina sérica en los adultos de Costa Rica para poder de
finir intervenciones sanitarias apropiadas.#^dnd^i2#^tm^les^kDeficiencia de vita
mina B12^i2#^tm^les^kHelicobacter pylori^i2#^tm^les^kCosta Rica^i2#University of
 Costa Rica^dOffice of Postgraduate Studies, (2) Office of Vice-president for Re
search#807-A2-308#Fundación de la Universidad de Costa Rica para la Investigació
n#217#other#34#20070205#5 February 2007#20071107#7 November 2007#a05v22n6.htm##
05720000000000649000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000400090121000300094049000800097158000300105030002400108
03100030013203200020013506500090013701400110014603500100015701201140016701201440
02810100036004250100031004610100039004920700205005310700099007360700067008350831
68300902085000802585085003602593085003902629085002302668083193702691085000804628
08500510463608500390468708500230472605801000474906000460484905800640489506000390
49591170006049980720003050041120009050071110016050161140009050321130016050410020
01305057#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a05v22n6.htm#S#f#3#1#article#1
#oa#en#br1.1#1#3.1#TAB#05#RPSP020#nd#Rev Panam Salud Publica#22#6#20071200#^f396
^l401#1020-4989#<B>Prevalence of mild serum vitamin B<SUB>12</SUB> deficiency in
 rural and urban Costa Rican young adults</B>^len#<B>Prevalencia de la deficienc
ia moderada de vitamina B<SUB>12</SUB> sérica en jóvenes adultos de zonas rurale
s y urbanas de Costa Rica</B>^les#^rND^1A01^nIleana^sHolst-Schumacher#^rND^1A02^
nRafael^sMonge-Rojas#^rND^1A03^nMauro^sBarrantes-Santamaría#University of Costa 
Rica^iA01^1Investigation Center for Abnormal Hemoglobins and Related Sicknesses^
cSan José^pCosta Rica^z2410-2050^e<A HREF="mailto:iholst@cariari.ucr.ac.cr">ihol
st@cariari.ucr.ac.cr</A>#Costa Rican Institute for Research and Education on Nut
rition and Health^iA02^cCartago^pCosta Rica#University of Costa Rica^iA03^1Healt
h Office^cSan José^pCosta Rica#^len^a<B>OBJECTIVE:&nbsp;</B>Recent studies have 
shown an increase of mild serum cobalamin (vitamin B<SUB>12</SUB>) deficiency in
 some Latin American countries; however, no data are available from Costa Rica. 
The purpose of this work was to establish the prevalence of serum vitamin B<SUB>
12</SUB> deficiency among Costa Rican young adults and to study some factors tha
t may help explain the serum cobalamin concentrations. <B>METHODS:&nbsp;</B>A cr
oss-sectional survey was conducted among 400 adults aged 20 to 40 years old from
 urban and rural areas of the central valley of Costa Rica to determine serum vi
tamin B<SUB>12</SUB> levels. Additionally, cobalamin dietary intake and the dete
ction of Helicobacter pylori IgG antibodies were studied as possible determinant
s of the serum vitamin B<SUB>12 </SUB>concentrations. <B>RESULTS:</B>&nbsp;The m
ean serum concentration of vitamin B<SUB>12</SUB> was 268 &plusmn; 125 pmol/L, a
nd no significant differences were found by gender or area. Study data indicate 
an overall prevalence of inadequate serum cobalamin levels of 42.4% (11.2% defic
ient and 31.2% marginal); more than 50% but less than 75% of individuals had an 
intake of vitamin B<SUB>12 </SUB>below the U.S. Estimated Average Requirement (E
AR) and 61.2% had IgG antibodies to <I>H. pylori</I>. <B>CONCLUSIONS:&nbsp;</B>T
he prevalence of mild serum vitamin B<SUB>12</SUB> deficiency in young Costa Ric
an subjects is as high as in other Latin American countries. More investigation 
should be done to elucidate the etiological factors that are generating deficien
t and marginal serum cobalamin levels in Costa Rican adults in order to define a
ppropriate public health actions.#^dnd^i1#^tm^len^kVitamin B 12 deficiency^i1#^t
m^len^k<I>Helicobacter pylori</I>^i1#^tm^len^kCosta Rica^i1#^les^a<B>OBJETIVO:&n
bsp;</B>Aunque estudios recientes han demostrado un incremento en el déficit mod
erado de cobalamina (vitamina B<SUB>12</SUB>) sérica en algunos países de Améric
a Latina, no hay datos de Costa Rica. El propósito de este trabajo fue determina
r la prevalencia de la deficiencia de vitamina B<SUB>12</SUB> sérica en jóvenes 
adultos de Costa Rica y estudiar algunos factores que pueden ayudar a explicar l
as concentraciones séricas de cobalamina. <B>MÉTODOS:&nbsp;</B>Se realizó un est
udio transversal para determinar los niveles de vitamina B<SUB>12</SUB> en el su
ero de 400 adultos de 20 a 40 años de edad de zonas urbanas y rurales del valle 
central de Costa Rica. Adicionalmente, se estudió la ingesta de cobalamina en la
 dieta y la presencia de anticuerpos IgG contra <I>Helicobacter pylori</I>, como
 posibles factores determinantes de las concentraciones séricas de vitamina B<SU
B>12</SUB>. <B>RESULTADOS:</B>&nbsp;La concentración media de vitamina B<SUB>12<
/SUB> en el suero fue de 268 &plusmn; 125 pmol/L; no se encontraron diferencias 
significativas entre los sexos ni entre las áreas de residencia. Estos datos dem
ostraron una prevalencia general de niveles insuficientes de cobalamina sérica d
e 42,4% (11,2% con déficit y 31,2% con concentraciones marginales); de las perso
nas estudiadas más de 50% -aunque menos de 75%- tenían una ingesta de vitamina B
<SUB>12</SUB> por debajo del valor de las necesidades promedio estimadas para lo
s Estados Unidos de América y 61,2% tenía anticuerpos contra H. pylori. <B>CONCL
USIONES:&nbsp;</B>La prevalencia de deficiencia moderada de vitamina B<SUB>12</S
UB> sérica en jóvenes costarricenses es tan elevada como en otros países latinoa
mericanos. Se necesitan más investigaciones para aclarar los factores etiológico
s que producen niveles insuficientes y marginales de cobalamina sérica en los ad
ultos de Costa Rica para poder definir intervenciones sanitarias apropiadas.#^dn
d^i2#^tm^les^kDeficiencia de vitamina B<SUB>12</SUB>^i2#^tm^les^k<I>Helicobacter
 pylori</I>^i2#^tm^les^kCosta Rica^i2#University of Costa Rica^dOffice of Postgr
aduate Studies, (2) Office of Vice-president for Research#<FONT FACE="Verdana" S
IZE=2>807-A2-308</FONT>#Fundación de la Universidad de Costa Rica para la Invest
igación#<FONT FACE="Verdana" SIZE=2>217</FONT>#other#34#20070205#5 February 2007
#20071107#7 November 2007#a05v22n6.htm##
05518000000000673000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700640013000720710003000850400003000880010
00600091042000200097120000400099038000400103121000300107049000800110158000300118
03000260012103100030014703200020015006500090015201400110016103500100017201200960
01820120126002780100036004040100031004400100039004710700161005100700101006710700
06900772083159300841085000802434085003602442085003202478085002302510083186502533
08500080439808500400440608500320444608500230447805801000450106000110460105800640
46120600004046761170006046800720003046861120009046891110016046981140009047141130
01604723002001304739008009204752#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a05v22
n6.htm#S#l#4#1#article#1#^mDec.^a2007#oa#en#br1.1#1#3.1#tab#05#RPSP020#nd#Rev. p
anam. salud pública#22#6#20071200#^f396^l401#1020-4989#Prevalence of mild serum 
vitamin B12 deficiency in rural and urban Costa Rican young adults^len#Prevalenc
ia de la deficiencia moderada de vitamina B12 sérica en jóvenes adultos de zonas
 rurales y urbanas de Costa Rica^les#^rND^1A01^nIleana^sHolst-Schumacher#^rND^1A
02^nRafael^sMonge-Rojas#^rND^1A03^nMauro^sBarrantes-Santamaría#^iA01^1University
 of Costa Rica^2Investigation Center for Abnormal Hemoglobins and Related Sickne
sses^cSan José^pCosta Rica^z2410-2050^eiholst@cariari.ucr.ac.cr#^iA02^1Costa Ric
an Institute for Research and Education on Nutrition and Health^cCartago^pCosta 
Rica#^iA03^1University of Costa Rica^2Health Office^cSan José^pCosta Rica#^len^a
OBJECTIVE: Recent studies have shown an increase of mild serum cobalamin (vitami
n B12) deficiency in some Latin American countries; however, no data are availab
le from Costa Rica. The purpose of this work was to establish the prevalence of 
serum vitamin B12 deficiency among Costa Rican young adults and to study some fa
ctors that may help explain the serum cobalamin concentrations. METHODS: A cross
-sectional survey was conducted among 400 adults aged 20 to 40 years old from ur
ban and rural areas of the central valley of Costa Rica to determine serum vitam
in B12 levels. Additionally, cobalamin dietary intake and the detection of Helic
obacter pylori IgG antibodies were studied as possible determinants of the serum
 vitamin B12 concentrations. RESULTS: The mean serum concentration of vitamin B1
2 was 268 &plusmn; 125 pmol/L, and no significant differences were found by gend
er or area. Study data indicate an overall prevalence of inadequate serum cobala
min levels of 42.4 percent (11.2 percent deficient and 31.2 percent marginal); m
ore than 50 percent but less than 75 percent of individuals had an intake of vit
amin B12 below the U.S. Estimated Average Requirement (EAR) and 61.2 percent had
 IgG antibodies to H. pylori. CONCLUSIONS: The prevalence of mild serum vitamin 
B12 deficiency in young Costa Rican subjects is as high as in other Latin Americ
an countries. More investigation should be done to elucidate the etiological fac
tors that are generating deficient and marginal serum cobalamin levels in Costa 
Rican adults in order to define appropriate public health actions.#^dnd^i1#^tm^l
en^kVitamin B 12 deficiency^i1#^tm^len^kHelicobacter pylori^i1#^tm^len^kCosta Ri
ca^i1#^les^aOBJETIVO: Aunque estudios recientes han demostrado un incremento en 
el déficit moderado de cobalamina (vitamina B12) sérica en algunos países de Amé
rica Latina, no hay datos de Costa Rica. El propósito de este trabajo fue determ
inar la prevalencia de la deficiencia de vitamina B12 sérica en jóvenes adultos 
de Costa Rica y estudiar algunos factores que pueden ayudar a explicar las conce
ntraciones séricas de cobalamina. MÉTODOS: Se realizó un estudio transversal par
a determinar los niveles de vitamina B12 en el suero de 400 adultos de 20 a 40 a
ños de edad de zonas urbanas y rurales del valle central de Costa Rica. Adiciona
lmente, se estudió la ingesta de cobalamina en la dieta y la presencia de anticu
erpos IgG contra Helicobacter pylori, como posibles factores determinantes de la
s concentraciones séricas de vitamina B12. RESULTADOS: La concentración media de
 vitamina B12 en el suero fue de 268 &plusmn; 125 pmol/L; no se encontraron dife
rencias significativas entre los sexos ni entre las áreas de residencia. Estos d
atos demostraron una prevalencia general de niveles insuficientes de cobalamina 
sérica de 42,4 por ciento (11,2 por ciento con déficit y 31,2 por ciento con con
centraciones marginales); de las personas estudiadas más de 50 por ciento -aunqu
e menos de 75 por ciento- tenían una ingesta de vitamina B12 por debajo del valo
r de las necesidades promedio estimadas para los Estados Unidos de América y 61,
2 por ciento tenía anticuerpos contra H. pylori. CONCLUSIONES: La prevalencia de
 deficiencia moderada de vitamina B12 sérica en jóvenes costarricenses es tan el
evada como en otros países latinoamericanos. Se necesitan más investigaciones pa
ra aclarar los factores etiológicos que producen niveles insuficientes y margina
les de cobalamina sérica en los adultos de Costa Rica para poder definir interve
nciones sanitarias apropiadas.#^dnd^i2#^tm^les^kDeficiencia de vitamina B12^i2#^
tm^les^kHelicobacter pylori^i2#^tm^les^kCosta Rica^i2#University of Costa Rica^d
Office of Postgraduate Studies, (2) Office of Vice-president for Research#807-A2
-308#Fundación de la Universidad de Costa Rica para la Investigación#217#other#3
4#20070205#5 February 2007#20071107#7 November 2007#a05v22n6.htm#Internet^ihttp:
//www.scielosp.org/scielo.php?script=sci_arttext&pid=S1020-49892007001100005##
00354000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704012100074002001300195#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a05v22n6.htm#S#p#5#1#article#114#<p align="right"><fon
t size="2" face="Verdana"><b>INVESTIGACI&Oacute;N ORIGINAL</b> ORIGINAL RESEARCH
</font></p>     ^cY#a05v22n6.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a05v22n6.htm#S#p#6#2#article#114#<p>&nbsp;</p>     ^cY
#a05v22n6.htm##
00398000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704016500074002001300239#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a05v22n6.htm#S#p#7#3#article#114#<p><font size="4" fac
e="verdana"><b>Prevalence of mild serum vitamin B<SUB>12</SUB>    deficiency in 
rural and urban Costa Rican young adults</b></font></p>     ^cY#a05v22n6.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a05v22n6.htm#S#p#8#4#article#114#<p>&nbsp;</p>     ^cY
#a05v22n6.htm##
00445000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704021200074002001300286#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a05v22n6.htm#S#p#9#5#article#114#<p><font size="3" fac
e="verdana"><b>Prevalencia de la deficiencia moderada de    vitamina B<SUB>12</S
UB> s&eacute;rica en j&oacute;venes adultos de zonas rurales    y urbanas de Cos
ta Rica</b></font></p>     ^cY#a05v22n6.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704002200075002001300097#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a05v22n6.htm#S#p#10#6#article#114#<p>&nbsp;</p>     ^c
Y#a05v22n6.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704002200075002001300097#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a05v22n6.htm#S#p#11#7#article#114#<p>&nbsp;</p>     ^c
Y#a05v22n6.htm##
00414000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704018000075002001300255#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a05v22n6.htm#S#p#12#8#article#114#<p><font size="2" fa
ce="Verdana"><b>Ileana Holst-Schumacher<sup>I</sup>; Rafael    Monge-Rojas<sup>I
I</sup>; Mauro Barrantes-Santamar&iacute;a<SUP>III</sup></b></font></p>     ^cY#
a05v22n6.htm##
00865000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704063100075002001300706#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a05v22n6.htm#S#p#13#9#article#114#<p><font size="2" fa
ce="Verdana"><SUP>I</sup>University of Costa Rica, Investigation    Center for A
bnormal Hemoglobins and Related Sicknesses, San Pedro de Montes    de Oca, San J
os&eacute;, Costa Rica. Address for correspondence and reprints:    Ileana Holst
-Schumacher, Investigation Center for Abnormal Hemoglobins and Related    Sickne
sses (CIHATA), University of Costa Rica, Postal Code 2410-2050, San Pedro    de 
Montes de Oca, San Jos&eacute;, Costa Rica; fax: (506) 225-2374/(506) 225-5440; 
   telephone: (506) 207-5440/(506) 207-4389; e-mail: <a href="mailto:iholst@cari
ari.ucr.ac.cr">iholst@cariari.ucr.ac.cr</a>    ^cY#a05v22n6.htm##
00377000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704014200076002001300218#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a05v22n6.htm#S#p#14#10#article#114#<br>   <SUP>II</sup
>Costa Rican Institute for Research and Education on Nutrition and    Health, Tr
es R&iacute;os, Cartago, Costa Rica    ^cY#a05v22n6.htm##
00375000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704014000076002001300216#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a05v22n6.htm#S#p#15#11#article#114#<br>   <sup>III</su
p>Health Office, University of Costa Rica, San Pedro de Montes de    Oca, San Jo
s&eacute;, Costa Rica</font></p>     ^cY#a05v22n6.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a05v22n6.htm#S#p#16#12#article#114#<p>&nbsp;</p>     ^
cY#a05v22n6.htm##
00279000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704004400076002001300120#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a05v22n6.htm#S#p#17#13#article#114#<p>&nbsp;</p> <hr s
ize="1" noshade>     ^cY#a05v22n6.htm##
00303000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704006800076002001300144#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a05v22n6.htm#S#p#18#14#article#114#<p><font size="2" f
ace="Verdana"><b>ABSTRACT</b></font></p>     ^cY#a05v22n6.htm##
00708000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704047300076002001300549#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a05v22n6.htm#S#p#19#15#article#114#<p><font size="2" f
ace="Verdana"><B>OBJECTIVE:&nbsp;</b>Recent studies have shown    an increase of
 mild serum cobalamin (vitamin B<SUB>12</SUB>) deficiency in some    Latin Ameri
can countries; however, no data are available from Costa Rica. The    purpose of
 this work was to establish the prevalence of serum vitamin B<SUB>12</SUB>    de
ficiency among Costa Rican young adults and to study some factors that may    he
lp explain the serum cobalamin concentrations.    ^cY#a05v22n6.htm##
00660000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704042500076002001300501#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a05v22n6.htm#S#p#20#16#article#114#<br>   <B>METHODS:&
nbsp;</b>A cross-sectional survey was conducted among 400 adults    aged 20 to 4
0 years old from urban and rural areas of the central valley of    Costa Rica to
 determine serum vitamin B<SUB>12</SUB> levels. Additionally, cobalamin    dieta
ry intake and the detection of Helicobacter pylori IgG antibodies were    studie
d as possible determinants of the serum vitamin B<SUB>12 </SUB>concentrations.  
  ^cY#a05v22n6.htm##
00744000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704050900076002001300585#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a05v22n6.htm#S#p#21#17#article#114#<br>   <B>RESULTS:<
/b>&nbsp;The mean serum concentration of vitamin B<SUB>12</SUB>    was 268 &plus
mn; 125 pmol/L, and no significant differences were found by gender or    area. 
Study data indicate an overall prevalence of inadequate serum cobalamin    level
s of 42.4% (11.2% deficient and 31.2% marginal); more than 50% but less    than 
75% of individuals had an intake of vitamin B<SUB>12 </SUB>below the U.S.    Est
imated Average Requirement (EAR) and 61.2% had IgG antibodies to <i>H. pylori</i
>.    ^cY#a05v22n6.htm##
00656000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704042100076002001300497#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a05v22n6.htm#S#p#22#18#article#114#<br>   <B>CONCLUSIO
NS:&nbsp;</b>The prevalence    of mild serum vitamin B<SUB>12</SUB> deficiency i
n young Costa Rican subjects    is as high as in other Latin American countries.
 More investigation should be    done to elucidate the etiological factors that 
are generating deficient and    marginal serum cobalamin levels in Costa Rican a
dults in order to define appropriate    public health actions.</font></p>     ^c
Y#a05v22n6.htm##
00395000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704016000076002001300236#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a05v22n6.htm#S#p#23#19#article#114#<p><font size="2" f
ace="Verdana"><b>Key words: </b>Vitamin B 12 deficiency,    <i>Helicobacter pylo
ri</i>, Costa Rica.</font></p> <hr size="1" noshade>     ^cY#a05v22n6.htm##
00302000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704006700076002001300143#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a05v22n6.htm#S#p#24#20#article#114#<p><font size="2" f
ace="Verdana"><b>RESUMEN</b></font></p>     ^cY#a05v22n6.htm##
00805000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704057000076002001300646#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a05v22n6.htm#S#p#25#21#article#114#<p><font size="2" f
ace="Verdana"><B>OBJETIVO:&nbsp;</b>Aunque estudios recientes    han demostrado 
un incremento en el d&eacute;ficit moderado de cobalamina (vitamina    B<SUB>12<
/SUB>) s&eacute;rica en algunos pa&iacute;ses de Am&eacute;rica Latina,    no ha
y datos de Costa Rica. El prop&oacute;sito de este trabajo fue determinar    la 
prevalencia de la deficiencia de vitamina B<SUB>12</SUB> s&eacute;rica en    j&o
acute;venes adultos de Costa Rica y estudiar algunos factores que pueden    ayud
ar a explicar las concentraciones s&eacute;ricas de cobalamina.    ^cY#a05v22n6.
htm##
00749000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704051400076002001300590#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a05v22n6.htm#S#p#26#22#article#114#<br>   <B>M&Eacute;
TODOS:&nbsp;</b>Se realiz&oacute; un estudio transversal para determinar    los 
niveles de vitamina B<SUB>12</SUB> en el suero de 400 adultos de 20 a 40    a&nt
ilde;os de edad de zonas urbanas y rurales del valle central de Costa Rica.    A
dicionalmente, se estudi&oacute; la ingesta de cobalamina en la dieta y la    pr
esencia de anticuerpos IgG contra <i>Helicobacter pylori</i>, como posibles    f
actores determinantes de las concentraciones s&eacute;ricas de vitamina B<SUB>12
</SUB>.    ^cY#a05v22n6.htm##
00949000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704071400076002001300790#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a05v22n6.htm#S#p#27#23#article#114#<br>   <B>RESULTADO
S:</b>&nbsp;La concentraci&oacute;n media de vitamina B<SUB>12</SUB>    en el su
ero fue de 268 &plusmn; 125 pmol/L; no se encontraron diferencias significativas
    entre los sexos ni entre las &aacute;reas de residencia. Estos datos demostr
aron    una prevalencia general de niveles insuficientes de cobalamina s&eacute;
rica    de 42,4% (11,2% con d&eacute;ficit y 31,2% con concentraciones marginale
s);    de las personas estudiadas m&aacute;s de 50% —aunque menos de 75%— ten&ia
cute;an    una ingesta de vitamina B<SUB>12</SUB> por debajo del valor de las ne
cesidades    promedio estimadas para los Estados Unidos de Am&eacute;rica y 61,2
% ten&iacute;a    anticuerpos contra H. pylori.    ^cY#a05v22n6.htm##
00723000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704048800076002001300564#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a05v22n6.htm#S#p#28#24#article#114#<br>   <B>CONCLUSIO
NES:&nbsp;</b>La prevalencia de deficiencia moderada de vitamina    B<SUB>12</SU
B> s&eacute;rica en j&oacute;venes costarricenses es tan elevada    como en otro
s pa&iacute;ses latinoamericanos. Se necesitan m&aacute;s investigaciones    par
a aclarar los factores etiol&oacute;gicos que producen niveles insuficientes    
y marginales de cobalamina s&eacute;rica en los adultos de Costa Rica para poder
    definir intervenciones sanitarias apropiadas.</font></p>     ^cY#a05v22n6.ht
m##
00410000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704017500076002001300251#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a05v22n6.htm#S#p#29#25#article#114#<p><font size="2" f
ace="Verdana"><b>Key words: </b>Deficiencia de vitamina B<SUB>12</SUB>,    <i>He
licobacter pylori</i>, Costa Rica.</font></p> <hr size="1" noshade>     ^cY#a05v
22n6.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a05v22n6.htm#S#p#30#26#article#114#<p>&nbsp;</p>     ^
cY#a05v22n6.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a05v22n6.htm#S#p#31#27#article#114#<p>&nbsp;</p>     ^
cY#a05v22n6.htm##
01078000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704084300076002001300919#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a05v22n6.htm#S#p#32#28#article#114#<p><font size="2" f
ace="Verdana">Vitamin B<SUB>12</SUB> or cobalamin deficiency    has been identif
ied frequently in older people and vegetarians (1–3). Nevertheless,    recent st
udies in Latin America have shown a high prevalence of mild serum vitamin    B<S
UB>12 </SUB>deficiency in younger, omnivorous subjects (4, 5). In 1995, a    Cub
an study reported a prevalence of deficient serum vitamin B<SUB>12</SUB>    valu
es ranging from 52 to 82% and marginal values ranging from 13 to 36%, respective
ly,    among a healthy population of middle-aged men (5). In another study, abou
t 45%    of fer- tile women in a rural Mexican community were identified with de
ficient    and marginal serum vitamin B<SUB>12</SUB> concentrations (4). In Cost
a Rica,    cobalamin status has not been assessed among the middle-aged populati
on. </font></p>     ^cY#a05v22n6.htm##
00501000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704026600076002001300342#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a05v22n6.htm#S#p#33#29#article#114#<p><font size="2" f
ace="Verdana">Low concentrations of vitamin B<SUB>12</SUB>    have been associat
ed with megaloblastic anemia (3), neuropsychiatric    manifestations (6), and hy
perhomocysteinemia, an important cardiovascular risk    factor (7).</font></p>  
   ^cY#a05v22n6.htm##
00721000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704048600076002001300562#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a05v22n6.htm#S#p#34#30#article#114#<p><font size="2" f
ace="Verdana">Cobalamin deficiency has been attributed to low    vitamin B<SUB>1
2</SUB> intake or protein-bound vitamin B<SUB>12 </SUB>malabsorption    syndrome
s (8). The low intake of foods with a high content of animal protein—main    die
tary sources of vitamin B<SUB>12</SUB>—markedly limits the intake of this    mic
ronutrient (9, 10), particularly in developing countries where availability    o
f these products is low and their cost is high.</font></p>     ^cY#a05v22n6.htm#
#
00953000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704071800076002001300794#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a05v22n6.htm#S#p#35#31#article#114#<p><font size="2" f
ace="Verdana">In several studies, food-cobalamin malabsorption    (FCM) has been
 associated with atrophic gastritis induced by a bacterium known    as <I>Helico
bacter pylori </I>(11, 12). Lack of or inadequate secretion of intrinsic    fact
or (due to pernicious anemia), gastric acid, and pepsin, which are needed    to 
release and absorb protein-bound cobalamin in food, can cause vitamin B<SUB>12</
SUB>    malabsorption (13). Likewise, hypochlorhydria and bacterial overgrowth i
n the    mucosa can play an important role in the malabsorption process (8, 12).
 Moderate    and high alcohol consumption has also been associated with vitamin 
B<SUB>12    </SUB>deficiency (14, 15). </font></p>     ^cY#a05v22n6.htm##
00577000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704034200076002001300418#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a05v22n6.htm#S#p#36#32#article#114#<p><font size="2" f
ace="Verdana">The purpose of this study was to determine the    prevalence of se
rum cobalamin deficiency among Costa Rican young adults and    to examine whethe
r dietary intake of vitamin B<SUB>12 </SUB>and the presence    of <I>H. pylori <
/I>help to explain serum vitamin B<SUB>12</SUB> concentrations.</font></p>     ^
cY#a05v22n6.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a05v22n6.htm#S#p#37#33#article#114#<p>&nbsp;</p>     ^
cY#a05v22n6.htm##
00316000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704008100076002001300157#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a05v22n6.htm#S#p#38#34#article#114#<p><font size="3" f
ace="Verdana"><b>MATERIALS AND METHODS</b></font></p>     ^cY#a05v22n6.htm##
00311000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704007600076002001300152#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a05v22n6.htm#S#p#39#35#article#114#<p><font size="2" f
ace="Verdana"><b>Study population</b></font></p>     ^cY#a05v22n6.htm##
01000000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704076500076002001300841#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a05v22n6.htm#S#p#40#36#article#114#<p><font size="2" f
ace="Verdana">A total of 400 adults from the central valley    of Costa Rica, ag
ed 20 to 40 years, were recruited for this study. Subjects    were asked to part
icipate through a written circular sent home with about 700    randomly selected
 boys and girls from 20 representative rural and urban schools.    A total of 49
0 adults offered to collaborate, but only 400 of them fulfilled    all the requi
rements for participation in the study. Inclusion criteria included    being of 
Costa Rican nationality and being between 20 and 40 years old. Exclusion    crit
eria included conditions such as vegetarianism, alcoholism, gastrointestinal    
disorders, and chronic diarrhea. Also excluded were people taking vitamin supple
ments.</font></p>     ^cY#a05v22n6.htm##
00313000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704007800076002001300154#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a05v22n6.htm#S#p#41#37#article#114#<p><font size="2" f
ace="Verdana"><b>Ethical procedures</b></font></p>     ^cY#a05v22n6.htm##
00540000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704030500076002001300381#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a05v22n6.htm#S#p#42#38#article#114#<p><font size="2" f
ace="Verdana">Written, informed consent was obtained from all    participants. T
he study protocol was approved by the Ethics Committees of the    Costa Rican In
stitute for Research and Education on Nutrition and Health (INCIENSA)    and the
 University of Costa Rica.</font></p>     ^cY#a05v22n6.htm##
00334000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009900076002001300175#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a05v22n6.htm#S#p#43#39#article#114#<p><font size="2" f
ace="Verdana"><b>Socio-demographic and dietary variables</b></font></p>     ^cY#
a05v22n6.htm##
01458000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704122300076002001301299#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a05v22n6.htm#S#p#44#40#article#114#<p><font size="2" f
ace="Verdana">Information about age, gender, area, economic    level, and vitami
n consumption were collected through validated instruments.    Madrigal's method
 was used to establish the socioeconomic status of study participants    based o
n their possession of various material goods and comforts in their homes    (16)
. Dietary intake of vitamin B<SUB>12</SUB> was determined through the use    of 
semi-quantitative 24-hour recall questionnaires. A series of photographs    of f
ood commonly consumed in Costa Rica and three-dimensional (3-D) food models    w
ere used to estimate portion size. The Food Processor‚ for Windows version    6.
0 (ESHA Research, Salem, Oregon, USA) was used to perform nutrient calculations 
   from dietary data (17). A comparison with the U.S. Estimated Average Requirem
ent    (EAR) for vitamin B<SUB>12 </SUB>was made to evaluate micronutrient intak
e,    and the recommended dietary allowance of 2.4 &#181;g for    vitamin B<SUB>
12</SUB> was considered. The EAR cut-point method (counting the    number of ind
ividuals with normal intake below fixed EAR-based cut-off points)    was used to
 assess the prevalence of inadequate intake of the vitamin (18).</font></p>     
^cY#a05v22n6.htm##
00316000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704008100076002001300157#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a05v22n6.htm#S#p#45#41#article#114#<p><font size="2" f
ace="Verdana"><b>Biochemical variables</b></font></p>     ^cY#a05v22n6.htm##
00739000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704050400076002001300580#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a05v22n6.htm#S#p#46#42#article#114#<p><font size="2" f
ace="Verdana">Blood was drawn after 8–12 hours of fasting by    antecubital veni
puncture according to the procedures of the Clinical and Laboratory    Standards
 Institute (CLSI; formerly the National Committee for Clinical Laboratory    Sta
ndards or NCCLS) (19) and collected into a plain tube for serum vitamin B<SUB>12
</SUB>    and immunological analyses. Serum was separated immediately from the b
lood cells    and stored at –20°C until the tests were performed.</font></p>    
 ^cY#a05v22n6.htm##
01164000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704092900076002001301005#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a05v22n6.htm#S#p#47#43#article#114#<p><font size="2" f
ace="Verdana">Vitamin B<SUB>12 </SUB>serum concentration was    determined with 
a commercial immunoassay using the Abbott IMx<SUP>&reg;</SUP>    System (Abbott 
Laboratories Diagnostics Division, Abbott Park, IL, USA), a fully    automated i
mmunoassay analyzer, and the intra-assay coefficient of variation    was &lt;6%.
 Internal quality control with deficient, normal, and high    serum concentratio
ns of vitamin B<SUB>12 </SUB>was performed to control variability    in the meas
urements. In the cases in which the samples exceeded &plusmn; 2 standard    devi
ations (SDs) of the average control value, the samples were analyzed again.    V
itamin B<SUB>12 </SUB>levels were classified as deficient (&lt;150 pmol/L),    m
arginal (150–221 pmol/L), and adequate (<U>&gt;</u>222 pmol/L) according to    t
he recommendations of the U.S. National Academy of Sciences Institute of Medicin
e    (20).</font></p>     ^cY#a05v22n6.htm##
00759000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704052400076002001300600#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a05v22n6.htm#S#p#48#44#article#114#<p><font size="2" f
ace="Verdana">Qualitative detection of IgG antibodies to <I>Helicobacter    pylo
ri</I> was performed using a commercial enzyme-linked immunoassay (ELISA)    kit
 (Panbio, Brisbane, Queensland, Australia). This test was limited to a sub-sampl
e    of study participants (139 individuals), however, due to its high cost. A r
esult    was considered negative when the test indicated &lt;9 Panbio units, equ
ivocal    when between 9–11 Panbio units, and positive when &gt;11 Panbio units 
(21).</font></p>     ^cY#a05v22n6.htm##
00308000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704007300076002001300149#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a05v22n6.htm#S#p#49#45#article#114#<p><font size="2" f
ace="Verdana"><b>Data analysis</b></font></p>     ^cY#a05v22n6.htm##
00977000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704074200076002001300818#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a05v22n6.htm#S#p#50#46#article#114#<p><font size="2" f
ace="Verdana">Statistical analysis was performed using the    Statistical Packag
e for Social Sciences (SPSS), version 10.0 for Windows (SPSS    Inc., Chicago, I
L, USA, 1999). Continuous variables are summarized using means    &plusmn; SD, a
nd categorical variables are presented as frequency distributions. In    order t
o study the behavior of the variables as age increases, the adult population    
was divided into two groups: 20–29 years and 30–40 years. Student's t-test was  
  used to compare the means of the continuous variables and chi-square tests wer
e    used to compare categorical data. Partial Spearman correlation coefficients
    were calculated to determine association between variables.</font></p>     ^
cY#a05v22n6.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a05v22n6.htm#S#p#51#47#article#114#<p>&nbsp;</p>     ^
cY#a05v22n6.htm##
00302000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704006700076002001300143#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a05v22n6.htm#S#p#52#48#article#114#<p><font size="3" f
ace="Verdana"><b>RESULTS</b></font></p>     ^cY#a05v22n6.htm##
00872000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704063700076002001300713#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a05v22n6.htm#S#p#53#49#article#114#<p><font size="2" f
ace="Verdana">The study sample consisted of 187 men and 213    women with a mean
 age of 32.5 &plusmn; 5.6 years; 76.8% of the individuals came from    urban are
as and 23.2% from rural areas (<a href="#tab01">Table 1</a>). The total    mean 
serum vitamin B<SUB>12</SUB> concentration of the study population was    268 &p
lusmn; 125 pmol/L, and no significant differences were found in the means of    
this micronutrient by gender, area, presence or absence of IgG antibodies for   
 <I>H. pylori</I>, age group (20–29 years or 30–40 years), or socioeconomic leve
l    of the subjects (data not shown).</font></p>     ^cY#a05v22n6.htm##
00271000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704003600076002001300112#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a05v22n6.htm#S#p#54#50#article#114#<p><a name="tab01">
</a></p>     ^cY#a05v22n6.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a05v22n6.htm#S#p#55#51#article#114#<p>&nbsp;</p>     ^
cY#a05v22n6.htm##
00315000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704008000076002001300156#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a05v22n6.htm#S#p#56#52#article#114#<p ALIGN="center"><
img src="/img/revistas/rpsp/v22n6/a05tab01.gif"></p>     ^cY#a05v22n6.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a05v22n6.htm#S#p#57#53#article#114#<p>&nbsp;</p>     ^
cY#a05v22n6.htm##
01046000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704081100076002001300887#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a05v22n6.htm#S#p#58#54#article#114#<p><font size="2" f
ace="Verdana">The overall prevalence of IgG antibodies to <I>H.    pylori</I> in
 the studied population was 61.2%, with a significantly higher    proportion of 
seropositive individuals in urban areas (48.9% vs. 12.2%, respectively;    <I>p<
/I> &lt; 0.001) (<a href="#tab01">Table 1</a>). No differences between    male a
nd female subjects were found in the prevalence of <I>H. pylori</I> antibodies, 
   and the proportion of seropositive individuals in the 30–40-year age group (5
6    out of 85) was higher than in the 20–29-year age group (29 out of 85), alth
ough    the difference was not statistically significant (<I>p</I> = 0.121) (dat
a not    shown). Vitamin B<SUB>12</SUB> average intake was higher than 50% but l
ower    than 75% of the EAR for this micronutrient. </font></p>     ^cY#a05v22n6
.htm##
01355000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704112000076002001301196#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a05v22n6.htm#S#p#59#55#article#114#<p><font size="2" f
ace="Verdana">More than 42% (42.4%) of the study participants    presented eithe
r deficient (11.2%) or marginal levels (31.2%) of serum vitamin    B<SUB>12</SUB
> (<a href="#tab02">Table 2</a>). The proportion of adults <U>&gt;</u>30    year
s old with marginal concentrations of vitamin B<SUB>12</SUB> was significantly  
  higher than the proportion of subjects &lt;30 years old (35.9% vs. 24.5%, resp
ectively;    <I>p</I> = 0.021) (data not shown). Likewise, the proportion of adu
lts with    deficient levels of vitamin B<SUB>12 </SUB>with a low socioeconomic 
profile    was significantly higher than the proportion of individuals with defi
cient vitamin    B<SUB>12 </SUB>concentrations and a high socioeconomic conditio
n (14.8% vs.    3.9%; <I>p</I> = 0.028). Weak associations were found between th
e presence of    IgG antibodies for <I>H. pylori</I> and the age group (<I>r</I>
 = 0.122) and    area (<I>r</I> = 0.110) of the subjects. Likewise, vitamin B<SU
B>12 </SUB>concentrations    levels correlated weakly with study participants' s
ocioeconomic level (<I>r</I>    = 0.114).</font></p>     ^cY#a05v22n6.htm##
00271000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704003600076002001300112#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a05v22n6.htm#S#p#60#56#article#114#<p><a name="tab02">
</a></p>     ^cY#a05v22n6.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a05v22n6.htm#S#p#61#57#article#114#<p>&nbsp;</p>     ^
cY#a05v22n6.htm##
00315000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704008000076002001300156#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a05v22n6.htm#S#p#62#58#article#114#<p align="center"><
img src="/img/revistas/rpsp/v22n6/a05tab02.gif"></p>     ^cY#a05v22n6.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a05v22n6.htm#S#p#63#59#article#114#<p>&nbsp;</p>     ^
cY#a05v22n6.htm##
00305000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704007000076002001300146#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a05v22n6.htm#S#p#64#60#article#114#<p><font size="3" f
ace="Verdana"><b>DISCUSSION</b></font></p>     ^cY#a05v22n6.htm##
01066000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704083100076002001300907#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a05v22n6.htm#S#p#65#61#article#114#<p><font size="2" f
ace="Verdana">For decades, it has been assumed that vitamin    B<SUB>12 </SUB>de
ficiency is unlikely to occur except under special circumstances,    such as the
 presence of pernicious anemia, vegetarianism, malabsorption syndromes,    bacte
rial overgrowth, and other clinical conditions in which the function of    the i
leum is impaired (2, 3). It has also been established that vitamin B<SUB>12</SUB
>    deficiency is common among the elderly, even in industrialized countries. N
evertheless,    reports of cobalamin deficiency status in Latin American childre
n and young    adults have been increasing over the past decade (5, 22, 23), and
 Allen (24)    has recently shown that at least 40% of individuals in the Americ
as had deficient    or marginal levels of serum vitamin B<SUB>12</SUB>. </font><
/p>     ^cY#a05v22n6.htm##
01387000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704115200076002001301228#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a05v22n6.htm#S#p#66#62#article#114#<p><font size="2" f
ace="Verdana">This is the first report indicating deficient    serum vitamin B<S
UB>12 </SUB>concentrations among Costa Ricans. Report    results suggest a signi
ficant problem, with almost 43% of the population presenting    marginal or defi
cient serum levels of cobalamin (<U>&lt;</u> 221 pmol/L). Given    that the stud
y participants were young and apparently healthy, this level of    vitamin B<SUB
>12</SUB> deficiency, which is common among the elderly (largely due to gastric 
atrophy), is striking. A significantly higher proportion    of individuals with 
marginal levels of vitamin B<SUB>12</SUB> was observed in    the older age group
 (30–40-year), clearly suggesting that this deficiency becomes    worse as age i
ncreases. Study data also suggest that the assumption of low prevalence    of vi
tamin B<SUB>12</SUB> deficiency among young adults need to be re-examined,    pa
rticularly because vitamin B<SUB>12</SUB> deficiency has been associated with   
 increased risk of cardiovascular disease and serious neurological manifestation
s,    including the development of Alzheimer's disease and dementia (25).</font>
</p>     ^cY#a05v22n6.htm##
00539000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704030400076002001300380#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a05v22n6.htm#S#p#67#63#article#114#<p><font size="2" f
ace="Verdana">Unlike Costa Rica and other Latin American countries    (24), whic
h have a prevalence of deficient and marginal levels of vitamin B<SUB>12</SUB>  
  of more than 40%, developed countries such as United States have a prevalence 
   of less than 3% (26). </font></p>     ^cY#a05v22n6.htm##
00827000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704059200076002001300668#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a05v22n6.htm#S#p#68#64#article#114#<p><font size="2" f
ace="Verdana">Vitamin B<SUB>12 </SUB>deficiency can occur in    individuals with
 dietary patterns that exclude animal or fortified foods, and    in adults who a
re unable to absorb vitamin B<SUB>12</SUB> from food (8). In    developing count
ries, low serum vitamin B<SUB>12 </SUB>concentrations<SUB>,</SUB>    could be a 
consequence of reduced consumption of animal protein due to its high    cost. Vi
tamin B<SUB>12 </SUB>is provided in foods of animal origin, including    dairy p
roducts and eggs, and is not a normal component of plant-based foods.    </font>
</p>     ^cY#a05v22n6.htm##
00697000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704046200076002001300538#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a05v22n6.htm#S#p#69#65#article#114#<p><font size="2" f
ace="Verdana">In several Latin American countries the diet    is characterized b
y a predominance of vegetables, so intake of dietary vitamin    B<SUB>12</SUB> i
s quite low (9, 10). According to the Food and Agricultural    Organization of t
he United Nations (FAO), per capita intake of animal products    in developing c
ountries constitutes less than one-third of the registered intake    in industri
alized countries (27). </font></p>     ^cY#a05v22n6.htm##
00605000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704037000076002001300446#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a05v22n6.htm#S#p#70#66#article#114#<p><font size="2" f
ace="Verdana">Although this study found no significant correlation    between se
rum vitamin B<SUB>12 </SUB>concentrations and socioeconomic level,    a higher p
revalence of young adults with deficient levels of cobalamin was observed    in 
those from low socioeconomic levels versus those with a higher socioeconomic    
condition. </font></p>     ^cY#a05v22n6.htm##
00608000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704037300076002001300449#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a05v22n6.htm#S#p#71#67#article#114#<p><font size="2" f
ace="Verdana"><I>H. pylori </i>infection has also been associated    with FCM (f
ood-cobalamin malabsorption), in some studies (11, 12, 28), but not    in others
 (29, 30). <I>H. pylori</I> infection induces a reduction in the production    o
f gastric acid and thus limits the release of vitamin    B<SUB>12</SUB> from the
 chymus (31). </font></p>     ^cY#a05v22n6.htm##
01332000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704109700076002001301173#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a05v22n6.htm#S#p#72#68#article#114#<p><font size="2" f
ace="Verdana">The presence of <I>H. pylori </I>IgG antibodies    in serum is hig
hly indicative of <I>H. pylori</I> infection (8) and can therefore    be used as
 a non-invasive means of screening large groups of people. Although,    in this 
study, the prevalence of <I>H. pylori</I> antibodies was high (61.2%),    an ass
ociation could not be ascertained between the presence of this bacterium    and 
deficient or marginal levels of serum vitamin B<SUB>12</SUB>. This situation    
is consistent with the one reported by Van Asselt et al. (8), who determined    
that <I>H. pylori</I> infection was related to atrophic gastritis but could    n
ot determine an association between the infection and mild vitamin B<SUB>12</SUB
>    deficiency. However, Carmel et al. (28) found the presence of IgG antibodie
s    to <I>H. pylori</I> in 75% of patients with severe FCM, and Serin et al. (3
2)    provided strong evidence of association between <I>H. pylori</I> infection
 and    vitamin B<SUB>12</SUB> deficiency, even in patients with minimal or no g
astric    atrophy.</font></p>     ^cY#a05v22n6.htm##
00590000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704035500076002001300431#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a05v22n6.htm#S#p#73#69#article#114#<p><font size="2" f
ace="Verdana">This study could not find an association between    the presence o
f the bacteria and age, probably because the study population    was too young (
mean age: 32.5 years). It is well known that the prevalence of    both <I>H. pyl
ori </I>antibodies and serum cobalamin deficiency increases with    age (8).</fo
nt></p>     ^cY#a05v22n6.htm##
01113000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704087800076002001300954#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a05v22n6.htm#S#p#74#70#article#114#<p><font size="2" f
ace="Verdana">The etiology of mild vitamin B<SUB>12</SUB> deficiency    in young
 Costa Rican subjects is unclear, and its clinical manifestations could    be mi
sdiagnosed if accompanied by high intake of folic acid. Several studies    have 
shown that folic acid deficiency is not a nutritional problem in the adult    Co
sta Rican population (33), probably due to the ongoing policy of fortifying    s
everal foods with synthetic folic acid established by the Costa Rican Ministry  
  of Health in 1997. Although high folic acid intake in the presence of vitamin 
   B<SUB>12 </SUB>deficiency can delay the clinical diagnosis of vitamin B<SUB>1
2    </SUB>deficiency–induced megaloblastic anemia, it does not affect the irrev
ersible    progression of neurological dysfunction and cognitive decline that re
sults from    cobalamin deficiency (6).</font></p>     ^cY#a05v22n6.htm##
01017000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704078200076002001300858#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a05v22n6.htm#S#p#75#71#article#114#<p><font size="2" f
ace="Verdana">More investigation should be done to elucidate    the etiological 
factors that are generating deficient and marginal levels of    serum vitamin B<
SUB>12</SUB> among Costa Rican young adults in order to define    appropriate pu
blic health actions. Synthetic cobalamin food fortification could    be a key st
rategy for public health in Costa Rica as well as other countries    in the Amer
icas where food is fortified with folic acid and vitamin B<SUB>12</SUB>    defic
iency is suspected to be common. The Pan American Health Organization has    ind
icated that the daily intake of 1 &#181;g of synthetic    vitamin B<SUB>12</SUB>
 from fortified foods is a reliable way to optimize the    status of this vitami
n in the Americas (34).</font></p>     ^cY#a05v22n6.htm##
00840000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704060500076002001300681#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a05v22n6.htm#S#p#76#72#article#114#<p><font size="2" f
ace="Verdana">The results of this study regarding intake of    vitamin B<SUB>12<
/SUB> should be interpreted with caution, as in some cases    the 24-hour recall
 questionnaire may have only been applied once among the adult    population (as
 opposed to the three-time intervention considered necessary for    adequate eva
luation nutrient intake). Taking this limitation into account, it    should be n
oted that a higher prevalence of adults with deficient concentrations    of coba
lamin was observed at low socioeconomic levels versus higher socioeconomic    le
vels. </font></p>     ^cY#a05v22n6.htm##
00613000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704037800076002001300454#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a05v22n6.htm#S#p#77#73#article#114#<p><font size="2" f
ace="Verdana">The results of this research indicated a high    prevalence of def
icient and marginal levels of serum vitamin B<SUB>12</SUB>    among Costa Rican 
young adults. However, no significant association was found    among the presenc
e of <I>H. pylori</I>, dietary intake of vitamin B<SUB>12</SUB>,    and serum le
vels of cobalamin. </font></p>     ^cY#a05v22n6.htm##
00738000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704050300076002001300579#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a05v22n6.htm#S#p#78#74#article#114#<p><font size="2" f
ace="Verdana"><B>Acknowledgements. </b>The authors are grateful    to Minor Soto
 Carranza and Roberto Chaves Vega for their help with blood sample    collection
. This work was supported by grants from three sources at the University    of C
osta Rica: (1) Office of Postgraduate Studies, (2) Office of Vice-president    f
or Research (Project 807-A2-308), and (3) Fundaci&oacute;n de la Universidad    
de Costa Rica para la Investigaci&oacute;n (Project 217). &nbsp;</font></p>     
^cY#a05v22n6.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a05v22n6.htm#S#p#79#75#article#114#<p>&nbsp;</p>     ^
cY#a05v22n6.htm##
00305000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704007000076002001300146#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a05v22n6.htm#S#p#80#76#article#114#<p><font size="3" f
ace="Verdana"><b>REFERENCES</b></font></p>     ^cY#a05v22n6.htm##
00572000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704032300078002001300401#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a05v22n6.htm#S#p#81#77#article#114#1#<p><f
ont size="2" face="Verdana">1. Joosten E, Van den Berg A, Riezler R, Naurath    
HJ, Lindenbaum J, Stabler SP, et al. Metabolic evidence that deficiencies of    
vitamin B<SUB>12</SUB> (cobalamin), folate, and vitamin B<SUB>6</SUB> occur    c
ommonly in elderly people. Am J Clin Nutr. 1993;58:468–76.</font></p>     ^cY#a0
5v22n6.htm##
00475000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704022600078002001300304#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a05v22n6.htm#S#p#82#78#article#114#2#<p><f
ont size="2" face="Verdana">2. Lindenbaum J, Rosenberg IH, Wilson PWF, Stabler  
  SP, Allen RH. Prevalence of cobalamin deficiency in the Framingham elderly pop
ulation.    Am J Clin Nutr. 1994;60:2–11.</font></p>     ^cY#a05v22n6.htm##
00545000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704029600078002001300374#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a05v22n6.htm#S#p#83#79#article#114#3#<p><f
ont size="2" face="Verdana">3. Refsum H, Yajnik CS, Gadkari M, Schneede J,    Vo
llset SE, &Ouml;rning L, et al. Hyperhomocysteinemia and elevated methylmalonic 
   acid indicate a high prevalence of cobalamin deficiency in Asian Indians. Am 
   J Clin Nutr. 2001;74:233–41.</font></p>     ^cY#a05v22n6.htm##
00493000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704024400078002001300322#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a05v22n6.htm#S#p#84#80#article#114#4#<p><f
ont size="2" face="Verdana">4. Black AK, Allen LH, Pelto GH, Chavez A. Iron,    
vitamin c and folate status in Mexico: associated factors in men and women and  
  during pregnancy and lactation. J Nutr. 1994;124:1179–88.</font></p>     ^cY#a
05v22n6.htm##
00526000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704027700078002001300355#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a05v22n6.htm#S#p#85#81#article#114#5#<p><f
ont size="2" face="Verdana">5. Arnaud J, Fleites-Mestre P, Chassagne M, Verdura 
   T, Garcia GI, Hernandez-Fernandez T, et al. Vitamin B intake and status in he
althy    Havanan men, 2 years after the Cuban neuropathy epidemic. Br J Nutr. 20
01;85:741–8.</font></p>     ^cY#a05v22n6.htm##
00478000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704022900078002001300307#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a05v22n6.htm#S#p#86#82#article#114#6#<p><f
ont size="2" face="Verdana">6. Lindenbaum J, Healton EB, Savage DG. Neuropsychia
tric    disorders caused by cobalamin deficiency in the absence of anemia or mac
rocytosis.    N Engl J Med. 1988;318:1720–8.</font></p>     ^cY#a05v22n6.htm##
00488000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704023900078002001300317#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a05v22n6.htm#S#p#87#83#article#114#7#<p><f
ont size="2" face="Verdana">7. Molgaard J, Malinow MR, Lassvik C, Holm AC,    Up
son B, Olsson AG. Hyperhomocyst(e)inaemia: an independent risk factor for    int
ermittent claudication. J Intern Med. 1992; 231:272–9.</font></p>     ^cY#a05v22
n6.htm##
00529000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704028000078002001300358#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a05v22n6.htm#S#p#88#84#article#114#8#<p><f
ont size="2" face="Verdana">8. Van Asselt DZB, de Groot L, Van Staveren WA,    B
lom HJ, Biemond I, Hoefnagels WHL. Role of cobalamin intake and atrophic gastrit
is    in mild cobalamin deficiency in older Dutch subjects. Am J Clin Nutr. 1998
;68:    328–34.</font></p>     ^cY#a05v22n6.htm##
00517000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704026800078002001300346#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a05v22n6.htm#S#p#89#85#article#114#9#<p><f
ont size="2" face="Verdana">9. Flores M, Melgar H, Cort&eacute;s C, Rivera    M,
 Rivera J, Sepulveda J. Consumo de energ&iacute;a y nutrimentos en mujeres    me
xicanas en edad reproductiva. Salud P&uacute;blica M&eacute;x. 1998;40: 161–71. 
   </font></p>     ^cY#a05v22n6.htm##
00570000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704032000079002001300399#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a05v22n6.htm#S#p#90#86#article#114#10#<p><
font size="2" face="Verdana">10. Monge-Rojas R, Barrantes M, Holst-Schumacher   
 I, Nu&ntilde;ez-Rivas H, Alfaro T, Rodr&iacute;guez S, et al. Biochemical indic
ators    of nutritional status and dietary intake in Costa Rican Cab&eacute;car 
Indian    adolescents. Food Nutr Bull. 2005;26(1): 3–16.</font></p>     ^cY#a05v
22n6.htm##
00487000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704023700079002001300316#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a05v22n6.htm#S#p#91#87#article#114#11#<p><
font size="2" face="Verdana">11. Shuval-Sudai O, Granot E. An association    bet
ween Helicobacter pylori infection and serum vitamin B<SUB>12</SUB> levels    in
 healthy adults. J Clin Gastroenterol. 2003;36:130–3.</font></p>     ^cY#a05v22n
6.htm##
00497000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704024700079002001300326#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a05v22n6.htm#S#p#92#88#article#114#12#<p><
font size="2" face="Verdana">12. Kaptan K, Beyan C, Ural AU, Cetin T, Avcu    F,
 Gulsen M, et al. Helicobacter pylori—is it a novel causative agent in vitamin  
  B<SUB>12</SUB> deficiency? Arch Intern Med. 2000;160:1349–53.</font></p>     ^
cY#a05v22n6.htm##
00506000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704025600079002001300335#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a05v22n6.htm#S#p#93#89#article#114#13#<p><
font size="2" face="Verdana">13. Ho C, Kauwell GPA, Bailey LB. Practitioners'   
 guide to meeting the vitamin B<SUB>12</SUB> Recommended Dietary Allowance for  
  people aged 51 years and older. J Am Diet Assoc. 1999 Jun;99(6):725–7.</font><
/p>     ^cY#a05v22n6.htm##
00527000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704027700079002001300356#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a05v22n6.htm#S#p#94#90#article#114#14#<p><
font size="2" face="Verdana">14. van Oijen MG, Laheij RJ, de Jong CA, Peters    
WH, Jansen JB. Vitamin B<SUB>12</SUB> status and its association with Helicobact
er    pylori infection in alcohol dependent patients. J Nutr Sci Vitaminol. 2004
;50(5):305–8.</font></p>     ^cY#a05v22n6.htm##
00498000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704024800079002001300327#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a05v22n6.htm#S#p#95#91#article#114#15#<p><
font size="2" face="Verdana">15. Beulens JW, Sierksma A, Schaafsma G, Kok    FJ,
 Struys EA, Jakobs C, et al. Kinetics of homocysteine metabolism after moderate 
   alcohol consumption. Alcohol Clin Exp Res. 2005;29(5):739–45.</font></p>     
^cY#a05v22n6.htm##
00442000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704019200079002001300271#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a05v22n6.htm#S#p#96#92#article#114#16#<p><
font size="2" face="Verdana">16. Madrigal J. La construcci&oacute;n de &iacute;n
dices.    San Jos&eacute; (Costa Rica): Editorial de la Universidad de Costa Ric
a; 1997.</font></p>     ^cY#a05v22n6.htm##
00511000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704026100079002001300340#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a05v22n6.htm#S#p#97#93#article#114#17#<p><
font size="2" face="Verdana">17. ESHA Research. The Food Processor<SUP>&reg;</SU
P>    for Windows: nutrition and fitness software, version 6.0 &#91;computer pro
gram&#93;.    Salem (OR): ESHA Research; 1995. &#91;1 diskette; 1 guide&#93;.</f
ont></p>     ^cY#a05v22n6.htm##
00480000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704023000079002001300309#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a05v22n6.htm#S#p#98#94#article#114#18#<p><
font size="2" face="Verdana">18. Barr SI, Murphy SP and Poos MI. Interpreting   
 and using the dietary references intakes in dietary assessment of individuals  
  and groups. J Am Diet Assoc. 2002;102:780–8.</font></p>     ^cY#a05v22n6.htm##
00502000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704025200079002001300331#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a05v22n6.htm#S#p#99#95#article#114#19#<p><
font size="2" face="Verdana">19. Clinical and Laboratory Standards Institute.   
 Procedures for the collection of diagnostic blood specimens by venipuncture:   
 approved standard. 5th ed. Wayne (PA): CLSI (formerly NCCLS); 2003.</font></p> 
    ^cY#a05v22n6.htm##
00578000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073888000300077704032700080002001300407#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a05v22n6.htm#S#p#100#96#article#114#20#<p>
<font size="2" face="Verdana">20. National Academy of Sciences, Institute of    
Medicine, Food and Nutrition Board. Dietary reference intakes for thiamin, ribof
lavin,    niacin, vitamin B-6, folate, vitamin B-12, pantothenic acid, biotin an
d choline.    Washington: National Academy Press; 1998:8.1–8.59.</font></p>     
^cY#a05v22n6.htm##
00391000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073888000300077704014000080002001300220#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a05v22n6.htm#S#p#101#97#article#114#21#<p>
<font size="2" face="Verdana">21. Helicobacter pylori IgG ELISA Kit. Queensland 
   (Australia): Panbio Limited; 2002.</font></p>     ^cY#a05v22n6.htm##
00584000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073888000300077704033300080002001300413#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a05v22n6.htm#S#p#102#98#article#114#22#<p>
<font size="2" face="Verdana">22. Rogers LM, Boy E, Miller JW, et al. High    pr
evalence of cobalamin deficiency in Guatemalan school children: associations    
with low plasma holotranscobalamin II and elevated serum methylmalonic acid    a
nd plasma homocysteine concentrations. Am J Clin Nutr. 2003;77:433–40.</font></p
>     ^cY#a05v22n6.htm##
00501000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073888000300077704025000080002001300330#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a05v22n6.htm#S#p#103#99#article#114#23#<p>
<font size="2" face="Verdana">23. Casterline JE, Allen LH, Ruel MT. Vitamin    B
<SUB>12</SUB> deficiency is very prevalent in lactating Guatemalan women and    
their infants at three months postpartum. J Nutr. 1997;127:1966–72.</font></p>  
   ^cY#a05v22n6.htm##
00413000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704016100081002001300242#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a05v22n6.htm#S#p#104#100#article#114#24#<p
><font size="2" face="Verdana">24. Allen LH. Folate and vitamin B<SUB>12</SUB>  
  status in the Americas. Nutr Rev. 2004;62(6 Pt 2):S29–33.</font></p>     ^cY#a
05v22n6.htm##
00507000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704025500081002001300336#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a05v22n6.htm#S#p#105#101#article#114#25#<p
><font size="2" face="Verdana">25. Wang, H-X, Wahlin A, Basun H, Fastbom J,    W
inblad B, Fratiglioni L. Vitamin B<SUB>12</SUB> and folate in relation to the   
 development of Alzheimer's disease. Neurology. 2001 May 8;56(9):1188–94.</font>
</p>     ^cY#a05v22n6.htm##
00491000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704023900081002001300320#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a05v22n6.htm#S#p#106#102#article#114#26#<p
><font size="2" face="Verdana">26. Wright JD, Bialostosky K, Gunter EW, Carroll 
   MD, Najjar MF, Bowman BA, et al. Blood folate and vitamin B<SUB>12</SUB>: Uni
ted    States, 1988–94. Vital Health Stat. 1998;243:1–78.</font></p>     ^cY#a05
v22n6.htm##
00585000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704033300081002001300414#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a05v22n6.htm#S#p#107#103#article#114#27#<p
><font size="2" face="Verdana">27. Jutzi S. Food safety: challenges and opportun
ities    facing production of livestock and livestock products. In: Pan American
 Health    Organization. 13th Inter-American Meeting at the Ministerial Level on
 Health    and Agriculture (RIMSA 13); 24–25 Apr 2003; Washington, D.C.</font></
p>     ^cY#a05v22n6.htm##
00441000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704018900081002001300270#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a05v22n6.htm#S#p#108#104#article#114#28#<p
><font size="2" face="Verdana">28. Carmel R, Perez-Perez GI, Blaser MJ. Helicoba
cter    pylori infection and food-cobalamin malabsorption. Dig Dis Sci. 1994;39:
309–14.</font></p>     ^cY#a05v22n6.htm##
00443000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704019100081002001300272#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a05v22n6.htm#S#p#109#105#article#114#29#<p
><font size="2" face="Verdana">29. Perez-Perez GI. Role of Helicobacter pylori  
  infection in the development of pernicious anemia. Clin Infect Dis. 1997;25:10
20–2.    </font></p>     ^cY#a05v22n6.htm##
00551000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704029900081002001300380#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a05v22n6.htm#S#p#110#106#article#114#30#<p
><font size="2" face="Verdana">30. Haruma K, Komoto K, Kawaguchi H, Okamoto    S
, Yoshihara M, Sumii K, et al. Pernicious anemia and Helicobacter pylori infecti
on    in Japan: evaluation in a country with a high prevalence of infection. Am 
J    Gastroenterol. 1995;90:1107–10. </font></p>     ^cY#a05v22n6.htm##
00492000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704024000081002001300321#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a05v22n6.htm#S#p#111#107#article#114#31#<p
><font size="2" face="Verdana">31. El-Omar E, Oien K, El-Nujumi A, Gillen D,    
Wirz A, Dahill S, et al. Helicobacter pylori infection and chronic gastric acid 
   hyposecretion. Gastroenterology. 1997 Jul;113(1):15–24.</font></p>     ^cY#a0
5v22n6.htm##
00531000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704027900081002001300360#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a05v22n6.htm#S#p#112#108#article#114#32#<p
><font size="2" face="Verdana">32. Serin E, Gumurdulu Y, Ozer B, Kayaselcuk    F
, Yilmaz U, Kocak R. Impact of Helicobacter pylori on the development of vitamin
    B<SUB>12</SUB> deficiency in the absence of gastric atrophy. Helicobacter. 2
002;7:337–41.    </font></p>     ^cY#a05v22n6.htm##
00467000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704021500081002001300296#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a05v22n6.htm#S#p#113#109#article#114#33#<p
><font size="2" face="Verdana">33. Chen LT, Rivera MA. The Costa Rican experienc
e:    reduction of neural tube defects following food fortification programs. Nu
tr    Rev. 2004;62(6 Pt 2):S40–3.</font></p>     ^cY#a05v22n6.htm##
00700000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704044800081002001300529#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a05v22n6.htm#S#p#114#110#article#114#34#<p
><font size="2" face="Verdana">34. Pan American Health Organization; Centers    
for Disease Control and Prevention; March of Dimes Birth Defects Foundation;    
United Nations Children's Fund; University of Chile, Institute of Nutrition    a
nd Food Technology. Flour fortification with iron, folic acid and vitamin B<SUB>
12</SUB>.    In: PAHO. Regional meeting report. Oct 9–10 2003; Santiago, Chile. 
Washington:    PAHO; 2004.</font></p>     ^cY#a05v22n6.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a05v22n6.htm#S#p#115#111#article#114#<p>&nbsp;</p>    
 ^cY#a05v22n6.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a05v22n6.htm#S#p#116#112#article#114#<p>&nbsp;</p>    
 ^cY#a05v22n6.htm##
00317000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704008000078002001300158#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a05v22n6.htm#S#p#117#113#article#114#<p><font size="2"
 face="Verdana">Manuscript received on 5 February 2007.    ^cY#a05v22n6.htm##
00324000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704008700078002001300165#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a05v22n6.htm#S#p#118#114#article#114#<br>   Revised ve
rsion accepted for publication on 7 November 2007.</font></p>     ^cY#a05v22n6.h
tm##
00744000000000337000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100017000770100022000940100
01700116010001800133010002000151010001800171810000600189012012500195030001500320
06500090033506400050034403100030034901400070035286500090035900200130036803500100
0381801001500391#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a05v22n6.htm#S#c#119#1
#article#34#1#^rND^sJoosten^nE#^rND^sVan den Berg^nA#^rND^sRiezler^nR#^rND^sNaur
ath^nHJ#^rND^sLindenbaum^nJ#^rND^sStabler^nSP#et al#Metabolic evidence that defi
ciencies of vitamin B12 (cobalamin), folate, and vitamin B6 occur commonly in el
derly people^len#Am J Clin Nutr#19930000#1993#58#468-76#20071200#a05v22n6.htm#00
02-9165#Am J Clin Nutr##
00643000000000313000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100020000770100020000970100
01800117010001800135010001600153012007600169030001500245065000900260064000500269
031000300274014000500277865000900282002001300291035001000304801001500314#v22n6#v
:\scielo\serial\rpsp\v22n6\markup\a05v22n6.htm#S#c#120#2#article#34#2#^rND^sLind
enbaum^nJ#^rND^sRosenberg^nIH#^rND^sWilson^nPWF#^rND^sStabler^nSP#^rND^sAllen^nR
H#Prevalence of cobalamin deficiency in the Framingham elderly population^len#Am
 J Clin Nutr#19940000#1994#60#2-11#20071200#a05v22n6.htm#0002-9165#Am J Clin Nut
r##
00734000000000337000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100016000770100017000930100
01700110010001800127010001800145010001600163810000600179012012500185030001500310
06500090032506400050033403100030033901400070034286500090034900200130035803500100
0371801001500381#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a05v22n6.htm#S#c#121#3
#article#34#3#^rND^sRefsum^nH#^rND^sYajnik^nCS#^rND^sGadkari^nM#^rND^sSchneede^n
J#^rND^sVollset^nSE#^rND^sÖrning^nL#et al#Hyperhomocysteinemia and elevated meth
ylmalonic acid indicate a high prevalence of cobalamin deficiency in Asian India
ns^len#Am J Clin Nutr#20010000#2001#74#233-41#20071200#a05v22n6.htm#0002-9165#Am
 J Clin Nutr##
00635000000000301000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100016000770100016000930100
01600109010001600125012012000141030000700261065000900268064000500277031000400282
014000800286865000900294002001300303035001000316801000700326#v22n6#v:\scielo\ser
ial\rpsp\v22n6\markup\a05v22n6.htm#S#c#122#4#article#34#4#^rND^sBlack^nAK#^rND^s
Allen^nLH#^rND^sPelto^nGH#^rND^sChavez^nA#Iron, vitamin c and folate status in M
exico: associated factors in men and women and during pregnancy and lactation^le
n#J Nutr#19940000#1994#124#1179-88#20071200#a05v22n6.htm#0022-3166#J Nutr##
00718000000000337000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100016000770100024000930100
01900117010001700136010001700153010002900170810000600199012010000205030001000305
06500090031506400050032403100030032901400060033286500090033800200130034703500100
0360801001000370#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a05v22n6.htm#S#c#123#5
#article#34#5#^rND^sArnaud^nJ#^rND^sFleites-Mestre^nP#^rND^sChassagne^nM#^rND^sV
erdura^nT#^rND^sGarcia^nGI#^rND^sHernandez-Fernandez^nT#et al#Vitamin B intake a
nd status in healthy Havanan men, 2 years after the Cuban neuropathy epidemic^le
n#Br J Nutr#20010000#2001#85#741-8#20071200#a05v22n6.htm#0007-1145#Br J Nutr##
00608000000000289000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100020000770100018000970100
01700115012010300132030001300235065000900248064000500257031000400262014000700266
865000900273002001300282035001000295801001300305#v22n6#v:\scielo\serial\rpsp\v22
n6\markup\a05v22n6.htm#S#c#124#6#article#34#6#^rND^sLindenbaum^nJ#^rND^sHealton^
nEB#^rND^sSavage^nDG#Neuropsychiatric disorders caused by cobalamin deficiency i
n the absence of anemia or macrocytosis^len#N Engl J Med#19880000#1988#318#1720-
8#20071200#a05v22n6.htm#0028-4793#N Engl J Med##
00671000000000325000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100018000770100018000950100
01700113010001500130010001500145010001700160012008600177030001300263065000900276
06400050028503100040029001400060029486500090030000200130030903500100032280100130
0332#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a05v22n6.htm#S#c#125#7#article#34#
7#^rND^sMolgaard^nJ#^rND^sMalinow^nMR#^rND^sLassvik^nC#^rND^sHolm^nAC#^rND^sUpso
n^nB#^rND^sOlsson^nAG#Hyperhomocyst(e)inaemia: an independent risk factor for in
termittent claudication^len#J Intern Med#19920000#1992#231#272-9#20071200#a05v22
n6.htm#0954-6820#J Intern Med##
00711000000000325000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100022000770100018000990100
02300117010001500140010001700155010002200172012010500194030001500299065000900314
06400050032303100030032801400070033186500090033800200130034703500100036080100150
0370#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a05v22n6.htm#S#c#126#8#article#34#
8#^rND^sVan Asselt^nDZB#^rND^sde Groot^nL#^rND^sVan Staveren^nWA#^rND^sBlom^nHJ#
^rND^sBiemond^nI#^rND^sHoefnagels^nWHL#Role of cobalamin intake and atrophic gas
tritis in mild cobalamin deficiency in older Dutch subjects^len#Am J Clin Nutr#1
9980000#1998#68#328-34#20071200#a05v22n6.htm#0002-9165#Am J Clin Nutr##
00673000000000325000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100016000770100016000930100
01600109010001600125010001600141010001900157012007900176030001800255065000900273
06400050028203100030028701400070029086500090029700200130030603500100031980100180
0329#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a05v22n6.htm#S#c#127#9#article#34#
9#^rND^sFlores^nM#^rND^sMelgar^nH#^rND^sCortés^nC#^rND^sRivera^nM#^rND^sRivera^n
J#^rND^sSepulveda^nJ#Consumo de energía y nutrimentos en mujeres mexicanas en ed
ad reproductiva^les#Salud Pública Méx#19980000#1998#40#161-71#20071200#a05v22n6.
htm#0036-3634#Salud pública Méx##
00753000000000349000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100021000790100019001000100
02600119010002100145010001600166010001900182810000600201012011000207030001500317
06500090033206400050034103100030034603200020034901400050035186500090035600200130
0365035001000378801001500388#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a05v22n6.h
tm#S#c#128#10#article#34#10#^rND^sMonge-Rojas^nR#^rND^sBarrantes^nM#^rND^sHolst-
Schumacher^nI#^rND^sNuñez-Rivas^nH#^rND^sAlfaro^nT#^rND^sRodríguez^nS#et al#Bioc
hemical indicators of nutritional status and dietary intake in Costa Rican Cabéc
ar Indian adolescents^len#Food Nutr Bull#20050000#2005#26#1#3-16#20071200#a05v22
n6.htm#0379-5721#Food Nutr Bull##
00596000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100022000790100016001010120
10400117030002100221065000900242064000500251031000300256014000600259865000900265
002001300274035001000287801002100297#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a0
5v22n6.htm#S#c#129#11#article#34#11#^rND^sShuval-Sudai^nO#^rND^sGranot^nE#An ass
ociation between Helicobacter pylori infection and serum vitamin B12 levels in h
ealthy adults^len#J Clin Gastroenterol#20030000#2003#36#130-3#20071200#a05v22n6.
htm#0192-0790#J Clin Gastroenterol##
00617000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100015000950100
01500110010001500125010001400140010001600154810000600170012008100176030002200257
710000200279031000400281014000800285865000900293002001300302#v22n6#v:\scielo\ser
ial\rpsp\v22n6\markup\a05v22n6.htm#S#c#130#12#article#34#12#^rND^sKaptan^nK#^rND
^sBeyan^nC#^rND^sUral^nAU#^rND^sCetin^nT#^rND^sAvcu^nF#^rND^sGulsen^nM#et al#Hel
icobacter pylori-is it a novel causative agent in vitamin B12 deficiency?^len#Ar
ch Intern Med. 2000#2#160#1349-53#20071200#a05v22n6.htm##
00639000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100012000790100019000910100
01700110012011700127030001600244065000900260064000900269031000300278032000200281
014000600283865000900289002001300298035001000311801001600321#v22n6#v:\scielo\ser
ial\rpsp\v22n6\markup\a05v22n6.htm#S#c#131#13#article#34#13#^rND^sHo^nC#^rND^sKa
uwell^nGPA#^rND^sBailey^nLB#Practitioners' guide to meeting the vitamin B12 Reco
mmended Dietary Allowance for people aged 51 years and older^len#J Am Diet Assoc
#19990600#1999 Jun#99#6#725-7#20071200#a05v22n6.htm#0002-8223#J Am Diet Assoc##
00660000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100020000790100017000990100
01800116010001700134010001700151012010800168030002100276710000200297065000900299
064000500308031000300313032000200316014000600318865000900324002001300333#v22n6#v
:\scielo\serial\rpsp\v22n6\markup\a05v22n6.htm#S#c#132#14#article#34#14#^rND^sva
n Oijen^nMG#^rND^sLaheij^nRJ#^rND^sde Jong^nCA#^rND^sPeters^nWH#^rND^sJansen^nJB
#Vitamin B12 status and its association with Helicobacter pylori infection in al
cohol dependent patients^len#J Nutr Sci Vitaminol#2#20040000#2004#50#5#305-8#200
71200#a05v22n6.htm##
00712000000000349000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100018000970100
01900115010001400134010001700148010001600165810000600181012007500187030002100262
06500090028306400050029203100030029703200020030001400070030286500090030900200130
0318035001000331801002100341#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a05v22n6.h
tm#S#c#133#15#article#34#15#^rND^sBeulens^nJW#^rND^sSierksma^nA#^rND^sSchaafsma^
nG#^rND^sKok^nFJ#^rND^sStruys^nEA#^rND^sJakobs^nC#et al#Kinetics of homocysteine
 metabolism after moderate alcohol consumption^len#Alcohol Clin Exp Res#20050000
#2005#29#5#739-45#20071200#a05v22n6.htm#0145-6008#Alcohol Clin Exp Res##
00458000000000229000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760160019000790180031000980660
02100129062004200150065000900192064000500201865000900206002001300215#v22n6#v:\sc
ielo\serial\rpsp\v22n6\markup\a05v22n6.htm#S#c#134#16#article#34#16#^rND^sMadrig
al^nJ.#La construcción de índices^les#San José^eCosta Rica#Editorial de la Unive
rsidad de Costa Rica#19970000#1997#20071200#a05v22n6.htm##
00526000000000253000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760170014000790180100000930660
01000193062001400203065000900217064000500226061001100231061000800242865000900250
002001300259#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a05v22n6.htm#S#c#135#17#ar
ticle#34#17#ESHA Research#The Food Processor® for Windows: nutrition and fitness
 software, version 6.0 [computer program]^len#Salem^eOR#ESHA Research#19950000#1
995#1 diskette#1 guide#20071200#a05v22n6.htm##
00589000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100015000790100017000940100
01500111012010600126030001600232031000500248032000400253014000600257865000900263
002001300272035001000285801001600295#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a0
5v22n6.htm#S#c#136#18#article#34#18#^rND^sBarr^nSI#^rND^sMurphy^nSP#^rND^sPoos^n
MI#Interpreting and using the dietary references intakes in dietary assessment o
f individuals and groups^len#J Am Diet Assoc#2002#102#780-8#20071200#a05v22n6.ht
m#0002-8223#J Am Diet Assoc##
00524000000000241000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760170034000790180099001130630
00200212066001000214062002200224065000900246064000500255865000900260002001300269
#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a05v22n6.htm#S#c#137#19#article#34#19#
Clinical and Laboratory Standards#Procedures for the collection of diagnostic bl
ood specimens by venipuncture: approved standard^len#5#Wayne^ePA#CLSI (formerly 
NCCLS)#20030000#2003#20071200#a05v22n6.htm##
00651000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760110029000790110048001080120
14700156030002300303710000200326065000900328064000500337031000200342014000400344
020000300348865000900351002001300360#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a0
5v22n6.htm#S#c#138#20#article#34#20#National Academy of Sciences#Institute of Me
dicine, Food and Nutrition Board#Dietary reference intakes for thiamin, riboflav
in, niacin, vitamin B-6, folate, vitamin B-12, pantothenic acid, biotin and chol
ine. Washington^len#National Academy Press#2#19980000#1998#8#1-8#59#20071200#a05
v22n6.htm##
00419000000000229000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760180038000790660011001170670
01000128062001500138065000900153064000500162865000900167002001300176#v22n6#v:\sc
ielo\serial\rpsp\v22n6\markup\a05v22n6.htm#S#c#139#21#article#34#21#Helicobacter
 pylori IgG ELISA Kit^len#Queensland#Australia#Panbio Limited#20020000#2002#2007
1200#a05v22n6.htm##
00723000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100013000960100
01700109810000600126012020300132030001500335065000900350064000500359031000300364
014000700367865000900374002001300383035001000396801001500406#v22n6#v:\scielo\ser
ial\rpsp\v22n6\markup\a05v22n6.htm#S#c#140#22#article#34#22#^rND^sRogers^nLM#^rN
D^sBoy^nE#^rND^sMiller^nJW#et al#High prevalence of cobalamin deficiency in Guat
emalan school children: associations with low plasma holotranscobalamin II and e
levated serum methylmalonic acid and plasma homocysteine concentrations^len#Am J
 Clin Nutr#20030000#2003#77#433-40#20071200#a05v22n6.htm#0002-9165#Am J Clin Nut
r##
00613000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100021000790100016001000100
01500116012012000131030000700251065000900258064000500267031000400272014000800276
865000900284002001300293035001000306801000700316#v22n6#v:\scielo\serial\rpsp\v22
n6\markup\a05v22n6.htm#S#c#141#23#article#34#23#^rND^sCasterline^nJE#^rND^sAllen
^nLH#^rND^sRuel^nMT#Vitamin B12 deficiency is very prevalent in lactating Guatem
alan women and their infants at three months postpartum^len#J Nutr#19970000#1997
#127#1966-72#20071200#a05v22n6.htm#0022-3166#J Nutr##
00516000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790120050000950300
00900145065000900154064000500163031000300168032000200171061000500173014000700178
865000900185002001300194035001000207801000900217#v22n6#v:\scielo\serial\rpsp\v22
n6\markup\a05v22n6.htm#S#c#142#24#article#34#24#^rND^sAllen^nLH#Folate and vitam
in B12 status in the Americas^len#Nutr Rev#20040000#2004#62#6#Pt 2#S29-33#200712
00#a05v22n6.htm#0029-6643#Nutr Rev##
00685000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100016000950100
01500111010001700126010001700143010002100160012008100181030001000262065000900272
06400110028103100030029203200020029501400080029786500090030500200130031403500100
0327801001000337#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a05v22n6.htm#S#c#143#2
5#article#34#25#^rND^sWang^nH-X#^rND^sWahlin^nA#^rND^sBasun^nH#^rND^sFastbom^nJ#
^rND^sWinblad^nB#^rND^sFratiglioni^nL#Vitamin B12 and folate in relation to the 
development of Alzheimer's disease^len#Neurology#20010508#2001 May 8#56#9#1188-9
4#20071200#a05v22n6.htm#0028-3878#Neurology##
00640000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100021000960100
01700117010001800134010001700152010001700169810000600186012005700192030001800249
71000020026706500090026906400050027803100040028301400050028786500090029200200130
0301#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a05v22n6.htm#S#c#144#26#article#34
#26#^rND^sWright^nJD#^rND^sBialostosky^nK#^rND^sGunter^nEW#^rND^sCarroll^nMD#^rN
D^sNajjar^nMF#^rND^sBowman^nBA#et al#Blood folate and vitamin B12: United States
, 1988-94^len#Vital Health Stat#2#19980000#1998#243#1-78#20071200#a05v22n6.htm##
00626000000000241000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100015000790120100000940170
03300194018009400227065000900321064001500330066001700345865000900362002001300371
#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a05v22n6.htm#S#c#145#27#article#34#27#
^rND^sJutzi^nS#Food safety: challenges and opportunities facing production of li
vestock and livestock products^len#Pan American Health Organization#13th Inter-A
merican Meeting at the Ministerial Level on Health and Agriculture (RIMSA 13)^le
n#20030425#24-25 Apr 2003#Washington^eD.C.#20071200#a05v22n6.htm##
00571000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100022000950100
01700117012006700134030001200201065000900213064000500222031000300227014000700230
865000900237002001300246035001000259801001200269#v22n6#v:\scielo\serial\rpsp\v22
n6\markup\a05v22n6.htm#S#c#146#28#article#34#28#^rND^sCarmel^nR#^rND^sPerez-Pere
z^nGI#^rND^sBlaser^nMJ#Helicobacter pylori infection and food-cobalamin malabsor
ption^len#Dig Dis Sci#19940000#1994#39#309-14#20071200#a05v22n6.htm#0163-2116#Di
g Dis Sci##
00537000000000265000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100022000790120082001010300
01600183065000900199064000500208031000300213014000700216865000900223002001300232
035001000245801001600255#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a05v22n6.htm#S
#c#147#29#article#34#29#^rND^sPerez-Perez^nGI#Role of Helicobacter pylori infect
ion in the development of pernicious anemia^len#Clin Infect Dis#19970000#1997#25
#1020-2#20071200#a05v22n6.htm#1058-4838#Clin Infect Dis##
00746000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100016000950100
01900111010001700130010001900147010001500166810000600181012012600187030001900313
06500090033206400050034103100030034601400080034986500090035700200130036603500100
0379801001900389#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a05v22n6.htm#S#c#148#3
0#article#34#30#^rND^sHaruma^nK#^rND^sKomoto^nK#^rND^sKawaguchi^nH#^rND^sOkamoto
^nS#^rND^sYoshihara^nM#^rND^sSumii^nK#et al#Pernicious anemia and Helicobacter p
ylori infection in Japan: evaluation in a country with a high prevalence of infe
ction^len#Am J Gastroenterol#19950000#1995#90#1107-10#20071200#a05v22n6.htm#0002
-9270#Am J Gastroenterol##
00700000000000349000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100014000960100
01900110010001600129010001400145010001600159810000600175012007300181030001700254
06500090027106400090028003100040028903200020029301400060029586500090030100200130
0310035001000323801001700333#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a05v22n6.h
tm#S#c#149#31#article#34#31#^rND^sEl-Omar^nE#^rND^sOien^nK#^rND^sEl-Nujumi^nA#^r
ND^sGillen^nD#^rND^sWirz^nA#^rND^sDahill^nS#et al#Helicobacter pylori infection 
and chronic gastric acid hyposecretion^len#Gastroenterology#19970700#1997 Jul#11
3#1#15-24#20071200#a05v22n6.htm#0016-5085#Gastroenterology##
00698000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100015000790100019000940100
01400113010002000127010001600147010001500163012011300178030001300291065000900304
06400050031303100020031801400070032086500090032700200130033603500100034980100130
0359#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a05v22n6.htm#S#c#150#32#article#34
#32#^rND^sSerin^nE#^rND^sGumurdulu^nY#^rND^sOzer^nB#^rND^sKayaselcuk^nF#^rND^sYi
lmaz^nU#^rND^sKocak^nR#Impact of Helicobacter pylori on the development of vitam
in B12 deficiency in the absence of gastric atrophy^len#Helicobacter#20020000#20
02#7#337-41#20071200#a05v22n6.htm#1083-4389#HELICOBACTER##
00596000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100015000790100017000940120
10300111030000900214065000900223064000500232031000300237032000200240061000500242
014000600247865000900253002001300262035001000275801000900285#v22n6#v:\scielo\ser
ial\rpsp\v22n6\markup\a05v22n6.htm#S#c#151#33#article#34#33#^rND^sChen^nLT#^rND^
sRivera^nMA#The Costa Rican experience: reduction of neural tube defects followi
ng food fortification programs^len#Nutr Rev#20040000#2004#62#6#Pt 2#S40-3#200712
00#a05v22n6.htm#0029-6643#Nutr Rev##
00839000000000349000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760110033000790110043001120110
04000155011003100195011006400226012006200290052000800352053002700360055001200387
05400170039905600120041605700090042806600110043706200050044806500090045306400050
0462865000900467002001300476#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a05v22n6.h
tm#S#c#152#34#article#34#34#Pan American Health Organization#Centers for Disease
 Control and Prevention#March of Dimes Birth Defects Foundation#United Nations C
hildren's Fund#University of Chile^dInstitute of Nutrition and Food Technology#F
lour fortification with iron, folic acid and vitamin B12^len#PAHO^i1#Regional me
eting report^i1#20031010^i1#Oct 9-10 2003^i1#Santiago^i1#Chile^i1#Washington#PAH
O#20040000#2004#20071200#a05v22n6.htm##
00271000000000169000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670910009000690920007000780020013000857030
00300098#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a06v22n6.htm#S#o#1#1#text#1#20
080215#102629#a06v22n6.htm#16##
00603000000000337000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670710003000690400003000720010006000750420
00200081120000400083038000300087121000300090049000800093158000300101030002400104
03100030012803200020013106500090013301400110014203500100015312300020016301200870
0165002001300252#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a06v22n6.htm#S#h#2#1#t
ext#1#co#es#br1.1#1#3.1#ND#06#RPSP030#nd#Rev Panam Salud Publica#22#6#20071200#^
f402^l402#1020-4989#1#Eficacia de la vacuna contra la influenza y su impacto en 
las inequidades en salud^les#a06v22n6.htm##
00610000000000337000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670710003000690400003000720010006000750420
00200081120000400083038000300087121000300090049000800093158000300101030002400104
03100030012803200020013106500090013301400110014203500100015312300020016301200940
0165002001300259#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a06v22n6.htm#S#f#3#1#t
ext#1#co#es#br1.1#1#3.1#ND#06#RPSP030#nd#Rev Panam Salud Publica#22#6#20071200#^
f402^l402#1020-4989#1#<B>Eficacia de la vacuna contra la influenza y su impacto 
en las inequidades en salud</B>^les#a06v22n6.htm##
00719000000000349000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670640013000690710003000820400003000850010
00600088042000200094120000400096121000300100049000800103158000300111030002600114
03100030014003200020014306500090014501400110015403500100016512300020017501200870
0177002001300264008009200277#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a06v22n6.h
tm#S#l#4#1#text#1#^mdic.^a2007#co#es#br1.1#1#3.1#06#RPSP030#nd#Rev. panam. salud
 pública#22#6#20071200#^f402^l402#1020-4989#1#Eficacia de la vacuna contra la in
fluenza y su impacto en las inequidades en salud^les#a06v22n6.htm#Internet^ihttp
://www.scielosp.org/scielo.php?script=sci_arttext&pid=S1020-49892007001100006##
00322000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704009300070002001300163#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a06v22n6.htm#S#p#5#1#text#12#<p align="right"><font si
ze="2" face="Verdana"><b>INSTANT&Aacute;NEAS</b></font></p>     ^cY#a06v22n6.htm
##
00251000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704002200070002001300092#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a06v22n6.htm#S#p#6#2#text#12#<p>&nbsp;</p>     ^cY#a06
v22n6.htm##
00374000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704014500070002001300215#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a06v22n6.htm#S#p#7#3#text#12#<p><font size="4" face="v
erdana"><b>Eficacia de la vacuna contra la influenza    y su impacto en las ineq
uidades en salud</b></font></p>     ^cY#a06v22n6.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704002200070002001300092#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a06v22n6.htm#S#p#8#4#text#12#<p>&nbsp;</p>     ^cY#a06
v22n6.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704002200070002001300092#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a06v22n6.htm#S#p#9#5#text#12#<p>&nbsp;</p>     ^cY#a06
v22n6.htm##
01150000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704092000071002001300991#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a06v22n6.htm#S#p#10#6#text#12#<p><font size="2" face="
Verdana">En la d&eacute;cada de 1990, la vacunaci&oacute;n    contra la influenz
a se encontraba entre las intervenciones sanitarias dirigidas    a los adultos m
ayores m&aacute;s efectivas en funci&oacute;n del costo y su    aplicaci&oacute;
n se consideraba una medida indispensable en la atenci&oacute;n    de este sensi
ble grupo de la poblaci&oacute;n. Por otra parte, se ha establecido    que la im
plementaci&oacute;n de programas sanitarios, como la vacunaci&oacute;n,    puede
 llevar a un aumento en las inequidades en salud y se ha empleado la hip&oacute;
tesis    de la equidad inversa para explicar ese efecto. Seg&uacute;n esta hip&o
acute;tesis,    las mejoras generales logradas mediante estas intervenciones alc
anzan primero    a los grupos sociales de mejor situaci&oacute;n econ&oacute;mic
a que a los m&aacute;s    pobres, lo que aumenta la brecha de desigualdades.</fo
nt></p>     ^cY#a06v22n6.htm##
01054000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704082400071002001300895#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a06v22n6.htm#S#p#11#7#text#12#<p><font size="2" face="
Verdana">La vacunaci&oacute;n de los ancianos que viven    en la comunidad tiene
 detractores. Algunos autores consideran que la mayor efectividad    se logra en
 adultos mayores que permanecen en instituciones —como hogares de    ancianos— p
or largos per&iacute;odos de tiempo, a pesar de reconocer su efecto    ben&eacut
e;fico general en cuanto a evitar complicaciones secundarias y hospitalizaciones
    y reducir el riesgo de muerte. Sin embargo, la informaci&oacute;n disponible
    proviene principalmente de estudios realizados en pa&iacute;ses templados. E
n    los pa&iacute;ses tropicales y de clima c&aacute;lido no se ha establecido 
totalmente    la magnitud de la carga de la influenza y no se ha estudiado adecu
adamente la    eficacia de la vacuna contra esta enfermedad.</font></p>     ^cY#
a06v22n6.htm##
00895000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704066500071002001300736#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a06v22n6.htm#S#p#12#8#text#12#<p><font size="2" face="
Verdana">En este estudio se evalu&oacute; la eficacia    de la vacunaci&oacute;n
 contra la influenza en personas de 65 a&ntilde;os de    edad o m&aacute;s de la
 ciudad de S&atilde;o Paulo, Brasil. Para ello se estim&oacute;    la reducci&oa
cute;n de la mortalidad atribuible a esta enfermedad antes de la    implementaci
&oacute;n de las campa&ntilde;as de vacunaci&oacute;n (1993–1997)    y despu&eac
ute;s (1998–2002), cuando la vacunaci&oacute;n abarcaba m&aacute;s    de 60% de 
los adultos mayores. Adem&aacute;s, se evalu&oacute; la magnitud de    las difer
encias en la mortalidad de las diferentes zonas de la ciudad.</font></p>     ^cY
#a06v22n6.htm##
00955000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704072500071002001300796#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a06v22n6.htm#S#p#13#9#text#12#<p><font size="2" face="
Verdana">Se observ&oacute; una notable reducci&oacute;n    en la mortalidad por 
neumon&iacute;a e influenza en las personas de 65 a&ntilde;os    o m&aacute;s du
rante el per&iacute;odo posterior a la vacunaci&oacute;n. El    n&uacute;mero de
 hospitalizaciones por neumon&iacute;a se redujo en 19,1% en    ese grupo de eda
d en las temporadas invernales (de junio a agosto) en el per&iacute;odo    1999–
2001, en comparaci&oacute;n con los a&ntilde;os que precedieron a la vacunaci&oa
cute;n.    No se encontr&oacute; reducci&oacute;n alguna en el n&uacute;mero de 
hospitalizaciones    o de muertes por neumon&iacute;a e influenza en los grupos 
de personas menores    de 65 a&ntilde;os.</font></p>     ^cY#a06v22n6.htm##
00998000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704076700072002001300839#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a06v22n6.htm#S#p#14#10#text#12#<p><font size="2" face=
"Verdana">La reducci&oacute;n proporcional en la mortalidad    por neumon&iacute
;a e influenza en cada distrito de la ciudad permiti&oacute;    identificar un p
atr&oacute;n geogr&aacute;fico. Las zonas centrales de la ciudad    —ocupadas po
r familias de mejor situaci&oacute;n socioecon&oacute;mica— mostraron    una men
or reducci&oacute;n, mientras que las zonas con reducciones medias o    elevadas
 en la mortalidad por estas causas se caracterizaban por una mayor pobreza.    E
stos resultados indican que los segmentos de la poblaci&oacute;n que viv&iacute;
an    en &aacute;reas m&aacute;s pobres de la ciudad se beneficiaron m&aacute;s 
con    la vacunaci&oacute;n que los que viv&iacute;an en las zonas m&aacute;s ri
cas.</font></p>     ^cY#a06v22n6.htm##
00699000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704046800072002001300540#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a06v22n6.htm#S#p#15#11#text#12#<p><font size="2" face=
"Verdana">A pesar de que las tasas de vacunaci&oacute;n    no se estimaron por z
onas y que el bajo n&uacute;mero de muertes por neumon&iacute;a    e influenza e
n las personas de 65 a&ntilde;os o m&aacute;s en cada distrito    no permiti&oac
ute; evaluar los cambios a ese nivel, estos resultados respaldan    la hip&oacut
e;tesis de que la vacunaci&oacute;n influy&oacute; positivamente    en el perfil
 de equidad de la ciudad.</font></p>     ^cY#a06v22n6.htm##
01314000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704108300072002001301155#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a06v22n6.htm#S#p#16#12#text#12#<p><font size="2" face=
"Verdana">De esta forma, se encontr&oacute; una asociaci&oacute;n    significati
va entre la vacunaci&oacute;n contra la influenza en personas de    65 a&ntilde;
os o m&aacute;s y la reducci&oacute;n en la mortalidad general y    espec&iacute
;fica por neumon&iacute;a e influenza y con la reducci&oacute;n    de las inequi
dades en salud. Se puede revertir la hip&oacute;tesis de la equidad    inversa s
i existe la voluntad pol&iacute;tica y el compromiso de implementar    intervenc
iones sanitarias con acceso universal, efectivo y expedito. Por su    efectivida
d general y su contribuci&oacute;n en la reducci&oacute;n de las inequidades    
en salud, la vacunaci&oacute;n contra la influenza en S&atilde;o Paulo demostr&o
acute;    ser una estrategia factible para promover al mismo tiempo una mejor sa
lud y    una mayor justicia social. (Ferreira Antunes JL, Alves Waldman E, Borre
ll C,    Paiva TM. Effectiveness of influenza vaccination and its impact on heal
th inequalities.    Int J Epidemiol. Advance Access published October 31, 2007.)
</font></p>     ^cY#a06v22n6.htm##
00271000000000169000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670910009000690920007000780020013000857030
00300098#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a07v22n6.htm#S#o#1#1#text#1#20
080215#102631#a07v22n6.htm#16##
00588000000000337000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670710003000690400003000720010006000750420
00200081120000400083038000300087121000300090049000800093158000300101030002400104
03100030012803200020013106500090013301400110014203500100015312300020016301200720
0165002001300237#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a07v22n6.htm#S#h#2#1#t
ext#1#co#es#br1.1#1#3.1#ND#07#RPSP030#nd#Rev Panam Salud Publica#22#6#20071200#^
f402^l403#1020-4989#1#Factores de riesgo de infarto agudo del miocardio en Améri
ca Latina^les#a07v22n6.htm##
00595000000000337000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670710003000690400003000720010006000750420
00200081120000400083038000300087121000300090049000800093158000300101030002400104
03100030012803200020013106500090013301400110014203500100015312300020016301200790
0165002001300244#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a07v22n6.htm#S#f#3#1#t
ext#1#co#es#br1.1#1#3.1#ND#07#RPSP030#nd#Rev Panam Salud Publica#22#6#20071200#^
f402^l403#1020-4989#1#<B>Factores de riesgo de infarto agudo del miocardio en Am
érica Latina</B>^les#a07v22n6.htm##
00704000000000349000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670640013000690710003000820400003000850010
00600088042000200094120000400096121000300100049000800103158000300111030002600114
03100030014003200020014306500090014501400110015403500100016512300020017501200720
0177002001300249008009200262#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a07v22n6.h
tm#S#l#4#1#text#1#^mdic.^a2007#co#es#br1.1#1#3.1#07#RPSP030#nd#Rev. panam. salud
 pública#22#6#20071200#^f402^l403#1020-4989#1#Factores de riesgo de infarto agud
o del miocardio en América Latina^les#a07v22n6.htm#Internet^ihttp://www.scielosp
.org/scielo.php?script=sci_arttext&pid=S1020-49892007001100007##
00322000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704009300070002001300163#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a07v22n6.htm#S#p#5#1#text#12#<p align="right"><font si
ze="2" face="Verdana"><b>INSTANT&Aacute;NEAS</b></font></p>     ^cY#a07v22n6.htm
##
00251000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704002200070002001300092#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a07v22n6.htm#S#p#6#2#text#12#<p>&nbsp;</p>     ^cY#a07
v22n6.htm##
00366000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704013700070002001300207#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a07v22n6.htm#S#p#7#3#text#12#<p><font size="4" face="v
erdana"><b>Factores de riesgo de infarto agudo del miocardio    en Am&eacute;ric
a Latina</b></font></p>     ^cY#a07v22n6.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704002200070002001300092#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a07v22n6.htm#S#p#8#4#text#12#<p>&nbsp;</p>     ^cY#a07
v22n6.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704002200070002001300092#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a07v22n6.htm#S#p#9#5#text#12#<p>&nbsp;</p>     ^cY#a07
v22n6.htm##
00836000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704060600071002001300677#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a07v22n6.htm#S#p#10#6#text#12#<p><font size="2" face="
Verdana">En Am&eacute;rica Latina, 31% de todas las muertes    y aproximadamente
 la mitad de las relacionadas con enfermedades no trasmisibles    en el a&ntilde
;o 2000 se debieron a enfermedades cardiovasculares y se estima    que estas con
tinuar&aacute;n siendo la principal causa de muerte en nuestra    Regi&oacute;n 
en las pr&oacute;ximas d&eacute;cadas. Sin embargo, la informaci&oacute;n    sob
re los diversos factores de riesgo de enfermedades cardiovasculares y su    prev
alencia en diferentes poblaciones en Am&eacute;rica Latina es escasa e incomplet
a.</font></p>     ^cY#a07v22n6.htm##
00805000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704057500071002001300646#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a07v22n6.htm#S#p#11#7#text#12#<p><font size="2" face="
Verdana">En este trabajo se presentan los resultados correspondientes    a Am&ea
cute;rica Latina de INTERHEART, un estudio de casos incidentes y controles    en
 el que se evaluaron aproximadamente 15 000 pacientes con infarto agudo del    m
iocardio (IAM) y un n&uacute;mero similar de controles en 52 pa&iacute;ses.    S
u objetivo fue determinar si los factores de riesgo de infarto ten&iacute;an    
el mismo grado de asociaci&oacute;n en diferentes regiones del mundo y estimar  
  el riesgo poblacional atribuible a esos factores.</font></p>     ^cY#a07v22n6.
htm##
01123000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704089300071002001300964#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a07v22n6.htm#S#p#12#8#text#12#<p><font size="2" face="
Verdana">En Am&eacute;rica Latina se estudiaron 1 237    personas hospitalizadas
 por su primer IAM dentro de las primeras 24 horas de    la aparici&oacute;n de 
los s&iacute;ntomas, entre febrero de 1999 y marzo de    2003. Se excluyeron los
 pacientes que presentaban signos de choque cardiog&eacute;nico    o enfermedade
s cr&oacute;nicas graves. Se seleccionaron 1 888 controles pareados    por edad 
(con una diferencia m&aacute;xima de 5 a&ntilde;os), sexo e instituci&oacute;n, 
   con los mismos criterios de exclusi&oacute;n de los casos, m&aacute;s la ause
ncia    de enfermedad card&iacute;aca o angina. Los pa&iacute;ses participantes 
en Am&eacute;rica    Latina fueron Argentina, Brasil, Chile, Colombia, Guatemala
 y M&eacute;xico.    La edad promedio de los casos fue de 59 &plusmn; 12 a&ntild
e;os; 74,9% de los    participantes eran hombres.</font></p>     ^cY#a07v22n6.ht
m##
00919000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704068900071002001300760#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a07v22n6.htm#S#p#13#9#text#12#<p><font size="2" face="
Verdana">Los factores asociados con el IAM fueron: antecedentes    de hipertensi
&oacute;n (raz&oacute;n de posibilidades &#91;<I>odds ratio</I>, OR&#93;    = 2,
81; intervalo de confianza de 95% &#91;IC95%&#93;: 2,39 a 3,31), antecedentes   
 de diabetes mellitus (OR = 2,59; IC95%: 2,09 a 3,22), tabaquismo (OR = 2,31;   
 IC95%: 1,97 a 2,71), estr&eacute;s permanente (OR = 2,81; IC95%:    2,07 a 3,82
), aumento en la relaci&oacute;n de apo B/apo A1 (OR = 2,31; IC95%:    1,83 a 2,
94, entre el primer tercil y el &uacute;ltimo) y un mayor &iacute;ndice    cintu
ra-cadera (OR = 2,49; IC95%: 1,97 a 3,14, entre el primer tercil y el &uacute;lt
imo).</font></p>     ^cY#a07v22n6.htm##
00895000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704066400072002001300736#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a07v22n6.htm#S#p#14#10#text#12#<p><font size="2" face=
"Verdana">El consumo diario de frutas o verduras (OR =    0,63; IC95%: 0,51 a 0,
78) y la pr&aacute;ctica regular de ejercicios f&iacute;sicos    tuvieron un efe
cto protector (OR = 0,67; IC95%: 0,55 a 0,82). No se encontr&oacute;    asociaci
&oacute;n significativa entre el IAM y el nivel socioecon&oacute;mico    (seg&ua
cute;n el nivel educacional o los ingresos), la depresi&oacute;n y el    consumo
 de alcohol. Los factores de riesgo mencionados y la falta de consumo    diario 
de frutas o verduras y de ejercicios f&iacute;sicos tuvieron una asociaci&oacute
;n    conjunta significativa (OR = 63,0; IC95%: 23,7 a 168,0)</font></p>     ^cY
#a07v22n6.htm##
01046000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704081500072002001300887#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a07v22n6.htm#S#p#15#11#text#12#<p><font size="2" face=
"Verdana">La prevalencia de un factor de riesgo en la poblaci&oacute;n    est&aa
cute; representada, aunque en forma no precisa, por la prevalencia del    factor
 de riesgo en el grupo de control. El mayor riesgo poblacional atribuible    cor
respondi&oacute; a la obesidad abdominal (48,5%; IC95%: 35,8 a 56,2), al    incr
emento en la relaci&oacute;n de apo B/apo A1 (40,8%; IC95%: 30,3 a 52,2)    y al
 tabaquismo (38,4%; IC95%: 32,8 a 44,4). El efecto conjunto de estos factores   
 explica 88% de los casos de IAM en esta poblaci&oacute;n. En comparaci&oacute;n
    con el resto de los pa&iacute;ses que participaron en el estudio INTERHEART,
    el riesgo poblacional atribuible a la obesidad abdominal y al estr&eacute;s 
   permanente fue superior en Am&eacute;rica Latina.</font></p>     ^cY#a07v22n6
.htm##
00937000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704070600072002001300778#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a07v22n6.htm#S#p#16#12#text#12#<p><font size="2" face=
"Verdana">En resumen, estos resultados demuestran que el    tabaquismo, los nive
les alterados de los l&iacute;pidos, la obesidad abdominal    y la hipertensi&oa
cute;n arterial pueden explicar la mayor&iacute;a de los casos    de IAM ocurrid
os en Am&eacute;rica Latina. Las autoridades sanitarias nacionales    deben dise
&ntilde;ar y poner en pr&aacute;ctica estrategias preventivas basadas    en esto
s factores de riesgo, ya que son de f&aacute;cil determinaci&oacute;n    y posib
les de controlar. (Lanas F, Avezum A, Bautista LE, Diaz R, Luna M, Islam    S, e
t al. Risk factors for acute myocardial infarction in Latin America. Circulation
.    2007;115:1067–74.)</font></p>     ^cY#a07v22n6.htm##
00271000000000169000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670910009000690920007000780020013000857030
00300098#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a08v22n6.htm#S#o#1#1#text#1#20
080215#102632#a08v22n6.htm#14##
00625000000000337000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670710003000690400003000720010006000750420
00200081120000400083038000300087121000300090049000800093158000300101030002400104
03100030012803200020013106500090013301400110014203500100015312300020016301201090
0165002001300274#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a08v22n6.htm#S#h#2#1#t
ext#1#co#es#br1.1#1#3.1#ND#08#RPSP030#nd#Rev Panam Salud Publica#22#6#20071200#^
f403^l404#1020-4989#1#Estudio multicéntrico prospectivo sobre los riesgos y bene
ficios del parto por cesárea en América Latina^les#a08v22n6.htm##
00632000000000337000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670710003000690400003000720010006000750420
00200081120000400083038000300087121000300090049000800093158000300101030002400104
03100030012803200020013106500090013301400110014203500100015312300020016301201160
0165002001300281#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a08v22n6.htm#S#f#3#1#t
ext#1#co#es#br1.1#1#3.1#ND#08#RPSP030#nd#Rev Panam Salud Publica#22#6#20071200#^
f403^l404#1020-4989#1#<B>Estudio multicéntrico prospectivo sobre los riesgos y b
eneficios del parto por cesárea en América Latina</B>^les#a08v22n6.htm##
00741000000000349000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670640013000690710003000820400003000850010
00600088042000200094120000400096121000300100049000800103158000300111030002600114
03100030014003200020014306500090014501400110015403500100016512300020017501201090
0177002001300286008009200299#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a08v22n6.h
tm#S#l#4#1#text#1#^mdic.^a2007#co#es#br1.1#1#3.1#08#RPSP030#nd#Rev. panam. salud
 pública#22#6#20071200#^f403^l404#1020-4989#1#Estudio multicéntrico prospectivo 
sobre los riesgos y beneficios del parto por cesárea en América Latina^les#a08v2
2n6.htm#Internet^ihttp://www.scielosp.org/scielo.php?script=sci_arttext&pid=S102
0-49892007001100008##
00322000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704009300070002001300163#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a08v22n6.htm#S#p#5#1#text#10#<p align="right"><font si
ze="2" face="Verdana"><b>INSTANT&Aacute;NEAS</b></font></p>     ^cY#a08v22n6.htm
##
00251000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704002200070002001300092#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a08v22n6.htm#S#p#6#2#text#10#<p>&nbsp;</p>     ^cY#a08
v22n6.htm##
00417000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704018800070002001300258#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a08v22n6.htm#S#p#7#3#text#10#<p><font size="4" face="v
erdana"><b>Estudio multic&eacute;ntrico prospectivo sobre    los riesgos y benef
icios del parto por ces&aacute;rea en Am&eacute;rica Latina</b></font></p>     ^
cY#a08v22n6.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704002200070002001300092#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a08v22n6.htm#S#p#8#4#text#10#<p>&nbsp;</p>     ^cY#a08
v22n6.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704002200070002001300092#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a08v22n6.htm#S#p#9#5#text#10#<p>&nbsp;</p>     ^cY#a08
v22n6.htm##
01184000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704095400071002001301025#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a08v22n6.htm#S#p#10#6#text#10#<p><font size="2" face="
Verdana">En las &uacute;ltimas tres d&eacute;cadas se    han producido profundos
 cambios en el modo de dar a luz y en los &iacute;ndices    de supervivencia de 
los reci&eacute;n nacidos. Entre esos cambios se encuentran    los recientes esf
uerzos para reducir el n&uacute;mero de partos por ces&aacute;rea,    a la vez q
ue se trata de satisfacer las preferencias obst&eacute;tricas de las    embaraza
das. Seg&uacute;n algunos autores, el aumento en las tasas de partos    por ces&
aacute;rea en hospitales est&aacute; asociado con un incremento en la    morbili
dad, tanto en las madres como en los reci&eacute;n nacidos, sin ning&uacute;n   
 beneficio general evidente. Por lo tanto, hay una urgente necesidad de brindar 
   a las mujeres y a los proveedores de salud una informaci&oacute;n clara y cie
nt&iacute;ficamente    respaldada sobre los posibles riesgos y beneficios asocia
dos con este tipo de    parto.</font></p>     ^cY#a08v22n6.htm##
01298000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704106800071002001301139#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a08v22n6.htm#S#p#11#7#text#10#<p><font size="2" face="
Verdana">Para estimar los riesgos y beneficios del parto    por ces&aacute;rea e
n comparaci&oacute;n con el parto vaginal, as&iacute; como    las tasas de morbi
lidad y mortalidad en las madres y los reci&eacute;n nacidos    asociadas con el
 parto por ces&aacute;rea —ya sea por prescripci&oacute;n m&eacute;dica    o ele
ctiva— se realiz&oacute; un estudio prospectivo de cohorte como parte de    la e
ncuesta general sobre salud materna y perinatal realizada por la Organizaci&oacu
te;n    Mundial de la Salud. Participaron 120 instituciones de ocho pa&iacute;se
s de    Am&eacute;rica Latina seleccionados de manera aleatoria (Argentina, Bras
il,    Cuba, Ecuador, M&eacute;xico, Nicaragua, Paraguay y Per&uacute;). Se eval
uaron    97 095 partos del total de 106 546 registrados entre septiembre de 2004
 y marzo    de 2005 en las instituciones participantes, para una cobertura total
 de 91%.    Los datos se ajustaron por las caracter&iacute;sticas institucionale
s, cl&iacute;nicas,    demogr&aacute;ficas y obst&eacute;tricas.</font></p>     
^cY#a08v22n6.htm##
01880000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704165000071002001301721#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a08v22n6.htm#S#p#12#8#text#10#<p><font size="2" face="
Verdana">Las mujeres que tuvieron parto por ces&aacute;rea    presentaron mayor 
riesgo de complicaciones graves que las mujeres que parieron    por v&iacute;a v
aginal, tanto si la ces&aacute;rea se decidi&oacute; durante    la operaci&oacut
e;n (raz&oacute;n de posibilidades &#91;<I>odds ratio</I>, OR&#93; =    2,0; int
ervalo de confianza de 95% &#91;IC95%&#93;: 1,6 a 2,5) como por elecci&oacute;n 
   de la madre (OR = 2,3; IC95%: 1,7 a 3,1). El riesgo de necesitar tratamiento 
   con antibi&oacute;ticos despu&eacute;s del parto fue cinco veces mayor en las
    mujeres con ces&aacute;rea (en cualquiera de las dos modalidades) que en las
    mujeres que parieron por v&iacute;a vaginal. En los partos por ces&aacute;re
a    con presentaci&oacute;n cef&aacute;lea del feto, independientemente de posi
bles    variables confusoras y de la edad gestacional, se observ&oacute; una ten
dencia    al aumento del riesgo de permanecer siete d&iacute;as o m&aacute;s en 
las unidades    de cuidados intensivos neonatales (OR = 2,1; IC95%: 1,8 a 2,6 en
 las ces&aacute;reas    decididas durante el parto; OR = 1,9; IC95%: 1,6 a 2,3 e
n las ces&aacute;reas    electivas) y de muerte neonatal antes del alta m&eacute
;dica (OR = 1,7; IC95%:    1,3 a 2,2 y OR = 1,9; IC95%: 1,5 a 2,6, respectivamen
te). Estos aumentos en    el riesgo se mantuvieron elevados incluso despu&eacute
;s de excluir del an&aacute;lisis    los casos de ces&aacute;reas por sufrimient
o fetal. En los casos de presentaci&oacute;n    fetal de nalgas, los partos por 
ces&aacute;rea tuvieron un efecto protector    con respecto al riesgo de muerte 
fetal.</font></p>     ^cY#a08v22n6.htm##
00982000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704075200071002001300823#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a08v22n6.htm#S#p#13#9#text#10#<p><font size="2" face="
Verdana">La decisi&oacute;n de realizar una ces&aacute;rea    cuando el feto se 
presenta de cabeza se basa generalmente en tres elementos:    a) por complicacio
nes graves de emergencia que se presentan durante el parto    y requieren de una
 ces&aacute;rea; b) para evitar complicaciones perinatales,    previstas seg&uac
ute;n los resultados de estudios realizados durante el parto,    aunque se sabe 
que las t&eacute;cnicas m&aacute;s frecuentemente empleadas producen    numeroso
s resultados positivos falsos; y c) por la solicitud de la madre, muchas    vece
s como reflejo de una posici&oacute;n social, cultural o econ&oacute;mica,    o 
de consideraciones legales ajenas a las necesidades m&eacute;dicas. </font></p> 
    ^cY#a08v22n6.htm##
00907000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704067600072002001300748#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a08v22n6.htm#S#p#14#10#text#10#<p><font size="2" face=
"Verdana">Los resultados de este estudio prospectivo multic&eacute;ntrico    con
firman que en los casos de presentaci&oacute;n cef&aacute;lea del feto, este    
procedimiento quir&uacute;rgico est&aacute; significativamente asociado con    u
na mayor morbilidad y mortalidad de la madre, el feto y el reci&eacute;n nacido,
    independientemente del escenario m&eacute;dico y sociocultural en que se rea
lice.    (Villar J, Carroli G, Zavaleta N, Donner A, Wojdyla D, Faundes A, et al
. Maternal    and neonatal individual risks and benefits associated with caesare
an delivery:    multicentre prospective study. Br Med J. 2007; 335:1025.)</font>
</p>     ^cY#a08v22n6.htm##
00275000000000169000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700910009000720920007000810020013000887030
00400101#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a09v22n6.htm#S#o#1#1#article#1
#20080215#102634#a09v22n6.htm#158##
02827000000000577000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000300090121000300093049000800096158000300104030002400107
03100030013103200020013406500090013601400110014503500100015601200980016601201030
02640100035003670100025004020700088004270850008005150850029005230850022005520850
02600574085002000600085002100620085002100641083139400662085000802056085002502064
08500220208908500360211108500290214708500300217608500210220611700060222707200030
2233002001302236#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a09v22n6.htm#S#h#2#1#a
rticle#1#oa#es#br1.1#1#3.1#ND#09#RPSP050#nd#Rev Panam Salud Publica#22#6#2007120
0#^f405^l416#1020-4989#Evolución del concepto etnia/raza y su impacto en la form
ulación de políticas para la equidad^les#The evolution of the ethnicity/race con
cept and its impact on framing policies that promote equity^len#^rND^1A01^nCrist
ina^sTorres-Parodi#^rND^1A01^nMónica^sBolis#Organización Panamericana de la Salu
d^iA01^cWashington^sD.C.^pEstados Unidos de América#^dnd^i1#^tm^les^kderechos hu
manos^i1#^tm^les^kprejuicio^i1#^tm^les^ketnia y salud^i1#^tm^les^kequidad^i1#^tm
^les^krevisión^i1#^tm^les^kAméricas^i1#^len^aAcknowledging the differences betwe
en individuals based on their unique identity is a basic requirement for achievi
ng equity. A review of international human rights efforts and the recommendation
s and declarations of global conferences and regional summits as they redirect p
olicy to battle discrimination shows a positive evolution in the concept of ethn
icity/race. This is evident in the transition from using "invisible" differences
 as an equalizing measure to respecting lifestyle diversity and acknowledging th
at individuals have a right to be valued for their differences. This evolution i
n the ethnicity/race concept has been pivotal to building multiethnic, multicult
ural, and multilingual nations in which minority groups are involved in framing 
equitable health policies and programs. This study covers the time period from 1
948 to the present day, identifying four stages in the concept's evolution that 
coincide with milestones in the political and social relationship between govern
ment institutions and ethnic minority groups. The results of these five decades 
of positive progress is a heightened appreciation for differences, which underli
es multiethnic societies and surpasses any one of the tangible benefits received
 by minority groups. The progress of democratic societies depends heavily on thi
s concept, one that ensure a stronger foundation for future development.#^dnd^i2
#^tm^len^khuman rights^i2#^tm^len^kprejudice^i2#^tm^len^kethnic group and health
^i2#^tm^len^kequity in health^i2#^tm^len^kliterature review^i2#^tm^len^kAmericas
^i2#other#27#a09v22n6.htm##
02841000000000577000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000300090121000300093049000800096158000300104030002400107
03100030013103200020013406500090013601400110014503500100015601201050016601201100
02710100035003810100025004160700088004410850008005290850029005370850022005660850
02600588085002000614085002100634085002100655083139400676085000802070085002502078
08500220210308500360212508500290216108500300219008500210222011700060224107200030
2247002001302250#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a09v22n6.htm#S#f#3#1#a
rticle#1#oa#es#br1.1#1#3.1#ND#09#RPSP050#nd#Rev Panam Salud Publica#22#6#2007120
0#^f405^l416#1020-4989#<B>Evolución del concepto etnia/raza y su impacto en la f
ormulación de políticas para la equidad</B>^les#<B>The evolution of the ethnicit
y/race concept and its impact on framing policies that promote equity</B>^len#^r
ND^1A01^nCristina^sTorres-Parodi#^rND^1A01^nMónica^sBolis#Organización Panameric
ana de la Salud^iA01^cWashington^sD.C.^pEstados Unidos de América#^dnd^i1#^tm^le
s^kderechos humanos^i1#^tm^les^kprejuicio^i1#^tm^les^ketnia y salud^i1#^tm^les^k
equidad^i1#^tm^les^krevisión^i1#^tm^les^kAméricas^i1#^len^aAcknowledging the dif
ferences between individuals based on their unique identity is a basic requireme
nt for achieving equity. A review of international human rights efforts and the 
recommendations and declarations of global conferences and regional summits as t
hey redirect policy to battle discrimination shows a positive evolution in the c
oncept of ethnicity/race. This is evident in the transition from using "invisibl
e" differences as an equalizing measure to respecting lifestyle diversity and ac
knowledging that individuals have a right to be valued for their differences. Th
is evolution in the ethnicity/race concept has been pivotal to building multieth
nic, multicultural, and multilingual nations in which minority groups are involv
ed in framing equitable health policies and programs. This study covers the time
 period from 1948 to the present day, identifying four stages in the concept's e
volution that coincide with milestones in the political and social relationship 
between government institutions and ethnic minority groups. The results of these
 five decades of positive progress is a heightened appreciation for differences,
 which underlies multiethnic societies and surpasses any one of the tangible ben
efits received by minority groups. The progress of democratic societies depends 
heavily on this concept, one that ensure a stronger foundation for future develo
pment.#^dnd^i2#^tm^len^khuman rights^i2#^tm^len^kprejudice^i2#^tm^len^kethnic gr
oup and health^i2#^tm^len^kequity in health^i2#^tm^len^kliterature review^i2#^tm
^len^kAmericas^i2#other#27#a09v22n6.htm##
02945000000000589000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700640013000720710003000850400003000880010
00600091042000200097120000400099121000300103049000800106158000300114030002600117
03100030014303200020014606500090014801400110015703500100016801200980017801201030
02760100035003790100025004140700090004390850008005290850029005370850022005660850
02600588085002000614085002100634085002100655083139400676085000802070085002502078
08500220210308500360212508500290216108500300219008500210222011700060224107200030
2247002001302250008009202263#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a09v22n6.h
tm#S#l#4#1#article#1#^mdic.^a2007#oa#es#br1.1#1#3.1#09#RPSP050#nd#Rev. panam. sa
lud pública#22#6#20071200#^f405^l416#1020-4989#Evolución del concepto etnia/raza
 y su impacto en la formulación de políticas para la equidad^les#The evolution o
f the ethnicity/race concept and its impact on framing policies that promote equ
ity^len#^rND^1A01^nCristina^sTorres-Parodi#^rND^1A01^nMónica^sBolis#^iA01^1Organ
ización Panamericana de la Salud^cWashington^sD.C.^pEstados Unidos de América#^d
nd^i1#^tm^les^kderechos humanos^i1#^tm^les^kprejuicio^i1#^tm^les^ketnia y salud^
i1#^tm^les^kequidad^i1#^tm^les^krevisión^i1#^tm^les^kAméricas^i1#^len^aAcknowled
ging the differences between individuals based on their unique identity is a bas
ic requirement for achieving equity. A review of international human rights effo
rts and the recommendations and declarations of global conferences and regional 
summits as they redirect policy to battle discrimination shows a positive evolut
ion in the concept of ethnicity/race. This is evident in the transition from usi
ng "invisible" differences as an equalizing measure to respecting lifestyle dive
rsity and acknowledging that individuals have a right to be valued for their dif
ferences. This evolution in the ethnicity/race concept has been pivotal to build
ing multiethnic, multicultural, and multilingual nations in which minority group
s are involved in framing equitable health policies and programs. This study cov
ers the time period from 1948 to the present day, identifying four stages in the
 concept's evolution that coincide with milestones in the political and social r
elationship between government institutions and ethnic minority groups. The resu
lts of these five decades of positive progress is a heightened appreciation for 
differences, which underlies multiethnic societies and surpasses any one of the 
tangible benefits received by minority groups. The progress of democratic societ
ies depends heavily on this concept, one that ensure a stronger foundation for f
uture development.#^dnd^i2#^tm^len^khuman rights^i2#^tm^len^kprejudice^i2#^tm^le
n^kethnic group and health^i2#^tm^len^kequity in health^i2#^tm^len^kliterature r
eview^i2#^tm^len^kAmericas^i2#other#27#a09v22n6.htm#Internet^ihttp://www.scielos
p.org/scielo.php?script=sci_arttext&pid=S1020-49892007001100009##
00344000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704011100074002001300185#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a09v22n6.htm#S#p#5#1#article#127#<p align="right"><fon
t size="2" face="Verdana"><b>TEMAS DE ACTUALIDAD </b>CURRENT    TOPICS</font></p
>     ^cY#a09v22n6.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a09v22n6.htm#S#p#6#2#article#127#<p>&nbsp;</p>     ^cY
#a09v22n6.htm##
00430000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704019700074002001300271#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a09v22n6.htm#S#p#7#3#article#127#<p><font size="4" fac
e="verdana"><b><a name="tx"></a>Evoluci&oacute;n del concepto    etnia/raza y su
 impacto en la formulaci&oacute;n de pol&iacute;ticas para la    equidad</b></fo
nt></p>     ^cY#a09v22n6.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a09v22n6.htm#S#p#8#4#article#127#<p>&nbsp;</p>     ^cY
#a09v22n6.htm##
00395000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704016200074002001300236#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a09v22n6.htm#S#p#9#5#article#127#<p><font size="3" fac
e="verdana"><b>The evolution of the ethnicity/race concept    and its impact on 
framing policies that promote equity </b></font></p>     ^cY#a09v22n6.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704002200075002001300097#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a09v22n6.htm#S#p#10#6#article#127#<p>&nbsp;</p>     ^c
Y#a09v22n6.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704002200075002001300097#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a09v22n6.htm#S#p#11#7#article#127#<p>&nbsp;</p>     ^c
Y#a09v22n6.htm##
00370000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704013600075002001300211#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a09v22n6.htm#S#p#12#8#article#127#<p><font size="2" fa
ce="Verdana"><b>Cristina Torres-Parodi<a href="#nt"><sup>*</sup></a>;    M&oacut
e;nica Bolis</b></font></p>     ^cY#a09v22n6.htm##
00386000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704015200075002001300227#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a09v22n6.htm#S#p#13#9#article#127#<p><font size="2" fa
ce="Verdana">Organizaci&oacute;n Panamericana de la Salud,    Washington, D.C., 
Estados Unidos de Am&eacute;rica</font></p>     ^cY#a09v22n6.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a09v22n6.htm#S#p#14#10#article#127#<p>&nbsp;</p>     ^
cY#a09v22n6.htm##
00279000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704004400076002001300120#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a09v22n6.htm#S#p#15#11#article#127#<p>&nbsp;</p> <hr s
ize="1" noshade>     ^cY#a09v22n6.htm##
00422000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704018700076002001300263#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a09v22n6.htm#S#p#16#12#article#127#<p><font size="2" f
ace="Verdana"><B>Palabras clave: </b>derechos humanos, prejuicio,    etnia y sal
ud, equidad, revisi&oacute;n, Am&eacute;ricas.</font></p> <hr size="1" noshade> 
    ^cY#a09v22n6.htm##
00303000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704006800076002001300144#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a09v22n6.htm#S#p#17#13#article#127#<p><font size="2" f
ace="Verdana"><b>SYNOPSIS</b></font></p>     ^cY#a09v22n6.htm##
01726000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704149100076002001301567#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a09v22n6.htm#S#p#18#14#article#127#<p><font size="2" f
ace="Verdana">Acknowledging the differences between individuals    based on thei
r unique identity is a basic requirement for achieving equity.    A review of in
ternational human rights efforts and the recommendations and declarations    of 
global conferences and regional summits as they redirect policy to battle    dis
crimination shows a positive evolution in the concept of ethnicity/race.    This
 is evident in the transition from using "invisible" differences    as an equali
zing measure to respecting lifestyle diversity and acknowledging    that individ
uals have a right to be valued for their differences. This evolution    in the e
thnicity/race concept has been pivotal to building multiethnic, multicultural,  
  and multilingual nations in which minority groups are involved in framing equi
table    health policies and programs. This study covers the time period from 19
48 to    the present day, identifying four stages in the concept's evolution tha
t coincide    with milestones in the political and social relationship between g
overnment    institutions and ethnic minority groups. The results of these five 
decades of    positive progress is a heightened appreciation for differences, wh
ich underlies    multiethnic societies and surpasses any one of the tangible ben
efits received    by minority groups. The progress of democratic societies depen
ds heavily on    this concept, one that ensure a stronger foundation for future 
development.</font></p>     ^cY#a09v22n6.htm##
00427000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704019200076002001300268#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a09v22n6.htm#S#p#19#15#article#127#<p><font size="2" f
ace="Verdana"><B>Key words:</b> human rights, prejudice, ethnic    group and hea
lth, equity in health, literature review, Americas.</font></p> <hr size="1" nosh
ade>     ^cY#a09v22n6.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a09v22n6.htm#S#p#20#16#article#127#<p>&nbsp;</p>     ^
cY#a09v22n6.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002300076002001300099#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a09v22n6.htm#S#p#21#17#article#127#<p>&nbsp; </p>     
^cY#a09v22n6.htm##
01254000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704101900076002001301095#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a09v22n6.htm#S#p#22#18#article#127#<p><font size="2" f
ace="Verdana">En Am&eacute;rica Latina existen notables desigualdades    en rela
ci&oacute;n con el estado de salud y el acceso a los servicios de salud    de gr
upos &eacute;tnicos/raciales en comparaci&oacute;n con el resto de la poblaci&oa
cute;n.    Esta situaci&oacute;n es frecuente en pa&iacute;ses con diferentes ni
veles de    desarrollo, lo que indica que no es solo consecuencia del nivel econ
&oacute;mico    del pa&iacute;s, sino tambi&eacute;n de las estructuras pol&iacu
te;tico-sociales    prevalecientes. Uno de los requisitos fundamentales para alc
anzar la equidad    es reconocer las diferencias que se derivan de la propia ide
ntidad de los individuos.    Es por ello que este estudio pretende, desde el ent
endimiento de la evoluci&oacute;n    del concepto etnia/raza, contribuir a la fo
rmulaci&oacute;n de pol&iacute;ticas    y programas de salud con un enfoque de e
quidad y facilitar la participaci&oacute;n    de los grupos &eacute;tnicos/racia
les en este proceso.</font></p>     ^cY#a09v22n6.htm##
01698000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704146300076002001301539#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a09v22n6.htm#S#p#23#19#article#127#<p><font size="2" f
ace="Verdana">Para este estudio se analiz&oacute; la evoluci&oacute;n    del con
cepto etnia/raza en los tratados, convenios y declaraciones internacionales    d
e derechos humanos y en las recomendaciones y declaraciones que sobre el tema   
 han emitido las conferencias mundiales y las cumbres regionales, en el entendid
o    de que estos instrumentos constituyen fundamentos centrales para el desarro
llo    de pol&iacute;ticas dirigidas a combatir la discriminaci&oacute;n. Para r
evisar    la evoluci&oacute;n del concepto etnia/raza tambi&eacute;n se tuvieron
 en cuenta    elementos provenientes de la historia de los movimientos sociales 
y pol&iacute;ticos    orientados a superar la discriminaci&oacute;n y el racismo
. El estudio abarc&oacute;    de 1948 hasta septiembre de 2007, per&iacute;odo e
n el que el tema de los derechos    humanos y la superaci&oacute;n del racismo, 
la discriminaci&oacute;n y la xenofobia    ha estado persistentemente presente e
n las agendas pol&iacute;ticas internacionales    acompa&ntilde;ando una evoluci
&oacute;n positiva del concepto etnia/raza. La    progresiva actualizaci&oacute;
n de este concepto es relevante, ya que ha permitido    incluir en el &aacute;mb
ito de los grupos beneficiarios a los pueblos ind&iacute;genas    que tradiciona
lmente se autodefinieron como &eacute;tnicos/raciales y a otros    grupos como l
os afrodescendientes, los migrantes y los pueblos rom (gitanos).</font></p>     
^cY#a09v22n6.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a09v22n6.htm#S#p#24#20#article#127#<p>&nbsp;</p>     ^
cY#a09v22n6.htm##
00353000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704011800076002001300194#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a09v22n6.htm#S#p#25#21#article#127#<p><font size="3" f
ace="Verdana"><b>ETNIA/RAZA: DIVERSAS ETAPAS EN EL DESARROLLO    CONCEPTUAL</b><
/font></p>     ^cY#a09v22n6.htm##
01637000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704140200076002001301478#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a09v22n6.htm#S#p#26#22#article#127#<p><font size="2" f
ace="Verdana">El esfuerzo internacional sostenido a lo largo    de m&aacute;s de
 cinco d&eacute;cadas ha permitido desarrollar una amplia bater&iacute;a    de i
nstrumentos para superar las barreras de la discriminaci&oacute;n, el racismo   
 y la xenofobia. El punto de partida de este proceso fue la Declaraci&oacute;n  
  Universal de los Derechos Humanos (1)<a name="tx01"></a><a href="#nt01"><sup>1
</sup></a>    y culmin&oacute; con los mandatos emanados de la Tercera Conferenc
ia Mundial    contra el Racismo, la Discriminaci&oacute;n Racial, la Xenofobia y
 las Formas    Conexas de Intolerancia realizada en Durban, Sud&aacute;frica, en
 2001 (2).    El an&aacute;lisis de estos instrumentos permite identificar cuatr
o etapas,    en las que se distingue una evoluci&oacute;n positiva del concepto 
etnia/raza,    y revisar c&oacute;mo este concepto se incorpora a los lineamient
os internacionales    para promover los derechos humanos de las minor&iacute;as 
&eacute;tnicas/raciales.<a name="tx02"></a><a href="#nt02"><SUP>2</SUP></a>    E
stas etapas coinciden con distintos momentos del desarrollo de las relaciones   
 pol&iacute;ticas y sociales entre las instituciones del Estado y las minor&iacu
te;as    &eacute;tnicas/ raciales y tienen su fundamento en las distintas manera
s de    enfocar la ciudadan&iacute;a en general y la de estos grupos en particul
ar.</font></p>     ^cY#a09v22n6.htm##
01361000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704112600076002001301202#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a09v22n6.htm#S#p#27#23#article#127#<p><font size="2" f
ace="Verdana">Si bien el debate sobre la existencia de diferencias    de car&aac
ute;cter biol&oacute;gico entre los seres humanos a&uacute;n no se    ha agotado
<a name="tx03"></a><a href="#nt03"><SUP>3</SUP></a>, en el Informe    de la Reun
i&oacute;n de Consulta sobre la Conferencia Mundial contra el Racismo,    la Dis
criminaci&oacute;n Racial, la Xenofobia y las Formas Conexas de Intolerancia,   
 celebrada en Bellagio, Italia, del 24 al 28 de enero de 2000, se afirma que    
"&#91;L&#93;a inmensa mayor&iacute;a de los expertos en la materia coincide en  
  que, desde el punto de vista cient&iacute;fico y antropol&oacute;gico, el conc
epto    de que los seres humanos pueden dividirse y clasificarse definitivamente
 en    distintas ‘razas' carece de fundamento. No hay m&aacute;s que una raza: l
a raza    humana" (6). Por ende, la noci&oacute;n de raza no es una entidad biol
&oacute;gica    y debe entenderse a la luz de la historia y de las relaciones so
ciales. Esta    evoluci&oacute;n se refleja en los lineamientos internacionales 
de la lucha    contra la discriminaci&oacute;n.</font></p>     ^cY#a09v22n6.htm#
#
01731000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704149600076002001301572#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a09v22n6.htm#S#p#28#24#article#127#<p><font size="2" f
ace="Verdana">La "etnicidad" se refiere a la identificaci&oacute;n    de una col
ectividad humana a partir de antecedentes hist&oacute;ricos y un pasado    com&u
acute;n, as&iacute; como de una lengua, s&iacute;mbolos y leyendas compartidos. 
   Originalmente, este t&eacute;rmino se empleaba en el lenguaje corriente para 
   hacer referencia a "naciones", aunque tambi&eacute;n estuvo asociada    con l
o "salvaje" o poco desarrollado y se us&oacute; como sin&oacute;nimo    de "trib
al". Los esfuerzos acad&eacute;micos realizados en las d&eacute;cadas    de 1970
 y 1980 perfeccionaron la definici&oacute;n de etnicidad y la relacionaron    co
n las diferencias culturales. La identidad &eacute;tnica de las personas,    tan
to en el orden individual como colectivo, no es un factor est&aacute;tico    o i
nmutable sino que, por el contrario, "la etnicidad surge y se transforma    en e
l contexto de las relaciones y conflictos sociales" (7). Entender a    los seres
 humanos en el marco de su humanidad compartida permite visualizar    m&aacute;s
 claramente las relaciones de sumisi&oacute;n y de exclusi&oacute;n    injustas 
que se agazapaban en las clasificaciones arbitrarias del orden social.    Estos 
mecanismos de sumisi&oacute;n, que operaban seg&uacute;n las diferencias    en e
l fenotipo, tuvieron su origen en el colonialismo y persistieron ocultas    bajo
 el discurso del mestizaje y de categor&iacute;as tales como "pueblo",    "campe
sinos" o "clase".</font></p>     ^cY#a09v22n6.htm##
00319000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704008400076002001300160#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a09v22n6.htm#S#p#29#25#article#127#<p><font size="2" f
ace="Verdana"><b>Primera etapa: 1948–1970</b></font></p>     ^cY#a09v22n6.htm##
01301000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704106600076002001301142#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a09v22n6.htm#S#p#30#26#article#127#<p><font size="2" f
ace="Verdana">La Declaraci&oacute;n Universal de los Derechos    Humanos marc&oa
cute; el comienzo de un nuevo paradigma al constituirse en un    cat&aacute;logo
 de derechos reconocidos universalmente como sustento de la justicia    y la paz
. La Declaraci&oacute;n retom&oacute; los derechos m&aacute;s cl&aacute;sicos   
 en relaci&oacute;n con el derecho a la vida, la libertad, la prohibici&oacute;n
    de la trata de esclavos, la igualdad ante la ley, la libertad de circulaci&o
acute;n,    el derecho de opini&oacute;n, a un juicio imparcial, a la libertad d
e pensamiento,    de conciencia y de religi&oacute;n y de reuni&oacute;n. Adem&a
acute;s, incorpor&oacute;    otros derechos fortalecidos en per&iacute;odos m&aa
cute;s recientes, tales como    el derecho a la representaci&oacute;n pol&iacute
;tica, la libre elecci&oacute;n    del trabajo, la sindicalizaci&oacute;n, la in
violabilidad del domicilio, la    prohibici&oacute;n de la detenci&oacute;n arbi
traria y la igualdad de remuneraci&oacute;n    por una misma tarea.</font></p>  
   ^cY#a09v22n6.htm##
01046000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704081100076002001300887#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a09v22n6.htm#S#p#31#27#article#127#<p><font size="2" f
ace="Verdana">En su primer considerando, la Declaraci&oacute;n    utiliza el con
cepto de familia humana<a name="tx04"></a><a href="#nt04"><SUP>4</SUP></a>    y 
en sus art&iacute;culos sucesivos hace referencia a la raza, el color (aludiendo
    sin dudas al color de la piel), el sexo, el idioma, la religi&oacute;n, la o
pini&oacute;n    pol&iacute;tica o de cualquier otra &iacute;ndole, el origen na
cional o social,    la posici&oacute;n econ&oacute;mica, el nacimiento o cualqui
er otra condici&oacute;n.    Por lo tanto, si bien la Declaraci&oacute;n fue pre
cursora en alentar la igualdad,    seg&uacute;n parece desprenderse de la termin
olog&iacute;a adoptada, no permiti&oacute;    superar las visiones fragmentadas 
en t&eacute;rminos de la condici&oacute;n    humana.</font></p>     ^cY#a09v22n6
.htm##
00829000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704059400076002001300670#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a09v22n6.htm#S#p#32#28#article#127#<p><font size="2" f
ace="Verdana">Aparentemente, la Declaraci&oacute;n utiliz&oacute;    los t&eacut
e;rminos raza, origen nacional y religi&oacute;n sin otorgarles la    elaboraci&
oacute;n conceptual necesaria para crear las bases de una igualdad    que no fue
ra meramente de forma, sino que se sustentara en elementos de fondo.    En parti
cular, el uso del vocablo "raza" parece indicar que admite    la existencia de r
azas desde el punto de vista biol&oacute;gico y no sociol&oacute;gico,    como s
urgi&oacute; m&aacute;s tarde en la Reuni&oacute;n de Consulta de Bellagio.</fon
t></p>     ^cY#a09v22n6.htm##
02012000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704177700076002001301853#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a09v22n6.htm#S#p#33#29#article#127#<p><font size="2" f
ace="Verdana">De lo anterior se derivar&iacute;a que la Declaraci&oacute;n    Un
iversal de los Derechos Humanos podr&iacute;a haber dado lugar a interpretacione
s    contraproducentes. Si bien la Declaraci&oacute;n no eludi&oacute; la existe
ncia    de diferencias en t&eacute;rminos de sexo, color o religi&oacute;n, la i
nterpretaci&oacute;n    del mandato en cuanto a la acepci&oacute;n de raza, como
 categor&iacute;a de    discriminaci&oacute;n que hab&iacute;a que eliminar, lle
v&oacute; a producir    pr&aacute;cticas que atentaban contra la misma igualdad 
que buscaban, al generar    en algunos pa&iacute;ses una "cultura del silencio" 
que prefiri&oacute;    no preguntar el origen &eacute;tnico o racial de las pers
onas para no evidenciar    desigualdades. La cultura del silencio se constituy&o
acute; sobre el entendido    de que la "identidad cultural" tiene un car&aacute;
cter reservado    y que pertenece a la esfera privada de las personas. Esto llev
&oacute; a dar    igual tratamiento, por ejemplo, a la identidad religiosa o a l
a orientaci&oacute;n    sexual, que al origen &eacute;tnico de las personas, sin
 tomar en consideraci&oacute;n    que estas identidades —por tener diferentes ma
nifestaciones— tienen diferentes    percepciones e implicaciones y que algunas s
on m&aacute;s privadas que otras.    Muchas veces, como medio para llegar a la i
gualdad se prefiri&oacute; "invisibilizar"    las diferencias. Esto se nota en p
articular en la exclusi&oacute;n de la variable    raza en la recolecci&oacute;n
 de informaci&oacute;n estad&iacute;stica y en    la formulaci&oacute;n de pol&i
acute;ticas de car&aacute;cter universalista,    que no fueron sensibles a las n
ecesidades espec&iacute;ficas de los diferentes    grupos.</font></p>     ^cY#a0
9v22n6.htm##
01067000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704083200076002001300908#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a09v22n6.htm#S#p#34#30#article#127#<p><font size="2" f
ace="Verdana">En Am&eacute;rica Latina, algunos pa&iacute;ses    como M&eacute;x
ico y Per&uacute; fueron precursores en reconocer el peso de    las culturas pre
colombinas en la construcci&oacute;n de la identidad nacional,    pero la &oacut
e;ptica imperante en esta etapa fue a&uacute;n la antropol&oacute;gica,    enten
dida m&aacute;s como legado de un pasado heroico que como realidad social    pre
sente. La ideolog&iacute;a del indigenismo, vehiculizada desde las instituciones
    del Estado,<a name="tx05"></a><a href="#nt05"><SUP>5</SUP></a> ten&iacute;a 
   la tendencia de analizar a sus beneficiarios como "ex&oacute;ticos"    y much
as veces entend&iacute;an sus acciones como civilizadoras frente a lo    "salvaj
e", pero con un mensaje cultural monol&iacute;tico y etnoc&eacute;ntrico.</font>
</p>     ^cY#a09v22n6.htm##
00950000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704071500076002001300791#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a09v22n6.htm#S#p#35#31#article#127#<p><font size="2" f
ace="Verdana">Por otra parte, los procesos de descolonizaci&oacute;n    ocurrido
s a partir de la segunda mitad del decenio de 1950 en todo el mundo    modificar
on las relaciones de poder entre los grupos de diferentes or&iacute;genes    &ea
cute;tnicos. Esta descolonizaci&oacute;n contribuy&oacute; a eliminar las    bar
reras propias de las sociedades coloniales, que se caracterizaban por limitar   
 el acceso igualitario de los individuos a la ciudadan&iacute;a, y tuvo efectos 
   positivos en la recuperaci&oacute;n de identidades culturales, territorios,  
  lenguas y autonom&iacute;as, con la consiguiente conquista de la participaci&o
acute;n    social y pol&iacute;tica.</font></p>     ^cY#a09v22n6.htm##
01166000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704093100076002001301007#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a09v22n6.htm#S#p#36#32#article#127#<p><font size="2" f
ace="Verdana">Otra influencia decisiva en este cambio de enfoque    sobre el tra
tamiento de las minor&iacute;as &eacute;tnicas/ raciales fue el    movimiento pa
ra el rescate de los derechos civiles de la poblaci&oacute;n estadounidense    d
e ascendencia africana. El movimiento de los derechos civiles en los Estados    
Unidos de Am&eacute;rica luch&oacute; contra la segregaci&oacute;n a la que    e
staban sometidos sus ciudadanos de ascendencia africana y produjo una brecha    
en la cultura del silencio. En este per&iacute;odo tambi&eacute;n se comenz&oacu
te;    a distinguir entre la discriminaci&oacute;n individual por el origen &eac
ute;tnico/racial    y la de car&aacute;cter institucional. El movimiento de los 
derechos civiles    en los Estados Unidos fue el catalizador de la sociedad civi
l organizada que    reclamaba los derechos de las comunidades de descendientes d
e africanos.</font></p>     ^cY#a09v22n6.htm##
01884000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704164900076002001301725#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a09v22n6.htm#S#p#37#33#article#127#<p><font size="2" f
ace="Verdana">En 1965 se adopt&oacute; la Convenci&oacute;n    Internacional sob
re la Eliminaci&oacute;n de Todas las Formas de Discriminaci&oacute;n    Racial 
(8), la que por primera vez incorpor&oacute; una definici&oacute;n operativa    
de discriminaci&oacute;n racial como "toda distinci&oacute;n, exclusi&oacute;n, 
   restricci&oacute;n o preferencia basada en motivos de raza, color, linaje u  
  origen nacional o &eacute;tnico que tenga por objeto o por resultado anular   
 o menoscabar el reconocimiento, goce o ejercicio, en condiciones de igualdad,  
  de los derechos humanos y libertades fundamentales en las esferas pol&iacute;t
ica,    social o cultural, o en cualquier otra esfera de la vida p&uacute;blica"
    (art&iacute;culo 1). La Convenci&oacute;n incorpor&oacute;, tambi&eacute;n p
or    primera vez, una anticipaci&oacute;n a las acciones hoy llamadas afirmativ
as    al establecer en su art&iacute;culo 1.4 que "&#91;L&#93;as medidas especia
les adoptadas    con el fin exclusivo de asegurar el adecuado progreso de cierto
s grupos raciales    o &eacute;tnicos o de ciertas personas que requieran la pro
tecci&oacute;n que    pueda ser necesaria con objeto de garantizarles, en condic
iones de igualdad,    el disfrute o ejercicio de los derechos humanos y de las l
ibertades fundamentales    no se considerar&aacute;n como medidas de discriminac
i&oacute;n racial, siempre    que no conduzcan, como consecuencia, al mantenimie
nto de derechos distintos    para los diferentes grupos raciales y que no se man
tengan en vigor despu&eacute;s    de alcanzados los objetivos para los cuales se
 tomaron".</font></p>     ^cY#a09v22n6.htm##
00630000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704039500076002001300471#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a09v22n6.htm#S#p#38#34#article#127#<p><font size="2" f
ace="Verdana">La Convenci&oacute;n garantiza, asimismo, todos    los derechos ci
viles, pol&iacute;ticos, econ&oacute;micos, sociales y culturales:    trabajo, v
ivienda, salud p&uacute;blica y asistencia m&eacute;dica, seguridad    social, e
ducaci&oacute;n, participaci&oacute;n en las actividades culturales    y libre a
cceso a los lugares p&uacute;blicos.</font></p>     ^cY#a09v22n6.htm##
01682000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704144700076002001301523#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a09v22n6.htm#S#p#39#35#article#127#<p><font size="2" f
ace="Verdana">Otro importante instrumento internacional adoptado    en este per&
iacute;odo fue el Pacto Internacional de Derechos Econ&oacute;micos,    Sociales
 y Culturales (9). En su art&iacute;culo 2.2 se recupera la misma definici&oacut
e;n    de la Declaraci&oacute;n Universal de los Derechos Humanos, al referirse 
a "&#91;L&#93;os    Estados Partes en el presente Pacto se comprometen a garanti
zar el ejercicio    de los derechos que en &eacute;l se enuncian, sin discrimina
ci&oacute;n alguna    por motivos de raza, color, sexo, idioma, religi&oacute;n,
 opini&oacute;n pol&iacute;tica    o de otra &iacute;ndole, origen nacional o so
cial, posici&oacute;n econ&oacute;mica,    nacimiento o cualquier otra condici&o
acute;n social". Sin embargo, en el    art&iacute;culo 13 agrega un elemento nue
vo al hacer un llamamiento a los Estados    Partes a reconocer el derecho de tod
a persona a la educaci&oacute;n, con el    fin de hacer de ella un instrumento p
ara el desarrollo de la personalidad y    la dignidad humanas y el respeto a los
 derechos humanos y las libertades fundamentales.    De esta forma, confiere a l
a educaci&oacute;n la funci&oacute;n de "capacitar    a todas las personas para 
participar efectivamente en una sociedad libre, favorecer    la comprensi&oacute
;n, la tolerancia y la amistad entre todas las naciones y    entre todos los gru
pos raciales, &eacute;tnicos y religiosos . . ."</font></p>     ^cY#a09v22n6.htm
##
00793000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704055800076002001300634#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a09v22n6.htm#S#p#40#36#article#127#<p><font size="2" f
ace="Verdana">Si bien el Pacto es novedoso al aportar la tolerancia    como regl
a de convivencia social y en entender que la dignidad humana se construye    sob
re la base de la educaci&oacute;n, omite incorporar entre los componentes    de 
la educaci&oacute;n la revalorizaci&oacute;n de los aspectos culturales de    lo
s distintos grupos. Esto puede haber sido el reflejo de procesos de aculturaci&o
acute;n    que prescindieron de los aportes hist&oacute;ricos de las culturas de
 los grupos    &eacute;tnicos/raciales.</font></p>     ^cY#a09v22n6.htm##
01143000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704090800076002001300984#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a09v22n6.htm#S#p#41#37#article#127#<p><font size="2" f
ace="Verdana">En la Regi&oacute;n de las Am&eacute;ricas, la    Organizaci&oacut
e;n de Estados Americanos se hizo eco de esta discusi&oacute;n    y en 1969 adop
t&oacute; la Convenci&oacute;n Americana sobre Derechos Humanos    (10), que en 
su art&iacute;culo 1 establece que "los Estados Partes &#91;.    . .&#93; se com
prometen a respetar los derechos y libertades reconocidos en ella    y a garanti
zar su libre y pleno ejercicio a toda persona que est&eacute; sujeta    a su jur
isdicci&oacute;n, sin discriminaci&oacute;n alguna por motivos de raza,    color
, sexo, idioma, religi&oacute;n, opiniones pol&iacute;ticas o de cualquier    ot
ra &iacute;ndole, origen nacional o social, posici&oacute;n econ&oacute;mica,   
 nacimiento o cualquier otra condici&oacute;n social". Como puede observarse,   
 se mantienen conceptos semejantes a los adoptados hasta ese momento.</font></p>
     ^cY#a09v22n6.htm##
01690000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704145500076002001301531#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a09v22n6.htm#S#p#42#38#article#127#<p><font size="2" f
ace="Verdana">En s&iacute;ntesis, en esta etapa se hicieron    algunos aportes f
undamentales para el desarrollo del concepto etnia/raza, con    una participaci&
oacute;n m&aacute;s amplia de las agencias del sistema internacional    en el de
sarrollo de conceptos que se profundizaron en d&eacute;cadas posteriores    y co
mienza el reconocimiento de los derechos sociales. Tambi&eacute;n se hace    la 
distinci&oacute;n entre la discriminaci&oacute;n racial y la "discriminaci&oacut
e;n    positiva", que tiene como objetivo corregir diferencias indeseables que  
  son frutos de la opresi&oacute;n o de las exclusiones pasadas. Sin embargo,   
 persisti&oacute; una visi&oacute;n de individuos diferentes en relaci&oacute;n 
   con las categor&iacute;as enunciadas: raza, color, sexo, idioma, religi&oacut
e;n,    condici&oacute;n social, lugar de nacimiento; el <I>otro </I>se consider
aba    todav&iacute;a como <I>no perteneciente.</I> Es posible concluir que    a
 pesar de los avances logrados en este per&iacute;odo, se mantuvo una perspectiv
a    etnoc&eacute;ntrica. En Am&eacute;rica Latina, esta situaci&oacute;n coexis
ti&oacute;    con una sociedad civil muy incipiente dedicada a lo &eacute;tnico 
y con un enfoque    de rescate antropol&oacute;gico desde lo estatal que puso &e
acute;nfasis en    la asimilaci&oacute;n y el mestizaje como bases para la const
rucci&oacute;n    de sociedades m&aacute;s igualitarias.</font></p>     ^cY#a09v
22n6.htm##
00319000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704008400076002001300160#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a09v22n6.htm#S#p#43#39#article#127#<p><font size="2" f
ace="Verdana"><b>Segunda etapa: 1971–1990</b></font></p>     ^cY#a09v22n6.htm##
01261000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704102600076002001301102#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a09v22n6.htm#S#p#44#40#article#127#<p><font size="2" f
ace="Verdana">En esta segunda etapa se inici&oacute; el reconocimiento    de la 
necesidad de trabajar en la eliminaci&oacute;n de pol&iacute;ticas segregacionis
tas    respaldadas por el Estado. Con tal fin, en 1973 se adopt&oacute; la Conve
nci&oacute;n    Internacional sobre la Represi&oacute;n y el Castigo del Crimen 
de Apartheid,    que tipifica el <I>apartheid</I> como crimen de lesa humanidad.
 Esta Convenci&oacute;n    califica los actos inhumanos que resultaban de las po
l&iacute;ticas y pr&aacute;cticas    del <I>apartheid</I> y las pol&iacute;ticas
 y pr&aacute;cticas an&aacute;logas    de segregaci&oacute;n y discriminaci&oacu
te;n racial, que se definieron en su    art&iacute;culo II como cr&iacute;menes 
que violan los principios del derecho    internacional y los prop&oacute;sitos y
 principios de la Carta de las Naciones    Unidas. Por tanto, el <I>apartheid</I
> adquiere tambi&eacute;n el car&aacute;cter    de amenaza para la paz y la segu
ridad internacionales (11).</font></p>     ^cY#a09v22n6.htm##
01677000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704144200076002001301518#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a09v22n6.htm#S#p#45#41#article#127#<p><font size="2" f
ace="Verdana">En las dos d&eacute;cadas subsiguientes, los    principios y valor
es acu&ntilde;ados en la etapa precedente se recuperaron,    tanto en las instan
cias sectoriales como por parte de las diferentes agencias    de las Naciones Un
idas. Es as&iacute; que en 1978, la Organizaci&oacute;n de    las Naciones Unida
s para la Educaci&oacute;n la Ciencia y la Cultura (UNESCO)    emiti&oacute; la 
Declaraci&oacute;n sobre la Raza y los Prejuicios Raciales    (12). Esta Declara
ci&oacute;n, producida en el marco del Primer Decenio de Lucha    contra el Raci
smo y la Discriminaci&oacute;n, es categ&oacute;rica al establecer    en su art&
iacute;culo 1 que "&#91;T&#93;odos los seres humanos pertenecen a la    misma es
pecie y tienen el mismo origen. Nacen iguales en dignidad y derechos    y todos 
forman parte de la humanidad". En el art&iacute;culo 1.2 se reconoce    que "&#9
1;T&#93;odos los individuos y los grupos tienen derecho a ser diferentes,    a c
onsiderarse y ser considerados como tales". Esto constituy&oacute; una    evoluc
i&oacute;n en cuanto a la concepci&oacute;n de la Declaraci&oacute;n Universal  
  de los Derechos Humanos, centrada en conceder derechos por encima de toda dife
rencia.    El segundo aporte de la Declaraci&oacute;n de la UNESCO es que la sup
eraci&oacute;n    del racismo y la discriminaci&oacute;n est&aacute; asociada al
 logro de condiciones    de justicia y paz.</font></p>     ^cY#a09v22n6.htm##
01410000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704117500076002001301251#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a09v22n6.htm#S#p#46#42#article#127#<p><font size="2" f
ace="Verdana">A partir de esta Declaraci&oacute;n se reconoce    que todos los s
eres humanos pertenecen a la misma especie y tienen derecho a    ser diferentes 
y a considerarse y ser considerados en sus diferencias. Comienza    a conformars
e la figura de la diversidad de las formas de vida que se traduce    en el derec
ho a la "diferencia", aunque estas diferencias "no    pueden en ning&uacute;n ca
so servir de pretexto a los prejuicios raciales; no    pueden legitimar ni en de
recho ni de hecho ninguna pr&aacute;ctica discriminatoria,    ni fundar la pol&i
acute;tica de <I>apartheid</I> que constituye la forma extrema    del racismo" (
art&iacute;culo 2.2). Entonces, el derecho no se confiere    con un criterio con
nivente que hace de su reconocimiento una prerrogativa etnoc&eacute;ntrica,    s
ino como algo propio del g&eacute;nero humano como un todo. Esta nueva conceptua
lizaci&oacute;n    tiene una gran importancia en la evoluci&oacute;n posterior d
el concepto etnia/raza,    para la definici&oacute;n de la identidad cultural y 
la solidificaci&oacute;n    de la tolerancia.<a name="tx06"></a><a href="#nt06">
<SUP>6</sup></a></font></p>     ^cY#a09v22n6.htm##
01716000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704148100076002001301557#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a09v22n6.htm#S#p#47#43#article#127#<p><font size="2" f
ace="Verdana">En el &aacute;mbito de la salud, la Conferencia    Internacional s
obre Atenci&oacute;n Primaria de Salud, reunida en Alma Ata,    Kazajst&aacute;n
, ex Uni&oacute;n Sovi&eacute;tica, en 1978 (13), mostr&oacute;    preocupaci&oa
cute;n por atender las necesidades de salud de los grupos vulnerables,    cuyo a
cceso a la atenci&oacute;n estaba restringido por factores "geogr&aacute;ficos, 
   culturales, pol&iacute;ticos, sociales o financieros". Si bien no se hace    
menci&oacute;n al origen &eacute;tnico como un determinante social de la situaci
&oacute;n    de salud o del acceso a los servicios, el esp&iacute;ritu que impre
gna a la    Declaraci&oacute;n de Alma Ata (13), que surge de la Conferencia, es
 que al    dise&ntilde;ar pol&iacute;ticas y programas de salud se deben conside
rar las    condiciones econ&oacute;micas y las caracter&iacute;sticas sociales d
el pa&iacute;s    y de sus comunidades. Asimismo, la Declaraci&oacute;n de Alma 
Ata focaliz&oacute;    la atenci&oacute;n en la priorizaci&oacute;n de lo local 
y favoreci&oacute;    la inclusi&oacute;n de los niveles locales, en los que se 
concentran los grupos    &eacute;tnicos/ raciales. En la misma l&iacute;nea, la 
atenci&oacute;n primaria    promueve la participaci&oacute;n comunitaria en el d
ise&ntilde;o de pol&iacute;ticas    y reconoce que esta constituye un medio para
 valorizar la diversidad sociopol&iacute;tica    y cultural del complejo naciona
l.</font></p>     ^cY#a09v22n6.htm##
01166000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704093100076002001301007#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a09v22n6.htm#S#p#48#44#article#127#<p><font size="2" f
ace="Verdana">En la estrategia planteada de atenci&oacute;n    primaria se recon
oci&oacute; el papel positivo de las curanderas y parteras    tradicionales como
 agentes de influencia en las pr&aacute;cticas sanitarias    de la comunidad. Es
 importante destacar que ya en 1978, la atenci&oacute;n primaria    de salud rec
onoci&oacute; la posibilidad de complementar la capacitaci&oacute;n    de los ag
entes de la medicina tradicional e incorporarlos a los sistemas nacionales    de
 salud. En consonancia con la Resoluci&oacute;n del Comit&eacute; Regional    pa
ra &Aacute;frica de la Organizaci&oacute;n Mundial de la Salud, aprobada en    2
000, en ese continente se adopt&oacute; en 2001 la medicina tradicional como    
una estrategia prioritaria para extender la cobertura de los servicios y las    
autoridades de salud convinieron en establecer una d&eacute;cada para su desarro
llo    (14).</font></p>     ^cY#a09v22n6.htm##
01085000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704085000076002001300926#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a09v22n6.htm#S#p#49#45#article#127#<p><font size="2" f
ace="Verdana">En esta etapa se produjo en Am&eacute;rica Latina    un profundo r
eplanteo de las democracias, como consecuencia del regreso progresivo    al cons
titucionalismo en la mayor&iacute;a de los pa&iacute;ses. La nueva democracia   
 comenz&oacute; con la reconstrucci&oacute;n del Estado mediante la descentraliz
aci&oacute;n    administrativa. Esta estrategia revaloriz&oacute; lo local y evi
denci&oacute;    la existencia de grupos a nivel comunitario —como los grupos &e
acute;tnicos/raciales—    que manten&iacute;an vivas sus culturas y tradiciones.
 A esto se agreg&oacute;    una revisi&oacute;n de la relaci&oacute;n Estado-ind
ividuo, que se manifest&oacute;    en la necesidad de hacer efectivo un conjunto
 de derechos que hab&iacute;an    estado suspendidos durante los reg&iacute;mene
s de facto.</font></p>     ^cY#a09v22n6.htm##
01321000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704108600076002001301162#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a09v22n6.htm#S#p#50#46#article#127#<p><font size="2" f
ace="Verdana">Los procesos de transici&oacute;n a la democracia    en Am&eacute;
rica Latina dieron lugar a una revitalizaci&oacute;n de la sociedad    civil y g
eneraron nuevos foros de discusi&oacute;n y reivindicaci&oacute;n de    los dere
chos comprendidos en el concepto de ciudadan&iacute;a. Como parte de    este pro
ceso, la sociedad civil se diversific&oacute; e incorpor&oacute; organizaciones 
   que representaban temas y segmentos de la poblaci&oacute;n que no hab&iacute;
an    estado organizados anteriormente. Las organizaciones de mujeres y las que 
representaban    a minor&iacute;as &eacute;tnicas/raciales, junto con las entida
des de nivel    local, se organizaron para reivindicar una mayor participaci&oac
ute;n y medidas    para eliminar la discriminaci&oacute;n de g&eacute;nero y &ea
cute;tnica/racial.    Surgi&oacute; entonces, como un nuevo desaf&iacute;o de la
 democracia, la necesidad    de responder al reclamo de inclusi&oacute;n social 
y pol&iacute;tica de grupos    que hasta entonces hab&iacute;an permanecido marg
inados.</font></p>     ^cY#a09v22n6.htm##
01384000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704114900076002001301225#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a09v22n6.htm#S#p#51#47#article#127#<p><font size="2" f
ace="Verdana">En esta etapa, Am&eacute;rica Latina fue tambi&eacute;n    escenar
io de una actividad creciente del movimiento por los derechos de las    mujeres 
y se obtuvieron importantes logros en t&eacute;rminos de participaci&oacute;n   
 pol&iacute;tica y de acceso al mercado de trabajo. Por otra parte, favorecidos 
   por los procesos de reconstrucci&oacute;n democr&aacute;tica, los movimientos
    que representaban a las minor&iacute;as &eacute;tnicas avanzaron en la elabo
raci&oacute;n    y "complejizaci&oacute;n" de sus plataformas de reivindicacione
s.    Nuevos temas —como el reconocimiento de ser Estados pluri&eacute;tnicos, p
luriculturales    y multiling&uuml;es— acompa&ntilde;aron las demandas sobre la 
construcci&oacute;n    de las identidades y derechos de los pueblos ind&iacute;g
enas. En este per&iacute;odo,    tambi&eacute;n el movimiento ind&iacute;gena ga
n&oacute; solidez en su estructura,    super&oacute; segmentaciones, articul&oac
ute; sus redes y fortaleci&oacute;    su capacidad de di&aacute;logo con el Esta
do, lo que le permiti&oacute; ejercer    funciones de abogac&iacute;a.</font></p
>     ^cY#a09v22n6.htm##
01271000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704103600076002001301112#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a09v22n6.htm#S#p#52#48#article#127#<p><font size="2" f
ace="Verdana">El Convenio 169 sobre Pueblos Ind&iacute;genas    y Tribales en Pa
&iacute;ses Independientes (15), adoptado por la Organizaci&oacute;n    Mundial 
del Trabajo en 1989, fue uno de los instrumentos clave para fortalecer    el pro
ceso de estructuraci&oacute;n del movimiento social que representaba a    los pu
eblos ind&iacute;genas. Desde la etapa de su discusi&oacute;n, este Convenio    
se caracteriz&oacute; por la participaci&oacute;n social. La participaci&oacute;
n    de los l&iacute;deres y representantes de las comunidades de base fue decis
iva    en la definici&oacute;n misma de los pueblos ind&iacute;genas y tribales,
 lo    que contribuy&oacute; a la construcci&oacute;n de la propia identidad de 
los    pa&iacute;ses de la Regi&oacute;n. Para Am&eacute;rica Latina, este Conve
nio    tiene la particularidad de haberse discutido y adoptado en los a&ntilde;o
s previos    a la conmemoraci&oacute;n de los 500 a&ntilde;os de la llegada de l
os europeos    a las Am&eacute;ricas.</font></p>     ^cY#a09v22n6.htm##
01654000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704141900076002001301495#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a09v22n6.htm#S#p#53#49#article#127#<p><font size="2" f
ace="Verdana">Este Convenio reconoci&oacute; la necesidad de    revisar la norma
tiva internacional con vistas a eliminar la orientaci&oacute;n    hacia la asimi
laci&oacute;n, propia de la etapa anterior. Asimismo, consider&oacute;    como s
us beneficiarios a dos grupos &eacute;tnicos: los pueblos tribales y los    pueb
los ind&iacute;genas.<a name="tx07"></a><a href="#nt07"><SUP>7</SUP></a>    Los 
pueblos tribales se distinguen de otros sectores de la colectividad nacional    
"por sus condiciones sociales, culturales y econ&oacute;micas" y se    encuentra
n "regidos total o parcialmente por sus propias costumbres o tradiciones    o po
r una legislaci&oacute;n especial. Se consideran pueblos ind&iacute;genas    a l
os descendientes de las poblaciones que habitaban el pa&iacute;s antes de    la 
&eacute;poca de la conquista o la colonizaci&oacute;n o del establecimiento    d
e las actuales fronteras estatales y "que, cualquiera que sea su situaci&oacute;
n    jur&iacute;dica, conserv&#91;e&#93;n todas sus propias instituciones social
es, econ&oacute;micas,    culturales y pol&iacute;ticas, o parte de ellas" (Art&
iacute;culo 1.a y    1.b). Esta definici&oacute;n tambi&eacute;n establece que u
n componente central    de la identidad es la preservaci&oacute;n de las cultura
s propias y la conservaci&oacute;n    de sus instituciones sociales, econ&oacute
;micas y culturales.</font></p>     ^cY#a09v22n6.htm##
01111000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704087600076002001300952#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a09v22n6.htm#S#p#54#50#article#127#<p><font size="2" f
ace="Verdana">La aprobaci&oacute;n del Convenio 169 inspir&oacute;    la formula
ci&oacute;n de legislaciones basadas en el concepto operativo de poblaciones    
ind&iacute;genas y tribales. Si bien este concepto fue aceptado a nivel global  
  y se aplic&oacute; a todas las culturas que anteced&iacute;an al proceso de   
 colonizaci&oacute;n, en Am&eacute;rica Latina gener&oacute; dos importantes    
fen&oacute;menos. El primero de ellos fue la identificaci&oacute;n m&aacute;s   
 adecuada de los pueblos ind&iacute;genas y tribales en su especificidad y con  
  sus caracter&iacute;sticas e identidades propias; el otro, fue la "invisibiliz
aci&oacute;n"    de un importante contingente humano cuyos ancestros llegaron a 
la Regi&oacute;n    en condiciones forzadas durante la &eacute;poca colonial, co
mo los descendientes    de africanos.</font></p>     ^cY#a09v22n6.htm##
01252000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704101700076002001301093#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a09v22n6.htm#S#p#55#51#article#127#<p><font size="2" f
ace="Verdana">La imposibilidad de encuadrar a los afrodescendientes    en la cat
egorizaci&oacute;n operativa utilizada por el Convenio 169 —porque    al ser tra
sladados a la Regi&oacute;n perdieron sus lenguas de origen y la mayor&iacute;a 
   de sus instituciones no sobrevivieron al proceso de la di&aacute;spora— ocasi
on&oacute;    su exclusi&oacute;n de las pol&iacute;ticas y programas con enfoqu
e &eacute;tnico    generados durante el decenio de 1990. M&aacute;s aun, por las
 condiciones de    su inserci&oacute;n pol&iacute;tica, econ&oacute;mica y socia
l, este grupo fue    susceptible a las pol&iacute;ticas de asimilaci&oacute;n, c
on la consiguiente    debilitaci&oacute;n de su identidad. En el &aacute;mbito a
cad&eacute;mico de    algunos pa&iacute;ses de la regi&oacute;n, como Brasil, Co
lombia y Ecuador,    se comenzaron a cuestionar los mitos de la "democracia raci
al" y el    mestizaje como v&iacute;a para crear la identidad (16) y lograr la i
ntegraci&oacute;n.</font></p>     ^cY#a09v22n6.htm##
01660000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704142500076002001301501#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a09v22n6.htm#S#p#56#52#article#127#<p><font size="2" f
ace="Verdana">En esta segunda etapa se revitaliz&oacute; el    tema de los derec
hos humanos en las agencias del Sistema de las Naciones Unidas,    las que apoya
ron la ampliaci&oacute;n de este tema al &aacute;mbito sectorial    y social. La
 lucha contra el racismo y la discriminaci&oacute;n asumi&oacute;    nuevas form
as en la medida en que en la Regi&oacute;n se formulaban reivindicaciones    rel
acionadas con el multiculturalismo de las sociedades y la necesidad de otorgar  
  a los Estados la capacidad de representar a sociedades multi&eacute;tnicas y  
  multiling&uuml;es. En este proceso se consolidaron liderazgos ind&iacute;genas
    que ya se perfilaban desde mediados de la d&eacute;cada de 1970, lo que dio 
   lugar a un movimiento de reivindicaci&oacute;n de car&aacute;cter &eacute;tni
co.    La gran mayor&iacute;a de los pueblos precolombinos se asumieron a s&iacu
te;    mismos como pueblos ind&iacute;genas y se reconocieron como grupos &eacut
e;tnicos,    lo que dio a la identidad cultural un valor de elemento constitutiv
o. Al importante    contingente de latinoamericanos descendientes de africanos —
a los que en algunos    documentos se refieren como afrolatinos— "invisibilizado
s" se sumaron    otros grupos de menor peso demogr&aacute;fico, como algunos gru
pos de inmigrantes    y pueblos rom, que conservaban un marcado acervo cultural 
y ling&uuml;&iacute;stico.</font></p>     ^cY#a09v22n6.htm##
00949000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704071400076002001300790#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a09v22n6.htm#S#p#57#53#article#127#<p><font size="2" f
ace="Verdana">En esta etapa, algunos pa&iacute;ses fueron pioneros    en estudia
r las condiciones de vida de los grupos &eacute;tnicos y en identificar    los e
lementos centrales de la identidad. Estos estudios permitieron profundizar    en
 la evoluci&oacute;n del concepto etnia/raza. Los pueblos ind&iacute;genas,    a
poyados en el proceso generado por la discusi&oacute;n del Convenio 169, desempe
&ntilde;aron    un papel muy activo y ganaron presencia a nivel del Estado. Est&
aacute; claro    que uno de sus mayores logros fue el reconocimiento de la ident
idad como elemento    constitutivo del individuo y vivir la identidad propia se 
elev&oacute; a nivel    de derecho.</font></p>     ^cY#a09v22n6.htm##
00319000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704008400076002001300160#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a09v22n6.htm#S#p#58#54#article#127#<p><font size="2" f
ace="Verdana"><b>Tercera etapa: 1991–2000</b></font></p>     ^cY#a09v22n6.htm##
00839000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704060400076002001300680#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a09v22n6.htm#S#p#59#55#article#127#<p><font size="2" f
ace="Verdana">En esta etapa, la Conferencia Mundial de Derechos    Humanos refre
nd&oacute; en la Declaraci&oacute;n y Programa de Acci&oacute;n    de Viena de 1
993 la importancia de la democracia y del desarrollo para la vigencia    de los 
derechos (17). Con esta Declaraci&oacute;n, el rechazo a la discriminaci&oacute;
n    sali&oacute; del &aacute;mbito individual y se insert&oacute; en la agenda 
estatal    al analizar las modalidades para albergar la diversidad. Asimismo, se
 asociaron    los conceptos de no discriminaci&oacute;n y de inclusi&oacute;n so
cial.</font></p>     ^cY#a09v22n6.htm##
01189000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704095400076002001301030#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a09v22n6.htm#S#p#60#56#article#127#<p><font size="2" f
ace="Verdana">Esta Declaraci&oacute;n fue novedosa por diversificar    los fen&o
acute;menos que se quer&iacute;an superar, como la xenofobia y la intolerancia. 
   La Declaraci&oacute;n tambi&eacute;n ampli&oacute; el alcance de los grupos  
  vulnerables al incorporar a las mujeres, las minor&iacute;as ling&uuml;&iacute
;sticas,    los ni&ntilde;os y ni&ntilde;as, los discapacitados, los pueblos ind
&iacute;genas    y los trabajadores migrantes. M&aacute;s aun, en su inciso 24 s
e establec&iacute;a    la obligaci&oacute;n de los Estados de adoptar y mantener
 "medidas adecuadas    en el plano nacional, en particular en materia de educaci
&oacute;n, salud y    apoyo social, para promover y proteger los derechos de los
 sectores vulnerables    de la poblaci&oacute;n y asegurar la participaci&oacute
;n de las personas pertenecientes    a esos sectores en la b&uacute;squeda de un
a soluci&oacute;n a sus problemas".</font></p>     ^cY#a09v22n6.htm##
00995000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704076000076002001300836#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a09v22n6.htm#S#p#61#57#article#127#<p><font size="2" f
ace="Verdana">La Conferencia Mundial de Derechos Humanos termin&oacute;    con l
a recomendaci&oacute;n a la Asamblea General, a la Comisi&oacute;n de Derechos  
  Humanos y a otros &oacute;rganos y organismos del Sistema de las Naciones Unid
as,    de proclamar el Decenio de las Naciones Unidas para los Derechos Humanos.
 La    Conferencia recomend&oacute; tambi&eacute;n que la Comisi&oacute;n de Der
echos    Humanos examinara cada a&ntilde;o los progresos logrados en la aplicaci
&oacute;n    de las recomendaciones de la Declaraci&oacute;n y Programa de Acci&
oacute;n    de Viena. Con esta solicitud se estimul&oacute; la adopci&oacute;n e
n los Estados    de las medidas necesarias para lograr los objetivos mencionados
.</font></p>     ^cY#a09v22n6.htm##
01271000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704103600076002001301112#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a09v22n6.htm#S#p#62#58#article#127#<p><font size="2" f
ace="Verdana">En este per&iacute;odo, el Comit&eacute; de Derechos    Econ&oacut
e;micos, Sociales y Culturales del Consejo Econ&oacute;mico y Social    de las N
aciones Unidas hizo una revisi&oacute;n sobre la aplicaci&oacute;n del    art&ia
cute;culo 13 del Pacto Internacional de Derechos Econ&oacute;micos, Sociales    
y Culturales, de 1966, relativo al derecho de toda persona a la educaci&oacute;n
.    Con relaci&oacute;n al p&aacute;rrafo 2 en particular, el Comit&eacute; est
ableci&oacute;    en su observaci&oacute;n No. 13 que los Estados tienen la obli
gaci&oacute;n    de "respetar, proteger y llevar a efecto cada una de las caract
er&iacute;sticas    fundamentales (disponibilidad, accesibilidad, aceptabilidad 
y adaptabilidad)    del derecho a la educaci&oacute;n". La aceptabilidad de la e
ducaci&oacute;n    implica la adopci&oacute;n de "medidas positivas para que la 
educaci&oacute;n    sea culturalmente aceptable para las minor&iacute;as y las p
oblaciones ind&iacute;genas"    (18).</font></p>     ^cY#a09v22n6.htm##
01338000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704110300076002001301179#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a09v22n6.htm#S#p#63#59#article#127#<p><font size="2" f
ace="Verdana">La Conferencia de las Naciones Unidas sobre el    Medio Ambiente y
 el Desarrollo, celebrada en R&iacute;o de Janeiro, Brasil,    en 1992, asoci&oa
cute; el tema de las poblaciones ind&iacute;genas al mantenimiento    de la esta
bilidad ambiental y a la interdependencia creciente entre los pa&iacute;ses.    
La Agenda 21, que surgi&oacute; de esa reuni&oacute;n cumbre, puso &eacute;nfasi
s    en el uso racional de los recursos y su conservaci&oacute;n con miras al de
sarrollo    sostenible. Apareci&oacute; entonces el &eacute;nfasis en que "las p
oblaciones    ind&iacute;genas y sus comunidades, as&iacute; como otras comunida
des locales,    desempe&ntilde;an un papel fundamental en la ordenaci&oacute;n d
el medio ambiente    y en el desarrollo, debido a sus conocimientos y pr&aacute;
cticas tradicionales".    Como consecuencia, se estableci&oacute; que los Estado
s deben reconocer y apoyar    debidamente la identidad, cultura e intereses de e
sas poblaciones y posibilitar    su participaci&oacute;n efectiva en el logro de
l desarrollo sostenible.</font></p>     ^cY#a09v22n6.htm##
01413000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704117800076002001301254#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a09v22n6.htm#S#p#64#60#article#127#<p><font size="2" f
ace="Verdana">Esto signific&oacute; dar prioridad a la participaci&oacute;n    d
e las poblaciones ind&iacute;genas en la planificaci&oacute;n del desarrollo    
sostenible y reconocer el v&iacute;nculo entre ellas y los territorios ricos    
en recursos naturales en los que habitan. Al mismo tiempo, se potenci&oacute;   
 el conocimiento ancestral de esas poblaciones sobre la utilizaci&oacute;n de   
 dichos recursos, lo que significaba reconocer la importancia de la diversidad  
  desde un enfoque que trasciende lo cultural para insertarse en lo cient&iacute
;fico.    Surgi&oacute; as&iacute; una nueva estrategia para el empoderamiento d
e esas    poblaciones mediante el cumplimiento de los convenios derivados de la 
Agenda    21 y la obligaci&oacute;n de legislar a nivel nacional sobre el derech
o de propiedad    intelectual y cultural ind&iacute;gena y la protecci&oacute;n 
del ambiente.    Si bien la Agenda 21 promovi&oacute; el apoyo a la medicina tra
dicional, la    referencia a las poblaciones ind&iacute;genas dej&oacute; fuera 
a otros grupos    &eacute;tnicos de poblaci&oacute;n tambi&eacute;n numerosa, co
mo los afrolatinos.</font></p>     ^cY#a09v22n6.htm##
01331000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704109600076002001301172#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a09v22n6.htm#S#p#65#61#article#127#<p><font size="2" f
ace="Verdana">La Declaraci&oacute;n de la IV Conferencia de    las Naciones Unid
as sobre la Mujer, realizada en 1995 en Beijing, China (19),    hizo una sola me
nci&oacute;n al tema etnia/raza al instar a los Estados a "&#91;I&#93;ntensifica
r    los esfuerzos para asegurar el disfrute, en condiciones de igualdad, de tod
os    los derechos humanos y libertades fundamentales a todas las mujeres y las 
ni&ntilde;as    que se enfrentan con m&uacute;ltiples barreras para su empoderam
iento y su avance    por factores tales como la raza, la edad, el idioma, el ori
gen &eacute;tnico,    la cultura, la religi&oacute;n o la discapacidad o porque 
son poblaci&oacute;n    ind&iacute;gena". El gran aporte de esta Declaraci&oacut
e;n radica en hacer    evidente que cuando existen factores de discriminaci&oacu
te;n que se superponen,    como los de g&eacute;nero y los de origen &eacute;tni
co/ racial, la vulnerabilidad    de la poblaci&oacute;n se intensifica. El orige
n &eacute;tnico/racial aparece    como un determinante social de las condiciones
 de vida y salud.</font></p>     ^cY#a09v22n6.htm##
00964000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704072900076002001300805#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a09v22n6.htm#S#p#66#62#article#127#<p><font size="2" f
ace="Verdana">En 1994 comenz&oacute; el Decenio Internacional    de las Poblacio
nes Ind&iacute;genas del Mundo, convocado por las Naciones Unidas    (20), y se 
estableci&oacute; como meta fortalecer la cooperaci&oacute;n internacional    pa
ra la soluci&oacute;n de los problemas que enfrentan los ind&iacute;genas    en 
aspectos tales como los derechos humanos, la educaci&oacute;n, el medio ambiente
,    el desarrollo y la salud. Se invit&oacute; a los gobiernos a establecer com
it&eacute;s    nacionales y otras estructuras de car&aacute;cter permanente en l
os que participaran    representantes de las poblaciones ind&iacute;genas, a fin
 de planificar las    actividades para el decenio.</font></p>     ^cY#a09v22n6.h
tm##
01713000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704147800076002001301554#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a09v22n6.htm#S#p#67#63#article#127#<p><font size="2" f
ace="Verdana">El tema &eacute;tnico apareci&oacute; con mucha    fuerza en las a
gendas de los pa&iacute;ses desarrollados, en particular de Europa,    debido a 
crueles enfrentamientos entre diferentes grupos &eacute;tnicos que    produjeron
 p&eacute;rdidas de vidas, oportunidades truncadas para las generaciones    j&oa
cute;venes y un considerable contingente de refugiados en muchos pa&iacute;ses  
  europeos. Entre 1992 y 1995, tres grupos &eacute;tnicos —los serbios, los croa
tas    y los musulmanes— se enfrentaron cruelmente en la Rep&uacute;blica de Bos
nia    y Herzegovina. En Ruanda, las milicias de los hutus asesinaron a m&aacute
;s    de 800 000 tutsis. Alrededor de 10% de la poblaci&oacute;n de Ruanda fue v
&iacute;ctima    de la violencia &eacute;tnica en solo tres meses y, seg&uacute;
n el Fondo de    las Naciones Unidas para la Infancia (UNICEF), 95 000 ni&ntilde
;os perdieron    a sus padres en el conflicto. Este tipo de enfrentamientos llev
&oacute; a los    gobiernos de los pa&iacute;ses desarrollados y a las organizac
iones internacionales    a incorporar los temas de la discriminaci&oacute;n, la 
xenofobia y el racismo    en sus agendas. En el Sistema de las Naciones Unidas, 
esta preocupaci&oacute;n    se expres&oacute; en la convocatoria a la Tercera Co
nferencia Mundial contra    el Racismo, la Discriminaci&oacute;n Racial, la Xeno
fobia y las Forma Conexas    de Intolerancia, que se celebrar&iacute;a en 2001.<
/font></p>     ^cY#a09v22n6.htm##
00857000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704062200076002001300698#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a09v22n6.htm#S#p#68#64#article#127#<p><font size="2" f
ace="Verdana">En la Regi&oacute;n de las Am&eacute;ricas, esta    tercera etapa 
est&aacute; marcada por la conmemoraci&oacute;n del quinto centenario    del arr
ibo de los europeos a las Am&eacute;ricas, lo que condujo a la revalorizaci&oacu
te;n    de lo pluricultural como caracter&iacute;stica de las sociedades actuale
s. Hay    una inflexi&oacute;n importante en el espacio que se le otorgaba a lo 
&eacute;tnico,    pues dej&oacute; de ser solamente una categor&iacute;a de la h
istoria precolombina    para convertirse en un componente social y demogr&aacute
;fico de la actualidad.</font></p>     ^cY#a09v22n6.htm##
01092000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704085700076002001300933#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a09v22n6.htm#S#p#69#65#article#127#<p><font size="2" f
ace="Verdana">La revitalizaci&oacute;n de la democracia en    la Regi&oacute;n s
e acompa&ntilde;&oacute; de la realizaci&oacute;n sistem&aacute;tica    de las C
umbres de Jefes de Estado y de Gobierno de Am&eacute;rica Latina, Espa&ntilde;a 
   y Portugal, iniciadas en 1991 en Guadalajara, M&eacute;xico. Estas reuniones 
   constituyen un espacio de discusi&oacute;n de temas de desarrollo pol&iacute;
tico    y social, basado en la revalorizaci&oacute;n de los v&iacute;nculos hist
&oacute;ricos    que unen a Espa&ntilde;a, Portugal y Am&eacute;rica Latina. Coi
ncidiendo con    los preparativos para la celebraci&oacute;n de los 500 a&ntilde
;os de interacci&oacute;n    entre Europa y las Am&eacute;ricas, la Cumbre de Gu
adalajara busc&oacute; proyectar    la fuerza de la comunidad iberoamericana en 
el tercer milenio.</font></p>     ^cY#a09v22n6.htm##
01332000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704109700076002001301173#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a09v22n6.htm#S#p#70#66#article#127#<p><font size="2" f
ace="Verdana">El anuncio de la adopci&oacute;n por parte de    la comunidad inte
rnacional de 1993 como A&ntilde;o Internacional de los Pueblos    Ind&iacute;gen
as tambi&eacute;n contribuy&oacute; a que en la Declaraci&oacute;n    de la Cumb
re se reconociera el aporte de los pueblos ind&iacute;genas y "la    inmensa con
tribuci&oacute;n de los pueblos ind&iacute;genas al desarrollo y    pluralidad d
e nuestras sociedades y &#91;se reiterara el&#93; compromiso por su bienestar   
 econ&oacute;mico y social, as&iacute; como la obligaci&oacute;n de respetar    
sus derechos y su identidad cultural" (21). Como consecuencia de esto,    los je
fes de Estado y de gobierno iberoamericanos propusieron crear un fondo    iberoa
mericano para el desarrollo de los pueblos ind&iacute;genas, con el apoyo    de 
los organismos internacionales. El objetivo de este fondo es contribuir a    res
olver favorablemente "los problemas acuciantes de los pueblos originarios,    al
 margen de cualquier sentido de reservas ind&iacute;genas o compensaciones    pa
ternalistas" (21).</font></p>     ^cY#a09v22n6.htm##
01438000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704120300076002001301279#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a09v22n6.htm#S#p#71#67#article#127#<p><font size="2" f
ace="Verdana">En el curso de la Segunda Cumbre Iberoamericana,    celebrada en 1
992 en Madrid, Espa&ntilde;a, se hicieron operativas las conclusiones    emanada
s de la Cumbre de Guadalajara de 1991 y se firm&oacute; el Convenio Constitutivo
    del Fondo para el Desarrollo de los Pueblos Ind&iacute;genas de Am&eacute;ri
ca    Latina y el Caribe. La Tercera Cumbre, celebrada en 1993 en la ciudad de B
ah&iacute;a,    Brasil, inform&oacute; sobre los avances en la organizaci&oacute
;n de este Fondo.<a name="tx08"></a><a href="#nt08"><SUP>8</SUP></a>    El Conve
nio estableci&oacute; dos &oacute;rganos de direcci&oacute;n: la Asamblea    Gen
eral y el Consejo Directivo. En ambos &oacute;rganos se previ&oacute; la    part
icipaci&oacute;n de los gobiernos y de delegados de los pueblos ind&iacute;genas
,    lo que favorec&iacute;a la creaci&oacute;n de un mecanismo de canalizaci&oa
cute;n    directa de las demandas de estos pueblos. La Asamblea General deb&iacu
te;a aprobar    los proyectos que el Fondo desarrollara, lo que garantizaba el r
espaldo de los    delegados de los pueblos ind&iacute;genas en la gesti&oacute;n
 t&eacute;cnica    de la instituci&oacute;n.</font></p>     ^cY#a09v22n6.htm##
01521000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704128600076002001301362#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a09v22n6.htm#S#p#72#68#article#127#<p><font size="2" f
ace="Verdana">En los pa&iacute;ses de Am&eacute;rica Latina,    en particular, s
e comenz&oacute; a repensar el tema de la construcci&oacute;n    de la naci&oacu
te;n en el marco de las transiciones democr&aacute;ticas, y el    cuestionamient
o de la naturaleza de sus sociedades volvi&oacute; con fuerza    a entrar en la 
agenda social. Se analizaron los mecanismos de integraci&oacute;n    social util
izados en el pasado y sus resultados. La estrategia de asimilaci&oacute;n    que
 minimizaba las diferencias entre los grupos se ve&iacute;a ahora superada    po
r otra que llevaba a valorizarlas y se sustituy&oacute; el concepto de homogeniz
aci&oacute;n    y el etnoculturalismo por el de sociedades plurales multicultura
les. La tolerancia    a la diversidad comenz&oacute; a ser un nuevo valor propio
 de este paradigma    que llev&oacute; a la necesidad de crear una nueva concepc
i&oacute;n del sujeto    de derecho, que permitiera reconocer al diferente como 
un igual pleno (22).    A nivel m&aacute;s global, esta etapa coincidi&oacute; c
on la posmodernidad,    caracterizada por repensar la identidad desde la diferen
cia. "La identidad    se ve como algo construido mediante complejos proceso de r
elacionalidad y representaci&oacute;n"    (16).</font></p>     ^cY#a09v22n6.htm#
#
01171000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704093600076002001301012#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a09v22n6.htm#S#p#73#69#article#127#<p><font size="2" f
ace="Verdana">Como s&iacute;ntesis de este per&iacute;odo en    la Regi&oacute;n
 de las Am&eacute;ricas se puede anotar que el tema de los derechos    de los pu
eblos ind&iacute;genas comenz&oacute; a incorporarse a todas las manifestaciones
    pol&iacute;ticas, se reconocieron sus saberes, se crearon instancias de dist
intas    naturalezas a nivel nacional (unidades, programas o institutos), se est
ableci&oacute;    un marco temporal para mantener activos los esfuerzos y se apr
ob&oacute; el    Decenio de los Pueblos Ind&iacute;genas. Se acept&oacute; que p
ara poder alcanzar    logros tangibles, se necesitaban compromisos s&oacute;lido
s que no se interrumpieran    con los cambios de gobierno. Tambi&eacute;n se ini
ci&oacute; el an&aacute;lisis    de los factores discriminatorios cuando son acu
mulativos, como el g&eacute;nero,    la etnia/raza y la pobreza, como demuestran
 muchos estudios.</font></p>     ^cY#a09v22n6.htm##
01089000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704085400076002001300930#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a09v22n6.htm#S#p#74#70#article#127#<p><font size="2" f
ace="Verdana">No obstante, se debe se&ntilde;alar que el inter&eacute;s    estuv
o fundamentalmente centrado en los pueblos ind&iacute;genas y se prest&oacute;  
  mucho menos atenci&oacute;n a otros grupos, como los migrantes, los pueblos   
 rom y los afrolatinos. En el mejor de los casos, esas poblaciones entraban en  
  una categor&iacute;a m&aacute;s difusa como "otros", tal como se observ&oacute
;    durante esta etapa en algunas de las boletas de recolecci&oacute;n de infor
maci&oacute;n    en censos y encuesta de hogares. Por lo tanto, persisti&oacute;
 la idea de que    los pueblos ind&iacute;genas eran los &uacute;nicos que conta
ban con una riqueza    cultural que les permit&iacute;a definirse como "grupo es
pecial",    mientras el resto se mezclaba an&oacute;nimo en el conjunto de la po
blaci&oacute;n.</font></p>     ^cY#a09v22n6.htm##
00331000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009600076002001300172#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a09v22n6.htm#S#p#75#71#article#127#<p><font size="2" f
ace="Verdana"><b>Cuarta etapa: 2001 hasta el presente</b></font></p>     ^cY#a09
v22n6.htm##
01132000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704089700076002001300973#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a09v22n6.htm#S#p#76#72#article#127#<p><font size="2" f
ace="Verdana">Esta etapa est&aacute; marcada por el proceso    de organizaci&oac
ute;n y la realizaci&oacute;n de la Tercera Conferencia Mundial    contra el Rac
ismo, la Discriminaci&oacute;n Racial, la Xenofobia y las Formas    Conexas de I
ntolerancia, convocada por las Naciones Unidas y celebrada del 31    de agosto a
l 7 de septiembre de 2001 en Durban, Sud&aacute;frica. El aporte    m&aacute;s n
ovedoso de esta Conferencia fue la incorporaci&oacute;n expresa    de los descen
dientes de africanos, los migrantes y los desplazados como poblaciones    benefi
ciarias de las pol&iacute;ticas antidiscriminatorias (2). La Conferencia    refl
ej&oacute; la coyuntura sociopol&iacute;tica imperante, en la que las migracione
s    econ&oacute;micas y los desplazamientos por los conflictos &eacute;tnicos e
n    Serbia y en Bosnia y Herzegovina impactaron a Europa.</font></p>     ^cY#a0
9v22n6.htm##
00716000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704048100076002001300557#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a09v22n6.htm#S#p#77#73#article#127#<p><font size="2" f
ace="Verdana">Am&eacute;rica Latina desempe&ntilde;&oacute;    un papel muy din&
aacute;mico en el proceso de preparaci&oacute;n de esta Conferencia,    especial
mente por la coordinaci&oacute;n de los pa&iacute;ses en el seguimiento    de lo
s acuerdos preexistentes en materia de derechos humanos, en particular    de los
 acuerdos adoptados en la reuni&oacute;n regional preparatoria, realizada    en 
diciembre de 2000 en Santiago, Chile (23).</font></p>     ^cY#a09v22n6.htm##
01522000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704128700076002001301363#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a09v22n6.htm#S#p#78#74#article#127#<p><font size="2" f
ace="Verdana">Otro aspecto en el que se destac&oacute; la Regi&oacute;n    fue p
or el surgimiento de un nuevo actor social a nivel regional: los afrodescendient
es,    ya que independientemente del pa&iacute;s en que habitaran, compart&iacut
e;an    ancestros provenientes de &Aacute;frica con el consiguiente acervo cultu
ral    com&uacute;n. Esta caracter&iacute;stica permiti&oacute; articular una re
d de    organizaciones de base integradas por descendientes de africanos o dedic
adas    a temas prioritarios de sus comunidades. Por &uacute;ltimo, se logr&oacu
te;    estrechar la relaci&oacute;n entre personas con ancestros africanos comun
es    que viv&iacute;an en Am&eacute;rica Latina, el Caribe de habla inglesa y l
os    Estados Unidos de Am&eacute;rica. Esta relaci&oacute;n, a partir de una ba
se    cultural com&uacute;n, solo pudo lograrse mediante el reconocimiento de te
ner    un mismo origen y circunstancias de vida similares. El proceso de abogac&
iacute;a    promovido por el segmento de la sociedad civil compuesto por afrodes
cendientes    logr&oacute; incidir en la Declaraci&oacute;n de Durban y llev&oac
ute; a que    los delegados repudiaran no solo la esclavitud, sino tambi&eacute;
n la trata    transatl&aacute;ntica de esclavos.</font></p>     ^cY#a09v22n6.htm
##
00869000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704063400076002001300710#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a09v22n6.htm#S#p#79#75#article#127#<p><font size="2" f
ace="Verdana">Adem&aacute;s de definir todos los grupos v&iacute;ctimas    del r
acismo, la Conferencia de Durban identific&oacute; las diversas formas    de dis
criminaci&oacute;n: el racismo, la discriminaci&oacute;n racial, la xenofobia   
 y otras formas conexas de intolerancia. Por &uacute;ltimo, mediante su Plan    
de Acci&oacute;n, ahond&oacute; en recomendaciones que deben contribuir a que   
 los Estados superen esta cr&iacute;tica situaci&oacute;n de cara al nuevo milen
io,    con &eacute;nfasis en aspectos ambientales, educacionales, laborales y, m
uy    particularmente, en la salud.</font></p>     ^cY#a09v22n6.htm##
01741000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704150600076002001301582#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a09v22n6.htm#S#p#80#76#article#127#<p><font size="2" f
ace="Verdana">La Conferencia de Durban y los avances organizativos    de la soci
edad civil permitieron consolidar pol&iacute;ticas y lograr que a    partir de 2
001 los compromisos de algunos gobiernos se visibilizaran, y los    conceptos de
 grupo &eacute;tnico y de diversidad cultural estuvieran presentes    con mayor 
frecuencia en las declaraciones de los jefes de Estado. Las Naciones    Unidas a
doptaron progresivamente este nuevo paradigma en el tratamiento de los    grupos
 &eacute;tnicos y lo traslad&oacute; a los foros de gravitaci&oacute;n    pol&ia
cute;tica. Por ejemplo, en las palabras dirigidas por el ex Secretario    Genera
l de la Organizaci&oacute;n de las Naciones Unidas Kofi Annan a los Jefes    de 
Estado reunidos en la XIII Cumbre Iberoamericana de Jefes de Estado y de    Gobi
erno de Am&eacute;rica Latina, Espa&ntilde;a y Portugal, realizada en noviembre 
   de 2003 en Santa Cruz de la Sierra, Bolivia, enfatiz&oacute; que ". . .    un
a estrategia de desarrollo digna de este nombre no puede soslayar las desigualda
des    patentes ente los distintos grupos sociales, lo cual es aun m&aacute;s ci
erto    cuando diferencias socioecon&oacute;micas coinciden con las divisiones &
eacute;tnicas.    Habr&iacute;a que prestar especial atenci&oacute;n a las neces
idades de quienes    comparten la amarga experiencia de la marginaci&oacute;n, y
a se trate de minor&iacute;as    o mayor&iacute;as, de ascendencia africana u or
igen ind&iacute;gena" (24).</font></p>     ^cY#a09v22n6.htm##
01565000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704133000076002001301406#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a09v22n6.htm#S#p#81#77#article#127#<p><font size="2" f
ace="Verdana">En este per&iacute;odo se celebraron la IV Cumbre    de las Am&eac
ute;ricas en noviembre de 2005 en Mar del Plata, Argentina, y la    XVI Cumbre I
beroamericana de Jefes de Estado y de Gobierno de Am&eacute;rica    Latina, Espa
&ntilde;a y Portugal, en Montevideo, Uruguay, un a&ntilde;o despu&eacute;s.    E
n la primera de estas Cumbres se reafirm&oacute; la urgencia de prestar atenci&o
acute;n    especial a las necesidades basadas en el g&eacute;nero, as&iacute; co
mo a las    necesidades espec&iacute;ficas de los pueblos ind&iacute;genas y afr
odescendientes,    entre otros grupos en situaci&oacute;n de vulnerabilidad. Asi
mismo, los participantes    en la Cumbre reafirmaron "su compromiso de respetar 
los derechos de los    pueblos ind&iacute;genas" y de "concluir exitosamente las
 negociaciones    de la Declaraci&oacute;n Americana sobre los Derechos de los P
ueblos Ind&iacute;genas".    Se comprometieron tambi&eacute;n a "respetar los de
rechos de los afrodescendientes    y asegurar su pleno acceso a las oportunidade
s de educaci&oacute;n en todos    los niveles y al trabajo decente que les ayuda
r&aacute; a superar la pobreza    y la exclusi&oacute;n social y contribuir&aacu
te; a que se aumente su participaci&oacute;n    en todos los sectores de la soci
edad" (25).</font></p>     ^cY#a09v22n6.htm##
01171000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704093600076002001301012#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a09v22n6.htm#S#p#82#78#article#127#<p><font size="2" f
ace="Verdana">La Cumbre Iberoamericana de Jefes de Estado y    de Gobierno de Am
&eacute;rica Latina, Espa&ntilde;a y Portugal, celebrada en    Montevideo en 200
6, adopt&oacute; la Carta Cultural Iberoamericana, que afirma    que "las cultur
as tradicionales, ind&iacute;genas, de afrodescendientes    y de poblaciones mig
rantes en sus m&uacute;ltiples manifestaciones son parte    relevante de la cult
ura y de la diversidad cultural iberoamericana, y constituyen    un patrimonio f
undamental para la humanidad". En las recomendaciones de    esta Cumbre se inst&
oacute; a la elaboraci&oacute;n de indicadores espec&iacute;ficos    en relaci&o
acute;n con los pueblos ind&iacute;genas y afrodescendientes, que    sirvan de h
erramienta &uacute;til para avanzar en la lucha contra la exclusi&oacute;n    y 
la pobreza en que se encuentran estos grupos en muchos pa&iacute;ses de la    Re
gi&oacute;n (26).</font></p>     ^cY#a09v22n6.htm##
01562000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704132700076002001301403#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a09v22n6.htm#S#p#83#79#article#127#<p><font size="2" f
ace="Verdana">En esta &uacute;ltima etapa, las Naciones Unidas    adoptaron el 1
3 de septiembre de 2007 la Declaraci&oacute;n de los Pueblos Ind&iacute;genas   
 (27), que recupera el esp&iacute;ritu del Convenio 169 de 1989. La Declaraci&oa
cute;n    reconoce a los integrantes de los pueblos ind&iacute;genas los mismos 
derechos    de que goza el resto de los miembros de la sociedad. Establece, adem
&aacute;s,    derechos espec&iacute;ficos, entre ellos el derecho a sus pr&aacut
e;cticas tradicionales,    al respeto de sus conocimientos y culturas, a la repa
triaci&oacute;n de sus    objetos de culto, a la revitalizaci&oacute;n de sus si
stemas de escritura y    a la creaci&oacute;n de establecimientos educativos en 
su propia cultura e idioma.    Este reconocimiento tiene implicaciones en la for
mulaci&oacute;n de pol&iacute;ticas    y en la construcci&oacute;n de Estados mu
lti&eacute;tnicos, multiculturales    y multiling&uuml;es. Asimismo, reconoce el
 derecho a la libre determinaci&oacute;n    y autogobierno de los pueblos ind&ia
cute;genas y a la propiedad y el usufructo    de las tierras que hist&oacute;ric
amente les pertenecieron, con lo cual contribuye    a reafirmar la responsabilid
ad del Estado de crear canales para su participaci&oacute;n    social y pol&iacu
te;tica.</font></p>     ^cY#a09v22n6.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a09v22n6.htm#S#p#84#80#article#127#<p>&nbsp;</p>     ^
cY#a09v22n6.htm##
00307000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704007200076002001300148#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a09v22n6.htm#S#p#85#81#article#127#<p><font size="3" f
ace="Verdana"><b>CONCLUSIONES</b></font></p>     ^cY#a09v22n6.htm##
00866000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704063100076002001300707#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a09v22n6.htm#S#p#86#82#article#127#<p><font size="2" f
ace="Verdana">Este estudio muestra la evoluci&oacute;n positiva    experimentada
 por el concepto etnia/raza en los principales documentos y convenios    interna
cionales. El tratamiento del tema est&aacute; relacionado con la b&uacute;squeda
    de la igualdad y la superaci&oacute;n de los resultados de la opresi&oacute;
n    a la que hab&iacute;an estado sometidos los grupos &eacute;tnicos/raciales.
    Un hito importante en esta evoluci&oacute;n es el reconocimiento de que todo
s    los seres humanos pertenecen a la misma especie y tienen el mismo origen y 
que    la humanidad es una sola.</font></p>     ^cY#a09v22n6.htm##
01229000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704099400076002001301070#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a09v22n6.htm#S#p#87#83#article#127#<p><font size="2" f
ace="Verdana">Si bien se reconoci&oacute; que la humanidad    es una unidad indi
visible, solo tiempo despu&eacute;s se acept&oacute; la existencia    de identid
ades diversas que, por primera vez, generaron el derecho a ser vividas    en sus
 diferencias. Se acept&oacute; tambi&eacute;n que las diferencias entre    los s
eres humanos son producto de formas de vida, creencias y cosmovisiones    que da
n lugar a comportamientos diversos y se manifiestan en maneras de vestir,    len
guajes, rituales, terapias, alimentaci&oacute;n y formas de organizaci&oacute;n 
   social diferentes. Como resultado de esta evoluci&oacute;n, en la Regi&oacute
;n    de las Am&eacute;ricas se reconoce dentro del conglomerado de grupos &eacu
te;tnicos/raciales    no solo a los pueblos ind&iacute;genas, sino a otros grupo
s como los afrodescendientes,    los migrantes, los pueblos rom, los desplazados
 y los refugiados, ya que todos    ellos tienen acervos culturales propios.</fon
t></p>     ^cY#a09v22n6.htm##
01105000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704087000076002001300946#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a09v22n6.htm#S#p#88#84#article#127#<p><font size="2" f
ace="Verdana">La evoluci&oacute;n del concepto etnia/raza influye    en la formu
laci&oacute;n de pol&iacute;ticas p&uacute;blicas de diversas maneras.    La ide
ntificaci&oacute;n de las diferencias permite precisar las necesidades    concre
tas de los beneficiarios. En lugar de pensar en un beneficiario abstracto,    co
n las limitaciones que ello ocasiona, se deben tomar en cuenta los elementos    
que conforman la identidad para dise&ntilde;ar programas m&aacute;s sensibles   
 a sus particularidades. Las pol&iacute;ticas, entonces, no se restringen a obse
rvar    igualdad de trato frente a las diferencias de fenotipo o al color de la 
piel    —que homogeneizaba la oferta de servicios—, sino que deben buscar facili
tar    el acceso en consideraci&oacute;n a los requisitos derivados de la divers
idad    propia de sus culturas.</font></p>     ^cY#a09v22n6.htm##
01287000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704105200076002001301128#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a09v22n6.htm#S#p#89#85#article#127#<p><font size="2" f
ace="Verdana">La sensibilidad del campo social por el respeto    a la diversidad
 llev&oacute; a una identificaci&oacute;n de la discriminaci&oacute;n    institu
cional, distinta de la discriminaci&oacute;n de la esfera interpersonal;    se d
ebe distinguir la discriminaci&oacute;n que ejercen los individuos, incluso    c
uando prestan servicios, de la omisi&oacute;n de las instituciones en adaptar   
 la oferta de sus servicios a las necesidades particulares de los beneficiarios.
    Como prueba de esto, en la &uacute;ltima generaci&oacute;n de pol&iacute;tic
as    se incorporan acciones afirmativas, como una forma de reducir las inequida
des    persistentes derivadas de exclusiones propias de &eacute;pocas anteriores
. La    equidad, entendida como la superaci&oacute;n de las diferencias injustas
 y evitables,    ha constituido un elemento muy positivo como trazador de las po
l&iacute;ticas    p&uacute;blicas dirigidas a combatir la discriminaci&oacute;n,
 ya que esta es    injusta y evitable por naturaleza.</font></p>     ^cY#a09v22n
6.htm##
01246000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704101100076002001301087#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a09v22n6.htm#S#p#90#86#article#127#<p><font size="2" f
ace="Verdana">En la &uacute;ltima etapa, los acuerdos de los    jefes de Estado 
de la Regi&oacute;n han tenido un efecto positivo en el proceso    de revisi&oac
ute;n de las responsabilidades del Estado en el combate contra    la discriminac
i&oacute;n. Esto ha llevado a la creaci&oacute;n de instituciones    con mandato
s m&aacute;s amplios, cuya funci&oacute;n es velar por la incorporaci&oacute;n  
  de la perspectiva &eacute;tnica/racial en todos los niveles del Estado y promo
ver    programas espec&iacute;ficos de desarrollo, como la Secretar&iacute;a par
a la    Promoci&oacute;n de las Pol&iacute;ticas de Equidad Racial de Brasil y e
l Fondo    para el Desarrollo Ind&iacute;gena, entre otras. Como complemento se 
ha fortalecido    la participaci&oacute;n social en el diagn&oacute;stico de la 
situaci&oacute;n    y en el dise&ntilde;o y formulaci&oacute;n de pol&iacute;tic
as y programas,    con el consiguiente empoderamiento de los grupos &eacute;tnic
os/raciales.</font></p>     ^cY#a09v22n6.htm##
00852000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704061700076002001300693#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a09v22n6.htm#S#p#91#87#article#127#<p><font size="2" f
ace="Verdana">En &uacute;ltima instancia, el resultado del    proceso de evoluci
&oacute;n positiva del concepto etnia/raza en las &uacute;ltimas    cinco d&eacu
te;cadas, se ha traducido en una mayor valorizaci&oacute;n del reconocimiento   
 de las diferencias, lo que define a las sociedades plurales y multi&eacute;tnic
as    y trasciende el beneficio que reciben los grupos en s&iacute; mismos. Este
 concepto    se constituye as&iacute; en un factor sustancial para el avance de 
las sociedades    democr&aacute;ticas y sienta bases m&aacute;s s&oacute;lidas p
ara el desarrollo.</font></p>     ^cY#a09v22n6.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a09v22n6.htm#S#p#92#88#article#127#<p>&nbsp;</p>     ^
cY#a09v22n6.htm##
00306000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704007100076002001300147#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a09v22n6.htm#S#p#93#89#article#127#<p><font size="3" f
ace="Verdana"><b>REFERENCIAS</b></font></p>     ^cY#a09v22n6.htm##
00668000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704041900078002001300497#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a09v22n6.htm#S#p#94#90#article#127#1#<p><f
ont size="2" face="Verdana"> 1. Naciones Unidas. Declaraci&oacute;n Universal   
 de los Derechos Humanos. Resoluci&oacute;n de la Asamblea General 217 A (iii); 
   10 de diciembre de 1948. Nueva York: Naciones Unidas; 1948. Hallado en <a hre
f="http://www.un.org/spanish/aboutun/hrights.htm" target="_blank">http://www.un.
org/spanish/aboutun/hrights.htm</a>.    Acceso el 14 de noviembre de 2007.</font
></p>     ^cY#a09v22n6.htm##
00846000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704059700078002001300675#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a09v22n6.htm#S#p#95#91#article#127#2#<p><f
ont size="2" face="Verdana"> 2. Naciones Unidas. Informe de la Conferencia    Mu
ndial contra el Racismo, la Discriminaci&oacute;n Racial, la Xenofobia y las    
Formas Conexas de Intolerancia; 31 de agosto a 8 de septiembre de 2001; Durban, 
   Sud&aacute;frica. Nueva York: Naciones Unidas; 2002. (Documento A/CONF.189/  
  12). Hallado en <a href="http://www.unhchr.ch/huridocda/huridoca.nsf/(Symbol)/
A.Conf.189.12.Sp?Opendocument" target="_blank">http://www.unhchr.ch/huridocda/hu
ridoca.nsf/(Symbol)/A.Conf.189.12.Sp?Opendocument</a>.    Acceso el 14 de noviem
bre de 2007.</font></p>     ^cY#a09v22n6.htm##
00394000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704014500078002001300223#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a09v22n6.htm#S#p#96#92#article#127#3#<p><f
ont size="2" face="Verdana"> 3. Gannett, L. The biological reification of    rac
e. Br J Philos Scie. 2004;55(2): 323–45.</font></p>     ^cY#a09v22n6.htm##
00423000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704017400078002001300252#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a09v22n6.htm#S#p#97#93#article#127#4#<p><f
ont size="2" face="Verdana"> 4. Long JC, Kittles RA. Human genetic diversity    
and the nonexistence of biological race. Hum Biol. 2003;75(4):449–71.</font></p>
     ^cY#a09v22n6.htm##
00395000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704014600078002001300224#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a09v22n6.htm#S#p#98#94#article#127#5#<p><f
ont size="2" face="Verdana"> 5. Mayr E. The biology of race and the concept    o
f equality. Daedalus. 2002;131(1): 89–94.</font></p>     ^cY#a09v22n6.htm##
00633000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704038400078002001300462#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a09v22n6.htm#S#p#99#95#article#127#6#<p><f
ont size="2" face="Verdana"> 6. Naciones Unidas. Nota del Secretario General    
por la que se transmite el informe de la Reuni&oacute;n de Consulta sobre la    
Conferencia Mundial contra el Racismo, la Discriminaci&oacute;n Racial, la Xenof
obia    y las Formas Conexas de Intolerancia. Nueva York: Naciones Unidas; 2000.
 (Documento    A/CONF.189/PC.1/ 10. 8).</font></p>     ^cY#a09v22n6.htm##
00455000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073888000200077704020500079002001300284#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a09v22n6.htm#S#p#100#96#article#127#7#<p><
font size="2" face="Verdana"> 7. Koonings K, Silva P. Construcciones &eacute;tni
cas    y din&aacute;mica sociocultural en Am&eacute;rica Latina. Quito: Edicione
s Abya    Yala; 1999.</font></p>     ^cY#a09v22n6.htm##
00654000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073888000200077704040400079002001300483#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a09v22n6.htm#S#p#101#97#article#127#8#<p><
font size="2" face="Verdana"> 8. Naciones Unidas. Convenci&oacute;n Internaciona
l    sobre la Eliminaci&oacute;n de Todas las Formas de Discriminaci&oacute;n Ra
cial.    Nueva York; 1965. Hallado en <a href="http://www.unhchr.ch/spanish/html
/menu3/b/d_icerd_sp.htm" target="_blank">http://www.unhchr.ch/spanish/html/menu3
/b/d_icerd_sp.htm</a>.    Acceso el 14 de noviembre de 2007.</font></p>     ^cY#
a09v22n6.htm##
00633000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073888000200077704038300079002001300462#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a09v22n6.htm#S#p#102#98#article#127#9#<p><
font size="2" face="Verdana"> 9. Naciones Unidas. Pacto Internacional de Derecho
s    Econ&oacute;micos, Sociales y Culturales. Nueva York: Naciones Unidas; 1966
.    Hallado en <a href="http://www.unhchr.ch/spanish/html/menu3/b/a_cescr_sp.ht
m" target="_blank">http://www.unhchr.ch/spanish/html/menu3/b/a_cescr_    sp.htm<
/a>. Acceso el 14 de noviembre de 2007.</font></p>     ^cY#a09v22n6.htm##
00669000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073888000300077704041800080002001300498#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a09v22n6.htm#S#p#103#99#article#127#10#<p>
<font size="2" face="Verdana"> 10. Organizaci&oacute;n de Estados Americanos.   
 Convenci&oacute;n Americana sobre Derechos Humanos (Pacto de San Jos&eacute;   
 de Costa Rica). Washington, D.C.: OEA; 1969. Hallado en <a href="http://www.oas
.org/juridico/spanish/tratados/b-32.html" target="_blank">http://www.oas.org/jur
idico/spanish/tratados/b-32.html</a>.    Acceso el 14 de noviembre de 2007.</fon
t></p>     ^cY#a09v22n6.htm##
00630000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704037800081002001300459#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a09v22n6.htm#S#p#104#100#article#127#11#<p
><font size="2" face="Verdana"> 11. Naciones Unidas. Convenci&oacute;n Internaci
onal    sobre la Represi&oacute;n y el Castigo del Crimen de Apartheid. Nueva Yo
rk:    1973. Hallado en <a href="http://www.unhchr.ch/spanish/html/menu3/b/11_sp
.htm" target="_blank">http://www.unhchr.ch/spanish/html/menu3/b/11_sp.htm</a>.  
  Acceso el 14 de noviembre de 2007.</font></p>     ^cY#a09v22n6.htm##
00693000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704044100081002001300522#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a09v22n6.htm#S#p#105#101#article#127#12#<p
><font size="2" face="Verdana"> 12. Organizaci&oacute;n de las Naciones Unidas  
  para la Educaci&oacute;n, la Ciencia y la Cultura. Declaraci&oacute;n sobre   
 la Raza y los Prejuicios Raciales. Par&iacute;s: UNESCO; 1978. Hallado en <a hr
ef="http://www.unhchr.ch/spanish/html/menu3/b/d_prejud_sp.htm" target="_blank">h
ttp://www.unhchr.ch/spanish/html/menu3/b/d_prejud_sp.htm</a>.    Acceso el 14 de
 noviembre de 2007.</font></p>     ^cY#a09v22n6.htm##
00584000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704033200081002001300413#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a09v22n6.htm#S#p#106#102#article#127#13#<p
><font size="2" face="Verdana"> 13. Organizaci&oacute;n Mundial de la Salud.    
Atenci&oacute;n Primaria de Salud. Informe de la Conferencia Internacional sobre
    Atenci&oacute;n Primaria de Salud; 6–2 de septiembre de 1978; Alma-Ata, Kaza
jst&aacute;n,    ex Uni&oacute;n Sovi&eacute;tica. Ginebra: OMS; 1979.</font></p
>     ^cY#a09v22n6.htm##
00432000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704018000081002001300261#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a09v22n6.htm#S#p#107#103#article#127#14#<p
><font size="2" face="Verdana"> 14. Chatora R. An overview of the traditional   
 medicine situation in the African Region. WHO Afr Health Mon. 2003; 4(1):4–7.</
font></p>     ^cY#a09v22n6.htm##
00675000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704042300081002001300504#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a09v22n6.htm#S#p#108#104#article#127#15#<p
><font size="2" face="Verdana"> 15. Organizaci&oacute;n Internacional del Trabaj
o.    Convenio sobre Pueblos Ind&iacute;genas y Tribales en Pa&iacute;ses Indepe
ndientes.    Ginebra: OIT; 1989. (Documento OIT No. 169). Hallado en <a href="ht
tp://www.unhchr.ch/spanish/html/menu3/b/62_sp.htm" target="_blank">http://www.un
hchr.ch/spanish/html/menu3/b/62_sp.htm</a>.    Acceso el 14 de noviembre de 2007
.</font></p>     ^cY#a09v22n6.htm##
00397000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704014500081002001300226#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a09v22n6.htm#S#p#109#105#article#127#16#<p
><font size="2" face="Verdana"> 16. Wade P. Raza y etnicidad en Am&eacute;rica  
  Latina. Quito: Ediciones Abya Yala; 2000.</font></p>     ^cY#a09v22n6.htm##
00505000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704025300081002001300334#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a09v22n6.htm#S#p#110#106#article#127#17#<p
><font size="2" face="Verdana"> 17. Naciones Unidas, Asamblea General. Declaraci
&oacute;n    y Programa de Acci&oacute;n de Viena. Conferencia Mundial de Derech
os Humanos.    Viena: Naciones Unidas; 1993. (Documento A/CONF.157/23).</font></
p>     ^cY#a09v22n6.htm##
00750000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704049800081002001300579#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a09v22n6.htm#S#p#111#107#article#127#18#<p
><font size="2" face="Verdana"> 18. Naciones Unidas, Consejo Econ&oacute;mico   
 y Social, Comit&eacute; de Derechos Econ&oacute;micos, Sociales y Culturales.  
  El derecho a la educaci&oacute;n (Art&iacute;culo 13). Aplicaci&oacute;n del  
  Pacto Internacional de Derechos Econ&oacute;micos, Sociales y Culturales. 21.°
    Per&iacute;odo de Sesiones. Ginebra: Oficina del Alto Comisionado de las Nac
iones    Unidas para los Derechos Humanos; 1999. (Documento E/C.12/1999/10).</fo
nt></p>     ^cY#a09v22n6.htm##
00454000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704020200081002001300283#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a09v22n6.htm#S#p#112#108#article#127#19#<p
><font size="2" face="Verdana"> 19. Naciones Unidas. Informe sobre la Cuarta    
Conferencia Mundial sobre la Mujer. Nueva York: Naciones Unidas; 1996. (Document
o    A/CONF.177/20).</font></p>     ^cY#a09v22n6.htm##
00537000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704028500081002001300366#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a09v22n6.htm#S#p#113#109#article#127#20#<p
><font size="2" face="Verdana"> 20. Naciones Unidas, Asamblea General. Resoluci&
oacute;n    de la Asamblea General 48/163 sobre el Decenio Internacional de las 
Poblaciones    Ind&iacute;genas del Mundo. Nueva York: Naciones Unidas; 1994. (D
ocumento A/RES/48/163).</font></p>     ^cY#a09v22n6.htm##
00778000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704052600081002001300607#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a09v22n6.htm#S#p#114#110#article#127#21#<p
><font size="2" face="Verdana"> 21. Cumbre Iberoamericana. Declaraci&oacute;n   
 de Guadalajara. I Cumbre Iberoamericana de Jefes de Estado y de Gobierno de    
Am&eacute;rica Latina, Espa&ntilde;a y Portugal; 19 de julio de 1991; Guadalajar
a,    M&eacute;xico. Hallado en <a href="http://www.integracionsur.com/americala
tina/CumbreALatinaEuropaDclGuadalajara.htm" target="_blank">http://www.integraci
onsur.com/americalatina/CumbreALatinaEuropaDclGuadalajara.htm</a>.    Acceso el 
14 de noviembre de 2007.</font></p>     ^cY#a09v22n6.htm##
00403000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704015100081002001300232#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a09v22n6.htm#S#p#115#111#article#127#22#<p
><font size="2" face="Verdana"> 22. Touraine A. Pourrant-nous vivre ensemble?   
 Egaux et diff&eacute;rents. Paris: Fayard; 1998.</font></p>     ^cY#a09v22n6.ht
m##
01054000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704080200081002001300883#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a09v22n6.htm#S#p#116#112#article#127#23#<p
><font size="2" face="Verdana"> 23. Naciones Unidas. Conferencia Mundial Contra 
   el Racismo, la Discriminaci&oacute;n Racial, la Xenofobia y las Formas Conexa
s    de Intolerancia. Informe del Seminario regional de expertos para Am&eacute;
rica    Latina y el Caribe sobre medidas econ&oacute;micas, sociales y jur&iacut
e;dicas    para luchar contra el racismo, con referencia especial a los grupos v
ulnerables;    25–27 de octubre de 2000; Santiago, Chile. Nueva York: Naciones U
nidas; 2001.    (Documento A/CONF.189/PC.2/5). Hallado en <a href="http://www.un
hchr.ch/huridocda/huridoca.nsf/(Symbol)/A.CONF.189.PC.2.5.Sp?Opendocument" targe
t="_blank">http://www.unhchr.ch/huridocda/huridoca.nsf/(Symbol)/A.CONF.189.PC.2.
5.Sp?Opendocument</a>.    Acceso el 14 de noviembre de 2007.</font></p>     ^cY#
a09v22n6.htm##
00550000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704029800081002001300379#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a09v22n6.htm#S#p#117#113#article#127#24#<p
><font size="2" face="Verdana"> 24. Annan K. Discurso ante la XIII Cumbre Iberoa
mericana    de Jefes de Estado y de Gobierno de Am&eacute;rica Latina, Espa&ntil
de;a y Portugal;    14 de noviembre de 2003; Santa Cruz de la Sierra, Bolivia. N
ueva York: Naciones    Unidas; 2003.</font></p>     ^cY#a09v22n6.htm##
00793000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704054100081002001300622#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a09v22n6.htm#S#p#118#114#article#127#25#<p
><font size="2" face="Verdana"> 25. Declaraci&oacute;n de Mar del Plata. Crear  
  trabajo para enfrentar la pobreza y fortalecer la gobernabilidad democr&aacute
;tica.    Cuarta Cumbre de las Am&eacute;ricas; 5 de noviembre de 2005; Mar del 
Plata,    Argentina. Buenos Aires; 2005. Hallado en <a href="http://www.iin.oea.
org/DECLARACIONES/declaracion_IV_Cumbre_de_las_Americas.htm" target="_blank">htt
p://www.iin.oea.org/DECLARACIONES/declaracion_IV_Cumbre_de_las_Americas.htm</a>.
    Acceso el 29 de septiembre de 2007.</font></p>     ^cY#a09v22n6.htm##
00813000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704056100081002001300642#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a09v22n6.htm#S#p#119#115#article#127#26#<p
><font size="2" face="Verdana"> 26. Cumbre Iberoamericana. Declaraci&oacute;n   
 de Montevideo. XVI Cumbre Iberoamericana de Jefes de Estado y de Gobierno de   
 Am&eacute;rica Latina, Espa&ntilde;a y Portugal; 5 de noviembre de 2006; Montev
ideo,    Uruguay. Hallado en <a href="http://www.cinterfor.org.uy/public/spanish
/region/ampro/cinterfor/temas/employer/eventos/xvi_dec.pdf" target="_blank">http
://www.cinterfor.org.uy/public/spanish/region/ampro/cinterfor/temas/employer/eve
ntos/xvi_dec.pdf</a>.    Acceso el 14 de noviembre de 2007.</font></p>     ^cY#a
09v22n6.htm##
00655000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704040300081002001300484#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a09v22n6.htm#S#p#120#116#article#127#27#<p
><font size="2" face="Verdana"> 27. Naciones Unidas. Declaraci&oacute;n de las  
  Naciones Unidas sobre los Derechos de los Pueblos Ind&iacute;genas. Nueva York
:    Naciones Unidas; 2006. (Documento A/RES/61/295). Hallado en <a href="http:/
/www.servindi.org/pdf/ONU_Dec_PI.pdf" target="_blank">http://www.    servindi.or
g/pdf/ONU_ Dec_PI.pdf</a>. Acceso el 14 de noviembre de 2007.</font></p>     ^cY
#a09v22n6.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a09v22n6.htm#S#p#121#117#article#127#<p>&nbsp;</p>    
 ^cY#a09v22n6.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a09v22n6.htm#S#p#122#118#article#127#<p>&nbsp;</p>    
 ^cY#a09v22n6.htm##
00548000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704031100078002001300389#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a09v22n6.htm#S#p#123#119#article#127#<p><font size="2"
 face="Verdana"><a></a><a name="nt"></a><a href="#tx">*</a> La    correspondenci
a se debe enviar a Cristina Torres-Parodi, 525 Twenty-third Street    NW, Washin
gton, D.C. 20037, United States of America. Correo electr&oacute;nico:    <a hre
f="mailto:torrescr@paho.org">torrescr@paho.org    ^cY#a09v22n6.htm##
00885000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704064800078002001300726#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a09v22n6.htm#S#p#124#120#article#127#<br>   </a><a nam
e="nt01"></a><a href="#tx01">1</a> Existen antecedentes previos, en    t&eacute;
rminos de la igualdad ante la ley y la justicia, en la Declaraci&oacute;n    de 
los Derechos del Hombre y del Ciudadano de Francia (1789). Los decretos del    4
 y del 11 de agosto de 1789, tambi&eacute;n de Francia, suprimieron los derechos
    feudales. Otro antecedente es la Convenci&oacute;n sobre la Esclavitud, de l
a    Sociedad de las Naciones (9 de marzo de 1927), posteriormente modificada po
r    el protocolo aprobado en la Sede de las Naciones Unidas el 7 de diciembre d
e    1953 y que entr&oacute; en vigencia el 7 de julio de 1955.    ^cY#a09v22n6.
htm##
00606000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704036900078002001300447#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a09v22n6.htm#S#p#125#121#article#127#<br>   <a name="n
t02"></a><a href="#tx02">2</a> El concepto de minor&iacute;a al cual    se alude
 en este trabajo no se refiere al porcentaje de la poblaci&oacute;n    &eacute;t
nica/racial respecto al total de la poblaci&oacute;n de un pa&iacute;s,    sino 
a los grupos &eacute;tnicos con insuficiente nivel de representaci&oacute;n    p
ol&iacute;tica y social.    ^cY#a09v22n6.htm##
00955000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704071800078002001300796#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a09v22n6.htm#S#p#126#122#article#127#<br>   <a name="n
t03"></a><a href="#tx03">3</a> Los avances cient&iacute;ficos han    puesto de m
anifiesto que desde el punto de vista gen&eacute;tico, cada individuo    es &uac
ute;nico y que esta variaci&oacute;n excede a las variaciones que existen    ent
re grupos. No obstante, la producci&oacute;n cient&iacute;fica no es todav&iacut
e;a    categ&oacute;rica en la interpretaci&oacute;n de la influencia del contex
to    sociohist&oacute;rico en la determinaci&oacute;n de esa diversidad y en c&
oacute;mo    las diferencias biol&oacute;gicas impactan la din&aacute;mica y la 
construcci&oacute;n    social de identidades. V&eacute;anse al respecto los trab
ajos de Gannet (3),    Long y Kittles (4) y Mayr (5).    ^cY#a09v22n6.htm##
00516000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704027900078002001300357#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a09v22n6.htm#S#p#127#123#article#127#<br>   <a name="n
t04"></a><a href="#tx04">4</a> "Considerando que la libertad,    la justicia y l
a paz en el mundo tienen por base el reconocimiento de la dignidad    intr&iacut
e;nseca y de los derechos iguales inalienables de todos los miembros    de la fa
milia humana".    ^cY#a09v22n6.htm##
00522000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704028500078002001300363#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a09v22n6.htm#S#p#128#124#article#127#<br>   <a name="n
t05"></a><a href="#tx05">5</a> En la primera mitad del siglo XX, en    algunos p
a&iacute;ses de Am&eacute;rica Latina, como Colombia, M&eacute;xico    y Per&uac
ute;, se crearon resguardos para los ind&iacute;genas e institutos    para el es
tudio de su cultura.    ^cY#a09v22n6.htm##
00572000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704033500078002001300413#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a09v22n6.htm#S#p#129#125#article#127#<br>   <a name="n
t06"></a><a href="#tx06">6</a> Se entiende por identidad cultural    la facultad
 que tienen los seres humanos de vivir diferente en raz&oacute;n    de la varied
ad de sus culturas, del medio ambiente y de su historia. De esta    facultad se 
desprenden dos derechos: a vivir diferente y a preservar la identidad.    ^cY#a0
9v22n6.htm##
00502000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704026500078002001300343#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a09v22n6.htm#S#p#130#126#article#127#<br>   <a name="n
t07"></a><a href="#tx07">7</a> Antes de la emisi&oacute;n del Convenio    169 se
 utilizaba una terminolog&iacute;a diversa para referirse a los pueblos    preco
lombinos: abor&iacute;genes, nativos, indios e ind&iacute;genas, entre    otros.
    ^cY#a09v22n6.htm##
01225000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704098800078002001301066#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a09v22n6.htm#S#p#131#127#article#127#<br>   <a name="n
t08"></a><a href="#tx08">8</a> El Comit&eacute; Interino del Fondo    comenz&oac
ute; a funcionar en 1994 con Bolivia, Chile, M&eacute;xico y Nicaragua,    un re
presentante del Gobierno de Espa&ntilde;a y un representante del Gobierno    de 
Portugal. Para esa fecha hab&iacute;an firmado el Convenio Argentina, Bolivia,  
  Brasil, Chile, Colombia, Costa Rica, Cuba, Ecuador, Espa&ntilde;a, Honduras,  
  M&eacute;xico, Nicaragua, Panam&aacute;, Paraguay, Portugal, Rep&uacute;blica 
   Dominicana y Uruguay; Per&uacute; y Venezuela hab&iacute;an manifestado su in
ter&eacute;s    en ser miembros. Los organismos internacionales que apoyaron el 
proyecto fueron    el Banco Interamericano de Desarrollo, el Instituto Indigenis
ta Interamericano,    la Organizaci&oacute;n Internacional del Trabajo, la Organ
izaci&oacute;n de    las Naciones Unidas para la Educaci&oacute;n, la Ciencia y 
la Cultura, y el    Programa de las Naciones Unidas para el Desarrollo.</font></
p>     ^cY#a09v22n6.htm##
00623000000000265000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750170016000770180122000930660
01100215062001600226065000900242064000500251037004600256110000900302109002400311
865000900335002001300344#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a09v22n6.htm#S
#c#132#1#article#27#1#Naciones Unidas#Declaración Universal de los Derechos Huma
nos: Resolución de la Asamblea General 217 A (iii); 10 de diciembre de 1948^les#
Nueva York#Naciones Unidas#19480000#1948#http://www.un.org/spanish/aboutun/hrigh
ts.htm#20071114#14 de noviembre de 2007#20071200#a09v22n6.htm##
00830000000000325000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750170016000770530118000930550
01200211054004200223056001000265057001300275056001400288052001900302055001200321
05400080033306100250034103700830036611000090044910900240045886500090048200200130
0491#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a09v22n6.htm#S#c#133#2#article#27#
2#Naciones Unidas#Conferencia Mundial contra el Racismo, la Discriminación Racia
l, la Xenofobia y las Formas Conexas de Intolerancia^i1#20010908^i1#31 de agosto
 a 8 de septiembre de 2001^i1#Durban^i1#Sudáfrica^i1#Nueva York^i1#Naciones Unid
as^i1#20020000^i1#2002^i1#Documento A/CONF.189/ 12#http://www.unhchr.ch/huridocd
a/huridoca.nsf/(Symbol)/A.Conf.189.12.Sp?Opendocument#20071114#14 de noviembre d
e 2007#20071200#a09v22n6.htm##
00466000000000265000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100017000770120039000940300
01700133710000200150065000900152064000500161031000300166032000200169014000700171
865000900178002001300187#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a09v22n6.htm#S
#c#134#3#article#27#3#^rND^sGannett^nL#The biological reification of race^len#Br
 J Philos Scie#2#20040000#2004#55#2#323-45#20071200#a09v22n6.htm##
00544000000000289000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100015000770100018000920120
06800110030000900178065000900187064000500196031000300201032000200204014000700206
865000900213002001300222035001000235801000900245#v22n6#v:\scielo\serial\rpsp\v22
n6\markup\a09v22n6.htm#S#c#135#4#article#27#4#^rND^sLong^nJC#^rND^sKittles^nRA#H
uman genetic diversity and the nonexistence of biological race^len#Hum Biol#2003
0000#2003#75#4#449-71#20071200#a09v22n6.htm#0018-7143#Hum Biol##
00497000000000277000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100014000770120052000910300
00900143065000900152064000500161031000400166032000200170014000600172865000900178
002001300187035001000200801000900210#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a0
9v22n6.htm#S#c#136#5#article#27#5#^rND^sMayr^nE#The biology of race and the conc
ept of equality^len#Daedalus#20020000#2002#131#1#89-94#20071200#a09v22n6.htm#001
1-5266#Daedalus##
00648000000000241000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750170016000770180217000930660
01100310062001600321065000900337064000500346061003300351865000900384002001300393
#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a09v22n6.htm#S#c#137#6#article#27#6#Na
ciones Unidas#Nota del Secretario General por la que se transmite el informe de 
la Reunión de Consulta sobre la Conferencia Mundial contra el Racismo, la Discri
minación Racial, la Xenofobia y las Formas Conexas de Intolerancia^les#Nueva Yor
k#Naciones Unidas#20000000#2000#Documento A/CONF.189/PC.1/ 10. 8#20071200#a09v22
n6.htm##
00484000000000241000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750160018000770160015000950180
07000110066000600180062002000186065000900206064000500215865000900220002001300229
#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a09v22n6.htm#S#c#138#7#article#27#7#^r
ND^sKoonings^nK#^rND^sSilva^nP#Construcciones étnicas y dinámica sociocultural e
n América Latina^les#Quito#Ediciones Abya Yala#19990000#1999#20071200#a09v22n6.h
tm##
00587000000000253000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750170016000770530094000930560
01400187055001200201054000800213037005700221110000900278109002400287865000900311
002001300320#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a09v22n6.htm#S#c#139#8#art
icle#27#8#Naciones Unidas#Convención Internacional sobre la Eliminación de Todas
 las Formas de Discriminación Racial^i1#Nueva York^i1#19650000^i1#1965^i1#http:/
/www.unhchr.ch/spanish/html/menu3/b/d_icerd_sp.htm#20071114#14 de noviembre de 2
007#20071200#a09v22n6.htm##
00583000000000265000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750170016000770180070000930660
01100163062001600174065000900190064000500199037005800204110000900262109002400271
865000900295002001300304#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a09v22n6.htm#S
#c#140#9#article#27#9#Naciones Unidas#Pacto Internacional de Derechos Económicos
, Sociales y Culturales^les#Nueva York#Naciones Unidas#19660000#1966#http://www.
unhchr.ch/spanish/html/menu3/b/a_cescr_ sp.htm#20071114#14 de noviembre de 2007#
20071200#a09v22n6.htm##
00621000000000265000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760170035000790530081001140560
02300195052000700218055001200225054000800237037005500245065000900300064002400309
865000900333002001300342#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a09v22n6.htm#S
#c#141#10#article#27#10#Organización de Estados Americanos#Convención Americana 
sobre Derechos Humanos (Pacto de San José de Costa Rica)^i1#Washington^i1^eD.C.^
i1#OEA^i1#19690000^i1#1969^i1#http://www.oas.org/juridico/spanish/tratados/b-32.
html#20071114#14 de noviembre de 2007#20071200#a09v22n6.htm##
00574000000000253000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760170016000790530084000950560
01400179055001200193054000800205037005200213065000900265064002400274865000900298
002001300307#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a09v22n6.htm#S#c#142#11#ar
ticle#27#11#Naciones Unidas#Convención Internacional sobre la Represión y el Cas
tigo del Crimen de Apartheid^i1#Nueva York^i1#19730000^i1#1973^i1#http://www.unh
chr.ch/spanish/html/menu3/b/11_sp.htm#20071114#14 de noviembre de 2007#20071200#
a09v22n6.htm##
00620000000000265000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760170079000790180056001580660
00600214062000700220065000900227064000500236037005800241110000900299109002400308
865000900332002001300341#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a09v22n6.htm#S
#c#143#12#article#27#12#Organización de las Naciones Unidas para la Educación, l
a Ciencia y la Cultura#Declaración sobre la Raza y los Prejuicios Raciales^les#P
arís#UNESCO#19780000#1978#http://www.unhchr.ch/spanish/html/menu3/b/d_prejud_sp.
htm#20071114#14 de noviembre de 2007#20071200#a09v22n6.htm##
00638000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760170033000790180031001120530
06200143055001200205054002900217056002600246057002200272056001100294052000700305
065000900312064000500321865000900326002001300335#v22n6#v:\scielo\serial\rpsp\v22
n6\markup\a09v22n6.htm#S#c#144#13#article#27#13#Organización Mundial de la Salud
#Atención Primaria de Salud^les#Conferencia Internacional sobre Atención Primari
a de Salud^i1#19780906^i1#6-2 de septiembre de 1978^i1#Alma-Ata^i1^eKazajstán^i1
#ex Unión Soviética^i1#Ginebra^i1#OMS^i1#19790000#1979#20071200#a09v22n6.htm##
00503000000000265000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790120076000960300
01900172710000200191065000900193064000500202031000200207032000200209014000400211
865000900215002001300224#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a09v22n6.htm#S
#c#145#14#article#27#14#^rND^sChatora^nR#An overview of the traditional medicine
 situation in the African Region^len#WHO Afr Health Mon#2#20030000#2003#4#1#4-7#
20071200#a09v22n6.htm##
00635000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760170039000790530072001180560
01100190052000700201055001200208054000800220061002200228037005200250110000900302
109002400311865000900335002001300344#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a0
9v22n6.htm#S#c#146#15#article#27#15#Organización Internacional del Trabajo#Conve
nio sobre Pueblos Indígenas y Tribales en Países Independientes^i1#Ginebra^i1#OI
T^i1#19890000^i1#1989^i1#Documento OIT No. 169#http://www.unhchr.ch/spanish/html
/menu3/b/62_sp.htm#20071114#14 de noviembre de 2007#20071200#a09v22n6.htm##
00424000000000229000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760160014000790180039000930660
00600132062002000138065000900158064000500167865000900172002001300181#v22n6#v:\sc
ielo\serial\rpsp\v22n6\markup\a09v22n6.htm#S#c#147#16#article#27#16#^rND^sWade^n
P#Raza y etnicidad en América Latina^les#Quito#Ediciones Abya Yala#20000000#2000
#20071200#a09v22n6.htm##
00550000000000253000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760170034000790180046001130530
04300159056000900202052001900211055001200230054000800242061002400250865000900274
002001300283#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a09v22n6.htm#S#c#148#17#ar
ticle#27#17#Naciones Unidas^dAsamblea General#Declaración y Programa de Acción d
e Viena^les#Conferencia Mundial de Derechos Humanos^i1#Viena^i1#Naciones Unidas^
i1#19930000^i1#1993^i1#Documento A/CONF.157/23#20071200#a09v22n6.htm##
00718000000000241000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760170098000790180152001770660
00800329062007800337065000900415064000500424061002500429865000900454002001300463
#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a09v22n6.htm#S#c#149#18#article#27#18#
Naciones Unidas^dConsejo Económico y Social, Comité de Derechos Económicos, Soci
ales y Culturales#El derecho a la educación (Artículo 13): Aplicación del Pacto 
Internacional de Derechos Económicos, Sociales y Culturales. 21.° Período de Ses
iones^les#Ginebra#Oficina del Alto Comisionado de las Naciones Unidas para los D
erechos Humanos#19990000#1999#Documento E/C.12/1999/10#20071200#a09v22n6.htm##
00487000000000241000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760170016000790180063000950660
01100158062001600169065000900185064000500194061002400199865000900223002001300232
#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a09v22n6.htm#S#c#150#19#article#27#19#
Naciones Unidas#Informe sobre la Cuarta Conferencia Mundial sobre la Mujer^les#N
ueva York#Naciones Unidas#19960000#1996#Documento A/CONF.177/20#20071200#a09v22n
6.htm##
00556000000000241000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760170034000790180115001130660
01100228062001600239065000900255064000500264061002300269865000900292002001300301
#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a09v22n6.htm#S#c#151#20#article#27#20#
Naciones Unidas^dAsamblea General#Resolución de la Asamblea General 48/163 sobre
 el Decenio Internacional de las Poblaciones Indígenas del Mundo^les#Nueva York#
Naciones Unidas#19940000#1994#Documento A/RES/48/163#20071200#a09v22n6.htm##
00708000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760170022000790180031001010530
10100132055001200233054002300245056001500268057001000283037008200293110000900375
109002400384865000900408002001300417#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a0
9v22n6.htm#S#c#152#21#article#27#21#Cumbre Iberoamericana#Declaración de Guadala
jara^les#Cumbre Iberoamericana de Jefes de Estado y de Gobierno de América Latin
a, España y Portugal^nI^i1^i1#19910719^i1#19 de julio de 1991^i1#Guadalajara^i1#
México^i1#http://www.integracionsur.com/americalatina/CumbreALatinaEuropaDclGuad
alajara.htm#20071114#14 de noviembre de 2007#20071200#a09v22n6.htm##
00431000000000229000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760160018000790180055000970660
00600152062000700158065000900165064000500174865000900179002001300188#v22n6#v:\sc
ielo\serial\rpsp\v22n6\markup\a09v22n6.htm#S#c#153#22#article#27#22#^rND^sTourai
ne^nA#Pourrant-nous vivre ensemble?: Egaux et différents^lfr#Paris#Fayard#199800
00#1998#20071200#a09v22n6.htm##
01017000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760170016000790180119000950530
19300214055001200407054002800419056001200447057000900459066001100468062001600479
06500090049506400050050406100280050903700870053711000090062410900240063386500090
0657002001300666#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a09v22n6.htm#S#c#154#2
3#article#27#23#Naciones Unidas#Conferencia Mundial Contra el Racismo, la Discri
minación Racial, la Xenofobia y las Formas Conexas de Intolerancia^les#Seminario
 regional de expertos para América Latina y el Caribe sobre medidas económicas, 
sociales y jurídicas para luchar contra el racismo, con referencia especial a lo
s grupos vulnerables^i1#20001027^i1#25-27 de octubre de 2000^i1#Santiago^i1#Chil
e^i1#Nueva York#Naciones Unidas#20010000#2001#Documento A/CONF.189/PC.2/5#http:/
/www.unhchr.ch/huridocda/huridoca.nsf/(Symbol)/A.CONF.189.PC.2.5.Sp?Opendocument
#20071114#14 de noviembre de 2007#20071200#a09v22n6.htm##
00616000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760160015000790530104000940550
01200198054002700210056002700237057001100264066001100275062001600286065000900302
064000500311865000900316002001300325#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a0
9v22n6.htm#S#c#155#24#article#27#24#^rND^sAnnan^nK#Cumbre Iberoamericana de Jefe
s de Estado y de Gobierno de América Latina, España y Portugal^nXIII^i1^i1#20031
114^i1#14 de noviembre de 2003^i1#Santa Cruz de la Sierra^i1#Bolivia^i1#Nueva Yo
rk#Naciones Unidas#20030000#2003#20071200#a09v22n6.htm##
00697000000000265000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760180148000790650009002270640
02300236066001400259067001000273066001300283037007900296110000900375109002500384
865000900409002001300418#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a09v22n6.htm#S
#c#156#25#article#27#25#Declaración de Mar del Plata: Crear trabajo para enfrent
ar la pobreza y fortalecer la gobernabilidad democrática. Cuarta Cumbre de las A
méricas^les#20051105#5 de noviembre de 2005#Mar del Plata#Argentina#Buenos Aires
#http://www.iin.oea.org/DECLARACIONES/declaracion_IV_Cumbre_de_las_Americas.htm#
20070929#29 de septiembre de 2007#20071200#a09v22n6.htm##
00731000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760170022000790180030001010530
10300131055001200234054002600246056001400272057001100286037010100297110000900398
109002400407865000900431002001300440#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a0
9v22n6.htm#S#c#157#26#article#27#26#Cumbre Iberoamericana#Declaración de Montevi
deo^les#Cumbre Iberoamericana de Jefes de Estado y de Gobierno de América Latina
, España y Portugal^nXVI^i1^i1#20061105^i1#5 de noviembre de 2006^i1#Montevideo^
i1#Uruguay^i1#http://www.cinterfor.org.uy/public/spanish/region/ampro/cinterfor/
temas/employer/eventos/xvi_dec.pdf#20071114#14 de noviembre de 2007#20071200#a09
v22n6.htm##
00620000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760170016000790180083000950660
01100178062001600189065000900205064000500214061002300219037004500242110000900287
109002400296865000900320002001300329#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a0
9v22n6.htm#S#c#158#27#article#27#27#Naciones Unidas#Declaración de las Naciones 
Unidas sobre los Derechos de los Pueblos Indígenas^les#Nueva York#Naciones Unida
s#20060000#2006#Documento A/RES/61/295#http://www. servindi.org/pdf/ONU_ Dec_PI.
pdf#20071114#14 de noviembre de 2007#20071200#a09v22n6.htm##
00275000000000169000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700910009000720920007000810020013000887030
00400101#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a10v22n6.htm#S#o#1#1#article#1
#20080215#102638#a10v22n6.htm#174##
02864000000000517000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000300090121000300093049000800096158000300104030002400107
03100030013103200020013406500090013601400110014503500100015601200800016601200840
02460100029003300100031003590700117003900700102005070850008006090850021006170850
03200638085002000670083154700690085000802237085002202245085003702267085002002304
117000602324072000302330002001302333#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a1
0v22n6.htm#S#h#2#1#article#1#oa#en#br1.1#1#3.1#ND#10#RPSP050#nd#Rev Panam Salud 
Publica#22#6#20071200#^f417^l424#1020-4989#Violence among youth in Jamaica: a gr
owing public health risk and challenge^len#La violencia en jóvenes de Jamaica: u
n creciente riesgo y reto de salud pública^les#^rND^1A01^nDelores E.^sSmith#^rND
^1A02^nKatherine E.^sGreen#University of Tennessee^iA01^1Department of Child and
 Family Studies^cKnoxville^sTennessee^pUnited States of America#Northcentral Uni
versity^iA02^1School of Education^cPrescott Valley^sArizona^pUnited States of Am
erica#^dnd^i1#^tm^len^kviolence^i1#^tm^len^kadolescent behavior^i1#^tm^len^kJama
ica^i1#^les^aEn Jamaica, la abrumadora mayoría de los jóvenes son personas bien 
ajustadas social y emocionalmente. Sin embargo, el aumento vertiginoso de las ag
resiones y la violencia en la niñez, y la conducta delincuencial entre los jóven
es se han convertido en una gran preocupación para la sociedad y constituyen un 
grave problema de salud pública. A falta de investigaciones definitivas sobre la
s causas, las especulaciones apuntan a la frustración, los sentimientos de inada
ptabilidad y la falta de autonomía de los jóvenes. El propósito de este artículo
 es revisar la literatura y describir la información existente relacionada con l
a violencia en Jamaica y evaluar la plausibilidad de las suposiciones de la pobl
ación acerca de los factores relacionados con este problema. Según la literatura
 analizada, hay una convergencia de factores a niveles micro y macro que influye
n fuertemente en el comportamiento de los niños y los jóvenes jamaicanos. En est
e trabajo, estos factores se operacionalizan en tres niveles: el individual, el 
contexto social proximal (la familia y la escuela) y el contexto social distal (
i.e., las circunstancias económicas). A partir de la literatura, se concluye que
 el comportamiento violento de algunos jóvenes jamaicanos puede tener sus raíces
 en la confluencia de los problemas que abruman a las familias, los niños y los 
jóvenes. La exposición de los niños a la violencia, tanto en el seno familiar co
mo en la escuela, es particularmente preocupante. Se discuten las implicaciones 
para las decisiones en políticas.#^dnd^i2#^tm^les^kviolencia^i2#^tm^les^kconduct
a del adolescente^i2#^tm^les^kJamaica^i2#other#51#a10v22n6.htm##
02892000000000517000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000300090121000300093049000800096158000300104030002400107
03100030013103200020013406500090013601400110014503500100015601200940016601200980
02600100029003580100031003870700117004180700102005350850008006370850021006450850
03200666085002000698083154700718085000802265085002202273085003702295085002002332
117000602352072000302358002001302361#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a1
0v22n6.htm#S#f#3#1#article#1#oa#en#br1.1#1#3.1#ND#10#RPSP050#nd#Rev Panam Salud 
Publica#22#6#20071200#^f417^l424#1020-4989#<B>Violence among youth in Jamaica</B
>: <B>a growing public health risk and challenge</B>^len#<B>La violencia en jóve
nes de Jamaica</B>: <B>un creciente riesgo y reto de salud pública</B>^les#^rND^
1A01^nDelores E.^sSmith#^rND^1A02^nKatherine E.^sGreen#University of Tennessee^i
A01^1Department of Child and Family Studies^cKnoxville^sTennessee^pUnited States
 of America#Northcentral University^iA02^1School of Education^cPrescott Valley^s
Arizona^pUnited States of America#^dnd^i1#^tm^len^kviolence^i1#^tm^len^kadolesce
nt behavior^i1#^tm^len^kJamaica^i1#^les^aEn Jamaica, la abrumadora mayoría de lo
s jóvenes son personas bien ajustadas social y emocionalmente. Sin embargo, el a
umento vertiginoso de las agresiones y la violencia en la niñez, y la conducta d
elincuencial entre los jóvenes se han convertido en una gran preocupación para l
a sociedad y constituyen un grave problema de salud pública. A falta de investig
aciones definitivas sobre las causas, las especulaciones apuntan a la frustració
n, los sentimientos de inadaptabilidad y la falta de autonomía de los jóvenes. E
l propósito de este artículo es revisar la literatura y describir la información
 existente relacionada con la violencia en Jamaica y evaluar la plausibilidad de
 las suposiciones de la población acerca de los factores relacionados con este p
roblema. Según la literatura analizada, hay una convergencia de factores a nivel
es micro y macro que influyen fuertemente en el comportamiento de los niños y lo
s jóvenes jamaicanos. En este trabajo, estos factores se operacionalizan en tres
 niveles: el individual, el contexto social proximal (la familia y la escuela) y
 el contexto social distal (i.e., las circunstancias económicas). A partir de la
 literatura, se concluye que el comportamiento violento de algunos jóvenes jamai
canos puede tener sus raíces en la confluencia de los problemas que abruman a la
s familias, los niños y los jóvenes. La exposición de los niños a la violencia, 
tanto en el seno familiar como en la escuela, es particularmente preocupante. Se
 discuten las implicaciones para las decisiones en políticas.#^dnd^i2#^tm^les^kv
iolencia^i2#^tm^les^kconducta del adolescente^i2#^tm^les^kJamaica^i2#other#51#a1
0v22n6.htm##
02982000000000529000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700640013000720710003000850400003000880010
00600091042000200097120000400099121000300103049000800106158000300114030002600117
03100030014303200020014606500090014801400110015703500100016801200800017801200840
02580100028003420100030003700700119004000700104005190850008006230850021006310850
03200652085002000684083154700704085000802251085002202259085003702281085002002318
117000602338072000302344002001302347008009202360#v22n6#v:\scielo\serial\rpsp\v22
n6\markup\a10v22n6.htm#S#l#4#1#article#1#^mDec.^a2007#oa#en#br1.1#1#3.1#10#RPSP0
50#nd#Rev. panam. salud pública#22#6#20071200#^f417^l424#1020-4989#Violence amon
g youth in Jamaica: a growing public health risk and challenge^len#La violencia 
en jóvenes de Jamaica: un creciente riesgo y reto de salud pública^les#^rND^1A01
^nDelores E^sSmith#^rND^1A02^nKatherine E^sGreen#^iA01^1University of Tennessee^
2Department of Child and Family Studies^cKnoxville^sTennessee^pUnited States of 
America#^iA02^1Northcentral University^2School of Education^cPrescott Valley^sAr
izona^pUnited States of America#^dnd^i1#^tm^len^kviolence^i1#^tm^len^kadolescent
 behavior^i1#^tm^len^kJamaica^i1#^les^aEn Jamaica, la abrumadora mayoría de los 
jóvenes son personas bien ajustadas social y emocionalmente. Sin embargo, el aum
ento vertiginoso de las agresiones y la violencia en la niñez, y la conducta del
incuencial entre los jóvenes se han convertido en una gran preocupación para la 
sociedad y constituyen un grave problema de salud pública. A falta de investigac
iones definitivas sobre las causas, las especulaciones apuntan a la frustración,
 los sentimientos de inadaptabilidad y la falta de autonomía de los jóvenes. El 
propósito de este artículo es revisar la literatura y describir la información e
xistente relacionada con la violencia en Jamaica y evaluar la plausibilidad de l
as suposiciones de la población acerca de los factores relacionados con este pro
blema. Según la literatura analizada, hay una convergencia de factores a niveles
 micro y macro que influyen fuertemente en el comportamiento de los niños y los 
jóvenes jamaicanos. En este trabajo, estos factores se operacionalizan en tres n
iveles: el individual, el contexto social proximal (la familia y la escuela) y e
l contexto social distal (i.e., las circunstancias económicas). A partir de la l
iteratura, se concluye que el comportamiento violento de algunos jóvenes jamaica
nos puede tener sus raíces en la confluencia de los problemas que abruman a las 
familias, los niños y los jóvenes. La exposición de los niños a la violencia, ta
nto en el seno familiar como en la escuela, es particularmente preocupante. Se d
iscuten las implicaciones para las decisiones en políticas.#^dnd^i2#^tm^les^kvio
lencia^i2#^tm^les^kconducta del adolescente^i2#^tm^les^kJamaica^i2#other#51#a10v
22n6.htm#Internet^ihttp://www.scielosp.org/scielo.php?script=sci_arttext&pid=S10
20-49892007001100010##
00341000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704010800074002001300182#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a10v22n6.htm#S#p#5#1#article#119#<p align="right"><fon
t size="2" face="Verdana"><b>TEMAS DE ACTUALIDAD </b>CURRENT TOPICS</font></p>  
   ^cY#a10v22n6.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a10v22n6.htm#S#p#6#2#article#119#<p>&nbsp;</p>     ^cY
#a10v22n6.htm##
00388000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704015500074002001300229#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a10v22n6.htm#S#p#7#3#article#119#<p><font size="4" fac
e="verdana"><a name="tx"></a><b>Violence among youth in Jamaica:    a growing pu
blic health risk and challenge</b></font></p>     ^cY#a10v22n6.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a10v22n6.htm#S#p#8#4#article#119#<p>&nbsp;</p>     ^cY
#a10v22n6.htm##
00390000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704015700074002001300231#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a10v22n6.htm#S#p#9#5#article#119#<p><font size="3" fac
e="verdana"><b>La violencia en j&oacute;venes de Jamaica:    un creciente riesgo
 y reto de salud p&uacute;blica </b></font></p>     ^cY#a10v22n6.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704002200075002001300097#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a10v22n6.htm#S#p#10#6#article#119#<p>&nbsp;</p>     ^c
Y#a10v22n6.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704002200075002001300097#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a10v22n6.htm#S#p#11#7#article#119#<p>&nbsp;</p>     ^c
Y#a10v22n6.htm##
00390000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704015600075002001300231#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a10v22n6.htm#S#p#12#8#article#119#<p><font size="2" fa
ce="Verdana"><b>Delores E. Smith<SUP>I</SUP>; Katherine E.    Green<SUP>II, </su
p><a href="#nt"><sup>*</sup></a></b></font></p>     ^cY#a10v22n6.htm##
00401000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704016700075002001300242#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a10v22n6.htm#S#p#13#9#article#119#<p><font size="2" fa
ce="Verdana"><SUP>I</sup>Department of Child and Family Studies,    University o
f Tennessee, Knoxville, Tennessee, United States of America    ^cY#a10v22n6.htm#
#
00374000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704013900076002001300215#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a10v22n6.htm#S#p#14#10#article#119#<br>   <SUP>II</sup
>School of Education, Northcentral    University, Prescott Valley, Arizona, Unit
ed States of America</font></p>     ^cY#a10v22n6.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a10v22n6.htm#S#p#15#11#article#119#<p>&nbsp;</p>     ^
cY#a10v22n6.htm##
00279000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704004400076002001300120#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a10v22n6.htm#S#p#16#12#article#119#<p>&nbsp;</p> <hr s
ize="1" noshade>     ^cY#a10v22n6.htm##
00370000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704013500076002001300211#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a10v22n6.htm#S#p#17#13#article#119#<p><font size="2" f
ace="Verdana"><B>Key words: </b>violence, adolescent behavior,    Jamaica.</font
></p> <hr size="1" noshade>     ^cY#a10v22n6.htm##
00303000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704006800076002001300144#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a10v22n6.htm#S#p#18#14#article#119#<p><font size="2" f
ace="Verdana"><b>SINOPSIS</b></font></p>     ^cY#a10v22n6.htm##
02059000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704182400076002001301900#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a10v22n6.htm#S#p#19#15#article#119#<p><font size="2" f
ace="Verdana">En Jamaica, la abrumadora mayor&iacute;a de los    j&oacute;venes 
son personas bien ajustadas social y emocionalmente. Sin embargo,    el aumento 
vertiginoso de las agresiones y la violencia en la ni&ntilde;ez,    y la conduct
a delincuencial entre los j&oacute;venes se han convertido en una    gran preocu
paci&oacute;n para la sociedad y constituyen un grave problema de    salud p&uac
ute;blica. A falta de investigaciones definitivas sobre las causas,    las espec
ulaciones apuntan a la frustraci&oacute;n, los sentimientos de inadaptabilidad  
  y la falta de autonom&iacute;a de los j&oacute;venes. El prop&oacute;sito de  
  este art&iacute;culo es revisar la literatura y describir la informaci&oacute;
n    existente relacionada con la violencia en Jamaica y evaluar la plausibilida
d    de las suposiciones de la poblaci&oacute;n acerca de los factores relaciona
dos    con este problema. Seg&uacute;n la literatura analizada, hay una converge
ncia    de factores a niveles micro y macro que influyen fuertemente en el compo
rtamiento    de los ni&ntilde;os y los j&oacute;venes jamaicanos. En este trabaj
o, estos    factores se operacionalizan en tres niveles: el individual, el conte
xto social    proximal (la familia y la escuela) y el contexto social distal (i.
e., las circunstancias    econ&oacute;micas). A partir de la literatura, se conc
luye que el comportamiento    violento de algunos j&oacute;venes jamaicanos pued
e tener sus ra&iacute;ces    en la confluencia de los problemas que abruman a la
s familias, los ni&ntilde;os    y los j&oacute;venes. La exposici&oacute;n de lo
s ni&ntilde;os a la violencia,    tanto en el seno familiar como en la escuela, 
es particularmente preocupante.    Se discuten las implicaciones para las decisi
ones en pol&iacute;ticas.</font></p>     ^cY#a10v22n6.htm##
00373000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704013800076002001300214#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a10v22n6.htm#S#p#20#16#article#119#<p><font size="2" f
ace="Verdana"><B>Palabras clave:</b> violencia, conducta del    adolescente, Jam
aica.</font></p> <hr size="1">     ^cY#a10v22n6.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a10v22n6.htm#S#p#21#17#article#119#<p>&nbsp;</p>     ^
cY#a10v22n6.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a10v22n6.htm#S#p#22#18#article#119#<p>&nbsp;</p>     ^
cY#a10v22n6.htm##
01120000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704088500076002001300961#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a10v22n6.htm#S#p#23#19#article#119#<p><font size="2" f
ace="Verdana">Although the overwhelming majority of Jamaican    children and ado
lescents are well adjusted, a substantial group exhibits high    levels of malad
justment and deficient functioning (1). A perfunctory review    of Jamaican news
papers and television talk-shows reveals that violence, particularly    violence
 perpetrated by youths, is of major concern in every sector of Jamaican    socie
ty. Although aggressive and violent behaviors are not new in Jamaica, the    rec
ent escalation of criminal violence among the adolescent population has become  
  a major public policy issue and a serious public health problem. Violent activ
ities    have become more vicious and the perpetrators more ruthless than what t
he typical    Jamaican over 40 years of age is used to (M. Jones, Social Scienti
st, personal    communication, 8 March 2006). </font></p>     ^cY#a10v22n6.htm##
01684000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704144900076002001301525#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a10v22n6.htm#S#p#24#20#article#119#<p><font size="2" f
ace="Verdana">The purpose of this article is to review the    relevant literatur
e, describe the existing knowledge regarding aggression and    violence among ch
ildren and youth in the Jamaican context, and evaluate the    plausibility of po
pular assumptions regarding the correlates of aggressive and    violent outcomes
 in Jamaican children and youth. This article assesses the relationship    betwe
en ecological processes and youth outcomes in Jamaica and is organized    in the
 following manner: the first section addresses the incidence of violence    and 
its impact on society; the next section focuses on the overall conceptual    fra
mework and its usefulness in assessing child outcomes in the Jamaican context.  
  Pursuant to that, the individual attributes of violent outcomes are addressed,
    as well as two levels of the ecological environment: the proximal (near) env
ironment    and the distal (far) environment. In the proximal context, the issue
 of parental    involvement is addressed as two separate issues: father absence 
and mother absence.    This is because a substantial number of Jamaican children
, historically, have    not had "involved" fathers, and recently, the issue of m
other absence    has featured prominently in the discussions surrounding youth p
roblem behaviors    in Jamaica. The final section summarizes the article and dis
cusses implications    for policy decision making.</font></p>     ^cY#a10v22n6.h
tm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a10v22n6.htm#S#p#25#21#article#119#<p>&nbsp;</p>     ^
cY#a10v22n6.htm##
00323000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704008800076002001300164#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a10v22n6.htm#S#p#26#22#article#119#<p><font size="3" f
ace="Verdana"><b>STATE OF VIOLENCE IN JAMAICA</b></font></p>     ^cY#a10v22n6.ht
m##
01253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704101800076002001301094#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a10v22n6.htm#S#p#27#23#article#119#<p><font size="2" f
ace="Verdana">In 2000, Jamaica ranked third in the world in    murders per capit
a (2). By the end of 2005, police crime data indicated a record    number of ann
ual homicides (63.0 per 100 000 inhabitants), a rate greater than    three times
 the global average of 19.4 per 100 000 (2). These statistics are    in addition
 to the high rates of rape, stab wounds and other injuries, and assaults    (2, 
3). Consistent with global trends, young males from 15–29 years of age are    di
sproportionately represented, both as victims and perpetrators of violence.    I
n 2002, this demographic group was responsible for 80% of the violent crimes,   
 75% of the murders, and 98% of all major crimes committed in Jamaica (3, 4).   
 Also in 2002, 55% of those arrested were males under 25 years of age. Among    
the new admissions to correctional institutions in 2002, 32% were under 25 years
    of age and 83 % were males (4). From 68%–76% of homicides involved the use o
f    firearms (5). </font></p>     ^cY#a10v22n6.htm##
00871000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704063600076002001300712#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a10v22n6.htm#S#p#28#24#article#119#<p><font size="2" f
ace="Verdana">Violence is the leading cause    of death in young Jamaican males 
and the fifth leading cause of death for people    of all ages (3). An increasin
g number of women and children are also victims    of violent criminal activity.
 Police records for 2003 indicate that females    were the victims of the 1 308 
reported cases of rape and 9% of the murders (6).    In 2004, 119 children were 
murdered and 430 suffered gunshot wounds. In the    same year, children represen
ted 70% of the victims of sexual crimes; males 16–25    years of age were arrest
ed for 47% of the rape cases (5, 6). </font></p>     ^cY#a10v22n6.htm##
01393000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704115800076002001301234#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a10v22n6.htm#S#p#29#25#article#119#<p><font size="2" f
ace="Verdana">The focus here is on violence perpetrated by    youth because Jama
ica, a small island democracy of 4 411 square miles within    the Region of the 
Americas, has one of the highest youth-perpetrated violence    rates in the worl
d (2, 5). However, research on social processes and child outcomes    in the Reg
ion, particularly in Jamaica, is sparse. Consequently, little is known    about 
the relationship between local ecological processes and the high incidence    of
 aggression and violence among Jamaican children and youth. Nevertheless,    the
re have been various conjectures about the root causes of youth dysfunctional   
 outcomes. While many of these speculations, most originating from the local    
media, have been targeted at the socialization practices of Jamaican parents,   
 much less blame has been directed at related macro-level factors, such as urban
ization    and its attending problems. However, a large body of international re
search    has demonstrated that violence is a complex and multifaceted phenomeno
n. Therefore,    no single factor can explain its etiology or existence (5, 7).<
/font></p>     ^cY#a10v22n6.htm##
00333000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009800076002001300174#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a10v22n6.htm#S#p#30#26#article#119#<p><font size="2" f
ace="Verdana"><b>Impact of violence on Jamaican society</b></font></p>     ^cY#a
10v22n6.htm##
02073000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704183800076002001301914#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a10v22n6.htm#S#p#31#27#article#119#<p><font size="2" f
ace="Verdana">The devastating impact of widespread violence    on social order h
as been widely documented. As is the case worldwide, all types    of violence po
se serious public health risks and exact both direct and indirect    costs on so
ciety (3, 7, 8). The impact in terms of death, injuries, short- and    long-term
 disabilities, and mental anguish is vast (7). In addition, violence    impedes 
social advancement and deters economic growth and development. Violence    inhib
its the recruitment and retention of a highly skilled workforce and forces    so
ciety to expend a disproportionate amount of its national budget on violence-rel
ated    health care, security, and crime fighting (3). Jamaica is no exception, 
spending    an extraordinarily high percentage of its gross domestic product on 
violence-related    issues and struggling with reduced human capital, productivi
ty, and quality    of life (2, 7, 8). Moreover, the high cost of doing business 
makes the society    unable to compete in the global economy (2, 3). According t
o Brown (9) ".    . . investments from both local and foreign sources, which cou
ld create new    employment, are being shelved; the educational system is being 
affected; social    interactions are being disrupted; and, the citizens are grip
ped in fear, unable    to live normal lives which prevail in other civil societi
es." In monetary    terms, violence costs the country an estimated J$ 15 billion
 in health care,    lost economic activities, and human suffering; violence rela
ted injuries cost    the economy more than J$ 700 million per year (3). It is wo
rthy of note that,    consistent with global trends, the costs of violence are u
nevenly distributed    since violent crimes are concentrated among the lowest ec
onomic segment of society    (3, 5, 7).</font></p>     ^cY#a10v22n6.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a10v22n6.htm#S#p#32#28#article#119#<p>&nbsp;</p>     ^
cY#a10v22n6.htm##
00315000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704008000076002001300156#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a10v22n6.htm#S#p#33#29#article#119#<p><font size="3" f
ace="Verdana"><b>CONCEPTUAL FRAMEWORK</b></font></p>     ^cY#a10v22n6.htm##
01169000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704093400076002001301010#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a10v22n6.htm#S#p#34#30#article#119#<p><font size="2" f
ace="Verdana">Ecological systems theory has been identified    as one of the pre
eminent perspectives in assessing and understanding human development    and beh
avior (2, 7). The framework emphasizes how inseparable the individual    and the
 social environment are, and underscores the saliency of their interactions    i
n effecting developmental outcomes (10). The perspective implies that to underst
and    an individual's development, the interrelationships of the multiple proce
sses    and contexts within which that individual develops must be understood. T
he framework    assumes that developmental outcomes emanate from a complex web o
f exchanges    between the individual and the culture. These exchanges take plac
e within a    system of proximal and distal contexts to either promote or stifle
 development;    therefore, all systems work together to influence what the indi
vidual becomes.</font></p>     ^cY#a10v22n6.htm##
00848000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704061300076002001300689#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a10v22n6.htm#S#p#35#31#article#119#<p><font size="2" f
ace="Verdana">Proximal processes consist of    the direct interactions between t
he individual and the immediate environment.    Distal processes, on the other h
and, are those interactions that occur outside    of the immediate environment, 
but nevertheless affect the individual through    consequences on the proximal p
rocesses. Consistent with the theory, it is argued    here that violent tendenci
es in some Jamaican adolescents develop from the interactions    of distinct soc
ial forces and youth characteristics, often via feedback from    the environment
 to the child.</font></p>     ^cY#a10v22n6.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a10v22n6.htm#S#p#36#32#article#119#<p>&nbsp;</p>     ^
cY#a10v22n6.htm##
00321000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704008600076002001300162#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a10v22n6.htm#S#p#37#33#article#119#<p><font size="3" f
ace="Verdana"><b>INDIVIDUAL CHARACTERISTICS</b></font></p>     ^cY#a10v22n6.htm#
#
01606000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704137100076002001301447#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a10v22n6.htm#S#p#38#34#article#119#<p><font size="2" f
ace="Verdana">Personal characteristics such as low self-esteem,    poor social p
roblem-solving skills, and low empathy (11, 12) have been identified    as robus
t predictors of violent tendencies in children and youth. In one study    (11), 
inhibition, negative self-representation, and low sense-of-self predicted    the
 development of aggression and overall maladjustment in children. Maladjusted   
 youth show a propensity to exhibit increased resistance to social integration  
  and gravitate toward dysfunctional peer activities such as gangs (13, 14). Tho
se    activities fill the youth's need for identity, sense of belonging, and wor
thiness    (14). One study, employing causal modeling techniques, concluded that
 youth    who suffered from deficient self-esteem tended to restore their self-e
steem    by engaging in delinquent activities (14). In Jamaica, the prevailing c
ontention    is that many Jamaican children and youth suffer from chronic feelin
gs of unworthiness    and lack hope for the future, a belief espoused by a promi
nent leader who noted    that Jamaican youth ". . . do not have any inspiration 
or motivation to    plan positively for the future. The decline in values and at
titudes among some    of our youth can be traced to the fact that they too have 
given up and don't    have the drive to go on" (15).</font></p>     ^cY#a10v22n6
.htm##
01509000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704127400076002001301350#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a10v22n6.htm#S#p#39#35#article#119#<p><font size="2" f
ace="Verdana">Biology is another factor that has been implicated    in violent t
endencies, but the relationship is unclear. However, there is strong    scientif
ic evidence suggesting that many adverse biological outcomes may be    a result 
of deficient social environments. For example, harsh prenatal and postnatal    e
nvironments may be responsible for poor brain development and function. Studies 
   have shown damage to or deficiency in the prefrontal cortex of the brain of  
  criminally violent individuals (16). Studies have also shown that children who
    had "received damage to their prefrontal cortex before age 7, developed    a
bnormal social behavior, characterized by an inability to control frustration,  
  anger, and aggression" (16). Furthermore, fetal exposure to tobacco, alcohol, 
   drugs, and/or lead during and after pregnancy can result in stunted nerve and
    brain cells in the child, causing neurological problems; postnatal exposure 
   to those same toxins have similar consequences (17). Maternal depression can 
   impede the maternal response and stimulation needed for optimal emotional fun
ctioning,    while inadequate pre- and postnatal nutrition can stunt growth in a
ll aspects    of development (17). </font></p>     ^cY#a10v22n6.htm##
00892000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704065700076002001300733#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a10v22n6.htm#S#p#40#36#article#119#<p><font size="2" f
ace="Verdana">In Jamaica, exposure to toxins is high among    children. Studies 
have reported evidence of severe lead toxicity in Jamaican    children, which is
 often manifested as seizures or other neurological problems    (18). Also, desp
ite improvement in the nutritional status of Jamaican children    over the last 
decade, it continues to lag behind international standards (19).    As indicated
 in the sections that follow, many Jamaican families experience    other harsh s
ocial environments that have been shown to adversely affect biological    proces
ses and can lead to developmental and behavioral problems.</font></p>     ^cY#a1
0v22n6.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a10v22n6.htm#S#p#41#37#article#119#<p>&nbsp;</p>     ^
cY#a10v22n6.htm##
00315000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704008000076002001300156#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a10v22n6.htm#S#p#42#38#article#119#<p><font size="3" f
ace="Verdana"><b>PROXIMAL ENVIRONMENT</b></font></p>     ^cY#a10v22n6.htm##
00307000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704007200076002001300148#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a10v22n6.htm#S#p#43#39#article#119#<p><font size="2" f
ace="Verdana"><b>Childrearing</b></font></p>     ^cY#a10v22n6.htm##
00999000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704076400076002001300840#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a10v22n6.htm#S#p#44#40#article#119#<p><font size="2" f
ace="Verdana">Research has shown that parental nurturance and    responsiveness 
facilitate favorable child outcomes. Conversely, punitive and    neglectful pare
nting put children at risk for undesirable consequences (20,    21). Also, the a
cademic literature has suggested that harsh parenting is a serious    risk facto
r for children's aggressive and violent behaviors; hostile and abusive    famili
es produce violent children and youth (21–23). Both cross-sectional and    retro
spective studies have shown a positive relationship between physical punishment 
   and aggressive behavior (22, 23). One study found this relationship to be par
ticularly    robust for boys who lacked close identification with their fathers 
(22).</font></p>     ^cY#a10v22n6.htm##
02164000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704192900076002001302005#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a10v22n6.htm#S#p#45#41#article#119#<p><font size="2" f
ace="Verdana">The literature has purported that the discipline    typically prac
ticed by Jamaican parents and caregivers teaches children to be    violent (24, 
25). Flogging, a culturally sanctioned form of punishment, is the    primary dis
ciplinary practice utilized by the majority of parents and caregivers,    while 
spanking (as opposed to flogging) is practiced by only 3% (25). Adults    "hitti
ng &#91;children&#93; with a belt and sticks is omnipresent. There is also    pu
shing, with children being flung bodily into furniture . . . &#91;and&#93; boxin
g,    hitting, kicking and chopping children" (4). These are common responses   
 to perceived misbehavior. "Children are regularly smacked, flogged,    and even
 threatened with weapons" (26). In 1998, 80% of children in childcare    facilit
ies in Jamaica reported experiencing abusive incidents at the hands of    caregi
vers (24). A study by the Jamaican Ministry of Health, found that 84%    of chil
dren reported being beaten with an object at home while another 8% reported    b
eing kicked, bitten, or beaten up (4). In 2002, 2 183 children were treated    i
n emergency rooms across the island for injuries inflicted by parents and caregi
vers;    70% of those cases involved the use of sharp or blunt instruments and 1
8% involved    the use of bodily force (4). Undoubtedly, the pervasive use of ha
rsh physical    punishment in the home (and society) has legitimized the use of 
violence against    children (1, 24, 25). It may be instructive to know that in 
a Jamaican study,    66% of boys and 50% of girls in the Jamaican sample rated a
s "highly aggressive"    were from homes where physical punishment was the prima
ry disciplinary measure    (27). Scholars have contended that if society employe
d strategies to reduce    abusive, hostile parenting, the incidence of societal 
violence would decrease    significantly (21, 23).</font></p>     ^cY#a10v22n6.h
tm##
00315000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704008000076002001300156#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a10v22n6.htm#S#p#46#42#article#119#<p><font size="2" f
ace="Verdana"><b>Parental involvement</b></font></p>     ^cY#a10v22n6.htm##
00934000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704069900076002001300775#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a10v22n6.htm#S#p#47#43#article#119#<p><font size="2" f
ace="Verdana">"Parental involvement in their children's    lives is one of the m
ost important—if not the single most important—contributor    to children's heal
thy psychological development" (21). Therefore, parents    who are detached phys
ically and/or emotionally put their children at risk for    serious negative dev
elopmental outcomes (22, 28). Studies have shown that, in    comparison to their
 peers with involved parents, adolescents with disengaged    parents are signifi
cantly more likely to exhibit psychiatric difficulties, school    failure, and s
erious misconduct (e.g., delinquency, alcohol and drug use, violence,    and sex
ual precocity) (21).</font></p>     ^cY#a10v22n6.htm##
01524000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704128900076002001301365#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a10v22n6.htm#S#p#48#44#article#119#<p><font size="2" f
ace="Verdana"><b>Father absence.</b> A father in the home,    indepen-dent of mo
ther's contribution, serves a protective function against    maladaptive outcome
s (29). In the United States, empirical studies have indicated    that children 
from homes where there is no father present experience significantly    more phy
sical, cognitive, psychiatric, and behavioral problems than their peers    resid
ing in homes with a father present (30). For example, a child with a nonresident
ial    father is five times more likely to live in poverty; two times more likel
y to    suffer physical, educational, and emotional neglect; at 120% greater ris
k to    suffer some type of abuse; and has significantly higher odds of incarcer
ation    than their peers with a father present in the home (31). Children from 
father-absent    homes often harbor feelings of hostility and rejection, have a 
high occurrence    of association with deviant peers, and involvement in negativ
e peer activities    (32). Conversely, the academic literature has explicated th
e positive consequences    for overall family well-being when the child's father
 is present and involved    in his or her life (30–32). In the United States, 85
% of prison inmates had    no father at home (33).</font></p>     ^cY#a10v22n6.h
tm##
01984000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704174900076002001301825#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a10v22n6.htm#S#p#49#45#article#119#<p><font size="2" f
ace="Verdana">In Jamaica, a high rate of father-absence has    been the norm his
torically. However, in present day Jamaica, family dispersal    and the diminuti
on of the extended kin leave many children without the traditional    compensato
ry network (29). The noticeable increase in the number of street children,    es
pecially in urban Jamaica, and the concomitant rise in the incidence and severit
y    of problem and criminal behaviors among youth, have stirred renewed interes
t    in the effect of father-absence on the developmental outcomes of Jamaican c
hildren    (29, 33–35). Some have posited that in Jamaica, the combination of fa
ther absence    and female dominance is responsible for the low levels of respon
sibility and    high aggression and hostility in Jamaican males (34). Also, Wrig
ht (35) delineated    father absence and, by default, deficient parenting as the
 principal causes    of youth problem behaviors. Crawford-Brown (28) examined th
e relevance and importance    of the father in delinquent outcome in Jamaican ad
olescent boys and found that    77% of delinquent youth in the sample indicated 
the presence of negative role    models in their lives; 70% implicated their fat
hers as that negative role model.    Keddie (36) found that Jamaican girls witho
ut a father residing in the home    were three times more likely to become pregn
ant than their father-present peers.    Sharpe (37) maintained that the distress
 brought on by way of absent fathers    and the accompanying family instability 
put Jamaican children at serious risk    for physical injury, developmental dela
ys, and psychopathological difficulties,    issues, she contended, that are too 
crucial for society to ignore.</font></p>     ^cY#a10v22n6.htm##
02166000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704193100076002001302007#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a10v22n6.htm#S#p#50#46#article#119#<p><font size="2" f
ace="Verdana"><b>Mother-absence.</b> Despite the "new"    societal alarm regardi
ng mother absence, the phenomenon is not new. A sizable    Caribbean literature 
has documented the practice of mother-absence in the region    (38). Traditional
ly, when mothers migrated from rural to urban areas of the    country in search 
of economic opportunities, children were left in the care    of close family mem
bers, such as grandparents and aunts. In present-day Jamaica,    children are, i
n many cases, abandoned and left to fend for themselves when    their mothers or
 parents emigrate overseas in search of a better standard of    living for thems
elves and their families (39). In other instances, children    are left with str
angers or in the care of older siblings who are often themselves    children, dy
namics that put children at extremely high risk for physical and    sexual abuse
 (39, 40). Like father absence, mother absence has been speculated    to be a pr
imary cause of youth social ills. In one study, 60% of delinquent    teenagers a
t correctional institutions in Jamaica had mothers who had migrated    abroad (3
9, 40). Crawford-Brown (28) examined the relationships between family    variabl
es and conduct disorder in a group of Jamaican adolescent boys and found    moth
er-absence, low contact with mother, and instability in living arrangements    t
o be the factors most related to adolescent conduct disorder. Specifically,    8
7% of the conduct-disordered group were boys from homes where the mother was    
absent during childhood, compared to only 13% for the comparison group. In addit
ion,    81% of mothers of boys in the study group reported little contact with t
heir    children during childhood, compared to 19% of mothers in the comparison 
group.    Furthermore, 92% of the conduct-disordered children had experienced tw
o to six    changes in parental living arrangements.</font></p>     ^cY#a10v22n6
.htm##
00832000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704059700076002001300673#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a10v22n6.htm#S#p#51#47#article#119#<p><font size="2" f
ace="Verdana">According to Campbell (39), the phenomenon of    mother absence in
 Jamaica is both significant and disturbing because in the    past mother had al
ways "been there" to provide the physical and emotional    comfort the developin
g child so desperately needs. Yet, increasing economic,    social, and psycholog
ical demands on parents have deprived children of the security    they need from
 adults. Feelings of insecurity and perceptions of neglect on    the part of chi
ldren can engender mental health problems and behavioral difficulties    (21).</
font></p>     ^cY#a10v22n6.htm##
01122000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704088700076002001300963#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a10v22n6.htm#S#p#52#48#article#119#<p><font size="2" f
ace="Verdana"><b>The context of school.</b> School is another    critical compon
ent of the child socialization process. School is the setting    in which childr
en spend most of their day outside of the family, and therefore,    is a prime f
actor in children's adjustment and functioning. In addition, academic    achieve
ment is a salient aspect of children's self-worth, a strong deterrent    to devi
ancy (21), and a robust indicator of social and economic potential (41).    Ther
efore, the quality of the school experience is a key ingredient in identity    d
evelopment, morality, and interpersonal relationships (41, 42). School contexts 
   that pupils perceive as harsh, oppressive, and threatening foster frustration
,    resentment, school failure, and hostility in pupils, factors that potentiat
e    serious adverse life consequences (41, 42).</font></p>     ^cY#a10v22n6.htm
##
01446000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704121100076002001301287#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a10v22n6.htm#S#p#53#49#article#119#<p><font size="2" f
ace="Verdana">The quality and efficacy of the    teaching-learning process in th
e Jamaican context has been deemed problematic.    The extreme disciplinary meas
ures meted out to children at home extend into    the school where corporal puni
shment is utilized both as a disciplinary ritual    and a pedagogical strategy (
24, 25). In one study, 91% of the teacher-respondents    reported using corporal
 punishment (43). In another study, 63% of the girls    reported that they had b
een physically punished by their teachers (44), and    in still another study, t
eachers defended "the necessity to use the strap"    and cited the biblical dict
um "not to spare the rod and spoil the child"    (24). Ustanny (4) summarized lo
cal research and noted that corporal punishment    was identified as the greates
t risk factor for school aggression especially    among boys; 80% of boys and 70
% of girls reported a lifetime prevalence of being    beaten with an object and 
14% of boys and 1% of girls indicated that they carried    a weapon (most often 
a knife) to school all the time; students reporting academic    difficulties wer
e significantly more likely to fight with a weapon. </font></p>     ^cY#a10v22n6
.htm##
01074000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704083900076002001300915#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a10v22n6.htm#S#p#54#50#article#119#<p><font size="2" f
ace="Verdana">Day (42) hypothesized that the indiscipline,    lack of social res
ponsibility, and belligerency evidenced in Jamaican youth    were directly linke
d to the harsh treatment, specifically corporal punishment,    administered to c
hildren by teachers. He reasoned that such treatment created    distress, anger,
 and rage in pupils. "Deeming themselves recipients of    injustice, they &#91;y
outh&#93; sometimes proceed to wreak vengeance on the school and    the communit
y. . . . Violence begets violence and neither academic learning    nor the acqui
sition of values can be enhanced by the application of force"    (42). A summary
 of research published by the Jamaican Ministry of Health (4)    linked the patt
ern of male involvement in crime to the societal practice of    child battering.
</font></p>     ^cY#a10v22n6.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a10v22n6.htm#S#p#55#51#article#119#<p>&nbsp;</p>     ^
cY#a10v22n6.htm##
00309000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704007400076002001300150#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a10v22n6.htm#S#p#56#52#article#119#<p><font size="3" f
ace="Verdana"><b>DISTAL CONTEXT</b></font></p>     ^cY#a10v22n6.htm##
00324000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704008900076002001300165#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a10v22n6.htm#S#p#57#53#article#119#<p><font size="2" f
ace="Verdana"><b>Poverty and income inequality</b></font></p>     ^cY#a10v22n6.h
tm##
01697000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704146200076002001301538#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a10v22n6.htm#S#p#58#54#article#119#<p><font size="2" f
ace="Verdana">Family economic status is a macro-level contextual    factor that 
exerts a powerful effect on family functioning and child developmental    outcom
es. Compared to their more financially advantaged peers, children from    low-in
come families tend to have more negative family, school, and societal    consequ
ences (45), partly because families experiencing poverty possess neither    the 
material nor the psychological resources to protect their children from    the p
ressures that accompany economic deprivation (25, 45). The strains of poverty   
 may contribute to parental mental health problems, which in turn, elevate negat
ive    parenting; negative parenting increases the risk for conduct disorders in
 children    (45, 46). For example, stressful social and economic conditions may
 create anger,    frustration, and hostility in parents; parents in turn may dis
place their anger    and frustration on their children to the point of abuse (25
). Although, physical    punishment is not confined to people in chronic poverty
, research has consistently    shown that such extreme discipline tends to be mo
re frequent and severe among    low-income groups; among more advantaged groups 
physical punishment might be    used less regularly and tempered by other non-vi
olent means of discipline (21,    25). Steinberg (21) maintained that, "By far, 
the most insidious cause    of negative parenting is poverty." </font></p>     ^
cY#a10v22n6.htm##
01333000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704109800076002001301174#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a10v22n6.htm#S#p#59#55#article#119#<p><font size="2" f
ace="Verdana">Poverty increases families' vulnerability    to crime and violence
. Although violence is not confined to urban communities    or the economically 
disadvantaged of society, violent crimes tend to be concentrated    in urban inn
er-city neighborhoods where the residents are both the victims and    perpetrato
rs of violent crimes. Moreover, the urban poor tend to exhibit greater    tolera
nce for and more positive attitudes toward deviancy and illicit activities    (e
.g., the drug trade), behaviors that are invariably tied to ruthless community  
  violence (7, 47). Besides, economic hardship enhances youth susceptibility to 
   gang membership and warfare and their attending problems, such as violent cri
minality    and early violent death (46, 47). Gang membership increases the prob
ability    of alcohol consumption, illegal drug use, and the use of weapons in c
onflict    resolution (8). Access to, distribution, and trafficking of drugs and
 firearms    are associated with increased levels of violent crimes, especially 
murder (3,    47). </font></p>     ^cY#a10v22n6.htm##
01820000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704158500076002001301661#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a10v22n6.htm#S#p#60#56#article#119#<p><font size="2" f
ace="Verdana">Undoubtedly, chronic poverty and escalating violence    wield an e
xacting toll on a significant proportion of the Jamaican population,    particul
arly those residing in the urban inner cities. Kingston, the capital    city, ac
counts for 25% of the total population and over 70% of its violent crime    (47)
. Families in the inner-cities neighborhoods invariably experience social    iso
lation, chronic unemployment, high incidence of domestic and community violence,
    and involvement in illegal activities (46, 47). Because of their relative la
ck    of physical, social, and economic power, youth from economically disadvant
aged    families experience higher rates of physical and sexual abuse and other 
forms    of psychological abuse than their more advantaged counterparts (8), dyn
amics    that are likely to exacerbate anger, fear, and despair in people in tho
se contexts    and lead to severe behavior problems (8, 45, 47). Furthermore, po
verty increases    youth susceptibility to gang membership, gang warfare, and th
eir attending problems,    such as violent criminality and premature death (3, 4
7). A substantial body    of empirical studies has demonstrated a robust link be
tween poverty and various    maladaptive outcomes in children and youth; these i
nclude elevated levels of    delinquency and criminality (21, 46). So potent is 
the effect of poverty on    youth outcomes that many social scientists assume th
at poverty alleviation would    reduce antisocial behaviors, in general, and vio
lence, in particular (21).</font></p>     ^cY#a10v22n6.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a10v22n6.htm#S#p#61#57#article#119#<p>&nbsp;</p>     ^
cY#a10v22n6.htm##
00306000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704007100076002001300147#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a10v22n6.htm#S#p#62#58#article#119#<p><font size="3" f
ace="Verdana"><b>CONCLUSIONS</b></font></p>     ^cY#a10v22n6.htm##
00992000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704075700076002001300833#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a10v22n6.htm#S#p#63#59#article#119#<p><font size="2" f
ace="Verdana">Although antisocial behavior among young people    in Jamaica is n
ot new, it has become more frequent and vicious than it was historically.    Hen
ce, behavior problems have changed both quantitatively and qualitatively    and 
have a more devastating impact on society than they formerly did (47). However, 
   youth outcomes do not occur or persist in a vacuum but result from the confou
nding    effect of several personal and environmental factors. For example, inep
t parenting,    problematic child socialization, and youth disengagement from sc
hool are social    factors that have dire consequences for children, families, a
nd society; when    poverty is added, the detrimental sequelae are compounded.</
font></p>     ^cY#a10v22n6.htm##
01053000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704081800076002001300894#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a10v22n6.htm#S#p#64#60#article#119#<p><font size="2" f
ace="Verdana">If the human ecological reasoning    is correct, it would appear t
hat the social dynamics of Jamaican society have    led some children to encount
er a complex and potent mix of negative experiences    that has put them at risk
 for compromised development. Arguably, chronic poverty    severely inhibits man
y families' capacity to provide the basic necessities for    their children and 
hinders caregivers' ability to engage in the desirable affective    and nurturin
g behaviors that have been shown to effect optimal child development.    Therefo
re, it is incumbent on society to make an investment of time, effort,    and mon
ey to institute programs aimed at reducing poverty (21), and by extension,    al
leviating dysfunctional and maladaptive behaviors in youth.</font></p>     ^cY#a
10v22n6.htm##
01958000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704172300076002001301799#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a10v22n6.htm#S#p#65#61#article#119#<p><font size="2" f
ace="Verdana">Because children are the most    vulnerable victims and witnesses 
of violence, strategies to protect them are    imperative. Also, because the fac
tors that jeopardize optimal child outcomes    are embedded in the family, commu
nity, and society, workable approaches must    be directed at all those levels. 
Furthermore, because of the interconnectedness    of all three levels, a change 
at one level will improve outcomes for children    and youth (7, 24). Multi-pron
ged programs have shown great promise as both a    prevention strategy and an in
tervention in reducing the likelihood of more costly    interventions later on (
48). Those programs typically address the problematic    dynamics of the whole f
amily. They provide services to teach good parenting    skills, marital and fami
ly counselling, and quality child-care programs. Good    quality programs help c
reate healthy family relationships, keep children and    youth in school, and th
wart behavioral problems (48). The High/Scope Perry Preschool    Project in the 
United States has demonstrated that every dollar invested on    high quality pre
school programs saved society US$ 16 in taxes, with an overall    economic retur
n to the public of US$ 244 812 per participant. The program included    a parent
 involvement component where teachers visited the child's home each    week and 
spent 1.5 hours with each mother and child to involve the mother in    the educa
tional process and help implement the preschool curriculum at home. At    age 40
, adults who had attended the high quality preschool program were 42%    less li
kely to be incarcerated and had a 36% lower arrest rate for violent crimes    (4
9). </font></p>     ^cY#a10v22n6.htm##
01932000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704169700076002001301773#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a10v22n6.htm#S#p#66#62#article#119#<p><font size="2" f
ace="Verdana">Numerous observers have called    for sweeping reforms of the enti
re Jamaican educational system. Their various    proposals are typified by Espue
t's (42) contention that to "save"    Jamaican youth, the chronic illness of the
 education system must be addressed    and "no less than a complete revamping of
 Jamaica's education system is    now required." For example, teacher preparatio
n programs must focus on    the relevant theoretical and empirical information r
egarding best practices    for contemporary students (25). The United Nations (2
4) has suggested, among    other things, the intensification of the teacher trai
ning programs and institution    of a comprehensive school guidance program. Pre
vatt and Kelly (50) contended    that the most successful academic programs were
 those that were responsive to    youth's academic, emotional, and social challe
nges. Effective programs provided    a caring and non-threatening environment wh
ere students felt nurtured and industrious.    Those programs engaged in develop
ing strong parent-school partnerships and fostered    good interpersonal relatio
nships (i.e., teacher-parent, teacher-student, and    student-student). They als
o provided academic remediation and teacher and parenting    training in child b
ehavior management, and social skills for students (50, 51).    Other effective 
societal strategies include reducing youth access to firearms,    punishing viol
ence and rewarding non-violence (8), and reorganizing the juvenile    justice sy
stem to provide adequate space for juveniles who have been apprehended,    rathe
r than placing them in jails as is commonly done now (24).</font></p>     ^cY#a1
0v22n6.htm##
00747000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704051200076002001300588#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a10v22n6.htm#S#p#67#63#article#119#<p><font size="2" f
ace="Verdana">In sum, the academic literature suggests that    oppressive enviro
nments are closely linked to hostility and violence. Therefore,    policymakers 
must focus on both prevention and intervention strategies to reduce    children'
s exposure to violence and youth involvement in violence. To prevent    and redu
ce violence in ensuing generations, it is obligatory that risk factors    at all
 levels of the ecological system be addressed, preferably simultaneously.</font>
</p>     ^cY#a10v22n6.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a10v22n6.htm#S#p#68#64#article#119#<p>&nbsp;</p>     ^
cY#a10v22n6.htm##
00305000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704007000076002001300146#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a10v22n6.htm#S#p#69#65#article#119#<p><font size="3" f
ace="Verdana"><b>REFERENCES</b></font></p>     ^cY#a10v22n6.htm##
00579000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704033000078002001300408#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a10v22n6.htm#S#p#70#66#article#119#1#<p><f
ont size="2" face="Verdana">1. Williams L. Anywhere yuh be, yu not safe:    Adol
escence and violence in Jamaica. Available from: <a href="http://www.unicef.org/
evaldatabase/files/JAM_2001_803.pdf" target="_blank">http://www.unicef.org/evald
atabase/files/JAM_2001_803.pdf</a>.    Accessed on 20 March 2006.</font></p>    
 ^cY#a10v22n6.htm##
00585000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704033600078002001300414#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a10v22n6.htm#S#p#71#67#article#119#2#<p><f
ont size="2" face="Verdana">2. World Bank. Crime,    violence, and development: 
trends, costs, and policy options in the Caribbean.    A joint report by the Uni
ted Nations Office on Drugs and Crime and the Latin    America and the Caribbean
 Region of the World Bank. Washington: DC; 2007. (Report    no. 37820).</font></
p>     ^cY#a10v22n6.htm##
00403000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704015400078002001300232#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a10v22n6.htm#S#p#72#68#article#119#3#<p><f
ont size="2" face="Verdana">3. World Bank. Jamaica:    The road to sustained gro
wth. Washington, DC; 2003. (Report no. 26088-JM).</font></p>     ^cY#a10v22n6.ht
m##
00583000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704033400078002001300412#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a10v22n6.htm#S#p#73#69#article#119#4#<p><f
ont size="2" face="Verdana">4. Ustanny A. Battered boys—Research links harsh    
punishment to crime levels. Available from: <a href="http://www.jamaica-gleaner.
com/gleaner/20040111/lead/lead1.html" target="_blank">http://www.jamaica-gleaner
.com/gleaner/20040111/lead/lead1.html</a>.    Accessed 31 March 2004.</font></p>
     ^cY#a10v22n6.htm##
00542000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704029300078002001300371#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a10v22n6.htm#S#p#74#70#article#119#5#<p><f
ont size="2" face="Verdana">5. UNICEF. Situation analysis of Jamaican children, 
   2005. Available from: <a href="http://www.unicef.org/jamaica/situationanalysi
s.pdf" target="_blank">http://www.unicef.org/jamaica/situationanalysis.pdf</a>. 
   Accessed 5 February 2006.</font></p>     ^cY#a10v22n6.htm##
00440000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704019100078002001300269#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a10v22n6.htm#S#p#75#71#article#119#6#<p><f
ont size="2" face="Verdana">6. Bailey B. Gender    profile: Jamaica. Center for 
Gender and Development Studies. University of the    West Indies, Mona, Jamaica;
 2005.</font></p>     ^cY#a10v22n6.htm##
00390000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704014100078002001300219#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a10v22n6.htm#S#p#76#72#article#119#7#<p><f
ont size="2" face="Verdana">7. World Health Organization.    World report on vio
lence and health. Geneva: WHO; 2002.</font></p>     ^cY#a10v22n6.htm##
00631000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704038200078002001300460#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a10v22n6.htm#S#p#77#73#article#119#8#<p><f
ont size="2" face="Verdana">8. Weaver K, Maddaleno M. Youth violence in    Latin
 America: current situation and violence prevention strategies. Rev Panam    Sal
ud Publica. 1999;5(4/5): 338–43. Available from: <a href="http://www.scielosp.or
g/pdf/rpsp/v5n4-5/v5n4tm4.pdf">http://www.scielosp.org/pdf/rpsp/v5n4-5/v5n4tm4.p
df</a>.    Accessed 15 October 2007. </font></p>     ^cY#a10v22n6.htm##
00555000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704030600078002001300384#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a10v22n6.htm#S#p#78#74#article#119#9#<p><f
ont size="2" face="Verdana">9. Brown P. P. J. Patterson's collapsing legacy.    
Available from: <a href="http://www.jamaica-gleaner.com/gleaner/20050731/lead/le
ad5.html" target="_blank">http://www.jamaica-gleaner.com/gleaner/20050731/lead/l
ead5.html</a>.    Accessed 31 July 2005. </font></p>     ^cY#a10v22n6.htm##
00454000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704020400079002001300283#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a10v22n6.htm#S#p#79#75#article#119#10#<p><
font size="2" face="Verdana">10. Bronfenbrenner U, Ceci,    SJ. Nature-nurture r
econceptualized in development perspective: A bioecological    model. Psychol. R
ev., 101(4):568–86. </font></p>     ^cY#a10v22n6.htm##
00602000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704035200079002001300431#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a10v22n6.htm#S#p#80#76#article#119#11#<p><
font size="2" face="Verdana">11. Watson M, Fischer K. Pathways to aggression    
through inhibited temperament and parental violence. Available from; <a href="ht
tp://www.gse.harvard.edu/news/features/fischersummary.html" target="_blank">http
://www.gse.harvard.edu/news/features/fischersummary.html</a>.    Accessed 16 Mar
ch 2006.</font></p>     ^cY#a10v22n6.htm##
00529000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704027900079002001300358#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a10v22n6.htm#S#p#81#77#article#119#12#<p><
font size="2" face="Verdana">12. Cowen EL, Work WC,    Wyman PA, Parker GR, Wann
on M, Gribble P. Test comparisons among stress-affected,    stress-resilient, an
d nonclassified fourth through sixth-grade children. J Community    Psychol.1992
; 20(4):200–14.</font></p>     ^cY#a10v22n6.htm##
00490000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704024000079002001300319#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a10v22n6.htm#S#p#82#78#article#119#13#<p><
font size="2" face="Verdana">13. Elliot GC, Cunningham    SM, Linder M, Colangel
o M, Gross M. Child physical abuse and self-perceived    social isolation among 
adolescents. J Interpers Violence. 2005; 20(12):1663–84.</font></p>     ^cY#a10v
22n6.htm##
00522000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704027200079002001300351#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a10v22n6.htm#S#p#83#79#article#119#14#<p><
font size="2" face="Verdana">14. Reasoner RW. Review of self-esteem research.   
 Available from: <a href="http://www.self-esteem-nase.org/research.shtml" target
="_blank">http://www.self-esteem-nase.org/research.shtml</a>.    Accessed 20 Mar
ch 2006.</font></p>     ^cY#a10v22n6.htm##
00665000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704041500079002001300494#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a10v22n6.htm#S#p#84#80#article#119#15#<p><
font size="2" face="Verdana">15. JIS. Young Men Need Greater Self Worth Says    
PM Thursday. Available from <a href="http://www.jis.gov.jm/officepm/html/2006082
4t130000-0500_9817_jis_young_men_need_greater_self_worth_says_pm.asp" target="_b
lank">http://www.jis.gov.jm/officepm/html/20060824t130000-0500_9817_jis_young_me
n_need_greater_self_worth_says_pm.asp</a>.    Accessed 20 October 2007.</font></
p>     ^cY#a10v22n6.htm##
00560000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704031000079002001300389#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a10v22n6.htm#S#p#85#81#article#119#16#<p><
font size="2" face="Verdana">16. Society for Neuroscience. Violent brains.    Av
ailable from:<a href="http://apu.sfn.org/index.cfm?pagename=brainBriefings_viole
ntbrains" target="_blank">http://apu.sfn.org/index.cfm?pagename=brainBriefings_v
iolent    brains</a>. Accessed 12 August 2006.</font></p>     ^cY#a10v22n6.htm##
00544000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704029400079002001300373#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a10v22n6.htm#S#p#86#82#article#119#17#<p><
font size="2" face="Verdana">17. National Center for Children in Poverty.    Pov
erty and Brain Development in Early Childhood. Available from: <a href="http://w
ww.nccp.org/pub_pbd99.html" target="_blank">http://www.nccp.org/pub_pbd99.html</
a>    Accessed 19 August 2006.</font></p>     ^cY#a10v22n6.htm##
00568000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704031800079002001300397#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a10v22n6.htm#S#p#87#83#article#119#18#<p><
font size="2" face="Verdana">18. Evans-Gilbert, W. Lead poisoning in Jamaican   
 children. Available from <a href="http://www.jamaica-gleaner.com/gleaner/200404
14/news/news5.html" target="_blank">http://www.jamaica-gleaner.com/gleaner/20040
414/news/news5.html</a>.    Accessed 3 September 2004.</font></p>     ^cY#a10v22
n6.htm##
00627000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704037700079002001300456#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a10v22n6.htm#S#p#88#84#article#119#19#<p><
font size="2" face="Verdana">19. PIOJ-Planning Institute of Jamaica and Statisti
cal    Institute. Eradicating extreme hunger and poverty: A review of the Jamaic
an    situation. Available from: <a href="http://www.pioj.gov.jm/piojdocs/specia
l/Beginnings/" target="_blank">http://www.pioj.gov.jm/piojdocs/special/Beginning
s/</a>.    Accessed 4 March 2006.</font></p>     ^cY#a10v22n6.htm##
00478000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704022800079002001300307#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a10v22n6.htm#S#p#89#85#article#119#20#<p><
font size="2" face="Verdana">20. Gershoff ET. Corporal    punishment by parents 
and associated child behaviors and experiences: A meta-analytic    and theoretic
al review. Psychol Bull.2002; 128(4):539–79.</font></p>     ^cY#a10v22n6.htm##
00599000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704034900079002001300428#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a10v22n6.htm#S#p#90#86#article#119#21#<p><
font size="2" face="Verdana">21. Steinberg L. Youth violence: Do parents and    
families make a difference? National Institute of Justice Journal, April 2000.  
  Available from: <a href="http://www.ncjrs.gov/pdffiles1/jr000243f.pdf" target=
"_blank">http://www.ncjrs.gov/pdffiles1/jr000243f.pdf</a>.    Accessed 23 March 
2006.</font></p>     ^cY#a10v22n6.htm##
00462000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704021200079002001300291#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a10v22n6.htm#S#p#91#87#article#119#22#<p><
font size="2" face="Verdana">22. Lefkowitz M, Eron L,    Walder L, Huesmann L. G
rowing up to be violent: A longitudinal study of the    development of aggressio
n. New York: Pergamon; 1999.</font></p>     ^cY#a10v22n6.htm##
00490000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704024000079002001300319#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a10v22n6.htm#S#p#92#88#article#119#23#<p><
font size="2" face="Verdana">23. Straus MA, Yodanis    CL. (1996). Corporal puni
shment in adolescence and physical assaults on spouses    in later life: what ac
counts for the link? J Marriage Fam. 1999; 58(4):825–41.</font></p>     ^cY#a10v
22n6.htm##
00600000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704035000079002001300429#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a10v22n6.htm#S#p#93#89#article#119#24#<p><
font size="2" face="Verdana">24. United Nations. Convention on the rights    of 
the Child—Jamaica, 1999. Available from; <a href="http://www.crin.org/docs/resou
rces/treaties/crc.33/Jamaica_ngo_report.pdf" target="_blank">http://www.crin.org
/docs/resources/treaties/crc.33/Jamaica_ngo_report.pdf</a>.    Accessed 30 March
 2006.</font></p>     ^cY#a10v22n6.htm##
00430000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704018000079002001300259#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a10v22n6.htm#S#p#94#90#article#119#25#<p><
font size="2" face="Verdana">25. Smith DE, Mosby G. Jamaican child-rearing    pr
actices: The role of corporal punishment. Adolescence. 2003;38(150): 370–81.</fo
nt></p>     ^cY#a10v22n6.htm##
00454000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704020400079002001300283#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a10v22n6.htm#S#p#95#91#article#119#26#<p><
font size="2" face="Verdana">26. World Bank. A review    of gender issues in the
 Dominican Republic, Haiti, and Jamaica. Washington:    DC: World Bank; 2002. (R
eport No. 21866-LAC)</font></p>     ^cY#a10v22n6.htm##
00400000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704015000079002001300229#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a10v22n6.htm#S#p#96#92#article#119#27#<p><
font size="2" face="Verdana">27. Headley B. The false    promise of flogging. Th
e Sunday Gleaner 1994. August 14:A23 (col. 2).</font></p>     ^cY#a10v22n6.htm##
00439000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704018900079002001300268#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a10v22n6.htm#S#p#97#93#article#119#28#<p><
font size="2" face="Verdana">28. Crawford-Brown C. The    impact of parenting on
 conduct disorder in Jamaican male adolescents. Adolescence.    1999; 34(134):41
7–36.</font></p>     ^cY#a10v22n6.htm##
00529000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704027900079002001300358#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a10v22n6.htm#S#p#98#94#article#119#29#<p><
font size="2" face="Verdana">29. Leo-Rhynie EA. Class,    race, and gender issue
s in child rearing in the Caribbean. In: Jaipaul L, Rooparine    J, Brown, J, ed
s. Caribbean Families: diversity among ethnic groups. Greenwich,    CT: Ablex; 1
997. Pp. 25–56.</font></p>     ^cY#a10v22n6.htm##
00503000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704025300079002001300332#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a10v22n6.htm#S#p#99#95#article#119#30#<p><
font size="2" face="Verdana">30. Robin MW, Spires RC.    The consequences of fat
her absence: A cross-cultural perspective. In: Adler,    LL, ed. Cross-cultural 
research in human development. New York: Praeger; 1989.    Pp. 47–57.</font></p>
     ^cY#a10v22n6.htm##
00526000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073888000300077704027500080002001300355#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a10v22n6.htm#S#p#100#96#article#119#31#<p>
<font size="2" face="Verdana">31. National Fatherhood Initiative. The father    
factor. Available from <a href="http://www.fatherhood.org/father_factor.asp" tar
get="_blank">https://www.fatherhood.org/father_factor.asp</a>.    Accessed 14 Oc
tober 2007. </font></p>     ^cY#a10v22n6.htm##
00415000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073888000300077704016400080002001300244#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a10v22n6.htm#S#p#101#97#article#119#32#<p>
<font size="2" face="Verdana">32. Fagan PF, Rector R.    The effects of divorce 
on America. Washington, DC: The Heritage Foundation;    2000.</font></p>     ^cY
#a10v22n6.htm##
00565000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073888000300077704031400080002001300394#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a10v22n6.htm#S#p#102#98#article#119#33#<p>
<font size="2" face="Verdana">33. Luton, D.Absent fathers force societal breakdo
wn.    Available from: <a href="http://www.jamaica-gleaner.com/gleaner/20070923/
news/news1.html" target="_blank">http://www.jamaica-gleaner.com/gleaner/20070923
/news/news1.html</a>.    Accessed 17 October 2007. </font></p>     ^cY#a10v22n6.
htm##
00511000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073888000300077704026000080002001300340#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a10v22n6.htm#S#p#103#99#article#119#34#<p>
<font size="2" face="Verdana">34. Hamilton M. A review of educational research  
  in Jamaica. In: Miller E, ed. Education and society in the Commonwealth Caribb
ean.    Jamaica: Institute of Social and Economic Research; 1991. Pp. 105–42.</f
ont></p>     ^cY#a10v22n6.htm##
00404000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704015200081002001300233#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a10v22n6.htm#S#p#104#100#article#119#35#<p
><font size="2" face="Verdana">35. Wright K. Dads blamed    for delinquent youth
s. The Sunday Gleaner 2000. October 1: C11(col 1).</font></p>     ^cY#a10v22n6.h
tm##
00426000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704017400081002001300255#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a10v22n6.htm#S#p#105#101#article#119#36#<p
><font size="2" face="Verdana">36. Keddie AM. Psychosocial    factors associated
 with teenage pregnancy in Jamaica. Adolescence.1992;27(108):    873–90.</font><
/p>     ^cY#a10v22n6.htm##
00511000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704025900081002001300340#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a10v22n6.htm#S#p#106#102#article#119#37#<p
><font size="2" face="Verdana">37. Sharpe J. Mental health    issues and family 
socialization in the Caribbean. In: Rooparine JL, Brown J,    eds. Caribbean fam
ilies: Diversity among ethnic groups. Greenwich: Ablex; 1997.    Pp. 259–270.</f
ont></p>     ^cY#a10v22n6.htm##
00397000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704014500081002001300226#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a10v22n6.htm#S#p#107#103#article#119#38#<p
><font size="2" face="Verdana">38. Barrow C. Family in    the Caribbean: Themes 
and perspectives. Jamaica: Ian Randle;1996.</font></p>     ^cY#a10v22n6.htm##
00400000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704014800081002001300229#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a10v22n6.htm#S#p#108#104#article#119#39#<p
><font size="2" face="Verdana">39. Campbell J. Horrors    of the barrel kids. Th
e Sunday Gleaner 1995. October 29: A1 (col.1).</font></p>     ^cY#a10v22n6.htm##
00368000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704011600081002001300197#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a10v22n6.htm#S#p#109#105#article#119#40#<p
><font size="2" face="Verdana">40. Larmer, B. The barrel    children. Newsweek 1
996:127(8) 45.</font></p>     ^cY#a10v22n6.htm##
00553000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704030100081002001300382#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a10v22n6.htm#S#p#110#106#article#119#41#<p
><font size="2" face="Verdana">41. Espeut P. School reform. Available from <a hr
ef="http://www.jamaica-gleaner.com/gleaner/20040107/cleisure/cleisure4.html" tar
get="_blank">http://www.jamaica-gleaner.com/gleaner/20040107/cleisure/cleisure4.
html</a>.    Accessed 10 February 2004.</font></p>     ^cY#a10v22n6.htm##
00404000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704015200081002001300233#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a10v22n6.htm#S#p#111#107#article#119#42#<p
><font size="2" face="Verdana">42. Day G. The only permanent    solution to crim
e. The Sunday Gleaner 1994. October 2: B7 (col.1).</font></p>     ^cY#a10v22n6.h
tm##
00414000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704016200081002001300243#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a10v22n6.htm#S#p#112#108#article#119#43#<p
><font size="2" face="Verdana">43. Browne R. Parental    neglect: A factor causi
ng indiscipline. The Sunday Gleaner 1994. May 1: A3 (col.1).</font></p>     ^cY#
a10v22n6.htm##
00557000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704030500081002001300386#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a10v22n6.htm#S#p#113#109#article#119#44#<p
><font size="2" face="Verdana">44. Walker SP, Grantham-McGregor    SM, Himes JH,
 Williams S, Duff EM. School performance in adolescent Jamaican    girls: associ
ations with health, social and behavioral characteristics, and    risk factors f
or dropout. J Adolesc. 1998. 21(1) 109–122.</font></p>     ^cY#a10v22n6.htm##
00390000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704013800081002001300219#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a10v22n6.htm#S#p#114#110#article#119#45#<p
><font size="2" face="Verdana">45. Evans GW. The environment    of childhood pov
erty. Am Psychol. 2004;59(2): 77–92.</font></p>     ^cY#a10v22n6.htm##
00467000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704021500081002001300296#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a10v22n6.htm#S#p#115#111#article#119#46#<p
><font size="2" face="Verdana">46. Ary DV, Duncan TE, Biglan A, Metzler CW,    N
oell JW, Smolkowski K. Development of adolescent problem behavior. J Abnorm    C
hild Psychol. 1999;25(2): 141–50.</font></p>     ^cY#a10v22n6.htm##
00458000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704020600081002001300287#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a10v22n6.htm#S#p#116#112#article#119#47#<p
><font size="2" face="Verdana">47. Harriot A. Crime trends    in the Caribbean. 
Report to the United Nations Office on Drugs and Crime. University    of the Wes
t Indies, Jamaica, 2002.</font></p>     ^cY#a10v22n6.htm##
00631000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704037900081002001300460#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a10v22n6.htm#S#p#117#113#article#119#48#<p
><font size="2" face="Verdana">48. DeBord K. Communicating program value of    f
amily life and parenting education programs to decision makers. J Extension.    
2005; 43 (2). Article Number 2IAW2. Available from: <a href="http://www.joe.org/
joe/2005april/iw2.shtml" target="_blank">http://www.joe.org/joe/2005april/iw2.sh
tml</a>.    Accessed 14 October 2007.</font></p>     ^cY#a10v22n6.htm##
00680000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704042800081002001300509#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a10v22n6.htm#S#p#118#114#article#119#49#<p
><font size="2" face="Verdana">49. Schweinhart LJ. The High/Scope Perry Preschoo
l    study through Age 40: summary, conclusions, and frequently asked questions.
    Available from: <a href="http://www.highscope.org/file/Research/PerryProject
/3specialsummaryco10607.pdf" target="_blank">http://www.highscope.org/file/Resea
rch/PerryProject/3specialsummary%20co1%2006%2007.pdf</a>.    Accessed 15 October
 2007.</font></p>     ^cY#a10v22n6.htm##
00428000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704017600081002001300257#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a10v22n6.htm#S#p#119#115#article#119#50#<p
><font size="2" face="Verdana">50. Prevatt F, Kelly F.    Dropping out of school
: a review of intervention programs. J Sch Psychol. 2003;    41(5):377–95.</font
></p>     ^cY#a10v22n6.htm##
00389000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704013700081002001300218#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a10v22n6.htm#S#p#120#116#article#119#51#<p
><font size="2" face="Verdana">51. Berk, L. Infants, children, and adolescents. 
   New York: Allyn and Bacon, 2005.</font></p>     ^cY#a10v22n6.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a10v22n6.htm#S#p#121#117#article#119#<p>&nbsp;</p>    
 ^cY#a10v22n6.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a10v22n6.htm#S#p#122#118#article#119#<p>&nbsp;</p>    
 ^cY#a10v22n6.htm##
00544000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704030700078002001300385#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a10v22n6.htm#S#p#123#119#article#119#<p><font size="2"
 face="Verdana"><a name="nt"></a><a href="#tx">*</a> Send correspondence    to: 
Katherine E. Green, 10000 University Drive, Prescott Valley, AZ 86314, USA;    t
elephone: +01-865-573-2221; fax: +01-928-541-7817; e-mail: <a href="mailto:kgree
n@ncu.edu">kgreen@ncu.edu</a>.</font></p>     ^cY#a10v22n6.htm##
00486000000000217000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750160018000770180070000950370
05800165065000900223064001400232865000900246002001300255#v22n6#v:\scielo\serial\
rpsp\v22n6\markup\a10v22n6.htm#S#c#124#1#article#51#1#^rND^sWilliams^nL#Anywhere
 yuh be, yu not safe: Adolescence and violence in Jamaica^len#http://www.unicef.
org/evaldatabase/files/JAM_2001_803.pdf#20060320#20 March 2006#20071200#a10v22n6
.htm##
00604000000000229000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750170011000770180218000880660
01500306065000900321064000500330061001700335865000900352002001300361#v22n6#v:\sc
ielo\serial\rpsp\v22n6\markup\a10v22n6.htm#S#c#125#2#article#51#2#World Bank#Cri
me, violence, and development: trends, costs, and policy options in the Caribbea
n. A joint report by the United Nations Office on Drugs and Crime and the Latin 
America and the Caribbean Region of the World Bank^len#Washington^eDC#20070000#2
007#Report no. 37820#20071200#a10v22n6.htm##
00431000000000229000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750170011000770180042000880660
01500130065000900145064000500154061002000159865000900179002001300188#v22n6#v:\sc
ielo\serial\rpsp\v22n6\markup\a10v22n6.htm#S#c#126#3#article#51#3#World Bank#Jam
aica: The road to sustained growth^len#Washington^eDC#20030000#2003#Report no. 2
6088-JM#20071200#a10v22n6.htm##
00487000000000217000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750160017000770180066000940370
06400160110000900224109001400233865000900247002001300256#v22n6#v:\scielo\serial\
rpsp\v22n6\markup\a10v22n6.htm#S#c#127#4#article#51#4#^rND^sUstanny^nA#Battered 
boys-Research links harsh punishment to crime levels^len#http://www.jamaica-glea
ner.com/gleaner/20040111/lead/lead1.html#20040331#31 March 2004#20071200#a10v22n
6.htm##
00451000000000217000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750170007000770180050000840370
05200134110000900186109001600195865000900211002001300220#v22n6#v:\scielo\serial\
rpsp\v22n6\markup\a10v22n6.htm#S#c#128#5#article#51#5#UNICEF#Situation analysis 
of Jamaican children, 2005^len#http://www.unicef.org/jamaica/situationanalysis.p
df#20060205#5 February 2006#20071200#a10v22n6.htm##
00485000000000241000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750160016000770180028000930620
07300121066000500194067000800199065000900207064000500216865000900221002001300230
#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a10v22n6.htm#S#c#129#6#article#51#6#^r
ND^sBailey^nB#Gender profile: Jamaica^len#Center for Gender and Development Stud
ies. University of the West Indies#Mona#Jamaica#20050000#2005#20071200#a10v22n6.
htm##
00420000000000229000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750170026000770180040001030660
00700143062000400150065000900154064000500163865000900168002001300177#v22n6#v:\sc
ielo\serial\rpsp\v22n6\markup\a10v22n6.htm#S#c#130#7#article#51#7#World Health O
rganization#World report on violence and health^len#Geneva#WHO#20020000#2002#200
71200#a10v22n6.htm##
00712000000000325000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100016000770100019000930120
09000112030002400202065000900226064000500235031000200240032000400242014000700246
03700520025306500090030506400160031486500090033000200130033903500100035280100240
0362#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a10v22n6.htm#S#c#131#8#article#51#
8#^rND^sWeaver^nK#^rND^sMaddaleno^nM#Youth violence in Latin America: current si
tuation and violence prevention strategies^len#Rev Panam Salud Publica#19990000#
1999#5#4/5#338-43#http://www.scielosp.org/pdf/rpsp/v5n4-5/v5n4tm4.pdf#20071015#1
5 October 2007#20071200#a10v22n6.htm#1020-4989#Rev Panam Salud Publica##
00459000000000217000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750160022000770180034000990370
06400133065000900197064001300206865000900219002001300228#v22n6#v:\scielo\serial\
rpsp\v22n6\markup\a10v22n6.htm#S#c#132#9#article#51#9#^rND^sBrown^nP. P. J.#Patt
erson's collapsing legacy^len#http://www.jamaica-gleaner.com/gleaner/20050731/le
ad/lead5.html#20050731#31 July 2005#20071200#a10v22n6.htm##
00509000000000253000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100024000790100015001030120
08600118030001400204710000200218031000400220032000200224014000700226865000900233
002001300242#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a10v22n6.htm#S#c#133#10#ar
ticle#51#10#^rND^sBronfenbrenner^nU#^rND^sCeci^nSJ#Nature-nurture reconceptualiz
ed in development perspective: A bioecological model^len#Psychol. Rev.#2#101#4#5
68-86#20071200#a10v22n6.htm##
00527000000000229000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760160016000790160017000950180
07900112037006100191110000900252109001400261865000900275002001300284#v22n6#v:\sc
ielo\serial\rpsp\v22n6\markup\a10v22n6.htm#S#c#134#11#article#51#11#^rND^sWatson
^nM#^rND^sFischer^nK#Pathways to aggression through inhibited temperament and pa
rental violence^len#http://www.gse.harvard.edu/news/features/fischersummary.html
#20060316#16 March 2006#20071200#a10v22n6.htm##
00728000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100015000950100
01600110010001700126010001600143010001700159012011600176030002000292065000900312
06400050032103100030032603200020032901400070033186500090033800200130034703500100
0360801002000370#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a10v22n6.htm#S#c#135#1
2#article#51#12#^rND^sCowen^nEL#^rND^sWork^nWC#^rND^sWyman^nPA#^rND^sParker^nGR#
^rND^sWannon^nM#^rND^sGribble^nP#Test comparisons among stress-affected, stress-
resilient, and nonclassified fourth through sixth-grade children^len#J Community
 Psychol#19920000#1992#20#4#200-14#20071200#a10v22n6.htm#0090-4392#J Community P
sychol##
00633000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100021000960100
01600117010001900133010001500152012007900167030002100246710000200267065000900269
064000500278031000300283032000300286014000800289865000900297002001300306#v22n6#v
:\scielo\serial\rpsp\v22n6\markup\a10v22n6.htm#S#c#136#13#article#51#13#^rND^sEl
liot^nGC#^rND^sCunningham^nSM#^rND^sLinder^nM#^rND^sColangelo^nM#^rND^sGross^nM#
Child physical abuse and self-perceived social isolation among adolescents^len#J
 Interpers Violence#2#20050000#2005#20#12#1663-84#20071200#a10v22n6.htm##
00443000000000217000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760160019000790180035000980370
04700133110000900180109001400189865000900203002001300212#v22n6#v:\scielo\serial\
rpsp\v22n6\markup\a10v22n6.htm#S#c#137#14#article#51#14#^rND^sReasoner^nRW#Revie
w of self-esteem research^len#http://www.self-esteem-nase.org/research.shtml#200
60320#20 March 2006#20071200#a10v22n6.htm##
00515000000000217000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760170004000790180055000830370
11200138110000900250109001600259865000900275002001300284#v22n6#v:\scielo\serial\
rpsp\v22n6\markup\a10v22n6.htm#S#c#138#15#article#51#15#JIS#Young Men Need Great
er Self Worth Says PM Thursday^len#http://www.jis.gov.jm/officepm/html/20060824t
130000-0500_9817_jis_young_men_need_greater_self_worth_says_pm.asp#20071020#20 O
ctober 2007#20071200#a10v22n6.htm##
00455000000000217000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760170025000790180019001040370
06800123110000900191109001500200865000900215002001300224#v22n6#v:\scielo\serial\
rpsp\v22n6\markup\a10v22n6.htm#S#c#139#16#article#51#16#Society for Neuroscience
#Violent brains^len#http://apu.sfn.org/index.cfm?pagename=brainBriefings_violent
 brains#20060812#12 August 2006#20071200#a10v22n6.htm##
00480000000000217000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760170040000790180053001190370
03500172110000900207109002400216865000900240002001300249#v22n6#v:\scielo\serial\
rpsp\v22n6\markup\a10v22n6.htm#S#c#140#17#article#51#17#National Center for Chil
dren in Poverty#Poverty and Brain Development in Early Childhood^len#http://www.
nccp.org/pub_pbd99.html#20060819#Accessed 19 August 2006#20071200#a10v22n6.htm##
00472000000000217000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760160023000790180040001020370
06400142065000900206064001700215865000900232002001300241#v22n6#v:\scielo\serial\
rpsp\v22n6\markup\a10v22n6.htm#S#c#141#18#article#51#18#^rND^sEvans-Gilbert^nW#L
ead poisoning in Jamaican children^len#http://www.jamaica-gleaner.com/gleaner/20
040414/news/news5.html#20040903#3 September 2004#20071200#a10v22n6.htm##
00528000000000217000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760170056000790180079001350370
05200214110000900266109001300275865000900288002001300297#v22n6#v:\scielo\serial\
rpsp\v22n6\markup\a10v22n6.htm#S#c#142#19#article#51#19#Planning Institute of Ja
maica and Statistical Institute#Eradicating extreme hunger and poverty: A review
 of the Jamaican situation^len#http://www.pioj.gov.jm/piojdocs/special/Beginning
s/#20060304#4 March 2006#20071200#a10v22n6.htm##
00583000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100019000790120122000980300
01300220065000900233064000500242031000400247032000200251014000700253865000900260
002001300269035001000282801001300292#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a1
0v22n6.htm#S#c#143#20#article#51#20#^rND^sGershoff^nET#Corporal punishment by pa
rents and associated child behaviors and experiences: A meta-analytic and theore
tical review^len#Psychol Bull#20020000#2002#128#4#539-79#20071200#a10v22n6.htm#0
033-2909#Psychol Bull##
00563000000000253000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760160019000790180063000980620
03800161065000900199064001100208037004500219110000900264109001400273865000900287
002001300296#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a10v22n6.htm#S#c#144#21#ar
ticle#51#21#^rND^sSteinberg^nL#Youth violence: Do parents and families make a di
fference?^len#National Institute of Justice Journal#20000400#April 2000#http://w
ww.ncjrs.gov/pdffiles1/jr000243f.pdf#20060323#23 March 2006#20071200#a10v22n6.ht
m##
00550000000000265000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760160019000790160014000980160
01600112016001800128018008400146066000900230062000900239065000900248064000500257
865000900262002001300271#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a10v22n6.htm#S
#c#145#22#article#51#22#^rND^sLefkowitz^nM#^rND^sEron^nL#^rND^sWalder^nL#^rND^sH
uesmann^nL#Growing up to be violent: A longitudinal study of the development of 
aggression^len#New York#Pergamon#19990000#1999#20071200#a10v22n6.htm##
00645000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100018000960650
00900114064000500123012011500128030001500243065000900258064000500267031000300272
032000200275014000700277865000900284002001300293035001000306801001500316#v22n6#v
:\scielo\serial\rpsp\v22n6\markup\a10v22n6.htm#S#c#146#23#article#51#23#^rND^sSt
raus^nMA#^rND^sYodanis^nCL#19960000#1996#Corporal punishment in adolescence and 
physical assaults on spouses in later life: what accounts for the link?^len#J Ma
rriage Fam#19990000#1999#58#4#825-41#20071200#a10v22n6.htm#0022-2445#J Marriage 
Fam##
00487000000000217000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760170015000790180056000940370
07400150065000900224064001400233865000900247002001300256#v22n6#v:\scielo\serial\
rpsp\v22n6\markup\a10v22n6.htm#S#c#147#24#article#51#24#United Nations#Conventio
n on the rights of the Child-Jamaica, 1999^len#http://www.crin.org/docs/resource
s/treaties/crc.33/Jamaica_ngo_report.pdf#20060330#30 March 2006#20071200#a10v22n
6.htm##
00554000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100015000950120
07000110030001200180065000900192064000500201031000300206032000400209014000700213
865000900220002001300229035001000242801001200252#v22n6#v:\scielo\serial\rpsp\v22
n6\markup\a10v22n6.htm#S#c#148#25#article#51#25#^rND^sSmith^nDE#^rND^sMosby^nG#J
amaican child-rearing practices: The role of corporal punishment^len#Adolescence
#20030000#2003#38#150#370-81#20071200#a10v22n6.htm#0001-8449#Adolescence##
00492000000000241000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760170011000790180077000900660
01500167062001100182065000900193064000500202061002100207865000900228002001300237
#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a10v22n6.htm#S#c#149#26#article#51#26#
World Bank#A review of gender issues in the Dominican Republic, Haiti, and Jamai
ca.^len#Washington^eDC#World Bank#20020000#2002#Report No. 21866-LAC#20071200#a1
0v22n6.htm##
00463000000000253000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790120034000960300
01900130710000200149065000900151064001600160031000400176061000700180865000900187
002001300196#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a10v22n6.htm#S#c#150#27#ar
ticle#51#27#^rND^sHeadley^nB#The false promise of flogging^len#The Sunday Gleane
r#2#19940814#1994. August 14#A23#col. 2#20071200#a10v22n6.htm##
00542000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100024000790120077001030300
01200180065000900192064000500201031000300206032000400209014000700213865000900220
002001300229035001000242801001200252#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a1
0v22n6.htm#S#c#151#28#article#51#28#^rND^sCrawford-Brown^nC#The impact of parent
ing on conduct disorder in Jamaican male adolescents^len#Adolescence#19990000#19
99#34#134#417-36#20071200#a10v22n6.htm#0001-8449#Adolescence##
00626000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100021000790120069001000160
01700169016001900186016001500205018005400220066001400274062000600288065000900294
064000500303014000600308865000900314002001300323#v22n6#v:\scielo\serial\rpsp\v22
n6\markup\a10v22n6.htm#S#c#152#29#article#51#29#^rND^sLeo-Rhynie^nEA#Class, race
, and gender issues in child rearing in the Caribbean^len#^rED^sJaipaul^nL#^rED^
sRooparine^nJ#^rED^sBrown^nJ#Caribbean Families: diversity among ethnic groups^l
en#Greenwich^eCT#Ablex#19970000#1997#25-56#20071200#a10v22n6.htm##
00583000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100017000950120
06900112016001600181018004900197066000900246062000800255065000900263064000500272
014000600277865000900283002001300292#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a1
0v22n6.htm#S#c#153#30#article#51#30#^rND^sRobin^nMW#^rND^sSpires^nRC#The consequ
ences of father absence: A cross-cultural perspective^len#^rED^sAdler^nLL#Cross-
cultural research in human development^len#New York#Praeger#19890000#1989#47-57#
20071200#a10v22n6.htm##
00442000000000217000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760170031000790180022001100370
04500132110000900177109001600186865000900202002001300211#v22n6#v:\scielo\serial\
rpsp\v22n6\markup\a10v22n6.htm#S#c#154#31#article#51#31#National Fatherhood Init
iative#The father factor^len#https://www.fatherhood.org/father_factor.asp#200710
14#14 October 2007#20071200#a10v22n6.htm##
00466000000000241000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760160016000790160016000950180
03800111066001500149062002400164065000900188064000500197865000900202002001300211
#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a10v22n6.htm#S#c#155#32#article#51#32#
^rND^sFagan^nPF#^rND^sRector^nR#The effects of divorce on America^len#Washington
^eDC#The Heritage Foundation#20000000#2000#20071200#a10v22n6.htm##
00467000000000217000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760160015000790180044000940370
06400138110000900202109001600211865000900227002001300236#v22n6#v:\scielo\serial\
rpsp\v22n6\markup\a10v22n6.htm#S#c#156#33#article#51#33#^rND^sLuton^nD#Absent fa
thers force societal breakdown^len#http://www.jamaica-gleaner.com/gleaner/200709
23/news/news1.html#20071017#17 October 2007#20071200#a10v22n6.htm##
00576000000000265000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790120048000970160
01600145018005600161066000800217062004200225065000900267064000500276014000700281
865000900288002001300297#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a10v22n6.htm#S
#c#157#34#article#51#34#^rND^sHamilton^nM#A review of educational research in Ja
maica^len#^rED^sMiller^nE#Education and society in the Commonwealth Caribbean^le
n#Jamaica#Institute of Social and Economic Research#19910000#1991#105-42#2007120
0#a10v22n6.htm##
00465000000000253000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790120038000950300
01900133710000200152065000900154064001600163031000400179061000600183865000900189
002001300198#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a10v22n6.htm#S#c#158#35#ar
ticle#51#35#^rND^sWright^nK#Dads blamed for delinquent youths^len#The Sunday Gle
aner#2#20001001#2000. October 1#C11#col 1#20071200#a10v22n6.htm##
00527000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790120069000960300
01200165065000900177064000500186031000300191032000400194014000700198865000900205
002001300214035001000227801001200237#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a1
0v22n6.htm#S#c#159#36#article#51#36#^rND^sKeddie^nAM#Psychosocial factors associ
ated with teenage pregnancy in Jamaic^len#Adolescence#19920000#1992#27#108#873-9
0#20071200#a10v22n6.htm#0001-8449#Adolescence##
00589000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790120067000950160
02000162016001500182018005400197066001000251062000600261065000900267064000500276
014000800281865000900289002001300298#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a1
0v22n6.htm#S#c#160#37#article#51#37#^rND^sSharpe^nJ#Mental health issues and fam
ily socialization in the Caribbean^len#^rED^sRooparine^nJL#^rED^sBrown^nJ#Caribb
ean families: Diversity among ethnic groups^len#Greenwich#Ablex#19970000#1997#25
9-270#20071200#a10v22n6.htm##
00433000000000229000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760160016000790180053000950660
00800148062001100156065000900167064000500176865000900181002001300190#v22n6#v:\sc
ielo\serial\rpsp\v22n6\markup\a10v22n6.htm#S#c#161#38#article#51#38#^rND^sBarrow
^nC#Family in the Caribbean: Themes and perspectives^len#Jamaica#Ian Randle#1996
0000#1996#20071200#a10v22n6.htm##
00460000000000253000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790120031000970300
01900128710000200147065000900149064001700158031000300175061000600178865000900184
002001300193#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a10v22n6.htm#S#c#162#39#ar
ticle#51#39#^rND^sCampbell^nJ#Horrors of the barrel kids^len#The Sunday Gleaner#
2#19951029#1995. October 29#A1#col.1#20071200#a10v22n6.htm##
00470000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790120024000950300
00900119065000900128064000500137031000400142032000200146020000300148865000900151
002001300160035001000173801000900183#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a1
0v22n6.htm#S#c#163#40#article#51#40#^rND^sLarmer^nB#The barrel children^len#News
week#19960000#1996#127#8#45#20071200#a10v22n6.htm#0028-9604#NEWSWEEK##
00451000000000217000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760160016000790180018000950370
07200113110000900185109001700194865000900211002001300220#v22n6#v:\scielo\serial\
rpsp\v22n6\markup\a10v22n6.htm#S#c#164#41#article#51#41#^rND^sEspeut^nP#School r
eform^len#http://www.jamaica-gleaner.com/gleaner/20040107/cleisure/cleisure4.htm
l#20040210#10 February 2004#20071200#a10v22n6.htm##
00464000000000253000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760160013000790180041000920300
01900133710000200152065000900154064001600163031000300179032000600182865000900188
002001300197#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a10v22n6.htm#S#c#165#42#ar
ticle#51#42#^rND^sDay^nG#The only permanent solution to crime^len#The Sunday Gle
aner#2#19941002#1994. October 2#B7#col.1#20071200#a10v22n6.htm##
00474000000000253000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790120052000950300
01900147710000200166065000900168064001200177031000300189061000600192865000900198
002001300207#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a10v22n6.htm#S#c#166#43#ar
ticle#51#43#^rND^sBrowne^nR#Parental neglect: A factor causing indiscipline^len#
The Sunday Gleaner#2#19940501#1994. May 1#A3#col.1#20071200#a10v22n6.htm##
00725000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100028000960100
01600124010001800140010001500158012014700173030001000320065000900330064000500339
03100030034403200020034701400080034986500090035700200130036603500100037980100100
0389#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a10v22n6.htm#S#c#167#44#article#51
#44#^rND^sWalker^nSP#^rND^sGrantham-McGregor^nSM#^rND^sHimes^nJH#^rND^sWilliams^
nS#^rND^sDuff^nEM#School performance in adolescent Jamaican girls: associations 
with health, social and behavioral characteristics, and risk factors for dropout
^len#J Adolesc#19980000#1998#21#1#109-122#20071200#a10v22n6.htm#0140-1971#J Adol
esc##
00493000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790120041000950300
01100136065000900147064000500156031000300161032000200164014000600166865000900172
002001300181035001000194801001100204#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a1
0v22n6.htm#S#c#168#45#article#51#45#^rND^sEvans^nGW#The environment of childhood
 poverty^len#Am Psychol#20040000#2004#59#2#77-92#20071200#a10v22n6.htm#0003-066X
#Am Psychol##
00669000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100014000790100017000930100
01600110010001800126010001600144010002000160012004700180030002300227065000900250
06400050025903100030026403200020026701400070026986500090027600200130028503500100
0298801002300308#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a10v22n6.htm#S#c#169#4
6#article#51#46#^rND^sAry^nDV#^rND^sDuncan^nTE#^rND^sBiglan^nA#^rND^sMetzler^nCW
#^rND^sNoell^nJW#^rND^sSmolkowski^nK#Development of adolescent problem behavior^
len#J Abnorm Child Psychol#19990000#1999#25#2#141-50#20071200#a10v22n6.htm#0091-
0627#J Abnorm Child Psychol##
00490000000000229000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760160017000790180090000960620
03000186066000800216065000900224064000500233865000900238002001300247#v22n6#v:\sc
ielo\serial\rpsp\v22n6\markup\a10v22n6.htm#S#c#170#47#article#51#47#^rND^sHarrio
t^nA#Crime trends in the Caribbean: Report to the United Nations Office on Drugs
 and Crime^len#University of the West Indies#Jamaica#20020000#2002#20071200#a10v
22n6.htm##
00625000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790120099000950300
01200194710000200206065000900208064000500217031000300222032000200225031000600227
037004300233065000900276064001600285865000900301002001300310#v22n6#v:\scielo\ser
ial\rpsp\v22n6\markup\a10v22n6.htm#S#c#171#48#article#51#48#^rND^sDeBord^nK#Comm
unicating program value of family life and parenting education programs to decis
ion makers^len#J Extension#2#20050000#2005#43#2#2IAW2#http://www.joe.org/joe/200
5april/iw2.shtml#20071014#14 October 2007#20071200#a10v22n6.htm##
00564000000000217000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760160022000790180110001010370
08800211065000900299064001600308865000900324002001300333#v22n6#v:\scielo\serial\
rpsp\v22n6\markup\a10v22n6.htm#S#c#172#49#article#51#49#^rND^sSchweinhart^nLJ#Th
e High/Scope Perry Preschool study through Age 40: summary, conclusions, and fre
quently asked questions^len#http://www.highscope.org/file/Research/PerryProject/
3specialsummary%20co1%2006%2007.pdf#20071015#15 October 2007#20071200#a10v22n6.h
tm##
00549000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100015000960120
06200111030001400173065000900187064000500196031000300201032000200204014000700206
865000900213002001300222035001000235801001400245#v22n6#v:\scielo\serial\rpsp\v22
n6\markup\a10v22n6.htm#S#c#173#50#article#51#50#^rND^sPrevatt^nF#^rND^sKelly^nF#
Dropping out of school: a review of intervention programs^len#J Sch Psychol#2003
0000#2003#41#5#377-95#20071200#a10v22n6.htm#0022-4405#J Sch Psychol##
00423000000000229000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760160014000790180039000930660
00900132062001600141065000900157064000500166865000900171002001300180#v22n6#v:\sc
ielo\serial\rpsp\v22n6\markup\a10v22n6.htm#S#c#174#51#article#51#51#^rND^sBerk^n
L#Infants, children, and adolescents^len#New York#Allyn and Bacon#20050000#2005#
20071200#a10v22n6.htm##
00274000000000169000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700910009000720920007000810020013000887030
00300101#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a11v22n6.htm#S#o#1#1#article#1
#20080215#102641#a11v22n6.htm#98##
03022000000000601000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000300090121000300093049000800096158000300104030002400107
03100030013103200020013406500090013601400110014503500100015601200810016601201000
02470100029003470100028003760100036004040100028004400100024004680700192004920700
07000684085000800754085003600762085002700798085003200825085003900857085002100896
08312930091708500080221008500440221808500350226208500390229708500420233608500210
2378117000602399072000202405002001302407#v22n6#v:\scielo\serial\rpsp\v22n6\marku
p\a11v22n6.htm#S#h#2#1#article#1#oa#en#br1.1#1#3.1#ND#11#RPSP050#nd#Rev Panam Sa
lud Publica#22#6#20071200#^f425^l431#1020-4989#Emergency medical training for he
alth promoters in Central and South America^len#Entrenamiento médico en urgencia
s para promotores de salud de América Central y América del Sur^les#^rND^1A01^nR
obert^sPartridge#^rND^1A01^nLawrence^sProano#^rND^1A02^nGeorge^sSkarbek-Borowski
#^rND^1A01^nDavid^sBouslough#^rND^1A02^nScott^sCohen#Alpert Medical School at Br
own University^iA01^1Rhode Island Hospital^2Department of Emergency Medicine^3Di
vision of International Emergency Medicine^cProvidence^sRI^pUnited States of Ame
rica#Global Pediatric Alliance^iA02^cOakland^sCA^pUnited States of America#^dnd^
i1#^tm^len^kdelivery of health care^i1#^tm^len^knurse midwives^i1#^tm^len^kprima
ry health care^i1#^tm^len^kemergency medical services^i1#^tm^len^kAmericas^i1#^l
es^aLos promotores de salud, las parteras y otros proveedores de cuidados médico
s básicos trabajan en comunidades locales de todo el mundo para mejorar y facili
tar la atención sanitaria. No hay suficiente información que describa los progra
mas educacionales dirigidos a mejorar los conocimientos y las habilidades de los
 promotores de salud y sobre su impacto sanitario a largo plazo. Muchas iniciati
vas educacionales dirigidas a los promotores de salud consisten en intervencione
s aisladas que permiten evaluar sus conocimientos inmediatamente después de la i
ntervención, pero no miden los progresos a largo plazo en la base de conocimient
os o la atención sanitaria. La Alianza Pediátrica Global -una organización sin á
nimo de lucro basada en los EE.UU. que trabaja con personal médico y sanitario l
ocal- creó un programa educacional para promotores sanitarios y parteras en Ecua
dor, Guatemala, México y Nicaragua con un enfoque centrado en reducir la mortali
dad materna e infantil y en mejorar la atención primaria y de urgencias. En este
 artículo se describen estas iniciativas educacionales diseñadas para mejorar la
s habilidades de los promotores de salud y las parteras mediante un entrenamient
o médico avanzado y sostenible, ajustadas a las necesidades específicas de cada 
comunidad.#^dnd^i2#^tm^les^kprestación de atención de salud^i2#^tm^les^kenfermer
as obstetrices^i2#^tm^les^katención primaria de salud^i2#^tm^les^kservicios médi
cos de urgencia^i2#^tm^les^kAméricas^i2#other#9#a11v22n6.htm##
03036000000000601000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000300090121000300093049000800096158000300104030002400107
03100030013103200020013406500090013601400110014503500100015601200880016601201070
02540100029003610100028003900100036004180100028004540100024004820700192005060700
07000698085000800768085003600776085002700812085003200839085003900871085002100910
08312930093108500080222408500440223208500350227608500390231108500420235008500210
2392117000602413072000202419002001302421#v22n6#v:\scielo\serial\rpsp\v22n6\marku
p\a11v22n6.htm#S#f#3#1#article#1#oa#en#br1.1#1#3.1#ND#11#RPSP050#nd#Rev Panam Sa
lud Publica#22#6#20071200#^f425^l431#1020-4989#<B>Emergency medical training for
 health promoters in Central and South America</B>^len#<B>Entrenamiento médico e
n urgencias para promotores de salud de América Central y América del Sur</B>^le
s#^rND^1A01^nRobert^sPartridge#^rND^1A01^nLawrence^sProano#^rND^1A02^nGeorge^sSk
arbek-Borowski#^rND^1A01^nDavid^sBouslough#^rND^1A02^nScott^sCohen#Alpert Medica
l School at Brown University^iA01^1Rhode Island Hospital^2Department of Emergenc
y Medicine^3Division of International Emergency Medicine^cProvidence^sRI^pUnited
 States of America#Global Pediatric Alliance^iA02^cOakland^sCA^pUnited States of
 America#^dnd^i1#^tm^len^kdelivery of health care^i1#^tm^len^knurse midwives^i1#
^tm^len^kprimary health care^i1#^tm^len^kemergency medical services^i1#^tm^len^k
Americas^i1#^les^aLos promotores de salud, las parteras y otros proveedores de c
uidados médicos básicos trabajan en comunidades locales de todo el mundo para me
jorar y facilitar la atención sanitaria. No hay suficiente información que descr
iba los programas educacionales dirigidos a mejorar los conocimientos y las habi
lidades de los promotores de salud y sobre su impacto sanitario a largo plazo. M
uchas iniciativas educacionales dirigidas a los promotores de salud consisten en
 intervenciones aisladas que permiten evaluar sus conocimientos inmediatamente d
espués de la intervención, pero no miden los progresos a largo plazo en la base 
de conocimientos o la atención sanitaria. La Alianza Pediátrica Global -una orga
nización sin ánimo de lucro basada en los EE.UU. que trabaja con personal médico
 y sanitario local- creó un programa educacional para promotores sanitarios y pa
rteras en Ecuador, Guatemala, México y Nicaragua con un enfoque centrado en redu
cir la mortalidad materna e infantil y en mejorar la atención primaria y de urge
ncias. En este artículo se describen estas iniciativas educacionales diseñadas p
ara mejorar las habilidades de los promotores de salud y las parteras mediante u
n entrenamiento médico avanzado y sostenible, ajustadas a las necesidades especí
ficas de cada comunidad.#^dnd^i2#^tm^les^kprestación de atención de salud^i2#^tm
^les^kenfermeras obstetrices^i2#^tm^les^katención primaria de salud^i2#^tm^les^k
servicios médicos de urgencia^i2#^tm^les^kAméricas^i2#other#9#a11v22n6.htm##
03142000000000613000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700640013000720710003000850400003000880010
00600091042000200097120000400099121000300103049000800106158000300114030002600117
03100030014303200020014606500090014801400110015703500100016801200810017801201000
02590100029003590100028003880100036004160100028004520100024004800700194005040700
07200698085000800770085003600778085002700814085003200841085003900873085002100912
08312930093308500080222608500440223408500350227808500390231308500420235208500210
2394117000602415072000202421002001302423008009202436#v22n6#v:\scielo\serial\rpsp
\v22n6\markup\a11v22n6.htm#S#l#4#1#article#1#^mDec.^a2007#oa#en#br1.1#1#3.1#11#R
PSP050#nd#Rev. panam. salud pública#22#6#20071200#^f425^l431#1020-4989#Emergency
 medical training for health promoters in Central and South America^len#Entrenam
iento médico en urgencias para promotores de salud de América Central y América 
del Sur^les#^rND^1A01^nRobert^sPartridge#^rND^1A01^nLawrence^sProano#^rND^1A02^n
George^sSkarbek-Borowski#^rND^1A01^nDavid^sBouslough#^rND^1A02^nScott^sCohen#^iA
01^1Alpert Medical School at Brown University^2Rhode Island Hospital^3Department
 of Emergency Medicine. Division of International Emergency Medicine^cProvidence
^sRI^pUnited States of America#^iA02^1Global Pediatric Alliance^cOakland^sCA^pUn
ited States of America#^dnd^i1#^tm^len^kdelivery of health care^i1#^tm^len^knurs
e midwives^i1#^tm^len^kprimary health care^i1#^tm^len^kemergency medical service
s^i1#^tm^len^kAmericas^i1#^les^aLos promotores de salud, las parteras y otros pr
oveedores de cuidados médicos básicos trabajan en comunidades locales de todo el
 mundo para mejorar y facilitar la atención sanitaria. No hay suficiente informa
ción que describa los programas educacionales dirigidos a mejorar los conocimien
tos y las habilidades de los promotores de salud y sobre su impacto sanitario a 
largo plazo. Muchas iniciativas educacionales dirigidas a los promotores de salu
d consisten en intervenciones aisladas que permiten evaluar sus conocimientos in
mediatamente después de la intervención, pero no miden los progresos a largo pla
zo en la base de conocimientos o la atención sanitaria. La Alianza Pediátrica Gl
obal -una organización sin ánimo de lucro basada en los EE.UU. que trabaja con p
ersonal médico y sanitario local- creó un programa educacional para promotores s
anitarios y parteras en Ecuador, Guatemala, México y Nicaragua con un enfoque ce
ntrado en reducir la mortalidad materna e infantil y en mejorar la atención prim
aria y de urgencias. En este artículo se describen estas iniciativas educacional
es diseñadas para mejorar las habilidades de los promotores de salud y las parte
ras mediante un entrenamiento médico avanzado y sostenible, ajustadas a las nece
sidades específicas de cada comunidad.#^dnd^i2#^tm^les^kprestación de atención d
e salud^i2#^tm^les^kenfermeras obstetrices^i2#^tm^les^katención primaria de salu
d^i2#^tm^les^kservicios médicos de urgencia^i2#^tm^les^kAméricas^i2#other#9#a11v
22n6.htm#Internet^ihttp://www.scielosp.org/scielo.php?script=sci_arttext&pid=S10
20-49892007001100011##
00340000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000300070704010800073002001300181#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a11v22n6.htm#S#p#5#1#article#85#<p align="right"><font
 size="2" face="Verdana"><b>TEMAS DE ACTUALIDAD </b>CURRENT TOPICS</font></p>   
  ^cY#a11v22n6.htm##
00254000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000300070704002200073002001300095#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a11v22n6.htm#S#p#6#2#article#85#<p>&nbsp;</p>     ^cY#
a11v22n6.htm##
00388000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000300070704015600073002001300229#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a11v22n6.htm#S#p#7#3#article#85#<p><font size="4" face
="verdana"><a name="tx"></a><b>Emergency medical training    for health promoter
s in Central and South America</b></font></p>     ^cY#a11v22n6.htm##
00254000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000300070704002200073002001300095#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a11v22n6.htm#S#p#8#4#article#85#<p>&nbsp;</p>     ^cY#
a11v22n6.htm##
00411000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000300070704017900073002001300252#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a11v22n6.htm#S#p#9#5#article#85#<p><font size="3" face
="verdana"><b>Entrenamiento m&eacute;dico en urgencias para    promotores de sal
ud de Am&eacute;rica Central y Am&eacute;rica del Sur</b></font></p>     ^cY#a11
v22n6.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000300071704002200074002001300096#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a11v22n6.htm#S#p#10#6#article#85#<p>&nbsp;</p>     ^cY
#a11v22n6.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000300071704002200074002001300096#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a11v22n6.htm#S#p#11#7#article#85#<p>&nbsp;</p>     ^cY
#a11v22n6.htm##
00482000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000300071704024900074002001300323#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a11v22n6.htm#S#p#12#8#article#85#<p><font size="2" fac
e="Verdana"><b>Robert Partridge<sup>I, </sup><a href="#end"><sup>*</sup></a>;   
 Lawrence Proano<SUP>I</SUP>; George Skarbek-Borowski<SUP>II</SUP>; David Bouslo
ugh<SUP>I</SUP>;    Scott Cohen<SUP>II</sup></b></font></p>     ^cY#a11v22n6.htm
##
00478000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000300071704024500074002001300319#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a11v22n6.htm#S#p#13#9#article#85#<p><font size="2" fac
e="Verdana"><SUP>I</sup>Division of International Emergency    Medicine, Departm
ent of Emergency Medicine, Alpert Medical School at Brown University,    Rhode I
sland Hospital, Providence, RI, United States of America    ^cY#a11v22n6.htm##
00338000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704010400075002001300179#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a11v22n6.htm#S#p#14#10#article#85#<br>   <SUP>II</sup>
Global Pediatric Alliance, Oakland, CA, United States of America</font></p>     
^cY#a11v22n6.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a11v22n6.htm#S#p#15#11#article#85#<p>&nbsp;</p>     ^c
Y#a11v22n6.htm##
00278000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704004400075002001300119#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a11v22n6.htm#S#p#16#12#article#85#<p>&nbsp;</p> <hr si
ze="1" noshade>     ^cY#a11v22n6.htm##
00429000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704019500075002001300270#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a11v22n6.htm#S#p#17#13#article#85#<p><font size="2" fa
ce="Verdana"><B>Key words: </b>delivery of health care, nurse    midwives, prima
ry health care, emergency medical services, Americas.</font></p> <hr size="1" no
shade>     ^cY#a11v22n6.htm##
00302000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704006800075002001300143#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a11v22n6.htm#S#p#18#14#article#85#<p><font size="2" fa
ce="Verdana"><b>SINOPSIS</b></font></p>     ^cY#a11v22n6.htm##
01750000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704151600075002001301591#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a11v22n6.htm#S#p#19#15#article#85#<p><font size="2" fa
ce="Verdana">Los promotores de salud, las parteras y otros    proveedores de cui
dados m&eacute;dicos b&aacute;sicos trabajan en comunidades    locales de todo e
l mundo para mejorar y facilitar la atenci&oacute;n sanitaria.    No hay suficie
nte informaci&oacute;n que describa los programas educacionales    dirigidos a m
ejorar los conocimientos y las habilidades de los promotores de    salud y sobre
 su impacto sanitario a largo plazo. Muchas iniciativas educacionales    dirigid
as a los promotores de salud consisten en intervenciones aisladas que    permite
n evaluar sus conocimientos inmediatamente despu&eacute;s de la intervenci&oacut
e;n,    pero no miden los progresos a largo plazo en la base de conocimientos o 
la atenci&oacute;n    sanitaria. La Alianza Pedi&aacute;trica Global —una organi
zaci&oacute;n sin    &aacute;nimo de lucro basada en los EE.UU. que trabaja con 
personal m&eacute;dico    y sanitario local— cre&oacute; un programa educacional
 para promotores sanitarios    y parteras en Ecuador, Guatemala, M&eacute;xico y
 Nicaragua con un enfoque centrado    en reducir la mortalidad materna e infanti
l y en mejorar la atenci&oacute;n    primaria y de urgencias. En este art&iacute
;culo se describen estas iniciativas    educacionales dise&ntilde;adas para mejo
rar las habilidades de los promotores    de salud y las parteras mediante un ent
renamiento m&eacute;dico avanzado y sostenible,    ajustadas a las necesidades e
spec&iacute;ficas de cada comunidad.</font></p>     ^cY#a11v22n6.htm##
00498000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704026400075002001300339#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a11v22n6.htm#S#p#20#16#article#85#<p><font size="2" fa
ce="Verdana"><B>Palabras clave:</b> prestaci&oacute;n de atenci&oacute;n    de s
alud, enfermeras obstetrices, atenci&oacute;n primaria de salud, servicios    m&
eacute;dicos de urgencia, Am&eacute;ricas.</font></p> <hr size="1" noshade>     
^cY#a11v22n6.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a11v22n6.htm#S#p#21#17#article#85#<p>&nbsp;</p>     ^c
Y#a11v22n6.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a11v22n6.htm#S#p#22#18#article#85#<p>&nbsp;</p>     ^c
Y#a11v22n6.htm##
01437000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704120300075002001301278#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a11v22n6.htm#S#p#23#19#article#85#<p><font size="2" fa
ce="Verdana">Underserved regions in the developing world are    challenging area
s to provide emergency medical care. As populations in these    often remote or 
isolated districts may have minimal access to regular health    care, contacts w
ith medical providers are frequently episodic and driven by    an acute conditio
n. Health promoters—practitioners who provide basic medical    care and promote 
public health in numerous countries across Central and South    America, Asia an
d Africa—help to fill this void. Typically, health promoters    are certified th
rough a formal training program in their country and come from    the same popul
ation as the clients they serve, which helps them form a link    between their c
ommunity and the dominant health care system in the region (1–2).    Access to h
ealth and social services in regions served by health promoters is    usually mi
nimal, resulting in high morbidity and mortality associated with preventable    
diseases. Health promoters strive to improve the overall health of these communi
ties    by supplementing and improving the curative, preventive, and promotional
 aspects    of the existing health system. </font></p>     ^cY#a11v22n6.htm##
00977000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704074300075002001300818#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a11v22n6.htm#S#p#24#20#article#85#<p><font size="2" fa
ce="Verdana">Evaluations of the public health impact of health    promoters have
 identified specific benefits for the populations they serve,    as well as chal
lenges and limitations. A review of Peruvian health promoters    indicated that 
they had the greatest impact on boosting vaccination coverage    and increasing 
use of available public health services. Sustainability was a    problem, howeve
r, with only 40% of health promoters originally trained still    active 3 years 
after their training and supervision had ended (3). In Bangladesh,    the impact
 of village health promoters was limited by methods used, time constraints,    a
nd extreme poverty and illiteracy in the population served (4).</font></p>     ^
cY#a11v22n6.htm##
01049000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704081500075002001300890#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a11v22n6.htm#S#p#25#21#article#85#<p><font size="2" fa
ce="Verdana">To have a positive impact on public health in    indigenous or rura
l populations, health promoters must: (1) determine the health    status of a po
pulation, (2) gain acceptance by taking into account community    cultural belie
fs and practices, (3) improve health care outcomes from both emergent    and non
-emergent medical conditions using available resources, and (4) ensure    the ef
fort is sustainable. Many health systems that use health promoters have    no ab
ility or mechanism to assess the impact of health promoters, no means for    hea
lth promoters to advance their education or skills, and no plan for sustainabili
ty.    These limitations can hinder the ability of health promoters to bring abo
ut    lasting gains in patient care and public health. </font></p>     ^cY#a11v2
2n6.htm##
00804000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704057000075002001300645#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a11v22n6.htm#S#p#26#22#article#85#<p><font size="2" fa
ce="Verdana">One factor in health promoters' effectiveness    is the level and s
cope of their education, which varies widely. Data describing    the long-term h
ealth impact of educational programs for health promoters are    scant. Many edu
cational efforts directed toward health promoters consist of    just one interve
ntion. These programs may assess health promoters' knowledge    immediately afte
r the educational intervention, but they do not measure long-term    improvement
s in scope of knowledge or health care provision. </font></p>     ^cY#a11v22n6.h
tm##
00968000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704073400075002001300809#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a11v22n6.htm#S#p#27#23#article#85#<p><font size="2" fa
ce="Verdana">Physicians, midwives, and nurses at the U.S.-based    nonprofit age
ncy Global Pediatric Alliance (GPA) have worked with health promoters,    midwiv
es, and physicians in Central and South America for 5 years. Working directly   
 with local health promoters and other medical personnel, GPA staff have created
    an education program for health promoters in Guatemala, Nicaragua, Mexico, a
nd    Ecuador, with a focus on reducing maternal and infant mortality and improv
ing    primary and emergency care. These programs are designed to take maximum a
dvantage    of health promoters' strengths as well as local capacity and to addr
ess limitations    based on prior program experiences.</font></p>     ^cY#a11v22
n6.htm##
00819000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704058500075002001300660#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a11v22n6.htm#S#p#28#24#article#85#<p><font size="2" fa
ce="Verdana">This paper describes these educational efforts,    which were devel
oped to enhance the skills of health promoters and midwives    by offering advan
ced, sustainable emergency medical training that would otherwise    be unavailab
le. The goal of this program is to improve emergency and routine    care by deve
loping long-term relationships with these frontline health care    providers, ev
aluating their educational needs, providing tailored training,    and facilitati
ng the development of community leaders and future educators.    </font></p>    
 ^cY#a11v22n6.htm##
00765000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704053100075002001300606#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a11v22n6.htm#S#p#29#25#article#85#<p><font size="2" fa
ce="Verdana">Two key elements of this program are sustainability    and customiz
ation of training in emergency care. Sustainability has been an    issue for a n
umber of programs, where the knowledge imparted is lost once a    health promote
r leaves the field. These examples support the concept that ongoing    training 
and integration of new health promoters into the education program    are necess
ary to ensure a lasting and significant improvement in acute care    and public 
health (3).</font></p>     ^cY#a11v22n6.htm##
01054000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704082000075002001300895#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a11v22n6.htm#S#p#30#26#article#85#<p><font size="2" fa
ce="Verdana">The impact of tailoring health promoter training    for specific po
pulations is less well documented. Educational programs used    with a group of 
health promoters in one country have been successfully applied    in other count
ries, but the long-term health impact of these programs has not    been well stu
died (5). Anecdotally, there is considerable evidence that standardized    train
ing programs often fail to take into account such basic issues as variability   
 in health status, availability of equipment, and local cultural beliefs and    
practices related to health care. For that reason, GPA's training is designed   
 to take into account the health problems, capacities, cultural attitudes, and  
  desired public health outcomes of each population served. </font></p>     ^cY#
a11v22n6.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a11v22n6.htm#S#p#31#27#article#85#<p>&nbsp;</p>     ^c
Y#a11v22n6.htm##
00313000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704007900075002001300154#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a11v22n6.htm#S#p#32#28#article#85#<p><font size="3" fa
ce="Verdana"><b>PROJECT DESCRIPTION</b></font></p>     ^cY#a11v22n6.htm##
00796000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704056200075002001300637#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a11v22n6.htm#S#p#33#29#article#85#<p><font size="2" fa
ce="Verdana">In Central and South America, access to health    services can vary
 widely. Impoverished and rural communities may have village    health promoters
 and/or midwives, or they may not have any access to heath care    services. For
mal medical and public health training for health promoters and    midwives is i
nconsistent. Existing health promoters and midwives may have extensive    practi
cal experience, but most have no opportunities for learning emergency    care or
 new techniques or advancing their skills.</font></p>     ^cY#a11v22n6.htm##
00303000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704006900075002001300144#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a11v22n6.htm#S#p#34#30#article#85#<p><font size="2" fa
ce="Verdana"><b>Guatemala</b></font></p>     ^cY#a11v22n6.htm##
00722000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704048800075002001300563#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a11v22n6.htm#S#p#35#31#article#85#<p><font size="2" fa
ce="Verdana">The educational program for the GPA project site    in Guatemala, k
nown as Ak'Tenemit, has focused on providing workshops on emergency    care and 
advanced primary care, particularly treatment of acutely ill or injured    child
ren. This module was developed because an acute need was identified by    health
 promoters working at the clinic. A program was created by these health    promo
ters along with physicians and nurses from GPA. </font></p>     ^cY#a11v22n6.htm
##
01134000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704090000075002001300975#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a11v22n6.htm#S#p#36#32#article#85#<p><font size="2" fa
ce="Verdana">Ak'Tenemit is a community-run health care and    educational center
 on the banks of the Rio Dulce. Located deep in the country's    eastern rainfor
est, the site is accessible only by boat or on foot. The clinic    has a staff o
f four health promoters but no permanent physician; it relies exclusively    on 
donations for all medical supplies and equipment. Ak'Tenemit serves a population
    of approximately 10,000 to 15,000, mostly indigenous Q'eqchi'-speaking peopl
e    of Mayan descent. The region lacks roads, electricity, and adequate potable
    water. The nearest hospital is reachable only by a one-hour motorboat journe
y    that is well beyond the financial and logistical reach of the majority of t
he    population. Consequently, the clinic's health promoters and midwives are t
he    sole health care providers for most of this community.</font></p>     ^cY#
a11v22n6.htm##
00966000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704073200075002001300807#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a11v22n6.htm#S#p#37#33#article#85#<p><font size="2" fa
ce="Verdana">The Ak'Tenemit health promoters have considerably    more training 
and experience than do health promoters from the surrounding area.    Once a wee
k, Ak'Tenemit sends a team of its health care workers to an outlying    village 
where they assist in the running of a day clinic and lead an educational    work
shop on acute care for local health promoters. Few resources exist to provide   
 the health promoters and midwives at the main Ak'Tenemit clinic with continuing
    medical training, however. The clinic houses much in the way of unused emerg
ency    supplies and equipment that were donated without consideration of whethe
r the    staff had the necessary skills to use them.</font></p>     ^cY#a11v22n6
.htm##
00839000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704060500075002001300680#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a11v22n6.htm#S#p#38#34#article#85#<p><font size="2" fa
ce="Verdana">The object of GPA's educational program at Ak'Tenemit    was to pro
vide workshops on advanced primary care, with a focus on the acutely    ill or i
njured patient. Based on conversations with leading health promoters    at the c
linic, GPA was able to design a tailored intervention that directly    addressed
 priority health care concerns of the community. Training modules were    develo
ped for management of the most commonly encountered medical and traumatic    eme
rgencies, taking into consideration available resources and cultural preferences
.    </font></p>     ^cY#a11v22n6.htm##
01273000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704103900075002001301114#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a11v22n6.htm#S#p#39#35#article#85#<p><font size="2" fa
ce="Verdana">Training emphasized the basic requirements for    effective clinica
l assessment, including a thorough medical history, a detailed    physical exam,
 and carefully interpreting vital signs. It also highlighted the    signs and sy
mptoms of dehydration in both pediatric and adult patients, recognition    of re
spiratory distress, and the distinction between asthma and pneumonia. Treatment 
   guidelines were covered in detail, including the calculation of oral and intr
avenous    fluid replacement; placement of intravenous catheters; indications fo
r beta-agonists,    steroids, epinephrine and antibiotics; and the correct use o
f inhalers and spacer    devices. Intensive, hands-on workshops covered burn and
 wound management, with    a focus on the importance of wound irrigation, infect
ion control, and wound    management techniques ranging from simple skin closure
 to tendon repair. Indications    for hospital transfer and techniques for patie
nt stabilization were also covered.    </font></p>     ^cY#a11v22n6.htm##
00732000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704049800075002001300573#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a11v22n6.htm#S#p#40#36#article#85#<p><font size="2" fa
ce="Verdana">Educational projects at this site have been conducted    once annua
lly for 4 years. These educational workshops take place over a period    of 3 da
ys, and include the active health promoters in the region (<I>n </I>=    20), as
 well as midwives (<I>n </I>= 20). Because the same group of health promoters   
 attends each workshop, each educational module is different from the previous  
  one and is specifically tailored to participants' needs.</font></p>     ^cY#a1
1v22n6.htm##
00303000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704006900075002001300144#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a11v22n6.htm#S#p#41#37#article#85#<p><font size="2" fa
ce="Verdana"><b>Nicaragua</b></font></p>     ^cY#a11v22n6.htm##
00766000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704053200075002001300607#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a11v22n6.htm#S#p#42#38#article#85#<p><font size="2" fa
ce="Verdana">Two educational sites have been developed in    Nicaragua to respon
d to needs on different levels. The initial project was centered    at a rural w
omen's health clinic. The clinic serves villages with limited road    access and
 insufficient potable water, and represents the only health care available    in
 the area. The need for educational programs was identified by local midwives   
 and health promoters and developed in conjunction with U.S.-based physicians   
 and nurses.</font></p>     ^cY#a11v22n6.htm##
00674000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704044000075002001300515#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a11v22n6.htm#S#p#43#39#article#85#<p><font size="2" fa
ce="Verdana">Two of the major health issues faced by this    community are mater
nal and child care. The initial focus of this effort has    been to provide adva
nced training in prenatal care, normal and abnormal/ high-risk    pregnancy and 
delivery, and pediatric primary and emergency care. To provide    this training,
 GPA created a semiannual workshop attended by midwives from 13    communities. 
</font></p>     ^cY#a11v22n6.htm##
00710000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704047600075002001300551#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a11v22n6.htm#S#p#44#40#article#85#<p><font size="2" fa
ce="Verdana">These workshops were conducted in conjunction    with a nationwide 
women's resource center called Casa de la Mujer. Casa de la    Mujer offers many
 services to poor women, and has close ties to remote health    promoters and mi
dwives. Among the supportive programs Casa de la Mujer offers    these health wo
rkers is an on-site doctor who visits the remote areas in which    they work and
 sees patients on a periodic basis. </font></p>     ^cY#a11v22n6.htm##
01119000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704088500075002001300960#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a11v22n6.htm#S#p#45#41#article#85#<p><font size="2" fa
ce="Verdana">Initially, the trainers considered these workshops    less effectiv
e than the ones conducted in Guatemala. This was partly because    many of the h
ealth promoters lived in areas with an established health center    in relativel
y close proximity that could provide a higher level of care, and    partly becau
se the health promoters were older and more clinically experienced.    As a resu
lt, these health promoters were less receptive to the educational initiative.   
 Therefore, the educational thrust in this area has now been directed mainly    
to the midwives at Casa de la Mujer, many of whom were younger and less clinical
ly    experienced than the health promoters, especially in obstetrical emergenci
es.    The program has been made more effective by carefully identifying clinica
lly    active midwives for advanced training.</font></p>     ^cY#a11v22n6.htm##
00956000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704072200075002001300797#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a11v22n6.htm#S#p#46#42#article#85#<p><font size="2" fa
ce="Verdana">A second educational program was begun in Nicaragua    after establ
ishing relationships with the health promoters and midwives serving    outlying 
communities. These health workers often worked closely with hospital-based    me
dical staff when acutely ill patients were referred for a higher level of    car
e. Hospital-based physicians and nurses expressed interest in receiving speciali
zed    pediatric emergency training that would help ensure the continuity of car
e from    the rural village to the hospital. This program was initiated at Hospi
tal Japon    Amistad in Granada, Nicaragua, which primarily serves indigent pati
ents and    patients from rural villages. </font></p>     ^cY#a11v22n6.htm##
01080000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704084600075002001300921#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a11v22n6.htm#S#p#47#43#article#85#<p><font size="2" fa
ce="Verdana">Through this program, 14 physicians and nurses    have become certi
fied by the American Academy of Pediatrics' Newborn Resuscitation    Program (NR
P). At the request of the hospital's nursing staff, NRP and other    educational
 programs have been initiated for labor and delivery RNs and midwives.    These 
programs now run semiannually, with the goal of educating 20 working midwives,  
  20 RNs and several physicians in each session. In addition, patient care proto
cols    are being developed with a neonatologist and the intensive care nursery 
(ICN)    staff. In the future, a pediatric advanced life support (PALS) course w
ill be    offered to physicians, RNs, and health promoters. Another major goal i
s to establish    ongoing NRP certification courses for other physicians in Nica
ragua.</font></p>     ^cY#a11v22n6.htm##
00886000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704065200075002001300727#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a11v22n6.htm#S#p#48#44#article#85#<p><font size="2" fa
ce="Verdana">Creating effective educational programs in emergency    care for he
alth promoters and midwives within the confines of the health care    system in 
Nicaragua has been a challenge. A major issue is the historical lack    of respe
ct for health promoters and midwives on the part of physicians. This    lack of 
respect can impede the effectiveness of education programs in several    ways: i
t impedes communication between health promoters and physicians (including    tr
ainers); it interferes with coordination of care; and it can cause delays    in 
transferring seriously ill patients to the hospital.</font></p>     ^cY#a11v22n6
.htm##
01114000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704088000075002001300955#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a11v22n6.htm#S#p#49#45#article#85#<p><font size="2" fa
ce="Verdana">Educational programs will have to help bridge    the gap between th
ese caregivers to succeed in this setting. Improvement in    patient care will c
ome from creating an environment in which village health    workers feel comfort
able sending patients to the hospital early in the disease    process (e.g., wit
h pediatric respiratory disease or maternal hemorrhage in    labor) without fear
 of criticism or condescension. This is a major problem in    many countries whe
re health promoters practice; overcoming it has been shown    to be a critical f
actor in reducing maternal morbidity and mortality. By including    midwives and
 health promoters in the NRP and other educational programs at Hospital    Japon
 Amistad, the GPA initiative may be helping to bridge this gap between    provid
ers who are trained at different levels.</font></p>     ^cY#a11v22n6.htm##
00301000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704006700075002001300142#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a11v22n6.htm#S#p#50#46#article#85#<p><font size="2" fa
ce="Verdana"><b>Ecuador</b></font></p>     ^cY#a11v22n6.htm##
01069000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704083500075002001300910#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a11v22n6.htm#S#p#51#47#article#85#<p><font size="2" fa
ce="Verdana">An entirely different program was developed for    the Quechua peop
le of Kachiwanushka village in Ecuador's Amazon Basin. The Quechua    are a self
-sustaining community of indigenous people, living in an area with    insufficie
nt potable water and high rates of parasitosis and respiratory illness.    This 
group has limited access to and minimal ability to afford hospital-based    rout
ine or emergency medical care. As a group, the Quechua have little faith    in g
overnment health programs. The community members themselves requested help    wi
th medical education and public health measures. Specific needs, especially    i
n emergency care, were identified by a local physician, Peace Corps volunteers, 
   and GPA staff, who worked together to implement an educational program. </fon
t></p>     ^cY#a11v22n6.htm##
01774000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704154000075002001301615#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a11v22n6.htm#S#p#52#48#article#85#<p><font size="2" fa
ce="Verdana">This program is the first to have direct involvement    from an in-
country physician practitioner. The physician is a general practitioner    in Qu
ito who is pursuing a master's degree in public health. The educational    progr
am in emergency care developed with this physician is similar to the GPA    prog
rams in Guatemala and Nicaragua. Workshops introduce important concepts    in em
ergent conditions, primary care, rehydration, machete and wound care, family    
planning, and integration of traditional medicine techniques. The program is    
focused on training 9 villagers as regional health promoters, who serve the    v
illage of Kachiwanushka (population about 150) and 5 surrounding villages of    
similar size. Workshops in the Kachiwanushka region are conducted over a 1–2    
day period and were given monthly when the program was initiated 3 years ago.   
 They now occur every other month. In addition, because the request for this    
initiative came from the local community, community-wide health education traini
ng    has been given annually during the 3 years of this project. Attendance has
 averaged    approximately 55 people from the 5 local villages. This community-w
ide training    initiative and increased awareness of good health practices may 
have some direct    benefits. The Kachiwanushka villagers recently implemented a
 clean water project    and built a well with a simple pumping system that deliv
ers potable water to    the village kitchen and schoolhouse.</font></p>     ^cY#
a11v22n6.htm##
01207000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704097300075002001301048#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a11v22n6.htm#S#p#53#49#article#85#<p><font size="2" fa
ce="Verdana">The success of this program is due in part to    having a dedicated
 in-country physician who is able to travel to Amazona from    Quito as often as
 every 4 weeks for conferences and workshops. Increased frequency    of training
 means that new concepts can be introduced at a faster rate and existing    conc
epts can be reinforced. A small number of regional and local physicians    and v
olunteers assist in this effort, and have become more involved as the success   
 of this program has grown. These individuals are currently assisting in develop
ing    new educational sites and participants in other villages in the Amazona r
egion.    Local physicians have also allowed health promoters to do a modified e
xternship    at regional health posts as a result of this effort. Importantly, i
t is anticipated    that this arrangement will help improve cooperation and unde
rstanding between    health promoters and physicians.</font></p>     ^cY#a11v22n
6.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a11v22n6.htm#S#p#54#50#article#85#<p>&nbsp;</p>     ^c
Y#a11v22n6.htm##
00305000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704007100075002001300146#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a11v22n6.htm#S#p#55#51#article#85#<p><font size="3" fa
ce="Verdana"><b>DISCUSSION </b></font></p>     ^cY#a11v22n6.htm##
00320000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704008600075002001300161#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a11v22n6.htm#S#p#56#52#article#85#<p><font size="2" fa
ce="Verdana"><b>Creating long-term success</b></font></p>     ^cY#a11v22n6.htm##
00995000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704076100075002001300836#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a11v22n6.htm#S#p#57#53#article#85#<p><font size="2" fa
ce="Verdana">Although other organizations have done similar    work teaching hea
lth promoters and midwives in developing countries, most of    these efforts wer
e not specifically designed to meet local needs and capabilities    and thus wer
e not ultimately sustainable. GPA's programs have met these challenges    largel
y by: (1) providing ongoing training to ensure continued motivation and    skill
-building in emergency care; and (2) tailoring educational modules to take    in
to account the previous education and experience of local health promoters    an
d midwives, the limits of the existing health system, and the practice of    ass
essing educational needs in conjunction with local health promoters and midwives
.</font></p>     ^cY#a11v22n6.htm##
01153000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704091900075002001300994#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a11v22n6.htm#S#p#58#54#article#85#<p><font size="2" fa
ce="Verdana">As educational programs for local health providers    are often not
 applicable to other contexts, specific assessments and educational    intervent
ions must be made for different geographic areas. The need for localization    o
f training was particularly evident in Nicaragua, where health promoters and    
midwives were highly experienced, and many no longer worked in the rural setting
,    which limited the effectiveness of the module adapted from the program in G
uatemala.    Having made a commitment to en-sure the sustainability of the progr
am, GPA retooled    the educational module and addressed the health promoter–phy
sician relationship    to adapt the program to the local context. This modified 
approach increased    both the participation by other health providers, includin
g physicians and midwives,    and the level of interest among health promoters.<
/font></p>     ^cY#a11v22n6.htm##
00312000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704007800075002001300153#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a11v22n6.htm#S#p#59#55#article#85#<p><font size="2" fa
ce="Verdana"><b>Tailoring training</b></font></p>     ^cY#a11v22n6.htm##
01271000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704103700075002001301112#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a11v22n6.htm#S#p#60#56#article#85#<p><font size="2" fa
ce="Verdana">Within the health domain, <I>tailoring</I> refers    to situations 
in which the content and delivery of one's message is altered    to address the 
unique needs, interests, motives, and perceived barriers of different    individ
uals or groups (6–7). Health education materials are typically generic;    to se
rve as broad a population as possible they tend to try to be all things    to al
l people, providing as much information as possible in a single communication   
 (8). However, if a health education intervention is to have lasting impact,    
it is critical to understand the demands placed on the audience not only in    t
he initial learning process but also subsequently, particularly with regard    t
o the availability of resources that will allow the newly acquired knowledge    
to be retained. In other words, the first step in planning an educational interv
ention    should be an assessment of participants' skills and resources relative
 to the    demands of the course (9).</font></p>     ^cY#a11v22n6.htm##
01312000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704107800075002001301153#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a11v22n6.htm#S#p#61#57#article#85#<p><font size="2" fa
ce="Verdana">Participants must be assessed in terms of all    variables necessar
y for performance of the target behavior, including the personal    characterist
ics and skills required by the behavior itself. For example, one    of the modul
es of the advanced primary care workshop at Ak'Tenemit involves    the recogniti
on of dehydration in children and the development of intravenous    rehydration 
skills. If the target behavior is "retention of IV hydration    skills," several
 variables must be satisfied for the behavior to be both    learned and retained
 (such as the ability to learn from a lecture format, the    acceptance of new t
echnology, and opportunities to practice one's skills). Each    of these requisi
tes is in turn dependent upon multiple variables (such as literacy,    support o
f the local medical community, and financial and educational resources).    The 
causal chain that appears in <a href="#fig01">Figure 1</a> outlines the    dynam
ics that exist between these correlates and predictors of the target behavior.</
font></p>     ^cY#a11v22n6.htm##
00270000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704003600075002001300111#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a11v22n6.htm#S#p#62#58#article#85#<p><a name="fig01"><
/a></p>     ^cY#a11v22n6.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a11v22n6.htm#S#p#63#59#article#85#<p>&nbsp;</p>     ^c
Y#a11v22n6.htm##
00314000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704008000075002001300155#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a11v22n6.htm#S#p#64#60#article#85#<p align="center"><i
mg src="/img/revistas/rpsp/v22n6/a11fig01.gif"></p>     ^cY#a11v22n6.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a11v22n6.htm#S#p#65#61#article#85#<p>&nbsp;</p>     ^c
Y#a11v22n6.htm##
01708000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704147400075002001301549#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a11v22n6.htm#S#p#66#62#article#85#<p><font size="2" fa
ce="Verdana">Other examples of ways in which GPA has attempted    to tailor its 
training modules include assessments of participants' educational    level in he
alth care, as well as their expertise with the available equipment    and resour
ces. For example, Guatemalan health promoters learn about intravenous    fluids 
and antibiotics, while health promoters in Ecuador learn indications    and tech
niques for preparing oral rehydration solution. Health promoters in    the Rio D
ulce region of Guatemala are experienced and well educated and have    intraveno
us supplies and fluids available, whereas, in the Amazona region in    Ecuador, 
health promoters have no real equipment or formal health education    course tra
ining. Therefore, program goals at the latter site have been tailored    to teac
h early recognition of the signs and symptoms of dehydration, and administration
    of oral rehydration solution (ORS) early in the course of the illness. Anoth
er    example of educational tailoring is that remotely located health promoters
 in    Amazona are taught to recognize early the signs of respiratory distress, 
and    to initiate transport to a facility with a higher level of care. Health p
romoters    in the Rio Dulce region of Guatemala, due to prior education and exp
erience,    are taught when to administer oxygen, when to administer intravenous
 versus    oral antibiotics, and ways to administer nebulized medications.</font
></p>     ^cY#a11v22n6.htm##
00308000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704007400075002001300149#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a11v22n6.htm#S#p#67#63#article#85#<p><font size="2" fa
ce="Verdana"><b>Sustainability</b></font></p>     ^cY#a11v22n6.htm##
00767000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704053300075002001300608#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a11v22n6.htm#S#p#68#64#article#85#<p><font size="2" fa
ce="Verdana">GPA achieves program sustainability by focusing    on a small numbe
r of core sites to provide a foundation for health promoter    and midwife emerg
ency care training in a particular geographic area. The goal    is not to expand
 efforts beyond what is sustainable in the long term. Using    a train-the-train
er approach, educators identify the health promoters who are    best suited to i
mpart the new knowledge they are acquiring and include them    as teachers in fu
ture modules.</font></p>     ^cY#a11v22n6.htm##
01250000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704101600075002001301091#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a11v22n6.htm#S#p#69#65#article#85#<p><font size="2" fa
ce="Verdana">Personnel selection is a key factor in achieving    successful and 
sustainable workshops. GPA strives to select individuals with    extraordinary m
otivation coupled with a high level of expertise. The 2- to 4-person    team tea
ching at a site must have a good understanding of the participants they    are t
eaching, including their living and work conditions and their educational    and
 work experience. They must also understand and share GPA's vision, that    the 
education process must involve mutual respect between trainers and participants,
    as well as its values—hard work in curriculum development, along with optimi
sm.    Although the executive director provides the staff with guidelines, once 
an    individual is invited as a volunteer, he or she has broad autonomy. This a
pproach    allows volunteers to take ownership of their work, elicits their best
 efforts,    and engenders their loyalty, keeping staff enthusiasm high and mini
mizing turnover.</font></p>     ^cY#a11v22n6.htm##
00872000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704063800075002001300713#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a11v22n6.htm#S#p#70#66#article#85#<p><font size="2" fa
ce="Verdana">Site selection is also critical for sustainability.    It is import
ant to select teaching participants who are actually busy seeing    patients in 
their daily life in their village or community. In addition, to    have the grea
test impact, and to make the most effective use of funds, sites    should be sel
ected in part for the lack of other available health care services.    For examp
le, in an area where a government clinic exists, the impact of training    healt
h promoters would be limited because the population at large is more used    to 
using the established health services.</font></p>     ^cY#a11v22n6.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a11v22n6.htm#S#p#71#67#article#85#<p>&nbsp;</p>     ^c
Y#a11v22n6.htm##
00306000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704007200075002001300147#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a11v22n6.htm#S#p#72#68#article#85#<p><font size="3" fa
ce="Verdana"><b>FUTURE PLANS</b></font></p>     ^cY#a11v22n6.htm##
00901000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704066700075002001300742#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a11v22n6.htm#S#p#73#69#article#85#<p><font size="2" fa
ce="Verdana">In the future, GPA plans to select a coordinator    for each site. 
This individual will function as the site point person, maintaining    contact w
ith other site participants and planning and coordinating local workshops.    Th
e major role of the site coordinator will be to continually gauge local needs   
 and tailor programs for optimal effectiveness. In addition, as part of the Ecua
dorian    program, GPA is planning to partner with and offer micro-grants to oth
er health    promoter and midwife training programs. This will augment their ong
oing efforts    with sustainable financial and educational support.</font></p>  
   ^cY#a11v22n6.htm##
00778000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704054400075002001300619#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a11v22n6.htm#S#p#74#70#article#85#<p><font size="2" fa
ce="Verdana">Work will begin soon on formally assessing and    evaluating the im
pact of these educational programs in emergency care on the    practices of loca
l health promoters and midwives, and on the health of the populations    they se
rve. This evaluation process will identify gaps in the current educational    pr
ogram, new areas of focus for educational interventions, and ways to make    hea
lth promoter and midwife education translate into improved emergency care    del
ivery in the community. </font></p>     ^cY#a11v22n6.htm##
00640000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704040600075002001300481#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a11v22n6.htm#S#p#75#71#article#85#<p><font size="2" fa
ce="Verdana">Creating successful programs in acute care training    with this mo
del is a work in progress. Fundamental components must be developed    and susta
ined through the evolution of the project and organization as a whole.    Antici
pating problems and understanding mistakes can be critical learning points    fo
r program improvement in developing countries.</font></p>     ^cY#a11v22n6.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a11v22n6.htm#S#p#76#72#article#85#<p>&nbsp;</p>     ^c
Y#a11v22n6.htm##
00304000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704007000075002001300145#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a11v22n6.htm#S#p#77#73#article#85#<p><font size="3" fa
ce="Verdana"><B>REFERENCES</b></font></p>     ^cY#a11v22n6.htm##
00410000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000200075704016200077002001300239#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a11v22n6.htm#S#p#78#74#article#85#1#<p><fo
nt size="2" face="Verdana">1. Eng E, Young R. Lay health advisors as community  
  change agents. Fam Community Health. 1992;15(1):24–40.</font></p>     ^cY#a11v
22n6.htm##
00406000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000200075704015800077002001300235#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a11v22n6.htm#S#p#79#75#article#85#2#<p><fo
nt size="2" face="Verdana">2. Jezewski MA. Culture brokering in migrant    farmw
orker health care. West J Nurs Res. 1990;12:497–513.</font></p>     ^cY#a11v22n6
.htm##
00485000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000200075704023700077002001300314#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a11v22n6.htm#S#p#80#76#article#85#3#<p><fo
nt size="2" face="Verdana">3. Christensen PB, Karlqvist S. Community health    w
orkers in a Peruvian slum area: an evaluation of their impact on health behavior
.    Bull. Pan Am Health Organ. 1990;24(2):183–196.</font></p>     ^cY#a11v22n6.
htm##
00399000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000200075704015100077002001300228#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a11v22n6.htm#S#p#81#77#article#85#4#<p><fo
nt size="2" face="Verdana">4. Taha AZ. How to make the most of village health   
 promoters. World Hlth Forum. 1997;18:278–81.</font></p>     ^cY#a11v22n6.htm##
00485000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000200075704023700077002001300314#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a11v22n6.htm#S#p#82#78#article#85#5#<p><fo
nt size="2" face="Verdana">5. Bailey JE, Coombs DW. Effectiveness of an    Indon
esian model for rapid training of Guatemalan health workers in diarrhea    case 
management. J Community Health. 1996;21(4):269–276.</font></p>     ^cY#a11v22n6.
htm##
00444000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000200075704019600077002001300273#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a11v22n6.htm#S#p#83#79#article#85#6#<p><fo
nt size="2" face="Verdana">6. Kreuter MW, Strecher VJ, Glassman B. One size    d
oes not fit all: the case for tailoring print materials. Ann Behav Med. 1999;21(
4):278–83.</font></p>     ^cY#a11v22n6.htm##
00533000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000200075704028500077002001300362#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a11v22n6.htm#S#p#84#80#article#85#7#<p><fo
nt size="2" face="Verdana">7. Petty RE, Barden J, Wheeler SC. The elaboration   
 likelihood model of persuasion. In: DiClemente RJ, Crosby RA, Kegler MC, eds.  
  Emerging theories in health promotion practice and research. San Francisco:   
 Jossey-Bass; 2002.</font></p>     ^cY#a11v22n6.htm##
00460000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000200075704021200077002001300289#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a11v22n6.htm#S#p#85#81#article#85#8#<p><fo
nt size="2" face="Verdana">8. Strecher VK, Rimer BK, Monaco KD. Development    o
f a new self-help guide—freedom from smoking for you and your family. Health    
Educ Q. 1989;16(1):101–12.</font></p>     ^cY#a11v22n6.htm##
00422000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000200075704017400077002001300251#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a11v22n6.htm#S#p#86#82#article#85#9#<p><fo
nt size="2" face="Verdana">9. Rakowski W. The potential variances of tailoring  
  in health behavior interventions. Ann Behav Med. 1999;21(4):284–9.</font></p> 
    ^cY#a11v22n6.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a11v22n6.htm#S#p#87#83#article#85#<p>&nbsp;</p>     ^c
Y#a11v22n6.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a11v22n6.htm#S#p#88#84#article#85#<p>&nbsp;</p>     ^c
Y#a11v22n6.htm##
00681000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704044700075002001300522#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a11v22n6.htm#S#p#89#85#article#85#<p><font size="2" fa
ce="Verdana"><a name="end"></a><a href="#tx">*</a> Send correspondence    and re
quests for reprints to: Dr. Robert Partridge, Department of Emergency    Medicin
e/Claverick 2, Rhode Island Hospital, 593 Eddy St, Providence, RI 02903,    Unit
ed States of America; telephone: (401) 444-5826; fax: (401) 444-6662; e-mail:   
 <a href="mailto:Robert_ Partridge_MD@Brown.edu">Robert_ Partridge_MD@Brown.edu<
/a>    </font></p>     ^cY#a11v22n6.htm##
00543000000000289000450000400060000070200480000670500020005470600020005670000030
00587010002000617090008000637080002000711180002000730100013000750100015000880120
05100103030002100154065000900175064000500184031000300189032000200192014000600194
865000900200002001300209035001000222801002100232#v22n6#v:\scielo\serial\rpsp\v22
n6\markup\a11v22n6.htm#S#c#90#1#article#9#1#^rND^sEng^nE#^rND^sYoung^nR#Lay heal
th advisors as community change agents^len#Fam Community Health#19920000#1992#15
#1#24-40#20071200#a11v22n6.htm#0160-6379#Fam Community Health##
00505000000000265000450000400060000070200480000670500020005470600020005670000030
00587010002000617090008000637080002000711180002000730100019000750120056000940300
01600150065000900166064000500175031000300180014000800183865000900191002001300200
035001000213801001600223#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a11v22n6.htm#S
#c#91#2#article#9#2#^rND^sJezewski^nMA#Culture brokering in migrant farmworker h
ealth care^len#West J Nurs Res#19900000#1990#12#497-513#20071200#a11v22n6.htm#01
93-9459#West J Nurs Res##
00574000000000277000450000400060000070200480000670500020005470600020005670000030
00587010002000617090008000637080002000711180002000730100022000750100019000970120
10300116030002600219710000200245065000900247064000500256031000300261032000200264
014000800266865000900274002001300283#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a1
1v22n6.htm#S#c#92#3#article#9#3#^rND^sChristensen^nPB#^rND^sKarlqvist^nS#Communi
ty health workers in a Peruvian slum area: an evaluation of their impact on heal
th behavior^len#Bull. Pan Am Health Organ#2#19900000#1990#24#2#183-196#20071200#
a11v22n6.htm##
00462000000000253000450000400060000070200480000670500020005470600020005670000030
00587010002000617090008000637080002000711180002000730100015000750120053000900300
01700143710000200160065000900162064000500171031000300176014000700179865000900186
002001300195#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a11v22n6.htm#S#c#93#4#arti
cle#9#4#^rND^sTaha^nAZ#How to make the most of village health promoters^len#Worl
d Hlth Forum#2#19970000#1997#18#278-81#20071200#a11v22n6.htm##
00613000000000289000450000400060000070200480000670500020005470600020005670000030
00587010002000617090008000637080002000711180002000730100017000750100017000920120
11700109030001900226065000900245064000500254031000300259032000200262014000800264
865000900272002001300281035001000294801001900304#v22n6#v:\scielo\serial\rpsp\v22
n6\markup\a11v22n6.htm#S#c#94#5#article#9#5#^rND^sBailey^nJE#^rND^sCoombs^nDW#Ef
fectiveness of an Indonesian model for rapid training of Guatemalan health worke
rs in diarrhea case management^len#J Community Health#19960000#1996#21#4#269-276
#20071200#a11v22n6.htm#0094-5145#J Community Health##
00588000000000301000450000400060000070200480000670500020005470600020005670000030
00587010002000617090008000637080002000711180002000730100018000750100019000930100
01800112012007000130030001400200065000900214064000500223031000300228032000200231
014000700233865000900240002001300249035001000262801001400272#v22n6#v:\scielo\ser
ial\rpsp\v22n6\markup\a11v22n6.htm#S#c#95#6#article#9#6#^rND^sKreuter^nMW#^rND^s
Strecher^nVJ#^rND^sGlassman^nB#One size does not fit all: the case for tailoring
 print materials^len#Ann Behav Med#19990000#1999#21#4#278-83#20071200#a11v22n6.h
tm#0883-6612#Ann Behav Med##
00659000000000301000450000400060000070200480000670500020005470600020005670000030
00587010002000617090008000637080002000711180002000730100016000750100016000910100
01800107012005100125016002100176016001700197016001700214018006400231066001400295
062001200309065000900321064000500330865000900335002001300344#v22n6#v:\scielo\ser
ial\rpsp\v22n6\markup\a11v22n6.htm#S#c#96#7#article#9#7#^rND^sPetty^nRE#^rND^sBa
rden^nJ#^rND^sWheeler^nSC#The elaboration likelihood model of persuasion^len#^rE
D^sDiClemente^nRJ#^rED^sCrosby^nRA#^rED^sKegler^nMC#Emerging theories in health 
promotion practice and research^len#San Francisco#Jossey-Bass#20020000#2002#2007
1200#a11v22n6.htm##
00601000000000301000450000400060000070200480000670500020005470600020005670000030
00587010002000617090008000637080002000711180002000730100019000750100016000940100
01700110012008600127030001400213065000900227064000500236031000300241032000200244
014000700246865000900253002001300262035001000275801001400285#v22n6#v:\scielo\ser
ial\rpsp\v22n6\markup\a11v22n6.htm#S#c#97#8#article#9#8#^rND^sStrecher^nVK#^rND^
sRimer^nBK#^rND^sMonaco^nKD#Development of a new self-help guide-freedom from sm
oking for you and your family^len#Health Educ Q#19890000#1989#16#1#101-12#200712
00#a11v22n6.htm#0195-8402#Health Educ Q##
00530000000000277000450000400060000070200480000670500020005470600020005670000030
00587010002000617090008000637080002000711180002000730100018000750120074000930300
01400167065000900181064000500190031000300195032000200198014000600200865000900206
002001300215035001000228801001400238#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a1
1v22n6.htm#S#c#98#9#article#9#9#^rND^sRakowski^nW#The potential variances of tai
loring in health behavior interventions^len#Ann Behav Med#19990000#1999#21#4#284
-9#20071200#a11v22n6.htm#0883-6612#Ann Behav Med##
00275000000000169000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700910009000720920007000810020013000887030
00400101#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a12v22n6.htm#S#o#1#1#article#1
#20080215#102643#a12v22n6.htm#109##
02733000000000577000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000300090121000300093049000800096158000300104030002400107
03100030013103200020013406500090013601400110014503500100015601200970016601200660
02630100041003290100034003700700082004040700091004860700123005770700054007000850
00800754085004800762085003900810085003500849085001900884083110700903085000802010
08500290201808500240204708500170207108500260208808500190211411700060213307200030
2139002001302142#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a12v22n6.htm#S#h#2#1#a
rticle#1#oa#pt#br1.1#1#3.1#ND#12#RPSP050#nd#Rev Panam Salud Publica#22#6#2007120
0#^f432^l437#1020-4989#Experiências internacionais de regulamentação das alegaçõ
es de saúde em rótulos de alimentos^lpt#International experiences with health cl
aims in food labeling^len#^rND^1A01 A02^nJanine Giuberti^sCoutinho#^rND^1A03 A04
^nElisabetta^sRecine#Ministério da Saúde^iA01^1Coordenação Geral da Política de 
Alimentação e Nutrição#Universidade de Brasília^iA02^1Observatório de Políticas 
de Segurança Alimentar e Nutrição#Universidade de Brasília^iA03^1Faculdade de Ci
ências da Saúde^2Observatório de Políticas de Segurança Alimentar e Nutrição#Açã
o Brasileira pela Nutrição e Direitos Humanos^iA04#^dnd^i1#^tm^lpt^kAlegação de 
propriedades funcionais^i1#^tm^lpt^klegislação sobre alimentos^i1#^tm^lpt^krotul
agem de alimentos^i1#^tm^lpt^kBrasil^i1#^len^aWith ever-increasing frequency, co
nsumers are seeking information on the foods they eat. Food labels are an import
ant source of this type of information, and the Codex Alimentarius, created by t
he World Health Organization and the Food and Agriculture Organization of the Un
ited Nations, provides a global reference for coordinated food quality and ident
ification standards. The Codex Alimentarius agenda includes nutritional informat
ion and "health claims," which are defined as any representation that states, su
ggests, or implies that a relationship exists between a food or a constituent of
 that food and health. Although food labeling seems to effectively assist consum
ers in choosing among processed foods, consumers are not always capable of readi
ng or interpreting nutritional information correctly, so health claims may allow
 for more precise decision-making for these products. The present paper examines
 the use of health claims in countries and regions that have already implemented
 this type of regulation (Brazil, Chile, Canada, United States of America, the E
uropean Union, and Japan).#^dnd^i2#^tm^len^kfunctional claim^i2#^tm^len^klegisla
tion^i2#^tm^len^kfood^i2#^tm^len^kfood labeling^i2#^tm^len^kBrazil^i2#other#20#a
12v22n6.htm##
02747000000000577000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000300090121000300093049000800096158000300104030002400107
03100030013103200020013406500090013601400110014503500100015601201040016601200730
02700100041003430100034003840700082004180700091005000700123005910700054007140850
00800768085004800776085003900824085003500863085001900898083110700917085000802024
08500290203208500240206108500170208508500260210208500190212811700060214707200030
2153002001302156#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a12v22n6.htm#S#f#3#1#a
rticle#1#oa#pt#br1.1#1#3.1#ND#12#RPSP050#nd#Rev Panam Salud Publica#22#6#2007120
0#^f432^l437#1020-4989#<B>Experiências internacionais de regulamentação das aleg
ações de saúde em rótulos de alimentos</B>^lpt#<B>International experiences with
 health claims in food labeling</B>^len#^rND^1A01 A02^nJanine Giuberti^sCoutinho
#^rND^1A03 A04^nElisabetta^sRecine#Ministério da Saúde^iA01^1Coordenação Geral d
a Política de Alimentação e Nutrição#Universidade de Brasília^iA02^1Observatório
 de Políticas de Segurança Alimentar e Nutrição#Universidade de Brasília^iA03^1F
aculdade de Ciências da Saúde^2Observatório de Políticas de Segurança Alimentar 
e Nutrição#Ação Brasileira pela Nutrição e Direitos Humanos^iA04#^dnd^i1#^tm^lpt
^kAlegação de propriedades funcionais^i1#^tm^lpt^klegislação sobre alimentos^i1#
^tm^lpt^krotulagem de alimentos^i1#^tm^lpt^kBrasil^i1#^len^aWith ever-increasing
 frequency, consumers are seeking information on the foods they eat. Food labels
 are an important source of this type of information, and the Codex Alimentarius
, created by the World Health Organization and the Food and Agriculture Organiza
tion of the United Nations, provides a global reference for coordinated food qua
lity and identification standards. The Codex Alimentarius agenda includes nutrit
ional information and "health claims," which are defined as any representation t
hat states, suggests, or implies that a relationship exists between a food or a 
constituent of that food and health. Although food labeling seems to effectively
 assist consumers in choosing among processed foods, consumers are not always ca
pable of reading or interpreting nutritional information correctly, so health cl
aims may allow for more precise decision-making for these products. The present 
paper examines the use of health claims in countries and regions that have alrea
dy implemented this type of regulation (Brazil, Chile, Canada, United States of 
America, the European Union, and Japan).#^dnd^i2#^tm^len^kfunctional claim^i2#^t
m^len^klegislation^i2#^tm^len^kfood^i2#^tm^len^kfood labeling^i2#^tm^len^kBrazil
^i2#other#20#a12v22n6.htm##
02857000000000589000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700640013000720710003000850400003000880010
00600091042000200097120000400099121000300103049000800106158000300114030002600117
03100030014303200020014606500090014801400110015703500100016801200970017801200660
02750100041003410100034003820700084004160700093005000700125005930700056007180850
00800774085004800782085003900830085003500869085001900904083110700923085000802030
08500290203808500240206708500170209108500260210808500190213411700060215307200030
2159002001302162008009202175#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a12v22n6.h
tm#S#l#4#1#article#1#^mdez.^a2007#oa#pt#br1.1#1#3.1#12#RPSP050#nd#Rev. panam. sa
lud pública#22#6#20071200#^f432^l437#1020-4989#Experiências internacionais de re
gulamentação das alegações de saúde em rótulos de alimentos^lpt#International ex
periences with health claims in food labeling^len#^rND^1A01 A02^nJanine Giuberti
^sCoutinho#^rND^1A03 A04^nElisabetta^sRecine#^iA01^1Ministério da Saúde^2Coorden
ação Geral da Política de Alimentação e Nutrição#^iA02^1Universidade de Brasília
^2Observatório de Políticas de Segurança Alimentar e Nutrição#^iA03^1Universidad
e de Brasília^2Faculdade de Ciências da Saúde^3Observatório de Políticas de Segu
rança Alimentar e Nutrição#^iA04^1Ação Brasileira pela Nutrição e Direitos Human
os#^dnd^i1#^tm^lpt^kAlegação de propriedades funcionais^i1#^tm^lpt^klegislação s
obre alimentos^i1#^tm^lpt^krotulagem de alimentos^i1#^tm^lpt^kBrasil^i1#^len^aWi
th ever-increasing frequency, consumers are seeking information on the foods the
y eat. Food labels are an important source of this type of information, and the 
Codex Alimentarius, created by the World Health Organization and the Food and Ag
riculture Organization of the United Nations, provides a global reference for co
ordinated food quality and identification standards. The Codex Alimentarius agen
da includes nutritional information and "health claims," which are defined as an
y representation that states, suggests, or implies that a relationship exists be
tween a food or a constituent of that food and health. Although food labeling se
ems to effectively assist consumers in choosing among processed foods, consumers
 are not always capable of reading or interpreting nutritional information corre
ctly, so health claims may allow for more precise decision-making for these prod
ucts. The present paper examines the use of health claims in countries and regio
ns that have already implemented this type of regulation (Brazil, Chile, Canada,
 United States of America, the European Union, and Japan).#^dnd^i2#^tm^len^kfunc
tional claim^i2#^tm^len^klegislation^i2#^tm^len^kfood^i2#^tm^len^kfood labeling^
i2#^tm^len^kBrazil^i2#other#20#a12v22n6.htm#Internet^ihttp://www.scielosp.org/sc
ielo.php?script=sci_arttext&pid=S1020-49892007001100012##
00340000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000300070704010800073002001300181#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a12v22n6.htm#S#p#5#1#article#85#<p align="right"><font
 size="2" face="Verdana"><b>TEMAS DE ACTUALIDAD </b>CURRENT TOPICS</font></p>   
  ^cY#a12v22n6.htm##
00254000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000300070704002200073002001300095#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a12v22n6.htm#S#p#6#2#article#85#<p>&nbsp;</p>     ^cY#
a12v22n6.htm##
00455000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000300070704022300073002001300296#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a12v22n6.htm#S#p#7#3#article#85#<p><font size="4" face
="verdana"><a name="tx"></a><b>Experi&ecirc;ncias internacionais    de regulamen
ta&ccedil;&atilde;o das alega&ccedil;&otilde;es de sa&uacute;de    em r&oacute;t
ulos de alimentos</b></font></p>     ^cY#a12v22n6.htm##
00254000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000300070704002200073002001300095#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a12v22n6.htm#S#p#8#4#article#85#<p>&nbsp;</p>     ^cY#
a12v22n6.htm##
00356000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000300070704012400073002001300197#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a12v22n6.htm#S#p#9#5#article#85#<p><font size="3" face
="verdana"><b>International experiences with health claims    in food labeling</
b></font></p>     ^cY#a12v22n6.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000300071704002200074002001300096#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a12v22n6.htm#S#p#10#6#article#85#<p>&nbsp;</p>     ^cY
#a12v22n6.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000300071704002200074002001300096#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a12v22n6.htm#S#p#11#7#article#85#<p>&nbsp;</p>     ^cY
#a12v22n6.htm##
00397000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000300071704016400074002001300238#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a12v22n6.htm#S#p#12#8#article#85#<p><font size="2" fac
e="Verdana"><b>Janine Giuberti Coutinho<sup>I, </sup><a href="#end"><sup>*</sup>
</a>;    Elisabetta Recine<SUP>II</sup></b></font></p>     ^cY#a12v22n6.htm##
00571000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000300071704033800074002001300412#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a12v22n6.htm#S#p#13#9#article#85#<p><font size="2" fac
e="Verdana"><SUP>I</sup>Minist&eacute;rio da Sa&uacute;de,    Coordena&ccedil;&a
tilde;o Geral da Pol&iacute;tica de Alimenta&ccedil;&atilde;o    e Nutri&ccedil;
&atilde;o, e Universidade de Bras&iacute;lia (UnB), Observat&oacute;rio    de Po
l&iacute;ticas de Seguran&ccedil;a Alimentar e Nutri&ccedil;&atilde;o    ^cY#a12
v22n6.htm##
00574000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704034000075002001300415#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a12v22n6.htm#S#p#14#10#article#85#<br>   <SUP>II</sup>
Universidade de Bras&iacute;lia    (UnB), Faculdade de Ci&ecirc;ncias da Sa&uacu
te;de, Depto de Nutri&ccedil;&atilde;o,    e Observat&oacute;rio de Pol&iacute;t
icas de Seguran&ccedil;a Alimentar e Nutri&ccedil;&atilde;o;    A&ccedil;&atilde
;o Brasileira pela Nutri&ccedil;&atilde;o e Direitos Humanos</font></p>     ^cY#
a12v22n6.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a12v22n6.htm#S#p#15#11#article#85#<p>&nbsp;</p>     ^c
Y#a12v22n6.htm##
00278000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704004400075002001300119#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a12v22n6.htm#S#p#16#12#article#85#<p>&nbsp;</p> <hr si
ze="1" noshade>     ^cY#a12v22n6.htm##
00463000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704022900075002001300304#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a12v22n6.htm#S#p#17#13#article#85#<p><font size="2" fa
ce="Verdana"><b>Palavras-chave: </b>Alega&ccedil;&atilde;o    de propriedades fu
ncionais, legisla&ccedil;&atilde;o sobre alimentos, rotulagem    de alimentos, B
rasil.</font> </p> <hr size="1" noshade>     ^cY#a12v22n6.htm##
00302000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704006800075002001300143#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a12v22n6.htm#S#p#18#14#article#85#<p><font size="2" fa
ce="Verdana"><b>SYNOPSIS</b></font></p>     ^cY#a12v22n6.htm##
01429000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704119500075002001301270#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a12v22n6.htm#S#p#19#15#article#85#<p><font size="2" fa
ce="Verdana">With ever-increasing frequency, consumers are    seeking informatio
n on the foods they eat. Food labels are an important source    of this type of 
information, and the Codex Alimentarius, created by the World    Health Organiza
tion and the Food and Agriculture Organization of the United    Nations, provide
s a global reference for coordinated food quality and identification    standard
s. The Codex Alimentarius agenda includes nutritional information and    "health
 claims," which are defined as any representation that states,    suggests, or i
mplies that a relationship exists between a food or a constituent    of that foo
d and health. Although food labeling seems to effectively assist    consumers in
 choosing among processed foods, consumers are not always capable    of reading 
or interpreting nutritional information correctly, so health claims    may allow
 for more precise decision-making for these products. The present paper    exami
nes the use of health claims in countries and regions that have already    imple
mented this type of regulation (Brazil, Chile, Canada, United States of    Ameri
ca, the European Union, and Japan).</font></p>     ^cY#a12v22n6.htm##
00389000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704015500075002001300230#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a12v22n6.htm#S#p#20#16#article#85#<p><font size="2" fa
ce="Verdana"><B>Key words:</b> functional claim; legislation,    food; food labe
ling, Brazil.</font></p> <hr size="1" noshade>     ^cY#a12v22n6.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a12v22n6.htm#S#p#21#17#article#85#<p>&nbsp;</p>     ^c
Y#a12v22n6.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a12v22n6.htm#S#p#22#18#article#85#<p>&nbsp;</p>     ^c
Y#a12v22n6.htm##
01693000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704145900075002001301534#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a12v22n6.htm#S#p#23#19#article#85#<p><font size="2" fa
ce="Verdana">Os consumidores no mundo inteiro procuram, cada    vez mais, inform
a&ccedil;&otilde;es sobre os alimentos que consomem. Uma fonte    importante par
a obter esse tipo de informa&ccedil;&atilde;o s&atilde;o os r&oacute;tulos    do
s alimentos, que, muitas vezes, disp&otilde;em de dados sobre o conte&uacute;do 
   nutricional, bem com frases que relacionam o seu consumo com benef&iacute;cio
s    para a sa&uacute;de. A disponibiliza&ccedil;&atilde;o de informa&ccedil;&ot
ilde;es    adequadas e compreens&iacute;veis sobre o conte&uacute;do nutricional
, que n&atilde;o    levem o consumidor a erro, pode contribuir para a promo&cced
il;&atilde;o da    sa&uacute;de e a redu&ccedil;&atilde;o do risco de doen&ccedi
l;as relacionadas    &agrave; alimenta&ccedil;&atilde;o e &agrave; nutri&ccedil;
&atilde;o, conforme    descreve a Estrat&eacute;gia Global em Alimenta&ccedil;&a
tilde;o Saud&aacute;vel,    Atividade F&iacute;sica e Sa&uacute;de aprovada na 5
7ª Assembl&eacute;ia    da Organiza&ccedil;&atilde;o Mundial da Sa&uacute;de (OM
S), em 22 de maio de    2004 (1, 2). Cento e quatro pa&iacute;ses membros da OMS
, inclusive o Brasil,    foram signat&aacute;rios dessa estrat&eacute;gia. Algun
s desses pa&iacute;ses    possuem legisla&ccedil;&otilde;es que prev&ecirc;em a 
rotulagem nutricional    obrigat&oacute;ria, bem como normatizam outros aspectos
 acerca da comercializa&ccedil;&atilde;o    dos alimentos. </font></p>     ^cY#a
12v22n6.htm##
01330000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704109600075002001301171#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a12v22n6.htm#S#p#24#20#article#85#<p><font size="2" fa
ce="Verdana">Uma refer&ecirc;ncia mundial    para a harmoniza&ccedil;&atilde;o d
os padr&otilde;es de qualidade e identidade    de alimentos &eacute; o Codex Ali
mentarius, criado em 1963 ap&oacute;s aprova&ccedil;&atilde;o    na Confer&ecirc
;ncia da Organiza&ccedil;&atilde;o das Na&ccedil;&otilde;es Unidas    para a Ali
menta&ccedil;&atilde;o e a Agricultura (<I>Food and Agriculture Organization,   
 </I>FAO) e na Assembl&eacute;ia Mundial de Sa&uacute;de (3). O grande objetivo 
   do Codex Alimentarius &eacute; proteger a sa&uacute;de do consumidor e encora
jar    pr&aacute;ticas justas no mercado internacional. Esse organismo internaci
onal    tamb&eacute;m coordena todos os trabalhos sobre padr&otilde;es de alimen
tos    realizados por organiza&ccedil;&otilde;es governamentais e n&atilde;o gov
ernamentais    internacionais. Embora a Organiza&ccedil;&atilde;o Mundial do Com
&eacute;rcio    reconhe&ccedil;a o Codex como refer&ecirc;ncia internacional par
a o mercado,    a sua implementa&ccedil;&atilde;o nos pa&iacute;ses &eacute; vol
unt&aacute;ria. </font></p>     ^cY#a12v22n6.htm##
01252000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704101800075002001301093#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a12v22n6.htm#S#p#25#21#article#85#<p><font size="2" fa
ce="Verdana">Entre as agendas do Codex est&atilde;o    a rotulagem nutricional e
 as alega&ccedil;&otilde;es de sa&uacute;de, estas    definidas como uma represe
nta&ccedil;&atilde;o que sugira ou implique que o    alimento apresenta determin
adas caracter&iacute;sticas relativas a origem, propriedades    nutricionais, na
tureza, produ&ccedil;&atilde;o, processamento, composi&ccedil;&atilde;o    e qua
lquer outra qualidade (4). Partindo do pressuposto de que a rotulagem nutriciona
l    pode ser efetiva no processo de escolha mais adequada dos alimentos embalad
os    industrializados, mas que, entretanto, nem sempre o consumidor est&aacute;
 apto    a ler e interpretar as informa&ccedil;&otilde;es nutricionais, as alega
&ccedil;&otilde;es    de sa&uacute;de, quando apropriadas, podem contribuir para
 informar o consumidor,    j&aacute; que muitas vezes s&atilde;o mensagens diret
as e orientam com maior    precis&atilde;o a escolha de determinados produtos pe
los consumidores. </font></p>     ^cY#a12v22n6.htm##
01351000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704111700075002001301192#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a12v22n6.htm#S#p#26#22#article#85#<p><font size="2" fa
ce="Verdana">No que diz respeito &agrave;s    alega&ccedil;&otilde;es de sa&uacu
te;de, o Codex Alimentarius estabelece que    estas somente devem ser permitidas
 se forem consistentes com as pol&iacute;ticas    de sa&uacute;de nacionais, bas
eadas em evid&ecirc;ncias cient&iacute;ficas,    e que devem ser feitas no conte
xto da dieta global. Ainda, estabelece que tais    alega&ccedil;&otilde;es n&ati
lde;o podem sugerir que o alimento previne doen&ccedil;as    e, principalmente, 
que elas n&atilde;o podem encorajar pr&aacute;ticas alimentares    n&atilde;o sa
ud&aacute;veis (5). De acordo com o Codex, o termo "alega&ccedil;&atilde;o    de
 sa&uacute;de" significa qualquer representa&ccedil;&atilde;o que faz,    sugere
 ou implica uma rela&ccedil;&atilde;o entre o alimento ou um componente    do al
imento e a sa&uacute;de. Essa defini&ccedil;&atilde;o engloba tr&ecirc;s    cate
gorias: alega&ccedil;&atilde;o de fun&ccedil;&atilde;o de nutriente, alega&ccedi
l;&atilde;o    de fun&ccedil;&atilde;o aumentada e alega&ccedil;&atilde;o de ris
co reduzido    de doen&ccedil;as (6).</font></p>     ^cY#a12v22n6.htm##
01298000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704106400075002001301139#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a12v22n6.htm#S#p#27#23#article#85#<p><font size="2" fa
ce="Verdana">A alega&ccedil;&atilde;o de fun&ccedil;&atilde;o    de nutriente de
screve o papel fisiol&oacute;gico do nutriente no crescimento    e desenvolvimen
to das fun&ccedil;&otilde;es normais do organismo, por exemplo,    "o c&aacute;l
cio ajuda no desenvolvimento de ossos e dentes fortes".    A alega&ccedil;&atild
e;o de fun&ccedil;&atilde;o aumentada relaciona os benef&iacute;cios    espec&ia
cute;ficos do consumo de alimentos e de seus constituintes a fun&ccedil;&otilde;
es    fisiol&oacute;gicas ou a atividades biol&oacute;gicas, como por exemplo, "
certos    oligossacar&iacute;deos n&atilde;o digeridos melhoram o crescimento de
 bact&eacute;rias    espec&iacute;ficas da flora intestinal". Por sua vez, a ale
ga&ccedil;&atilde;o    de risco reduzido de doen&ccedil;as relaciona o consumo d
e determinado alimento    &agrave; redu&ccedil;&atilde;o do risco de desenvolvim
ento de algumas doen&ccedil;as,    por exemplo, o "ferro pode ajudar a reduzir o
 risco de anemia. Este alimento    &eacute; rico em ferro" (7). </font></p>     
^cY#a12v22n6.htm##
01793000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704155900075002001301634#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a12v22n6.htm#S#p#28#24#article#85#<p><font size="2" fa
ce="Verdana">Os pa&iacute;ses apresentam diferentes    abordagens na regula&cced
il;&atilde;o das alega&ccedil;&otilde;es de sa&uacute;de.    Uma extensa revis&a
tilde;o realizada por Hawkes (5) revelou que, entre 74 pa&iacute;ses    estudado
s, a maioria (35 pa&iacute;ses) n&atilde;o apresentava regula&ccedil;&atilde;o  
  espec&iacute;fica para as alega&ccedil;&otilde;es de sa&uacute;de. Trinta pa&i
acute;ses    n&atilde;o permitem que se declare no r&oacute;tulo qualquer rela&c
cedil;&atilde;o    direta entre o consumo de um alimento ou componente e uma doe
n&ccedil;a. Somente    sete pa&iacute;ses permitem alega&ccedil;&otilde;es espec
&iacute;ficas de redu&ccedil;&atilde;o    de risco ou alega&ccedil;&otilde;es de
 sa&uacute;de espec&iacute;ficas, e tr&ecirc;s    pa&iacute;ses determinam alega
&ccedil;&otilde;es de sa&uacute;de espec&iacute;ficas    relacionadas a determin
ados produtos (5). Nessas duas &uacute;ltimas modalidades,    as rela&ccedil;&ot
ilde;es entre o alimento ou componente do alimento e a redu&ccedil;&atilde;o    
do risco de doen&ccedil;as j&aacute; est&atilde;o estabelecidas, de acordo com  
  evid&ecirc;ncias cient&iacute;ficas endossadas nacionalmente. Alguns pa&iacute
;ses    classificam esse tipo de alega&ccedil;&atilde;o como gen&eacute;rica ou 
horizontal    (7). E, por &uacute;ltimo, um grande n&uacute;mero de pa&iacute;se
s (23 pa&iacute;ses)    permite alega&ccedil;&otilde;es de fun&ccedil;&atilde;o 
de nutriente ou outras    alega&ccedil;&otilde;es de fun&ccedil;&atilde;o (5). <
/font></p>     ^cY#a12v22n6.htm##
00762000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704052800075002001300603#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a12v22n6.htm#S#p#29#25#article#85#<p><font size="2" fa
ce="Verdana">Este artigo destaca a experi&ecirc;ncia    de alguns pa&iacute;ses 
frente &agrave; ado&ccedil;&atilde;o das alega&ccedil;&otilde;es    de sa&uacute
;de em r&oacute;tulos de alimentos embalados. A sele&ccedil;&atilde;o    dos pa&
iacute;ses descritos a seguir visou a tra&ccedil;ar um panorama das medidas    q
ue os pa&iacute;ses adotam, bem como dar visibilidade aos pa&iacute;ses que    s
e destacam na regulamenta&ccedil;&atilde;o das alega&ccedil;&otilde;es de sa&uac
ute;de. </font></p>     ^cY#a12v22n6.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a12v22n6.htm#S#p#30#26#article#85#<p>&nbsp;</p>     ^c
Y#a12v22n6.htm##
00300000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704006600075002001300141#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a12v22n6.htm#S#p#31#27#article#85#<p><font size="3" fa
ce="verdana"><b>BRASIL</b></font></p>     ^cY#a12v22n6.htm##
00573000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704033900075002001300414#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a12v22n6.htm#S#p#32#28#article#85#<p><font size="2" fa
ce="Verdana">No Brasil, todas as informa&ccedil;&otilde;es    presentes nos r&oa
cute;tulos de alimentos s&atilde;o regulamentadas pela Ag&ecirc;ncia    Nacional
 de Vigil&acirc;ncia Sanit&aacute;ria (ANVISA), que &eacute; uma autarquia    es
pecial do Minist&eacute;rio da Sa&uacute;de do Brasil (8). </font></p>     ^cY#a
12v22n6.htm##
02020000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704178600075002001301861#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a12v22n6.htm#S#p#33#29#article#85#<p><font size="2" fa
ce="Verdana">Levando em conta o papel da alimenta&ccedil;&atilde;o    na promo&c
cedil;&atilde;o da sa&uacute;de, a necessidade de avaliar a seguran&ccedil;a    
e analisar o risco com base em crit&eacute;rios cient&iacute;ficos, a freq&uuml;
&ecirc;ncia    com que o consumidor &eacute; confundido com alega&ccedil;&otilde
;es n&atilde;o    demonstradas cientificamente nos r&oacute;tulos e a tend&ecirc
;ncia do Codex    Alimentarius de disciplinar as alega&ccedil;&otilde;es sobre a
s propriedades    funcionais dos alimentos ou de seus componentes, a ANVISA regu
lamenta os alimentos    com alega&ccedil;&otilde;es de propriedades funcionais o
u de sa&uacute;de (9).    Para avaliar de forma cont&iacute;nua e din&acirc;mica
 os produtos alimentares    com alega&ccedil;&otilde;es de sa&uacute;de, a ANVIS
A conta com a Comiss&atilde;o    de Assessoramento T&eacute;cnico-Cient&iacute;f
ico em Alimentos Funcionais e    Novos Alimentos (CTCAF). A constitui&ccedil;&at
ilde;o dessa Comiss&atilde;o    foi a primeira medida adotada para avaliar a seg
uran&ccedil;a do uso e a efic&aacute;cia    das alega&ccedil;&otilde;es proposta
s para constar na rotulagem. A CTCAF se    baseia em uma s&eacute;rie de princ&i
acute;pios, com destaque para as evid&ecirc;ncias    cient&iacute;ficas da alega
&ccedil;&atilde;o, a avalia&ccedil;&atilde;o caso    a caso com base em conhecim
entos cient&iacute;ficos atuais e o grau de conson&acirc;ncia    entre a alega&c
cedil;&atilde;o e as pol&iacute;ticas Nacional de Alimenta&ccedil;&atilde;o    e
 Nutri&ccedil;&atilde;o e de Promo&ccedil;&atilde;o da Sa&uacute;de do Minist&ea
cute;rio    da Sa&uacute;de. Todas as decis&otilde;es tomadas podem ser reavalia
das com    base em novas evid&ecirc;ncias cient&iacute;ficas (9). </font></p>   
  ^cY#a12v22n6.htm##
01876000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704164200075002001301717#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a12v22n6.htm#S#p#34#30#article#85#<p><font size="2" fa
ce="Verdana">De acordo com a legisla&ccedil;&atilde;o vigente,    as alega&ccedi
l;&otilde;es s&atilde;o permitidas, em car&aacute;ter opcional,    desde que o a
limento que alegar propriedades funcionais ou de sa&uacute;de al&eacute;m    das
 fun&ccedil;&otilde;es nutricionais b&aacute;sicas produza efeitos metab&oacute;
licos,    fisiol&oacute;gicos ou ben&eacute;ficos &agrave; sa&uacute;de comprova
dos. Ainda,    tais alega&ccedil;&otilde;es podem fazer refer&ecirc;ncia &agrave
; manuten&ccedil;&atilde;o    geral da sa&uacute;de, ao papel fisiol&oacute;gico
 dos nutrientes e n&atilde;o    nutrientes e &agrave; redu&ccedil;&atilde;o de r
isco para doen&ccedil;as. N&atilde;o    s&atilde;o permitidas alega&ccedil;&otil
de;es de sa&uacute;de que fa&ccedil;am    refer&ecirc;ncia &agrave; cura ou &agr
ave; preven&ccedil;&atilde;o de doen&ccedil;as    (9). Todas as alega&ccedil;&ot
ilde;es de sa&uacute;de atualmente aprovadas pela    ANVISA est&atilde;o dispon&
iacute;veis no <I>site</I> <a href="http://www.anvisa.gov.br" target="_blank">ww
w.anvisa.gov.br</a>.    Um exemplo &eacute; "as fibras alimentares auxiliam o fu
ncionamento do    intestino. Seu consumo deve estar associado a uma alimenta&cce
dil;&atilde;o    equilibrada e h&aacute;bitos de vida saud&aacute;veis". &Eacute
; importante    ressaltar que cada alega&ccedil;&atilde;o aprovada pela Comiss&a
tilde;o apresenta    uma s&eacute;rie de restri&ccedil;&otilde;es relacionadas a
o produto, restri&ccedil;&otilde;es    essas que devem ser obedecidas no caso de
 as alega&ccedil;&otilde;es serem declaradas    nos r&oacute;tulos dos alimentos
. </font></p>     ^cY#a12v22n6.htm##
01016000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704078200075002001300857#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a12v22n6.htm#S#p#35#31#article#85#<p><font size="2" fa
ce="Verdana">Como pa&iacute;s membro do Mercado    Comum do Sul (Mercosul), o Br
asil deve respeitar as resolu&ccedil;&otilde;es    harmonizadas e aprovadas pelo
 Grupo Mercado Comum (GMC) (10). Os projetos de    resolu&ccedil;&atilde;o harmo
nizados s&atilde;o submetidos &agrave; consulta    p&uacute;blica previamente &a
grave; sua aprova&ccedil;&atilde;o pelo GMC, de    forma a dar transpar&ecirc;nc
ia aos assuntos negociados e a possibilitar o recebimento    de cr&iacute;ticas 
e sugest&otilde;es da sociedade, tecnicamente fundamentadas.    As resolu&ccedil
;&otilde;es Mercosul aprovadas pelo GMC devem ser incorporadas    aos ordenament
os jur&iacute;dicos nacionais por interm&eacute;dio dos organismos    competente
s de cada pa&iacute;s.</font></p>     ^cY#a12v22n6.htm##
01155000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704092100075002001300996#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a12v22n6.htm#S#p#36#32#article#85#<p><font size="2" fa
ce="Verdana">Em 1994, foi inicga&ccedil;&atilde;o    de sa&uacute;de", O Minist&
eacute;rio da Sa&uacute;de do Chile denomina    de "declara&ccedil;&atilde;o de 
propriedades saud&aacute;veis dos alimentos"    as mensagens dirigidas aos conia
do o processo de discuss&atilde;o e harmoniza&ccedil;&atilde;o    da rotulagem n
utricional obrigat&oacute;ria no Mercosul, por interesse do Brasil,    de forma 
a atender as diretrizes da Pol&iacute;tica Nacional de Alimenta&ccedil;&atilde;o
    e Nutri&ccedil;&atilde;o (10). Dentre os quatro pa&iacute;ses membros do Mer
cosul    —Argentina, Brasil, Uruguai e Paraguai—, o Brasil se destaca pela prese
n&ccedil;a    de legisla&ccedil;&atilde;o no tema. A Argentina e o Uruguai n&ati
lde;o apresentam    regula&ccedil;&atilde;o para alega&ccedil;&otilde;es de sa&u
acute;de (5). N&atilde;o    foram encontradas refer&ecirc;ncias para o Paraguai.
 </font></p>     ^cY#a12v22n6.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a12v22n6.htm#S#p#37#33#article#85#<p>&nbsp;</p>     ^c
Y#a12v22n6.htm##
00299000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704006500075002001300140#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a12v22n6.htm#S#p#38#34#article#85#<p><font size="3" fa
ce="Verdana"><b>CHILE</b></font></p>     ^cY#a12v22n6.htm##
00836000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704060200075002001300677#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a12v22n6.htm#S#p#39#35#article#85#<p><font size="2" fa
ce="Verdana">Ao inv&eacute;s de "alega&ccedil;&atilde;o    de sa&uacute;de", O M
inist&eacute;rio da Sa&uacute;de do Chile denomina    de "declara&ccedil;&atilde
;o de propriedades saud&aacute;veis dos alimentos"    as mensagens dirigidas aos
 consumidores    e que demonstram uma associa&ccedil;&atilde;o entre o alimento 
e um nutriente    e uma condi&ccedil;&atilde;o relacionada com a sa&uacute;de do
 indiv&iacute;duo    (11). A declara&ccedil;&atilde;o de propriedades saud&aacut
e;veis apresenta    o mesmo significado do termo proposto pelo Codex Alimentariu
s.</font></p>     ^cY#a12v22n6.htm##
01422000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704118800075002001301263#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a12v22n6.htm#S#p#40#36#article#85#<p><font size="2" fa
ce="Verdana">Assim, entende-se por declara&ccedil;&atilde;o    de propriedades s
aud&aacute;veis qualquer representa&ccedil;&atilde;o que afirme,    sugira ou im
plique haver uma rela&ccedil;&atilde;o entre o alimento ou produto    alimentar,
 o nutriente ou outra subst&acirc;ncia contida no alimento e uma condi&ccedil;&a
tilde;o    relacionada &agrave; sa&uacute;de. Para a determina&ccedil;&atilde;o 
dessas    mensagens, foram considerados o perfil epidemiol&oacute;gico do Chile,
 os principais    problemas de sa&uacute;de relacionados &agrave; alimenta&ccedi
l;&atilde;o e    &agrave; nutri&ccedil;&atilde;o e, ainda, os guias de alimenta&
ccedil;&atilde;o    saud&aacute;vel daquele pa&iacute;s. As associa&ccedil;&otil
de;es entre alimentos    e nutrientes e os requisitos que os alimentos devem cum
prir foram pensados e    aprovados por um grupo de conhecedores nacionais. As me
nsagens saud&aacute;veis    descritas s&atilde;o associadas a gordura total, gor
dura saturada, &aacute;cidos    graxos trans, s&oacute;dio, c&aacute;lcio, carot
eno, vitamina A, vitamina C,    &aacute;cido f&oacute;lico, ferro, colesterol e 
fibra diet&eacute;tica (11).</font></p>     ^cY#a12v22n6.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a12v22n6.htm#S#p#41#37#article#85#<p>&nbsp;</p>     ^c
Y#a12v22n6.htm##
00308000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704007400075002001300149#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a12v22n6.htm#S#p#42#38#article#85#<p><font size="3" fa
ce="Verdana"><b>ESTADOS UNIDOS</b></font></p>     ^cY#a12v22n6.htm##
01146000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704091200075002001300987#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a12v22n6.htm#S#p#43#39#article#85#<p><font size="2" fa
ce="Verdana">Nos Estados Unidos, &eacute; de responsabilidade    da Administra&c
cedil;&atilde;o de Alimentos e Medicamentos (<I>Food and Drug    Administration<
/I>, FDA), mais especificamente do Centro para a Seguran&ccedil;a    Alimentar e
 Nutri&ccedil;&atilde;o Aplicada (<I>Food Safety and Applied Nutrition</I>,    C
FSAN), regulamentar a rotulagem nutricional dos produtos aliment&iacute;cios.   
 Naquele pa&iacute;s, o conceito de alega&ccedil;&atilde;o de sa&uacute;de enfoc
a    a rela&ccedil;&atilde;o entre o alimento, um componente do alimento ou supl
emento    alimentar e a redu&ccedil;&atilde;o do risco de doen&ccedil;a ou condi
&ccedil;&atilde;o    de sa&uacute;de (12). Vai ao encontro das categorias alega&
ccedil;&atilde;o    de fun&ccedil;&atilde;o aumentada e alega&ccedil;&atilde;o d
e risco reduzido    de doen&ccedil;as propostas pelo Codex Alimentarius.</font><
/p>     ^cY#a12v22n6.htm##
01253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704101900075002001301094#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a12v22n6.htm#S#p#44#40#article#85#<p><font size="2" fa
ce="Verdana">O processo de estabelecimento    das alega&ccedil;&otilde;es de sa&
uacute;de nos Estados Unidos teve in&iacute;cio    em 1980, a partir da associa&
ccedil;&atilde;o entre uma ind&uacute;stria de    cereais matinais e o Instituto
 Nacional do C&acirc;ncer. Ambas tinham o objetivo    de aumentar o n&iacute;vel
 de conhecimento do p&uacute;blico norte-americano    em rela&ccedil;&atilde;o a
o papel de uma alimenta&ccedil;&atilde;o rica em fibras    na redu&ccedil;&atild
e;o do c&acirc;ncer. Esse fato repercutiu em um processo    de consulta p&uacute
;blica para avaliar a necessidade das alega&ccedil;&otilde;es    de sa&uacute;de
 nos alimentos (13). Tal necessidade foi fortalecida em 1989,    quando a Comiss
&atilde;o Federal de Com&eacute;rcio dos Estados Unidos concluiu    que o intere
sse dos consumidores pela rela&ccedil;&atilde;o entre a fibra alimentar    e o r
isco de c&acirc;ncer havia resultado em um aumento do consumo de alimentos    ri
cos em fibras (13).</font></p>     ^cY#a12v22n6.htm##
00753000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704051900075002001300594#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a12v22n6.htm#S#p#45#41#article#85#<p><font size="2" fa
ce="Verdana">Dessa forma, o congresso norte-americano    aprovou, em 1990, uma l
ei relativa &agrave; rotulagem de alimentos e educa&ccedil;&atilde;o    nutricio
nal (<I>Nutrition Labeling and Education Act</I>, NLEA), dando autoridade    ao 
FDA para permitir as alega&ccedil;&otilde;es de sa&uacute;de nos r&oacute;tulos 
   de alimentos. Em 1993, o FDA finalizou as regulamenta&ccedil;&otilde;es, esta
belecendo    os requerimentos para as alega&ccedil;&otilde;es de sa&uacute;de. <
/font></p>     ^cY#a12v22n6.htm##
02599000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704236500075002001302440#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a12v22n6.htm#S#p#46#42#article#85#<p><font size="2" fa
ce="Verdana">Atualmente, o CFSAN aprova 12 tipos de alega&ccedil;&otilde;es    d
e sa&uacute;de gen&eacute;ricas. Todas as informa&ccedil;&otilde;es referentes  
  &agrave;s alega&ccedil;&otilde;es s&atilde;o p&uacute;blicas e ficam dispon&ia
cute;veis    no <I>site</I> do FDA (<a href="http://www.cfsan.fda.gov/~dms/lab-s
sa.html#denial" target="_blank">http://www.cfsan.fda.gov/~dms/lab-ssa.html#denia
l</a>).    As alega&ccedil;&otilde;es de sa&uacute;de se referem &agrave; rela&c
cedil;&atilde;o    entre a ingest&atilde;o de alimentos ou nutrientes e o aument
o do risco de desenvolvimento    de algumas doen&ccedil;as. As diversas formas d
e alega&ccedil;&otilde;es de    sa&uacute;de envolvem as seguintes combina&ccedi
l;&otilde;es: 1) c&aacute;lcio    &times; osteoporose; 2) s&oacute;dio &times; h
ipertens&atilde;o; 3) gordura    diet&eacute;tica &times; c&acirc;ncer; 4) gordu
ra saturada e colesterol &times;    doen&ccedil;as do cora&ccedil;&atilde;o; 5) 
gr&atilde;os ricos em fibras, frutas    e vegetais &times; c&acirc;ncer; 6) frut
as, vegetais e produtos ricos em gr&atilde;os    que contenham fibras sol&uacute
;veis &times; doen&ccedil;as do cora&ccedil;&atilde;o;    7) frutas e vegetais &
times; c&acirc;ncer; 8) &aacute;cido f&oacute;lico &times;    doen&ccedil;as do 
tubo neural; 9) a&ccedil;&uacute;car &times; c&aacute;rie    dent&aacute;ria; 10
) fibras sol&uacute;veis de algumas fontes alimentares &times;    doen&ccedil;as
 do cora&ccedil;&atilde;o; 11) prote&iacute;na de soja &times;    doen&ccedil;as
 do cora&ccedil;&atilde;o; e 12) plantas ester&oacute;is &times;    doen&ccedil;
as do cora&ccedil;&atilde;o (14). &Eacute; importante ressaltar    que, para tod
as as combina&ccedil;&otilde;es acima descritas, h&aacute; orienta&ccedil;&otild
e;es    sobre o requerimento espec&iacute;fico de cada nutriente no produto e so
bre    como a mensagem deve vir declarada nos r&oacute;tulos de alimentos. Tamb&
eacute;m    &eacute; limitado o uso da alega&ccedil;&atilde;o para determinados 
alimentos.    Por exemplo, a alega&ccedil;&atilde;o que menciona a rela&ccedil;&
atilde;o entre    o aumento do consumo de gr&atilde;os ricos em fibras, frutas e
 vegetais e a    diminui&ccedil;&atilde;o do risco de desenvolvimento de c&acirc
;ncer &eacute;    limitado ao uso em alimentos como gr&atilde;os, frutas e veget
ais. </font></p>     ^cY#a12v22n6.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a12v22n6.htm#S#p#47#43#article#85#<p>&nbsp;</p>     ^c
Y#a12v22n6.htm##
00307000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704007300075002001300148#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a12v22n6.htm#S#p#48#44#article#85#<p><font size="3" fa
ce="Verdana"><b>CANAD&Aacute;</b></font></p>     ^cY#a12v22n6.htm##
00922000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704068800075002001300763#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a12v22n6.htm#S#p#49#45#article#85#<p><font size="2" fa
ce="Verdana">A experi&ecirc;ncia canadense iniciou-se em 1998,    quando o Insti
tuto Nacional de Nutri&ccedil;&atilde;o do governo do Canad&aacute;    conduziu 
um estudo quali-quantitativo com o objetivo de subsidiar o estabelecimento    da
s alega&ccedil;&otilde;es de sa&uacute;de gen&eacute;ricas voltadas ao contexto 
   canadense (7). Naquele ano, o Minist&eacute;rio da Sa&uacute;de do Canad&aacu
te;    publicou, ap&oacute;s 2 anos de consulta p&uacute;blica, uma pol&iacute;t
ica    que preconizava o uso de alega&ccedil;&otilde;es de sa&uacute;de e defini
a que    as alega&ccedil;&otilde;es poderiam ser espec&iacute;ficas ou gen&eacut
e;ricas.</font></p>     ^cY#a12v22n6.htm##
01769000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704153500075002001301610#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a12v22n6.htm#S#p#50#46#article#85#<p><font size="2" fa
ce="Verdana">Em junho de 2001, com o objetivo    de proporcionar, nos r&oacute;t
ulos de alimentos, mais informa&ccedil;&atilde;o    aos consumidores sobre os be
nef&iacute;cios e o papel da alimenta&ccedil;&atilde;o    em rela&ccedil;&atilde
;o ao risco de desenvolvimento de certas doen&ccedil;as,    o Minist&eacute;rio 
da Sa&uacute;de do Canad&aacute; prop&ocirc;s cinco alega&ccedil;&otilde;es    d
e sa&uacute;de gen&eacute;ricas: 1) uma alimenta&ccedil;&atilde;o saud&aacute;ve
l    contendo alimentos ricos em pot&aacute;ssio e pobre em s&oacute;dio pode di
minuir    o risco de press&atilde;o alta, um fator de risco para infarto e doen&
ccedil;as    do cora&ccedil;&atilde;o; 2) uma alimenta&ccedil;&atilde;o saud&aac
ute;vel com    quantidades adequadas de c&aacute;lcio e vitamina D, associada &a
grave; atividade    f&iacute;sica regular, ajuda a ter ossos fortes e pode reduz
ir o risco de osteoporose;    3) uma alimenta&ccedil;&atilde;o saud&aacute;vel, 
pobre em gordura saturada    e trans pode reduzir o risco de doen&ccedil;as do c
ora&ccedil;&atilde;o; 4)    uma alimenta&ccedil;&atilde;o saud&aacute;vel, rica 
em hortali&ccedil;as e frutas    variadas, pode reduzir o risco de alguns tipos 
de c&acirc;ncer; 5) n&atilde;o    promove c&aacute;rie dent&aacute;ria (15). Tai
s alega&ccedil;&otilde;es    se enquadram nas categorias alega&ccedil;&atilde;o 
de fun&ccedil;&atilde;o aumentada    e alega&ccedil;&atilde;o de risco reduzido 
de doen&ccedil;as propostas pelo    Codex Alimentarius.</font></p>     ^cY#a12v2
2n6.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a12v22n6.htm#S#p#51#47#article#85#<p>&nbsp;</p>     ^c
Y#a12v22n6.htm##
00322000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704008800075002001300163#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a12v22n6.htm#S#p#52#48#article#85#<p><font size="3" fa
ce="Verdana"><b>UNI&Atilde;O EUROP&Eacute;IA</b></font></p>     ^cY#a12v22n6.htm
##
01525000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704129100075002001301366#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a12v22n6.htm#S#p#53#49#article#85#<p><font size="2" fa
ce="Verdana">A Comiss&atilde;o Europ&eacute;ia &eacute; a    institui&ccedil;&at
ilde;o que representa e defende os interesses da Uni&atilde;o    Europ&eacute;ia
, sendo a Dire&ccedil;&atilde;o Geral para a Sa&uacute;de e Prote&ccedil;&atilde
;o    do Consumidor (DG-SANCO) o &oacute;rg&atilde;o respons&aacute;vel pela imp
lementa&ccedil;&atilde;o    das leis relativas &agrave; seguran&ccedil;a de alim
entos e produtos, aos direitos    dos consumidores e &agrave; prote&ccedil;&atil
de;o da sa&uacute;de dos indiv&iacute;duos    (16). Especialmente no que diz res
peito &agrave; regulamenta&ccedil;&atilde;o    de alimentos, o &oacute;rg&atilde
;o respons&aacute;vel no &acirc;mbito da Uni&atilde;o    Europ&eacute;ia &eacute
; a Autoridade Europ&eacute;ia para Seguran&ccedil;a    Alimentar (<I>European F
ood Safety Authority, </I>EFSA), criada em 2002, que    discute a rotulagem nutr
icional e as alega&ccedil;&otilde;es de sa&uacute;de.    De maio a junho de 2007
, a EFSA disponibilizou para consulta p&uacute;blica    eletr&ocirc;nica uma pro
posta de autoriza&ccedil;&atilde;o das alega&ccedil;&otilde;es    de sa&uacute;d
e referentes &agrave; redu&ccedil;&atilde;o do risco de doen&ccedil;as    (17). 
A proposta ainda n&atilde;o se encontra finalizada.</font></p>     ^cY#a12v22n6.
htm##
00890000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704065600075002001300731#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a12v22n6.htm#S#p#54#50#article#85#<p><font size="2" fa
ce="Verdana">H&aacute; tamb&eacute;m iniciativas nacionais    de regulamenta&cce
dil;&atilde;o das alega&ccedil;&otilde;es de sa&uacute;de.    A Su&eacute;cia la
n&ccedil;ou um programa auto-regulat&oacute;rio em 1990. Assim,    os fabricante
s de alimentos foram autorizados a utilizar alega&ccedil;&otilde;es    de sa&uac
ute;de gen&eacute;ricas, desde que essas apresentassem rela&ccedil;&otilde;es   
 estabelecidas cientificamente, como "o &aacute;cido f&oacute;lico pode    reduz
ir o risco da mulher de ter um beb&ecirc; com defeito no tubo neural. O    alime
nto X &eacute; rico em &aacute;cido f&oacute;lico" (18).</font></p>     ^cY#a12v
22n6.htm##
01132000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704089800075002001300973#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a12v22n6.htm#S#p#55#51#article#85#<p><font size="2" fa
ce="Verdana">Em 1999, o governo sueco delegou    &agrave; Administra&ccedil;&ati
lde;o Nacional de Alimentos a responsabilidade    de investigar o ponto de vista
 dos consumidores em rela&ccedil;&atilde;o &agrave;s    alega&ccedil;&otilde;es 
saud&aacute;veis e aos benef&iacute;cios que tais mensagens    poderiam trazer a
os consumidores e, ainda, de investigar as medidas necess&aacute;rias    para qu
e essas alega&ccedil;&otilde;es fossem estabelecidas para produtos espec&iacute;
ficos    (19). Atualmente, o governo sueco aceita alega&ccedil;&otilde;es saud&a
acute;veis    gen&eacute;ricas. As organiza&ccedil;&otilde;es suecas de consumid
ores s&atilde;o    favor&aacute;veis ao uso dessas alega&ccedil;&otilde;es, pois
 consideram que    os consumidores devem ter acesso correto, compreens&iacute;ve
l e relevante &agrave;s    informa&ccedil;&otilde;es (19).</font></p>     ^cY#a1
2v22n6.htm##
01858000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704162400075002001301699#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a12v22n6.htm#S#p#56#52#article#85#<p><font size="2" fa
ce="Verdana">Em 2000, o Reino Unido lan&ccedil;ou    uma iniciativa para unifica
r as alega&ccedil;&otilde;es de sa&uacute;de (<I>Joint    Health Claims Initiati
ve</I>) com o objetivo de assegurar que as alega&ccedil;&otilde;es    n&atilde;o
 confundissem os consumidores, al&eacute;m de garantir a distin&ccedil;&atilde;o
    entre as alega&ccedil;&otilde;es de sa&uacute;de e medicinais e de promover 
   a consist&ecirc;ncia no uso das alega&ccedil;&otilde;es de sa&uacute;de no Re
ino    Unido, na Europa e internacionalmente (18). Essa iniciativa aprovou seis 
alega&ccedil;&otilde;es    de sa&uacute;de gen&eacute;ricas. As alega&ccedil;&ot
ilde;es relacionam o consumo    de gordura saturada com o colesterol sang&uuml;&
iacute;neo, o consumo de alimentos    integrais com um cora&ccedil;&atilde;o sau
d&aacute;vel, o consumo de frutas    e vegetais com a diminui&ccedil;&atilde;o d
o risco de c&acirc;ncer de est&ocirc;mago,    o consumo de frutas com a diminui&
ccedil;&atilde;o do risco de c&acirc;ncer    de pulm&atilde;o, o consumo de vege
tais com a diminui&ccedil;&atilde;o do risco    de c&acirc;ncer renal e o consum
o de prote&iacute;na de soja com a diminui&ccedil;&atilde;o    do colesterol san
g&uuml;&iacute;neo. Programas semelhantes foram adotados em    outros pa&iacute;
ses da Europa, como a Fran&ccedil;a, a B&eacute;lgica, a Holanda,    a Espanha e
 a Finl&acirc;ndia. A ind&uacute;stria inicialmente mostrou boa aceita&ccedil;&a
tilde;o    a essas a&ccedil;&otilde;es, mas requisitou, em seguida, a harmoniza&
ccedil;&atilde;o    das normas vigentes nos diversos programas. </font></p>     
^cY#a12v22n6.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a12v22n6.htm#S#p#57#53#article#85#<p>&nbsp;</p>     ^c
Y#a12v22n6.htm##
00306000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704007200075002001300147#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a12v22n6.htm#S#p#58#54#article#85#<p><font size="3" fa
ce="Verdana"><b>JAP&Atilde;O</b></font></p>     ^cY#a12v22n6.htm##
01157000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704092300075002001300998#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a12v22n6.htm#S#p#59#55#article#85#<p><font size="2" fa
ce="Verdana">O Jap&atilde;o foi o primeiro pa&iacute;s a desenvolver    alega&cc
edil;&otilde;es de sa&uacute;de (5) atrav&eacute;s de seu Minist&eacute;rio    d
a Sa&uacute;de e Bem-Estar. Naquele pa&iacute;s, as alega&ccedil;&otilde;es    d
e sa&uacute;de s&atilde;o legalizadas atrav&eacute;s da denomina&ccedil;&atilde;
o    de alimentos para uso de sa&uacute;de espec&iacute;fico (<I>Foods for Speci
fied    Health Use</I>, FOSHU). Esses s&atilde;o divididos em duas categorias: a
limentos    para uso espec&iacute;fico de sa&uacute;de e alimentos com alega&cce
dil;&otilde;es    de fun&ccedil;&atilde;o de nutriente (20). Os FOSHU s&atilde;o
 idealizados para    usos espec&iacute;ficos como a melhora das condi&ccedil;&ot
ilde;es gastrintestinais,    a redu&ccedil;&atilde;o dos n&iacute;veis de colest
erol, press&atilde;o arterial    e glicose sang&uuml;&iacute;nea, entre outros (
5).</font></p>     ^cY#a12v22n6.htm##
01084000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704085000075002001300925#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a12v22n6.htm#S#p#60#56#article#85#<p><font size="2" fa
ce="Verdana">A maioria das descri&ccedil;&otilde;es    de alimentos para uso esp
ec&iacute;fico &eacute; semelhante &agrave; categoria    de alega&ccedil;&atilde
;o de fun&ccedil;&atilde;o do Codex Alimentarius.    Atualmente, h&aacute; 251 i
tens aprovados na categoria de uso espec&iacute;fico.    Apesar de essas descri&
ccedil;&otilde;es serem permitidas para mencionar um    efeito ben&eacute;fico e
m um est&aacute;gio preliminar de uma doen&ccedil;a    ou estado de sa&uacute;de
, a descri&ccedil;&atilde;o que relaciona o alimento    &agrave; doen&ccedil;a n
&atilde;o &eacute; permitida. A categoria com alega&ccedil;&atilde;o    de fun&c
cedil;&atilde;o de nutriente no Jap&atilde;o &eacute; semelhante &agrave;    ale
ga&ccedil;&atilde;o de fun&ccedil;&atilde;o de nutriente aprovada pelo Codex em 
1997 (20).</font></p>     ^cY#a12v22n6.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a12v22n6.htm#S#p#61#57#article#85#<p>&nbsp;</p>     ^c
Y#a12v22n6.htm##
00311000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704007700075002001300152#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a12v22n6.htm#S#p#62#58#article#85#<p><font size="3" fa
ce="Verdana"><b>CONCLUS&Otilde;ES</b></font></p>     ^cY#a12v22n6.htm##
01353000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704111900075002001301194#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a12v22n6.htm#S#p#63#59#article#85#<p><font size="2" fa
ce="Verdana">A ocorr&ecirc;ncia global de doen&ccedil;as relacionadas    ao aume
nto do consumo de gorduras saturadas e hidrogenadas e &agrave; substitui&ccedil;
&atilde;o    do consumo de frutas e hortali&ccedil;as por alimentos energeticame
nte densos    e pobres em nutrientes justifica a preocupa&ccedil;&atilde;o, tant
o da popula&ccedil;&atilde;o    em risco, quanto dos &oacute;rg&atilde;os que vi
sam &agrave; prote&ccedil;&atilde;o    da sa&uacute;de do consumidor, quanto ao 
tipo de informa&ccedil;&atilde;o disponibilizada    nos r&oacute;tulos de alimen
tos. Nesse contexto, a OMS elaborou a Estrat&eacute;gia    Global para a Promo&c
cedil;&atilde;o da Alimenta&ccedil;&atilde;o, Atividade    F&iacute;sica e Sa&ua
cute;de, que contempla recomenda&ccedil;&otilde;es concretas    para a promo&cce
dil;&atilde;o da alimenta&ccedil;&atilde;o saud&aacute;vel.    Entre essas recom
enda&ccedil;&otilde;es inclui-se a elabora&ccedil;&atilde;o    de mensagens cons
istentes, coerentes, simples e populares que possam facilitar    escolhas mais s
aud&aacute;veis pelos consumidores (2).</font></p>     ^cY#a12v22n6.htm##
01024000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704079000075002001300865#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a12v22n6.htm#S#p#64#60#article#85#<p><font size="2" fa
ce="Verdana">Pouco ainda se entende sobre o papel das alega&ccedil;&otilde;es   
 de sa&uacute;de, mensagens diretas que orientam a escolha de determinados produ
tos,    na educa&ccedil;&atilde;o alimentar e nutricional, escolha alimentar e, 
principalmente    na alimenta&ccedil;&atilde;o saud&aacute;vel. As alega&ccedil;
&otilde;es de    sa&uacute;de podem, por vezes, ser prejudiciais, por exemplo, s
e n&atilde;o    estiverem contextualizadas em rela&ccedil;&atilde;o &agrave; ali
menta&ccedil;&atilde;o    como um todo. Entretanto, se forem coerentes com as po
l&iacute;ticas de sa&uacute;de    e nutri&ccedil;&atilde;o dos pa&iacute;ses, &e
acute; prov&aacute;vel que essas    alega&ccedil;&otilde;es sirvam para proteger
 a sa&uacute;de do consumidor.</font></p>     ^cY#a12v22n6.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a12v22n6.htm#S#p#65#61#article#85#<p>&nbsp;</p>     ^c
Y#a12v22n6.htm##
00311000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704007700075002001300152#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a12v22n6.htm#S#p#66#62#article#85#<p><font size="3" fa
ce="Verdana"><b>REFER&Ecirc;NCIAS</b></font></p>     ^cY#a12v22n6.htm##
00535000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000200075704028700077002001300364#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a12v22n6.htm#S#p#67#63#article#85#1#<p><fo
nt size="2" face="Verdana">1. World Health Organization/Food and Agriculture    
Organization. Diet, nutrition and the prevention of chronic diseases. Report    
of a joint WHO/FAO expert consultation. Genebra: WHO/FAO; 2003. (WHO Technical  
  Report Series 916).</font></p>     ^cY#a12v22n6.htm##
00699000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000200075704045100077002001300528#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a12v22n6.htm#S#p#68#64#article#85#2#<p><fo
nt size="2" face="Verdana">2. World Health Organization. Integrated prevention  
  of noncommunicable diseases. Global Strategy on Diet, Physical Activity and   
 Health &#91;site da Internet&#93;. Dispon&iacute;vel em: <a href="http://www.wh
o.int/dietphysicalactivity/strategy/eb11344/en/index.html" target="_blank">http:
//www.who.int/dietphysicalactivity/strategy/eb11344/en/index.html</a>    . Acess
ado em novembro de 2007. </font></p>     ^cY#a12v22n6.htm##
00636000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000200075704038800077002001300465#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a12v22n6.htm#S#p#69#65#article#85#3#<p><fo
nt size="2" face="Verdana">3. Food and Agriculture Organization of The    United
 Nations/World Health Organization. Understanding the codex alimentarius    &#91
;site da Internet&#93;. Dispon&iacute;vel em: <a href="http://www.fao.org/docrep
/w9114e/W9114e00.htm" target="_blank">http://www.fao.org/docrep/w9114e/W9114e00.
htm</a>.    Acessado em novembro de 2007. </font></p>     ^cY#a12v22n6.htm##
00645000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000200075704039700077002001300474#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a12v22n6.htm#S#p#70#66#article#85#4#<p><fo
nt size="2" face="Verdana">4. Food and Agriculture Organization of The    United
 Nations/World Health Organization &#91;site da Internet&#93;. Codex general gui
delines    on claims. Dispon&iacute;vel em: <a href="ftp://ftp.fao.org/codex/sta
ndard/en/CXG_001e.pdf" target="_blank">ftp://ftp.fao.org/codex/standard/en/CXG_0
01e.pdf</a>.    Acessado em 16 de janeiro de 2004. </font></p>     ^cY#a12v22n6.
htm##
00407000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000200075704015900077002001300236#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a12v22n6.htm#S#p#71#67#article#85#5#<p><fo
nt size="2" face="Verdana">5. Hawkes C. Nutrition    labels and health claims: t
he global regulatory environment. Genebra: WHO; 2004.</font></p>     ^cY#a12v22n
6.htm##
00654000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000200075704040600077002001300483#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a12v22n6.htm#S#p#72#68#article#85#6#<p><fo
nt size="2" face="Verdana">6. Food and Agriculture Organization of The    United
 Nations/World Health Organization. Guidelines for use of nutrition claims.    D
ispon&iacute;vel em: <a href="http://www.codexalimentarius.net/download/standard
s/351/CXG_023e.pdf" target="_blank">www.codexalimentarius.net/download/standards
/351/CXG_023e.pdf</a>.    Acessado em 16 de janeiro de 2004.</font></p>     ^cY#
a12v22n6.htm##
00730000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000200075704048200077002001300559#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a12v22n6.htm#S#p#73#69#article#85#7#<p><fo
nt size="2" face="Verdana">7. Health Canada, Health Protection Branch.    Consul
tation document. Standards of evidence for evaluating foods with health    claim
s: a proposed framework. Dispon&iacute;vel em <a href="http://www.hc-sc.gc.ca/fn
-an/alt_formats/hpfbdgpsa/pdf/label-etiquet/consultation_doc_e.pdf" target="_bla
nk">http://www.hc-sc.gc.ca/fn-an/alt_formats/hpfbdgpsa/pdf/label-etiquet/consult
ation_doc_e.pdf</a>.    Acessado em 20 de abril de 2002.</font></p>     ^cY#a12v
22n6.htm##
00690000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000200075704044200077002001300519#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a12v22n6.htm#S#p#74#70#article#85#8#<p><fo
nt size="2" face="Verdana">8. Brasil, Minist&eacute;rio    da Sa&uacute;de, Ag&e
circ;ncia Nacional de Vigil&acirc;ncia Sanit&aacute;ria.    Lei 9 782, de 26 de 
Janeiro de 1999. Define o Sistema Nacional de Vigil&acirc;ncia    Sanit&aacute;r
ia, cria a Ag&ecirc;ncia Nacional de Vigil&acirc;ncia Sanit&aacute;ria,    e d&a
acute; outras provid&ecirc;ncias. Di&aacute;rio Oficial da Uni&atilde;o    1999.
 27 de Janeiro. </font></p>     ^cY#a12v22n6.htm##
00723000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000200075704047500077002001300552#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a12v22n6.htm#S#p#75#71#article#85#9#<p><fo
nt size="2" face="Verdana">9. Brasil, Minist&eacute;rio    da Sa&uacute;de, Ag&e
circ;ncia Nacional de Vigil&acirc;ncia Sanit&aacute;ria.    Resolu&ccedil;&atild
e;o RDC 18 de 30 de Abril de 1999. Diretrizes b&aacute;sicas    para a an&aacute
;lise e comprova&ccedil;&atilde;o de propriedades funcionais    e/ou de sa&uacut
e;de alegadas em rotulagem de alimentos. Di&aacute;rio Oficial    da Uni&atilde;
o 1999. 3 de maio:se&ccedil;&atilde;o 1 (pt 11). </font></p>     ^cY#a12v22n6.ht
m##
00537000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000300075704028800078002001300366#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a12v22n6.htm#S#p#76#72#article#85#10#<p><f
ont size="2" face="Verdana">10. Mercado Comum do Sul. Sobre o Mercosul &#91;site
    da Internet&#93;. Dispon&iacute;vel em: <a href="http://www.mercosul.gov.br/
documentos" target="_blank">http://www.mercosul.gov.br/documentos</a>.    Acessa
do em novembro de 2007.</font></p>     ^cY#a12v22n6.htm##
00424000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000300075704017500078002001300253#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a12v22n6.htm#S#p#77#73#article#85#11#<p><f
ont size="2" face="Verdana">11. Araya HL, Vera G, Zacarias I, Castillo C.    Eti
quetado nutricional de los alimentos. Rev Chil Nutr. 1996;24(1):83–91.</font></p
>     ^cY#a12v22n6.htm##
00708000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000300075704045900078002001300537#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a12v22n6.htm#S#p#78#74#article#85#12#<p><f
ont size="2" face="Verdana">12. Food and Drug Administration, Department    of H
ealth and Human Services, Center for Food Safety and Applied Nutrition.    Claim
s that can be made for conventional foods and dietary supplements &#91;site    d
a Internet&#93;. Dispon&iacute;vel em: <a href="http://www.cfsan.fda.gov/~dms/hc
laims.html" target="_blank">http://www.cfsan.fda.gov/~dms/hclaims.html</a>.    A
cessado em 23 de setembro de 2003.</font></p>     ^cY#a12v22n6.htm##
00451000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000300075704020200078002001300280#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a12v22n6.htm#S#p#79#75#article#85#13#<p><f
ont size="2" face="Verdana">13. Ippolito P, Mathios A.    Health claims in adver
tising and labeling: a study of the cereal market. Washington:    Federal Trade 
Commission; 1989.</font></p>     ^cY#a12v22n6.htm##
00654000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000300075704040500078002001300483#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a12v22n6.htm#S#p#80#76#article#85#14#<p><f
ont size="2" face="Verdana">14. Food and Drug Administration, Center for    Food
 Safety and Applied Nutrition. Health claims that meet significant scientific   
 agreement &#91;site da Internet&#93;. Dispon&iacute;vel em: <a href="http://www
.cfsan.fda.gov/~dms/lab-ssa.html#regs" target="_blank">http://www.cfsan.fda.gov/
~dms/lab-ssa.html#regs</a>.    Acessado em novembro de 2007.</font></p>     ^cY#
a12v22n6.htm##
00454000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000300075704020500078002001300283#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a12v22n6.htm#S#p#81#77#article#85#15#<p><f
ont size="2" face="Verdana">15. Gorman D. Health Canada's    regulatory initiati
ve regarding foods with health claims &#91;editorial&#93;. Can J    Public Healt
h. 2002;93(5):325–6.</font></p>     ^cY#a12v22n6.htm##
00513000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000300075704026400078002001300342#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a12v22n6.htm#S#p#82#78#article#85#16#<p><f
ont size="2" face="Verdana">16. Hill and Knowlton. Study    on nutritional, heal
th and ethical claims in the European Union for the European    Commission direc
torate general for health and consumer protection. Bruxelas:    DGSanCo; 2000. <
/font></p>     ^cY#a12v22n6.htm##
00858000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000300075704060900078002001300687#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a12v22n6.htm#S#p#83#79#article#85#17#<p><f
ont size="2" face="Verdana">17. European Food Safety Authority. Public consultat
ion    on the draft Opinion of the Scientific Panel on Dietetic Products, Nutrit
ion    and Allergies on the scientific and technical guidance for the preparatio
n and    presentation of the application for authorisation of a health claim &#9
1;site da    Internet&#93;. Dispon&iacute;vel em: <a href="http://www.efsa.europ
a.eu/EFSA/efsa_locale-1178620753812_1178624363361.htm" target="_blank">http://ww
w.efsa.europa.eu/EFSA/efsa_    locale-1178620753812_1178624363361.htm</a>. Acess
ado em novembro de 2007.</font></p>     ^cY#a12v22n6.htm##
00428000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000300075704017900078002001300257#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a12v22n6.htm#S#p#84#80#article#85#18#<p><f
ont size="2" face="Verdana">18. Hurt E. International    guidelines and experien
ces on health claims in Europe. Asia Pac J Clin Nutr.    2002;11(2):S90–3.</font
></p>     ^cY#a12v22n6.htm##
00465000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000300075704021600078002001300294#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a12v22n6.htm#S#p#85#81#article#85#19#<p><f
ont size="2" face="Verdana">19. National Food Administration.    Investigation o
n health claims about foods. Uppsala, Su&eacute;cia: National    Food Administra
tion; 2000. (Technical Report).</font></p>     ^cY#a12v22n6.htm##
00426000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000300075704017700078002001300255#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a12v22n6.htm#S#p#86#82#article#85#20#<p><f
ont size="2" face="Verdana">20. Shimiziu T. Newly established regulation    in J
apan: foods with health claims. Asia Pac J Clin Nutr. 2002;11(2): S94–6.</font><
/p>     ^cY#a12v22n6.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a12v22n6.htm#S#p#87#83#article#85#<p>&nbsp;</p>     ^c
Y#a12v22n6.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a12v22n6.htm#S#p#88#84#article#85#<p>&nbsp;</p>     ^c
Y#a12v22n6.htm##
00503000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704026900075002001300344#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a12v22n6.htm#S#p#89#85#article#85#<p><font size="2" fa
ce="Verdana"><a name="end"></a><a href="#tx">*</a> Correspond&ecirc;ncia:    SMP
W, quadra 25, conjunto 04, casa 01, CEP 71745-504, Bras&iacute;lia, DF, Brasil. 
   E-mail: <a href="mailto:janinegc@yahoo.com">janinegc@yahoo.com</a></font></p>
     ^cY#a12v22n6.htm##
00604000000000277000450000400060000070200480000670500020005470600020005670000030
00587010002000617090008000637080003000711180002000740170026000760170034001020180
10600136066000800242062000400250062000400254065000900258064000500267025002800272
031000400300865000900304002001300313#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a1
2v22n6.htm#S#c#90#1#article#20#1#World Health Organization#Food and Agriculture 
Organization#Diet, nutrition and the prevention of chronic diseases: Report of a
 joint WHO/FAO expert consultation^len#Genebra#WHO#FAO#20030000#2003#WHO Technic
al Report Series#916#20071200#a12v22n6.htm##
00577000000000229000450000400060000070200480000670500020005470600020005670000030
00587010002000617090008000637080003000711180002000740170026000760180109001020610
01700211037007100228110000900299109001700308865000900325002001300334#v22n6#v:\sc
ielo\serial\rpsp\v22n6\markup\a12v22n6.htm#S#c#91#2#article#20#2#World Health Or
ganization#Integrated prevention of noncommunicable diseases: Global Strategy on
 Diet, Physical Activity and Health^len#site da Internet#http://www.who.int/diet
physicalactivity/strategy/eb11344/en/index.html#20071100#novembro de 2007#200712
00#a12v22n6.htm##
00552000000000241000450000400060000070200480000670500020005470600020005670000030
00587010002000617090008000637080003000711180002000740170056000760170026001320180
04100158061001700199037004600216110000900262109001700271865000900288002001300297
#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a12v22n6.htm#S#c#92#3#article#20#3#Foo
d and Agriculture Organization of The United Nations#World Health Organization#U
nderstanding the codex alimentarius^len#site da Internet#http://www.fao.org/docr
ep/w9114e/W9114e00.htm#20071100#novembro de 2007#20071200#a12v22n6.htm##
00558000000000241000450000400060000070200480000670500020005470600020005670000030
00587010002000617090008000637080003000711180002000740170056000760170026001320610
01700158018003900175037004900214110000900263109002200272865000900294002001300303
#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a12v22n6.htm#S#c#93#4#article#20#4#Foo
d and Agriculture Organization of The United Nations#World Health Organization#s
ite da Internet#Codex general guidelines on claims^len#ftp://ftp.fao.org/codex/s
tandard/en/CXG_001e.pdf#20040116#16 de janeiro de 2004#20071200#a12v22n6.htm##
00444000000000229000450000400060000070200480000670500020005470600020005670000030
00587010002000617090008000637080003000711180002000740160016000760180074000920660
00800166062000400174065000900178064000500187865000900192002001300201#v22n6#v:\sc
ielo\serial\rpsp\v22n6\markup\a12v22n6.htm#S#c#94#5#article#20#5#^rND^sHawkes^nC
#Nutrition labels and health claims: the global regulatory environment^len#Geneb
ra#WHO#20040000#2004#20071200#a12v22n6.htm##
00546000000000229000450000400060000070200480000670500020005470600020005670000030
00587010002000617090008000637080003000711180002000740170056000760170026001320180
04300158037006200201065000900263064002200272865000900294002001300303#v22n6#v:\sc
ielo\serial\rpsp\v22n6\markup\a12v22n6.htm#S#c#95#6#article#20#6#Food and Agricu
lture Organization of The United Nations#World Health Organization#Guidelines fo
r use of nutrition claims^len#www.codexalimentarius.net/download/standards/351/C
XG_023e.pdf#20040116#16 de janeiro de 2004#20071200#a12v22n6.htm##
00599000000000229000450000400060000070200480000670500020005470600020005670000030
00587010002000617090008000637080003000711180002000740170040000760610022001160180
08800138037009200226110000900318109002000327865000900347002001300356#v22n6#v:\sc
ielo\serial\rpsp\v22n6\markup\a12v22n6.htm#S#c#96#7#article#20#7#Health Canada^d
Health Protection Branch#Consultation document#Standards of evidence for evaluat
ing foods with health claims: a proposed framework^len#http://www.hc-sc.gc.ca/fn
-an/alt_formats/hpfbdgpsa/pdf/label-etiquet/consultation_doc_e.pdf#20020420#20 d
e abril de 2002#20071200#a12v22n6.htm##
00619000000000229000450000400060000070200480000670500020005470600020005670000030
00587010002000617090008000637080003000711180002000740110070000760120166001460300
02400312710000200336065000900338064002000347865000900367002001300376#v22n6#v:\sc
ielo\serial\rpsp\v22n6\markup\a12v22n6.htm#S#c#97#8#article#20#8#Brasil^dMinisté
rio da Saúde, Agência Nacional de Vigilância Sanitária#Lei 9 782, de 26 de Janei
ro de 1999: Define o Sistema Nacional de Vigilância Sanitária, cria a Agência Na
cional de Vigilância Sanitária, e dá outras providências^lpt#Diário Oficial da U
nião#2#19990127#1999. 27 de Janeiro#20071200#a12v22n6.htm##
00646000000000241000450000400060000070200480000670500020005470600020005670000030
00587010002000617090008000637080003000711180002000740110070000760120169001460300
02400315710000200339065000900341064001600350061001600366865000900382002001300391
#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a12v22n6.htm#S#c#98#9#article#20#9#Bra
sil^dMinistério da Saúde, Agência Nacional de Vigilância Sanitária#Resolução RDC
 18 de 30 de Abril de 1999: Diretrizes básicas para a análise e comprovação de p
ropriedades funcionais e/ou de saúde alegadas em rotulagem de alimentos^lpt#Diár
io Oficial da União#2#19990503#1999. 3 de maio#seção 1 (pt 11)#20071200#a12v22n6
.htm##
00453000000000229000450000400060000070200480000670500020005470600020005670000030
00587010003000617090008000647080003000721180003000750170021000780180021000990610
01700120037003800137065000900175064001700184865000900201002001300210#v22n6#v:\sc
ielo\serial\rpsp\v22n6\markup\a12v22n6.htm#S#c#99#10#article#20#10#Mercado Comum
 do Sul#Sobre o Mercosul^lpt#site da Internet#http://www.mercosul.gov.br/documen
tos#20071100#novembro de 2007#20071200#a12v22n6.htm##
00588000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100014000950100
01800109010001800127012004400145030001400189065000900203064000500212031000300217
032000200220014000600222865000900228002001300237035001000250801001400260#v22n6#v
:\scielo\serial\rpsp\v22n6\markup\a12v22n6.htm#S#c#100#11#article#20#11#^rND^sAr
aya^nHL#^rND^sVera^nG#^rND^sZacarias^nI#^rND^sCastillo^nC#Etiquetado nutricional
 de los alimentos^les#Rev Chil Nutr#19960000#1996#24#1#83-91#20071200#a12v22n6.h
tm#0716-1549#Rev Chil Nutr##
00636000000000253000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760170029000790170040001080170
04500148018007500193061001700268037004300285110000900328109002300337865000900360
002001300369#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a12v22n6.htm#S#c#101#12#ar
ticle#20#12#Food and Drug Administration#Department of Health and Human Services
#Center for Food Safety and Applied Nutrition#Claims that can be made for conven
tional foods and dietary supplements^len#site da Internet#http://www.cfsan.fda.g
ov/~dms/hclaims.html#20030923#23 de setembro de 2003#20071200#a12v22n6.htm##
00504000000000241000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760160018000790160017000970180
07600114066001100190062002500201065000900226064000500235865000900240002001300249
#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a12v22n6.htm#S#c#102#13#article#20#13#
^rND^sIppolito^nP#^rND^sMathios^nA#Health claims in advertising and labeling: a 
study of the cereal market^len#Washington#Federal Trade Commission#19890000#1989
#20071200#a12v22n6.htm##
00558000000000229000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760170075000790180061001540610
01700215037004800232065000900280064001700289865000900306002001300315#v22n6#v:\sc
ielo\serial\rpsp\v22n6\markup\a12v22n6.htm#S#c#103#14#article#20#14#Food and Dru
g Administration^dCenter for Food Safety and Applied Nutrition#Health claims tha
t meet significant scientific agreement^len#site da Internet#http://www.cfsan.fd
a.gov/~dms/lab-ssa.html#regs#20071100#novembro de 2007#20071200#a12v22n6.htm##
00547000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790120077000950300
02000172065000900192064000500201031000300206032000200209014000600211865000900217
002001300226035001000239801002000249#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a1
2v22n6.htm#S#c#104#15#article#20#15#^rND^sGorman^nD#Health Canada's regulatory i
nitiative regarding foods with health claims^len#Can J Public Health#20020000#20
02#93#5#325-6#20071200#a12v22n6.htm#0008-4263#Can J Public Health##
00537000000000229000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760170018000790180157000970660
00900254062000800263065000900271064000500280865000900285002001300294#v22n6#v:\sc
ielo\serial\rpsp\v22n6\markup\a12v22n6.htm#S#c#105#16#article#20#16#Hill and Kno
wlton#Study on nutritional, health and ethical claims in the European Union for 
the European Commission directorate general for health and consumer protection^l
en#Bruxelas#DGSanCo#20000000#2000#20071200#a12v22n6.htm##
00729000000000229000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760170031000790180248001100610
01700358037007600375110000900451109001700460865000900477002001300486#v22n6#v:\sc
ielo\serial\rpsp\v22n6\markup\a12v22n6.htm#S#c#106#17#article#20#17#European Foo
d Safety Authority#Public consultation on the draft Opinion of the Scientific Pa
nel on Dietetic Products, Nutrition and Allergies on the scientific and technica
l guidance for the preparation and presentation of the application for authorisa
tion of a health claim^len#site da Internet#http://www.efsa.europa.eu/EFSA/efsa_
 locale-1178620753812_1178624363361.htm#20071100#novembro de 2007#20071200#a12v2
2n6.htm##
00501000000000265000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100014000790120072000930300
02100165710000200186065000900188064000500197031000300202032000200205014000600207
865000900213002001300222#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a12v22n6.htm#S
#c#107#18#article#20#18#^rND^sHurt^nE#International guidelines and experiences o
n health claims in Europe^len#Asia Pac J Clin Nutr#2#20020000#2002#11#2#S90-3#20
071200#a12v22n6.htm##
00506000000000253000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760170029000790180047001080660
00800155067000700163062002900170065000900199064000500208061001700213865000900230
002001300239#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a12v22n6.htm#S#c#108#19#ar
ticle#20#19#National Food Administration#Investigation on health claims about fo
ods^len#Uppsala#Suécia#National Food Administration#20000000#2000#Technical Repo
rt#20071200#a12v22n6.htm##
00501000000000265000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790120068000970300
02100165710000200186065000900188064000500197031000300202032000200205014000600207
865000900213002001300222#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a12v22n6.htm#S
#c#109#20#article#20#20#^rND^sShimiziu^nT#Newly established regulation in Japan:
 foods with health claims^len#Asia Pac J Clin Nutr#2#20020000#2002#11#2#S94-6#20
071200#a12v22n6.htm##
00271000000000169000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670910009000690920007000780020013000857030
00300098#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a13v22n6.htm#S#o#1#1#text#1#20
080215#102646#a13v22n6.htm#83##
00990000000000421000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670710003000690400003000720010006000750420
00200081120000400083038000300087121000300090049000800093158000300101030002400104
03100030012803200020013106500090013301400110014203500100015312300020016301200940
01650100034002590100034002930700118003270100034004450700067004791170006005460720
00300552002001300555#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a13v22n6.htm#S#h#2
#1#text#1#le#en#br1.1#1#3.1#ND#13#RPSP100#nd#Rev Panam Salud Publica#22#6#200712
00#^f438^l440#1020-4989#1#The importance of research on the association between 
socioeconomic conditions and asthma^len#^rND^1A01^nSérgio Souza da^sCunha#^rND^1
A01^nMauricio Lima^sBarreto#Universidade Federal de Bahia^iA01^1Instituto de Saú
de Coletiva^cSalvador^sBahia^z40.110-040^pBrazil^ecunhass@ufba.br#^rND^1A02^nLau
ra Cunha^sRodrigues#London School of Hygiene and Tropical Medicine United Kingdo
m^iA02#other#24#a13v22n6.htm##
01043000000000421000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670710003000690400003000720010006000750420
00200081120000400083038000300087121000300090049000800093158000300101030002400104
03100030012803200020013106500090013301400110014203500100015312300020016301201100
01650100034002750100034003090700155003430100034004980700067005321170006005990720
00300605002001300608#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a13v22n6.htm#S#f#3
#1#text#1#le#en#br1.1#1#3.1#ND#13#RPSP100#nd#Rev Panam Salud Publica#22#6#200712
00#^f438^l440#1020-4989#1#<B> </B> <b>The importance of research on the associat
ion between socioeconomic conditions and asthma</b>^len#^rND^1A01^nSérgio Souza 
da^sCunha#^rND^1A01^nMauricio Lima^sBarreto#Universidade Federal de Bahia^iA01^1
Instituto de Saúde Coletiva^cSalvador^sBahia^z40.110-040^pBrazil^e<A HREF="mailt
o:cunhass@ufba.br">cunhass@ufba.br</A>#^rND^1A02^nLaura Cunha^sRodrigues#London 
School of Hygiene and Tropical Medicine United Kingdom^iA02#other#24#a13v22n6.ht
m##
01110000000000433000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670640013000690710003000820400003000850010
00600088042000200094120000400096121000300100049000800103158000300111030002600114
03100030014003200020014306500090014501400110015403500100016512300020017501200940
01770100034002710100034003050700120003390100034004590700069004931170006005620720
00300568002001300571008009200584#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a13v22
n6.htm#S#l#4#1#text#1#^mDec.^a2007#le#en#br1.1#1#3.1#13#RPSP100#nd#Rev. panam. s
alud pública#22#6#20071200#^f438^l440#1020-4989#1#The importance of research on 
the association between socioeconomic conditions and asthma^len#^rND^1A01^nSérgi
o Souza da^sCunha#^rND^1A01^nMauricio Lima^sBarreto#^iA01^1Universidade Federal 
de Bahia^2Instituto de Saúde Coletiva^cSalvador^sBahia^z40.110-040^pBrazil^ecunh
ass@ufba.br#^rND^1A02^nLaura Cunha^sRodrigues#^iA02^1London School of Hygiene an
d Tropical Medicine United Kingdom#other#24#a13v22n6.htm#Internet^ihttp://www.sc
ielosp.org/scielo.php?script=sci_arttext&pid=S1020-49892007001100013##
00317000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704008800070002001300158#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a13v22n6.htm#S#p#5#1#text#55#<p align="right"><font si
ze="2" face="Verdana"><b>CARTAS </b>LETTERS</font></p>     ^cY#a13v22n6.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704002200070002001300092#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a13v22n6.htm#S#p#6#2#text#55#<p>&nbsp;</p>     ^cY#a13
v22n6.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704002200070002001300092#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a13v22n6.htm#S#p#7#3#text#55#<p>&nbsp;</p>     ^cY#a13
v22n6.htm##
01107000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704087800070002001300948#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a13v22n6.htm#S#p#8#4#text#55#<p><font size="2" face="V
erdana">La Revista Panamericana de Salud P&uacute;blica/Pan    American Journal 
of Public Health<i> se complace en publicar cartas de los lectores    dirigidas 
a estimular el di&aacute;logo sobre los diversos aspectos de la salud    p&uacut
e;blica en las Am&eacute;ricas, as&iacute; como a esclarecer, discutir    o come
ntar de manera constructiva las ideas expuestas en la revista. Las cartas    deb
en estar firmadas por el autor y especificar su afiliaci&oacute;n profesional   
 y direcci&oacute;n postal o electr&oacute;nica. Cuando se trate de comentarios 
   sobre un art&iacute;culo que requieran contestaci&oacute;n del autor, se proc
urar&aacute;    conseguir esa respuesta con el fin de publicar ambas cartas. La 
redacci&oacute;n    se reserva el derecho de editar las cartas recibidas y resum
irlas para mayor    claridad.</i></font></p>     ^cY#a13v22n6.htm##
01009000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704078000070002001300850#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a13v22n6.htm#S#p#9#5#text#55#<p><font size="2" face="V
erdana">The Revista Panamericana de Salud P&uacute;blica/Pan    American Journal
 of Public Health<i> publishes letters from readers for the    purpose of stimul
ating dialogue on various aspects of public health in the Americas    and of con
structively clarifying, discussing, and critiquing the ideas expressed    throug
hout its pages. Letters should be signed by the author and include his    or her
 professional affiliation and mailing or E-mail addresses. If a commentary    on
 a given article requires a reply from the author, an effort will be made    to 
obtain the reply and to publish both letters. The editorial team reserves    the
 right to edit all letters received and to condense them so as to improve    the
ir clarity.</i></font></p>     ^cY#a13v22n6.htm##
00252000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704002200071002001300093#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a13v22n6.htm#S#p#10#6#text#55#<p>&nbsp;</p>     ^cY#a1
3v22n6.htm##
00252000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704002200071002001300093#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a13v22n6.htm#S#p#11#7#text#55#<p>&nbsp;</p>     ^cY#a1
3v22n6.htm##
00382000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704015200071002001300223#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a13v22n6.htm#S#p#12#8#text#55#<p><font size="3" face="
Verdana"><b>THE IMPORTANCE OF RESEARCH ON THE ASSOCIATION    BETWEEN SOCIOECONOM
IC CONDITIONS AND ASTHMA</b></font></p>     ^cY#a13v22n6.htm##
01718000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704148800071002001301559#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a13v22n6.htm#S#p#13#9#text#55#<p><font size="2" face="
Verdana">After your excellent issue on asthma (1), you    will be aware that the
 prevalence of asthma has increased in several countries,    especially in afflu
ent Western countries and Latin America. In our opinion,    studies of the relat
ionship between asthma and socioeconomic differentials provide    an opportunity
 to advance our knowledge of what causes asthma and may even lead    to the poss
ibility of preventing it. The speed of this increase suggests an    environmenta
l rather than genetic source. It has been hypothesized that this    increase was
 a consequence of better living conditions and hence less exposure    to infecti
on, the so-called hygiene hypothesis. This hypothesis is supported    by the hig
h rates of asthma in affluent countries and a greater prevalence of    atopic di
seases in populations with higher socioeconomic status (SES). However,    there 
is increasing evidence of a greater frequency of asthma in populations    of low
er SES in affluent societies, such as African Americans in the United    States 
(2, 3) and subpopulations in Europe (4, 5), as well as in some Latin    American
 countries where societies are characterized by a marked inequality    in wealth
, with large pockets of poverty. We believe there is a need for further    studi
es on SES and asthma and that some major methodologic aspects must be addressed 
   to find the right answer; we list them below and propose guidelines for resea
rch.</font></p>     ^cY#a13v22n6.htm##
00788000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704055700072002001300629#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a13v22n6.htm#S#p#14#10#text#55#<p><font size="2" face=
"Verdana">First, we must establish how    and why the direction of the associati
on with SES has changed over time, as    has been observed in some places. For e
xample, surveys in Sweden showed that    the population of lower SES had lower p
revalence of asthma in earlier cohorts,    but later cohorts had the highest rat
es, a reversal of the effect with successive    generations (6). In a study in G
ermany, higher prevalence of asthma was found    in previous generations with hi
gh SES but not in recent ones (7).</font></p>     ^cY#a13v22n6.htm##
01481000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704125000072002001301322#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a13v22n6.htm#S#p#15#11#text#55#<p><font size="2" face=
"Verdana">Second, we need to assess the    effect of SES at the collective as we
ll as at the individual level. SES at the    individual level is more closely re
lated to factors such as genetic makeup,    family resources, living standards, 
occupation, education, diet, and indoor    environment. At the collective level,
 it may be related to, for example, community    resources and outdoor environme
ntal exposures. There is some evidence that SES    at the collective level is as
sociated with asthma morbidity; for instance, a    study in the United States sh
owed increased prevalence of asthma in children    exposed to community violence
 (8). This evidence is particularly important in    Latin America, where violenc
e has become a major cause of morbidity and mortality    (9). In addition, deter
mination at the collective level can be seen as resulting    from two opposing f
orces (10): (1) poor people can benefit from living in richer    areas because o
f better access to collective resources and less exposure to    hazards (collect
ive model), and (2) disparities in SES among individuals can    lead to social b
arriers, less social cohesion, and ultimately health disparities    (inequality 
model).</font></p>     ^cY#a13v22n6.htm##
01027000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704079600072002001300868#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a13v22n6.htm#S#p#16#12#text#55#<p><font size="2" face=
"Verdana">Third, it is important to discriminate    atopic from nonatopic diseas
es and other phenotypes (11) in studying    the social determination of asthma. 
Asthma has been conceived as a syndrome    resulting from different biological p
athways because of different combinations    of causes (12). The most well-descr
ibed factor is sensitization by allergens,    which leads to the common classifi
cation of asthma as atopic and nonatopic.    Asthma is also defined in terms of 
transient, persistent, and late-onset cases.    Epidemiologic studies do not alw
ays present data according to these classifications.    This diversity of causes
 of asthma raises the possibility of distinct etiologies    and thus also distin
ct potential preventive measures.</font></p>     ^cY#a13v22n6.htm##
01287000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704105600072002001301128#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a13v22n6.htm#S#p#17#13#text#55#<p><font size="2" face=
"Verdana">Fourth is the potential artefact    of better ascertainment of severe 
(untreated) asthma (13). The unexpected (from    the hygiene hypothesis perspect
ive) greater prevalence among those with lower    SES could be an artefact refle
cting differences not in the prevalence of asthma    but in the prevalence of se
vere asthma, with severe disease being more likely    to be diagnosed. It is now
 possible through well-planned asthma management programs    and the use of prev
entive drugs like inhaled steroids to reduce the frequency    and severity of as
thma attacks. If poverty leads to worse control and consequently    more severe 
asthma, and severe disease is more likely to be identified in surveys,    a grea
ter frequency of uncontrolled asthma among the poor (resulting from less    acce
ss to good management programs) can be misinterpreted as an increase in    the p
revalence of asthma among the poor. It is important to separate clearly    the p
resence of asthma from the presence of severe asthma.</font></p>     ^cY#a13v22n
6.htm##
01571000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704134000072002001301412#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a13v22n6.htm#S#p#18#14#text#55#<p><font size="2" face=
"Verdana">Fifth, in an attempt to explain the SES differentials    of asthma fre
quency and to develop preventive measures, it is important to develop    concept
ual models of causation, focusing on identifying potential "changeable    causes
" (14). Information in the literature suggests that changes in factors    such a
s physical activity, sanitation, and some infections are related to the    preva
lence of asthma, and these factors are also related to SES. These changes    str
engthen the idea that SES is not a "cause" by itself, but this    association wi
th asthma is mediated by factors that differ according to SES    and that have c
hanged over time. For instance, it may not be enough to describe    individuals 
as "poor" and "rich" or as "black"    and "white." It is essential to identify t
he changeable factors that    mediate the association between SES and health out
comes. Investigations of the    causal pathway of asthma may require methodologi
c approaches beyond the traditional    risk-factor analysis and a higher degree 
of theorization to test alternative    hypotheses. For instance, hierarchical (1
5) or structural (16) equation modeling    has been used to investigate the caus
ality involving genetic and environmental    factors as well as to evaluate cont
rol intervention.</font></p>     ^cY#a13v22n6.htm##
01265000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704103400072002001301106#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a13v22n6.htm#S#p#19#15#text#55#<p><font size="2" face=
"Verdana">In our opinion, a better understanding of the    different moments whe
n SES could have an impact on the progress from genetic    predisposition to occ
urrence of severe disease (and the causal pathways) is    key to formulating fut
ure programs for asthma prevention. It will determine    whether prevention of a
sthma is possible and feasible and whether it should    be done at the primary, 
secondary, or tertiary level. Attempts have been made    at different levels of 
prevention (17–21). Primary prevention will probably    require very earlier int
erventions to influence priming of the immune system    in earlier life. Seconda
ry intervention may be based on identifying mild (maybe    even undiagnosed) cas
es for intervention to remove factors associated with progression    of the dise
ase (possible factors are obesity, diet, indoor smoking, allergen    exposure, p
hysical activity, and air pollution). Prevention at the tertiary    level will i
nclude managing severe asthma. </font></p>     ^cY#a13v22n6.htm##
01656000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704142500072002001301497#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a13v22n6.htm#S#p#20#16#text#55#<p><font size="2" face=
"Verdana">Latin American societies may    be a very useful setting for more in-d
epth epidemiologic studies on etiological    factors and social context (22–24).
 The prevalence of asthma is high, an "anomaly"    in the hygiene hypothesis tha
t predicts lower prevalence in areas with high    exposure to infection; the pop
ulation in Latin America is highly heterogeneous    in terms of living standards
 (where the "Europes" and "least-developed    countries" share the same urban sp
ace) and lifestyles and environmental    exposures are changing fast. If prevale
nce rates are high, it is reasonable    to assume that populations in urban area
s of Latin America are already exposed    to the environmental changes behind th
e increase in asthma but without the living    standard in the most Western affl
uent countries. We suggest more studies beyond    the traditional "risk factor e
pidemiology," studies aimed at testing    causal frameworks to assess disease bu
rden in specific study sites, investigating    the nature and intensity of curre
nt changeable exposures and which of these    exposures explains the SES dispari
ty. Moreover, studies should be conducted    to assess exposures and prevalence 
between study sites at different stages of    social development, which may shed
 light on the mechanisms behind the changes    in prevalence in time and space a
nd across generations.</font></p>     ^cY#a13v22n6.htm##
00485000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704025400072002001300326#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a13v22n6.htm#S#p#21#17#text#55#<p><font size="2" face=
"Verdana"><B>Acknowledgments.</b> All authors participate    in the program Soci
al Changes in Asthma and Allergy in Latin American, Wellcome    Trust, Ref 07240
5/Z/ 03/Z. The authors have no competing interests.</font></p>     ^cY#a13v22n6.
htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a13v22n6.htm#S#p#22#18#text#55#<p>&nbsp;</p>     ^cY#a
13v22n6.htm##
00321000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704009000072002001300162#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a13v22n6.htm#S#p#23#19#text#55#<p align="right"><font 
size="2" face="Verdana"><b>S&eacute;rgio Souza da Cunha</b>    ^cY#a13v22n6.htm#
#
00274000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704004300072002001300115#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a13v22n6.htm#S#p#24#20#text#55#<br>   <b>Mauricio Lima
 Barreto</b>    ^cY#a13v22n6.htm##
00275000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704004400072002001300116#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a13v22n6.htm#S#p#25#21#text#55#<br>   Universidade Fed
eral de Bahia    ^cY#a13v22n6.htm##
00280000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704004900072002001300121#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a13v22n6.htm#S#p#26#22#text#55#<br>   Instituto de Sa&
uacute;de Coletiva    ^cY#a13v22n6.htm##
00276000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704004500072002001300117#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a13v22n6.htm#S#p#27#23#text#55#<br>   Rua Bas&iacute;l
io da Gama S/N    ^cY#a13v22n6.htm##
00287000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704005600072002001300128#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a13v22n6.htm#S#p#28#24#text#55#<br>   Canela, Salvador
 Bahia 40.110-040, Brazil    ^cY#a13v22n6.htm##
00319000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704008800072002001300160#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a13v22n6.htm#S#p#29#25#text#55#<br>   E-mail: <a href=
"mailto:cunhass@ufba.br">cunhass@ufba.br</a>.</font></p>     ^cY#a13v22n6.htm##
00314000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704008300072002001300155#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a13v22n6.htm#S#p#30#26#text#55#<p align="right"><font 
size="2" face="Verdana"><b>Laura Cunha Rodrigues</b>    ^cY#a13v22n6.htm##
00270000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704003900072002001300111#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a13v22n6.htm#S#p#31#27#text#55#<br>   London School of
 Hygiene    ^cY#a13v22n6.htm##
00267000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704003600072002001300108#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a13v22n6.htm#S#p#32#28#text#55#<br>   and Tropical Med
icine    ^cY#a13v22n6.htm##
00272000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704004100072002001300113#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a13v22n6.htm#S#p#33#29#text#55#<br>   United Kingdom</
font></p>     ^cY#a13v22n6.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a13v22n6.htm#S#p#34#30#text#55#<p>&nbsp;</p>     ^cY#a
13v22n6.htm##
00301000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704007000072002001300142#v22n6#v:\scielo
\serial\rpsp\v22n6\markup\a13v22n6.htm#S#p#35#31#text#55#<p><font size="3" face=
"verdana"><b>References</b></font></p>     ^cY#a13v22n6.htm##
00513000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000200072704026800074002001300342#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a13v22n6.htm#S#p#36#32#text#55#1#<p><font 
size="2" face="Verdana">1. Gonzales M, Malcoe    LH, Myers OB, Espinoza J. Risk 
factors for asthma and cough among Hispanic children    in the southwestern Unit
ed States of America, 2003–2004. Rev Panam Salud Publica.    2007;21(5):274–81.<
/font></p>     ^cY#a13v22n6.htm##
00359000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000200072704011400074002001300188#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a13v22n6.htm#S#p#37#33#text#55#2#<p><font 
size="2" face="Verdana">2. Rona RJ. Asthma and    poverty. Thorax. 2000;55(3):23
9–44.</font></p>     ^cY#a13v22n6.htm##
00396000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000200072704015100074002001300225#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a13v22n6.htm#S#p#38#34#text#55#3#<p><font 
size="2" face="Verdana">3. Gold DR, Wright R.    Population disparities in asthm
a. Annu Rev Public Health. 2005;26:89–113.</font></p>     ^cY#a13v22n6.htm##
00490000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000200072704024500074002001300319#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a13v22n6.htm#S#p#39#35#text#55#4#<p><font 
size="2" face="Verdana">4. Netuveli G, Hurwitz    B, Sheikh A. Ethnic variations
 in incidence of asthma episodes in England &amp;    Wales: national study of 50
2,482 patients in primary care. Respir Res. 2005;21:120.</font></p>     ^cY#a13v
22n6.htm##
00473000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000200072704022800074002001300302#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a13v22n6.htm#S#p#40#36#text#55#5#<p><font 
size="2" face="Verdana">5. Lindbaek M, Wefring    KW, Grangard EH, Ovsthus K. So
cioeconomical conditions as risk factors for bronchial    asthma in children age
d 4-5 yrs. Eur Respir J. 2003;21:105–8.</font></p>     ^cY#a13v22n6.htm##
00450000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000200072704020500074002001300279#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a13v22n6.htm#S#p#41#37#text#55#6#<p><font 
size="2" face="Verdana">6. Braback L, Hjern    A, Rasmussen F. Social class in a
sthma and allergic rhinitis: a national cohort    over three decades. Eur Respir
 J. 2005;26:1–5.</font></p>     ^cY#a13v22n6.htm##
00487000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000200072704024200074002001300316#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a13v22n6.htm#S#p#42#38#text#55#7#<p><font 
size="2" face="Verdana">7. Bergmann RL, Edenharter    G, Bergmann KE, Lau S, Wah
n U. Socioeconomic status is a risk factor for allergy    in parents but not in 
their children. Clin Exp Allergy. 2000;30(12):1740–5.</font></p>     ^cY#a13v22n
6.htm##
00481000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000200072704023600074002001300310#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a13v22n6.htm#S#p#43#39#text#55#8#<p><font 
size="2" face="Verdana">8. Wright RJ, Mitchell    H, Visness CM, Cohen S, Stout 
J, Evans R, et al. Community violence and asthma    morbidity: the Inner-City As
thma Study. Am J Public Health. 2004;94:625–32.</font></p>     ^cY#a13v22n6.htm#
#
00489000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000200072704024400074002001300318#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a13v22n6.htm#S#p#44#40#text#55#9#<p><font 
size="2" face="Verdana">9. Frenk J, Frejka T,    Bobadilla JL, Stern C, Lozano R
, Sepulveda J, et al. La transici&oacute;n epidemiol&oacute;gica    en Am&eacute
;rica Latina. Bol Oficina Sanit Panam. 1991;111:485–96.</font></p>     ^cY#a13v2
2n6.htm##
00433000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000300072704018700075002001300262#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a13v22n6.htm#S#p#45#41#text#55#10#<p><font
 size="2" face="Verdana">10. Stafford M, Marmot M.    Neighbourhood deprivation 
and health: does it affect us all equally? Int J Epidemiol.    2003;32: 357–66.<
/font></p>     ^cY#a13v22n6.htm##
00441000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000300072704019500075002001300270#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a13v22n6.htm#S#p#46#42#text#55#11#<p><font
 size="2" face="Verdana">11. Stein RT, Martinez FD.    Asthma phenotypes in chil
dhood: lessons from an epidemiological approach. Paediatr    Respir Rev. 2004;5:
155–61.</font></p>     ^cY#a13v22n6.htm##
00394000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000300072704014800075002001300223#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a13v22n6.htm#S#p#47#43#text#55#12#<p><font
 size="2" face="Verdana">12. A plea to abandon asthma    as a disease concept &#
91;editorial&#93;. Lancet. 2006;368:705.</font></p>     ^cY#a13v22n6.htm##
00425000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000300072704017900075002001300254#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a13v22n6.htm#S#p#48#44#text#55#13#<p><font
 size="2" face="Verdana">13. Mielck A, Reitmeir P,    Wjst M. Severity of childh
ood asthma by socioeconomic status. Int J Epidemiol.    1996;25:388–93.</font></
p>     ^cY#a13v22n6.htm##
00435000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000300072704018900075002001300264#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a13v22n6.htm#S#p#49#45#text#55#14#<p><font
 size="2" face="Verdana">14. Greenland S. Epidemiologic    measures and policy f
ormulation: lessons from potential outcomes. Emerg Themes    Epidemiol. 2005;2:5
.</font></p>     ^cY#a13v22n6.htm##
00501000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000300072704025500075002001300330#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a13v22n6.htm#S#p#50#46#text#55#15#<p><font
 size="2" face="Verdana">15. Cardoso MR, Cousens SN,    de Goes Siqueira LF, Alv
es FM, D'Angelo LA. Crowding: risk factor or protective    factor for lower resp
iratory disease in young children? BMC Public Health. 2004;4(1):19.</font></p>  
   ^cY#a13v22n6.htm##
00555000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000300072704030900075002001300384#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a13v22n6.htm#S#p#51#47#text#55#16#<p><font
 size="2" face="Verdana">16. Nystad W, Roysamb E, Magnus    P, Tambs K, Harris J
R. A comparison of genetic and environmental variance structures    for asthma, 
hay fever and eczema with symptoms of the same diseases: a study    of Norwegian
 twins. Int J Epidemiol. 2005;34: 1302–9.</font></p>     ^cY#a13v22n6.htm##
00543000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000300072704029700075002001300372#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a13v22n6.htm#S#p#52#48#text#55#17#<p><font
 size="2" face="Verdana">17. Joseph CL, Williams LK,    Ownby DR, Saltzgaber J, 
Johnson CC. Applying epidemiologic concepts of primary,    secondary, and tertia
ry prevention to the elimination of racial disparities    in asthma. J Allergy C
lin Immunol. 2006;117:233–40.</font></p>     ^cY#a13v22n6.htm##
00557000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000300072704031100075002001300386#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a13v22n6.htm#S#p#53#49#text#55#18#<p><font
 size="2" face="Verdana">18. Charrois T, Newman S,    Sin D, Senthilselvan A, Ts
uyuki RT. Improving asthma symptom control in rural    communities: the design o
f the Better Respiratory Education and Asthma Treatment    in Hinton and Edson s
tudy. Control Clin Trials. 2004;25: 502–14.</font></p>     ^cY#a13v22n6.htm##
00531000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000300072704028500075002001300360#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a13v22n6.htm#S#p#54#50#text#55#19#<p><font
 size="2" face="Verdana">19. Eggleston PA, Butz A,    Rand C, Curtin-Brosnan J, 
Kanchanaraksa S, Swartz L, et al. Home environmental    intervention in inner-ci
ty asthma: a randomized controlled clinical trial. Ann    Allergy Asthma Immunol
. 2005;95:518–24.</font></p>     ^cY#a13v22n6.htm##
00499000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000300072704025300075002001300328#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a13v22n6.htm#S#p#55#51#text#55#20#<p><font
 size="2" face="Verdana">20. Castro M, Zimmermann NA,    Crocker S, Bradley J, L
even C, Schechtman KG. Asthma intervention program prevents    readmissions in h
igh healthcare users. Am J Respir Crit Care Med. 2003;168:1095–9.</font></p>    
 ^cY#a13v22n6.htm##
00577000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000300072704033100075002001300406#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a13v22n6.htm#S#p#56#52#text#55#21#<p><font
 size="2" face="Verdana">21. Griffiths C, Foster G,    Barnes N, Eldridge S, Tat
e H, Begum S, et al. Specialist nurse intervention    to reduce unscheduled asth
ma care in a deprived multiethnic area: the east London    randomised controlled
 trial for high risk asthma (ELECTRA). BMJ. 2004;328(7432):144.</font></p>     ^
cY#a13v22n6.htm##
00442000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000300072704019600075002001300271#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a13v22n6.htm#S#p#57#53#text#55#22#<p><font
 size="2" face="Verdana">22. Pearce N, Douwes J. The    Latin American exception
: why is childhood asthma so prevalent in Brazil? J    Pediatr (Rio J). 2006; 82
:319–21.</font></p>     ^cY#a13v22n6.htm##
00634000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000300072704038800075002001300463#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a13v22n6.htm#S#p#58#54#text#55#23#<p><font
 size="2" face="Verdana">23. Barreto ML, Cunha SS,    Alcantara-Neves N, Carvalh
o LP, Cruz AA, Stein RT, et al. Risk factors and immunological    pathways for a
sthma and other allergic diseases in children: background and    methodology of 
a longitudinal study in a large urban center in Northeastern    Brazil (Salvador
-SCAALA Study). BMC Pulm Med. 2006;6:15.</font></p>     ^cY#a13v22n6.htm##
00628000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000300072704038200075002001300457#v22
n6#v:\scielo\serial\rpsp\v22n6\markup\a13v22n6.htm#S#p#59#55#text#55#24#<p><font
 size="2" face="Verdana">24. Cooper PJ, Chico ME, Vaca    MG, Rodriguez A, Alcan
tara-Neves NM, Genser B, et al. Risk factors for asthma    and allergy associate
d with urban migration: background and methodology of a    cross-sectional study
 in Afro-Ecuadorian school children in Northeastern Ecuador    (Esmeraldas-SCAAL
A Study). BMC Pulm Med. 2006;6:24.</font></p>     ^cY#a13v22n6.htm##
00680000000000313000450000400060000070200480000670500020005470600020005670000030
00587010002000617090005000637080003000681180002000710100018000730100017000910100
01600108010001800124012011800142030002400260065000900284064000500293031000300298
032000200301014000700303865000900310002001300319035001000332801002400342#v22n6#v
:\scielo\serial\rpsp\v22n6\markup\a13v22n6.htm#S#c#60#1#text#24#1#^rND^sGonzales
^nM#^rND^sMalcoe^nLH#^rND^sMyers^nOB#^rND^sEspinoza^nJ#Risk factors for asthma a
nd cough among Hispanic children in the southwestern United States of America, 2
003-2004^len#Rev Panam Salud Publica#20070000#2007#21#5#274-81#20071200#a13v22n6
.htm#1020-4989#Rev Panam Salud Publica##
00461000000000277000450000400060000070200480000670500020005470600020005670000030
00587010002000617090005000637080003000681180002000710100015000730120023000880300
00700111065000900118064000500127031000300132032000200135014000700137865000900144
002001300153035001000166801000700176#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a1
3v22n6.htm#S#c#61#2#text#24#2#^rND^sRona^nRJ#Asthma and poverty^len#Thorax#20000
000#2000#55#3#239-44#20071200#a13v22n6.htm#0040-6376#Thorax##
00521000000000277000450000400060000070200480000670500020005470600020005670000030
00587010002000617090005000637080003000681180002000710100015000730100016000880120
03700104030002300141065000900164064000500173031000300178014000700181865000900188
002001300197035001000210801002300220#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a1
3v22n6.htm#S#c#62#3#text#24#3#^rND^sGold^nDR#^rND^sWright^nR#Population disparit
ies in asthma^len#Annu Rev Public Health#20050000#2005#26#89-113#20071200#a13v22
n6.htm#0163-7525#Annu Rev Public Health##
00583000000000277000450000400060000070200480000670500020005470600020005670000030
00587010002000617090005000637080003000681180002000710100018000730100017000910100
01600108012012500124030001100249710000200260065000900262064000500271031000300276
032000400279865000900283002001300292#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a1
3v22n6.htm#S#c#63#4#text#24#4#^rND^sNetuveli^nG#^rND^sHurwitz^nB#^rND^sSheikh^nA
#Ethnic variations in incidence of asthma episodes in England & Wales: national 
study of 502,482 patients in primary care^len#Respir Res#2#20050000#2005#21#120#
20071200#a13v22n6.htm##
00621000000000301000450000400060000070200480000670500020005470600020005670000030
00587010002000617090005000637080003000681180002000710100018000730100018000910100
01900109010001700128012009300145030001300238065000900251064000500260031000300265
014000600268865000900274002001300283035001000296801001300306#v22n6#v:\scielo\ser
ial\rpsp\v22n6\markup\a13v22n6.htm#S#c#64#5#text#24#5#^rND^sLindbaek^nM#^rND^sWe
fring^nKW#^rND^sGrangard^nEH#^rND^sOvsthus^nK#Socioeconomical conditions as risk
 factors for bronchial asthma in children aged 4-5 yrs^len#Eur Respir J#20030000
#2003#21#105-8#20071200#a13v22n6.htm#0903-1936#Eur Respir J##
00580000000000289000450000400060000070200480000670500020005470600020005670000030
00587010002000617090005000637080003000681180002000710100017000730100015000900100
01900105012008700124030001300211065000900224064000500233031000300238014000400241
865000900245002001300254035001000267801001300277#v22n6#v:\scielo\serial\rpsp\v22
n6\markup\a13v22n6.htm#S#c#65#6#text#24#6#^rND^sBraback^nL#^rND^sHjern^nA#^rND^s
Rasmussen^nF#Social class in asthma and allergic rhinitis: a national cohort ove
r three decades^len#Eur Respir J#20050000#2005#26#1-5#20071200#a13v22n6.htm#0903
-1936#Eur Respir J##
00668000000000325000450000400060000070200480000670500020005470600020005670000030
00587010002000617090005000637080003000681180002000710100019000730100020000920100
01900112010001300131010001400144012009100158030001700249065000900266064000500275
03100030028003200030028301400070028686500090029300200130030203500100031580100170
0325#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a13v22n6.htm#S#c#66#7#text#24#7#^r
ND^sBergmann^nRL#^rND^sEdenharter^nG#^rND^sBergmann^nKE#^rND^sLau^nS#^rND^sWahn^
nU#Socioeconomic status is a risk factor for allergy in parents but not in their
 children^len#Clin Exp Allergy#20000000#2000#30#12#1740-5#20071200#a13v22n6.htm#
0954-7894#Clin Exp Allergy##
00682000000000337000450000400060000070200480000670500020005470600020005670000030
00587010002000617090005000637080003000681180002000710100017000730100018000900100
01800108010001500126010001500141010001500156810000600171012007300177030001900250
06500090026906400050027803100030028301400070028686500090029300200130030203500100
0315801001900325#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a13v22n6.htm#S#c#67#8#
text#24#8#^rND^sWright^nRJ#^rND^sMitchell^nH#^rND^sVisness^nCM#^rND^sCohen^nS#^r
ND^sStout^nJ#^rND^sEvans^nR#et al#Community violence and asthma morbidity: the I
nner-City Asthma Study^len#Am J Public Health#20040000#2004#94#625-32#20071200#a
13v22n6.htm#0090-0036#Am J Public Health##
00674000000000337000450000400060000070200480000670500020005470600020005670000030
00587010002000617090005000637080003000681180002000710100015000730100016000880100
02000104010001500124010001600139010001900155810000600174012005100180030002400231
06500090025506400050026403100040026901400070027386500090028000200130028903500100
0302801002400312#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a13v22n6.htm#S#c#68#9#
text#24#9#^rND^sFrenk^nJ#^rND^sFrejka^nT#^rND^sBobadilla^nJL#^rND^sStern^nC#^rND
^sLozano^nR#^rND^sSepulveda^nJ#et al#La transición epidemiológica en América Lat
ina^les#Bol Oficina Sanit Panam#19910000#1991#111#485-96#20071200#a13v22n6.htm#0
030-0632#Bol Oficina Sanit Panam##
00548000000000277000450000400060000070200480000670500020005470600020005670000030
00587010003000617090005000647080003000691180003000720100018000750100016000930120
07300109030001600182065000900198064000500207031000300212014000700215865000900222
002001300231035001000244801001600254#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a1
3v22n6.htm#S#c#69#10#text#24#10#^rND^sStafford^nM#^rND^sMarmot^nM#Neighbourhood 
deprivation and health: does it affect us all equally?^len#Int J Epidemiol#20030
000#2003#32#357-66#20071200#a13v22n6.htm#0300-5771#Int J Epidemiol##
00520000000000265000450000400060000070200480000670500020005470600020005670000030
00587010003000617090005000647080003000691180003000720100016000750100019000910120
07700110030002000187710000200207065000900209064000500218031000200223014000700225
865000900232002001300241#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a13v22n6.htm#S
#c#70#11#text#24#11#^rND^sStein^nRT#^rND^sMartinez^nFD#Asthma phenotypes in chil
dhood: lessons from an epidemiological approach^len#Paediatr Respir Rev#2#200400
00#2004#5#155-61#20071200#a13v22n6.htm##
00447000000000253000450000400060000070200480000670500020005470600020005670000030
00587010003000617090005000647080003000691180003000720120050000750300007001250650
00900132064000500141031000400146032000400150865000900154002001300163035001000176
801000700186#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a13v22n6.htm#S#c#71#12#tex
t#24#12#A plea to abandon asthma as a disease concept^len#Lancet#20060000#2006#3
68#705#20071200#a13v22n6.htm#0099-5355#Lancet##
00558000000000289000450000400060000070200480000670500020005470600020005670000030
00587010003000617090005000647080003000691180003000720100016000750100018000910100
01400109012005700123030001600180065000900196064000500205031000300210014000700213
865000900220002001300229035001000242801001600252#v22n6#v:\scielo\serial\rpsp\v22
n6\markup\a13v22n6.htm#S#c#72#13#text#24#13#^rND^sMielck^nA#^rND^sReitmeir^nP#^r
ND^sWjst^nM#Severity of childhood asthma by socioeconomic status^len#Int J Epide
miol#19960000#1996#25#388-93#20071200#a13v22n6.htm#0300-5771#Int J Epidemiol##
00496000000000253000450000400060000070200480000670500020005470600020005670000030
00587010003000617090005000647080003000691180003000720100019000750120083000940300
02300177710000200200065000900202064000500211031000200216032000200218865000900220
002001300229#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a13v22n6.htm#S#c#73#14#tex
t#24#14#^rND^sGreenland^nS#Epidemiologic measures and policy formulation: lesson
s from potential outcomes^len#Emerg Themes Epidemiol#2#20050000#2005#2#5#2007120
0#a13v22n6.htm##
00646000000000313000450000400060000070200480000670500020005470600020005670000030
00587010003000617090005000647080003000691180003000720100018000750100018000930100
02700111010001600138010001900154012009600173030001800269710000200287065000900289
064000500298031000200303032000200305020000300307865000900310002001300319#v22n6#v
:\scielo\serial\rpsp\v22n6\markup\a13v22n6.htm#S#c#74#15#text#24#15#^rND^sCardos
o^nMR#^rND^sCousens^nSN#^rND^sde Goes Siqueira^nLF#^rND^sAlves^nFM#^rND^sD'Angel
o^nLA#Crowding: risk factor or protective factor for lower respiratory disease i
n young children?^len#BMC Public Health#2#20040000#2004#4#1#19#20071200#a13v22n6
.htm##
00721000000000313000450000400060000070200480000670500020005470600020005670000030
00587010003000617090005000647080003000691180003000720100016000750100017000910100
01600108010001500124010001700139012016200156030001600318065000900334064000500343
031000300348014000800351865000900359002001300368035001000381801001600391#v22n6#v
:\scielo\serial\rpsp\v22n6\markup\a13v22n6.htm#S#c#75#16#text#24#16#^rND^sNystad
^nW#^rND^sRoysamb^nE#^rND^sMagnus^nP#^rND^sTambs^nK#^rND^sHarris^nJR#A compariso
n of genetic and environmental variance structures for asthma, hay fever and ecz
ema with symptoms of the same diseases: a study of Norwegian twins^len#Int J Epi
demiol#20050000#2005#34#1302-9.#20071200#a13v22n6.htm#0300-5771#Int J Epidemiol#
#
00716000000000313000450000400060000070200480000670500020005470600020005670000030
00587010003000617090005000647080003000691180003000720100017000750100019000920100
01600111010002000127010001800147012013400165030002300299065000900322064000500331
031000400336014000700340865000900347002001300356035001000369801002300379#v22n6#v
:\scielo\serial\rpsp\v22n6\markup\a13v22n6.htm#S#c#76#17#text#24#17#^rND^sJoseph
^nCL#^rND^sWilliams^nLK#^rND^sOwnby^nDR#^rND^sSaltzgaber^nJ#^rND^sJohnson^nCC#Ap
plying epidemiologic concepts of primary, secondary, and tertiary prevention to 
the elimination of racial disparities in asthma^len#J Allergy Clin Immunol#20060
000#2006#117#233-40#20071200#a13v22n6.htm#0091-6749#J Allergy Clin Immunol##
00726000000000313000450000400060000070200480000670500020005470600020005670000030
00587010003000617090005000647080003000691180003000720100018000750100016000930100
01300109010002300122010001800145012015300163030002000316065000900336064000500345
031000300350014000700353865000900360002001300369035001000382801002000392#v22n6#v
:\scielo\serial\rpsp\v22n6\markup\a13v22n6.htm#S#c#77#18#text#24#18#^rND^sCharro
is^nT#^rND^sNewman^nS#^rND^sSin^nD#^rND^sSenthilselvan^nA#^rND^sTsuyuki^nRT#Impr
oving asthma symptom control in rural communities: the design of the Better Resp
iratory Education and Asthma Treatment in Hinton and Edson study^len#Control Cli
n Trials#20040000#2004#25#502-14#20071200#a13v22n6.htm#0197-2456#Control Clin Tr
ials##
00737000000000337000450000400060000070200480000670500020005470600020005670000030
00587010003000617090005000647080003000691180003000720100020000750100014000950100
01400109010002400123010002300147010001600170810000600186012009700192030002700289
06500090031606400050032503100030033001400070033386500090034000200130034903500100
0362801002700372#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a13v22n6.htm#S#c#78#19
#text#24#19#^rND^sEggleston^nPA#^rND^sButz^nA#^rND^sRand^nC#^rND^sCurtin-Brosnan
^nJ#^rND^sKanchanaraksa^nS#^rND^sSwartz^nL#et al#Home environmental intervention
 in inner-city asthma: a randomized controlled clinical trial^len#Ann Allergy As
thma Immunol#20050000#2005#95#518-24#20071200#a13v22n6.htm#1081-1206#Ann Allergy
 Asthma Immunol##
00696000000000325000450000400060000070200480000670500020005470600020005670000030
00587010003000617090005000647080003000691180003000720100016000750100021000910100
01700112010001700129010001500146010002100161012007900182030002600261065000900287
06400050029603100040030101400070030586500090031200200130032103500100033480100260
0344#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a13v22n6.htm#S#c#79#20#text#24#20#
^rND^sCastro^nM#^rND^sZimmermann^nNA#^rND^sCrocker^nS#^rND^sBradley^nJ#^rND^sLev
en^nC#^rND^sSchechtman^nKG#Asthma intervention program prevents readmissions in 
high healthcare users^len#Am J Respir Crit Care Med#20030000#2003#168#1095-9#200
71200#a13v22n6.htm#1073-449X#Am J Respir Crit Care Med##
00771000000000349000450000400060000070200480000670500020005470600020005670000030
00587010003000617090005000647080003000691180003000720100019000750100016000940100
01600110010001800126010001400144010001500158810000600173012017500179030000400354
06500090035806400050036703100040037203200050037601400040038186500090038500200130
0394035001000407801000400417#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a13v22n6.h
tm#S#c#80#21#text#24#21#^rND^sGriffiths^nC#^rND^sFoster^nG#^rND^sBarnes^nN#^rND^
sEldridge^nS#^rND^sTate^nH#^rND^sBegum^nS#et al#Specialist nurse intervention to
 reduce unscheduled asthma care in a deprived multiethnic area: the east London 
randomised controlled trial for high risk asthma (ELECTRA)^len#BMJ#20040000#2004
#328#7432#144#20071200#a13v22n6.htm#0959-8138#BMJ##
00559000000000277000450000400060000070200480000670500020005470600020005670000030
00587010003000617090005000647080003000691180003000720100016000750100016000910120
08200107030001800189065000900207064000500216031000300221014000700224865000900231
002001300240035001000253801001800263#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a1
3v22n6.htm#S#c#81#22#text#24#22#^rND^sPearce^nN#^rND^sDouwes^nJ#The Latin Americ
an exception: why is childhood asthma so prevalent in Brazil?^len#J Pediatr (Rio
 J)#20060000#2006#82#319-21#20071200#a13v22n6.htm#0021-7557#J Pediatr (Rio J)##
00790000000000325000450000400060000070200480000670500020005470600020005670000030
00587010003000617090005000647080003000691180003000720100018000750100016000930100
02500109010001900134010001500153010001600168810000600184012021800190030001300408
71000020042106500090042306400050043203100020043701400030043986500090044200200130
0451#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a13v22n6.htm#S#c#82#23#text#24#23#
^rND^sBarreto^nML#^rND^sCunha^nSS#^rND^sAlcantara-Neves^nN#^rND^sCarvalho^nLP#^r
ND^sCruz^nAA#^rND^sStein^nRT#et al#Risk factors and immunological pathways for a
sthma and other allergic diseases in children: background and methodology of a l
ongitudinal study in a large urban center in Northeastern Brazil (Salvador-SCAAL
A Study)^len#BMC Pulm Med#2#20060000#2006#6#15#20071200#a13v22n6.htm##
00784000000000325000450000400060000070200480000670500020005470600020005670000030
00587010003000617090005000647080003000691180003000720100017000750100016000920100
01500108010001900123010002600142010001600168810000600184012021200190030001300402
71000020041506500090041706400050042603100020043103200030043386500090043600200130
0445#v22n6#v:\scielo\serial\rpsp\v22n6\markup\a13v22n6.htm#S#c#83#24#text#24#24#
^rND^sCooper^nPJ#^rND^sChico^nME#^rND^sVaca^nMG#^rND^sRodriguez^nA#^rND^sAlcanta
ra-Neves^nNM#^rND^sGenser^nB#et al#Risk factors for asthma and allergy associate
d with urban migration: background and methodology of a cross-sectional study in
 Afro-Ecuadorian school children in Northeastern Ecuador (Esmeraldas-SCAALA Stud
y)^len#BMC Pulm Med#2#20060000#2006#6#24#20071200#a13v22n6.htm##
